Drugs;Gene;Alleles;Genotype;Outcome_category;Effect_direction;Effect_category;Entity;Entity_name;Affected_Pop
SITAGLIPTIN;DPP4;TT;rs2909451;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;DPP4;TT;rs2909451;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SITAGLIPTIN;KCNQ1;GG;rs163184;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;KCNQ1;GG;rs163184;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
SITAGLIPTIN;DPP4;GG;rs4664443;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;DPP4;GG;rs4664443;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SITAGLIPTIN;CYP2C9;TT;rs1799853;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;CYP2C9;TT;rs1799853;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SITAGLIPTIN;GLP1R;AG;rs3765467;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;GLP1R;AG;rs3765467;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
FLUOXETINE;CYP2C19;;INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;CYP2C19;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
EXENATIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
EXENATIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
LIRAGLUTIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LIRAGLUTIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
CITALOPRAM;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ALBIGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
ALBIGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
DULAGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
DULAGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLP-1 RECEPTOR AGONISTS;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLP-1 RECEPTOR AGONISTS;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
EXENATIDE;TCF7L2;CT + TT;rs7903146;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
EXENATIDE;TCF7L2;CT + TT;rs7903146;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;HISTORY OF GASTRIC BYPASS SURGERY;PEOPLE
ALBIGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
ALBIGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
DULAGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
DULAGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE
ALBIGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
ALBIGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
DULAGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
DULAGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2XN;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
LURBINECTEDIN;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
LURBINECTEDIN;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
ALBIGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
ALBIGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
DULAGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
DULAGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
PHENYTOIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS;PEOPLE
PHENYTOIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS;PEOPLE
ALBIGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
ALBIGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
DULAGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
DULAGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLP-1 RECEPTOR AGONISTS;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN
RALOXIFENE-4′-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN
RALOXIFENE-4′-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
ARIPIPRAZOLE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
LEFLUNOMIDE;PON1;GG;rs705379;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
DABIGATRAN;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
DABIGATRAN;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ANTIEPILEPTICS;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE
ANTIEPILEPTICS;SCN1A;T;rs10167228;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*5;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*5;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
METHADONE;;;ACTIVITY;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;
TELMISARTAN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
TELMISARTAN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE
BILIRUBIN;UGT1A1;*28/*28;UGT1A1*1;OTHER;INCREASED;;DISEASE;NEOPLASMS;PEOPLE
BILIRUBIN;UGT1A1;*28/*28;UGT1A1*28;OTHER;INCREASED;;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE
CARVEDILOL;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;ANGINA PECTORIS;PEOPLE
CARVEDILOL;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;INCREASED;METABOLISM;OTHER;ANGINA PECTORIS;PEOPLE
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;;
OLANZAPINE;GSTM3;TCCTC/TCCTC;rs36120609;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
OLANZAPINE;GSTM3;TCCTC/TCCTC;rs36120609;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"TYPE 2""";PEOPLE
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"""OTHER:OBESITY""";PEOPLE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;CONCENTRATIONS;;;
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CLONIDINE;ADRA2C;GGGGAGCTTTCCCAGAGACCC/del + del/del;rs11269124;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:DYSLIPIDAEMIA;PEOPLE
DEXTROMETHORPHAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SIMVASTATIN ACID;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
SIMVASTATIN ACID;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:DYSLIPIDAEMIA;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;STROKE;PEOPLE
ASPIRIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;STROKE;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLONIC NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLONIC NEOPLASMS;PEOPLE
DEXTROMETHORPHAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIFAMPIN;SLCO1B1;TT;rs4149032;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
MODAFINIL;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;OTHER;METHAMPHETAMINE DEPENDENCE;PEOPLE
ISONIAZID;;AA;rs1495741;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
VALSARTAN;AGT;GG;rs699;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
MELOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED;RESPONSE;;;
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ELEXACAFTOR;CFTR;;DEFICIENCY;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CYSTIC FIBROSIS;PEOPLE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
REMIFENTANIL;ADRA2A;CG + GG;rs1800544;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
REMIFENTANIL;ADRA2A;CG + GG;rs1800544;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
WARFARIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;DOSAGE;INCREASED;DOSE;OTHER;THROMBOEMBOLISM;PEOPLE
WARFARIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;DOSAGE;INCREASED;DOSE;OTHER;THROMBOEMBOLISM;PEOPLE
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;PEOPLE
POSACONAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*6;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*6;CYP3A5*6;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
TACROLIMUS;CYP3A5;*7;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*7;CYP3A5*7;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;ORGAN TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;ORGAN TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;PEOPLE
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *2/*2;CYP2A6*1;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
NICOTINE;CYP2A6;*1/*2 + *2/*2;CYP2A6*2;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*28;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*36;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
DEXTROMETHORPHAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;BREAST NEOPLASMS;WOMEN
NICOTINE;CYP2A6;*46/*46;CYP2A6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
NICOTINE;CYP2A6;*46/*46;CYP2A6*46;METABOLISM/PK;INCREASED;CLEARANCE;;;
BUPRENORPHINE;SLC39A10;C;rs149319538;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
SIMVASTATIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
SIMVASTATIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;
SIMVASTATIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
SIMVASTATIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;;
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
DEXTROMETHORPHAN;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN
DEXTROMETHORPHAN;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN
LETROZOLE;CYP2A6;*1/*1;CYP2A6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*1;CYP2A6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*1;CYP2A6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*1;CYP2A6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*1;CYP2A6*12;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
DEXTROMETHORPHAN;CYP2D6;*1/*2;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*1/*2;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
RIVAROXABAN;ABCB1;CC;rs4148738;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
RIVAROXABAN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
DIAZEPAM;CYP2B6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHOTREXATE;TYMS;GG;rs2853542;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;ATIC;TT;rs4673993;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*60;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
DIHYDROPYRIDINE DERIVATIVES;NUMA1;AA + AG;rs10898815;OTHER;INCREASED;DISCONTINUATION;;;
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
CORTICOSTEROIDS;NR3C1;GG;rs10482634;EFFICACY;INCREASED;RESISTANCE;OTHER;NEPHROTIC SYNDROME;CHILDREN
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*10;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;HEART TRANSPLANTATION;PEOPLE
VALPROIC ACID;UGT1A6;TT;rs6759892;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
NICOTINE;CYP2A6;*46/*46;CYP2A6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*46/*46;CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
METHYLPHENIDATE;SYT1;AA + AG;rs2251214;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CHOP;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE
RITUXIMAB;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE
CHOP;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE
RITUXIMAB;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*11;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
N-DESMETHYLTAMOXIFEN;SEPTIN3;AG;rs11914200;METABOLISM/PK;DECREASED;METABOLISM;;;
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE
CITALOPRAM;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CITALOPRAM;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
N-DESMETHYLTAMOXIFEN;SREBF2;AC;rs133290;METABOLISM/PK;DECREASED;METABOLISM;;;
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*11;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
N-DESMETHYLTAMOXIFEN;TCF20;GG;rs5751251;METABOLISM/PK;INCREASED;METABOLISM;;;
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs2267439;METABOLISM/PK;INCREASED;METABOLISM;;;
PIROXICAM;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PIROXICAM;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs9607850;METABOLISM/PK;INCREASED;METABOLISM;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;AG;rs8140869;METABOLISM/PK;DECREASED;METABOLISM;;;
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
SOFOSBUVIR;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
VARENICLINE;CYP2A6;;HIGH ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
ETOPOSIDE;;AA;rs446112;OTHER;INCREASED;RESISTANCE;;;
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;DIABETES MELLITUS;PEOPLE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HYPERCHOLESTEROLEMIA;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OPIOIDS;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
LUMACAFTOR;CFTR;del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;;
AFATINIB;EGFR;GG;rs28929495;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
3-AMINOISOBUTYRATE;DPYD;TT;rs3918290;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;DOSAGE;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;EFFICACY;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE
MEXILETINE;CYP2D6;*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;OTHER;MYOTONIC DYSTROPHY;PEOPLE
MEXILETINE;CYP2D6;*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:NONDYSTROPHIC MYOTONIA;PEOPLE
3-AMINOISOBUTYRATE;UPB1;AA;rs143493067;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
3-AMINOISOBUTYRATE;AGXT2;TT;rs114286107;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*13;CYP2C9*1;PD;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*13;CYP2C9*13;PD;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;POSTOPERATIVE;PEOPLE
URACIL;DPYD;TT;rs3918290;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
2-AMINOHEPTANOATE;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
2-AMINOOCTANOIC ACID;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
2-HYDROXYLAURATE;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
CYSTEINE-S-SULFATE;NPC2;TT;rs140130028;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
L-ORNITHINE;NPC2;TT;rs140130028;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
5;UPB1;AA;rs143493067;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
6-DIHYDROTHYMINE;UPB1;AA;rs143493067;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;G;rs2273697;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RIVAROXABAN;CYP3A5;TT;rs776746;TOXICITY;DECREASED;CONCENTRATIONS;OTHER;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;CYP1A2*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;CYP1A2*30;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;CYP2C9*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;CYP2C9*9;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE
ARIPIPRAZOLE;CYP2D6;AA + AG;rs1065852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TIC DISORDERS;CHILDREN
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TIC DISORDERS;CHILDREN
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;DECREASED;CLEARANCE;OTHER;TIC DISORDERS;CHILDREN
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE
ESOMEPRAZOLE;CYP2C19;*17/*17;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*17/*17;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3A;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3C;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MELOXICAM;CYP2C9;*3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
MELOXICAM;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;UGT1A4;TT;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;GG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;DIABETES MELLITUS;PEOPLE
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HYPERCHOLESTEROLEMIA;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"TYPE 2""";PEOPLE
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"""OTHER:FATTY LIVER DISEASE""";PEOPLE
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"""OTHER:BODY WEIGHT CHANGES""";PEOPLE
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
LUMACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
SERTRALINE;DRD3;AG;rs167770;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
SERTRALINE;DRD3;AG;rs11721264;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER;PEOPLE
ILOPERIDONE;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
ILOPERIDONE METABOLITE P88;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
EFAVIRENZ;CYP2B6;*1/*4;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*4;CYP2B6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
VALPROIC ACID;CACNA1H;T;rs3751664;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
PENICILLIN G;IFNG;CC;rs1861494;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SYPHILIS;PEOPLE
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
PENICILLIN G;IFNG;TT;rs2430561;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SYPHILIS;PEOPLE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*1;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*1XN;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*2;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*2XN;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
RIVAROXABAN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;MEN
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;MEN
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
AVATROMBOPAG;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
AVATROMBOPAG;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*1;DOSAGE;;DOSE;;;
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*2;DOSAGE;;DOSE;;;
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*3;DOSAGE;;DOSE;;;
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*5;DOSAGE;;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
AVATROMBOPAG;ABCB1;AA + AG;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;PEOPLE
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ACUTE;PEOPLE
CLOZAPINE;NFIB;CT;rs28379954;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PITAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
PITAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
METHYLPHENIDATE;SLC6A2;GG;rs998424;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS;PEOPLE
LITHIUM;;T;rs7405404;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FENTANYL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;"GASTROINTESTINAL NEOPLASMS""";PEOPLE
FENTANYL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
FENTANYL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
FENTANYL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;"GASTROINTESTINAL NEOPLASMS""";PEOPLE
FENTANYL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
FENTANYL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
VARENICLINE;HYKK;CT + TT;rs7164594;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*5;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;MEN
LOSARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;MEN
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
BUPROPION;CYP2B6;GG;rs8109525;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*2;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*3;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*4;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*5;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEPHROTIC SYNDROME;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEPHROTIC SYNDROME;CHILDREN
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
MESALAZINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN
MESALAZINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN
MESALAZINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN
MESALAZINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN
MESALAZINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN
MESALAZINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN
MESALAZINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN
MESALAZINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN
MESALAZINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN
THIOGUANINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN
PIOGLITAZONE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;METABOLISM;;;
PIOGLITAZONE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;METABOLISM;;;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ORGAN TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ORGAN TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;ORGAN TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;ORGAN TRANSPLANTATION;CHILDREN
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1XN;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
EXEMESTANE;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
EXEMESTANE;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
WARFARIN;CYP4F2;*3;CYP4F2*1;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP4F2;*3;CYP4F2*3;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
CETUXIMAB;VEGFA;del/del;rs144854329;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
IBUPROFEN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
IBUPROFEN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
IBUPROFEN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;TROUGH CONCENTRATION;DISEASE;ULCERATIVE COLITIS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ATENOLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
WARFARIN;CYP2C9;*1/*6;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*6;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;
LETROZOLE;;C;rs7937;;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
PROPOFOL;CYP2C9;*1/*1 + *1/*2;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;PEOPLE
PROPOFOL;CYP2C9;*1/*1 + *1/*2;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
NOROXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
PAROXETINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
PAROXETINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
SERTRALINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
SERTRALINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
SERTRALINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
SERTRALINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DISULFIRAM;SLC6A3;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;rs28363170;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
PERINDOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CROHN DISEASE;PEOPLE
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CROHN DISEASE;PEOPLE
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CROHN DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MALARIA;CHILDREN
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MALARIA;CHILDREN
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MALARIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ARTEMETHER;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ARTEMETHER;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FLUOXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FLUOXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
EFAVIRENZ;CYP2B6;GG;rs36118214;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;CYP2B6*30;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;CYP2B6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;DOSAGE;INCREASED;METABOLISM;;;HEALTHY
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
QUINAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1A;EFFICACY;INCREASED;CLEARANCE;;;
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1A;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;UGT1A4;*3a;UGT1A4*3A;EFFICACY;INCREASED;CLEARANCE;;;
TESTOSTERONE;UGT1A4;*3a;UGT1A4*3A;METABOLISM/PK;INCREASED;CLEARANCE;;;
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;;DOSE;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1A;EFFICACY;DECREASED;CLEARANCE;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1A;METABOLISM/PK;DECREASED;CLEARANCE;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*2;EFFICACY;DECREASED;CLEARANCE;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*3A;EFFICACY;DECREASED;CLEARANCE;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*3A;METABOLISM/PK;DECREASED;CLEARANCE;;;
CURCUMIN;CFTR;AA + AG;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
IVACAFTOR;CFTR;AA + AG;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
3-HYDROXYCOTININE;CYP2A6;*1/*12;CYP2A6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
3-HYDROXYCOTININE;CYP2A6;*1/*12;CYP2A6*12;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;MEN
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*18;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*21;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*49;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*52;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*9;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*10;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*17;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*29;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*45;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*45;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*46;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*46;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;OTHER;CORONARY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;OTHER;CORONARY DISEASE;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHOTREXATE;HLA-G;del/del;rs371194629;EFFICACY;INCREASED;RESPONSE;EFFICACY;RHEUMATOID ARTHRITIS;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*3;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*4;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*5;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*6;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;CHILDREN
ESOMEPRAZOLE;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;CHILDREN
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*6;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;MEN
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
TRAMADOL;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;INFANTS
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*2;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
CHIGLITAZAR;PPARA;CC + CT;rs1800234;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
CHIGLITAZAR;PPARA;CC + CT;rs1800234;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
LAMOTRIGINE;UGT1A4;*1b;UGT1A4*1A;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
LAMOTRIGINE;UGT1A4;*1b;UGT1A4*1B;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE
AZATHIOPRINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;METABOLISM;;;
MERCAPTOPURINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;METABOLISM;;;
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
MERCAPTOPURINE;TPMT;;INTERMEDIATE ACTIVITY;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
SULFASALAZINE;NAT2;;SLOW ACETYLATOR;OTHER;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;POSTOPERATIVE;PEOPLE
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED;DOSE;;;CHILDREN
SUFENTANIL;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
SUFENTANIL;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
SUFENTANIL;CYP3A4;T/T;rs2242480;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;PAIN;WOMEN
TACROLIMUS;CYP3A4;C/C;rs2242480;OTHER;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;PAIN;WOMEN
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
BETA BLOCKING AGENTS;GRK5;T;rs4752292;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
INTERFERON BETA-1A;HLA-B;*15:01;HLA-B*15:01;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
RUBELLA VACCINES;HLA-B;*35:03;HLA-B*35:03;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
PEGINTERFERON ALFA-2A;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;GG;rs671531;EFFICACY;DECREASED;RESPONSE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A4;*1/*18;CYP3A4*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*18;CYP3A4*18;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A4;*18/*18;CYP3A4*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A4;*18/*18;CYP3A4*18;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
METHOTREXATE;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
RUBELLA VACCINES;HLA-C;*15:02;HLA-C*15:02;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*02:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*03:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*04:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*05:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*06:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*07:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*08:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*12:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*14:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*15:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*16:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*17:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*02:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*03:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*04:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*05:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*06:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*07:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*08:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*12:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*14:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*15:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*16:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*17:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
MEASLES VACCINES;HLA-DQA1;*01:04;HLA-DQA1*01:04;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
MEASLES VACCINES;HLA-DRB1;*01:01;HLA-DRB1*01:01;EFFICACY;;RESPONSE;;;CHILDREN
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;MEN
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;MEN
INTERFERON BETA-1A;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
ADALIMUMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
HEPATITIS VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
INFLUENZA VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED;RESPONSE;;;
MEASLES VACCINES;HLA-DRB1;*08:01;HLA-DRB1*08:01;EFFICACY;;RESPONSE;;;CHILDREN
INFLUENZA VACCINES;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;INCREASED;RESPONSE;;;
MONTELUKAST;CYP2C8;*4;CYP2C8*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MONTELUKAST;CYP2C8;*4;CYP2C8*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MONTELUKAST;CYP2C8;*3;CYP2C8*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
MONTELUKAST;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;CYP2C8*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;CYP2C8*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHOTREXATE;GGH;AA + AG;rs11545078;TOXICITY;INCREASED;DISCONTINUATION;SIDE EFFECT;RHEUMATOID ARTHRITIS;PEOPLE
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1;DOSAGE;DECREASED;DOSE;;;
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*3;DOSAGE;DECREASED;DOSE;;;
ROSIGLITAZONE;CYP2C8;*1/*3;CYP2C8*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ROSIGLITAZONE;CYP2C8;*1/*3;CYP2C8*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
IBUPROFEN;CYP2C8;*3;CYP2C8*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IBUPROFEN;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*5;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*7;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
SERTRALINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*9/*9;CYP2B6*1;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;
SERTRALINE;CYP2B6;*9/*9;CYP2B6*9;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;
ATORVASTATIN;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*15;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*11;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*11;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PITAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PITAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1;EFFICACY;INCREASED;RESPONSE;;;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*2;EFFICACY;INCREASED;RESPONSE;;;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*3;EFFICACY;INCREASED;RESPONSE;;;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*5;EFFICACY;INCREASED;RESPONSE;;;
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN
FLUVASTATIN;SLCO1B1;*14;SLCO1B1*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
FLUVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN
METHOTREXATE;SLCO1B1;*31;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*31;SLCO1B1*31;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*31;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*20;SLCO1B1*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*20;SLCO1B1*20;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*20;SLCO1B1*37;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CONJUGATED ESTROGENS;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MENOPAUSE;WOMEN
METHOTREXATE;SLCO1B1;*23;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*23;SLCO1B1*23;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*23;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ACENOCOUMAROL;CYP2C18;GG;rs1998591;DOSAGE;INCREASED;DOSE;;;CHILDREN
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;CHILDREN
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;OTHER;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;OTHER;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESISTANCE;OTHER;STROKE;PEOPLE
METHOTREXATE;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*37;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION;PEOPLE
3;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE
3;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE
4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE
4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE
BETA BLOCKING AGENTS;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOMYOPATHY;CHILDREN
BETA BLOCKING AGENTS;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;OTHER;DILATED;CHILDREN
HYDROXYBUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*1XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*4XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ATOMOXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE
DOCETAXEL;SULT1C4;G;rs1402467;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;SULT1C4;G;rs1402467;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
ATOMOXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;DOSAGE;DECREASED;DOSE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE
ATOMOXETINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE
ATOMOXETINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE
ENDOXIFEN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ENDOXIFEN;CYP2D6;*17;CYP2D6*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ENDOXIFEN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*17/*17;CYP2C19*1;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE
AMITRIPTYLINE;CYP2C19;*17/*17;CYP2C19*17;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE
CLOMIPRAMINE;CYP2C19;*17/*17;CYP2C19*1;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE
CLOMIPRAMINE;CYP2C19;*17/*17;CYP2C19*17;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*2;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*3;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*5;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*6;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*6;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*7;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
BREXPIPRAZOLE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;EFFICACY;INCREASED;RESPONSE;OTHER;ANXIETY DISORDERS;PEOPLE
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;RESPONSE;OTHER;DEPRESSION;PEOPLE
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;DECREASED;DISCONTINUATION;SIDE EFFECT;RHEUMATOID ARTHRITIS;PEOPLE
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
TRAMADOL;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
TRAMADOL;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
FLUOROURACIL;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
SERTRALINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;PANIC DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;PANIC DISORDER;PEOPLE
ENDOXIFEN;CYP3A4;*22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
ENDOXIFEN;CYP3A4;*22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*29;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
LIRAGLUTIDE;GLP1R;TT;rs10305420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LIRAGLUTIDE;GLP1R;TT;rs10305420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
OXYCODONE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;
OXYCODONE;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;DECREASED;METABOLISM;;;
OXYCODONE;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;DECREASED;METABOLISM;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LUNG TRANSPLANTATION;PEOPLE
GLICLAZIDE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
BEVACIZUMAB;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
CYCLOPHOSPHAMIDE;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
NICOTINE;CYP2A6;*4/*4;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*4;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
N-DESMETHYLCLOZAPINE;CYP3A4;;LOW ACTIVITY;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;OTHER;INCREASED;DISCONTINUATION;;;
N-DESMETHYLCLOZAPINE;CYP1A2;;LOW ACTIVITY;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DISULFIRAM;ALDH2;;DEFICIENCY;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*46 + *46/*46;CYP2A6*1;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*46 + *46/*46;CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*20;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*23;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*24;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*25;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*26;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*27;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*28;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PITAVASTATIN;SLCO1B1;*15/*15 + *15/*37;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PITAVASTATIN;SLCO1B1;*15/*15 + *15/*37;SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;VKORC1;C;rs11150606;DOSAGE;DECREASED;DOSE;;;
PITAVASTATIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PITAVASTATIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*1;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*2;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*4;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*9;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*14;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*38;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*38;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*46;METABOLISM/PK;DECREASED;METABOLISM;;;
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
OXALIPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ALPRAZOLAM;CYP3A4;;LOW ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN
ALPRAZOLAM;CYP3A4;;LOW ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:ANXIETY DISORDERS;MEN
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
ENDOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*8;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOZAPINE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS;PEOPLE
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*7;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*9;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*18;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
THIOGUANINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1;OTHER;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*4;OTHER;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*7;OTHER;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;DOSAGE;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;EFFICACY;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE
WARFARIN;CYP2C9;*1/*13;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*13;CYP2C9*13;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN
ROSUVASTATIN;SLCO1B1;A;rs11045854;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE
VENLAFAXINE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;
ESCITALOPRAM;CYP2C19;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;
SOMATROPIN RECOMBINANT;COL1A1;AA;rs1800012;DOSAGE;DECREASED;DOSE;OTHER;GROWTH HORMONE DEFICIENCY;PEOPLE
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*17;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*20;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*23;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*35;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
NICOTINE;CYP2A6;*1/*46;CYP2A6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
NICOTINE;CYP2A6;*1/*46;CYP2A6*46;METABOLISM/PK;INCREASED;CLEARANCE;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*20;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*23;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*24;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*25;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*26;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*27;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*28;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*46;METABOLISM/PK;DECREASED;METABOLISM;;;
VITAMIN B-COMPLEX;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
INCL. COMBINATIONS;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ROSUVASTATIN;SLCO1B1;GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;
VITAMIN B-COMPLEX;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
INCL. COMBINATIONS;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ATOMOXETINE;SLC6A2;A;rs12708954;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
CYCLOSPORINE;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;SIDE EFFECT;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;SIDE EFFECT;KIDNEY TRANSPLANTATION;PEOPLE
ROSUVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
RIZATRIPTAN;DRD2;AA + AG;rs6275;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;VKORC1;G;rs61162043;DOSAGE;INCREASED;DOSE;;;
SULFONAMIDES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED;RESPONSE;;;
UREA DERIVATIVES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED;RESPONSE;;;
NICOTINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
RISPERIDONE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM;CHILDREN
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ROSUVASTATIN;FOXA3;T;rs16980091;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
ROSUVASTATIN;SLCO1B1;C;rs34671512;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
SIROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SIROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
WARFARIN;CYP2C9;*2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
CYSTEAMINE;CFTR;CTT/del + del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE
DEXTROPROPOXYPHENE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
DEXTROPROPOXYPHENE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
FELODIPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
FELODIPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
CODEINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANEMIA;PEOPLE
CODEINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SICKLE CELL;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*1;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*1;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*2;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*2;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*17;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*17;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;MEN
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;;;MEN
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;MEN
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;;;MEN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*1;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*1;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*2;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*2;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*17;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*17;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CAPECITABINE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CAPECITABINE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
FLUOROURACIL;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
FLUOROURACIL;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAXANES;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAXANES;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
BUPROPION;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DEPRESSION;PEOPLE
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DEPRESSION;PEOPLE
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DEPRESSION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SALVIANOLIC ACID B;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;OTHER;CORONARY DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MEPHENYTOIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*2A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*3A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*4A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*8;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;MYASTHENIA GRAVIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;MYASTHENIA GRAVIS;PEOPLE
MEPHENYTOIN;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MEPHENYTOIN;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*2A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*3A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*4A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;UGT1A6;*1a;UGT1A6*8;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN
WARFARIN;CYP2C9;*8/*8;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*8/*8;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A4;*18;CYP3A4*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*18;CYP3A4*18;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;DOSE;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;DOSE;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS
ENDOXIFEN;CYP2D6;;NORMAL METABOLIZER AND ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
IMIPRAMINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LOW BACK PAIN;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:OSTEOARTHRITIS;PEOPLE
RASAGILINE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;WOMEN
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;WOMEN
ISONIAZID;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;MEN
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;MEN
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;
CORTICOSTEROIDS;NR1I2;del/del;rs3842689;EFFICACY;INCREASED;RESISTANCE;;;CHILDREN
PEGINTERFERON ALFA-2B;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
MEPHENYTOIN;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;METABOLISM;;;
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
OMEPRAZOLE;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;METABOLISM;;;
IRBESARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*4;METABOLISM/PK;INCREASED;EXPOSURE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1;EFFICACY;INCREASED;RESPONSE;;;
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1;METABOLISM/PK;INCREASED;RESPONSE;;;
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*2;EFFICACY;INCREASED;RESPONSE;;;
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*2;METABOLISM/PK;INCREASED;RESPONSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METFORMIN;SLC22A1;del/del;rs72552763;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
MORPHINE;SLC22A1;GAT/del + del/del;rs72552763;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
IMATINIB;GSTT1;null/null;GSTT1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;GSTT1;null/null;GSTT1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;GSTT1;null/null;GSTT1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;GSTT1;null/null;GSTT1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
GLUCOCORTICOIDS;HSD3B1;AA + AC;rs1047303;EFFICACY;INCREASED;RESISTANCE;OTHER;ASTHMA;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
LANSOPRAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;;CONCENTRATIONS;;;
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;;CONCENTRATIONS;;;
MORPHINE;SLC22A1;del/del;rs72552763;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN
METHOTREXATE;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*5;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
NORTRIPTYLINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
SILDENAFIL;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEART FAILURE;PEOPLE
SILDENAFIL;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEART FAILURE;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28 + *1/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28 + *1/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
METHADONE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOSARTAN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METHOTREXATE;SLCO1B1;*14;SLCO1B1*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*14;SLCO1B1*14;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;*14;SLCO1B1*37;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;DOSE;;;CHILDREN
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*6 + *1/*6;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*6 + *1/*6;UGT1A1*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
ROSUVASTATIN;RXRA;A;rs1805343;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*3;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*9;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*10;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*17;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*41;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PACLITAXEL;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;WOMEN
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;;METABOLISM;;;CHILDREN
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;;METABOLISM;;;CHILDREN
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;;METABOLISM;;;CHILDREN
BUPROPION;CYP2B6;*4;CYP2B6*4;OTHER;INCREASED;CLEARANCE;;;HEALTHY
BUPROPION;CYP2B6;*4;CYP2B6*4;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
GLATIRAMER ACETATE;CCR5;del;rs333;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*13;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*16;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*60;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*8;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN
GLIPIZIDE;TCF7L2;T;rs7903146;EFFICACY;INCREASED;RESPONSE;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CAROTID ARTERY DISEASES;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CAROTID ARTERY DISEASES;PEOPLE
CLOPIDOGREL;SLC14A2;T;rs12456693;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
CISPLATIN;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN
FLUOROURACIL;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
CAVOSONSTAT;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
RISPERIDONE;CYP2D6;*10 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10 + *5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN
ZUCLOPENTHIXOL;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;DOSAGE;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*4XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TRAMADOL;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
VORICONAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6 + *28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6 + *28;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6 + *28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TELMISARTAN;UGT1A3;*3;UGT1A3*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
TELMISARTAN;UGT1A3;*3;UGT1A3*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;CHILDREN
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
HALOPERIDOL;CYP2D6;*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*8;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
MEASLES VACCINES;HLA-B;*51:01;HLA-B*51:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
BUCINDOLOL;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;DOSAGE;DECREASED;DOSE;DISEASE;PSYCHOTIC DISORDER;PEOPLE
MEASLES VACCINES;HLA-B;*07:02;HLA-B*07:02;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
MEASLES VACCINES;HLA-B;*13:01;HLA-B*13:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
MEASLES VACCINES;HLA-B;*08:01;HLA-B*08:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
ROSUVASTATIN;ABCB11;G;rs7579275;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN
INFLUENZA VACCINES;HLA-DQB1;*03:03;HLA-DQB1*03:03;EFFICACY;DECREASED;RESPONSE;;;
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
MEASLES VACCINES;HLA-DQA1;*02:01;HLA-DQA1*02:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
MEASLES VACCINES;HLA-DRB1;*03:01;HLA-DRB1*03:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*20;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A4;*1/*20;CYP3A4*20;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
FLUOROURACIL;DPYD;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:GASTROINTESTINAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:RECTAL NEOPLASMS;PEOPLE
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
CISPLATIN;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN
FLUOROURACIL;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;CHILDREN
ROSUVASTATIN;ABCB11;G;rs2287622;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;
SIROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TEMSIROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
GRANISETRON;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
GRANISETRON;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
CODEINE;CYP2D6;*40;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*40;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*40;CYP2D6*40;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*40;CYP2D6*40;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*17;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*17;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*17;CYP2D6*17;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*17;CYP2D6*17;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;OTHER;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;OTHER;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CODEINE;CYP2D6;*6;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*6;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*6;CYP2D6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*6;CYP2D6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CODEINE;CYP2D6;*5;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*5;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
CODEINE;CYP2D6;*5;CYP2D6*5;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN
CODEINE;CYP2D6;*5;CYP2D6*5;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN
GRANISETRON;CYP1A1;*2A;CYP1A1*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
GRANISETRON;CYP1A1;*2A;CYP1A1*2A;METABOLISM/PK;INCREASED;CLEARANCE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CLOMIPRAMINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
CLOMIPRAMINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;UGT1A1;*28;UGT1A1*28;TOXICITY;DECREASED;DISCONTINUATION;DISEASE;HYPERLIPIDEMIAS;PEOPLE
ROCURONIUM;SLCO1A2;CC;rs7967354;DOSAGE;DECREASED;DOSE;;;WOMEN
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ROSUVASTATIN;ABCC2;A;rs8187692;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
FENTANYL;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
FENTANYL;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*3;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*4;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*10;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
VORICONAZOLE;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;
VORICONAZOLE;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ROSUVASTATIN;SLC10A1;T;rs56903885;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
VITAMIN K1;CYP4F2;*1/*3 + *3/*3;CYP4F2*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
VITAMIN K1;CYP4F2;*1/*3 + *3/*3;CYP4F2*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUMETANIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TORASEMIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TROPISETRON;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TROPISETRON;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
MORPHINE;SLC22A1;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VARENICLINE;CYP2A6;;NORMAL METABOLIZER;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL;METABOLISM/PK;INCREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*1A;METABOLISM/PK;INCREASED;METABOLISM;;;WOMEN
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*2;METABOLISM/PK;INCREASED;METABOLISM;;;WOMEN
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*3;METABOLISM/PK;INCREASED;METABOLISM;;;WOMEN
PHENAZEPAM;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
PHENAZEPAM;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:ANXIETY DISORDERS;MEN
PHENAZEPAM;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
PHENAZEPAM;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:ANXIETY DISORDERS;MEN
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
ROSUVASTATIN;NR1I2;T;rs12721616;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
DIMETHYL FUMARATE;GSTP1;GG;rs1695;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CELECOXIB;CYP2C9;*3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CELECOXIB;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ROSUVASTATIN;SLCO1B1;C;rs11045874;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
CELECOXIB;CYP2C9;*3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CELECOXIB;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CELECOXIB;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;OTHER;INCREASED;DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;OTHER;INCREASED;DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;OTHER;INCREASED;DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
O-DESMETHYLTRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LOW BACK PAIN;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:OSTEOARTHRITIS;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*5;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*10;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
CLOPIDOGREL;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;
TAMOXIFEN;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*9;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*10;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*35;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*35XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;OTHER;INCREASED;RESISTANCE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;OTHER;INCREASED;RESISTANCE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CAPECITABINE;TYMP;AA + AG;rs11479;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;TYMP;AA + AG;rs11479;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PHENYTOIN;CYP2C19;*2 + *3;CYP2C19*2;DOSAGE;;DOSE;DISEASE;EPILEPSY;CHILDREN
PHENYTOIN;CYP2C19;*2 + *3;CYP2C19*3;DOSAGE;;DOSE;DISEASE;EPILEPSY;CHILDREN
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PHENYTOIN;CYP2C9;*3;CYP2C9*3;DOSAGE;;DOSE;DISEASE;EPILEPSY;CHILDREN
ANTIPSYCHOTICS;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
FOLIC ACID;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
HYDROXYCHLOROQUINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
SULFASALAZINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;
"""INTERFERON ALFA-2A";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE
TROPISETRON;CYP2D6;*1/*1xN;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE
TROPISETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE
CYCLOSPORINE;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
PRAVASTATIN;ACE;del/del;rs1799752;EFFICACY;;RESPONSE;OTHER;NON-HYPERCHOLESTEROLAEMIC PATIENTS SCHEDULED FOR ANGIOPLASTY;PEOPLE
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*3;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*4;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*6;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*9;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*9;CYP2B6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CT;rs3918290;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;
ROSUVASTATIN;SLCO1B1;A;rs12305884;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
4-HYDROXYTAMOXIFEN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
METOPROLOL;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
IMATINIB;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;AT;rs67376798;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CAPECITABINE;DPYD;CG;rs75017182;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CG;rs75017182;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
SIROLIMUS;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TEMSIROLIMUS;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
FLUVASTATIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLUVASTATIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*2XN;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ROSUVASTATIN;SLCO1B1;A;rs11045873;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE
TACROLIMUS;;G;rs4646458;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*2;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*3;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*5;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*10;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ROCURONIUM;IAPP, SLCO1A2;CC;rs11045995;DOSAGE;DECREASED;DOSE;;;WOMEN
MEASLES VACCINES;HLA-B;*44:02;HLA-B*44:02;EFFICACY;;RESPONSE;;;CHILDREN
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE
METOPROLOL;CYP2D6;del/del;rs5030655;EFFICACY;INCREASED;RESPONSE;;;
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;;RESPONSE;;;
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*1;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*2;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*3;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*1;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*2;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*3;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*5;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ESTRONE SULFATE;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;INCREASED;;OTHER;BREAST NEOPLASMS;WOMEN
ESTRONE SULFATE;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;INCREASED;;OTHER;BREAST NEOPLASMS;WOMEN
HMG-COA_REDUCTASE_INHIBITORS;CXCL5;CC;rs352046;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
PAROXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*36;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DEXTROMETHORPHAN;TCF20;C;rs5758651;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DEXTRORPHAN;TCF20;C;rs5758651;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*9;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
CYCLOSPORINE;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
CYCLOSPORINE;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;;DOSE;;;
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*8;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
METFORMIN;CSMD1;CT + TT;rs2954625;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ESTRONE;SLCO1B1;*5/*5;SLCO1B1*1;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ESTRONE;SLCO1B1;*5/*5;SLCO1B1*5;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
VORICONAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;;;CHILDREN
MERCAPTOPURINE;NT5C2;AA + AG;rs72846714;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
BUPROPION;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
BUPROPION;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
HALOPERIDOL;CYP2D6;*2/*2;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*2/*2;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
CYCLOSPORINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
CYCLOSPORINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
IRINOTECAN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
WARFARIN;CYP2C9;*1/*8 + *8/*8;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
WARFARIN;CYP2C9;*1/*8 + *8/*8;CYP2C9*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*29;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*35;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
SERTRALINE;CYP2C18;GG;rs11188059;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SIMVASTATIN;CYP2D6;*14;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SIMVASTATIN;CYP2D6;*14;CYP2D6*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*7;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*7;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*7;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE
NICOTINE;CYP2A6;;HIGH ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN
FENTANYL;CYP2D6;*29;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE
FENTANYL;CYP2D6;*29;CYP2D6*29;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*10X2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*35;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
LEVONORGESTREL;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ADALIMUMAB;;T;rs9828223;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE
DEXTROMETHORPHAN;IP6K2;AG;rs61740999;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DEXTRORPHAN;IP6K2;AG;rs61740999;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
DEBRISOQUINE;CYP2D6;*29/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*29/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;WOMEN
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;WOMEN
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;WOMEN
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
LEVONORGESTREL;CYP2B6;CT;rs4803419;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
ATORVASTATIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CODEINE;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE
METOPROLOL;CYP2D6;*29/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*29/*29;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;*29/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
OMEPRAZOLE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS
OMEPRAZOLE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS
OMEPRAZOLE;CYP2C19;*2;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS
ATENOLOL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;DISEASE;KIDNEY DISORDER;PEOPLE
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;DISEASE;KIDNEY DISORDER;PEOPLE
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
LOPINAVIR;CYP3A4;*22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
LOPINAVIR;CYP3A4;*22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;ABCB1;C;rs3842;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
CITALOPRAM;SERPINE1;G;rs2227631;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SERPINE1;G;rs2227631;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
ATENOLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROCHLOROTHIAZIDE;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TAMOXIFEN;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*1;CYP2C9*2;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*1;CYP2C9*3;DOSAGE;INCREASED;DOSE;;;
TAMOXIFEN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
MERCAPTOPURINE;CNNM2;CC + CT;rs58700372;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
OXYCODONE;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
OXYCODONE;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
MONTELUKAST;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
MONTELUKAST;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
PHENYTOIN;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
PHENYTOIN;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
FLUOROURACIL;TYMS;TTAAAGTTA/del;rs11280056;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*2;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*10;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
ROSUVASTATIN;ABCC2;C;rs17216177;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE
CILOSTAZOL;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
CILOSTAZOL;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
RASAGILINE;SLC22A1;CT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
TACROLIMUS;CYP3A7;*1A/*1A;CYP3A7*1A;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A7;*1A/*1A;CYP3A7*1C;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
KETAMINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
KETAMINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:PAIN;PEOPLE
KETAMINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
KETAMINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:PAIN;PEOPLE
DEBRISOQUINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ROSUVASTATIN;ABCC2;T;rs7899457;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ROSUVASTATIN;ABCC2;A;rs8187706;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
FLURBIPROFEN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
FLURBIPROFEN;CYP2C9;*1/*1;CYP2C9*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PITAVASTATIN;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ETHANOL;SLC6A3;del;rs28363170;OTHER;INCREASED;RESPONSE;;;HEALTHY
ETHANOL;DRD2;A;rs1800497;DOSAGE;INCREASED;DOSE;;;CHILDREN
VARDENAFIL;CYP3A5;TT;rs776746;OTHER;INCREASED;CLEARANCE;;;MEN
VARDENAFIL;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;MEN
SIPOGLITAZAR;UGT2B15;*2;UGT2B15*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
SIPOGLITAZAR;UGT2B15;*2;UGT2B15*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ETHANOL;SLC6A3;del;rs28363170;TOXICITY;INCREASED;EXPOSURE;;;HEALTHY
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED;DOSE;;;CHILDREN
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;INCREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1A;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*2A;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:ATRIAL FLUTTER;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:ATRIAL FLUTTER;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE
ACETAMINOPHEN;UGT1A6;*2a/*2a + *1a/*2a;UGT1A6*1A;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ACETAMINOPHEN;UGT1A6;*2a/*2a + *1a/*2a;UGT1A6*2A;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACETAMINOPHEN;UGT2B15;*2;UGT2B15*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ACETAMINOPHEN;UGT2B15;*2;UGT2B15*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
HALOPERIDOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
METHADONE;OPRK1;TT;rs3802281;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
AZATHIOPRINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;OTHER;ULCERATIVE COLITIS;CHILDREN
AZATHIOPRINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;OTHER;OTHER:CROHN DISEASE;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN
CITALOPRAM;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
CITALOPRAM;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
MIANSERIN;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
MIANSERIN;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
MIRTAZAPINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
MIRTAZAPINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
PAROXETINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
PAROXETINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;AUTOIMMUNE DISEASES;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;AUTOIMMUNE DISEASES;PEOPLE
HYDROXYUREA;SIN3A;GG;rs7166737;EFFICACY;DECREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799964;EFFICACY;INCREASED;RESPONSE;DISEASE;SPONDYLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799964;EFFICACY;INCREASED;RESPONSE;DISEASE;ANKYLOSING;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*6;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*6;CYP3A5*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
RALTITREXED;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*7;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*7;CYP3A5*7;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*1;CYP2C9*3;DOSAGE;INCREASED;DOSE;;;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;
PEGINTERFERON ALFA-2A;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
VENLAFAXINE;CYP2D6;;NORMAL METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;
RASAGILINE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
ESCITALOPRAM;CYP2C19;;NORMAL METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*5;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LYMPHOMA;CHILDREN
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;B-CELL;CHILDREN
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LYMPHOMA;CHILDREN
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;B-CELL;CHILDREN
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER;PEOPLE
RASAGILINE;ABCC2;AA;rs2273697;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
BUPROPION;HTR2A;CC;rs2770296;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
CAPECITABINE;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;POOR METABOLIZER;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN
DONEPEZIL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ALZHEIMER DISEASE;PEOPLE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
RISPERIDONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FLUOXETINE;ABCB1;A;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;CHILDREN
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
RABEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DIPYRONE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DIPYRONE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ULCERATIVE COLITIS;CHILDREN
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:CROHN DISEASE;CHILDREN
AZATHIOPRINE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ULCERATIVE COLITIS;CHILDREN
AZATHIOPRINE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:CROHN DISEASE;CHILDREN
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
COTININE;CYP2B6;*1/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
COTININE;CYP2B6;*1/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2B6;*1/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
NICOTINE;CYP2B6;*1/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
METHADONE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
BUPROPION;DBH;CC;rs2873804;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
LEUCOVORIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE
LEUCOVORIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;PEOPLE
PACLITAXEL;GSTM1;non-null;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
PACLITAXEL;GSTM1;non-null;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
PLATINUM COMPOUNDS;GSTM1;non-null;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
PLATINUM COMPOUNDS;GSTM1;non-null;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE
CITALOPRAM;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CITALOPRAM;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;MEN
LISINOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;MEN
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TRIMIPRAMINE;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;SLC18A2;CC;rs363225;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*4;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
RALTEGRAVIR;UGT1A9;*3a;UGT1A9*3A;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
FLUVOXAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHADONE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHADONE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
FLUVOXAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
SERTRALINE;CYP2C18;TT;rs2860840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
4-HYDROXYTAMOXIFEN;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;OTHER;RECTAL NEOPLASMS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;SPONDYLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;ANKYLOSING;PEOPLE
HYDROXYAMITRIPTYLINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
HYDROXYAMITRIPTYLINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ACETYLCYSTEINE;EPHX1;;POOR METABOLIZER;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;PEOPLE
BUPROPION;SLC18A2;GG;rs363226;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE
METHYLPHENIDATE;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4XN;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*29;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE
FLUOROURACIL;DPYD;;DEFICIENCY;METABOLISM/PK;;CLEARANCE;DISEASE;HEAD AND NECK NEOPLASMS;PEOPLE
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*29;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
BUPROPION;FKBP5;TT;rs17614642;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
INTERFERON BETA-1A;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;MEN
ETHANOL;OPRM1;AG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;MEN
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;ESOPHAGITIS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;ESOPHAGITIS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;ESOPHAGITIS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LOSARTAN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
LOSARTAN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
TACROLIMUS;CYP3A4;GG;rs35599367;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
THALIDOMIDE;CYP2C19;*2;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;ERYTHEMA NODOSUM;PEOPLE
THALIDOMIDE;CYP2C19;*2;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:LEPROSY;PEOPLE
THALIDOMIDE;CYP2C19;*2;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;ERYTHEMA NODOSUM;PEOPLE
THALIDOMIDE;CYP2C19;*2;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:LEPROSY;PEOPLE
CARVEDILOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANGINA PECTORIS;PEOPLE
EFAVIRENZ;CYP2B6;*1/*1;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
NICOTINE;CYP2A6;;LOW ACTIVITY;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
PACLITAXEL;SLCO1B1;*5 + *15;SLCO1B1*5;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;WOMEN
PACLITAXEL;SLCO1B1;*5 + *15;SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;WOMEN
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LAMOTRIGINE;UGT2B7;CC;rs7668258;DOSAGE;INCREASED;CLEARANCE;;;
LAMOTRIGINE;UGT2B7;CC;rs7668258;METABOLISM/PK;INCREASED;CLEARANCE;;;
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
BUPRENORPHINE;UGT2B7;*2;UGT2B7;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;DOSAGE;INCREASED;DOSE;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
IMATINIB;ABCB1;AG;rs1045642;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AG;rs1045642;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
BUPROPION;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*6;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ENDOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*13;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE
HYDROXYBUPROPION;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
HYDROXYBUPROPION;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*22;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*22;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TEZACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C19;*1/*1;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C19;*1/*1;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C19;*1/*1;CYP2C19*3;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*6;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ATOMOXETINE;CYP2D6;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
GEMCITABINE;CDA;A;rs60369023;OTHER;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
GEMCITABINE;CDA;A;rs60369023;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
APIXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
DABIGATRAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
EDOXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
RIVAROXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
ATAZANAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
IMATINIB;ABCB1;A;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;A;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
ANTIDEPRESSANTS;FKBP5;CC;rs1360780;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMATINIB;ABCB1;A;rs1128503;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;A;rs1128503;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ANTIDEPRESSANTS;GNB3;CC + CT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMATINIB;ABCB1;A;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;A;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
METHADONE;OPRK1;CC;rs963549;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;DECREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;PPARA;G;rs4823613;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
INFLIXIMAB;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;POR;T;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
ANTIDEPRESSANTS;BDNF;CT;rs6265;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
BETA BLOCKING AGENTS;ADRB1;G;rs1801253;EFFICACY;DECREASED;RESPONSE;DISEASE;TACHYCARDIA;PEOPLE
FLECAINIDE;ADRB1;G;rs1801253;EFFICACY;DECREASED;RESPONSE;DISEASE;TACHYCARDIA;PEOPLE
METHOTREXATE;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;NEUROMYELITIS OPTICA;PEOPLE
EFAVIRENZ;CYP2B6;*18;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*18;CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;CC;rs13273672;EFFICACY;DECREASED;CLINICAL BENEFIT;DISEASE;ALCOHOL ABUSE;PEOPLE
CHORIONIC GONADOTROPIN;FSHR;CC;rs6166;DOSAGE;INCREASED;DOSE;;;WOMEN
BEPRIDIL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE
TACROLIMUS;CYP3A4;GG;rs35599367;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
NICARDIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE
NIMODIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE
CITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1A;DOSAGE;DECREASED;DOSE;DISEASE;ADRENAL HYPERPLASIA;CHILDREN
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1A;DOSAGE;DECREASED;DOSE;DISEASE;CONGENITAL;CHILDREN
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1C;DOSAGE;DECREASED;DOSE;DISEASE;ADRENAL HYPERPLASIA;CHILDREN
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1C;DOSAGE;DECREASED;DOSE;DISEASE;CONGENITAL;CHILDREN
DAUNORUBICIN;G6PD;A-202A_376G;G6PD A- 202A_376G;METABOLISM/PK;DECREASED;METABOLISM;;;
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*7;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;OTHER;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
METFORMIN;HNF1B;AA + AG;rs11868513;EFFICACY;INCREASED;RESPONSE;;;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
GLATIRAMER ACETATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
CAFFEINE;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1;OTHER;DECREASED;METABOLISM;;;
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*2;OTHER;DECREASED;METABOLISM;;;
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*3;OTHER;DECREASED;METABOLISM;;;
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;
"""INTERFERON ALFA-2A";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERONS""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""PEGINTERFERON ALFA-2A""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""PEGINTERFERON ALFA-2B""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
FLUOXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
PAROXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;;;
THIOGUANOSINE DIPHOSPHATE;TPMT;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE MONOPHOSPHATE;TPMT;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE TRIPHOSPHATE;TPMT;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
VALPROIC ACID;CYP2A6;*4;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;CYP2A6;*4;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
TEGAFUR;CYP2A6;*4;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
TEGAFUR;CYP2A6;*4;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*7;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*1/*7;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
WARFARIN;CYP4F2;*3/*3;CYP4F2*1;DOSAGE;INCREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP4F2;*3/*3;CYP4F2*3;DOSAGE;INCREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP2C9;*2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;CYP2C8*1;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;CYP2C8*3;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1;OTHER;DECREASED;METABOLISM;;;
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*4;OTHER;DECREASED;METABOLISM;;;
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*9;OTHER;DECREASED;METABOLISM;;;
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE
TOCILIZUMAB;IL6R;CT + TT;rs4845625;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
ROSUVASTATIN;ABCC2;T;rs17216198;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
FLUVASTATIN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
FLUVASTATIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
SULFAPYRIDINE;NAT2;*7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
"""INTERFERON ALFA-2A";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERONS""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""PEGINTERFERON ALFA-2A""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""PEGINTERFERON ALFA-2B""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HUMAN LIVER MICROSOMES;
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HUMAN LIVER MICROSOMES;
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
IBUPROFEN;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*2;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOSARTAN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TROPISETRON;CYP2D6;*3/*3;CYP2D6*3;EFFICACY;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
METOPROLOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOSARTAN;CYP2C9;*1/*2;CYP2C9*1;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE
LOSARTAN;CYP2C9;*1/*2;CYP2C9*2;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE
LOSARTAN;CYP2C9;*1/*2;CYP2C9*3;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL ISCHEMIA;PEOPLE
OLMESARTAN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
OLMESARTAN;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*2;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METOPROLOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*37;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SIMVASTATIN;CYP3A4;*1/*4;CYP3A4*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
SIMVASTATIN;CYP3A4;*1/*4;CYP3A4*4;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
LOSARTAN;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOSARTAN;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;;;WOMEN
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;;;WOMEN
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;;;WOMEN
NATEGLINIDE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NATEGLINIDE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
RISPERIDONE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
CARVEDILOL;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
CARVEDILOL;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
ROSUVASTATIN;ABCC2;T;rs3740066;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*4;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*5;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*6;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
CARVEDILOL;CYP2D6;*1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
CARVEDILOL;CYP2D6;*1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ZUCLOPENTHIXOL;CYP2D6;*3;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;*3;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
FLUOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;RESPONSE;EFFICACY;ALCOHOL ABUSE;MEN
FLUOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;RESPONSE;EFFICACY;EFFICACY:MAJOR DEPRESSIVE DISORDER;MEN
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
METFORMIN;;CG;rs6719578;EFFICACY;INCREASED;RESPONSE;;;
RISPERIDONE;CYP2D6;*10;CYP2D6*1;EFFICACY;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10;CYP2D6*10;EFFICACY;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MEPHENYTOIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MEPHENYTOIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
HALOPERIDOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRAMADOL;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
LANSOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
DEXLANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXLANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BENZBROMARONE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
BENZBROMARONE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
LABETALOL;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LABETALOL;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CELECOXIB;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CELECOXIB;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
BUPROPION;CYP2B6;*1/*22;CYP2B6*1;METABOLISM/PK;INCREASED;METABOLISM;;;
BUPROPION;CYP2B6;*1/*22;CYP2B6*22;METABOLISM/PK;INCREASED;METABOLISM;;;
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;DOSAGE;DECREASED;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;DOSAGE;DECREASED;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*17;DOSAGE;DECREASED;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*17;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;WOMEN
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;WOMEN
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;MEN
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;TOXICITY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;TOXICITY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;TOXICITY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PEGINTERFERON ALFA-2A;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;CYP2B6;CA/CA;rs70950385;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ASPIRIN;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
ASPIRIN;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
MEPHENYTOIN;CYP2C19;G;rs28399504;METABOLISM/PK;DECREASED;METABOLISM;;;
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
LAMIVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
STAVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*60;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*60;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
DOXEPIN;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DOXEPIN;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
BOCEPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ANEMIA;PEOPLE
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ANEMIA;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
TICAGRELOR;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;DISEASE:STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;DISEASE:STROKE;PEOPLE
EFAVIRENZ;CYP2B6;*11;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
EFAVIRENZ;CYP2B6;*11;CYP2B6*11;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;BIPOLAR DISORDER;PEOPLE
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;BIPOLAR DISORDER;PEOPLE
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;BIPOLAR DISORDER;PEOPLE
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
WARFARIN;POR;CT + TT;rs41301394;DOSAGE;INCREASED;DOSE;;;
METHADONE;DRD2;AA + AG;rs6275;;INCREASED;DOSE;OTHER;TREATMENT FOR HEROIN ADDICTION;PEOPLE
CARBOPLATIN;GSTP1;G;rs1695;TOXICITY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;PEOPLE
PACLITAXEL;GSTP1;G;rs1695;TOXICITY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;PEOPLE
VORICONAZOLE;CYP2C19;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*18;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CISPLATIN;MIR335;AA + AG;rs3807348;EFFICACY;INCREASED;RESPONSE;OTHER;MESOTHELIOMA;PEOPLE
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CELECOXIB;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CYCLOPHOSPHAMIDE;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOXORUBICIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
BUPRENORPHINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
BUPRENORPHINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;VKORC1;;LOW ACTIVITY;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
NIMODIPINE;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;INCREASED;EXPOSURE;;;HEALTHY
NIMODIPINE;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;INCREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CARBAMAZEPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;POSTOPERATIVE;PEOPLE
MIDAZOLAM;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
MIDAZOLAM;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A5;*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A5;*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FENTANYL;CYP2D6;*9;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE
FENTANYL;CYP2D6;*9;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIMVASTATIN;F3;CT;rs3917643;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL ISCHEMIA;PEOPLE
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ACETYLCHOLINE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
NITROPRUSSIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE
BEVACIZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CISPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
DOCETAXEL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
EPIRUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
TRASTUZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
FENTANYL;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
MEPERIDINE;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
MIDAZOLAM;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
FENTANYL;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
MEPERIDINE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
MIDAZOLAM;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
FENTANYL;UGT1A1;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
MEPERIDINE;UGT1A1;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
MIDAZOLAM;UGT1A1;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE
TACROLIMUS;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*1;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*3;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*4;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*9;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*10;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*41;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
IMATINIB;CYP3A4;C;rs2242480;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A4;C;rs2242480;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
FULVESTRANT;CYP2C9;;CYP2C9 POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
FULVESTRANT;CYP2C9;;CYP2C9 POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE
ANASTROZOLE;CYP2C9;;CYP2C9 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
ANASTROZOLE;CYP2C9;;CYP2C9 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;CHILDREN
ABATACEPT;HLA-DRB1;*04:05;HLA-DRB1*04:05;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ESOMEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;;RAPID METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ETANERCEPT;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
APATINIB;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
APATINIB;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
ESCITALOPRAM;CYP2C19;;CYP2C19 RAPID METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;;CHILDREN
ESCITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
SERTRALINE;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
DULOXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
AMOXICILLIN;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE
CLARITHROMYCIN;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE
CLARITHROMYCIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE
METOPROLOL;CYP2D6;A;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
BUPROPION;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;OTHER;OBESITY;PEOPLE
NALTREXONE;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;OTHER;OBESITY;PEOPLE
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs1065852;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TOLPERISONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TOLPERISONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TOLPERISONE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEART TRANSPLANTATION;PEOPLE
DAPOXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DAPOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
RISPERIDONE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;AUTISM SPECTRUM DISORDER;CHILDREN
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DOCETAXEL;PPARD;G;rs6922548;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;PPARD;G;rs6922548;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;RECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;RECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;INCREASED;TIME RESPONSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;PAIN;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;POSTOPERATIVE;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:CONSTIPATION;PEOPLE
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:CONSTIPATION;PEOPLE
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*65;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
DOCETAXEL;PPARD;G;rs7769719;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;PPARD;G;rs7769719;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;NEDD4;G;rs2288344;DOSAGE;INCREASED;DOSE;;;
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BIPOLAR DISORDER;PEOPLE
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BIPOLAR DISORDER;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;DDHD1;G;rs17126068;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE
PRIMAQUINE 5;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
6-ORTHOQUINONE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PRIMAQUINE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DESVENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;VKORC1;T;rs9923231;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SALBUTAMOL;;T;rs7903366;EFFICACY;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN
PALIPERIDONE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
RISPERIDONE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
LOSARTAN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;PK;NO DISEASE;PEOPLE
SULFAPYRIDINE;NAT2;*5/*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:DEPRESSION;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS;PEOPLE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*16;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE
SALBUTAMOL;;A;rs7081864;EFFICACY;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN
SULFINPYRAZONE;UGT1A9;T;rs72551330;METABOLISM/PK;INCREASED;METABOLISM;;;
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AA;rs1051792;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SPONDYLARTHROPATHIES;PEOPLE
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*4;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*9;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
SULFAPYRIDINE;NAT2;*5;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SULFAPYRIDINE;NAT2;*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
3;CYP2C19;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
LITHIUM;GSK3B;GG;rs6438552;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
LITHIUM;NR1D1, THRA;TT;rs2071427;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
TACROLIMUS;CYP3A5;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MORPHINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;INFANTS
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
SULFAPYRIDINE;NAT2;*5/*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE
ATOMOXETINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SULFAPYRIDINE;NAT2;*6;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SULFAPYRIDINE;NAT2;*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6J;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7G;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*39;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED;DISCONTINUATION;EFFICACY;CROHN DISEASE;PEOPLE
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SULFAPYRIDINE;NAT2;*6/*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ENZYME INHIBITORS;CYP19A1;CC;rs700518;OTHER;;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TACROLIMUS;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CORTICOSTEROIDS;FCER2;G;rs28364072;DOSAGE;INCREASED;DOSE;DISEASE;ASTHMA;CHILDREN
TACROLIMUS;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
HYDROCHLOROTHIAZIDE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
OLMESARTAN;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN
HALOPERIDOL;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE
ESCITALOPRAM;;G;rs12154537;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
MORPHINE;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ISONIAZID;NAT2;*4/*4;NAT2*4;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*6;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*6;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*7;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*7;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*14;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*14;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*16;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*16;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*19;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*4/*4;NAT2*19;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
DOCETAXEL;SLCO1B3;G;rs11045585;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
SULFAPYRIDINE;NAT2;*5/*7;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SULFAPYRIDINE;NAT2;*5/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
DOCETAXEL;SLCO1B3;A;rs7311358;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
DOCETAXEL;SLCO1B3;G;rs4149118;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6J;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7G;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN
SULFAPYRIDINE;NAT2;*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SULFAPYRIDINE;NAT2;*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;A;rs9934438;METABOLISM/PK;DECREASED;DOSE;;;
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
MIDAZOLAM;VDR;C;rs1544410;METABOLISM/PK;INCREASED;CLEARANCE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;GG;rs1154831;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SPONDYLARTHROPATHIES;PEOPLE
DIAZEPAM;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ESCITALOPRAM;CYP2C19;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;DEPRESSION;CHILDREN
ESCITALOPRAM;CYP2C19;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:ANXIETY DISORDERS;CHILDREN
METHADONE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;OTHER;HEROIN DEPENDENCE;PEOPLE
FLUOXETINE;CYP2D6;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;MAJOR DEPRESSIVE DISORDER;CHILDREN
FLUOXETINE;CYP2D6;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EFFICACY:OBSESSIVE-COMPULSIVE DISORDER;CHILDREN
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*6;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*7;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*14;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*16;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
SULFAPYRIDINE;NAT2;*5/*6;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
SULFAPYRIDINE;NAT2;*5/*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*14;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
CODEINE;CYP2D6;*1xN/*41;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*41;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*41;CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;T;rs7294;METABOLISM/PK;INCREASED;DOSE;;;
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;SUBSTANCE-RELATED DISORDERS;PEOPLE
MARAVIROC;CYP3A5;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;DECREASED;RESPONSE;;;
CODEINE;CYP2D6;*1/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1/*2xN;CYP2D6*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ENDOXIFEN;CYP2D6;;POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CODEINE;CYP2D6;*2xN/*41;CYP2D6*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*2xN/*41;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*2xN/*41;CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*10;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*10;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*10;CYP2D6*10;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ENDOXIFEN;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NORTRIPTYLINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
HALOPERIDOL;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
PERPHENAZINE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
QUETIAPINE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
MARAVIROC;CYP3A5;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;DOSAGE;INCREASED;TIME RESPONSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;INCREASED;TIME RESPONSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
NORTRIPTYLINE;CYP2D6;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
HYDROCODONE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IMIPRAMINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ATOMOXETINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TAMOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;DOSE;DISEASE;BREAST NEOPLASMS;WOMEN
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*36;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*2;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*36;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
TOLTERODINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
VENLAFAXINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2;DOSAGE;INCREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2XN;DOSAGE;INCREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
DESIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DESIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;AA + AC;rs890293;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN
VENLAFAXINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;
PERPHENAZINE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*2;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*3;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE
VORTIOXETINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;DISCONTINUATION;;;
VORTIOXETINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;DISCONTINUATION;;;
FENTANYL;;;METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PAIN;PEOPLE
ESCITALOPRAM;CYP2C19;;ULTRARAPID METABOLIZER PHENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
WARFARIN;CYP2C9;*1/*1;CYP2C9*2;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
WARFARIN;CYP2C9;*1/*1;CYP2C9*3;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
WARFARIN;CYP2C9;*1/*1;CYP2C9*8;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
NORTRIPTYLINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*14;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ESCITALOPRAM;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ETHANOL;OPRM1;G;rs2075572;EFFICACY;INCREASED;RESPONSE;;;
PROTON PUMP INHIBITORS;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;PEOPLE
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
METOPROLOL;CYP2D6;;POOR METABOLIZErs;DOSAGE;DECREASED;DOSE;;;
ETHANOL;OPRM1;T;rs548646;EFFICACY;INCREASED;RESPONSE;;;
GLICLAZIDE;KCNQ1;T;rs2237892;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLICLAZIDE;KCNQ1;T;rs2237892;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
NICOTINE;DRD2;G/del + del/del;rs1799732;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
PAROXETINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DESIPRAMINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LINAGLIPTIN;TCF7L2;CC + CT;rs7903146;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LINAGLIPTIN;TCF7L2;CC + CT;rs7903146;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
CITALOPRAM;CYP2C19;;POOR METABOLIZER PHENOTYPE;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;;POOR METABOLIZER PHENOTYPE;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ETHANOL;OPRM1;T;rs681243;EFFICACY;INCREASED;RESPONSE;;;
DEXTROMETHORPHAN;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
HYDROXYBUPROPION;CYP2B6;;CYP2B6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
TRAMADOL;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
AMOXICILLIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTRITIS;PEOPLE
CLARITHROMYCIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTRITIS;PEOPLE
ESOMEPRAZOLE;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTRITIS;PEOPLE
DABIGATRAN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ESCITALOPRAM;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;
VENLAFAXINE;CYP2D6;;POOR METABOLIZErs;EFFICACY;DECREASED;RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER;PEOPLE
BUPROPION;COMT;AG + GG;rs4680;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ARIPIPRAZOLE;CYP2D6;;INTERMEDIATE METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
FENTANYL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
FENTANYL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
HYDROCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
HYDROCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
HYDROMORPHONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
HYDROMORPHONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
METHADONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
METHADONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
MORPHINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
MORPHINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
VENLAFAXINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ETHANOL;OPRM1;A;rs1461773;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ETHANOL;OPRM1;T;rs3778148;EFFICACY;INCREASED;RESPONSE;;;
AMOXICILLIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE
CLARITHROMYCIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE
AMOXICILLIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE
CLARITHROMYCIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE
MIDAZOLAM;VDR;T;rs4516035;METABOLISM/PK;INCREASED;CLEARANCE;;;
CODEINE;CYP2D6;*1xN/*1;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*1;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*1;CYP2D6*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*1;CYP2D6*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CODEINE;CYP2D6;*1xN/*1;CYP2D6*6;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
OXYCODONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
OXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
OXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
NOROXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
AMITRIPTYLINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;RESPONSE;OTHER;PHANTOM LIMB SYNDROME;PEOPLE
NOROXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
TRAMADOL;CYP2D6;;POOR METABOLIZER PHENOTYPE;EFFICACY;INCREASED;RESPONSE;OTHER;PHANTOM LIMB SYNDROME;PEOPLE
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
NOROXYCODONE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
MORPHINE;COMT;A;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;LOW BACK PAIN;PEOPLE
VORICONAZOLE;CYP2C19;;POOR METABOLIZErs;EFFICACY;INCREASED;RESPONSE;;;
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
VENLAFAXINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
ATENOLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE
METOPROLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TAMSULOSIN;CYP2D6;;POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
GLICLAZIDE;KCNQ1;C;rs2237895;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLICLAZIDE;KCNQ1;C;rs2237895;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
WARFARIN;CYP2C9;;NORMAL METABOLIZErs;DOSAGE;INCREASED;DOSE;;;
SOLANIDINE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;OTHER;DEPRESSION;PEOPLE
FLECAINIDE;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;;CONCENTRATIONS;DISEASE;TACHYCARDIA;PEOPLE
FLECAINIDE;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;;CONCENTRATIONS;DISEASE;SUPRAVENTRICULAR;PEOPLE
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
PRIDOPIDINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TRAMADOL;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BUPROPION;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PREGNANCY;WOMEN
BUPROPION;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PREGNANCY;WOMEN
BUPROPION;CYP2C19;*2 + *3;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PREGNANCY;WOMEN
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
METHADONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;TOXICITY;INCREASED;METABOLISM;;;
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;METABOLISM/PK;INCREASED;METABOLISM;;;
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
CODEINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE
(S)-METHADONE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
METHOTREXATE;FOXP3;G;rs3761548;OTHER;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ATENOLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE
METOPROLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE
4-HYDROXYTAMOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
GEMCITABINE;NT5C2;TT;rs11598702;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEMCITABINE;CDA;TT;rs1048977;METABOLISM/PK;DECREASED;METABOLISM;;;
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*2;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*4;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*5;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*6;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*9;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*17;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*41;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;GG + GT;rs7202877;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;GG + GT;rs7202877;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
LANSOPRAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;PEOPLE
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
OLANZAPINE;CYP2C9;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;TOXICITY;INCREASED;METABOLISM;;;
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;METABOLISM/PK;INCREASED;METABOLISM;;;
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs2239179;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs1540339;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
ENDOXIFEN;CYP2C9;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;DOSAGE;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
CARISOPRODOL;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CARISOPRODOL;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LANSOPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
GEMIGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GEMIGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
LINAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LINAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
SAXAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
SAXAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
SITAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
VILDAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
VILDAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*6;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
GLICLAZIDE;CYP2C9;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
NORQUETIAPINE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;EXPOSURE;;;
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
TROPISETRON;CYP2D6;*1/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
TROPISETRON;CYP2D6;*1/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;
INDOMETHACIN;CYP2C9;G;rs2153628;EFFICACY;INCREASED;RESPONSE;;;
GEMCITABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TACROLIMUS;CYP3A5;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
VENLAFAXINE;SLC6A4;TT;rs25531;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;ANXIETY DISORDERS;PEOPLE
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
NIMODIPINE;CACNA1C;CC;rs2239128;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
ENDOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
NIMODIPINE;CACNA1C;CG;rs2239050;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRAMADOL;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MARAVIROC;CYP3A5;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
VENLAFAXINE;GABRQ;AA + AT;rs3810651;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METOPROLOL;CYP2D6;;NORMAL METABOLIZErs;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PREGNANCY;WOMEN
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
FENTANYL;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
HYDROMORPHONE;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
OPIOIDS;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
OXYCODONE;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
2-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
2-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
4-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
4-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
CLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
IBOGAINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
ATORVASTATIN;CYP3A4;*2 + *22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;CYP3A4;*2 + *22;CYP3A4*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;CYP3A4;*2 + *22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
AMPHETAMINE;CYP2D6;;POOR METABOLIZER;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
LISDEXAMFETAMINE;CYP2D6;;POOR METABOLIZER;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;CC;rs502434;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;GRIA3;CC;rs502434;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NICOTINE;CYP2A6;*41;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*41;CYP2A6*41;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*39;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*39;CYP2A6*39;METABOLISM/PK;DECREASED;METABOLISM;;;
ISONIAZID;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:INFLAMMATION;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE;;DOSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;;DOSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*87;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*95;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*97;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
VORICONAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
1-HYDROXYMIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
1-HYDROXYMIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;TT;rs3761554;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;GRIA3;TT;rs3761554;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;
ISONIAZID;NAT2;;NAT2 INTERMEDIATE ACETYLATOR;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;TUBERCULOSIS;PEOPLE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*18;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*18;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE
TACROLIMUS;ABCC2;TT;rs3740066;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
LEVONORGESTREL;CYP2B6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;WOMEN
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;TT;rs3761555;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;GRIA3;TT;rs3761555;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;NKX2-6;AG + GG;rs310279;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
VENLAFAXINE;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;ANXIETY DISORDERS;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;PEOPLE
ANTIEPILEPTICS;;CC + CT;rs16935279;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BIPOLAR DISORDER;PEOPLE
ANTIEPILEPTICS;;CC + CT;rs16935279;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
FOLLITROPIN BETA;FSHR;CC + CT;rs6166;DOSAGE;INCREASED;DOSE;;;WOMEN
UROFOLLITROPIN;FSHR;CC + CT;rs6166;DOSAGE;INCREASED;DOSE;;;WOMEN
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;OTHER:PANIC DISORDER;PEOPLE
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*2;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*4;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*8;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*11;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
CISPLATIN;UBE2I;CG;rs9597;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
IRINOTECAN;UBE2I;CG;rs9597;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;FRAS1;AA + AG;rs4386623;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE
WARFARIN;FAM201A;AG + GG;rs1890109;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
VALPROIC ACID;SCN1A;T;rs3812718;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE
RISPERIDONE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
RISPERIDONE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL CANCER;PEOPLE
NICOTINE;DRD2;A;rs6277;EFFICACY;INCREASED;RESPONSE;;;MEN
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;DISEASE;DIABETES MELLITUS;PEOPLE
APIXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
DABIGATRAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
EDOXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
RIVAROXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ETHANOL;OPRM1;A;rs648007;EFFICACY;INCREASED;RESPONSE;;;
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
NICOTINE;CHRNA7;CC;rs2337980;EFFICACY;INCREASED;RESPONSE;;;WOMEN
BUPROPION;DRD2;GG;rs1799732;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;;CONCENTRATIONS;;;
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;;CONCENTRATIONS;;;
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PSYCHOTIC DISORDER;PEOPLE
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PSYCHOTIC DISORDER;PEOPLE
WARFARIN;EPHX1;A;rs1131873;DOSAGE;DECREASED;DOSE;;;
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
METFORMIN;SLC2A2;C;rs8192675;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;CONNECTIVE TISSUE DISEASES;PEOPLE
WARFARIN;CYP2C9;T;rs28371685;DOSAGE;DECREASED;DOSE;;;
DULOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
DULOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:DEPRESSIVE DISORDER;MEN
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
WARFARIN;CYP2C9;del;rs9332131;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
HYDROXYUREA;BCL11A;A;rs4671393;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;DOSE;;;
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
BETA BLOCKING AGENTS;KL;A/del + del/del;rs36217263;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
FLUOXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
BUPROPION;ACE;TT;rs8075924;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
LORAZEPAM;UGT2B7;A;rs7438284;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
VALPROIC ACID;UGT2B7;A;rs7438284;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
LORAZEPAM;UGT2B7;T;rs7439366;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
VALPROIC ACID;UGT2B7;T;rs7439366;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SUNITINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
SUNITINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;;
HYDROXYCHLOROQUINE;CYP3A4;CC;rs3735451;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
HYDROXYCHLOROQUINE;CYP3A4;CC;rs3735451;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;DEPRESSION;PEOPLE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
GEMCITABINE;RRM1;CT;rs11030918;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ROSUVASTATIN;HNF4A;C;rs3212207;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;;INTERMEDIATE METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;
ROSUVASTATIN;ABCC2;A;rs8187710;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
CYCLOSPORINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;MEN
CYCLOSPORINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;MEN
CYCLOSPORINE;CYP3A4;A;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ANXIETY DISORDERS;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ANXIETY DISORDERS;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ANXIETY DISORDERS;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:DEPRESSION;PEOPLE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
CODEINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CHRONIC KIDNEY FAILURE;PEOPLE
CODEINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CHRONIC KIDNEY FAILURE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DOCETAXEL;PPARD;T;rs3734254;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;PPARD;T;rs3734254;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
ATENOLOL;OR10P1;G;rs17117817;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
METOPROLOL;OR10P1;G;rs17117817;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1X2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
CARBOPLATIN;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
FAMOTIDINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:01;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:04;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:05;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:10;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*10:01;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHADONE;;AG + GG;rs17180299;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*9;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ATENOLOL;SNX9;A;rs2364349;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
METOPROLOL;SNX9;A;rs2364349;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
TACROLIMUS;;GT + TT;rs11265572;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
WARFARIN;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;
SIROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TEMSIROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
PERAMPANEL;CYP3A5;*3/*3;CYP3A5*1;;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
PERAMPANEL;CYP3A5;*3/*3;CYP3A5*3;;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
URACIL;DPYD;c.295_298delTCAT (*7);DPYD C.295_298DELTCAT (*7);METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.295_298delTCAT (*7);DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.2846A>T;DPYD C.2846A>T;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.2846A>T;DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.1679T>G (*13);DPYD C.1679T>G (*13);METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.1679T>G (*13);DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.1905+1G>A (*2A);DPYD C.1905+1G>A (*2A);METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
URACIL;DPYD;c.1905+1G>A (*2A);DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1XN;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2XN;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ESCITALOPRAM;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ESCITALOPRAM;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
EFAVIRENZ;ABCB1;CC;rs3842;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
EFAVIRENZ;CYP2B6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;INFANTS
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*03:01;HLA-A*03:01;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*03:01;HLA-A*03:01;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*23:17;HLA-A*23:17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*23:17;HLA-A*23:17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;*57:03;HLA-B*57:03;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;*57:03;HLA-B*57:03;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*7;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*35;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;
ANTIDEPRESSANTS;CYP2C19;;POOR METABOLIZER;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHADONE;CYP2B6;*6 + *18;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*6 + *18;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;*6 + *18;CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
LAMOTRIGINE;UGT1A4;*3b;UGT1A4*3B;EFFICACY;DECREASED;CLINICAL BENEFIT;;;
DOCETAXEL;PPARD;C;rs2016520;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;PPARD;C;rs2016520;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;CHILDREN
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*4;EFFICACY;DECREASED;RESPONSE;;;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;
DOCETAXEL;CHST3;A;rs1871450;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;A;rs1871450;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
PROPOFOL;CYP2B6;*6;CYP2B6*1;TOXICITY;DECREASED;RESPONSE;OTHER;BRAIN INJURY;PEOPLE
PROPOFOL;CYP2B6;*6;CYP2B6*6;TOXICITY;DECREASED;RESPONSE;OTHER;BRAIN INJURY;PEOPLE
TILDRAKIZUMAB;PDE4D;CT/CT;rs10556657;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
BUPRENORPHINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
DIHYDROCODEINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
HYDROMORPHONE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
METHADONE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
MORPHINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
OXYCODONE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
PIRITRAMIDE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
TILIDINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
TRAMADOL;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DOCETAXEL;PPARD;C;rs1883322;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;PPARD;C;rs1883322;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
PHENYTOIN;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
VALPROIC ACID;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
CARBAMAZEPINE;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
VALPROIC ACID;CYP2C9;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
VALPROIC ACID;UGT1A6;*2a;UGT1A6*1A;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
VALPROIC ACID;UGT1A6;*2a;UGT1A6*2A;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
PHENYTOIN;CYP2C9;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE
DOCETAXEL;CHST3;A;rs12418;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;A;rs12418;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*1;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*28;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*60;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*1;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*28;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*60;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE
MIRABEGRON;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PEPTIC ULCER DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:ESOPHAGITIS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PEPTIC ULCER DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:ESOPHAGITIS;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PEPTIC ULCER DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:GASTROESOPHAGEAL REFLUX;PEOPLE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:ESOPHAGITIS;PEOPLE
MERCAPTOPURINE;TPMT;*1/*8;TPMT*1;METABOLISM/PK;DECREASED;METABOLISM;;;
MERCAPTOPURINE;TPMT;*1/*8;TPMT*8;METABOLISM/PK;DECREASED;METABOLISM;;;
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1X2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;CAESARIAN SECTION;WOMEN
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;WOMEN
DULOXETINE;DRD3;GG;rs963468;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;TYPE 2;PEOPLE
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;;
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;;;
EFAVIRENZ;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*17;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS;CHILDREN
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*17;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
DEHYDROARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
PIMOZIDE;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE
PIMOZIDE;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE
DOCETAXEL;CHST3;C;rs4148943;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;C;rs4148943;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
DOCETAXEL;CHST3;C;rs4148945;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;C;rs4148945;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
GLYBURIDE;ABCB11;G;rs4148776;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
IMATINIB;SLCO1B3;AA + AG;rs7311358;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLCO1B3;AA + AG;rs7311358;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;SLCO1B3;GG + GT;rs4149117;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLCO1B3;GG + GT;rs4149117;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1X2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1X2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
FESOTERODINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN
GLYBURIDE;CHST13;C;rs1054097;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
LACOSAMIDE;CYP2C19;;NORMAL METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;EPILEPSY;CHILDREN
FESOTERODINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ROSIGLITAZONE;CYP2C8;C;rs10509681;DOSAGE;INCREASED;METABOLISM;;;HEALTHY
ROSIGLITAZONE;CYP2C8;C;rs10509681;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
LACOSAMIDE;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;EPILEPSY;CHILDREN
FESOTERODINE;CYP3A4;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SURGERY;PEOPLE
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SURGERY;PEOPLE
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SURGERY;PEOPLE
CLOZAPINE;CYP2D6;;NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP2D6;;NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
EFAVIRENZ;CYP2B6;;CYP2B6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;CHILDREN
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE
METOPROLOL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOZAPINE;ITIH3;AA;rs2535629;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ATOMOXETINE;CYP2D6;;POOR METABOLIZER;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
COTININE;CYP2A6;;LOW ACTIVITY;METABOLISM/PK;INCREASED;METABOLISM;OTHER;TOBACCO USE DISORDER;PEOPLE
COTININE;CYP2A6;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*20;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*23;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*24;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*25;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*26;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*27;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*28;METABOLISM/PK;DECREASED;METABOLISM;;;
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ENDOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE
CAFFEINE;ADORA1;CC;rs10920573;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;APNEA OF PREMATURITY;INFANTS
NORQUETIAPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
NORQUETIAPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
AMLODIPINE;CACNA1D;GG;rs312481;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
PEGINTERFERON ALFA-2A;ZHX2;C;rs17289471;EFFICACY;INCREASED;RESPONSE;OTHER;HEPATITIS B VIRUS INFECTION;PEOPLE
BERBERINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;T;rs12248560;OTHER;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
RANIBIZUMAB;VEGFA;CC + CT;rs833069;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs4646449;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ONDANSETRON;CYP2D6;;POOR METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;PEOPLE
IMATINIB;ABCA3;GG + GT;rs150929;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCA3;GG + GT;rs150929;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
METFORMIN;CBARP, STK11;TT;rs2301759;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;CBARP, STK11;TT;rs2301759;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
METFORMIN;SLC22A3;T;rs3127602;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A3;T;rs3127602;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
METFORMIN;PRKAA1;A;rs11749180;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;PRKAA1;A;rs11749180;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
METFORMIN;SLC29A4;A;rs10234709;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC29A4;A;rs10234709;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
METFORMIN;PRKAG2;T;rs4725434;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;PRKAG2;T;rs4725434;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
METFORMIN;SLC47A1;A;rs2120274;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A1;A;rs2120274;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
METFORMIN;STK11;C;rs2301759;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;STK11;C;rs2301759;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
METFORMIN;SLC47A2;C;rs4621031;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A2;C;rs4621031;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
ALECTINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ALECTINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
METFORMIN;TCF7L2;T;rs7903146;EFFICACY;INCREASED;RESPONSE;;;
METHADONE;OPRK1;CC;rs3802279;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
N-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*29;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*45;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*29;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*45;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;IMMUNOGLOBULIN A VASCULITIS;CHILDREN
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;IMMUNOGLOBULIN A VASCULITIS;CHILDREN
TOCILIZUMAB;IL6R;AG + GG;rs35717427;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
N-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
TOCILIZUMAB;IL6R;CG + GG;rs6690230;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TOCILIZUMAB;IL6R;AA + AG;rs11265621;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TOCILIZUMAB;;AA;rs10108210;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TOCILIZUMAB;CLEC2D;GG;rs1560011;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TOCILIZUMAB;KCNMB1;AA + AG;rs703505;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT;PEOPLE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
MORPHINE;CCL11;AA;rs17809012;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;NEOPLASMS;PEOPLE
MORPHINE;CCL11;AA;rs17809012;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:PAIN;PEOPLE
MORPHINE;IL16;TT;rs4778889;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;NEOPLASMS;PEOPLE
MORPHINE;IL16;TT;rs4778889;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PAIN;PEOPLE
N-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
VALPROIC ACID;SLC16A1;GG;rs7169;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
N-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
N-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
TENOFOVIR;ABCC4;AC + CC;rs3742106;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ANTIDEPRESSANTS;FKBP5;CT + TT;rs1360780;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PATENT DUCTUS ARTERIOSUS;INFANTS
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PREMATURE BIRTH;INFANTS
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*5B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PATENT DUCTUS ARTERIOSUS;INFANTS
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*5B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PREMATURE BIRTH;INFANTS
FENTANYL;ABCC1;(A)14;rs58572178;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PAIN;CHILDREN
FENTANYL;ABCC1;(A)14;rs58572178;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;OTHER:PREMATURE BIRTH;CHILDREN
VORICONAZOLE;CYP2C19;*2 + *17;CYP2C19*2;DOSAGE;;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
VORICONAZOLE;CYP2C19;*2 + *17;CYP2C19*17;DOSAGE;;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
ROSUVASTATIN;ABCG2;;ABCG2 POOR METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
ROSUVASTATIN;NAT2;;NAT2 SLOW ACETYLATOR;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
ROSUVASTATIN;TPMT;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
DOXORUBICIN;CBR1;T;rs20572;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
SUNITINIB;KDR;AG;rs34231037;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
ANTIDEPRESSANTS;FKBP5;CC;rs3800373;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
GLICLAZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLICLAZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLIMEPIRIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLIMEPIRIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLIPIZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLIPIZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
GLYBURIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
GLYBURIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
ISONIAZID;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
RAMIPRIL;SLCO1B1;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
RAMIPRIL;ABCG2;;ABCG2 POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DULOXETINE;DRD3;CC + CT;rs324026;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;LEUKEMIA;PEOPLE
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;MYELOID;PEOPLE
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;ACUTE;PEOPLE
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;LEUKEMIA;PEOPLE
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;MYELOID;PEOPLE
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;ACUTE;PEOPLE
TENOFOVIR;ABCC4;TT;rs1751034;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
DULOXETINE;DRD3;CT;rs324023;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE
EFAVIRENZ;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE
EZETIMIBE;ABCG8;;DEFICIENCY;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE
EZETIMIBE;ABCG5;;DEFICIENCY;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DULOXETINE;DRD3;AG;rs167770;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BIPOLAR DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
TAMSULOSIN;CYP2D6;*10 + *41;CYP2D6*10;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PROSTATIC HYPERPLASIA;MEN
TAMSULOSIN;CYP2D6;*10 + *41;CYP2D6*41;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PROSTATIC HYPERPLASIA;MEN
HYDROXYUREA;HBG2;AA + AG;rs7482144;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN
HYDROXYUREA;HBG2;AA;rs7482144;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
FLUOROURACIL;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ANTIEPILEPTICS;SCN1A;AA + AT;rs121917953;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
METHOTREXATE;ENG;G;rs1800956;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;PKD1L2;A;rs16954698;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*1;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*2;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*3;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*4;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PREGABALIN;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ANTIDEPRESSANTS;FKBP5;TT;rs1360780;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
PITAVASTATIN;CYP2C9;;CYP2C9 POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
EFAVIRENZ;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE
ANTIDEPRESSANTS;FKBP5;AA;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;CYP2D6;;NORMAL METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
CLOZAPINE;CYP2D6;C;rs202102799;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP2D6;C;rs202102799;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
CLOZAPINE;CYP2D6;G;rs28371726;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP2D6;G;rs28371726;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
CLOZAPINE;DRD4;C;rs762502;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;DRD4;C;rs762502;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
NIFEDIPINE;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;PREGNANCY;WOMEN
CLOZAPINE;DRD4;del;rs2133251840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;DRD4;del;rs2133251840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
CLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
N-DESMETHYLCLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
N-DESMETHYLCLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
EXENATIDE;SORCS1;GG;rs1416406;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
EXENATIDE;SORCS1;GG;rs1416406;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
LINAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LINAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
VILDAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
VILDAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
LINAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
LINAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SAXAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SAXAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
SITAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
VILDAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
VILDAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
MIDAZOLAM;NR1I2;CC;rs2461817;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;RESPIRATORY FAILURE REQUIRING ASSISTED VENTILATION;PEOPLE
METHADONE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
R-EDDP;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
S-EDDP;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
FLUOROURACIL;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:CROHN DISEASE;PEOPLE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:AUTOIMMUNE HEPATITIS;PEOPLE
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE
METFORMIN;SLC22A1;CC;rs2282143;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
METFORMIN;SLC22A2;CC;rs316019;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
METHACHOLINE;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;
TEMSIROLIMUS;NR1I2;TT;rs3814055;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TEMSIROLIMUS;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;;C;rs4646457;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;G;rs15524;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;A;rs12333983;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE
ATENOLOL;;A;rs294610;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
METOPROLOL;;A;rs294610;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ATENOLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
METOPROLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CAPECITABINE;DPYD;CT;rs56038477;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CT;rs56038477;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7975;OTHER;INCREASED;CLEARANCE;;;HEALTHY
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7975;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
DICHLOROACETIC ACID;GSTZ1, POMT2;C;rs1046428;OTHER;INCREASED;CLEARANCE;;;HEALTHY
DICHLOROACETIC ACID;GSTZ1, POMT2;C;rs1046428;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7972;OTHER;INCREASED;METABOLISM;;;HEALTHY
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7972;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
SUNITINIB;ABCB1;AA;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
FLUOROURACIL;DPYD;AG + GG;rs17376848;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
HYDROCHLOROTHIAZIDE;;AA + AG;rs11065987;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METHADONE;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
CAFFEINE;CYP1A2;CT;rs12720461;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ETHANOL;OPRM1;T;rs553202;EFFICACY;INCREASED;RESPONSE;;;
ETHANOL;OPRM1;A;rs524731;EFFICACY;INCREASED;RESPONSE;;;
NICOTINE;HINT1;CT + TT;rs3852209;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
OPIOIDS;OPRM1;AG;rs1799971;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE
OPIOIDS;OPRM1;AG;rs1799971;EFFICACY;DECREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
FLUOXETINE;CYP2D6;CT;rs3892097;EFFICACY;INCREASED;CONCENTRATIONS;EFFICACY;ALCOHOL ABUSE;MEN
FLUOXETINE;CYP2D6;CT;rs3892097;EFFICACY;INCREASED;CONCENTRATIONS;EFFICACY;EFFICACY:MAJOR DEPRESSIVE DISORDER;MEN
LEVODOPA;DBH;CT + TT;rs1611115;EFFICACY;INCREASED;RESPONSE;DISEASE;COCAINE DEPENDENCE;PEOPLE
QUETIAPINE;CYP1A2;AA;rs2069514;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VENLAFAXINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
AXITINIB;OR2B11;A;rs35305980;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE
SULFONAMIDES;KCNJ11;CT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;KCNJ11;CT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
SULFONAMIDES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
TIPIRACIL HYDROCHLORIDE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TRIFLURIDINE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
AXITINIB;UGT1A10, UGT1A8, UGT1A9;del;rs3832043;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE
AXITINIB;UGT1A7;G;rs17868323;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE
RISPERIDONE;HTR2C;A;rs3813928;EFFICACY;DECREASED;RESPONSE;DISEASE;AUTISM;CHILDREN
METHOTREXATE;MTRR;CT + TT;rs1532268;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
RISPERIDONE;HTR2A;CT + TT;rs6311;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM;CHILDREN
AXITINIB;ABCB1;A;rs1045642;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE
BUTORPHANOL;COMT;GG;rs6269;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
AXITINIB;ABCG2;T;rs2231142;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE
AXITINIB;ABCB1;T;rs2032582;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE
VORICONAZOLE;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN
ERLOTINIB;EGFR;GT + TT;rs121434568;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
BUTORPHANOL;COMT;CC;rs4633;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
SUNITINIB;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
SUNITINIB;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;DISEASE:METASTATIC NEOPLASM;PEOPLE
METHOTREXATE;SLC19A1;CC + TT;rs1051266;EFFICACY;DECREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IRINOTECAN_METABOLITE(SN-38);UGT1A9;TT;rs3832043;DOSAGE;INCREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
RISPERIDONE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM;CHILDREN
EFAVIRENZ;CYP2B6;CT;rs2279345;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
GLUCOCORTICOIDS;CRHR1;T;rs1876828;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;;;
IRINOTECAN_METABOLITE(SN-38);SLCO1B1;CC + CT;rs4149056;DOSAGE;INCREASED;DOSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
(S)-METHADONE;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
VORICONAZOLE;CYP2C19;AA + AG;rs4986893;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN
METHYLPHENIDATE;GRIN2B;CC;rs2284411;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
FENTANYL;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE
SALBUTAMOL;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
ATORVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;
ROSUVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;
SIMVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;
SALBUTAMOL;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
ATORVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;
ROSUVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;
SIMVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;
NICARDIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE
NIMODIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;CHILDREN
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
SIMVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
IRBESARTAN;APOB;AG;rs1367117;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IRBESARTAN;APOB;AG;rs1367117;METABOLISM/PK;;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IRBESARTAN;APOB;GG;rs1367117;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ATORVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
EFAVIRENZ;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
BENAZEPRIL;PRCP;GG + GT;rs2229437;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
EFAVIRENZ;UGT2B7;GG;rs28365062;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;OTHER;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
LAMIVUDINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
TENOFOVIR;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CLOPIDOGREL;ABCB1;G;rs1045642;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;ABCB1;G;rs1045642;OTHER;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
MIDAZOLAM;VDR;CT + TT;rs11568820;METABOLISM/PK;INCREASED;CLEARANCE;;;
METHYLDOPA;ARG2;G;rs3742879;EFFICACY;INCREASED;RESPONSE;OTHER;PREGNANCY;WOMEN
METHYLDOPA;ARG2;G;rs3742879;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:PRE-ECLAMPSIA;WOMEN
FLUOROURACIL;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
REPAGLINIDE;CYP2C8;C;rs10509681;DOSAGE;INCREASED;METABOLISM;;;HEALTHY
REPAGLINIDE;CYP2C8;C;rs10509681;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
REPAGLINIDE;CYP2C8;T;rs11572080;DOSAGE;INCREASED;METABOLISM;;;HEALTHY
REPAGLINIDE;CYP2C8;T;rs11572080;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ARIPIPRAZOLE;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;TT;rs12248560;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;TT;rs12248560;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;TT;rs12248560;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
OMEPRAZOLE;CYP2C19;TT;rs11188072;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;TT;rs11188072;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;TT;rs11188072;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
METHADONE;CYP2B6;TT;rs3211371;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
MERCAPTOPURINE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
GEMCITABINE;CMPK1;CC;rs1044457;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
DEXMEDETOMIDINE;ADRA2A;CG + GG;rs1800035;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;WOMEN
DEXMEDETOMIDINE;ADRA2A;CG + GG;rs1800035;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN
BUDESONIDE;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
FLUTICASONE / SALMETEROL;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
FORMOTEROL;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
OMALIZUMAB;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs775887911;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;WOMEN
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs775887911;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs201376588;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;WOMEN
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs201376588;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN
GEMCITABINE;CMPK1;GG;rs35687416;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
GEMCITABINE;DCTD;CC;rs12507552;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
BETA BLOCKING AGENTS;;T;rs139945292;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ROSUVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
GEMCITABINE;TENT4A;GG;rs274713;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
METHOTREXATE;FPGS;CT + TT;rs1544105;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
GEMCITABINE;CDC5L;CT + TT;rs992160;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
METHOTREXATE;TYMS;AA;rs2853539;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ATORVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
ROSUVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
SIMVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
BUDESONIDE;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
FLUTICASONE / SALMETEROL;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
FORMOTEROL;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
OMALIZUMAB;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
GEMCITABINE;SH2D5;GT + TT;rs10916852;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
ROSUVASTATIN;CETP;A;rs708272;EFFICACY;DECREASED;RESPONSE;;;
ATORVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CORONARY ARTERY DISEASE;PEOPLE
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CORONARY ARTERY DISEASE;PEOPLE
REPAGLINIDE;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;DECREASED;DOSE;;;
AZATHIOPRINE;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;ITPA;AC;rs1127354;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
REPAGLINIDE;SLCO1B1;TT;rs4149056;METABOLISM/PK;;EXPOSURE;;;HEALTHY
BUPRENORPHINE;CYP3A4;TT;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;ISCHEMIA;PEOPLE
BUPRENORPHINE;CYP3A4;TT;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PAIN;PEOPLE
PERINDOPRIL;AGTR1;AA;rs5186;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
NITRENDIPINE;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROMORPHONE;OPRM1;AG + GG;rs1799971;PD;INCREASED;RESPONSE;;;HEALTHY
LAMOTRIGINE;HNF4A;AA;rs2071197;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
LAMOTRIGINE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
LAMOTRIGINE;ABCG2;CC + CT;rs3114020;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
CYCLOSPORINE;TSPYL1;AG + GG;rs3828743;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;MEN
GEMCITABINE;CMPK1;CC;rs7543016;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
GEMCITABINE;ESR2;TT;rs944050;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
RISPERIDONE;DRD2;TT;rs1799978;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
IRINOTECAN;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
RISPERIDONE;DRD2;T;rs1799978;OTHER;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
GLUCOSE;SLCO1B1;TT;rs4149056;METABOLISM/PK;;CONCENTRATIONS;;;HEALTHY
WARFARIN;;A;rs12777823;DOSAGE;;DOSE;;;
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CONJUGATED ESTROGENS;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED;RESPONSE;DISEASE;MENOPAUSE;WOMEN
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;WOMEN
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
DIAZEPAM;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
ALPRAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ALCOHOL ABUSE;MEN
ALPRAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:ANXIETY DISORDERS;MEN
DIAZEPAM;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
CLOZAPINE;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:TOBACCO USE DISORDER;PEOPLE
SALBUTAMOL;IGF2R;AG;rs8191725;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
SALBUTAMOL;SLC24A4;AG;rs77441273;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
ALPRAZOLAM;CYP3A4;AG;rs35599367;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN
ALPRAZOLAM;CYP3A4;AG;rs35599367;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:ANXIETY DISORDERS;MEN
LANSOPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
LANSOPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
OMEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
RABEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
WARFARIN;VKORC1;AA;rs2359612;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OVARIAN NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASM OF ESOPHAGUS;PEOPLE
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASMS;PEOPLE
ULINASTATIN;MMP2;T;rs243865;EFFICACY;DECREASED;RESPONSE;OTHER;PANCREATITIS;PEOPLE
ANTIPSYCHOTICS;ABCB1;G;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ULINASTATIN;MMP9;T;rs3918242;EFFICACY;INCREASED;RESPONSE;OTHER;PANCREATITIS;PEOPLE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;NR1I2;CT + TT;rs2276707;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ANTIPSYCHOTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
IRINOTECAN;NR1I2;AA;rs10934498;TOXICITY;DECREASED;EXPOSURE;DISEASE;COLONIC NEOPLASMS;PEOPLE
IRINOTECAN;NR1I2;AA;rs10934498;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;COLONIC NEOPLASMS;PEOPLE
TACROLIMUS;IL10;CC;rs1800896;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
OLANZAPINE;DRD3;C;rs324026;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
MEASLES VACCINES;TLR3;CT;rs3775291;EFFICACY;DECREASED;RESPONSE;;;
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
TAMOXIFEN;ABCC2;CT;rs717620;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
SALBUTAMOL;;CT;rs77149876;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
ETANERCEPT;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
SALBUTAMOL;PAPPA2;CT;rs77977790;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
NORBUPRENORPHINE;OPRD1;GG;rs569356;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SALMETEROL;ADRB2;G;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;ASTHMA;CHILDREN
SALBUTAMOL;;AG;rs116551936;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
SALBUTAMOL;NCOA3;CT;rs115501901;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
SALBUTAMOL;;AG;rs74973995;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
SALBUTAMOL;CRHR2;CT;rs73294475;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
PHENPROCOUMON;CYP3A4;C;rs2740574;DOSAGE;DECREASED;DOSE;;;CHILDREN
SALBUTAMOL;ADCY9;AG;rs144315541;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
PERPHENAZINE;MCPH1;A;rs17570753;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PERPHENAZINE;CDH13;G;rs2116971;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PERPHENAZINE;SKOR2;G;rs9952628;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A2;AA;rs12943590;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
QUETIAPINE;KCNMA1;G;rs35793;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PERPHENAZINE;MAML3;A;rs11100483;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
VALPROIC ACID;UGT2B7;CC + CT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
METHACHOLINE;RUNX1;AA;rs11702779;OTHER;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
RISPERIDONE;LRP1B;G;rs874295;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
BEVACIZUMAB;HTRA1;AA;rs11200638;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
RISPERIDONE;PSMD14;A;rs9713;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;AGAP1;C;rs1869295;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
BEVACIZUMAB;ARMS2;TT;rs10490924;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
VALPROIC ACID;APEH;CC;rs3816877;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
RISPERIDONE;NPAS3;G;rs1315115;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;TMEFF2;G;rs3738883;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METFORMIN;PCK1;CT + TT;rs4810083;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;PCK1;CT + TT;rs4810083;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
ZIPRASIDONE;CDH4;A;rs4925300;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ZIPRASIDONE;LYN;G;rs1546519;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
BEVACIZUMAB;CFH;GG;rs800292;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED;DOSE;;;
ZIPRASIDONE;NALCN;C;rs9585618;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ZIPRASIDONE;CNTN4;A;rs17194378;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE
IMATINIB;SLCO1A2;CT + TT;rs4148978;TOXICITY;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
IMATINIB;SLCO1A2;CT + TT;rs4148978;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
IMATINIB;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
IMATINIB;SLCO1B3;GG;rs4149117;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;CALU;AA;rs2290228;DOSAGE;DECREASED;DOSE;;;
OLANZAPINE;;T;rs12610827;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
FENOFIBRATE;APOB;AA;rs676210;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
METHACHOLINE;RUNX1;AG + GG;rs11702779;OTHER;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
CITALOPRAM;SERPINE1;G;rs1799889;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SERPINE1;G;rs1799889;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHOTREXATE;MTR;G;rs1805087;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE
METHOTREXATE;MTR;G;rs1805087;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
FLUOXETINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
MIRTAZAPINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
PAROXETINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
VENLAFAXINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE
OLANZAPINE;CSMD1;A;rs17070785;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;PLAGL1;C;rs2247408;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
SIROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
OLANZAPINE;PLAGL1;A;rs3819811;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
SIROLIMUS;CYP3A5;CC;rs4646453;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
OLANZAPINE;PTPRN2;C;rs221253;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
IMATINIB;SLC22A1;AA + AG;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A1;AA + AG;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED;DOSE;;;
PERPHENAZINE;PRKCE;C;rs2278773;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PERPHENAZINE;;C;rs11774231;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
HYDROCHLOROTHIAZIDE;DOT1L;CT + TT;rs2269879;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
PAROXETINE;ADM;CC;rs11042725;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
TILDRAKIZUMAB;ATG5;CT;rs9373839;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
TILDRAKIZUMAB;IL17RC;CC;rs708567;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
CITALOPRAM;BDNF;TT;rs7124442;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ARIPIPRAZOLE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN
CLOZAPINE;OXT;T;rs2740204;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
DIAZEPAM;CYP3A4;GG;rs35599367;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN
METHOTREXATE;MTHFR;G;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CROHN DISEASE;PEOPLE
METHOTREXATE;DHFR;C;rs408626;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CROHN DISEASE;PEOPLE
REPAGLINIDE;NOS1AP;T;rs10494366;DOSAGE;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;NOS1AP;T;rs10494366;DOSAGE;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
REPAGLINIDE;NOS1AP;T;rs10494366;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;NOS1AP;T;rs10494366;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
CITALOPRAM;BDNF;TT;rs7103411;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
LAMIVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
LOPINAVIR;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
RITONAVIR;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ZIDOVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FLUOXETINE;BDNF;CT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TILDRAKIZUMAB;TNFAIP3;GG;rs610604;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
ANTIDEPRESSANTS;ERICH3;CC;rs11580409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
CLOPIDOGREL;CYP2C19;CT;rs12248560;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
ARIPIPRAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
PAROXETINE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ENTACAPONE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE
CLOZAPINE;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELMISARTAN;SLCO1B3;C;rs60140950;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CLOZAPINE;CYP2D6;GG;rs16947;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DYSLIPIDAEMIA;PEOPLE
SIMVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DYSLIPIDAEMIA;PEOPLE
IVACAFTOR;CFTR;C;rs121909011;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
IMATINIB;ULK3;GG;rs2290573;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ULK3;GG;rs2290573;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
CLOZAPINE;DRD1;GT;rs265976;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
INTERFERONS;STAT3;GG;rs4796793;EFFICACY;INCREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
TAMOXIFEN;SLCO2B1;AA + AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;DOSAGE;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;DOSAGE;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;DOSAGE;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;
RISPERIDONE;HRH3;TT;rs3787430;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;AC + CC;rs2884737;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;
RISPERIDONE;HRH3;TT;rs3787429;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ARIPIPRAZOLE;TAAR6;AA + AG;rs4305746;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PEGINTERFERON ALFA-2A;IL6;G;rs1800795;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
SULFASALAZINE;ABCG2;TT;rs2231142;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PEGINTERFERON ALFA-2A;IL6;G;rs1800796;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IL6;G;rs1800797;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ROSUVASTATIN;ABCG2;AA + AG;rs2199936;EFFICACY;INCREASED;RESPONSE;;;
ILOPERIDONE;CNTF, ZFP91-CNTF;GG;rs1800169;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
DISULFIRAM;OPRD1;CC;rs678849;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
ERYTHROPOIETIN;STIM1;AG + GG;rs1561876;EFFICACY;INCREASED;RESISTANCE;OTHER;KIDNEY DISORDER;PEOPLE
ERYTHROPOIETIN;STIM1;AG + GG;rs1561876;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:ANEMIA;PEOPLE
LATANOPROST;PTGFR;CC;rs3753380;EFFICACY;INCREASED;RESPONSE;;;
RANIBIZUMAB;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
FUROSEMIDE;ABCC4;T;rs17268282;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
METFORMIN;SLC22A1;CC;rs622342;EFFICACY;;RESPONSE;OTHER;GENETIC VARIATION AT RS2289669;PEOPLE
MORPHINE;COMT;T;rs737866;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;T;rs737866;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;G;rs2075507;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;G;rs2075507;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
ANTIEPILEPTICS;CYP1A1;AA;rs2606345;EFFICACY;DECREASED;RESPONSE;DISEASE;EPILEPSY;WOMEN
MORPHINE;COMT;A;rs5746849;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;A;rs5746849;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT, TXNRD2;C;rs7287550;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT, TXNRD2;C;rs7287550;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;A;rs6269;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;A;rs6269;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
CARBAMAZEPINE;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
MORPHINE;COMT;A;rs740603;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;A;rs740603;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;ABCC3;T;rs4793665;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
TACROLIMUS;POR;T;rs1057868;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
N-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
N-DESMETHYLTRAMADOL;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
TRAMADOL;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;ABCC2;CC;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
ATAZANAVIR;SORCS2;A;rs73208473;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;HIV INFECTIOUS DISEASE;WOMEN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;CC;rs9304742;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CARBAMAZEPINE;UGT2B7;AA;rs28365063;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;NR1I2;T;rs3814055;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;CC + CT;rs2916205;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
SULFONAMIDES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED;RESPONSE;;;
UREA DERIVATIVES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED;RESPONSE;;;
SUMATRIPTAN;GNB3;CT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;CLUSTER HEADACHE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;G;rs1135840;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
CANNABINOIDS;TRPV1;CC;rs8065080;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
CANNABINOIDS;UGT2B7;AA;rs7438135;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;AA;rs11126740;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
IMATINIB;ABCG2;GT;rs2231142;OTHER;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
IMATINIB;ABCG2;GT;rs2231142;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
REPAGLINIDE;KCNJ11;T;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;KCNJ11;T;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
TRAMADOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
TRAMADOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
REPAGLINIDE;TCF7L2;TT;rs290487;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;TCF7L2;TT;rs290487;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
MORPHINE;COMT;A;rs4680;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;A;rs4680;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
CARBAMAZEPINE;EPHX1;TT;rs1051740;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
MORPHINE;COMT;C;rs4818;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;C;rs4818;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
ERYTHROPOIETIN;ORAI1;GG + GT;rs12320939;EFFICACY;INCREASED;RESISTANCE;OTHER;KIDNEY DISORDER;PEOPLE
ERYTHROPOIETIN;ORAI1;GG + GT;rs12320939;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:ANEMIA;PEOPLE
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
MORPHINE;COMT;A;rs2239393;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;COMT;A;rs2239393;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MORPHINE;ARVCF, COMT;T;rs165728;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;ARVCF, COMT;T;rs165728;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
CARBAMAZEPINE;ABCB1;AG;rs4148740;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;ABCB1;TT;rs4148739;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
MORPHINE;ARVCF, COMT;T;rs174699;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;ARVCF, COMT;T;rs174699;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
ANTIPSYCHOTICS;DRD2;del;rs1799732;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;CETP;AA;rs1532624;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;CT + TT;rs6908425;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;SIK3;AA;rs533556;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;CT + TT;rs12191877;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
RITODRINE;KCNMB2;TT;rs7624046;EFFICACY;DECREASED;RESPONSE;;;
CARBAMAZEPINE;ABCC2;AA + AG;rs4148386;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;
CARBAMAZEPINE;ABCC2;CT + TT;rs3740066;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;MEN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
RITODRINE;KCNMB2;CC;rs9839376;EFFICACY;DECREASED;RESPONSE;;;
WARFARIN;GGCX;G;rs11676382;DOSAGE;DECREASED;DOSE;;;
CARBAMAZEPINE;NR1I2;G;rs7643645;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
MORPHINE;METTL21A;CC;rs2952768;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
MORPHINE;METTL21A;CC;rs2952768;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
CARBAMAZEPINE;NR1I2;T;rs4688040;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CANNABINOIDS;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
CARBAMAZEPINE;NR1I2;C;rs2461817;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CITALOPRAM;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
CITALOPRAM;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;GG;rs8050894;DOSAGE;DECREASED;DOSE;;;
CITALOPRAM;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ATAZANAVIR;ABCB1;AA + AG;rs1045642;DOSAGE;;DOSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ATAZANAVIR;SLCO1B1;TT;rs4149056;DOSAGE;;DOSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
ATAZANAVIR;NR1I2;TT;rs2472677;DOSAGE;;DOSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;VKORC1;AC;rs61742245;DOSAGE;INCREASED;DOSE;OTHER;WARFARIN MAINTENANCE TREATMENT;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;
DOCETAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PACLITAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
VINORELBINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
DOCETAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PACLITAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
VINORELBINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
DOCETAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PACLITAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
VINORELBINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
DOCETAXEL;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PACLITAXEL;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
VINORELBINE;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
OLANZAPINE;SLC26A9;A;rs11240594;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;SLC26A9;A;rs11240594;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
SOLANIDINE;NFIB;CC + CT;rs28379954;METABOLISM/PK;INCREASED;METABOLISM;;;
ZIPRASIDONE;EHF;A;rs286913;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ZIPRASIDONE;EHF;A;rs286913;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;SLC6A3;A;rs2975226;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;SLC6A3;A;rs2975226;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;IL1A;C;rs11677416;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;IL1A;C;rs11677416;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CYCLOSPORINE;POR;TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;C;rs1051740;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
FESOTERODINE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AA;rs10929302;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PIOGLITAZONE;PTPRD;CC;rs17584499;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
PIOGLITAZONE;PTPRD;CC;rs17584499;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
ACENOCOUMAROL;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED;DOSE;;;
WARFARIN;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED;DOSE;;;
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE
ACAMPROSATE;GRIN2B;A;rs2058878;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;PEOPLE
OLANZAPINE;ATP1A2;T;rs6688363;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;;T;rs8050896;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;TNFRSF11A;A;rs2980976;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;PPA2;G;rs2636697;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
METHOTREXATE;;A;rs1232027;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
METHOTREXATE;;A;rs1232027;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE
FENTANYL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
HYDROMORPHONE;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
OXYCODONE;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
TRAMADOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN
RISPERIDONE;PPA2;A;rs2636719;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;DOSAGE;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;DOSAGE;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
RASAGILINE;COMT;AA;rs4680;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;DOSAGE;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;DOSAGE;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
DISULFIRAM;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COCAINE DEPENDENCE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"PSORIATIC""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:CROHN DISEASE""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:PSORIASIS""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:SPONDYLITIS";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"ANKYLOSING""";PEOPLE
ISONIAZID;NAT2;AT;rs4646244;TOXICITY;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;AT;rs4646244;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE
HYDROCHLOROTHIAZIDE;BEST3;AA + AG;rs61747221;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"PSORIATIC""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:CROHN DISEASE""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:PSORIASIS""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:SPONDYLITIS";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"ANKYLOSING""";PEOPLE
NIFEDIPINE;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
DEFERIPRONE;UGT1A6;GG;rs6759892;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
PIOGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
PIOGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
PACLITAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
OPIOIDS;TNF;GG;rs1800629;DOSAGE;INCREASED;DOSE;OTHER;NEOPLASMS;CHILDREN
OPIOIDS;TNF;GG;rs1800629;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;CHILDREN
CARBAMAZEPINE;SCN1A;CT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;SCN1A;CT;rs3812718;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
PACLITAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
RISPERIDONE;TJP1;T;rs813676;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
OPIOIDS;IL6;A;rs1800797;DOSAGE;DECREASED;DOSE;OTHER;NEOPLASMS;CHILDREN
OPIOIDS;IL6;A;rs1800797;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PAIN;CHILDREN
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;DOSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
METHYLPHENIDATE;ADGRL3;CC + CT;rs734644;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
PACLITAXEL;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
FLUTICASONE PROPIONATE;CA10;CC + CT;rs967676;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
MONTELUKAST;CA10;CC + CT;rs967676;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
CARBAMAZEPINE;EPHX1;CT;rs1051740;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;CT;rs1051740;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;CC;rs1051740;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;CC;rs1051740;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
GEMCITABINE;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
FLUTICASONE PROPIONATE;;AA + AG;rs1786929;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
MONTELUKAST;;AA + AG;rs1786929;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
TACROLIMUS;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHYLPHENIDATE;ADGRL3;AG + GG;rs1355368;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
METHYLPHENIDATE;ADGRL3;CC + CG;rs6813183;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
RISPERIDONE;;C;rs7395555;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
RANIBIZUMAB;CFH;TT;rs1061170;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
OLANZAPINE;SPOPL;C;rs10170310;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
QUETIAPINE;PDE4D;T;rs17382202;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;;DOSE;;;
QUETIAPINE;PDE4D;G;rs17742120;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
QUETIAPINE;PDE4D;A;rs2164660;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE
PERINDOPRIL;AGTR1;CC + CT;rs5182;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
RISPERIDONE;TJP1;T;rs711355;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;TJP1;A;rs785423;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
TENOFOVIR ALAFENAMIDE;ABCB1;CT;rs3842;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
CLOZAPINE;SLC6A4;T;rs25531;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RALOXIFENE;UGT1A8;CC;rs1042597;EFFICACY;INCREASED;RESPONSE;DISEASE;MENOPAUSE;WOMEN
RALOXIFENE;UGT1A8;CC;rs1042597;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;WOMEN
ESOMEPRAZOLE;STAT6;CC + CT;rs1059513;EFFICACY;INCREASED;RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;CHILDREN
RISPERIDONE;WBP2NL;A;rs5758550;METABOLISM/PK;DECREASED;CLEARANCE;;;
PACLITAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ADALIMUMAB;CD40LG;T;rs1126535;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
RALOXIFENE;ESR1;CC;rs11543791;EFFICACY;DECREASED;RESPONSE;DISEASE;MENOPAUSE;WOMEN
RALOXIFENE;ESR1;CC;rs11543791;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;WOMEN
PERINDOPRIL;AGTR1;AA + AT;rs275651;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
LITHIUM;MYO1H;C;rs7959663;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
INFLIXIMAB;FCGR2A;G;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
LITHIUM;EPHX2;T;rs59724122;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LOSARTAN;FBXW12;CT;rs17080138;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LOSARTAN E-3174;FBXW12;CT;rs17080138;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LITHIUM;GRAMD1B;A;rs61123830;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
WARFARIN;VKORC1;T;rs7294;DOSAGE;DECREASED;DOSE;;;
LITHIUM;;A;rs66486766;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;;A;rs324899;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;;T;rs1611259;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;;A;rs6942227;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;DOSAGE;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CATECHOLAMINES;ADRB1;CC;rs1801253;DOSAGE;DECREASED;DOSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
ACENOCOUMAROL;APOE;CC;rs429358;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ACENOCOUMAROL;APOE;CC;rs429358;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE
LOSARTAN;ZNF703;CT;rs79707182;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LOSARTAN E-3174;ZNF703;CT;rs79707182;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PERINDOPRIL;BDKRB1;AA + AG;rs12050217;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
LOSARTAN;SLC17A4;A;rs11754288;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LOSARTAN E-3174;SLC17A4;A;rs11754288;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;VKORC1;A;rs17708472;DOSAGE;INCREASED;DOSE;;;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;C;rs680244;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
ADALIMUMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;G;rs16969968;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs680244;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;OTHER;GOUT;PEOPLE
LITHIUM;FAM177A1;T;rs79403677;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
CLOPIDOGREL;;A;rs2487032;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;G;rs11591741;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
LITHIUM;ADCY1;A;rs1521470;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;
REPAGLINIDE;KCNQ1;CT + TT;rs2237892;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;KCNQ1;CT + TT;rs2237892;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
LITHIUM;;A;rs7588746;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;FAM178B;A;rs6728642;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;EFFICACY;INCREASED;RESPONSE;OTHER;HEART FAILURE;PEOPLE
ZILEUTON;PRORP;AA;rs12436663;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
LOSARTAN;CYP2C9;GT;rs10509680;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LOSARTAN E-3174;CYP2C9;GT;rs10509680;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LITHIUM;ZNF804A;T;rs62200793;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;;A;rs1611255;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;;A;rs209474;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
REPAGLINIDE;KCNQ1;AC + CC;rs2237895;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;KCNQ1;AC + CC;rs2237895;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
LITHIUM;;A;rs3919583;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GLATIRAMER ACETATE;TGFB1;A;rs1800469;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
ANTIEPILEPTICS;ABCC2;CT + TT;rs3740066;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
N-DESMETHYLTAMOXIFEN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
GLUCOCORTICOIDS;GLCCI1;G;rs37973;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
AMLODIPINE;CYP3A4;AG + GG;rs2246709;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
TENELIGLIPTIN;FMO3;AG + GG;rs2266780;METABOLISM/PK;DECREASED;CLEARANCE;;;MEN
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;A;rs16969968;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
QUETIAPINE;COMT;C;rs4818;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
HYDROCHLOROTHIAZIDE;GPR83;GG;rs3758785;EFFICACY;DECREASED;RESPONSE;EFFICACY;ESSENTIAL HYPERTENSION;PEOPLE
QUETIAPINE;COMT;T;rs5993883;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TENELIGLIPTIN;FMO3;CT + TT;rs909530;METABOLISM/PK;DECREASED;CLEARANCE;;;MEN
MENOTROPINS;FSHR;CT;rs6166;;DECREASED;DOSE;;;WOMEN
QUETIAPINE;COMT;A;rs6269;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CANDESARTAN;GPR83;GG;rs3758785;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
TACROLIMUS;IL6;GG;rs1800795;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TENELIGLIPTIN;FMO3;AG + GG;rs2266782;METABOLISM/PK;DECREASED;CLEARANCE;;;MEN
PACLITAXEL;ABCB1;CT;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;OVARIAN NEOPLASMS;PEOPLE
HYDROCHLOROTHIAZIDE;HSD3B1;CC + CT;rs7553527;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROCHLOROTHIAZIDE;TTC6;CC + CT;rs177852;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
TENELIGLIPTIN;CYP3A4;CT + TT;rs2242480;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;MEN
GLATIRAMER ACETATE;IFNAR1;G;rs1012335;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
5-HYDROXYOMEPRAZOLE;;A;rs12777823;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
OMEPRAZOLE;;A;rs12777823;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;RESPONSE;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
METOPROLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
SALBUTAMOL;ADRB2;AA;rs1042713;PD;DECREASED;RESPONSE;;;HEALTHY
EFAVIRENZ;NR1I3;GG;rs3003596;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;ABCG2;GG + GT;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;GG + GT;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
TAMOXIFEN;CYP19A1;AA + AC;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
IMATINIB;ABCG2;CC + CT;rs13120400;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;CC + CT;rs13120400;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
METHOTREXATE;SLCO1B1;CT + TT;rs10841753;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IMATINIB;ABCG2;AC + CC;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;AC + CC;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
LACIDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
NIFEDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
NITRENDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
LUMEFANTRINE;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;WOMEN
LUMEFANTRINE;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;WOMEN
QUETIAPINE;HTR1A;TT;rs10042486;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;MEN
AMITRIPTYLINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
CLOMIPRAMINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMIPRAMINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
MILNACIPRAN;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
CHLORPROMAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
QUETIAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TRIFLUOPERAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FELODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
ATORVASTATIN;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE
CITALOPRAM;GSK3B;GG;rs334558;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;GSK3B;GG;rs334558;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ETHANOL;SRPRB;CT;rs17376019;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
ETHANOL;ALDH2;AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LUMEFANTRINE;CYP3A5;T;rs10264272;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;WOMEN
LUMEFANTRINE;CYP3A5;T;rs10264272;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;WOMEN
ATORVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE
ETHANOL;PGM1;CC;rs4643;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED;DOSE;;;
ACETALDEHYDE;ADH1A;CT;rs1229976;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED;DOSE;;;
LUMEFANTRINE;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;WOMEN
LUMEFANTRINE;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;WOMEN
ACETALDEHYDE;ALDH2;AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
INFLIXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ACETALDEHYDE;PGM1;CC;rs4643;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
VERAPAMIL;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ACETALDEHYDE;ADH1B;CT;rs1229984;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;PEOPLE
AMLODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FELODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
SUNITINIB;CYP3A5;T;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
N-DESMETHYLCLOZAPINE;UGT2B10;GT;rs61750900;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
LUMEFANTRINE;CYP3A4;T;rs2740574;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;WOMEN
LUMEFANTRINE;CYP3A4;T;rs2740574;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:PREGNANCY;WOMEN
CLOPIDOGREL;N6AMT1;G;rs2254638;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
VALPROIC ACID;UGT1A6;TT;rs6759892;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE
FENTANYL;ASTN2;CT + TT;rs7858836;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE
FENTANYL;ASTN2;CT + TT;rs7858836;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
BENAZEPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
IMIDAPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
FENTANYL;ASTN2;CC + CT;rs958804;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE
FENTANYL;ASTN2;CC + CT;rs958804;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
VALPROIC ACID;UGT1A6;AA;rs1105879;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A6;AA;rs2070959;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
VERAPAMIL;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ETIDRONIC ACID;COL1A1;AA + AC;rs1800012;EFFICACY;DECREASED;RESPONSE;DISEASE;METABOLIC BONE DISORDER;PEOPLE
VORICONAZOLE;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN
MORPHINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
NORTRIPTYLINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
RISPERIDONE;HTR1A;CG + GG;rs6295;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;MEN
DULOXETINE;;G;rs4858478;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;AT;rs67376798;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
VALPROIC ACID;UGT1A6;GG;rs6759892;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
DULOXETINE;ZNF385D;T;rs13093500;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FOLIC ACID;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
HYDROXYCHLOROQUINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
SULFASALAZINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DULOXETINE;ZNF385D;T;rs4334661;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FOLIC ACID;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
HYDROXYCHLOROQUINE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
SULFASALAZINE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DULOXETINE;;G;rs7625956;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CC;rs4646453;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TAMOXIFEN;SULT1A1;TT;rs1042028;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DULOXETINE;ZNF385D;G;rs7616119;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TERBUTALINE;ADRB2;CT;rs1800888;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
DULOXETINE;;T;rs2933304;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;CT;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DULOXETINE;NRXN1;T;rs4971678;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ZNF385D;G;rs12630569;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE
BEVACIZUMAB;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CAPECITABINE;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ERYTHROPOIETIN;HFE;A;rs1800562;DOSAGE;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE
ERYTHROPOIETIN;HFE;A;rs1800562;METABOLISM/PK;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE
DULOXETINE;;C;rs6700741;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE
ATENOLOL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE
ATENOLOL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CAPECITABINE;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ERYTHROPOIETIN;HFE;G;rs1799945;DOSAGE;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE
ERYTHROPOIETIN;HFE;G;rs1799945;METABOLISM/PK;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE
DULOXETINE;TEX10;C;rs6479008;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DULOXETINE;TEX10;A;rs7035619;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;TEX10;T;rs10989064;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DIGOXIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;
DULOXETINE;ATP10A;G;rs12595802;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;TEX10;G;rs7472;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;;G;rs56229625;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;;;
DULOXETINE;;G;rs61692318;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;;A;rs62319299;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
DULOXETINE;TEX10;G;rs10124893;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;INVS;G;rs10123866;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ABEMACICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN
ABEMACICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN
PALBOCICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN
PALBOCICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN
RIBOCICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN
RIBOCICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN
AMLODIPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
DULOXETINE;;C;rs10007051;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;CHILDREN
DULOXETINE;ZNF385D;C;rs9879065;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;;C;rs55881666;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
INFLIXIMAB;;CC + CT;rs2097432;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE
VALPROIC ACID;CYP2C9;CC + CT;rs4918758;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE
DULOXETINE;;A;rs11933890;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE
DULOXETINE;ZNF385D;C;rs9310658;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ZNF385D;A;rs7653345;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VALPROIC ACID;ABAT;GG;rs1731017;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE
DULOXETINE;ZNF385D;T;rs9310657;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ZNF385D;G;rs9824595;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ZNF385D;C;rs9873889;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ZNF385D;G;rs9819548;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
CAPECITABINE;CDA;CC;rs532545;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;GG;rs1799983;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HEART FAILURE;PEOPLE
WARFARIN;CYP2C9;C;rs56165452;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ADALIMUMAB;CRP;AG + GG;rs1130864;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
OLANZAPINE;CYP3A43;AA;rs472660;DOSAGE;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;CYP3A43;AA;rs472660;EFFICACY;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;CYP3A43;AA;rs472660;TOXICITY;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;CYP3A43;AA;rs472660;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
GLATIRAMER ACETATE;EOMES;T;rs2371108;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
CARVEDILOL;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANGINA PECTORIS;PEOPLE
ETOPOSIDE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
ADALIMUMAB;ATG5;CC + CT;rs9373839;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
DULOXETINE;MIEF2;G;rs56355515;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;MIEF2;G;rs12603700;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ADALIMUMAB;ATG5;CT + TT;rs510432;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE
DULOXETINE;MIEF2;G;rs3889402;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
AZATHIOPRINE;AOX1;G;rs55754655;EFFICACY;DECREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;AOX1;AG + GG;rs55754655;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;AA;rs1799998;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HEART FAILURE;PEOPLE
DULOXETINE;;G;rs58042962;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A4;C;rs2740574;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DULOXETINE;;T;rs10771997;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
FENOFIBRATE;LPL;GG;rs320;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
DULOXETINE;FCN2;T;rs3124955;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
FENOFIBRATE;APOA1;CG;rs2727786;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
DULOXETINE;FCN2;A;rs3128624;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;;A;rs7306991;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
GLATIRAMER ACETATE;CLEC16A;A;rs6498169;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;
DULOXETINE;;C;rs10771999;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;;A;rs10771998;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;SKIC3;G;rs12657120;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ETHOSUXIMIDE;CACNA1H;T;rs61734410;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN
DULOXETINE;SKIC3;G;rs4639250;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;;A;rs4437856;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ETHOSUXIMIDE;CACNA1I;T;rs3747178;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN
DULOXETINE;TREML4;A;rs9369266;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
AZATHIOPRINE;MOCOS;AA + AC;rs594445;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DULOXETINE;TREML4;G;rs13204353;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
LAMOTRIGINE;ABCB1;A;rs2032582;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN
CYCLOSPORINE;CALM1;T;rs12885713;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE
IRBESARTAN;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE
IRBESARTAN;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE
DULOXETINE;;C;rs2419128;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DULOXETINE;;G;rs12502866;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DULOXETINE;;T;rs12094644;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CAPECITABINE;CDA;AA + AC;rs2072671;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN
LAMOTRIGINE;CACNA1H;A;rs2753326;EFFICACY;INCREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN
RIVAROXABAN;ABCB1;GG;rs4728709;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
ATENOLOL;ADRA2A;GG;rs1800545;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE
ATENOLOL;ADRA2A;GG;rs1800545;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CYCLOSPORINE;;G;rs2874116;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE
IRBESARTAN;APOB;CC;rs1801701;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE
IRBESARTAN;APOB;CC;rs1801701;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE
RIVAROXABAN;ABCB1;CC;rs4148738;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
MEPHENYTOIN;CYP2C19;T;rs183701923;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;A;rs140278421;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;T;rs4803419;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CHLORPROMAZINE;DRD2;GG;rs1799732;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METHOTREXATE;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
BENAZEPRIL;AGT;TT;rs7079;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
OMEPRAZOLE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
OPIOIDS;OPRM1;AA;rs1799971;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;OPRM1;AA;rs1799971;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
NELFINAVIR;CYP2C19;AA;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TOLBUTAMIDE;CYP2C9;C;rs771237265;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TOLBUTAMIDE;CYP2C9;T;rs762081829;METABOLISM/PK;DECREASED;CLEARANCE;;;
METFORMIN;SLC22A1;A;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;A;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
MEPHENYTOIN;CYP2C19;A;rs145119820;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;C;rs761895497;METABOLISM/PK;DECREASED;CLEARANCE;;;
WARFARIN;F7;AA + AG;rs510317;DOSAGE;INCREASED;DOSE;;;
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MEPHENYTOIN;CYP2C19;T;rs61311738;METABOLISM/PK;DECREASED;CLEARANCE;;;
SULFONAMIDES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
SULFONAMIDES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
UREA DERIVATIVES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
BENAZEPRIL;AGT;G;rs4762;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
BENAZEPRIL;AGT;A;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FLUOROURACIL;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
BENAZEPRIL;AGT;T;rs7079;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
FENOFIBRATE;APOA5;CG + GG;rs3135506;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
PRAVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
SIMVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
EFAVIRENZ;CYP2B6;AG;rs35303484;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;CHILDREN
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
CITALOPRAM;;CT;rs585719;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
ISONIAZID;CYP2E1;A;rs6413432;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs4803419;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;CHILDREN
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
WARFARIN;GATA4;TT;rs2645400;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
WARFARIN;GATA4;TT;rs4841588;DOSAGE;INCREASED;DOSE;;;
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;GG;rs7662029;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
BUPRENORPHINE;UGT2B7;CC;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHOTREXATE;SLCO1B1;CC;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;CC;rs7439366;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
METHOTREXATE;SLC19A1;AA;rs2838958;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;AC + CC;rs1057910;METABOLISM/PK;DECREASED;DOSE;;;
SILDENAFIL;VEGFA;AA;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;MEN
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;HEALTHY
SILDENAFIL;VEGFA;AA + AC;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;MEN
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
CAPTOPRIL;ACE2;GG;rs2106809;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;WOMEN
CYCLOPHOSPHAMIDE;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOXORUBICIN;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
PACLITAXEL;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;PEOPLE
BUPRENORPHINE;UGT2B7;GG;rs7662029;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
ECULIZUMAB;CR1;AG + GG;rs2274567;EFFICACY;DECREASED;RESPONSE;DISEASE;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;PEOPLE
MIRABEGRON;UGT1A4;GT;rs2011425;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
MYCOPHENOLIC ACID;UGT1A1;AG;rs4148323;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
MIRABEGRON;UGT1A3;AA;rs2008584;METABOLISM/PK;DECREASED;HALF-LIFE TIME;;;HEALTHY
MIRABEGRON;SLC6A2;CC;rs12708954;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
CLOZAPINE;DRD1;G;rs686;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;AA;rs7438135;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
FLUVASTATIN;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
MIRABEGRON;SLC19A1;TT;rs1051266;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
CLOZAPINE;DRD3;TT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
MERCAPTOPURINE;TPMT;G;rs12199316;DOSAGE;INCREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TICAGRELOR;CYP3A4;CC;rs56324128;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CANDESARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
IRBESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE
IRBESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
DOCETAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;PEOPLE
PACLITAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;PEOPLE
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
TEGAFUR / GIMERACIL / OTERACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CANDESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
TICAGRELOR;SLCO1B1;C;rs113681054;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
TICAGRELOR;SLCO1B1;T;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
GEMCITABINE;SLC29A1;A;rs760370;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
PACLITAXEL;SLC29A1;A;rs760370;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUVOXAMINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
METHYLPHENIDATE;CES1;CT;rs71647871;DOSAGE;DECREASED;DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
METHYLPHENIDATE;CES1;CT;rs71647871;METABOLISM/PK;DECREASED;DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
TICAGRELOR;UGT2B7;TT;rs61361928;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
QUETIAPINE;HTR1A;GG;rs6295;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;MEN
TICAGRELOR;CYP3A43;G;rs62471956;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;MEN
LAMOTRIGINE;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
ACETAMINOPHEN;SULT1A1;CC;rs1042028;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
OPIOIDS;IL2;AA;rs2069762;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;IL2;AA;rs2069762;DOSAGE;INCREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE
OPIOIDS;BDNF;CC;rs6265;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;BDNF;CC;rs6265;DOSAGE;INCREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
VORICONAZOLE;CYP3A4;AG;rs4646437;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE
OPIOIDS;IL6;CC;rs1800795;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;IL6;CC;rs1800795;DOSAGE;INCREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE
ATENOLOL;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE
ATENOLOL;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE
IRBESARTAN;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE
IRBESARTAN;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE
TENOFOVIR;ABCC4;AA + AG;rs1059751;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEPATITIS B;PEOPLE
TENOFOVIR;ABCC4;AA + AG;rs1059751;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CHRONIC;PEOPLE
CAFFEINE;CYP1A1;T;rs2472297;METABOLISM/PK;INCREASED;METABOLISM;;;
DOCETAXEL;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
OPIOIDS;IL1B;AA + AG;rs1143634;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
OPIOIDS;IL1B;AA + AG;rs1143634;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASMS;PEOPLE
FENOFIBRATE;SCARB1;CT + TT;rs4238001;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
TENOFOVIR;SLC22A6;TT;rs4149170;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEPATITIS B;PEOPLE
TENOFOVIR;SLC22A6;TT;rs4149170;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CHRONIC;PEOPLE
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
OPIOIDS;OPRD1;CC;rs678849;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
OPIOIDS;OPRD1;CC;rs678849;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASMS;PEOPLE
ACENOCOUMAROL;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
IRBESARTAN;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE
IRBESARTAN;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE
PEGINTERFERON ALFA-2A;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ATALUREN;CFTR;T;rs75039782;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
FENOFIBRATE;APOA5;CC + CG;rs3135506;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
INSULIN RECOMBINANT;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
ZINC ACETATE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
METHYLPHENIDATE;DRD1;CT + TT;rs5326;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN
METFORMIN;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FENTANYL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FOLIC ACID;ATIC;CC;rs2372536;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ATIC;CC;rs2372536;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CORTICOSTEROIDS;ADAM33;AA;rs2853209;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;AA;rs2853209;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
LITHIUM;GADL1;T;rs17026688;EFFICACY;INCREASED;RESPONSE;OTHER;BIPOLAR DISORDER;PEOPLE
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
FOLIC ACID;ITPA;CC;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;TT;rs9923231;METABOLISM/PK;DECREASED;DOSE;;;
WARFARIN;GGCX;C;rs12714145;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;ADA;C;rs244076;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ADORA2A;T;rs5751876;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
FOLIC ACID;AMPD1;A;rs17602729;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;AMPD1;A;rs17602729;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
RITUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
FLUOROURACIL;EGFR;CC;rs2293347;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
ANTIDEPRESSANTS;TGFBR3;TT;rs12082710;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ALLOPURINOL;ABCG2;T;rs2231142;DOSAGE;INCREASED;DOSE;DISEASE;GOUT;PEOPLE
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;
RIFAMPIN;AADAC;GG;rs1803155;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;TUBERCULOSIS;PEOPLE
ABIRATERONE;SLCO2B1;AA + AG;rs1077858;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CETUXIMAB;AREG;AA;rs9996584;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PANITUMUMAB;AREG;AA;rs9996584;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CETUXIMAB;AREG;GG;rs1353295;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PANITUMUMAB;AREG;GG;rs1353295;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"BURKITT LYMPHOMA""";PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:LYMPHOMA";PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"T-CELL""";PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";PEOPLE
RIFAMPIN;ABCB1;CC;rs3842;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;TUBERCULOSIS;PEOPLE
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"BURKITT LYMPHOMA""";PEOPLE
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:LYMPHOMA";PEOPLE
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"T-CELL""";PEOPLE
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";PEOPLE
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
METHYLPHENIDATE;DRD1;CC + CT;rs4867798;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN
METHYLPHENIDATE;DRD3;TT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN
METHYLPHENIDATE;DRD4;AA;rs11246226;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
METHYLPHENIDATE;ADRA2A;CC;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN
METHYLPHENIDATE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN
ESTRONE SULFATE;SLCO1B1;C;rs10841753;EFFICACY;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN
DOBUTAMINE;GNAS;CC + CT;rs62205366;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
ESTRONE SULFATE;SLCO1B1;C;rs10841753;METABOLISM/PK;DECREASED;;OTHER;BREAST NEOPLASMS;WOMEN
WARFARIN;GGCX;TT;rs12714145;DOSAGE;INCREASED;DOSE;;;
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CETUXIMAB;AREG;GG;rs13104811;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PANITUMUMAB;AREG;GG;rs13104811;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CETUXIMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ANTIDEPRESSANTS;CRHR1;AA + AG;rs28364032;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;rs4148324;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
CYCLOSPORINE;POR;T;rs1057868;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
PEGINTERFERON ALFA-2A;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TIPIRACIL HYDROCHLORIDE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TRIFLURIDINE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ETHANOL;ADH1B;A;rs2018417;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1B;A;rs2018417;METABOLISM/PK;;METABOLISM;;;
ETHANOL;ADH1B;C;rs17033;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1B;C;rs17033;METABOLISM/PK;;METABOLISM;;;
ETHANOL;ADH1B;G;rs1229985;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1B;G;rs1229985;METABOLISM/PK;;METABOLISM;;;
PHENPROCOUMON;PPARA;A;rs4253728;DOSAGE;INCREASED;DOSE;;;
ETHANOL;ADH1A;A;rs931635;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1A;A;rs931635;METABOLISM/PK;;METABOLISM;;;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
METHADONE;KCNJ6;TT;rs2070995;;INCREASED;DOSE;DISEASE;SUBSTANCE-RELATED DISORDERS;PEOPLE
ETHANOL;ADH1C;A;rs283416;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1C;A;rs283416;METABOLISM/PK;;METABOLISM;;;
ROSIGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ROSIGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
ETHANOL;ADH1C;A;rs283411;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1C;A;rs283411;METABOLISM/PK;;METABOLISM;;;
ETHANOL;ADH1C;C;rs1662060;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1C;C;rs1662060;METABOLISM/PK;;METABOLISM;;;
TACROLIMUS;SUMO4;AA;rs237025;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;VKORC1;TT;rs17878544;DOSAGE;DECREASED;DOSE;;;
HMG-COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED;RESPONSE;;;
ACENOCOUMAROL;VKORC1;AA + AG;rs7200749;DOSAGE;INCREASED;DOSE;;;
HMG-COA_REDUCTASE_INHIBITORS;ABCG2;G;rs2231142;EFFICACY;DECREASED;RESPONSE;;;
ACENOCOUMAROL;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;A;rs7200749;DOSAGE;INCREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;
CITALOPRAM;NEDD4L;A;rs520210;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
HMG-COA_REDUCTASE_INHIBITORS;TOMM40;G;rs2075650;EFFICACY;DECREASED;RESPONSE;;;
ACENOCOUMAROL;VKORC1;CT + TT;rs55894764;DOSAGE;INCREASED;DOSE;;;
VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs28898617;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;CHILDREN
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
METHYLPHENIDATE;PEBP4;T;rs17685420;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE
ARIPIPRAZOLE;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
VERAPAMIL;ITGAL;C;rs2230433;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MIGRAINE DISORDER;PEOPLE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
PAZOPANIB;KDR;AG;rs34231037;EFFICACY;INCREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ETHANOL;ADH7;C;rs1154461;TOXICITY;;METABOLISM;;;
ETHANOL;ADH7;C;rs1154461;METABOLISM/PK;;METABOLISM;;;
HEPATITIS VACCINES;IL4R;C;rs1805015;EFFICACY;INCREASED;RESPONSE;;;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ETHANOL;ADH1A;C;rs1229967;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1A;C;rs1229967;METABOLISM/PK;;METABOLISM;;;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ETHANOL;ADH1A;C;rs2276332;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1A;C;rs2276332;METABOLISM/PK;;METABOLISM;;;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BENAZEPRIL;AGT;CC;rs5051;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IMIDAPRIL;AGT;CC;rs5051;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ETHANOL;ADH1A;C;rs1229976;TOXICITY;;METABOLISM;;;
ETHANOL;ADH1A;C;rs1229976;METABOLISM/PK;;METABOLISM;;;
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHOLANGITIS;PEOPLE
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;A;rs4244285;METABOLISM/PK;;EXPOSURE;;;
HEPATITIS VACCINES;IL13;T;rs1295686;EFFICACY;DECREASED;RESPONSE;;;
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
PEGINTERFERON ALFA-2B;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
DABIGATRAN;CES1;AA + AG;rs8192935;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
IRINOTECAN;VDR;TT;rs11574077;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
METHYLPHENIDATE;ADGRL3;AA;rs1868790;EFFICACY;DECREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
METHYLPHENIDATE;SNAP25;GG + GT;rs3746544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
METHYLPHENIDATE;SLC6A3;CC + CT;rs2550948;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;
INTERFERONS;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
MORPHINE;SLC22A1;AA + AG;rs34059508;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
PLATINUM;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;A;rs10514475;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;A;rs6108160;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
WARFARIN;LRP1;TT;rs1800139;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP4F2;T;rs2108622;EFFICACY;INCREASED;DOSE;;;
WARFARIN;LRP1;CC;rs1800154;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
NICOTINE;CYP2A6;T;rs56113850;METABOLISM/PK;DECREASED;CLEARANCE;;;
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RESPONSE;;;
INTERFERONS;IFNL3;GG;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PHENPROCOUMON;VKORC1;AA + AG;rs2359612;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP4F2;T;rs2108622;EFFICACY;INCREASED;DOSE;;;
PLATINUM COMPOUNDS;XRCC1;G;rs1799782;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
MORPHINE;SLC22A1;TT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN
FLUOROURACIL;LGR5;CC + CT;rs17109924;EFFICACY;INCREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
MORPHINE;SLC22A1;AA;rs34059508;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN
ACETAMINOPHEN;UGT2B15;A;rs1902023;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
MORPHINE;SLC22A1;AA;rs34130495;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN
ACETAMINOPHEN;UGT2B15;AA;rs1902023;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
ATORVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED;RESPONSE;;;
PRAVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED;RESPONSE;;;
CAPECITABINE;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED;DOSE;OTHER;NEOPLASMS;WOMEN
FLUOROURACIL;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED;DOSE;OTHER;NEOPLASMS;WOMEN
PITAVASTATIN;SLCO1B1;A;rs4363657;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
PITAVASTATIN LACTONE;SLCO1B1;A;rs4363657;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ROSUVASTATIN;ABCG2;AG + GG;rs1481012;EFFICACY;INCREASED;RESPONSE;;;
SOMATROPIN RECOMBINANT;CDK4;CC;rs2069502;EFFICACY;DECREASED;RESPONSE;DISEASE;TURNER SYNDROME;CHILDREN
ATORVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED;RESPONSE;;;
PRAVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED;RESPONSE;;;
METFORMIN;FMO5;A;rs7541245;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
ROSUVASTATIN;USP24;CC + CT;rs17111584;EFFICACY;DECREASED;RESPONSE;;;
PITAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
PITAVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
INTERFERON BETA-1A;RORA;TT;rs4774388;EFFICACY;INCREASED;RESPONSE;OTHER;MULTIPLE SCLEROSIS;PEOPLE
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
REMIMAZOLAM;CES1;CT + TT;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
NICOTINE;;T;rs113288603;METABOLISM/PK;DECREASED;CLEARANCE;;;
ROSUVASTATIN;APOE;CC + CT;rs71352238;EFFICACY;DECREASED;RESPONSE;;;
METHYLPHENIDATE;ADRA2A;GG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
NICOTINE;;A;rs12461964;METABOLISM/PK;DECREASED;CLEARANCE;;;
ROSUVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;RESPONSE;;;
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
SIMVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE
ROSUVASTATIN;LPA;AG + GG;rs10455872;EFFICACY;DECREASED;RESPONSE;;;
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs887829;METABOLISM/PK;INCREASED;METABOLISM;;;
METHYLPHENIDATE;BDNF;CC;rs6265;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
EFAVIRENZ;CYP2B6;GG + GT;rs3745274;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ATORVASTATIN;CYP3A7;G;rs45446698;METABOLISM/PK;INCREASED;METABOLISM;;;
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:TOBACCO USE DISORDER;PEOPLE
EFAVIRENZ;CYP2B6;G;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;T;rs2279345;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;;;
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;;;
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
EFAVIRENZ;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
SOMATROPIN RECOMBINANT;CDK4;TT;rs2270777;EFFICACY;INCREASED;RESPONSE;DISEASE;GROWTH HORMONE DEFICIENCY;CHILDREN
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ATALUREN;CFTR;T;rs75039782;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;
METFORMIN;PRPF31;C;rs254271;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;PRPF31;C;rs254271;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
GABAPENTIN;SLC7A5;AG;rs4240803;DOSAGE;INCREASED;DOSE;OTHER;NEUROPATHIC PAIN;PEOPLE
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
METFORMIN;NBEA;C;rs57081354;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;NBEA;C;rs57081354;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
SUMATRIPTAN;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
METFORMIN;SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
FENOTEROL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
FENOTEROL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
FENOTEROL;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
SUMATRIPTAN;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED;RESPONSE;OTHER;LUPUS NEPHRITIS;PEOPLE
SUMATRIPTAN;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
DRUGS USED IN DIABETES;IRS1;CT + TT;rs1801278;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
DRUGS USED IN DIABETES;IRS1;CT + TT;rs1801278;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
SUMATRIPTAN;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
METHOTREXATE;MTRR;A;rs1801394;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
FLUOROURACIL;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FENOTEROL;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
HYDROCHLOROTHIAZIDE;NEDD4L;A;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
WARFARIN;CYP4F2;CT;rs2108622;DOSAGE;INCREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE
EMTRICITABINE;ABCC2;TT;rs2273897;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EMTRICITABINE;ABCC2;TT;rs2273897;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;PEOPLE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
CYCLOGUANIL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
CYCLOGUANIL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
GABAPENTIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED;RESPONSE;OTHER;NEUROPATHIC PAIN;PEOPLE
PREGABALIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED;RESPONSE;OTHER;NEUROPATHIC PAIN;PEOPLE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
MORPHINE;COMT;AA;rs4680;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
MORPHINE;COMT;AA;rs4680;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
MORPHINE;COMT;AA;rs4680;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
MORPHINE;COMT;AA;rs4680;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
METFORMIN;CPA6;T;rs2162145;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;CPA6;T;rs2162145;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
SALBUTAMOL;DUSP1;G;rs881152;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;
TRAMADOL;SLC22A1;A;rs34059508;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
TACROLIMUS;SLCO1B3;GG + GT;rs4149117;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE
ESCITALOPRAM;IL11;CT + TT;rs1126757;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
CLOPIDOGREL;CES1;CT + TT;rs2307240;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
TACROLIMUS;SLC2A2;CC;rs1499821;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
ABIRATERONE;YBX1;AC + CC;rs10493112;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PROSTATIC NEOPLASMS;MEN
TACROLIMUS;NFATC4;CC + CT;rs1955915;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE
GRAZOPREVIR;SLCO1B1;C;rs4149056;PD;INCREASED;EXPOSURE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BISOPROLOL;CYP2D6;CC;rs1080985;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
GRAZOPREVIR;SLCO1B1;A;rs11045819;PD;INCREASED;EXPOSURE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;C;rs9923231;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;;;
WARFARIN;VKORC1;C;rs9923231;METABOLISM/PK;INCREASED;DOSE;;;
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;
METHADONE;BDNF, BDNF-AS;C;rs7127507;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ENALAPRIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METHADONE;BDNF, BDNF-AS;G;rs11030118;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;VKORC1;AG + GG;rs2359612;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;DECREASED;DOSE;;;CHILDREN
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
METHADONE;BDNF, BDNF-AS;C;rs1967554;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;
BISOPROLOL;CYP2D6;G;rs1080985;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;
METHADONE;BDNF;G;rs2030324;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
BISOPROLOL;CYP2D6;CT + TT;rs3892097;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME;PEOPLE
BUSULFAN;GSTA1;AA;rs3957357;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;TRANSPLANTATION;CHILDREN
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
ENALAPRIL;BDKRB2;TT;rs1799722;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METHADONE;BDNF;C;rs988748;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED;DOSE;;;
TRAMADOL;SLC22A1;C;rs55918055;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
CELECOXIB;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHADONE;BDNF;G;rs11030119;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE
TRAMADOL;SLC22A1;T;rs12208357;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
FENTANYL;CYP3A4;T;rs2242480;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;CYP3A4;T;rs2242480;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
CELECOXIB;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN
BISOPROLOL;CYP3A5;TT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
TRAMADOL;SLC22A1;A;rs34130495;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;AA;rs4149570;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;AA;rs4149570;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;AA + AG;rs5030728;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
METFORMIN;SLC47A1;CT + TT;rs8065082;EFFICACY;INCREASED;RESPONSE;OTHER;GLUCOSE INTOLERANCE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;TT;rs4696480;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;AA + AT;rs2430561;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;AA + AT;rs2430561;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;TT;rs352139;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;TT;rs352139;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
WARFARIN;VKORC1L1;AA;rs4072879;DOSAGE;DECREASED;DOSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CC + CT;rs3804099;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CT + TT;rs1816702;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SUFENTANIL;OPRM1;G;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
OPIOIDS;ENPP2;AA;rs2249015;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;ENPP2;AA;rs2249015;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
DONEPEZIL;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
GALANTAMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
ATORVASTATIN;APOE;CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;CC + CT;rs10499563;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;CC + CT;rs10499563;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;AA + AG;rs2275913;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;AA + AG;rs2275913;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
LATANOPROST;ABCC4;AC;rs11568658;EFFICACY;DECREASED;RESPONSE;DISEASE;OPEN-ANGLE GLAUCOMA;PEOPLE
ADALIMUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ETANERCEPT;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
USTEKINUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;CC + CT;rs1554973;EFFICACY;DECREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
BOTULINUM TOXIN TYPE A;CALCA;G;rs3781719;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE DISORDER;WOMEN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;AA + AG;rs2569190;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
BOTULINUM TOXIN TYPE A;TRPV1;A;rs222749;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE DISORDER;WOMEN
OPIOIDS;ENPP2;AA;rs7832704;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;ENPP2;AA;rs7832704;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AA + AG;rs4848306;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AA + AG;rs4848306;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;CC + CT;rs4251961;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;CG + GG;rs6927172;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;CG + GG;rs6927172;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;APOE;CC;rs429358;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE
LOSARTAN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
PEMETREXED;FOLR3;CT + TT;rs61734430;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PEMETREXED;FOLR3;CT + TT;rs61734430;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MESOTHELIOMA;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
METOPROLOL;GRK4;CT;rs1801058;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;WOMEN
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FLUOXETINE;HTR2A;GG;rs7997012;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;CHILDREN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATION;PEOPLE
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ELBASVIR / GRAZOPREVIR;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
METOPROLOL;GRK4;GT + TT;rs2960306;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;MEN
TACROLIMUS;ABCC2;CT + TT;rs3740066;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;ABCC2;CT + TT;rs3740066;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LYMPHOMA;PEOPLE
TACROLIMUS;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METOPROLOL;GRK4;CC;rs1024323;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;MEN
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATION;PEOPLE
METHADONE;GAD1;G;rs3762556;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
METHADONE;GAD1;TT;rs769404;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
ROCURONIUM;SLCO1A2;T/del + TT;rs3834939;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
CLOZAPINE;CYP1A2;AA + AC;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
ARIPIPRAZOLE;CYP2D6;GG;rs1058164;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ARIPIPRAZOLE;CYP2D6;AA;rs28371699;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TICAGRELOR;CYP4F2;AA;rs2074900;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CLOZAPINE;UGT1A4;C;rs2011404;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;UGT1A4;C;rs2011404;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
URIC ACID;VEGFC;C;rs1002976;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERTENSION;PEOPLE
LETERMOVIR;SLCO1B1;TT;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;;;
CLOZAPINE;UGT1A1;T;rs34946978;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;UGT1A1;T;rs34946978;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
METFORMIN;CAPN10;G;rs3792269;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
LETERMOVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;
LETERMOVIR;UGT1A1;AA + AG;rs4148323;METABOLISM/PK;INCREASED;EXPOSURE;;;
INTERFERON BETA-1A;FHIT;C;rs760316;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;FHIT;C;rs760316;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
GLYBURIDE;FMO2;T;rs7512785;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
METHOTREXATE;MTRR;AG + GG;rs1801394;EFFICACY;INCREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN
PROPRANOLOL;ADRB2;GG;rs1042713;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE
METHOTREXATE;ABCB1;AA;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN
CLOZAPINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;DECREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
METHOTREXATE;SLC16A7;T;rs12231740;EFFICACY;DECREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN
METHOTREXATE;ARID5B;CC;rs4948496;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CLOZAPINE;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
FENOFIBRATE;APOE;CT + TT;rs7412;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
METHOTREXATE;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
METHADONE;GAD1;G;rs3762555;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN
METHADONE;GAD1;G;rs3749034;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
CLOZAPINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE
IGURATIMOD;NAT2;AG + GG;rs1495741;EFFICACY;DECREASED;CLINICAL BENEFIT;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INTERFERON BETA-1A;;T;rs4278350;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;;T;rs4278350;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
ARIPIPRAZOLE;CYP2D6;CC;rs28371702;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SITAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
VILDAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
VILDAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
IGURATIMOD;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
INTERFERON BETA-1A;GAPVD1;G;rs2291858;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;GAPVD1;G;rs2291858;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
METHADONE;OPRD1;GG;rs204047;DOSAGE;INCREASED;DOSE;;;
METHADONE;OPRD1;AA;rs797397;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHADONE;OPRD1;GG;rs204047;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ANTIPSYCHOTICS;ZNF804A;AA;rs1344706;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PLATINUM COMPOUNDS;XRCC1;CC + CT;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
INTERFERON BETA-1A;GAPVD1;T;rs10819043;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;GAPVD1;T;rs10819043;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1A;;A;rs3133084;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;;A;rs3133084;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
CAPECITABINE;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOCETAXEL;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
GLYBURIDE;CYP51A1;G;rs7793861;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
INTERFERON BETA-1A;;G;rs1448673;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;;G;rs1448673;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
GLYBURIDE;FMO2;T;rs7515157;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
ANASTROZOLE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
AMISULPRIDE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
QUETIAPINE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
URIC ACID;BRINP3;T;rs950569;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERTENSION;PEOPLE
GLYBURIDE;UGT2B15;G;rs4148269;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
INTERFERON BETA-1A;GAPVD1;C;rs10760397;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;GAPVD1;C;rs10760397;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
URIC ACID;PADI4;G;rs2477134;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERTENSION;PEOPLE
INTERFERON BETA-1A;ZNF697;A;rs10494227;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;ZNF697;A;rs10494227;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
DOXORUBICIN;ABCC5;TT;rs1533682;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN
PLATINUM COMPOUNDS;XRCC3;AA + AG;rs861539;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GLYBURIDE;MAPK1;A;rs1803545;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
GLYBURIDE;ABCC5;A;rs3749442;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
ARIPIPRAZOLE;CYP2D6;GG;rs1135840;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
GLYBURIDE;SPINK5;T;rs2303070;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
GLYBURIDE;BDKRB2;A;rs5224;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
GLYBURIDE;MAPK1;G;rs3729910;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
IGURATIMOD;ABCB1;CT + TT;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
ETHANOL;KLB;A;rs11940694;TOXICITY;DECREASED;DOSE;;;
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GLYBURIDE;ESR1;T;rs2077647;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:AUTOIMMUNE DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:PSORIASIS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ANTIDEPRESSANTS;BDNF;C;rs6265;EFFICACY;INCREASED;RESISTANCE;;;
FLUNISOLIDE;TBXT;TT;rs2305089;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
GRANISETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;NAUSEA;PEOPLE
GRANISETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;PEOPLE
PALONOSETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;NAUSEA;PEOPLE
PALONOSETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;PEOPLE
TACROLIMUS;IL6;GG;rs1800795;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
VALPROIC ACID;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;T;rs1061622;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE
TACROLIMUS;IL6;GG;rs1800795;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
RASAGILINE;DRD2;CC;rs1076560;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
RASAGILINE;DRD2;CC;rs2283265;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CTLA4;AG + GG;rs4553808;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ANTIDEPRESSANTS;BDNF-AS;T;rs10501087;EFFICACY;INCREASED;RESISTANCE;;;
TACROLIMUS;IL3;AA;rs181781;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
LAMOTRIGINE;UGT1A4;CC;rs6755571;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;WOMEN
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED;DOSE;;;
TELAPREVIR;CYP24A1;C;rs2585428;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CTLA4;AA;rs4553808;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VARENICLINE;CHRNA4;GG;rs1044396;EFFICACY;DECREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
ESCITALOPRAM;CYP1A2;T;rs4646425;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP1A2;G;rs2069526;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;CYP1A2;C;rs4646427;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;RESISTANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;A;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLARTHROPATHIES;PEOPLE
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
MORPHINE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED;RESISTANCE;;;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED;RESISTANCE;;;
EFAVIRENZ;CYP2B6;AG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE
FLUTICASONE PROPIONATE;ORMDL3;AA + AG;rs2872507;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ABATACEPT;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
RITUXIMAB;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TOCILIZUMAB;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
VALPROIC ACID;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;
ATAZANAVIR / RITONAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
DEFERASIROX;ABCG2;CT + TT;rs13120400;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN
ATAZANAVIR / RITONAVIR;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;T;rs10509680;DOSAGE;DECREASED;DOSE;;;
ADALIMUMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
GOLIMUMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ANGIOTENSIN II;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ANTIEPILEPTICS;NR3C1;GG;rs41423247;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
DEFERASIROX;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
FLUVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED;RESPONSE;;;
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
TALINOLOL;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
LAMOTRIGINE;UGT2B7;TT;rs7439366;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;CC + CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
RITODRINE;PDE4B;AA;rs598961;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PREMATURE BIRTH;WOMEN
TACROLIMUS;CYP3A4;G;rs4986910;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;G;rs4986910;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
LAMOTRIGINE;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;WOMEN
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PLATINUM COMPOUNDS;XPA;CC;rs1800975;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ARIPIPRAZOLE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
DEHYDROARIPIPRAZOLE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ARIPIPRAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
ARIPIPRAZOLE;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;IL10;AA;rs1800871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ANTIHYPERTENSIVES;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE
HYDRALAZINE;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE
METHYLDOPA;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE
NIFEDIPINE;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;RHEUMATIC HEART DISEASE;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:CORONARY ARTERY DISEASE;PEOPLE
DACLATASVIR;VDR;TT;rs11568820;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
MORPHINE;COMT;AG + GG;rs4680;EFFICACY;INCREASED;DOSE;;;
METHYLDOPA;MMP9;CT + TT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE
DACLATASVIR;CYP24A1;CT + TT;rs2248359;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
CALCIUM CHANNEL BLOCKERS;NUMA1;GG;rs10898815;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
CALCIUM CHANNEL BLOCKERS;TANC2;GG;rs2429427;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
SIBUTRAMINE;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;OTHER;OBESITY;PEOPLE
CARBAMAZEPINE;ABCC2;AG;rs2273697;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
OXCARBAZEPINE;ABCC2;AG;rs2273697;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
BUSULFAN;GSTA1;T;rs3957356;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
S-EDDP;CYP2B6;CT;rs8192709;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
BUSULFAN;GSTA1;A;rs3957357;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN
SIMVASTATIN;UGT1A9;T;rs12052787;EFFICACY;INCREASED;RESPONSE;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIMVASTATIN;UGT1A9;A;rs2003569;EFFICACY;INCREASED;RESPONSE;;;
PLATINUM COMPOUNDS;ERCC4;TT;rs1799801;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
AMITRIPTYLINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
AMITRIPTYLINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CLOMIPRAMINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
CLOMIPRAMINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
DOXEPIN;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
DOXEPIN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
IMIPRAMINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
IMIPRAMINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
MAPROTILINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
MAPROTILINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
NORTRIPTYLINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
NORTRIPTYLINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
OPIPRAMOL;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
OPIPRAMOL;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE
PLATINUM COMPOUNDS;ERCC3;AG + GG;rs3738948;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TEGAFUR;CYP2A6;AA + AG;rs8192720;METABOLISM/PK;INCREASED;METABOLISM;;;
DIGOXIN;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;DOSE;;;HEALTHY
ANTIPSYCHOTICS;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
CHLORPROMAZINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
CLOZAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
HALOPERIDOL;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
OLANZAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
QUETIAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
RISPERIDONE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN
OXYCODONE;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE
OXYCODONE;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:PAIN;PEOPLE
TERBUTALINE;ADRB2;GG;rs1042714;METABOLISM/PK;INCREASED;RESPONSE;;;HEALTHY
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
BUPROPION;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
RISPERIDONE;HRH4;TT;rs4483927;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ATENOLOL;GRK4;T;rs2960306;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ATENOLOL;GRK4;T;rs1024323;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
CALCIUM CHANNEL BLOCKERS;PICALM;GG;rs588076;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
DELEOBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
FALDAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN
PROPOFOL;GABRA2;CC;rs11503014;OTHER;DECREASED;RESPONSE;;;
WARFARIN;HNF4A;T;rs3212198;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
CODEINE;CYP1B1;C;rs1056836;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN
TRAMADOL;CYP1B1;C;rs1056836;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;NR1I3;TT;rs2501873;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
VERAPAMIL;PCDHB8;G;rs3733694;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE DISORDER;PEOPLE
RIVAROXABAN;POR;TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
VERAPAMIL;PCDHB6;A;rs17844444;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE DISORDER;PEOPLE
CAPECITABINE;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
CETUXIMAB;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;
ATORVASTATIN;AGTR1;AC;rs5186;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;BDKRB2;CT;rs1799722;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
LOSARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
HEROIN;OPRM1;AG;rs9479757;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;T;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;MEN
SEROTONIN;MAOB;T;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;MEN
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
RIVAROXABAN;ABCB1;CT;rs4148738;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;TT;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;WOMEN
SEROTONIN;MAOB;TT;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;WOMEN
APIXABAN;POR;T;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
OXCARBAZEPINE;UGT1A9;CC;rs2741049;EFFICACY;INCREASED;RESPONSE;DISEASE;SEIZURES;PEOPLE
CODEINE;CYP1B1;A;rs1056837;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN
TRAMADOL;CYP1B1;A;rs1056837;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN
CANDESARTAN;CYP11B2;GG;rs1799998;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
3-HYDROXYCOTININE;;CC + CT;rs4105144;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
HYDROCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
OXYCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
3-HYDROXYCOTININE;EGLN2;AA + AG;rs3733829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE
HYDROCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
OXYCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
BENAZEPRIL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DEFERASIROX;CYP1A1;AC + CC;rs2606345;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PITRAKINRA;IL4R;GG;rs1029489;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
RADIOTHERAPY;CACNA2D3;AG + GG;rs11130424;EFFICACY;INCREASED;RESISTANCE;OTHER;NASOPHARYNGEAL NEOPLASMS;PEOPLE
HYDROXYUREA;MAP3K5;CC;rs9483947;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ANTIHYPERTENSIVES;CLNK;G;rs13144136;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROXYUREA;MAP3K5;CC;rs9376230;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
ATORVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;MEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
LENALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
THALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ANTIDEPRESSANTS;MAOA;AA;rs979605;METABOLISM/PK;DECREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHOTREXATE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ETHANOL;ALDH2;AG;rs671;OTHER;INCREASED;EXPOSURE;;;MEN
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
HYDROCHLOROTHIAZIDE;NEDD4L;CC + CG;rs292449;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
PITRAKINRA;IL4R;GG;rs8832;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PITRAKINRA;IL4R;AA;rs3024530;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
PITRAKINRA;IL4R;AA;rs1110470;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
PITRAKINRA;IL4R;AA;rs2239347;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
BENAZEPRIL;MTR;AG + GG;rs1805087;EFFICACY;DECREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
PITRAKINRA;IL4R;AA;rs1805010;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
VORICONAZOLE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;GG;rs9934438;TOXICITY;INCREASED;DOSE;;;
PHENPROCOUMON;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
PHENPROCOUMON;VKORC1;GG;rs9934438;TOXICITY;INCREASED;DOSE;;;
SULINDAC;FMO3;AA;rs2266782;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
MYCOPHENOLATE MOFETIL;SLCO1B3;A;rs7311358;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SULINDAC;FMO3;GG;rs2266780;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
MORPHINE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3;C;rs8105790;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;C;rs8105790;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ATORVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;
PEGINTERFERON ALFA-2A;IFNL3;C;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;C;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
MEMANTINE;NR1I2;CT + TT;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DEMENTIA;PEOPLE
BENAZEPRIL;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;G;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;G;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;A;rs7248668;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;A;rs7248668;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
AMISULPRIDE;ANKS1B;CC;rs7968606;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;C;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;C;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;C;rs4803219;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;C;rs4803219;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
MORPHINE;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
ESCITALOPRAM;;A;rs2069521;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
ROSUVASTATIN;SCARB1;CC;rs4238001;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MYOCARDIAL ISCHEMIA;PEOPLE
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
LACOSAMIDE;ABCC2;GG;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
OLANZAPINE;SV2C;TT;rs11960832;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CORTICOSTEROIDS;TBX21;CG;rs2240017;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
METHOTREXATE;ABCC1;GG;rs2238476;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ANTIDEPRESSANTS;HTR2A;AG + GG;rs6314;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CARBAMAZEPINE;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LAMOTRIGINE;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PHENYTOIN;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PRIMIDONE;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
CARBAMAZEPINE;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LAMOTRIGINE;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PHENYTOIN;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PRIMIDONE;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CARBAMAZEPINE;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LAMOTRIGINE;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PHENYTOIN;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PRIMIDONE;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
CARBAMAZEPINE;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LAMOTRIGINE;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PHENYTOIN;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PRIMIDONE;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
CARBAMAZEPINE;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LAMOTRIGINE;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PHENYTOIN;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
PRIMIDONE;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
DULOXETINE;ANO2;C;rs61908411;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;C;rs61908409;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;T;rs61908410;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;A;rs78615940;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;G;rs78482393;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;C;rs61908405;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;G;rs61908406;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;A;rs2781659;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
DULOXETINE;ANO2;C;rs61908404;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;A;rs61908408;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;A;rs61908407;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;G;rs17786412;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
DULOXETINE;ANO2;A;rs17786400;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHADONE;ABCB1;C;rs9282564;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
DULOXETINE;ANO2;G;rs61908403;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;T;rs61908402;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
DULOXETINE;ANO2;C;rs17724452;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
GLATIRAMER ACETATE;PVT1;A;rs2114358;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
DULOXETINE;;G;rs7316769;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;C;rs17724494;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;CT;rs56165452;DOSAGE;DECREASED;DOSE;;;
METHADONE;ABCB1;A;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
DULOXETINE;ANO2;T;rs17786394;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DULOXETINE;ANO2;G;rs17724464;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHADONE;UGT2B7;CT;rs7439366;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
PEMETREXED;CCND1;A;rs9344;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;CCND1;A;rs9344;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;
LIRAGLUTIDE;GLP1R;CT + TT;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;OBESITY;WOMEN
LIRAGLUTIDE;GLP1R;CT + TT;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:POLYCYSTIC OVARY SYNDROME;WOMEN
LAMOTRIGINE;CACNA1H;A;rs2753325;EFFICACY;INCREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN
AZATHIOPRINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;DOSE;;;
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;CC + CT;rs2297595;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
ASPIRIN;GP1BA;CT + TT;rs6065;EFFICACY;INCREASED;RESPONSE;;;MEN
FLUOROURACIL;DPYD;CT + TT;rs1801160;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
FLUOROURACIL;DPYD;GG;rs1801265;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
LACOSAMIDE;ABCC2;CC;rs717620;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
ANASTROZOLE;;G;rs11648166;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN
LACOSAMIDE;ABCC2;A;rs2273697;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN
LACOSAMIDE;ABCC2;T;rs717620;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN
ANASTROZOLE;;T;rs28845026;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRAZODONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS;PEOPLE
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
SIMVASTATIN ACID;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
METHOTREXATE;ARID5B;A;rs10994982;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS;PEOPLE
IMATINIB;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
FENOFIBRATE;PPARA;GG;rs4253778;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METHOTREXATE;SLC22A11;AT + TT;rs11231809;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ABCC1;AG + GG;rs246240;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs3846662;EFFICACY;DECREASED;RESPONSE;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA;WOMEN
METHOTREXATE;ABCC1;AG + GG;rs3784864;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CYCLOPHOSPHAMIDE;CYP2C19;AG + GG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;CC + CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;C;rs7254579;METABOLISM/PK;;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;;A;rs445925;EFFICACY;INCREASED;RESPONSE;;;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED;RESPONSE;;;
FENOFIBRATE;IL6;CC + CG;rs1800795;EFFICACY;INCREASED;RESPONSE;OTHER;PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASE;
RANIBIZUMAB;NRP1;T;rs2070296;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
ATORVASTATIN;CETP;GG;rs708272;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ATORVASTATIN;CETP;GG;rs708272;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
PEGINTERFERON ALFA-2A;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
METHOTREXATE;ABCG2;CC;rs13120400;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;PSORIASIS;PEOPLE
NICOTINE;DBH;GG;rs77905;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
NICOTINE;MAOA;TT;rs1137070;DOSAGE;INCREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
OMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
PANTOPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE
DEFERASIROX;VDR;AA;rs7975232;METABOLISM/PK;;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN
FLUVOXAMINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MILNACIPRAN;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
DEFERASIROX;VDR;G;rs2228570;METABOLISM/PK;;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN
ANTIPSYCHOTICS;GRM3;AA;rs6465084;TOXICITY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
METFORMIN;SLC47A1;AA;rs2289669;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A1;AA;rs2289669;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TYPE 2;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;NR1I3;G;rs2307424;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;NR1I3;AG;rs2307424;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ANTIHYPERTENSIVES;ATP2B1;CT + TT;rs12817819;EFFICACY;INCREASED;RESISTANCE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
ANTIHYPERTENSIVES;ATP2B1;CT + TT;rs12817819;EFFICACY;INCREASED;RESISTANCE;DISEASE;DISEASE:HYPERTENSION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;EPHX1;CT;rs1051741;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;PRSS53, VKORC1;CT;rs7294;DOSAGE;INCREASED;DOSE;;;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ISONIAZID;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ISONIAZID;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
AMLODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FELODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ISONIAZID;SLCO1B1;CC;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ISONIAZID;SLCO1B1;CC;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
CALCIUM CHANNEL BLOCKERS;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;;;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;A;rs2900478;EFFICACY;DECREASED;RESPONSE;;;
CALCIUM CHANNEL BLOCKERS;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;CELSR2;C;rs646776;EFFICACY;INCREASED;RESPONSE;;;
VALPROIC ACID;UGT2B7;GG;rs12233719;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
EFAVIRENZ;CYP2A6;T;rs28399454;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CALCIUM CHANNEL BLOCKERS;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ATAZANAVIR;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;CYP2B6;AG;rs2279343;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
VALPROIC ACID;UGT2B7;CT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED;DOSE;;;
WARFARIN;APOC1, APOE;T;rs429358;DOSAGE;DECREASED;DOSE;OTHER;HAPLOTYPE EPSILON2;PEOPLE
VALPROIC ACID;UGT2B7;TT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
WARFARIN;APOC1, APOE;T;rs7412;DOSAGE;DECREASED;DOSE;OTHER;HAPLOTYPE EPSILON2;PEOPLE
INFLIXIMAB;;CC + CT;rs2097432;EFFICACY;INCREASED;DISCONTINUATION;EFFICACY;CROHN DISEASE;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
PHOTODYNAMIC THERAPY;CFH;TT;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
VALPROIC ACID;UGT2B7;TT;rs7439366;METABOLISM/PK;;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
RISPERIDONE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN
FLUOXETINE;HTR1B;CC + TT;rs9361233;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;CHILDREN
EFAVIRENZ;CYP2B6;CC;rs8192709;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
INFLIXIMAB;;T;rs73277969;EFFICACY;INCREASED;DISCONTINUATION;EFFICACY;CROHN DISEASE;PEOPLE
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
ASPIRIN;CYP2C19;T;rs12248560;;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;T;rs12248560;;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ASPIRIN;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED;RESPONSE;;;
PRASUGREL;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED;RESPONSE;;;
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ASPIRIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;
PRASUGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;TT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
IVACAFTOR;CFTR;C;rs397508453;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;CHILDREN
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
LOVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SIMVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIMVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
LOVASTATIN;PPARA;AG + GG;rs4823613;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
NEVIRAPINE;CYP1A2;CC;rs762551;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;WOMEN
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
SEROTONIN;ERICH3;T;rs696692;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DEPRESSIVE DISORDER;PEOPLE
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TACROLIMUS;ABCB1;AG + GG;rs1045642;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;EFFICACY;INCREASED;RESPONSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
SEROTONIN;TSPAN5;G;rs11947402;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DEPRESSIVE DISORDER;PEOPLE
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;G;rs3761847;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
THALIDOMIDE;CTNNB1;AA;rs4533622;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:CARDIOMYOPATHIES;PEOPLE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PERIPHERAL VASCULAR DISEASES;PEOPLE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
CYCLOPHOSPHAMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
DEXAMETHASONE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
THALIDOMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
OPIOIDS;IL17A;A;rs2275913;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;IL17A;A;rs2275913;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
OPIOIDS;IL17A;A;rs2275913;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
OPIOIDS;IL17A;A;rs2275913;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
PLATINUM COMPOUNDS;CYP1A1;CC + CT;rs1048943;EFFICACY;INCREASED;RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
TACROLIMUS;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
CITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
ESCITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;DOSE;;;
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A7;TT;rs10211;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;;CHILDREN
WARFARIN;VKORC1;C;rs9923231;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;C;rs9923231;EFFICACY;INCREASED;DOSE;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;INCREASED;RESPONSE;;;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;RESPONSE;;;
ACETAMINOPHEN;OPRM1;AA;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;NEUROPATHIC PAIN;PEOPLE
TRAMADOL;OPRM1;AA;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;NEUROPATHIC PAIN;PEOPLE
RITUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHADONE;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
COTININE;UGT2B10;CC;rs2942857;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TOBACCO USE DISORDER;PEOPLE
FENTANYL;;GG;rs6961071;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;PEOPLE
FENTANYL;;GG;rs6961071;EFFICACY;INCREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;G;rs2359612;DOSAGE;INCREASED;DOSE;;;
CYCLOPHOSPHAMIDE;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
DOXORUBICIN;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
FEC100;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
FLUOROURACIL;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHADONE;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
TOCILIZUMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CARVEDILOL;ADRB2;GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
FENTANYL;;GG;rs13093031;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;PEOPLE
FENTANYL;;GG;rs13093031;EFFICACY;INCREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE
LOVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE
SIMVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE
COTININE;UGT2B10;CC;rs2942857;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;TOBACCO USE DISORDER;PEOPLE
CLOPIDOGREL;ABCB1;A;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE CORONARY SYNDROME;PEOPLE
CISPLATIN;ERCC1;A;rs11615;EFFICACY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;WOMEN
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED;DOSE;;;
WARFARIN;PRSS53, VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;DOSE;;;
PHENOBARBITAL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
TACROLIMUS;FMO3;CC;rs1800822;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
FENOFIBRATE;CRP;TT;rs1417938;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE
METFORMIN;SLC22A3;G;rs2076828;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FLUOXETINE;HTR1B;CC + TT;rs9361235;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;CHILDREN
N-DESMETHYLCLOZAPINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
WARFARIN;NQO1;GG;rs10517;DOSAGE;DECREASED;DOSE;;;
FENOFIBRATE;CRP;AG + GG;rs3091244;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE
PRAVASTATIN;MMP3;A/del + AA;rs35068180;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;MEN
N-DESMETHYLCLOZAPINE;UGT1A4;G;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
FENOFIBRATE;CRP;GG + GT;rs3091244;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE
FENTANYL;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE
FENTANYL;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:PAIN;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
CLOZAPINE;CYP2C18;T;rs1126545;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
SIMVASTATIN;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
DESLORATADINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED;RESPONSE;DISEASE;URTICARIA;PEOPLE
MIZOLASTINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED;RESPONSE;DISEASE;URTICARIA;PEOPLE
ATORVASTATIN;CYP3A5;TT;rs17161788;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
CAPECITABINE;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
FLUOROURACIL;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
LEUCOVORIN;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
OXALIPLATIN;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
OPIOIDS;;CC;rs2952768;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE
OPIOIDS;;CC;rs2952768;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;PCSK9;T;rs11591147;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
IMATINIB;CYP3A4;AG;rs28371759;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP3A4;AG;rs28371759;EFFICACY;INCREASED;RESPONSE;OTHER;BCR-ABL1 POSITIVE;PEOPLE
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HEART FAILURE;PEOPLE
CAPECITABINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
FLUOROURACIL;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
LEUCOVORIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;PEOPLE
IVACAFTOR / TEZACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;PEOPLE
CARVEDILOL;UGT2B7;T;rs12233719;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
BUPROPION;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
NICOTINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
VARENICLINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
BUPROPION;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
NICOTINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN
CARVEDILOL;UGT2B7;G;rs28365063;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;FMO3;CC;rs909530;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
DIGOXIN;ABCB1;AA + AT;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART FAILURE;PEOPLE
TACROLIMUS;NR1I2;CT + TT;rs3814055;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
LUMACAFTOR;CFTR;AA;rs121909047;EFFICACY;;RESPONSE;;;
METHADONE;CDH2;AA;rs8094439;EFFICACY;INCREASED;RESPONSE;;;
PERTUSSIS VACCINES;TLR4;AA;rs4986790;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHADONE;CDH2;CC;rs17446819;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
SORAFENIB;ABCG2;CT;rs2231137;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
NICOTINE;CYP2A6;CT + TT;rs376817657;METABOLISM/PK;DECREASED;METABOLISM;;;
SORAFENIB;ABCG2;GT;rs2231142;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
IMATINIB;SLC22A1;CC;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A1;CC;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
BILIRUBIN;UGT1A1;TT;rs887829;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
MERCAPTOPURINE;NUDT15;A;rs186364861;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IMIQUIMOD;TLR7;A;rs179008;EFFICACY;INCREASED;RESPONSE;DISEASE;BASAL CELL CARCINOMA;PEOPLE
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
METHOTREXATE;GGH;CC + CT;rs11545077;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;T;rs9923231;OTHER;DECREASED;DOSE;;;
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
CLOZAPINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE
OPIOIDS;TAOK3;AG + GG;rs1277441;DOSAGE;INCREASED;DOSE;OTHER;NEOPLASMS;PEOPLE
OPIOIDS;TAOK3;AG + GG;rs1277441;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
OPIOIDS;TAOK3;TT;rs795484;DOSAGE;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
OPIOIDS;TAOK3;TT;rs795484;DOSAGE;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
OPIOIDS;TAOK3;CT + TT;rs795484;DOSAGE;INCREASED;DOSE;OTHER;NEOPLASMS;PEOPLE
OPIOIDS;TAOK3;CT + TT;rs795484;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE
FENTANYL;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN
FENTANYL;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
TENOFOVIR;ABCC4;AC + CC;rs3742106;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
VITAMIN B12 AND FOLIC ACID;MTHFR;A;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERHOMOCYSTEINEMIA;PEOPLE
VITAMIN B12 AND FOLIC ACID;MTHFR;A;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:STROKE;PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;EXPOSURE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CAPTOPRIL;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
CAPTOPRIL;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;LEUKEMIA;PEOPLE
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;MYELOID;PEOPLE
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;ACUTE;PEOPLE
SILIBININ;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
MERCAPTOPURINE;TPMT;CC;rs1142345;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CITALOPRAM;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN
CITALOPRAM;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;MEN
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;C;rs1910167;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
CITALOPRAM;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ALCOHOL ABUSE;MEN
CITALOPRAM;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;MEN
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
ETANERCEPT;PSORS1C1;C;rs2233945;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MERCAPTOPURINE;ABCC4;AA;rs2274407;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
DISULFIRAM;TPH2;AA + AT;rs4290270;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
ENALAPRIL;NR3C2;TT;rs5522;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN
ACENOCOUMAROL;CYP2C9;T;rs4086116;DOSAGE;DECREASED;DOSE;;;
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN
ETANERCEPT;STAT4;T;rs7574865;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN
METHOTREXATE;GGH;AC + CC;rs11545076;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
DIGOXIN;ABCB1;AG;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;GOUT;PEOPLE
PRAVASTATIN;SLCO1B1;AG;rs4149015;EFFICACY;DECREASED;RESPONSE;;;
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;DECREASED;RESPONSE;;;
DIGOXIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
TEZACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE
FENOFIBRATE;ABCA1;CT;rs2230806;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
SERTRALINE;HTR2A;AA + AG;rs6313;DOSAGE;INCREASED;DOSE;OTHER;DEPRESSION;CHILDREN
SERTRALINE;HTR2A;AA + AG;rs6313;DOSAGE;INCREASED;DOSE;OTHER;OTHER:ANXIETY DISORDERS;CHILDREN
FENOFIBRATE;ABCA1;CC;rs2230808;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
PLATINUM COMPOUNDS;NUP107;C;rs79419059;EFFICACY;INCREASED;RESISTANCE;DISEASE;OVARIAN NEOPLASMS;WOMEN
FENOFIBRATE;ABCA1;TT;rs2230806;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
VENLAFAXINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE
WARFARIN;NQO1;AA;rs1800566;DOSAGE;DECREASED;DOSE;;;
KETOPROFEN;CYP2C9;CC;rs1799853;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
KETOPROFEN;CYP2C9;CC;rs1799853;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:DEPRESSIVE DISORDER;PEOPLE
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:MAJOR DEPRESSIVE DISORDER;PEOPLE
ADALIMUMAB;TANK;CC;rs1267067;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ADALIMUMAB;VEGFA;T;rs25648;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CARVEDILOL;ADRB1;GG;rs1801253;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE
TACROLIMUS;CYP3A5;GG;rs4646450;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
INFLIXIMAB;TNF;GG;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
HYDROCHLOROTHIAZIDE;VASP;AG + GG;rs10995;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ADALIMUMAB;TNFAIP3;T;rs2230926;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
METHOTREXATE;SLC19A1;AA + AG;rs2838958;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
SIMVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
SIMVASTATIN ACID;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
METHOTREXATE;SLC19A1;AG + GG;rs3788200;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
LITHIUM;NR1D1, THRA;T;rs2314339;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN
BEVACIZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
TRASTUZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
ACENOCOUMAROL;APOE;C;rs429358;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED;DOSE;;;
ATAZANAVIR;SORCS2;A;rs73208473;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
BEVACIZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CAPECITABINE;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CISPLATIN;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
DOCETAXEL;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
EPIRUBICIN;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
TRASTUZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
BEVACIZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CAPECITABINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
CISPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
DOCETAXEL;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
EPIRUBICIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
TRASTUZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
METHADONE;CNR1;CT + TT;rs806368;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
METHADONE;TPH2;GG;rs1386493;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
BUMETANIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
TORASEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
MORPHINE;UGT2B7;CT + TT;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE
MORPHINE;UGT2B7;CT + TT;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
SIMVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
EFAVIRENZ;CYP2B6;GG;rs35303484;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
METHADONE;CYP2B6;CT;rs16974799;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
METHADONE;OPRL1;CT;rs2229205;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
ROSUVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
ADRENERGICS;;T;rs34548976;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
INHALANTS;;T;rs34548976;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
TOPIRAMATE;GRIK1;AA + AC;rs2832407;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ALCOHOL-RELATED DISORDERS;PEOPLE
BUMETANIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TORASEMIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
CISPLATIN;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
TOPIRAMATE;GRIK1;AA + AC;rs2832407;EFFICACY;DECREASED;RESPONSE;DISEASE;ALCOHOL-RELATED DISORDERS;PEOPLE
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
CISPLATIN;ERCC1;AA;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;ERCC1;AA;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
BUMETANIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TORASEMIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
FLUVASTATIN;ABCB1;AA;rs1922242;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
GLICLAZIDE;KCNQ1;CT + TT;rs2237897;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
GLICLAZIDE;KCNQ1;CT + TT;rs2237897;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
WARFARIN;CYP4F11;G;rs1060467;DOSAGE;DECREASED;DOSE;;;
CARBOPLATIN;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED;RESPONSE;;;WOMEN
TAXANES;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED;RESPONSE;;;WOMEN
DEBRISOQUINE;CYP2D6;C;rs1080985;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2A6;AC;rs28399433;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
FLUVASTATIN;CETP;GG;rs4783961;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;ABCB1;CC + CT;rs9282564;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHOTREXATE;MTRR;AG + GG;rs1801394;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TENOFOVIR;IFNL3, IFNL4;C;rs12979860;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
GLUCOCORTICOIDS;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
METFORMIN;SLC22A1;A;rs622342;EFFICACY;INCREASED;RESPONSE;EFFICACY;DIABETES MELLITUS;PEOPLE
GLUCOCORTICOIDS;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
HYDROXYUREA;BCL11A;T;rs1427407;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
WARFARIN;CYP2C9;A;rs2860905;DOSAGE;DECREASED;DOSE;;;
FENTANYL;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE
FENTANYL;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;;MEN
WARFARIN;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED;DOSE;;;MEN
TIOTROPIUM;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
LUMEFANTRINE;ABCC2;AA;rs8187710;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MALARIA;CHILDREN
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;PEOPLE
ATORVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED;RESPONSE;;;
METHADONE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;MEN
BUMETANIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TORASEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
CLOPIDOGREL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;HYPERTENSION;PEOPLE
BUMETANIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
TORASEMIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
MORPHINE;UGT2B7;CT + TT;rs7439366;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE
MORPHINE;UGT2B7;CT + TT;rs7439366;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE
BUMETANIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
FUROSEMIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
TORASEMIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A6;AC + CC;rs1105879;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
CLOZAPINE;HTR2A;AA + AG;rs6314;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;
PRAVASTATIN;ACE;CG + GG;rs4341;EFFICACY;INCREASED;RESPONSE;;;
PRAVASTATIN;LPL;GG;rs328;EFFICACY;INCREASED;RESPONSE;;;
LOVASTATIN;CETP;AG;rs708272;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
FENTANYL;UGT2B7;CC;rs10028494;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE
FENTANYL;UGT2B7;CC;rs10028494;EFFICACY;DECREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE
METHOTREXATE;MTHFR;AA;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
NICOTINE;CHRNA3;A;rs1051730;METABOLISM/PK;INCREASED;DOSE;;;
FLUVASTATIN;LIPC;CC + CT;rs1800588;EFFICACY;INCREASED;RESPONSE;;;
CLOZAPINE;CYP1A1;T;rs2472297;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
METHYLPHENIDATE;CES1;CG;rs114119971;DOSAGE;DECREASED;DOSE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
SIMVASTATIN;LIPC;CT;rs1800588;EFFICACY;INCREASED;RESPONSE;;;
CISPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
FLUOROURACIL;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
ATORVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;RESPONSE;;;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
ATORVASTATIN;SLCO1B1;AC + CC;rs4149036;EFFICACY;INCREASED;RESPONSE;;;
ATORVASTATIN;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED;RESPONSE;;;
PERTUSSIS VACCINES;TLR4;GG;rs2770150;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
CISPLATIN;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
FLUOROURACIL;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
MITOXANTRONE;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
TACROLIMUS;ABCB1;AA + TT;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;NEPHROTIC SYNDROME;PEOPLE
LOVASTATIN;SLCO1B1;GT + TT;rs2291073;EFFICACY;INCREASED;RESPONSE;;;
TACROLIMUS;ABCB1;AA;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;NEPHROTIC SYNDROME;PEOPLE
CATECHOLAMINES;SLC22A3;T;rs8187725;OTHER;DECREASED;METABOLISM;;;
CATECHOLAMINES;SLC22A3;T;rs8187725;METABOLISM/PK;DECREASED;METABOLISM;;;
METFORMIN;SLC22A3;T;rs8187725;OTHER;DECREASED;METABOLISM;;;
METFORMIN;SLC22A3;T;rs8187725;METABOLISM/PK;DECREASED;METABOLISM;;;
LOVASTATIN;LDLR;TT;rs688;EFFICACY;INCREASED;RESPONSE;;;
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
FLUVASTATIN;CYP3A4;AG;rs4986910;EFFICACY;INCREASED;RESPONSE;;;
NALTREXONE;ADH1C;C;rs698;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN
NALTREXONE;ADH1B;A;rs2066702;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN
LOVASTATIN;LDLR;CC;rs5925;EFFICACY;INCREASED;RESPONSE;;;
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
FLUOXETINE;HTR2A;GG;rs6313;EFFICACY;DECREASED;TIME RESPONSE;OTHER;DEPRESSION;CHILDREN
FLUOXETINE;HTR2A;GG;rs6313;EFFICACY;DECREASED;TIME RESPONSE;OTHER;OTHER:ANXIETY DISORDERS;CHILDREN
NALTREXONE;ALDH2;G;rs671;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN
VARENICLINE;CYP2B6;AG + GG;rs8109525;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
TACROLIMUS;ABCB1;AG;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;INCREASED;DOSE;;;
CLOPIDOGREL;P2RY12;AA;rs2046934;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;;CHILDREN
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C19;C;rs3814637;DOSAGE;;DOSE;;;
TACROLIMUS;ABCB1;AA;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;A;rs4917639;DOSAGE;;DOSE;;;
WARFARIN;VKORC1;A;rs2359612;DOSAGE;;DOSE;;;
TACROLIMUS;CYP3A7;CG + GG;rs2257401;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;;CHILDREN
CLOPIDOGREL;P2RY12;GG;rs3732759;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE
ANTIBIOTICS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;CHILDREN
ESOMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;CHILDREN
CARFILZOMIB;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
DEXAMETHASONE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
LENALIDOMIDE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
DOLUTEGRAVIR;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
QUETIAPINE;DRD3;TT;rs6280;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
CLOPIDOGREL;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RESISTANCE;;;
CISPLATIN;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
FLUOROURACIL;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE
CARFILZOMIB;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
DEXAMETHASONE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
LENALIDOMIDE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
CARFILZOMIB;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
DEXAMETHASONE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
LENALIDOMIDE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;LIVER CANCER;PEOPLE
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE
SORAFENIB;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;HEPATITIS C VIRUS INFECTION;PEOPLE
SORAFENIB;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:LIVER CANCER;PEOPLE
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;METABOLISM/PK;DECREASED;EXPOSURE;;;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;CHILDREN
MYCOPHENOLIC ACID;ABCC2;T;rs717620;METABOLISM/PK;;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
FENTANYL;ATF2;A;rs7583431;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;PEOPLE
FENTANYL;ATF2;A;rs7583431;EFFICACY;INCREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE
MYCOPHENOLIC ACID;ABCC2;T;rs717620;METABOLISM/PK;;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;NR1I2;CT + TT;rs3814055;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
AFLIBERCEPT;ANO2;TT;rs2110166;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MACULAR DEGENERATION;PEOPLE
RANIBIZUMAB;ANO2;TT;rs2110166;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MACULAR DEGENERATION;PEOPLE
TACROLIMUS;NR1I2;CT + TT;rs3814055;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
VENLAFAXINE;SLC6A2;CC;rs2242446;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
BOCEPREVIR;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DONEPEZIL;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
GALANTAMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
ADALIMUMAB;FCGR2A;A;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
FLUOROURACIL;ENOSF1;CC;rs2612091;EFFICACY;INCREASED;RESPONSE;OTHER;STOMACH NEOPLASMS;PEOPLE
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
DACLATASVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
SOFOSBUVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ADALIMUMAB;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
LITHIUM;;T;rs78015114;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
CARBAMAZEPINE;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;
PHENOBARBITAL;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;
PHENYTOIN;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;
VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;
QUETIAPINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
LITHIUM;;T;rs79663003;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
APREMILAST;CYP3A4, TMEM130;C;rs1203844;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
APREMILAST;CYP3A4;A;rs35599367;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
ATORVASTATIN;MYLIP;AA;rs9370867;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
LITHIUM;;T;rs75222709;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;;G;rs74795342;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
APREMILAST;PDE4D;T;rs295943;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
SIMVASTATIN;SCAP;TT;rs12487736;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
CAFFEINE;CYP1A2;AA + AG;rs2069514;OTHER;DECREASED;METABOLISM;;;
CAFFEINE;CYP1A2;AA + AG;rs2069514;METABOLISM/PK;DECREASED;METABOLISM;;;
APREMILAST;CDKN2B, CDKN2B-AS1;G;rs1063192;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
PRAVASTATIN;LIPC;CT + TT;rs1800588;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
LOSARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
(R)-METHADONE;NR1I3;GG;rs2307424;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
OLANZAPINE;HTR2A;GG;rs6314;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
SIMVASTATIN;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
(R)-METHADONE;NR1I3;GG;rs3003596;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
BEVACIZUMAB;CFH;CT;rs1061170;DOSAGE;INCREASED;DOSE;DISEASE;MACULAR DEGENERATION;PEOPLE
METHADONE;OPRD1;CC;rs678849;EFFICACY;INCREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
AZATHIOPRINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
BEVACIZUMAB;ARMS2;GT + TT;rs10490924;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
SIMVASTATIN;ABCB1;CC;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED;DOSE;;;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
DEFERASIROX;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
BUDESONIDE;;AG + GG;rs2392165;EFFICACY;INCREASED;RESPONSE;OTHER;ASTHMA;CHILDREN
THIORIDAZINE;CYP2D6;CC + CG;rs1080985;METABOLISM/PK;DECREASED;METABOLISM;;;
PRAVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
DEFERASIROX;CYP1A2;CC + CT;rs2470890;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
DEFERASIROX;CYP1A2;AC + CC;rs762551;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ATORVASTATIN;ABCC2;AG;rs2273697;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
OLANZAPINE;DRD2;AA + AC;rs1076560;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
DEFERASIROX;CYP1A1;AC + CC;rs2606345;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
DEFERASIROX;UGT1A1;TT;rs887829;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
PRAVASTATIN;SLC10A1;A;rs2296651;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
ADALIMUMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ETANERCEPT;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CAPECITABINE;MTHFR;GG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE
DACLATASVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BUPRENORPHINE;;T;rs6973474;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
BUPRENORPHINE;;T;rs13169373;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;DISEASE;ALCOHOLIC PSYCHOSIS;MEN
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:ALCOHOL ABUSE;MEN
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:ALCOHOL-RELATED DISORDERS;MEN
NEVIRAPINE;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;WOMEN
IMATINIB;SLC22A1;GG;rs628031;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A1;GG;rs628031;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
NICOTINE;CHRNA5;A;rs16969968;DOSAGE;INCREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
BUPRENORPHINE;;G;rs62368105;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
BUPRENORPHINE;;T;rs11782370;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
ADALIMUMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ETANERCEPT;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
BUPRENORPHINE;;T;rs7205113;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
ETANERCEPT;IL10;CC;rs1800896;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
BUPRENORPHINE;ADAMTSL2;A;rs756770;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
(R)-METHADONE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ETANERCEPT;TGFB1;CG;rs1800471;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ATORVASTATIN;SLCO1B1;AG + GG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;T;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
METHOTREXATE;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
XK469;AOX1;G;rs10931910;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
SIMVASTATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
MERCAPTOPURINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;WOMEN
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A4;CT;rs4986907;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PHENPROCOUMON;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP4F2;AG + GG;rs2189784;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
PHENPROCOUMON;EPHX1;CC;rs1051740;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;EPHX1;CC;rs1051740;METABOLISM/PK;DECREASED;DOSE;;;
ASPIRIN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
DICLOFENAC;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
IBUPROFEN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
INDOMETHACIN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
KETOROLAC;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
NAPROXEN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
PHENPROCOUMON;PROC;CC;rs1799808;DOSAGE;INCREASED;DOSE;;;
PHENPROCOUMON;PROC;CC;rs1799808;METABOLISM/PK;INCREASED;DOSE;;;
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;DISEASE;EPILEPSY;PEOPLE
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
ATORVASTATIN;TNF;AA + AG;rs1800629;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
IMATINIB;SLC22A5;CG + GG;rs2631367;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
IMATINIB;SLC22A5;CG + GG;rs2631372;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
METFORMIN;SP1;G;rs784888;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ETANERCEPT;TNF;CT + TT;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;APOE;CC;rs7412;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE
WARFARIN;CYP3A4;AA;rs28371759;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;;;
WARFARIN;CYP1A2;GG;rs2069514;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
IMATINIB;ABCC4;AG;rs9561765;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;CHILDREN
ATORVASTATIN;DRD3;TT;rs6280;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;SLC15A2;TT;rs1143671;DOSAGE;DECREASED;DOSE;;;
ATORVASTATIN;MTHFR;AA + AG;rs1801133;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
LAMOTRIGINE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;DISEASE;EPILEPSY;PEOPLE
WARFARIN;EPHX1;CC;rs2260863;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
RITONAVIR;NR1I2;CC + CT;rs1523130;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
L-TRYPTOPHAN;SLC22A2;CC;rs316019;METABOLISM/PK;INCREASED;CLEARANCE;;;
WARFARIN;VKORC1;AA;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
PHENPROCOUMON;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;CHILDREN
RITONAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
RITONAVIR;ABCB1;AC + CC;rs2032582;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ERENUMAB;RAMP1;A;rs13386048;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE
ERENUMAB;RAMP1;A;rs13386048;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE
ERLOTINIB;CYP1A2;AA + AG;rs2472304;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SIROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
OLANZAPINE;BDNF;CC;rs6265;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RITONAVIR;NR1I2;AA + AG;rs6785049;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ERENUMAB;RAMP1;G;rs6431564;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE
ERENUMAB;RAMP1;G;rs6431564;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
LOSARTAN;SLC22A12;CC + CT;rs1529909;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
LOSARTAN;SLC22A12;CC + CT;rs1529909;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERURICEMIA;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
ERENUMAB;RAMP1;G;rs12465864;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE
ERENUMAB;RAMP1;G;rs12465864;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
LOSARTAN;SLC22A12;CT + TT;rs3825016;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
LOSARTAN;SLC22A12;CT + TT;rs3825016;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERURICEMIA;PEOPLE
ETHANOL;OPRM1;AG + GG;rs1799971;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
SIROLIMUS;IL10;CC;rs1800896;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
CYCLOSPORINE;ABCB1;CT;rs9282564;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
"""INTERFERON ALFA-2A";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BUPROPION;CYP2B6;AA;rs2279343;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
"""INTERFERON ALFA-2A";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
COTININE;PSMA4;A;rs57064725;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE
METHOTREXATE;ATIC;GG;rs16853826;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ABCC1;TT;rs35592;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
COTININE;CHRNA5;A;rs16969968;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
"""INTERFERON ALFA-2A";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2A";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
"""INTERFERON ALFA-2B";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
"""RIBAVIRIN""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
COTININE;;G;rs77107237;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE
CLOZAPINE;DTNBP1;CT + TT;rs742105;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN
COTININE;CHRNB4;A;rs10851907;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE
SIROLIMUS;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;SLCO1B3;AA;rs7311358;DOSAGE;DECREASED;DOSE;;;
WARFARIN;SLC15A2;AA;rs1143672;DOSAGE;DECREASED;DOSE;;;
"""INTERFERON ALFA-2A";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;SLCO1B3;GG;rs4149117;DOSAGE;DECREASED;DOSE;;;
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
COTININE;CHRNA3;A;rs7170068;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE
SUNITINIB;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP4F2;CC;rs2108622;EFFICACY;DECREASED;DOSE;;;
"""INTERFERON ALFA-2A";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""INTERFERON ALFA-2B";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
"""RIBAVIRIN""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
FLUPENTHIXOL;NFKB1;CT + TT;rs230504;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
MONTELUKAST;SLCO2B1;AG;rs12422149;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
MONTELUKAST;SLCO2B1;AG;rs12422149;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
DEFERASIROX;CYP24A1;CT + TT;rs927650;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
DEFERASIROX;CYP24A1;CT + TT;rs2585428;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
FLUPENTHIXOL;NFKB1;AG;rs3774959;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIDEPRESSANTS;TPH2;C;rs10879346;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHOTREXATE POLYGLUTAMATE;IMPDH1;GG;rs4731448;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CARBOPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
METHOTREXATE POLYGLUTAMATE;CEP72;TT;rs924607;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;IL10;TT;rs1800896;DOSAGE;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
MIRTAZAPINE;TPH2;C;rs1487278;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
VENLAFAXINE;TPH2;C;rs1487278;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
TACROLIMUS;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
BILIRUBIN;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE
CARBOPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
DEFERASIROX;CYP24A1;CT + TT;rs2248359;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
FLUPENTHIXOL;NFKB1;AT;rs230493;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METHOTREXATE POLYGLUTAMATE;SLCO1B3;AA + AG;rs7311358;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
NICOTINE;FMO3;AA;rs2266780;METABOLISM/PK;INCREASED;METABOLISM;;;
PAZOPANIB;VEGFA;A;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
METHOTREXATE POLYGLUTAMATE;FSTL5;AA + AC;rs3749598;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE POLYGLUTAMATE;ATG16L1;AG + GG;rs2241880;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
FLUOROURACIL;DPYD;CC;rs3918290;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;OTHER;DECREASED;METABOLISM;DISEASE;ASTHMA;PEOPLE
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;PEOPLE
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE
PAZOPANIB;VEGFA;G;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
ADALIMUMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
PAZOPANIB;VEGFA;T;rs833061;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
ETANERCEPT;PTTG1;CC + CT;rs2431697;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CISPLATIN;CMPK1;CC;rs4492666;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CMPK1;CC;rs4492666;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
BUPROPION;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
NICOTINE;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
VARENICLINE;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
VORICONAZOLE;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ETANERCEPT;HLA-B;TT;rs13437088;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ETANERCEPT;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CLOZAPINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ETANERCEPT;GBP6;AG + GG;rs928655;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
CELIPROLOL;ABCB1;G;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
CELIPROLOL;SLCO1A2;G;rs11568563;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
ETANERCEPT;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TEMOZOLOMIDE;ABCB1;AA + AG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;GLIOMA;PEOPLE
IVACAFTOR;SLC26A9;CC + CT;rs7512462;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
GEMCITABINE;DCK;AG + GG;rs66878317;METABOLISM/PK;INCREASED;CLEARANCE;;;
VORICONAZOLE;NR1I2;CC;rs3814057;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
MILNACIPRAN;ADRA2A;CC + CG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;GG;rs4244809;EFFICACY;DECREASED;RESISTANCE;DISEASE;OVARIAN NEOPLASMS;WOMEN
VORICONAZOLE;FMO3;AA;rs2266780;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;;
FLUVOXAMINE;FGF2;CC + CT;rs1449683;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
VORICONAZOLE;POR;GG;rs10954732;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
PLATINUM COMPOUNDS;INS-IGF2;GG;rs3842761;EFFICACY;DECREASED;RESISTANCE;DISEASE;OVARIAN NEOPLASMS;WOMEN
MILNACIPRAN;HTR1A;CC + CG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
VALPROIC ACID;SCN2A;AA + AG;rs17183814;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
VORICONAZOLE;NR1I2;AA;rs2461817;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
VORICONAZOLE;NR1I2;GG;rs3732359;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
METHOTREXATE;ABCC2;TT;rs3740066;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN
CISPLATIN;RRM1;TT;rs720106;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;RRM1;TT;rs720106;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
VORICONAZOLE;NR1I2;AA;rs7643645;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
SIMVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;RESPONSE;;;
CISPLATIN;RRM1;AA;rs232043;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;RRM1;AA;rs232043;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
CISPLATIN;CMPK1;CC;rs11211524;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;CMPK1;CC;rs11211524;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
SIMVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;;
CISPLATIN;RRM1;TT;rs2284449;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
GEMCITABINE;RRM1;TT;rs2284449;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ACENOCOUMAROL;GGCX;G;rs11676382;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;
METHOTREXATE;NR1I2;G;rs6785049;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN
RITUXIMAB;TGFB1;AG;rs1800470;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
RITUXIMAB;TGFB1;CG;rs1800471;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
SIMVASTATIN;CYP3A4;A;rs35599367;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
PIOGLITAZONE;ADIPOQ;GT;rs2241766;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
ROSUVASTATIN;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN
NALOXONE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;RESPONSE;;;
TIPIFARNIB;ABCB1;AA;rs1128503;OTHER;DECREASED;METABOLISM;;;
TIPIFARNIB;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;METABOLISM;;;
ETANERCEPT;ZNF816;CC;rs9304742;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;MEN
ANTIPSYCHOTICS;NRG1;G;rs13250975;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
METHOTREXATE;SLCO1A2;CC + CT;rs4149009;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ANTIPSYCHOTICS;;A;rs2513265;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;ADCY2;C;rs1544938;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;NRG1;A;rs17716295;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
NICOTINE;CHRNA5;GG;rs16969968;OTHER;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
METHADONE;DAO;TT;rs55944529;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
ANTIPSYCHOTICS;CCL2;G;rs4795893;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;CCL2;T;rs4586;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METHADONE;DAO;TT;rs55944529;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ESCITALOPRAM;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUOXETINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
FLUVOXAMINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
SERTRALINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;WOMEN
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:MALARIA;WOMEN
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;INCREASED;RESPONSE;;;
METHADONE;DRD1;TT;rs5326;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;INCREASED;RESPONSE;;;
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;INCREASED;RESPONSE;;;
RIFAMPIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE
METHYLPHENIDATE;CYP2D6;GG;rs1065852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED;RESPONSE;;;
METHYLPHENIDATE;CYP2D6;CG;rs1135840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;INCREASED;RESPONSE;;;
PRAVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED;RESPONSE;;;
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;;
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;VKORC1;AA + AG;rs7196161;DOSAGE;INCREASED;DOSE;;;
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;INCREASED;RESPONSE;;;
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;INCREASED;RESPONSE;;;
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;INCREASED;RESPONSE;;;
SUNITINIB;GLP1R;A;rs6923761;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;RENAL CELL CARCINOMA;PEOPLE
SUNITINIB;GLP1R;A;rs6923761;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:GASTROINTESTINAL STROMAL TUMORS;PEOPLE
DOXORUBICIN;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;PEOPLE
ATOMOXETINE;CYP2D6;CC;rs1135840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
BETA BLOCKING AGENTS;GRK5;A;rs3740563;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;G;rs2069705;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
MONTELUKAST;MLLT3;AA;rs6475448;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
BETA BLOCKING AGENTS;GRK5;A;rs10787959;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
BUPROPION;;C;rs1908557;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
BETA BLOCKING AGENTS;GRK5;A;rs11198893;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE
RIFAMPIN;CYP27B1;AG + GG;rs4646536;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE
CORTICOSTEROIDS;ST13;G;rs138335;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
RIFAMPIN;VDR;TT;rs1544410;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE
DOCETAXEL;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
METHADONE;CYP2B6;GG + GT;rs3745274;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
DOCETAXEL;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
RAMIPRIL;ADRB2;AA + AG;rs2053044;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"BREAST NEOPLASMS""";WOMEN
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";WOMEN
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";WOMEN
METHADONE;NGF;AA;rs2239622;DOSAGE;DECREASED;DOSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;INCREASED;EXPOSURE;OTHER;URINARY BLADDER NEOPLASMS;MEN
METHADONE;CYP2B6;AA + AG;rs2279343;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
GEMCITABINE;NT5C3A;AA;rs3750117;OTHER;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
GEMCITABINE;NT5C3A;AA;rs3750117;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
GEMCITABINE;NT5C2;TT;rs11598702;OTHER;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
GEMCITABINE;NT5C2;TT;rs11598702;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE
FENTANYL;PGAP6;T;rs199670311;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
REMIFENTANIL;PGAP6;T;rs199670311;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
OLANZAPINE;UGT1A4;GT;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIDEPRESSANTS;ADCY9;CC;rs2230739;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;STROKE;PEOPLE
ANTIPSYCHOTICS;PI4KA;AG + GG;rs165854;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;GRM3;AA + AT;rs1468412;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
BUDESONIDE;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
CORTICOSTEROIDS;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
FLUTICASONE / SALMETEROL;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
FLUTICASONE PROPIONATE;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
AZATHIOPRINE;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
CARBOPLATIN;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOCETAXEL;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
ANTIPSYCHOTICS;SLC1A3;AA + AG;rs1529461;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;GRM3;CC;rs2299214;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CARBOPLATIN;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOCETAXEL;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
ANTIPSYCHOTICS;GRM3;AG + GG;rs6465084;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CARBOPLATIN;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOCETAXEL;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
GEMCITABINE;CDA;CC;rs1048977;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
CARBOPLATIN;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOCETAXEL;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CORTICOSTEROIDS;ST13;G;rs138337;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
CARBOPLATIN;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOCETAXEL;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TRASTUZUMAB;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
ANTIPSYCHOTICS;SLC1A4;AA;rs10211524;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;GRM3;CC + CT;rs2299214;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
SUFENTANIL;COMT;AA;rs4680;DOSAGE;DECREASED;DOSE;;;CHILDREN
SUFENTANIL;COMT;AA;rs4680;EFFICACY;DECREASED;DOSE;;;CHILDREN
FLUINDIONE;VKORC1;TT;rs9923231;METABOLISM/PK;;DOSE;;;CHILDREN
APREMILAST;LEPR, LEPROT;AA + AG;rs1045895;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE
CARBOPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
CISPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
QUINAPRIL;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
OPIOIDS;KCNJ6;CC;rs6517442;DOSAGE;INCREASED;DOSE;OTHER;LOW BACK PAIN;PEOPLE
OLANZAPINE;CYP1A2;T/del;rs35694136;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE
OLANZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
PHENPROCOUMON;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
CAPECITABINE;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;NEOPLASMS;PEOPLE
FLUOROURACIL;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;NEOPLASMS;PEOPLE
TEGAFUR;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;NEOPLASMS;PEOPLE
KETOPROFEN;CYP2C9;AC;rs1057910;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE
KETOPROFEN;CYP2C9;AC;rs1057910;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE
ATORVASTATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED;METABOLISM;;;
CAFFEINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;METABOLISM;;;
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
ETANERCEPT;TNFRSF1B;GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;SPONDYLITIS;PEOPLE
ETANERCEPT;TNFRSF1B;GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;ANKYLOSING;PEOPLE
FENTANYL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
REMIFENTANIL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
APREMILAST;PDE4B;T;rs12745871;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
ATORVASTATIN;SCARB1;AA;rs5888;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
APREMILAST;TSPAN16;C;rs322144;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
PRAVASTATIN;FCAR;AA + AG;rs11666735;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;MEN
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
EPIRUBICIN;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
FENOFIBRATE;APOA1;G;rs964184;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE
ANTIEPILEPTICS;SCN1A;CT;rs10188577;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
APREMILAST;DOCK6;G;rs12979813;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
DAPTOMYCIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
NALTREXONE;DBH;CT + TT;rs1611115;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;MEN
GEMCITABINE;SLC28A2;CC;rs11854484;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ANTINEOPLASTIC AGENTS;ABCG2;GG;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
GEMCITABINE;SLC28A2;CC;rs1060896;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;G;rs2305795;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;PEOPLE
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;GG;rs1139130;EFFICACY;INCREASED;RESISTANCE;OTHER;TUBERCULOSIS;PEOPLE
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;PEOPLE
SUFENTANIL;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
SUFENTANIL;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
APREMILAST;ILF3;T;rs76966440;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;
CYCLOPHOSPHAMIDE;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
EPIRUBICIN;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
FLUOROURACIL;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
SULFASALAZINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;CHILDREN
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;CHILDREN
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;CHILDREN
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;PRSS53, VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
NORTRIPTYLINE;NOS3;TT;rs1799983;EFFICACY;INCREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
NORTRIPTYLINE;NOS3;TT;rs1799983;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE
ALLOPURINOL;GREM2;T;rs1934341;EFFICACY;INCREASED;RESPONSE;;;
COTININE;NAT1;AG + GG;rs13253389;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
ALLOPURINOL;GREM2;G;rs77567654;EFFICACY;INCREASED;RESPONSE;;;
TACROLIMUS;ABCB1;CC;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ALLOPURINOL;ABCG2;C;rs45499402;EFFICACY;DECREASED;RESPONSE;;;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;;;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
EXENATIDE;GLP1R;T;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
EXENATIDE;GLP1R;T;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
TOPIRAMATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
TOPIRAMATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE
LAMOTRIGINE;UGT2B7;TT;rs7668258;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;
BENAZEPRIL;AGT;GG;rs4762;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;MEN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
LAMOTRIGINE;UGT2B7;GG;rs28365063;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE
3;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;ABCC4;GG;rs7317112;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
BENAZEPRIL;AGTR1;GG;rs2640543;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;WOMEN
ALENDRONATE;MVK;GG;rs10161126;EFFICACY;INCREASED;RESPONSE;DISEASE;BONE DISEASES;WOMEN
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;ITPA;A;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
PEGINTERFERON ALFA-2A;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
PEGINTERFERON ALFA-2B;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
BENAZEPRIL;SPTA1;G;rs2106089;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;MEN
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
LOSARTAN;CYP2C9;AT + TT;rs1934969;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
IMATINIB;ABCB1;C;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;C;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ADALIMUMAB;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
SALBUTAMOL;COL2A1;GT + TT;rs3809324;PD;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN
ANTIPSYCHOTICS;CACNA1C;CC;rs2238087;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
"""DIURETICS""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""HYDROCHLOROTHIAZIDE""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""THIAZIDES";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"PLAIN""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ANTIPSYCHOTICS;CACNA1B;CC;rs2229949;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ACENOCOUMAROL;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;
CORTICOSTEROIDS;GLCCI1;GG;rs37973;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHINITIS;PEOPLE
DEFERASIROX;GC;AA;rs7041;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ASPIRIN;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
METHYLPHENIDATE;CES1;T;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
INTERFERON BETA-1A;CD58;CC;rs12044852;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
INTERFERON BETA-1B;CD58;CC;rs12044852;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;OTHER;ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;OTHER;"PSORIATIC""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;OTHER;"""OTHER:PSORIASIS""";PEOPLE
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;;;CHILDREN
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;OTHER;ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;OTHER;"PSORIATIC""";PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;OTHER;"""OTHER:PSORIASIS""";PEOPLE
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
ANTIPSYCHOTICS;CACNB2;TT;rs12245847;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
DEFERASIROX;UGT1A1;CC;rs887829;EFFICACY;DECREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ANTIPSYCHOTICS;CACNG3;TT;rs1859204;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
DEFERASIROX;UGT1A3;TT;rs1983023;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
DEFERASIROX;CYP27B1;GG;rs10877012;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A4;A;rs4646437;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;A;rs4646437;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
ADALIMUMAB;ATG16L1;CT + TT;rs10210302;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
ANTIPSYCHOTICS;CACNB2;CC;rs982003;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
DEFERASIROX;VDR;GG;rs731236;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
DEFERASIROX;VDR;TT;rs1544410;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
CAPECITABINE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CAPECITABINE;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;A;rs4646450;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;A;rs4646450;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
"""DIURETICS""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""HYDROCHLOROTHIAZIDE""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""THIAZIDES";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"PLAIN""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
WARFARIN;CYP2C9;CG;rs28371686;DOSAGE;DECREASED;DOSE;;;
ANTIPSYCHOTICS;CACNB2;TT;rs10741058;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
"""DIURETICS""";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""HYDROCHLOROTHIAZIDE""";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""THIAZIDES";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"PLAIN""";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ANTIPSYCHOTICS;CACNA2D3;AA;rs4505744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
"""DIURETICS""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""HYDROCHLOROTHIAZIDE""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""THIAZIDES";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"PLAIN""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IBUPROFEN;CYP2C9;AC;rs1057910;EFFICACY;DECREASED;TIME RESPONSE;OTHER;PATENT DUCTUS ARTERIOSUS;INFANTS
ANTIPSYCHOTICS;CACNA1E;TT;rs12060765;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CORTICOSTEROIDS;TAAR6;GG;rs7772821;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
SALBUTAMOL;VEGFA;CT + TT;rs3025039;PD;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
RANIBIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
MORPHINE;TAOK3;TT;rs795484;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;CHILDREN
MORPHINE;TAOK3;TT;rs795484;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN
MORPHINE;TAOK3;TT;rs795484;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;CHILDREN
MORPHINE;TAOK3;TT;rs795484;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN
PREDNISONE;NR3C1;G;rs6196;EFFICACY;DECREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;PEOPLE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AA;rs4148323;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
DOCETAXEL;;G;rs4842198;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
FLUVOXAMINE;HTR2A;CC;rs6311;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;DOSE;;;
PREDNISONE;NR3C1;A;rs258751;EFFICACY;DECREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;PEOPLE
LEDIPASVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A9;del/del;rs3832043;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
PHENYTOIN;CYP2C9;G;rs28371686;OTHER;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
PHENYTOIN;CYP2C9;G;rs28371686;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
IMATINIB;ABCG2;CT + TT;rs2231137;DOSAGE;DECREASED;DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
PREDNISONE;NR3C1;A;rs10052957;EFFICACY;DECREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;PEOPLE
IMATINIB;CYP1A2;CC;rs762551;DOSAGE;DECREASED;DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE
PHENYTOIN;CYP2C9;A;rs7900194;OTHER;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
PHENYTOIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE
LURASIDONE;HTR1A;CG + GG;rs6295;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
PHENYTOIN;CYP2C9;T;rs28371685;OTHER;INCREASED;METABOLISM;PK;NO DISEASE;PEOPLE
PHENYTOIN;CYP2C9;T;rs28371685;METABOLISM/PK;INCREASED;METABOLISM;PK;NO DISEASE;PEOPLE
PHENYTOIN;CYP2C9;del;rs9332131;OTHER;DECREASED;METABOLISM;PK;NO DISEASE;PEOPLE
PHENYTOIN;CYP2C9;del;rs9332131;METABOLISM/PK;DECREASED;METABOLISM;PK;NO DISEASE;PEOPLE
DOCETAXEL;RXRA;A;rs3132291;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
INFLIXIMAB;TNFRSF1B;G;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METFORMIN;SLC22A1;TT;rs12208357;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
CODEINE;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;;;WOMEN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CODEINE;UGT2B7;TT;rs7439366;DOSAGE;DECREASED;DOSE;;;WOMEN
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ANTIPSYCHOTICS;CACNB2;CC;rs4237348;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ANTIPSYCHOTICS;CACNB4;AA + AC;rs3768652;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE
ANTIPSYCHOTICS;CACNA2D3;CC;rs7427395;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;CACNB2;TT;rs1277733;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
SOFOSBUVIR;CES1;A;rs4513095;EFFICACY;DECREASED;RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PROPOFOL;SCN9A;AA + AG;rs6746030;OTHER;INCREASED;RESPONSE;;;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;CHILDREN
SALBUTAMOL;PRKG1;A;rs7081864;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ANTIPSYCHOTICS;BDNF;AG + GG;rs11030104;EFFICACY;INCREASED;RESISTANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
SUNITINIB;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
PROPOFOL;HTR2A;AA;rs6313;DOSAGE;DECREASED;DOSE;;;
ANTIPSYCHOTICS;BDNF-AS;CC + CT;rs10501087;EFFICACY;INCREASED;RESISTANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
PROPOFOL;GABRA1;GG;rs2279020;OTHER;INCREASED;RESPONSE;;;
SUNITINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
OPIOIDS;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
DOXORUBICIN;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PREDNISOLONE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
VINCRISTINE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;RESISTANCE;DISEASE;SCHIZOPHRENIA;PEOPLE
OPIOIDS;COMT;AG;rs4680;DOSAGE;DECREASED;DOSE;;;CHILDREN
"""METFORMIN""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
"""METFORMIN""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
"""SULFONAMIDES";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
"""SULFONAMIDES";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
"UREA DERIVATIVES""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
"UREA DERIVATIVES""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
PALIPERIDONE;NFIB;CT;rs28379954;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
RISPERIDONE;NFIB;CT;rs28379954;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;OTHER;TONSILLECTOMY;CHILDREN
SEVOFLURANE;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;OTHER;TONSILLECTOMY;CHILDREN
MORPHINE;TAOK3;GG;rs1277441;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;CHILDREN
MORPHINE;TAOK3;GG;rs1277441;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN
MORPHINE;TAOK3;GG;rs1277441;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;CHILDREN
MORPHINE;TAOK3;GG;rs1277441;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN
DOXORUBICIN;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PREDNISOLONE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
VINCRISTINE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;OTHER;ANEMIA;PEOPLE
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;OTHER;"SICKLE CELL""";PEOPLE
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;OTHER;"""OTHER:BETA-THALASSEMIA AND RELATED DISEASES""";PEOPLE
OXYCODONE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
OXYCODONE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
TACROLIMUS;CYP3A4;CT + TT;rs2242480;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HEART TRANSPLANTATION;PEOPLE
METHOTREXATE;SLCO1B1;A;rs11045821;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs11045821;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs11045821;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
BILIRUBIN;UGT1A;AG + GG;rs11563250;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
DEFERASIROX;UGT1A3;CT + TT;rs1983023;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
ADALIMUMAB;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
MORPHINE;SLC22A1;CT + TT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
MIDAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
MORPHINE;SLC22A1;CC + CT;rs55918055;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
BUPROPION;CYP2A6;T;rs4803381;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;T;rs4803381;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE
METFORMIN;SRR;CC + CT;rs391300;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SRR;CC + CT;rs391300;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
METHYLPHENIDATE;SLC6A2;AG + GG;rs5569;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ERYTHROMYCIN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
NICOTINE;CYP2A6;T;rs4803381;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOZAPINE;ABCB1;G;rs7787082;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CAFFEINE;CYP1A2;AA + AC;rs762551;METABOLISM/PK;INCREASED;METABOLISM;;;
ATENOLOL;;AA + AC;rs12346562;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROCHLOROTHIAZIDE;;AA + AC;rs12346562;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ATENOLOL;;AA + AG;rs1104514;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
MORPHINE;SLC22A1;AA + AG;rs34130495;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN
ATENOLOL;;GG + GT;rs10739150;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
CLOZAPINE;ABCB1;A;rs10248420;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
DEFERASIROX;UGT1A3;CC;rs3806596;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
TRANDOLAPRIL;PTPRD;T;rs4742610;EFFICACY;;RESISTANCE;DISEASE;HYPERTENSION;PEOPLE
VERAPAMIL;PTPRD;T;rs4742610;EFFICACY;;RESISTANCE;DISEASE;HYPERTENSION;PEOPLE
DEFERASIROX;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
"""METFORMIN""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
"""METFORMIN""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
"""SULFONAMIDES";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
"""SULFONAMIDES";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
"UREA DERIVATIVES""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
"UREA DERIVATIVES""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
SUNITINIB;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE
WARFARIN;VDR;GG;rs11168292;DOSAGE;INCREASED;DOSE;;;
4-HYDROXYTAMOXIFEN;SULT1A2;AA;rs1136703;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;SULT1A2;AA;rs1136703;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
WARFARIN;VDR;GG;rs4760658;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VDR;TT;rs11168293;DOSAGE;INCREASED;DOSE;;;
ADALIMUMAB;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETOPOSIDE;SLIT1;AA;rs2784917;METABOLISM/PK;DECREASED;INHIBITION;;;
METHOTREXATE;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;C;rs4149056;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs2306283;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs2306283;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ADALIMUMAB;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
4-HYDROXYTAMOXIFEN;SULT1A2;TT;rs1059491;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
ENDOXIFEN;SULT1A2;TT;rs1059491;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
METHOTREXATE;SLCO1B1;A;rs4149081;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs4149081;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;A;rs4149081;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ADALIMUMAB;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
ADALIMUMAB;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;SLCO1B1;C;rs11045879;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;C;rs11045879;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;SLCO1B1;C;rs11045879;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PHENYLEPHRINE;ADRB2;AA;rs1042713;DOSAGE;INCREASED;DOSE;;;WOMEN
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
ANASTROZOLE;CSMD1;G;rs6990851;EFFICACY;INCREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN
N-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
PEGINTERFERON ALFA-2B;;C;rs6806020;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;C;rs6806020;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
NICOTINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;;
ATORVASTATIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;CT + TT;rs7294;EFFICACY;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
PEGINTERFERON ALFA-2B;;A;rs1931704;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;A;rs1931704;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ACAMPROSATE;CHDH, IL17RB;A;rs6801605;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GG;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE
FENTANYL;ABCB1;AG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
COUMARIN;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;;
PEGINTERFERON ALFA-2B;IL21R;C;rs3093390;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IL21R;C;rs3093390;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BEVACIZUMAB;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PEGINTERFERON ALFA-2B;;A;rs7512595;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;A;rs7512595;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;CARD16;C;rs1792774;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;CARD16;C;rs1792774;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;CYP2C19;CC;rs3814637;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;AA + AC;rs1057910;DOSAGE;INCREASED;DOSE;;;
N-DESMETHYLTRAMADOL;ABCC2;TT;rs3740066;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
PEGINTERFERON ALFA-2B;;G;rs7750468;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;G;rs7750468;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;INCREASED;DOSE;;;
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
FENTANYL;ABCC3;C;rs11079921;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PAIN;CHILDREN
FENTANYL;ABCC3;C;rs11079921;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;OTHER:PREMATURE BIRTH;CHILDREN
PEGINTERFERON ALFA-2B;CARD16;A;rs1503391;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;CARD16;A;rs1503391;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;CASP1;T;rs557905;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;CASP1;T;rs557905;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;;A;rs2066911;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;A;rs2066911;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;CFAP44;G;rs13064411;EFFICACY;DECREASED;RESPONSE;;;
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
PEGINTERFERON ALFA-2B;CASP1;A;rs568910;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;CASP1;A;rs568910;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
NICOTINE;CHRNB2;AG;rs2072658;OTHER;INCREASED;RESPONSE;OTHER;DAILY SMOKING;PEOPLE
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs8330;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
NICOTINE;CHRNA4;C;rs2229959;OTHER;INCREASED;RESPONSE;OTHER;DAILY SMOKING;PEOPLE
PEGINTERFERON ALFA-2B;TUT7;C;rs17461620;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;TUT7;C;rs17461620;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ACETYLCYSTEINE;TOLLIP;TT;rs3750920;EFFICACY;INCREASED;RESPONSE;DISEASE;PULMONARY FIBROSIS;PEOPLE
OXCARBAZEPINE;ABCB1;A;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
OXCARBAZEPINE;UGT2B7;C;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs10929303;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ALLOPURINOL;ABCG2;GT + TT;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;GOUT;PEOPLE
OXCARBAZEPINE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
AMANTADINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
AMANTADINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
ANTICHOLINERGICS;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
ANTICHOLINERGICS;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
LEVODOPA;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
LEVODOPA;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
SELEGILINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
SELEGILINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
MORPHINE-3-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCOLIOSIS;CHILDREN
MORPHINE-3-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TONSILLECTOMY;CHILDREN
MORPHINE-6-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCOLIOSIS;CHILDREN
MORPHINE-6-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TONSILLECTOMY;CHILDREN
TACROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;CHILDREN
MORPHINE-3-GLUCURONIDE;ABCC3;TT;rs4148412;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TONSILLECTOMY;CHILDREN
GLUCOSE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;CONCENTRATIONS;DISEASE;TRANSPLANTATION;PEOPLE
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE
TACROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
SERTRALINE;GNB3;GG;rs5441;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
FENTANYL;CYP3A4;TT;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;WOMEN
FENTANYL;CYP3A4;TT;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
CYCLOSPORINE;ABCB1;A;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
HDL CHOLESTEROL;CRTC2;AA;rs8450;TOXICITY;DECREASED;CONCENTRATIONS;DISEASE;TRANSPLANTATION;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;GG;rs34130495;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
MYCOPHENOLIC ACID;ABCC2;TT;rs717620;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
N-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
O-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE
PHENYTOIN;CYP2C9;AA + AG;rs12782374;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;CYP2C9;AA + AG;rs12782374;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;DOSE;;;
FENTANYL;ABCC3;T;rs8077268;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PAIN;CHILDREN
FENTANYL;ABCC3;T;rs8077268;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;OTHER:PREMATURE BIRTH;CHILDREN
METHYLPHENIDATE;COMT;G;rs4680;EFFICACY;INCREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;T;rs1799853;METABOLISM/PK;DECREASED;DOSE;;;
PLATINUM COMPOUNDS;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;
CYCLOSPORINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;DECREASED;EXPOSURE;;;MEN
SIROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;METABOLISM;DISEASE;TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TRANSPLANTATION;PEOPLE
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
MYCOPHENOLIC ACID;UGT2B7;G;rs7662029;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METHYLPHENIDATE;TH;GG;rs2070762;EFFICACY;DECREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;IL18;CC + CG;rs5744247;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A4;CC + CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SIROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CETUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CARBAMAZEPINE;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
RISPERIDONE;HTR2C;CC;rs518147;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;WOMEN
CARBAMAZEPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
DESETHYLCHLOROQUINE;CYP2C8;C;rs7910936;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
HYDROXYCHLOROQUINE;CYP2C8;C;rs7910936;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
CARBAMAZEPINE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;CG;rs3738046;METABOLISM/PK;;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;CHILDREN
PHENYTOIN;CYP2C9;CT;rs1799853;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
SIMVASTATIN ACID;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PHENYTOIN;CYP2C19;AG;rs4244285;OTHER;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;CYP2C19;AG;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
CLOZAPINE;HTR2C;C;rs6318;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CARBAMAZEPINE;EPHX1;AG + GG;rs2234922;METABOLISM/PK;;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
SULFONAMIDES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
SULFONAMIDES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
UREA DERIVATIVES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
UREA DERIVATIVES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE
CARBOPLATIN;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE
CISPLATIN;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE
FLUOROURACIL;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE
TRAMADOL;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;EXPOSURE;;;
TRAMADOL;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;
CARBOPLATIN;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE
CISPLATIN;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE
FLUOROURACIL;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE
TRAMADOL;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CAFFEINE;ADORA1;CC;rs16851030;EFFICACY;INCREASED;RESPONSE;OTHER;APNEA OF PREMATURITY;INFANTS
TOCILIZUMAB;IL6R;CC + CT;rs4329505;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
RISPERIDONE;HTR2C;CC;rs1023574;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;WOMEN
RISPERIDONE;HTR2C;TT;rs9698290;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;WOMEN
"""DIURETICS""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""HYDROCHLOROTHIAZIDE""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""THIAZIDES";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"PLAIN""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ANTIDEPRESSANTS;RGS17;A;rs672170;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED;DOSE;;;
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED;CLEARANCE;;;
VORICONAZOLE;SLCO1B3;GT + TT;rs4149117;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;;;CHILDREN
OXALIPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ANTIDEPRESSANTS;NBEA;T;rs9315310;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ANTIDEPRESSANTS;CRH;C;rs4737771;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ANTIDEPRESSANTS;FHIT;C;rs49411;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ANTIDEPRESSANTS;PARP11;G;rs2532560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ANTIDEPRESSANTS;;T;rs2831440;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SILDENAFIL;GNB3;TT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;PEOPLE
ANTIDEPRESSANTS;MTRF1L;G;rs766127;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ATORVASTATIN;POR;CT + TT;rs1057868;EFFICACY;DECREASED;RESPONSE;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA;CHILDREN
TACROLIMUS;HSD11B1;AA;rs846908;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
SARILUMAB;IL6R;CC;rs4845625;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
SALVIANOLIC ACID B;NOS3;GG;rs1799983;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE
BUPROPION;COMT;AA + AG;rs165599;EFFICACY;INCREASED;RESPONSE;OTHER;SMOKERS;
BUPROPION;COMT;AA;rs737865;EFFICACY;DECREASED;RESPONSE;OTHER;SMOKERS;
SALBUTAMOL;CRHR2;G;rs2267715;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
DESETHYLCHLOROQUINE;CYP2C8;T;rs10882521;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
HYDROXYCHLOROQUINE;CYP2C8;T;rs10882521;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;INCREASED;DOSE;;;
ADALIMUMAB;HFE;CC + CT;rs2071303;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
ROSIGLITAZONE;LPIN1;G;rs10192566;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
ROSIGLITAZONE;LPIN1;G;rs10192566;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
TACROLIMUS;HSD11B1;AA;rs4844880;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DESETHYLCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
TACROLIMUS;HSD11B1;AA;rs846910;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ACENOCOUMAROL;GATA4;AG + GG;rs3735814;DOSAGE;DECREASED;DOSE;;;
"""BETA BLOCKING AGENTS";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"SELECTIVE""";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
"""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ANTIDEPRESSANTS;CTNNA3;C;rs10997242;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ALDOSTERONE ANTAGONISTS;NEDD4L;G;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
AMILORIDE;NEDD4L;G;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ANTIDEPRESSANTS;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SALBUTAMOL;CRHR2;A;rs255100;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
ANTIDEPRESSANTS;HTR2A;GG;rs6313;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ANTIDEPRESSANTS;CACNA1A;A;rs2112460;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
SALBUTAMOL;CRHR2;G;rs2284220;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
WARFARIN;ORM1;AG + GG;rs17650;DOSAGE;DECREASED;DOSE;;;
ANTIDEPRESSANTS;;T;rs521093;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MORPHINE;UGT2B7;CC;rs7439366;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;UGT2B7;CC;rs7439366;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED;DOSE;;;
ANTIDEPRESSANTS;RAPGEF5;C;rs16873129;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
VALPROIC ACID;ABCB1;AA;rs1128503;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
ANTIDEPRESSANTS;PON2;G;rs2299267;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CISPLATIN;GALNT18;GG;rs7937567;EFFICACY;INCREASED;RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
RITUXIMAB;;CC;rs3759467;EFFICACY;DECREASED;RESPONSE;DISEASE;VASCULITIS;PEOPLE
ANTIPSYCHOTICS;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
ARIPIPRAZOLE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
ARIPIPRAZOLE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
CLOZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
HALOPERIDOL;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
HALOPERIDOL;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
OLANZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
OLANZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
QUETIAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
QUETIAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CORTICOSTEROIDS;HDAC1;CC;rs1741981;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HODGKIN DISEASE;CHILDREN
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:RHABDOMYOSARCOMA;CHILDREN
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:MEDULLOBLASTOMA;CHILDREN
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:GLIOMA;CHILDREN
MORPHINE;TLR2;CC + CT;rs3804100;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;TLR2;CC + CT;rs3804100;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
MORPHINE;TLR2;CC + CT;rs3804100;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;TLR2;CC + CT;rs3804100;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
TACROLIMUS;CYP3A5;CT;rs776746;OTHER;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DOCETAXEL;CHST3;T;rs4148947;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;T;rs4148947;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
MORPHINE;IL1B;A;rs1143634;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;IL1B;A;rs1143634;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
MORPHINE;IL1B;A;rs1143634;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;IL1B;A;rs1143634;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
CISPLATIN;MLLT3;AA + AC;rs10964552;EFFICACY;DECREASED;RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MORPHINE;IL1B;A;rs1143634;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;IL1B;A;rs1143634;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
MORPHINE;IL1B;A;rs1143634;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;IL1B;A;rs1143634;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
DOCETAXEL;CHST3;A;rs4148950;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;A;rs4148950;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
ATORVASTATIN;MTTP;TT;rs1800591;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;MEN
NITROGLYCERIN;ALDH2;AA + AG;rs671;EFFICACY;DECREASED;RESPONSE;DISEASE;CONGENITAL HEART DEFECTS;CHILDREN
TOCILIZUMAB;GALNT18;CC;rs4910008;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CISPLATIN;RARS1;TT;rs244898;EFFICACY;INCREASED;RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
RISPERIDONE;ABCB1;AG + GG;rs2235048;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
NITROGLYCERIN;ALDH2;AA + AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CONGENITAL HEART DEFECTS;CHILDREN
NITROGLYCERIN;ALDH2;AA + AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PULMONARY HYPERTENSION;CHILDREN
DIGOXIN;ABCB1;AT;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TOCILIZUMAB;CD69;A;rs11052877;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PHENAZEPAM;CYP2C19;CC + CT;rs12248560;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL-RELATED DISORDERS;MEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HODGKIN DISEASE;CHILDREN
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:RHABDOMYOSARCOMA;CHILDREN
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:MEDULLOBLASTOMA;CHILDREN
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:GLIOMA;CHILDREN
ATENOLOL;;A;rs7184292;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ATENOLOL;XIRP2;C;rs7606603;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
CYCLOSPORINE;CYP3A7;TT;rs10211;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A7;CC;rs2257401;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;CC;rs12343867;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
NILOTINIB;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
NILOTINIB;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;OTHER;BCR-ABL1 POSITIVE;PEOPLE
HYDROCHLOROTHIAZIDE;;C;rs16872401;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;GG;rs3212217;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
CYCLOSPORINE;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CARVEDILOL;ADRB1;G;rs1801252;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
PAROXETINE;ABCB1;CC + CT;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
NILOTINIB;CYP1A1;CT + TT;rs1048943;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
NILOTINIB;CYP1A1;CT + TT;rs1048943;EFFICACY;INCREASED;RESPONSE;OTHER;BCR-ABL1 POSITIVE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;CG + GG;rs10754558;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
ATENOLOL;;GG;rs7184292;DOSAGE;DECREASED;DOSE;OTHER;HYPERTENSION;PEOPLE
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERLIPIDEMIAS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;GT + TT;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
CARVEDILOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
RISPERIDONE;AKT1;CT;rs3803300;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;AKT1;TT;rs2494732;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
IMATINIB;CYP2B6;GG + TT;rs3745274;EFFICACY;INCREASED;RESISTANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP2B6;GG + TT;rs3745274;EFFICACY;INCREASED;RESISTANCE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
WARFARIN;CYP2C19;AA + AG;rs4986893;DOSAGE;DECREASED;DOSE;;;
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C19;CT + TT;rs3814637;DOSAGE;DECREASED;DOSE;;;
CANNABIDIOL;AOC1;CT + TT;rs12539;EFFICACY;INCREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE
EFAVIRENZ;CYP2B6;CT + TT;rs3211371;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;CC;rs17250932;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HODGKIN DISEASE;CHILDREN
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:RHABDOMYOSARCOMA;CHILDREN
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:MEDULLOBLASTOMA;CHILDREN
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:GLIOMA;CHILDREN
DOCETAXEL;CHST3;C;rs730720;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
THALIDOMIDE;CHST3;C;rs730720;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;CC;rs8126756;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
CANNABIDIOL;SLC15A1;TT;rs1339067;EFFICACY;DECREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE
WARFARIN;;T;rs12772169;DOSAGE;;DOSE;;;
ROSIGLITAZONE;SLCO1B1;C;rs4149056;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;CG + GG;rs3212217;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;CC;rs1741981;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
RISPERIDONE;COMT;G;rs165599;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;GRM3;G;rs724226;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;AG;rs5744174;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
MORPHINE;KCNJ6;CC;rs6517442;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS
METHOTREXATE;ABCG2;GT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MORPHINE;KCNJ6;TT;rs6517442;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;INFANTS
REMIFENTANIL;KCNJ6;TT;rs6517442;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;INFANTS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;BIPOLAR DISORDER;PEOPLE
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:DEPRESSIVE DISORDER;PEOPLE
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOAFFECTIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ENALAPRIL;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
LITHIUM;CACNG2;TT;rs2284018;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
EFAVIRENZ;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ANASTROZOLE;;T;rs1437153;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
DOCETAXEL;ORM2;AA;rs2250242;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;PROSTATIC NEOPLASMS;MEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;
ETANERCEPT;CARD8;TT;rs2043211;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;CARD8;TT;rs2043211;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
METHOTREXATE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
ETANERCEPT;NLRP3;TT;rs4612666;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;NLRP3;TT;rs4612666;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ANASTROZOLE;DLG2;T;rs2449598;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;NEPHROTIC SYNDROME;CHILDREN
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;NEPHROTIC SYNDROME;CHILDREN
DIGOXIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
METHOTREXATE;MTHFR;AA;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
PEGINTERFERON ALFA-2B;HLA-DPA1;GG;rs3077;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE
PEGINTERFERON ALFA-2B;HLA-DPA1;GG;rs3077;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
RIVASTIGMINE;BCHE;CC;rs1803274;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
DIGOXIN;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ADALIMUMAB;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CANNABIDIOL;ABCC5;AA + AG;rs3749442;EFFICACY;DECREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;
EFAVIRENZ;CYP2B6;CC + CT;rs3181842;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
EFAVIRENZ;CYP2B6;AA + AG;rs707265;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
EFAVIRENZ;CYP2B6;CT + TT;rs7246465;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
SUFENTANIL;NFKBIA;TT;rs696;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
SUFENTANIL;NFKBIA;TT;rs696;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs1042389;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BIPOLAR DISORDER;PEOPLE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:DEPRESSIVE DISORDER;PEOPLE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOAFFECTIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
PAROXETINE;BDNF;TT;rs6265;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
REMIFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;
MORPHINE;COMT;GG;rs4680;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;INFANTS
MORPHINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS
REMIFENTANIL;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ADALIMUMAB;TLR2;T;rs3804099;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE
INFLIXIMAB;TLR2;T;rs3804099;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE
INTERFERON ALFA-N1;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
INTERFERON ALFA-N1;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HSCT;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
IMATINIB;ABCG2;GT;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;GT;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PEGINTERFERON ALFA-2B;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE
CLOZAPINE;CHRM1;CC;rs2075748;DOSAGE;DECREASED;DOSE;OTHER;SCHIZOPHRENIA;PEOPLE
CYCLOPHOSPHAMIDE;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
EPIRUBICIN;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
FLUOROURACIL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
INTERFERON ALFA-N1;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
INTERFERON ALFA-N1;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ERENUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
ERENUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE
FREMANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
FREMANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE
GALCANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE
GALCANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;DISEASE;ANEMIA;PEOPLE
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;DISEASE;"SICKLE CELL""";PEOPLE
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:BETA-THALASSEMIA AND RELATED DISEASES""";PEOPLE
ANASTROZOLE;CSMD1;T;rs6981827;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;DISEASE;ANEMIA;PEOPLE
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;DISEASE;"SICKLE CELL""";PEOPLE
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:BETA-THALASSEMIA AND RELATED DISEASES""";PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
DOXORUBICIN;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
EPIRUBICIN;NQO1;AA;rs1800566;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST CANCER CELL LINES;
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RESPONSE;OTHER;BREAST CANCER CELL LINES;
DOCETAXEL;MDM4;AA;rs1563828;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
EPIRUBICIN;MDM4;AA;rs1563828;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
GEMCITABINE;CDA;C;rs2072671;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs75982813;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
GLICLAZIDE;KCNJ11;TT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
GLICLAZIDE;KCNJ11;TT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;
DOXORUBICIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ARIPIPRAZOLE;DRD2;GG;rs6277;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
CAPECITABINE;AREG;AA + AC;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
RADIOTHERAPY;AREG;AA + AC;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
(S)-METHADONE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
(R)-METHADONE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
CAPECITABINE;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
RADIOTHERAPY;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE
CAPECITABINE;VEGFA;CG;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;VEGFA;CG;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ACETAMINOPHEN;UGT2B15;AA;rs1902023;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ARIPIPRAZOLE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
ACETAMINOPHEN;TRPV1;AA + AG;rs224534;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
CLOZAPINE;HTR3A;G;rs1150226;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;GRM7;CC;rs2069062;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
CLOZAPINE;HTR3A;A;rs2276302;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
GLUCOSE;COMT;AA + AG;rs4680;TOXICITY;INCREASED;CONCENTRATIONS;;;CHILDREN
CLOZAPINE;HTR3A;C;rs1062613;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ADALIMUMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DISCONTINUATION;DISEASE;KIDNEY DISORDER;PEOPLE
RISPERIDONE;GRID2;GG;rs1875705;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE
PACLITAXEL;ABCB1;CC;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TACROLIMUS;NR1I2;CC;rs2276707;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;
CAPECITABINE;VEGFA;AC;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
OXALIPLATIN;VEGFA;AC;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
WARFARIN;PRSS53, VKORC1;A;rs17886199;DOSAGE;DECREASED;DOSE;;;
4-HYDROXYATORVASTATIN;SLCO2B1;AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE
4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE
PACLITAXEL;ABCB1;AA + AT;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER;INCREASED;METABOLISM;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
2-HYDROXYATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE
4-HYDROXYATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE
ATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE
BEVACIZUMAB;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AA;rs4148323;DOSAGE;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
VALPROIC ACID;GABRA1;AA + AG;rs10068980;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CLOZAPINE;CHRM1;GG;rs1942499;DOSAGE;DECREASED;DOSE;OTHER;SCHIZOPHRENIA;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ROSUVASTATIN;SCAP;C;rs12487736;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
PEGINTERFERON ALFA-2B;IFNL3;CT;rs4803219;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;CT;rs4803219;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
BEVACIZUMAB;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN
ROCURONIUM;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;;;
MYCOPHENOLIC ACID;UGT1A9;AA + AT;rs6714486;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;CHILDREN
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
ROCURONIUM;SLCO1B1;AA;rs2306283;EFFICACY;DECREASED;RESPONSE;;;
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PERAMPANEL;CYP3A5, ZSCAN25;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;CHILDREN
MORPHINE;UGT2B7;AA + AG;rs7438135;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;INFANTS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;;GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;CHILDREN
PEGINTERFERON ALFA-2B;;CG + GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;;CG + GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
ACENOCOUMAROL;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
PHENPROCOUMON;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;MAINTENANCE DOSAGE BY 1.5 MG/WEEK;
ATENOLOL;EDN1;GT;rs5370;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;MEN
IRBESARTAN;EDN1;GT;rs5370;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;MEN
PAROXETINE;HTR2A;CC;rs6311;EFFICACY;INCREASED;RESPONSE;OTHER;OBSESSIVE-COMPULSIVE DISORDER;PEOPLE
PHENPROCOUMON;CYP2C9;T;rs4086116;DOSAGE;DECREASED;DOSE;OTHER;MAINTENANCE DOSAGE BY 2.2 MG/WEEK;
ATORVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
PRAVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
SIMVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
ATAZANAVIR;NR1I2;CT;rs2472677;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;CHILDREN
APIXABAN;CYP3A5;CC + CT;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
NIACIN;HCAR2;CT + TT;rs2454727;EFFICACY;DECREASED;RESPONSE;;;
ATORVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
PRAVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
SIMVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE
CEFTRIAXONE;ABCG2;TT;rs13120400;METABOLISM/PK;;CONCENTRATIONS;DISEASE;CENTRAL NERVOUS SYSTEM INFECTIOUS DISORDER;PEOPLE
RIBAVIRIN;ITPA;CC;rs1127354;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;CHILDREN
CREATINE;MOBP;AA + AG;rs616147;EFFICACY;INCREASED;RESPONSE;OTHER;AMYOTROPHIC LATERAL SCLEROSIS;PEOPLE
PEMETREXED;EXO1;AA + AG;rs1047840;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED;RESPONSE;DISEASE;TRANSPLANTATION;CHILDREN
PHENPROCOUMON;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;OTHER;MAINTENANCE DOSAGE BY 4.8 MG/WEEK;
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TRANSPLANTATION;CHILDREN
PROPOFOL;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED;DOSE;;;
ADALIMUMAB;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;DOSAGE;INCREASED;DOSE;DISEASE;MYELODYSPLASTIC SYNDROMES;PEOPLE
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;DOSE;DISEASE;MYELODYSPLASTIC SYNDROMES;PEOPLE
APIXABAN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
3;SLC6A2;TT;rs2242446;OTHER;DECREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;TT;rs2242446;OTHER;DECREASED;RESPONSE;;;
ATENOLOL;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
3;SLC6A2;GG;rs1861647;OTHER;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;GG;rs1861647;OTHER;INCREASED;RESPONSE;;;
3;SLC6A2;AA;rs36029;OTHER;INCREASED;RESPONSE;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;AA;rs36029;OTHER;INCREASED;RESPONSE;;;
ATENOLOL;AGT;CT + TT;rs5051;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ADALIMUMAB;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
CERTOLIZUMAB PEGOL;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
ETANERCEPT;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
GLUCOCORTICOIDS;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
INFLIXIMAB;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
METHOTREXATE;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
REPAGLINIDE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
REPAGLINIDE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
DISULFIRAM;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE
ADALIMUMAB;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
CERTOLIZUMAB PEGOL;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
ETANERCEPT;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
GLUCOCORTICOIDS;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
INFLIXIMAB;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
METHOTREXATE;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
SIROLIMUS;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
FELODIPINE;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;CLEARANCE;;;WOMEN
IRBESARTAN;CYP2C9;CT;rs1799853;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
NITRIC OXIDE;NAMPT;TT;rs1319501;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;PRE-ECLAMPSIA;WOMEN
TOCILIZUMAB;GALNT18;CC + CT;rs4910008;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
BUPRENORPHINE;OPRD1;AA;rs529520;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;WOMEN
NICOTINE;;C;rs12459249;METABOLISM/PK;DECREASED;METABOLISM;;;
WARFARIN;GGCX;AA + AG;rs2592551;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ARSENIC COMPOUNDS;AS3MT;C;rs11191439;TOXICITY;INCREASED;METABOLISM;;;HEALTHY
ARSENIC COMPOUNDS;AS3MT;C;rs11191439;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
ESCITALOPRAM;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
ATOMOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
DESVENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
DULOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
VENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
TOCILIZUMAB;IL6;CC;rs2069840;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ANTIDEPRESSANTS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
BENAZEPRIL;MTHFR;G;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
FLUOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
BENAZEPRIL;MTHFR;G;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
TRAMADOL;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";WOMEN
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:CAESARIAN SECTION""";WOMEN
PEMETREXED;CAMKK2;GT;rs1653586;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE
ABIRATERONE;SRD5A2;CC;rs523349;EFFICACY;INCREASED;RESPONSE;OTHER;PROSTATIC NEOPLASMS;MEN
BUPRENORPHINE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;WOMEN
CARBOPLATIN;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
LONAFARNIB;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
PACLITAXEL;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN
METHOTREXATE;ABCG2;GG;rs12505410;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE
ESCITALOPRAM;BMP5;A;rs41271330;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ENALAPRIL;CES1;CT;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METHOTREXATE;ABCG2;GT + TT;rs13137622;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE
METHOTREXATE;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE
AMLODIPINE;CYP3A4;CT + TT;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;WOMEN
TACROLIMUS;IL18;GG + GT;rs1946518;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
TACROLIMUS;IL10;TT;rs1800896;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;G;rs35303484;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
VALPROIC ACID;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN
METHOTREXATE;MTHFR;AG + GG;rs1801133;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;DECREASED;DOSE;DISEASE;LEUKOPENIA;PEOPLE
CELECOXIB;PTGS2;CC;rs689466;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
CLOZAPINE;NFIB;CT;rs28379954;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
METFORMIN;SLC22A1;AA + AG;rs594709;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;AA + AG;rs594709;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
IRINOTECAN;TDP1;GG;rs2401863;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LOSARTAN;CYP2C9;AA;rs1934969;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METFORMIN;SLC47A1;GG;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A1;GG;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
TACROLIMUS;IL18;CC + CG;rs5744247;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
DEXMEDETOMIDINE;CYP2D6;GG;rs16947;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;PEOPLE
CARBAMAZEPINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;CHILDREN
RIVAROXABAN;CYP3A4;T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;rs4148324;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE
EFAVIRENZ;ABCB1;C;rs3842;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
DEXMEDETOMIDINE;WBP2NL;AG + GG;rs5758550;TOXICITY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE
MEMANTINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;
WARFARIN;GGCX;CC;rs699664;DOSAGE;INCREASED;DOSE;;;
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CLOPIDOGREL;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;EXPOSURE;;;
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
RIVASTIGMINE;BCHE;CT;rs1803274;EFFICACY;INCREASED;RESPONSE;DISEASE;LEWY BODY DISEASE;PEOPLE
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
APIXABAN;ABCG2;G;rs2231142;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;GG;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;CC;rs3397;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
AMLODIPINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
LATANOPROST;PTGFR;CC;rs3766355;EFFICACY;INCREASED;RESPONSE;DISEASE;GLAUCOMA;PEOPLE
LATANOPROST;PTGFR;CC;rs3766355;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:OCULAR HYPERTENSION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;AA;rs1061631;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;C;rs3397;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
AMLODIPINE;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHADONE;NECTIN4;AA;rs11265549;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
OPIOID ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;
OTHER GENERAL ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;
VOLATILE ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;
OPIOID ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;
OTHER GENERAL ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;
VOLATILE ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;
METHADONE;NECTIN4;AA;rs11265549;DOSAGE;DECREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;DOSAGE;DECREASED;DOSE;OTHER;SURGERY;PEOPLE
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
DEXMEDETOMIDINE;ADRA2A;GG;rs1800544;DOSAGE;DECREASED;DOSE;OTHER;SURGERY;PEOPLE
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
IMATINIB;CYP2B6;GG + GT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;CYP2B6;GG + GT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
BENAZEPRIL;AGT;GG;rs7079;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;WOMEN
WARFARIN;CYP2C9;GG;rs9332098;DOSAGE;INCREASED;DOSE;;;
CANNABIDIOL;;CC;rs6729738;EFFICACY;INCREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE
METHOTREXATE;MTHFR;AG + GG;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
DEXMEDETOMIDINE;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE
WARFARIN;CYP2C9;TT;rs9332092;DOSAGE;INCREASED;DOSE;;;
HYDROCHLOROTHIAZIDE;TXNDC11;G;rs3784921;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
WARFARIN;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;
PAROXETINE;CYP1A2;A;rs762551;METABOLISM/PK;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
WARFARIN;CYP2C9;TT;rs1799853;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;TOXICITY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE
TOPOTECAN;ABCG2;AA + AG;rs4148157;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BRAIN NEOPLASMS;CHILDREN
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
RIVAROXABAN;CYP3A4;G;rs2246709;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
DULOXETINE;KMT2E;GG;rs117986340;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
RIVASTIGMINE;ACHE;TT;rs2571598;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN
DULOXETINE;NCAM1;TT;rs2303377;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
RIVAROXABAN;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
DULOXETINE;ZNF385D;TT;rs4261893;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
RIVAROXABAN;CYP3A4;C;rs3735451;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;
DEXMEDETOMIDINE;;CC;rs141294036;TOXICITY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE
AMPHETAMINE;CDH13;AG + GG;rs3784943;EFFICACY;INCREASED;RESPONSE;;;
EVEROLIMUS;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY STENOSIS;PEOPLE
DEXMEDETOMIDINE;KCNMB1;CC + CT;rs11739136;EFFICACY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE
MORPHINE;UGT2B7;CC + CT;rs7668282;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANEMIA;PEOPLE
MORPHINE;UGT2B7;CC + CT;rs7668282;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SICKLE CELL;PEOPLE
EFAVIRENZ;CYP2A7P1, CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PREGNANCY;WOMEN
DABIGATRAN;CES1;GG;rs8192935;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
ETHANOL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;DOSE;;;WOMEN
METHOTREXATE;CLCN6, MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;C1orf167, CLCN6, MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;MTR;AA;rs1805087;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
RANIBIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
ETHANOL;OPRM1;AA;rs10485057;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;DECREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE
METHOTREXATE;BIRC5;CG;rs9904341;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ACENOCOUMAROL;VKORC1;GG;rs9934438;EFFICACY;DECREASED;RESPONSE;;;
SALBUTAMOL;;A;rs17834628;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
NICOTINE;CHRNA3;A;rs1051730;DOSAGE;DECREASED;DOSE;OTHER;TOBACCO USE DISORDER;PEOPLE
ABIRATERONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
PREDNISOLONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE
PLATINUM;RICTOR;GG;rs6878291;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CLOZAPINE;DRD2;T;rs2514218;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METHOTREXATE;FASTKD3, MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
RANIBIZUMAB;KDR;AA + AG;rs2071559;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
ETHANOL;OPRM1;AG;rs1799971;OTHER;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE
BUSULFAN;GSTA1;CT;rs3957356;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
METHOTREXATE;ATIC;CT + TT;rs12995526;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CLOZAPINE;HTR3A;T;rs1062613;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
METHOTREXATE;ATIC;CT + TT;rs7563206;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CANDESARTAN;KCNK3;C;rs1275988;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BIPOLAR DISORDER;PEOPLE
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:DEPRESSION;PEOPLE
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS;PEOPLE
SUFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;OTHER;PAIN;CHILDREN
SUFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;CHILDREN
ADALIMUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED;RESPONSE;;;PEOPLE
IMMUNOGLOBULINS;CASP3, PRIMPOL;CT + TT;rs113420705;EFFICACY;DECREASED;RESPONSE;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;CHILDREN
SUFENTANIL;COMT;AA;rs4680;DOSAGE;INCREASED;DOSE;OTHER;PAIN;CHILDREN
SUFENTANIL;COMT;AA;rs4680;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;CHILDREN
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED;CONCENTRATIONS;OTHER;HEART VALVE REPLACEMENT;PEOPLE
IMMUNOGLOBULINS;COQ8B, ITPKC;CC + CG;rs28493229;EFFICACY;DECREASED;RESPONSE;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;CHILDREN
USTEKINUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
INFLIXIMAB;IL17F;CT;rs763780;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
HYDROCHLOROTHIAZIDE;CSK;C;rs1378942;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
SALBUTAMOL;;G;rs35661809;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
ANTIPSYCHOTICS;DRD3;CT + TT;rs6280;EFFICACY;INCREASED;RESISTANCE;OTHER;MOOD DISORDER;PEOPLE
ANTIPSYCHOTICS;DRD3;CT + TT;rs6280;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE
HYDROCHLOROTHIAZIDE;PDE3A;C;rs12579720;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
CANDESARTAN;SULT1C3;T;rs6722745;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ATENOLOL;STN1;A;rs4387287;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
METFORMIN;;TT;rs10783050;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;IL1B;GG;rs1143623;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;PEOPLE
CISPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
RIFAPENTINE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;
BEVACIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE
PEGAPTANIB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE
RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE
EPIRUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE
EPIRUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE
OXALIPLATIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;INCREASED;DOSE;OTHER;LEFT VENTRICULAR DYSFUNCTION;PEOPLE
EPIRUBICIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE
EPIRUBICIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
FLUOROURACIL;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE
FLUOROURACIL;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
OXALIPLATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE
OXALIPLATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BIPOLAR DISORDER;PEOPLE
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:DEPRESSION;PEOPLE
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS;PEOPLE
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;DECREASED;RESPONSE;OTHER;LEFT VENTRICULAR DYSFUNCTION;PEOPLE
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;OTHER;AUTOIMMUNE DISEASES;PEOPLE
NICOTINE;CHRNA3, CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
CLOZAPINE;HTR3A;G;rs2276302;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
IMATINIB;ABCB1;AT + TT;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AT + TT;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
TELMISARTAN;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
EFAVIRENZ;CYP2B6;T;rs8192719;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
LITHIUM;;CC;rs2769605;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
VALPROIC ACID;;CC;rs2769605;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
CISPLATIN;GNAS;CC;rs7121;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE
FLUOROURACIL;GNAS;CC;rs7121;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE
ATENOLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ATENOLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROCHLOROTHIAZIDE;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
METOPROLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
ONDANSETRON;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;
LITHIUM;DRD2;GG;rs1800497;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE
OLANZAPINE;DRD2;GG;rs1800497;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;;T;rs247616;EFFICACY;INCREASED;RESPONSE;;;
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
ADALIMUMAB;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
GLUCOCORTICOIDS;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
HYDROCHLOROTHIAZIDE;PRKAG2;A;rs10224002;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
AGOMELATINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
MELATONIN RECEPTOR AGONISTS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
VENLAFAXINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE
ADALIMUMAB;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CERTOLIZUMAB PEGOL;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
GLUCOCORTICOIDS;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;CHILDREN
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;CHILDREN
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;CHILDREN
HYDROCHLOROTHIAZIDE;PLCE1;A;rs932764;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
METOPROLOL;;T;rs1446468;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ATENOLOL;RRP1B;T;rs9306160;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
ATENOLOL;TBX2;C;rs8068318;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
AMISULPRIDE;DRD2;C;rs1079597;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
USTEKINUMAB;NFKBIA;CC;rs2145623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
HYDROCHLOROTHIAZIDE;ADO;C;rs10995311;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
PLATINUM COMPOUNDS;XBP1;CC;rs2269577;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
CANDESARTAN;DOT1L, PLEKHJ1;A;rs740406;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
USTEKINUMAB;ADAM33;CC;rs2787094;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
HYDROCHLOROTHIAZIDE;NUCB2;C;rs757081;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
USTEKINUMAB;;AG + GG;rs1975974;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
EXENATIDE;KCNQ1;G;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
EXENATIDE;KCNQ1;G;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE
USTEKINUMAB;AGBL4;CC + CT;rs191190;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
NORTRIPTYLINE;SLC39A14;C;rs17060812;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;
USTEKINUMAB;CHUK;CC + CG;rs11591741;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
USTEKINUMAB;HTR2A;CT + TT;rs6311;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;;
HYDROCHLOROTHIAZIDE;C5orf56;G;rs12521868;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
PITAVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
CANDESARTAN;SH2B3;T;rs3184504;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
CARBAMAZEPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
2-HYDROXYATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
2-HYDROXYATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
4-HYDROXYATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
4-HYDROXYATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
CARBAMAZEPINE;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
PAROXETINE;COMT;A;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
CAPECITABINE;TP53;GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
PACLITAXEL;TP53;GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
SUFENTANIL;CYP3A4;CC;rs2242480;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN
SUFENTANIL;CYP3A4;CC;rs2242480;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN
TRIGLYCERIDES;CYP19A1;A;rs749292;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRIGLYCERIDES;CYP19A1;A;rs749292;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
HDL CHOLESTEROL;CYP19A1;G;rs1062033;OTHER;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
HDL CHOLESTEROL;CYP19A1;G;rs1062033;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE DISEASES;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NORTRIPTYLINE;PPM1A;AA;rs2273623;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE
AMILORIDE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
SPIRONOLACTONE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
AZATHIOPRINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
DEFERASIROX;UGT1A3;CC;rs3806596;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
LOPINAVIR;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
PROPOFOL;CYP2B6;AA + AG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;;;
SPIRONOLACTONE;CYP4A11;CC;rs3890011;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
ATAZANAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
RIFAMPIN;AADAC;AA;rs1803155;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;TUBERCULOSIS;PEOPLE
APATINIB;CYP2C9;GG;rs1934968;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE
APATINIB METABOLITE M1-1;CYP2C9;GG;rs1934968;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;AT + TT;rs11075995;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;NEOPLASMS;PEOPLE
AMPRENAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ACAMPROSATE;;G;rs77583603;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE
EVEROLIMUS;CYP3A5;CC + CT;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART TRANSPLANTATION;PEOPLE
NALTREXONE;;A;rs12749274;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE
DEFERASIROX;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE
FLUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
RITONAVIR;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
RITONAVIR;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
FLUVASTATIN;APOE;CC;rs429358;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
RITONAVIR;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;PEOPLE
DEHYDROARIPIPRAZOLE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;SCHIZOPHRENIA;PEOPLE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;OTHER:TOBACCO USE DISORDER;PEOPLE
ETHANOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;;;CHILDREN
PREDNISOLONE;GATA3;AA;rs3824662;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;GSTM3;TT;rs7483;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AG;rs1051792;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ADALIMUMAB;TNF;CC;rs1799724;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;GG;rs1051792;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
FLUOXETINE;HTR1B;AA + TT;rs130058;EFFICACY;INCREASED;RESPONSE;DISEASE;MENTAL DISORDERS;CHILDREN
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CLOZAPINE;CYP1A2;AA;rs762551;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
FLUVASTATIN;APOE;TT;rs7412;EFFICACY;INCREASED;CLINICAL BENEFIT;;;
ADALIMUMAB;TNF;GG;rs361525;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
MORPHINE;SLC6A4;CC;rs1042173;DOSAGE;DECREASED;DOSE;OTHER;LUNG NEOPLASMS;PEOPLE
MORPHINE;SLC6A4;CC;rs1042173;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE
FLUOXETINE;TPH2;TT;rs4570625;EFFICACY;INCREASED;RESPONSE;DISEASE;MENTAL DISORDERS;CHILDREN
METHOTREXATE;ADORA2A-AS1;CT + TT;rs17004921;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ANTIEPILEPTICS;ABCB1;AA;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
ATENOLOL;ALDH1A2;T;rs261316;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
HYDROCHLOROTHIAZIDE;ALDH1A2;T;rs261316;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
CISPLATIN;REV3L;AG + GG;rs462779;EFFICACY;DECREASED;RESPONSE;DISEASE;OSTEOSARCOMA;PEOPLE
CISPLATIN;REV1;CT + TT;rs3087403;EFFICACY;INCREASED;RESPONSE;DISEASE;OSTEOSARCOMA;PEOPLE
ANTIEPILEPTICS;SCN1A;CC + CT;rs2298771;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN
AZITHROMYCIN;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
AZITHROMYCIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
LOPINAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
FENTANYL;OPRM1;AA;rs9384179;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;OPRM1;AA;rs9384179;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
FENTANYL;OPRM1;AA;rs9384179;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;OPRM1;AA;rs9384179;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FLUVASTATIN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
FENTANYL;KCNJ6;TT;rs2835859;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;KCNJ6;TT;rs2835859;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
FENTANYL;KCNJ6;TT;rs2835859;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;KCNJ6;TT;rs2835859;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
ABIRATERONE;HSD3B1;AC;rs1047303;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PROSTATIC NEOPLASMS;MEN
FENTANYL;;CC;rs2952768;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;;CC;rs2952768;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
FENTANYL;;CC;rs2952768;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;;CC;rs2952768;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
FENTANYL;;AA;rs11959113;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;;AA;rs11959113;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
FENTANYL;;AA;rs11959113;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE
FENTANYL;;AA;rs11959113;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;HEART TRANSPLANTATION;PEOPLE
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;EFFICACY;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;TOXICITY;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
BILIRUBIN;SOD2;GG;rs4880;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;HEALTHY
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION;PEOPLE
MONTELUKAST;UGT1A3;T;rs7604115;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
MONTELUKAST;ABCC9;T;rs704212;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
IVACAFTOR;CFTR;AA;rs77010898;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE
DOCETAXEL;AKR1C3;GG;rs1937840;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOXORUBICIN;AKR1C3;GG;rs1937840;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
CYCLOPHOSPHAMIDE;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
ANTIDEPRESSANTS;GRIK4;TT;rs1954787;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;AN INTERNATIONAL NORMALIZED RATIO (INR) OF 2.0-3.0;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;A;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
BUPRENORPHINE;OPRM1;CC + CG;rs2075572;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;C;rs2651899;EFFICACY;INCREASED;RESPONSE;OTHER;MIGRAINE WITH AURA;PEOPLE
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;C;rs2651899;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE
AFATINIB;NR1I2;AA + AG;rs6785049;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
RIVAROXABAN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY
LOPINAVIR;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;HIV INFECTIOUS DISEASE;CHILDREN
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;PEOPLE
ATAZANAVIR;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ANTIDEPRESSANTS;ABCB1;A;rs1128503;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHADONE;COMT;CC + CT;rs933271;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AG;rs2070959;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AG;rs2070959;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
ATAZANAVIR;ABCB1;AC + CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
ATAZANAVIR;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
METHOTREXATE;MTHFR;GT + TT;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
VALPROIC ACID;GRIN2B;AC;rs1019385;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;GRIN2B;AC;rs1019385;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;GRIN2B;CC;rs1019385;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;GRIN2B;CC;rs1019385;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
CARBAMAZEPINE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
CLOBAZAM;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
ETHOSUXIMIDE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LAMOTRIGINE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LEVETIRACETAM;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
OXCARBAZEPINE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
VALPROIC ACID;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN
LOPINAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
VALPROIC ACID;UGT1A6;AC;rs1105879;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A6;AC;rs1105879;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;BREAST NEOPLASMS;PEOPLE
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;OTHER:KIDNEY NEOPLASMS;PEOPLE
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;OTHER:NEUROENDOCRINE TUMORS;PEOPLE
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
AMISULPRIDE;SNAP25;CT;rs8636;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOPIDOGREL;ABCA1;A;rs2487032;METABOLISM/PK;INCREASED;METABOLISM;;;
CLOPIDOGREL;N6AMT1;G;rs2254638;METABOLISM/PK;DECREASED;METABOLISM;;;
TENOFOVIR;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN
SIROLIMUS;ABCB1;A;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE
ANTIPSYCHOTICS;NRXN1;AA;rs12467557;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;NRXN1;TT;rs10490162;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;DECREASED;RESPONSE;;;
DABIGATRAN;CES1;GG;rs8192935;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ATAZANAVIR;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE
CERTOLIZUMAB PEGOL;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE
GOLIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED;RESPONSE;;;
TACROLIMUS;CYP3A5;CC;rs776746;OTHER;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ATAZANAVIR;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs2070959;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs2070959;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CISPLATIN;DPYD;CT;rs3918290;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN
FLUOROURACIL;DPYD;CT;rs3918290;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN
CISPLATIN;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
DOCETAXEL;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
IRINOTECAN;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs6759892;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs6759892;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GT;rs6759892;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GT;rs6759892;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
VALPROIC ACID;UGT1A6;CC;rs1105879;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
VALPROIC ACID;UGT1A6;CC;rs1105879;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
10-MONOHYDROXY OXCARBAZEPINE;INSR;C;rs2396185;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN
ATAZANAVIR;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
RISPERIDONE;HTR1A;GG;rs6295;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
FENTANYL;CACNA1E;CC + CT;rs3845446;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE
FENTANYL;CACNA1E;CC + CT;rs3845446;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
FENTANYL;LAMB3;G;rs2076222;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;LAMB3;G;rs2076222;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
FENTANYL;LAMB3;G;rs2076222;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
FENTANYL;LAMB3;G;rs2076222;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE
CETUXIMAB;VEGFA;TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CETUXIMAB;VEGFA;GG;rs1570360;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CISPLATIN;MECP2;A;rs1734791;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;MECP2;A;rs1734791;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;MECP2;A;rs1734791;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;MECP2;A;rs1734787;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;MECP2;A;rs1734787;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;MECP2;A;rs1734787;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;MECP2;A;rs17435;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;MECP2;A;rs17435;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;MECP2;A;rs17435;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
VORICONAZOLE;CYP3A4;CT;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY
CISPLATIN;;T;rs5906072;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;;T;rs5906072;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;;T;rs5906072;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
PROCHLORPERAZINE;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;DECREASED;RESPONSE;OTHER;NAUSEA;PEOPLE
PROCHLORPERAZINE;DRD2;CT + TT;rs1079597;EFFICACY;DECREASED;RESPONSE;OTHER;NAUSEA;PEOPLE
METFORMIN;ATM;AC;rs11212617;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;ATM;AC;rs11212617;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
MORPHINE;OPRK1;A;rs1051660;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
MORPHINE;OPRK1;A;rs1051660;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE
CISPLATIN;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
ATORVASTATIN;HMGCR;CT + TT;rs17671591;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
ESCITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED;RESPONSE;OTHER;DEPRESSION;PEOPLE
CISPLATIN;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
TENOFOVIR ALAFENAMIDE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
CISPLATIN;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
DABIGATRAN;CES1;GG;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY
CISPLATIN;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
TACROLIMUS;CYP3A4;TT;rs2740574;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
APATINIB;CYP2C9;TT;rs34532201;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE
APATINIB METABOLITE M1-1;CYP2C9;TT;rs34532201;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE
CISPLATIN;;C;rs5934731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;;C;rs5934731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;;C;rs5934731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;;C;rs715171;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;;C;rs715171;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;;C;rs715171;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;;C;rs4932551;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;;C;rs4932551;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;;C;rs4932551;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;;T;rs7170769;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;;T;rs7170769;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;;T;rs7170769;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;;C;rs6458232;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;;C;rs6458232;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;;C;rs6458232;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
CISPLATIN;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
ALLOPURINOL;AOX1;G;rs3731722;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE
FEBUXOSTAT;AOX1;G;rs3731722;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE
PAZOPANIB;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTOIMMUNE DISEASES;PEOPLE
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED;RESPONSE;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
ALLOPURINOL;AOX1;T;rs11678615;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE
FEBUXOSTAT;AOX1;T;rs11678615;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
DIAZEPAM;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
ALLOPURINOL;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs34650714;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE
FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs34650714;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE
ALLOPURINOL;XDH;G;rs1884725;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE
FEBUXOSTAT;XDH;G;rs1884725;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE
ALLOPURINOL;AOX1;T;rs75995567;DOSAGE;INCREASED;DOSE;DISEASE;GOUT;PEOPLE
FEBUXOSTAT;AOX1;T;rs75995567;DOSAGE;INCREASED;DOSE;DISEASE;GOUT;PEOPLE
METFORMIN;SLC22A1;AC;rs622342;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;AC;rs622342;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
PROPOFOL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;;CHILDREN
METHOTREXATE;ABCC3;TT;rs4148416;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
TACROLIMUS;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN
METHOTREXATE;SLC19A1;CG;rs17004785;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
DONEPEZIL;BCHE;T;rs1803274;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;WOMEN
CISPLATIN;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
DOXORUBICIN;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
METHOTREXATE;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE
PAROXETINE;GDNF;CT + TT;rs2973049;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;GDNF;AA + AG;rs2216711;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;AA;rs4819554;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ATOMOXETINE;SLC6A2;T;rs3785143;EFFICACY;DECREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN
PAROXETINE;BDNF;CC + CT;rs6265;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ROSUVASTATIN;CETP;G;rs5882;EFFICACY;INCREASED;RESPONSE;;;
FLUOXETINE;CYP2D6;GT;rs28371703;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY
FLUOXETINE;CYP2D6;C;rs1135840;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;MEN
FLUOXETINE;CYP2D6;A;rs1065852;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY
RIVAROXABAN;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;OTHER;ATRIAL FIBRILLATION;PEOPLE
RISPERIDONE;COMT;GG;rs9606186;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RIVAROXABAN;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ATRIAL FIBRILLATION;PEOPLE
TACROLIMUS;C6;CC + TT;rs10052999;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;CHILDREN
TACROLIMUS;C6;CC + CT;rs9200;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
CISPLATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
DOXORUBICIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
METHOTREXATE;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
RISPERIDONE;RGS4;C;rs2661319;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
LAMOTRIGINE;SLC22A1;AA + AG;rs628031;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
RISPERIDONE;ANKK1;A;rs1800497;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;OTHER;TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CISPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
DOXORUBICIN;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
METHOTREXATE;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
PHENYTOIN;CYP2C9;C;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
PHENYTOIN;SCN1A;T;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;ABCB1;T;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs28371738;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
RIVAROXABAN;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
FLUVOXAMINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MILNACIPRAN;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
LANSOPRAZOLE;ABCB1;G;rs1045642;OTHER;INCREASED;METABOLISM;;;
LANSOPRAZOLE;ABCB1;G;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;
FLUVOXAMINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
MILNACIPRAN;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
PAROXETINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
LAMOTRIGINE;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
RIVAROXABAN;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
RIVAROXABAN;ABCB1;T;rs4148738;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE
PHENYTOIN;CYP2C9;AT + TT;rs1934969;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY HYPERTENSION;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;APOC1;G;rs4420638;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;APOC1;G;rs4420638;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY HYPERTENSION;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE
PHOTODYNAMIC THERAPY;F13A1;AA + AC;rs5985;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PULMONARY HYPERTENSION;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE
CITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;NPC1L1;G;rs2072183;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;NPC1L1;G;rs2072183;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;SORT1;T;rs629301;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;SORT1;T;rs629301;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE
MYCOPHENOLIC ACID;UGT1A9;del;rs3832043;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
BISOPROLOL;ACY3;T;rs2514036;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;MEN
MYCOPHENOLIC ACID;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
IMATINIB;BCL2L11;T;rs724710;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;BCL2L11;T;rs724710;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ITOPRIDE;FMO3;AA;rs2266782;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
METOPROLOL;SEPTIN3;G;rs56234624;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
ITOPRIDE;FMO3;GG;rs2266780;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE
MYCOPHENOLIC ACID;ABCC2;CT;rs3740066;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
GEMCITABINE;RRM1;AA;rs9937;EFFICACY;DECREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
TACROLIMUS;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE
BEVACIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
GEMCITABINE;RRM1;AC;rs183484;EFFICACY;DECREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
GEMCITABINE;RRM1;AC;rs183484;TOXICITY;DECREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AA;rs4148323;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
COTININE GLUCURONIDE;UGT1A9;CT;rs12471326;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
NICOTINE;CYP2A6;GT;rs145014075;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
BEVACIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
CYCLOSPORINE;CYP3A5;CC + CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY
GRANISETRON;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;NAUSEA;PEOPLE
GRANISETRON;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;PEOPLE
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;HEART FAILURE;PEOPLE
CARBAMAZEPINE;SCN1A;CC + CT;rs3812718;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
BEVACIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
ETANERCEPT;CD84;AG;rs6427528;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
LOPINAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;MEN
CARBAMAZEPINE;SCN1A;TT;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
METHADONE;OPRM1;AA;rs10485058;EFFICACY;INCREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
CARBAMAZEPINE;GABRA1;AA + AG;rs2290732;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
USTEKINUMAB;IL12B;CT;rs3213094;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE
TOCILIZUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
EFAVIRENZ;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ALFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CETUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;PEOPLE
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;PEOPLE
EFAVIRENZ;HNF4A;CC;rs1884613;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
METHADONE;ALDH5A1;CT + TT;rs2760118;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED;DISCONTINUATION;;;
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE
OLANZAPINE;CHAT;A;rs1880676;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;CHAT;A;rs1880676;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
PRAVASTATIN;ABCC2;CG;rs113646094;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
RAMIPRIL;ACE;CC + TT;rs4359;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
RAMIPRIL;ACE;AA + GG;rs4344;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;;DOSE;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GLOMERULONEPHRITIS;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MEMBRANOUS;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
OXYCODONE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED;RESPONSE;;;
PEGINTERFERON ALFA-2B;KLRK1;GG;rs1049174;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;KLRK1;GG;rs1049174;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CITALOPRAM;CRHR2;CC + CG;rs2270007;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
RIFAMPIN;NR1I2;AA + AG;rs3732357;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;TUBERCULOSIS;PEOPLE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OSTEOSARCOMA;CHILDREN
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
OXYCODONE;;CT;rs6848893;EFFICACY;DECREASED;RESPONSE;;;
PLATINUM COMPOUNDS;ATP7B;G;rs9535826;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
DEXAMETHASONE;NR3C1;CC;rs6198;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;BIPOLAR DISORDER;PEOPLE
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:DEPRESSION;PEOPLE
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE
PLATINUM COMPOUNDS;ATP7B;A;rs9535828;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
DEXAMETHASONE;NR3C1;AA;rs33388;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE
RISPERIDONE;CCL2;AA + AG;rs4795893;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
RISPERIDONE;CCL2;CC + CT;rs4586;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;EXPOSURE;;;HEALTHY
METHOTREXATE;FPGS;TT;rs1544105;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
METHOTREXATE;FPGS;TT;rs1544105;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
DEXAMETHASONE;NR3C1;TT;rs33389;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
ATORVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE
ROSUVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE
SIMVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE
CORTICOSTEROIDS;ADRB2;A;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;A;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN
RISPERIDONE;CCL2;GG;rs2857657;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
LAMOTRIGINE;UGT1A4;TT;rs2011425;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE
MERCAPTOPURINE;ITPA;A;rs1127354;METABOLISM/PK;;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
LAMOTRIGINE;UGT1A4;TT;rs2011425;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;
OLANZAPINE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
EFAVIRENZ;CYP2B6;CC;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NICOTINE;CHRNB3;G;rs4950;EFFICACY;INCREASED;RESPONSE;OTHER;SMOKERS;
NICOTINE;CHRNB3;G;rs4950;OTHER;INCREASED;RESPONSE;OTHER;SMOKERS;
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PLATINUM COMPOUNDS;HMGB1;CC;rs1412125;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
NICOTINE;CHRNB3;G;rs13280604;EFFICACY;INCREASED;RESPONSE;OTHER;SMOKERS;
NICOTINE;CHRNB3;G;rs13280604;OTHER;INCREASED;RESPONSE;OTHER;SMOKERS;
WARFARIN;VKORC1;G;rs749671;DOSAGE;INCREASED;DOSE;;;
DEXAMETHASONE;CYP3A4;AG;rs35599367;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE
OLANZAPINE;ABCB1;T;rs3842;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
PLATINUM COMPOUNDS;HMGB1;GG;rs2249825;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;G;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CISPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
CISPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:TOBACCO USE DISORDER;PEOPLE
RADIOTHERAPY;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE
RADIOTHERAPY;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:TOBACCO USE DISORDER;PEOPLE
LOSARTAN;ACE;AT + TT;rs4291;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED;RESPONSE;OTHER;MACULAR DEGENERATION;PEOPLE
OXYCODONE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;;
ADALIMUMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ADALIMUMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
USTEKINUMAB;TIRAP;CT + TT;rs8177374;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;OTHER;SCHIZOPHRENIA;PEOPLE
USTEKINUMAB;TLR5;AG + GG;rs5744174;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;CG + GG;rs11465996;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
RIVAROXABAN;BRD3;AA;rs467387;PD;INCREASED;RESPONSE;;;HEALTHY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AT + TT;rs4696480;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
USTEKINUMAB;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
WARFARIN;ABCB1;A;rs1045642;DOSAGE;INCREASED;DOSE;;;
WARFARIN;APOE;CC + CT;rs429358;DOSAGE;DECREASED;DOSE;;;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
USTEKINUMAB;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
REPAGLINIDE;NR1I2;GG;rs2276706;METABOLISM/PK;DECREASED;METABOLISM;;;MEN
COTININE;OPRM1;T;rs510769;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
RISPERIDONE;COMT;C;rs9606186;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
REPAGLINIDE;NR1I2;CC;rs3814058;METABOLISM/PK;DECREASED;METABOLISM;;;MEN
ATEZOLIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA;PEOPLE
BEVACIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA;PEOPLE
COTININE;OPRM1;T;rs12209447;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
RISPERIDONE;COMT;C;rs2020917;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
COTININE;OPRM1;T;rs3798676;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;
FENTANYL;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;;;CHILDREN
RISPERIDONE;COMT;C;rs933271;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
COTININE;OPRM1;T;rs553202;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
COTININE;OPRM1;G;rs1074287;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHADONE;OPRD1;AA + AC;rs529520;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE
COTININE;OPRM1;A;rs1799971;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
COTININE;OPRM1;T;rs6912029;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
PREDNISONE;EDNRA;CC + CT;rs5333;EFFICACY;INCREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;CHILDREN
REPAGLINIDE;NR1I2;CC;rs3814058;METABOLISM/PK;INCREASED;METABOLISM;;;MEN
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;TLR4;CC;rs1927907;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE
PAZOPANIB;NR1I2;T;rs3814055;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
ADALIMUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ACENOCOUMAROL;CALU;G;rs1043550;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
TACROLIMUS;IL18;GG + GT;rs1946518;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ADALIMUMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
ADALIMUMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
REPAGLINIDE;NR1I2;GG;rs2276706;METABOLISM/PK;INCREASED;METABOLISM;;;MEN
ADALIMUMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
INFLIXIMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
FLUOROURACIL;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
RADIOTHERAPY;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
FLUOROURACIL;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
RADIOTHERAPY;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
MYCOPHENOLIC ACID;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;
FLUOROURACIL;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
RADIOTHERAPY;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE
COTININE;OPRM1;T;rs563649;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
COTININE;OPRM1;G;rs2075572;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;
COTININE;OPRM1;G;rs7748401;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
COTININE;OPRM1;G;rs495491;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
COTININE;OPRM1;G;rs10457090;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
COTININE;OPRM1;G;rs3778152;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
PRAVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;
COTININE;OPRM1;T;rs589046;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHOTREXATE;NR1I2;T;rs3814055;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;OSTEOSARCOMA;CHILDREN
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHOTREXATE;ABCC3;C;rs4793665;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN
METHOTREXATE;NR1I2;G;rs7643038;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;OSTEOSARCOMA;CHILDREN
METHOTREXATE;ABCB1;C;rs9282564;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN
METHOTREXATE;ABCG2;T;rs2231142;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;OSTEOSARCOMA;CHILDREN
GLUCOCORTICOIDS;;AA;rs17446593;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN
DABIGATRAN GLUCURONIDE;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
SUNITINIB;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOZAPINE;NTRK2;CC;rs10465180;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE
WARFARIN;CYP2C9;G;rs9332238;DOSAGE;INCREASED;DOSE;;;
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED;RESISTANCE;OTHER;CORONARY DISEASE;PEOPLE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;WOMEN
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;CG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ERLOTINIB;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ERLOTINIB;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
METHOTREXATE;ABCC1;GG;rs28364006;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
DOLUTEGRAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
ERLOTINIB;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
LOSARTAN;AGTR1;CC;rs5186;EFFICACY;DECREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE
CLOPIDOGREL;KDR;T;rs2305948;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;DOSAGE;INCREASED;DOSE;OTHER;EPILEPSY;PEOPLE
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METFORMIN;ARFGEF3;AC;rs143276236;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;ARFGEF3;AC;rs143276236;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
TRASTUZUMAB;ERBB2;G;rs1136201;TOXICITY;;RESPONSE;;;
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;PEOPLE
METFORMIN;PRKAB2;A;rs7541245;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;PRKAB2;A;rs7541245;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;POR;CT + TT;rs1057868;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;PEOPLE
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;PEOPLE
PRAMIPEXOLE;DRD3;T;rs6280;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;GG;rs7196161;DOSAGE;DECREASED;DOSE;;;
ANTIDEPRESSANTS;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN
BENZODIAZEPINE DERIVATIVES;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN
MIRTAZAPINE;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PREGNANCY;PEOPLE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;CYP3A5;A;rs41303343;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
METFORMIN;SLC22A1;GG;rs628031;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A1;GG;rs628031;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE
TACROLIMUS;CYP3A5;T;rs10264272;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;T;rs10264272;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;VKORC1;AA;rs2884737;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED;DOSE;;;
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MYCOPHENOLIC ACID;ABCC2;CC;rs717620;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;PRSS53, VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
CAFFEINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;PEOPLE
WARFARIN;GGCX;CG;rs11676382;DOSAGE;DECREASED;DOSE;;;
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED;METABOLISM;OTHER;HEAVY COFFEE CONSUMPTION;PEOPLE
CAFFEINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HEAVY COFFEE CONSUMPTION;PEOPLE
TICAGRELOR;PEAR1;GT + TT;rs4661012;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN
TICAGRELOR;PEAR1;TT;rs12566888;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TICAGRELOR;PEAR1;AA;rs12041331;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN
TICAGRELOR;PEAR1;AA;rs12041331;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
WARFARIN;PRSS53, VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;AA + AG;rs2069885;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;AA + AG;rs2069885;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;NEUROMYELITIS OPTICA;PEOPLE
PREDNISOLONE;CD40;CC;rs1883832;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;OTHER;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;OTHER;LIVER TRANSPLANTATION;CHILDREN
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
ERENUMAB;CALCRL;G;rs6710852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE
ERENUMAB;CALCRL;G;rs6710852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE
TACROLIMUS;ABCB1;AA + TT;rs2032582;DOSAGE;DECREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN
TACROLIMUS;ABCB1;AA + TT;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED;DOSE;;;
HALOTHANE;RYR1;T;rs118192161;OTHER;INCREASED;RESPONSE;;;
WARFARIN;VKORC1;CC;rs8050894;DOSAGE;INCREASED;DOSE;;;
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED;DOSE;;;
2-HYDROXYATORVASTATIN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;AA + AG;rs2069812;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;AA + AG;rs2069812;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE
BETA BLOCKING AGENTS;BST1;A;rs28404156;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
SELECTIVE;BST1;A;rs28404156;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN
BISPHOSPHONATES;FDPS;T;rs2297480;EFFICACY;INCREASED;RESPONSE;DISEASE;OSTEOPOROSIS;PEOPLE
SIMVASTATIN;CETP;A;rs5882;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;TT;rs405509;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE
METHOTREXATE;ABCG2;GG;rs17731538;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SPONDYLARTHROPATHIES;PEOPLE
CYCLOSPORINE;UMOD;GT + TT;rs12917707;EFFICACY;INCREASED;RESPONSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
MODAFINIL;ABCB1;AC + CT;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;NARCOLEPSY;PEOPLE
MODAFINIL;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;NARCOLEPSY;PEOPLE
WARFARIN;MYC;CT;rs4645962;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;MYC;CT + TT;rs4645943;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;G;rs2234922;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
MODAFINIL;ABCB1;AG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;NARCOLEPSY;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SPONDYLARTHROPATHIES;PEOPLE
BISPHOSPHONATES;FDPS;A;rs11264359;EFFICACY;INCREASED;RESPONSE;DISEASE;OSTEOPOROSIS;PEOPLE
WARFARIN;MYC;CC;rs4645974;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PSORIASIS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SPONDYLARTHROPATHIES;PEOPLE
ATORVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED;DOSE;;;
SIMVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED;DOSE;;;
LEFLUNOMIDE;DHODH;CC;rs3213422;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
ANTIPSYCHOTICS;DRD2;G;rs1799732;EFFICACY;INCREASED;RESISTANCE;OTHER;MOOD DISORDER;PEOPLE
ANTIPSYCHOTICS;DRD2;G;rs1799732;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
RISPERIDONE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;HTR2A;AG;rs7997012;EFFICACY;INCREASED;RESISTANCE;OTHER;MOOD DISORDER;PEOPLE
ANTIPSYCHOTICS;HTR2A;AG;rs7997012;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE
METHADONE;CYP2B6;TT;rs3745274;DOSAGE;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHADONE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHADONE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
OLANZAPINE;HTR2A;AG + GG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
OLANZAPINE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
CARBAMAZEPINE;EPHX1;CC;rs1051740;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
EFAVIRENZ;CYP2B6;GG;rs3745274;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
CARBAMAZEPINE;EPHX1;GG;rs2234922;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
AZATHIOPRINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
AZATHIOPRINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
ETHANOL;OPRM1;CC + CT;rs3778150;;DECREASED;RESPONSE;;;
CARBAMAZEPINE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
ANTIEPILEPTICS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
RALOXIFENE;COMT;AG;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;MEN
RALOXIFENE;COMT;AG;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;MEN
PACLITAXEL;ABCC2;CT;rs717620;TOXICITY;DECREASED;DOSE;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;PEOPLE
RALOXIFENE;COMT;AA;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;MEN
RALOXIFENE;COMT;AA;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;MEN
BUPRENORPHINE;OPRD1;CT + TT;rs678849;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;ABCB1;AC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;MEN
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE
RISPERIDONE;TNIK;CC;rs7627954;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
RALOXIFENE;COMT;CG;rs4818;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
RALOXIFENE;COMT;CG;rs4818;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
METHADONE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
SUNITINIB;ABCB1;AA + AT;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
SUNITINIB;ABCB1;AA + AT;rs2032582;TOXICITY;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE
ADALIMUMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
INFLIXIMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
SUNITINIB;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;ABCB1;AG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;MEN
METHADONE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE
METHADONE;CYP2B6;AA;rs2279343;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
DOLUTEGRAVIR;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE
METHADONE;CYP2B6;GG;rs3745274;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
PREDNISOLONE;TLR4;T;rs4986791;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN
PERAMPANEL;CYP3A4;CG;rs4986908;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
TELBIVUDINE;TK2;CC + CT;rs3826160;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEPATITIS B;PEOPLE
TELBIVUDINE;TK2;CC + CT;rs3826160;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CHRONIC;PEOPLE
WARFARIN;EPHX1;TT;rs1877724;DOSAGE;DECREASED;DOSE;;;
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
ETHANOL;OPRM1;CC + CT;rs3778150;DOSAGE;INCREASED;DOSE;;;
OLANZAPINE;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY
CEFOTAXIME;SLC22A8;AT;rs11568482;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;RESPONSE;;;
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN
ESCITALOPRAM;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
DONEPEZIL;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE
GALANTAMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE
ESCITALOPRAM;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;
EFAVIRENZ;CYP2B6;TT;rs2279345;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
PERAMPANEL;CYP3A4;CT + TT;rs2242480;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN
DONEPEZIL;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
GALANTAMINE;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN
PREDNISOLONE;TLR4;G;rs4986790;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN
METHADONE;ABCB1;CC;rs2032582;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE
METHADONE;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
IRINOTECAN_METABOLITE(SN-38);ABCB1;AC + CC;rs12720066;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ANTIPSYCHOTICS;GABRB1;T;rs4627835;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
ANTIPSYCHOTICS;GABRB1;T;rs4627835;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;GABRB1;A;rs16860087;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE
ANTIPSYCHOTICS;GABRB1;A;rs16860087;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE
IRINOTECAN_METABOLITE(SN-38);ABCC1;CT + TT;rs35621;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CARBAMAZEPINE;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;OTHER;EPILEPSY;PEOPLE
LITHIUM;ASIC2;CC;rs11869731;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
IRINOTECAN_METABOLITE(SN-38);ABCC1;AT + TT;rs6498588;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
CAPECITABINE;HLA-G;GG;rs9380142;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;HLA-G;GG;rs9380142;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
ANTIDEPRESSANTS;MAPK1;AG;rs8136867;EFFICACY;INCREASED;RESPONSE;DISEASE;MENTAL DISORDERS;PEOPLE
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;DOSE;;;
CAPECITABINE;HLA-G;CT;rs17179108;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;HLA-G;CT;rs17179108;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
WARFARIN;VKORC1;CC;rs9923231;EFFICACY;INCREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN
DONEPEZIL;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
GALANTAMINE;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
FLUVOXAMINE;COMT;GG;rs4680;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
2-HYDROXYATORVASTATIN;PPARA;AA + AG;rs4253728;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY
LITHIUM;OR52E2;TT;rs16909440;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
LITHIUM;OR52J3;GG;rs2499984;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
ANTIDEPRESSANTS;CREB1;GG;rs889895;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
LITHIUM;;CC;rs16973410;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE
MERCAPTOPURINE;TPMT;C;rs1142345;EFFICACY;;EXPOSURE;DISEASE;LEUKEMIA;CHILDREN
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;RESPONSE;;;
DONEPEZIL;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
GALANTAMINE;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
RIVASTIGMINE;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE
ZIDOVUDINE;UGT2B7;G;rs28365062;METABOLISM/PK;INCREASED;METABOLISM;;;
ROSUVASTATIN;ABCG2;CT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
CHOLESTEROL;APOE;TT;rs429358;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
METHADONE;DRD2;AA;rs6275;DOSAGE;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHADONE;DRD2;AA;rs6275;METABOLISM/PK;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METFORMIN;SLC47A2;AA + AG;rs12943590;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC47A2;AA + AG;rs12943590;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
ATENOLOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
CARVEDILOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
DILTIAZEM;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
METOPROLOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
VERAPAMIL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
METHADONE;DRD2;CC;rs1799978;DOSAGE;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METHADONE;DRD2;CC;rs1799978;METABOLISM/PK;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE
METFORMIN;SLC22A2;AA + AC;rs316019;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
METFORMIN;SLC22A2;AA + AC;rs316019;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE
CARBAMAZEPINE;ABCB1;AA + AC;rs2032582;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE
ERYTHROMYCIN;ABCC2;TT;rs717620;OTHER;INCREASED;METABOLISM;;;
ERYTHROMYCIN;ABCC2;TT;rs717620;METABOLISM/PK;INCREASED;METABOLISM;;;
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;
CARBAMAZEPINE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE
ABIRATERONE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED;RESPONSE;OTHER;PROSTATIC NEOPLASMS;MEN
DUTASTERIDE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED;RESPONSE;OTHER;PROSTATIC NEOPLASMS;MEN
AZATHIOPRINE;PACSIN2;CT + TT;rs2413739;EFFICACY;DECREASED;RESPONSE;OTHER;IRRITABLE BOWEL SYNDROME;CHILDREN
ROSUVASTATIN;SLCO2B1;AA + AG;rs12422149;EFFICACY;DECREASED;RESPONSE;;;HEALTHY
GEFITINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
SILDENAFIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;MEN
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN
ABIRATERONE;SRD5A2;CC;rs523349;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PROSTATIC NEOPLASMS;MEN
GEFITINIB;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
TRIGLYCERIDES;CYP19A1;A;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRIGLYCERIDES;CYP19A1;A;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
TRIGLYCERIDES;CYP19A1;C;rs3759811;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRIGLYCERIDES;CYP19A1;C;rs3759811;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
HDL CHOLESTEROL;CYP19A1;G;rs1008805;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
HDL CHOLESTEROL;CYP19A1;G;rs1008805;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
TRIGLYCERIDES;CYP19A1;C;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRIGLYCERIDES;CYP19A1;C;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
METHOTREXATE;SLC19A1;AC + CC;rs1051296;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
HDL CHOLESTEROL;CYP19A1;G;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
HDL CHOLESTEROL;CYP19A1;G;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE
HDL CHOLESTEROL;CYP19A1;T;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
HDL CHOLESTEROL;CYP19A1;T;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
LEFLUNOMIDE;ESR1;TT;rs2234693;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
NEVIRAPINE;CYP2B6;GT;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
LEFLUNOMIDE;ESR1;AA;rs9340799;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN
2-HYDROXYATORVASTATIN;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
4-HYDROXYATORVASTATIN;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
ATORVASTATIN LACTONE;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY
USTEKINUMAB;C9orf72;CC + CT;rs774359;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
METHOTREXATE;GGH;GG;rs3758149;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
HDL CHOLESTEROL;CYP19A1;A;rs4646;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
HDL CHOLESTEROL;CYP19A1;A;rs4646;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
USTEKINUMAB;IL13;AA + AC;rs848;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TRIGLYCERIDES;CYP19A1;C;rs700518;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRIGLYCERIDES;CYP19A1;C;rs700518;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
USTEKINUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
TRIGLYCERIDES;CYP19A1;C;rs4775936;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN
TRIGLYCERIDES;CYP19A1;C;rs4775936;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;
USTEKINUMAB;STAT4;GT + TT;rs7574865;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
USTEKINUMAB;SLC22A4;CT;rs1050152;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
NICOTINE;CHRNA5;GG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
WARFARIN;STX1B;AA + AG;rs72800847;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP1A1;CC;rs3826041;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE
WARFARIN;DNMT3A;TT;rs2304429;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;NQO1;AA;rs10517;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
RALOXIFENE;ESR1;TT;rs2234693;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE
RALOXIFENE;ESR1;TT;rs2234693;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;
FENTANYL;DRD1;AG + GG;rs966775;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;PAIN;PEOPLE
FENTANYL;DRD1;AG + GG;rs966775;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;POSTOPERATIVE;PEOPLE
FLUTICASONE / SALMETEROL;CHRM2;A;rs8191992;EFFICACY;;RESPONSE;DISEASE;ASTHMA;PEOPLE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-HODGKIN LYMPHOMA;CHILDREN
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;PSYCHOTIC DISORDER;PEOPLE
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;PSYCHOTIC DISORDER;PEOPLE
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:LYMPHOMA;PEOPLE
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MYELODYSPLASTIC SYNDROMES;PEOPLE
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;DECREASED;DOSE;;;
WARFARIN;UGT1A1;CC;rs887829;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE
AZATHIOPRINE;ITPA;AA + AC;rs1127354;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
BEVACIZUMAB;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
FLUOROURACIL;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
IRINOTECAN;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;G;rs1800795;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
PLATINUM COMPOUNDS;;GG + GT;rs6983267;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
FLUVASTATIN;CYP2C9;G;rs77760615;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
METFORMIN;SLC22A2;TT;rs316009;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"PAIN""";PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;"PAIN""";PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE
FLUVASTATIN;SLCO1B1;T;rs58310495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;CHILDREN
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
FLUVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
PLATINUM COMPOUNDS;MALAT1;AG + GG;rs619586;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;HOTAIR;CC + CG;rs7958904;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
PLATINUM COMPOUNDS;H19;AA + AG;rs2839698;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;C;rs1051740;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;;
FLUTICASONE / SALMETEROL;CHRM2;A;rs6962027;EFFICACY;;RESPONSE;DISEASE;ASTHMA;PEOPLE
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;
BETA BLOCKING AGENTS;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOMYOPATHY;CHILDREN
BETA BLOCKING AGENTS;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;OTHER;DILATED;CHILDREN
SIMVASTATIN ACID;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
BETA BLOCKING AGENTS;ADRB2;A;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOMYOPATHY;CHILDREN
BETA BLOCKING AGENTS;ADRB2;A;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;DILATED;CHILDREN
FLUTICASONE / SALMETEROL;CHRM2;A;rs6962027;EFFICACY;;RESPONSE;DISEASE;ASTHMA;PEOPLE
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
CARBAMAZEPINE;EPHX1;G;rs2234922;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
FLUTICASONE PROPIONATE;CRHR1;T;rs1876831;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
RISPERIDONE;TNIK;AA;rs2088885;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE
FLUTICASONE PROPIONATE;CRHR1;T;rs1876828;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
METFORMIN;CSMD1;AC + CC;rs2617102;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
FLUTICASONE PROPIONATE;CRHR1;C;rs1876829;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
FLUTICASONE PROPIONATE;CRHR1;G;rs739645;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;;DOSE;;;
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;PK;CYP2A6 NORMAL;
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;PK;BUT NOT REDUCED;
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;PK;METABOLIZERS;
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:LYMPHOMA;PEOPLE
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MYELODYSPLASTIC SYNDROMES;PEOPLE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:LYMPHOMA;PEOPLE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MYELODYSPLASTIC SYNDROMES;PEOPLE
REMIFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;;;
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
REMIFENTANIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;;
FLUOROURACIL;DPYD;CC + CT;rs1801159;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE
CLOPIDOGREL;CES1;CT + TT;rs71647871;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY
CLOPIDOGREL;CES1;CT + TT;rs71647871;EFFICACY;INCREASED;RESPONSE;;;HEALTHY
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE
NALTREXONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OPIOID-RELATED DISORDERS;PEOPLE
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;STROKE;PEOPLE
GEMCITABINE;CMPK1;TT;rs1044457;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE
MERCAPTOPURINE;NUDT15;CC;rs55713253;DOSAGE;INCREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN
CYCLOPHOSPHAMIDE;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
DOXORUBICIN;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
PACLITAXEL;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE
DEOXY-THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;CHILDREN
THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;CHILDREN
AZATHIOPRINE;PACSIN2;CC + CT;rs2413739;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES;CHILDREN
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*1;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*1;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*2;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*2;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*4;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*4;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*5;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*5;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*9;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*9;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*17;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*17;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*29;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*29;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*34;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*34;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*39;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*39;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*41;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*41;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE
CYCLOSPORINE;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY
N-DESMETHYLCLOZAPINE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY
DULAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
DULAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
LIRAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
LIRAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
SEMAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE
SEMAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE
N-DESMETHYLCLOZAPINE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN
ARTEMETHER;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MALARIA;PEOPLE
LUMEFANTRINE;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MALARIA;PEOPLE
4-ENE VALPROIC ACID;CPT1A;GG;rs2228502;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE
METHOTREXATE;ATIC;CC + CT;rs4673991;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ADA;GT + TT;rs2057638;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ADA;CG + GG;rs6017375;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
METHOTREXATE;ADA;AA;rs371927;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE
LOSARTAN;CYP2C9;*1/*1;CYP2C9*1;;INCREASED;CLINICAL BENEFIT;;;
LOSARTAN;CYP2C9;*1/*1;CYP2C9*2;;INCREASED;CLINICAL BENEFIT;;;
LOSARTAN;CYP2C9;*1/*1;CYP2C9*3;;INCREASED;CLINICAL BENEFIT;;;
CODEINE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
HYDROCODONE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
OXYCODONE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
TRAMADOL;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;;CYP2D6 NORMAL METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
SITAGLIPTIN;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE
SITAGLIPTIN;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:DIABETES MELLITUS;PEOPLE
SALBUTAMOL;ADRB2;AA;rs1042717;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE
SALBUTAMOL;ADRB2;GG;rs1042714;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE
ZUCLOPENTHIXOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
PERPHENAZINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;CC;rs7754840;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;GG;rs7756992;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE
ANTIDEPRESSANTS;SLC22A3;AG + GG;rs2292334;DOSAGE;INCREASED;DOSE;OTHER;DEPRESSION;PEOPLE
BUPROPION;CYP2B6;*1/*1;CYP2B6*1;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;*1/*1;CYP2B6*6;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;
RANITIDINE;SLC22A1;del;rs72552763;METABOLISM/PK;DECREASED;TRANSPORT;;;
VORICONAZOLE;CYP2C19;*32;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*32;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*31;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*31;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*30;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*30;CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
VORICONAZOLE;CYP2C19;*29;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*29;CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
DICLOFENAC;CYP2C9;*54;CYP2C9*54;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*44;CYP2C9*44;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*42;CYP2C9*42;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*40;CYP2C9*40;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*52;CYP2C9*52;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*43;CYP2C9*43;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*45;CYP2C9*45;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*46;CYP2C9*46;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*39;CYP2C9*39;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*36;CYP2C9*36;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*55;CYP2C9*55;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*38;CYP2C9*38;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*48;CYP2C9*48;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*53;CYP2C9*53;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*47;CYP2C9*47;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*50;CYP2C9*50;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*37;CYP2C9*37;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*60;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*60;CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*60;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*60;CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
WARFARIN;CYP2C9;*60;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
WARFARIN;CYP2C9;*60;CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
;CYP2B6;*1/*1;CYP2B6*1;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;
;CYP2B6;*1/*1;CYP2B6*6;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;
CLOPIDOGREL;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
;CYP2E1;*7B;CYP2E1*7A;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;
;CYP2E1;*7B;CYP2E1*7B;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;
;ACE;del;rs1799752;;INCREASED;ENZYME ACTIVITY;ACE;;
FLUOXETINE;CYP2C19;*32;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;*32;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;*31;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;*31;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;*29;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;*29;CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
REMIMAZOLAM;CES1;C;rs200707504;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;A;rs35350960;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
DEXTROMETHORPHAN;CYP2D6;*26;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*26;CYP2D6*26;METABOLISM/PK;DECREASED;CLEARANCE;;;
ESTRONE SULFATE;SLCO2B1;T;rs1621378;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
ROSUVASTATIN;SLCO2B1;T;rs1621378;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
ESTRONE SULFATE;SLCO2B1;C;rs1009122956;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
ROSUVASTATIN;SLCO2B1;C;rs1009122956;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
ESTRONE SULFATE;SLCO2B1;T;rs199654337;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
ROSUVASTATIN;SLCO2B1;T;rs199654337;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
ESTRONE SULFATE;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;ACTIVITY;CYP3A4;;
;CYP2B6;CA/CA;rs70950385;OTHER;DECREASED;ACTIVITY;CYP2B6;;
LOSARTAN;AGTR1;A;rs12721226;OTHER;DECREASED;AFFINITY;;;
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
;NAMPT;CC + CT;rs3801266;OTHER;INCREASED;STEADY-STATE LEVEL;NAMPT;;
MEPHENYTOIN;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
;CYP2E1;*7A;CYP2E1*7;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;
;CYP2E1;*7A;CYP2E1*7A;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;
MEPHENYTOIN;CYP2C19;T;rs150152656;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;T;rs150152656;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
RALOXIFENE;UGT1A8;*2/*2;UGT1A8*1A;METABOLISM/PK;INCREASED;CLEARANCE;;;
RALOXIFENE;UGT1A8;*2/*2;UGT1A8*2;METABOLISM/PK;INCREASED;CLEARANCE;;;
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;DECREASED;FORMATION;;;
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;DECREASED;FORMATION;;;
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*35;METABOLISM/PK;DECREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*39;METABOLISM/PK;DECREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*53;METABOLISM/PK;DECREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*22;METABOLISM/PK;INCREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*26;METABOLISM/PK;INCREASED;CLEARANCE;;;
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*48;METABOLISM/PK;INCREASED;CLEARANCE;;;
METHADONE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
METHADONE;CYP2C19;A;rs72552267;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;C;rs118203756;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;CLEARANCE;;;
CAFFEINE;RYR1;T;rs118192177;OTHER;INCREASED;SENSITIVITY;;;
DEXTROMETHORPHAN;CYP2D6;*169;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*169;CYP2D6*169;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;G;rs76187628;METABOLISM/PK;INCREASED;CLEARANCE;;;
;CYP2D6;*169;CYP2D6*1;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;
;CYP2D6;*169;CYP2D6*169;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;
;CYP2D6;G;rs76187628;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;
RANITIDINE;SLC22A1;A;rs34130495;METABOLISM/PK;DECREASED;TRANSPORT;;;
RANITIDINE;SLC22A1;T;rs12208357;METABOLISM/PK;DECREASED;TRANSPORT;;;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;METABOLISM/PK;INCREASED;EXPRESSION;TYMS;;
;ABCC2;CG;rs113646094;OTHER;INCREASED;EXPRESSION;ABCC2;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
MIDAZOLAM;NR1I2;G;rs1464603;METABOLISM/PK;INCREASED;CLEARANCE;;;
MIDAZOLAM;NR1I2;G;rs1464602;METABOLISM/PK;INCREASED;CLEARANCE;;;
;CDA;del/del;rs3215400;;INCREASED;EXPRESSION;CDA;;
PHENYTOIN;CYP2C9;del;rs71486745;;DECREASED;EXPRESSION;CYP2C9;;
DEXTROMETHORPHAN;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
;CYP3A4;*8;CYP3A4*8;;DECREASED;STEADY-STATE LEVEL;CYP3A4;;
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
;CYP3A4;*12;CYP3A4*12;;DECREASED;ENZYME ACTIVITY;CYP3A4;;
;CYP3A4;*11;CYP3A4*11;;DECREASED;STEADY-STATE LEVEL;CYP3A4;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;C;rs11692021;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
;CYP2A6;*46;CYP2A6*46;;INCREASED;EXPRESSION;CYP2A6;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;G;rs34993780;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
COUMARIN;CYP2A6;*7 + *19;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
COUMARIN;CYP2A6;*7 + *19;CYP2A6*7;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
COUMARIN;CYP2A6;*7 + *19;CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;*7 + *19;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;*7 + *19;CYP2A6*7;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;*7 + *19;CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*7;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
;CYP2A6;*4;CYP2A6*1;;DECREASED;EXPRESSION;CYP2A6;;
;CYP2A6;*4;CYP2A6*4;;DECREASED;EXPRESSION;CYP2A6;;
COUMARIN;CYP2A6;*4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;
COUMARIN;CYP2A6;*4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;
;CYP2A6;*4/*9;CYP2A6*4;;DECREASED;EXPRESSION;CYP2A6;;
;CYP2A6;*4/*9;CYP2A6*9;;DECREASED;EXPRESSION;CYP2A6;;
COUMARIN;CYP2A6;*18;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
COUMARIN;CYP2A6;*18;CYP2A6*18;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
TEGAFUR;CYP2A6;*18;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
TEGAFUR;CYP2A6;*18;CYP2A6*18;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;G;rs72551344;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
NIMESULIDE;PTGS2;G;rs5273;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;PTGS2;;
NIMESULIDE;PTGS2;C;rs5272;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;PTGS2;;
;CYP2A6;*46;CYP2A6*46;;INCREASED;EXPRESSION;CYP2A6;;
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*7;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;
;CYP2A6;*46;CYP2A6*46;;INCREASED;TRANSCRIPTION;CYP2A6;;
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*6;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*30;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*10;METABOLISM/PK;INCREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*20;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
REGORAFENIB;CYP3A4;*20;CYP3A4*20;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
;ERCC2;TT;rs1799793;;INCREASED;EXPRESSION;ERCC2;;
;ERCC2;GG;rs13181;;INCREASED;EXPRESSION;ERCC2;;
VORICONAZOLE;CYP2C19;*23;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*23;CYP2C19*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*33;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*33;CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHOTREXATE;GGH;A;rs11545078;METABOLISM/PK;DECREASED;CLEARANCE;;;
;ERCC1;GG;rs11615;;INCREASED;EXPRESSION;ERCC1;;
;CDA;C/del + del/del;rs3215400;OTHER;INCREASED;EXPRESSION;CDA;;
CHLOROCRESOL;RYR1;del;rs121918596;OTHER;INCREASED;SENSITIVITY;;;
ELEXACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;CFTR;;
IVACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;CFTR;;
TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;CFTR;;
PHENYTOIN;CYP2C9;*31;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*31;CYP2C9*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*19;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*19;CYP2C9*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*27;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*27;CYP2C9*27;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*54;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*54;CYP2C9*54;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*53;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*53;CYP2C9*53;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*56;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*56;CYP2C9*56;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*55;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*55;CYP2C9*55;METABOLISM/PK;DECREASED;CLEARANCE;;;
EBASTINE;CYP2J2;(CTC)1;rs757528200;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUPROPION;CYP2B6;*1/*30;CYP2B6*1;OTHER;DECREASED;ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;*1/*30;CYP2B6*30;OTHER;DECREASED;ACTIVITY;CYP2B6;;
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*6;METABOLISM/PK;DECREASED;CLEARANCE;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
CYTARABINE;CDA;AA + AG;rs60369023;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CDA;;
CISPLATIN;ERCC2;GG;rs13181;TOXICITY;DECREASED;SENSITIVITY;;;
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED;SENSITIVITY;;;
CISPLATIN;GSTP1;AG;rs1695;TOXICITY;DECREASED;SENSITIVITY;;;
ATRASENTAN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*5;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*9;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*9;SLCO1B1*9;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*9;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*14;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*14;SLCO1B1*14;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*14;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
ATRASENTAN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;TRANSPORT;;;
ATRASENTAN;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
;CD38;T;rs1130169;;DECREASED;EXPRESSION;CD38;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;AFFINITY;;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;AFFINITY;;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
;DPYD;CG;rs75017182;OTHER;DECREASED;ACTIVITY;DPYD;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;;DECREASED;ENZYME ACTIVITY;TPMT;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;;DECREASED;ENZYME ACTIVITY;TPMT;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;;DECREASED;ENZYME ACTIVITY;TPMT;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
CELECOXIB;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;INCREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;DECREASED;SENSITIVITY;;;
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*15;OTHER;DECREASED;ENZYME ACTIVITY;CYP2A6;;
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*21;OTHER;DECREASED;ENZYME ACTIVITY;CYP2A6;;
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*22;OTHER;DECREASED;ENZYME ACTIVITY;CYP2A6;;
;SLCO1B1;*37;SLCO1B1*1;OTHER;INCREASED;EXPRESSION;SLCO1B1;;
;SLCO1B1;*37;SLCO1B1*37;OTHER;INCREASED;EXPRESSION;SLCO1B1;;
;SLCO1B1;*20;SLCO1B1*1;OTHER;INCREASED;EXPRESSION;SLCO1B1;;
;SLCO1B1;*20;SLCO1B1*20;OTHER;INCREASED;EXPRESSION;SLCO1B1;;
;SLCO1B1;*14;SLCO1B1*1;OTHER;INCREASED;EXPRESSION;SLCO1B1;;
;SLCO1B1;*14;SLCO1B1*14;OTHER;INCREASED;EXPRESSION;SLCO1B1;;
THIOGUANINE;TPMT;*16;TPMT*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
THIOGUANINE;TPMT;*16;TPMT*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
;CYP2C19;*19;CYP2C19*1;OTHER;DECREASED;EXPRESSION;CYP2C19;;
;CYP2C19;*19;CYP2C19*19;OTHER;DECREASED;EXPRESSION;CYP2C19;;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*19;CYP2C19*19;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
FLUVOXAMINE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;INCREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;INCREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;INCREASED;SENSITIVITY;;;
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;DPYD;;
CELECOXIB;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TRANYLCYPROMINE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TRANYLCYPROMINE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;DECREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TRANYLCYPROMINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TRANYLCYPROMINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*2;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*5;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*6;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*8;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*11;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*12;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*13;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;OTHER;INCREASED;SENSITIVITY;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*8;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUCONAZOLE;CYP2C19;*11;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*11;CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*11;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*11;CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*11;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*11;CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TROGLITAZONE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TROGLITAZONE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TRANYLCYPROMINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TRANYLCYPROMINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TROGLITAZONE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TROGLITAZONE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*2;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*5;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*6;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*7;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*9;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*12;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*14;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*17;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*18;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*19;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*20;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*21;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*22;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*23;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*30;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*1;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*2;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*3A;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*5;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*12;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*14;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*18;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*22;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
MERCAPTOPURINE;TPMT;*1/*1;TPMT*1;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*1;TPMT*3A;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*1;TPMT*3C;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;TPMT;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*28;CYP2C19*28;METABOLISM/PK;INCREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*23;CYP2C19*23;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*23;CYP2C19*23;METABOLISM/PK;INCREASED;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*28;CYP2C19*28;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*13;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*15;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*18;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*23;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*28;METABOLISM/PK;DECREASED;METABOLISM;;;
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*28;METABOLISM/PK;DECREASED;METABOLISM;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;;;
;ABCB1;AC + CC;rs2032582;METABOLISM/PK;INCREASED;ACTIVITY;ABCB1;;
;ABCB1;AG + GG;rs1128503;METABOLISM/PK;INCREASED;ACTIVITY;ABCB1;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;CYP2D6*53;METABOLISM/PK;INCREASED;CLEARANCE;;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*4;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*7;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*8;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*12;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*14;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*16;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*17;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*18;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*19;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*20;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*23;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*134;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*153;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;EXPRESSION;IFNAR1;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*134;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*153;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
TAMOXIFEN;CYP2D6;*2;CYP2D6*1;OTHER;DECREASED;ACTIVITY;CYP2D6;;
TAMOXIFEN;CYP2D6;*2;CYP2D6*2;OTHER;DECREASED;ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*49;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*55;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*54;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*54;CYP2D6*54;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
;CYP2C19;*16;CYP2C19*1;OTHER;DECREASED;FORMATION;CYP2C19;;
;CYP2C19;*16;CYP2C19*16;OTHER;DECREASED;FORMATION;CYP2C19;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*18;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*47;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*49;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*50;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*51;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*54;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*55;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*114;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*47;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*47;CYP2D6*47;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*18;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*18;CYP2D6*18;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
;TPMT;*3A + *3C + *24;TPMT*1;OTHER;DECREASED;EXPRESSION;TPMT;;
;TPMT;*3A + *3C + *24;TPMT*3A;OTHER;DECREASED;EXPRESSION;TPMT;;
;TPMT;*3A + *3C + *24;TPMT*3C;OTHER;DECREASED;EXPRESSION;TPMT;;
;TPMT;*3A + *3C + *24;TPMT*24;OTHER;DECREASED;EXPRESSION;TPMT;;
BUFURALOL;CYP2D6;*50;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*50;CYP2D6*50;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*36;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*36;CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*51;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*51;CYP2D6*51;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*2;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*3;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*11;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*29;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;
CERIVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;
CERIVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;
CERIVASTATIN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;
CERIVASTATIN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*2;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*9;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*10;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*18;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*23;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*5;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*6;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*7;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*9;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*17;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*18;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*19;METABOLISM/PK;DECREASED;FORMATION;;;
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*26;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*5;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*6;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*7;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*9;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*17;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*18;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*19;METABOLISM/PK;DECREASED;FORMATION;;;
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*26;METABOLISM/PK;DECREASED;FORMATION;;;
BUFURALOL;CYP2D6;*14;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*14;CYP2D6*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*53;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*53;CYP2D6*53;METABOLISM/PK;INCREASED;CLEARANCE;;;
;;C;rs9999111;OTHER;DECREASED;EXPRESSION;ABCG2;;
R-EDDP;CYP2B6;*4;CYP2B6*1;METABOLISM/PK;INCREASED;FORMATION;;;
R-EDDP;CYP2B6;*4;CYP2B6*4;METABOLISM/PK;INCREASED;FORMATION;;;
S-EDDP;CYP2B6;*4;CYP2B6*1;METABOLISM/PK;INCREASED;FORMATION;;;
S-EDDP;CYP2B6;*4;CYP2B6*4;METABOLISM/PK;INCREASED;FORMATION;;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*2;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*9;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*29;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*29;CYP2D6*29;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEBRISOQUINE;CYP2D6;*29;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEBRISOQUINE;CYP2D6;*29;CYP2D6*29;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1A;METABOLISM/PK;INCREASED;ACTIVITY;UGT1A6;;
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*2A;METABOLISM/PK;INCREASED;ACTIVITY;UGT1A6;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*18;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*23;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEBRISOQUINE;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEBRISOQUINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*2;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*9;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*14;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*16;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*23;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*24;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*28;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*32;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*28;METABOLISM/PK;INCREASED;CLEARANCE;;;
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*2;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3A;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*9;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*21;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*32;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*33;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*34;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*2;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3A;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*9;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*21;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*32;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*33;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*34;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*4;METABOLISM/PK;INCREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*9;METABOLISM/PK;INCREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*9;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*9;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*2;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*89;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*93;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*89;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*93;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*17;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
;CYP2D6;*92 + *96;CYP2D6*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
;CYP2D6;*92 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
;CYP2D6;*92 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
VORICONAZOLE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*6;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;*6;CYP2C19*6;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*4;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*5;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*10;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;UGT1A4;*3a;UGT1A4*1A;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;
OLANZAPINE;UGT1A4;*3a;UGT1A4*3A;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;
OMEPRAZOLE;CYP2C19;G;rs1361528097;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;ACTIVITY;ABCB1;;
BERBERINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;
COPTISINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;
BERBERINE;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;
BERBERINE;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;
COPTISINE;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;
COPTISINE;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;
OMEPRAZOLE;CYP2C19;T;rs1431015009;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
;SLCO1B1;*15;SLCO1B1*1;OTHER;DECREASED;EXPRESSION;SLCO1B1;;
;SLCO1B1;*15;SLCO1B1*15;OTHER;DECREASED;EXPRESSION;SLCO1B1;;
BUFURALOL;CYP2D6;A;rs1230912765;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
;CYP2B6;*27;CYP2B6*1;;DECREASED;EXPRESSION;CYP2B6;;
;CYP2B6;*27;CYP2B6*27;;DECREASED;EXPRESSION;CYP2B6;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;G;rs1466428833;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
BUFURALOL;CYP2D6;T;rs1058171;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
CORR-4A;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;CFTR;;
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;CFTR;;
OMEPRAZOLE;CYP2C19;G;rs148247410;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
EXEMESTANE;AKR1C3;T;rs62621365;METABOLISM/PK;DECREASED;AFFINITY;;;
EXEMESTANE;AKR1C4;A;rs11253043;METABOLISM/PK;DECREASED;AFFINITY;;;
OMEPRAZOLE;CYP2C19;T;rs1393133490;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;;;
MIDAZOLAM;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;;
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*24;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*24;CYP2C19*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;*24;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
OMEPRAZOLE;CYP2C19;*24;CYP2C19*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
;DPYD;AC;rs55886062;OTHER;DECREASED;ACTIVITY;DPYD;;
DOCETAXEL;ABCC10;TT;rs2125739;TOXICITY;INCREASED;SENSITIVITY;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
COUMARIN;CYP2A6;*1/*9;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
COUMARIN;CYP2A6;*1/*9;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
COUMARIN;CYP2A6;*1/*4;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
COUMARIN;CYP2A6;*1/*4;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEBRISOQUINE;CYP2D6;*75;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEBRISOQUINE;CYP2D6;*75;CYP2D6*75;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEBRISOQUINE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DEBRISOQUINE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
DACARBAZINE;CYP1A1;*4;CYP1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A1;*4;CYP1A1*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A1;*2C;CYP1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A1;*2C;CYP1A1*2C;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A2;*11;CYP1A2*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A2;*11;CYP1A2*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
;TPMT;*3A + *3C;TPMT*1;OTHER;DECREASED;ACTIVITY;TPMT;;
;TPMT;*3A + *3C;TPMT*3A;OTHER;DECREASED;ACTIVITY;TPMT;;
;TPMT;*3A + *3C;TPMT*3C;OTHER;DECREASED;ACTIVITY;TPMT;;
NICOTINE;CYP2A6;*17 + *35;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;*17 + *35;CYP2A6*17;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;*17 + *35;CYP2A6*35;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
MEPHENYTOIN;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;TOXICITY;INCREASED;CONCENTRATIONS;DEFICIENCY;;
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;METABOLISM/PK;INCREASED;CONCENTRATIONS;DEFICIENCY;;
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;TOXICITY;INCREASED;CONCENTRATIONS;DEFICIENCY;;
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;METABOLISM/PK;INCREASED;CONCENTRATIONS;DEFICIENCY;;
OMEPRAZOLE;CYP2C19;A;rs140278421;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEFITINIB;CYP2D6;*92 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
GEFITINIB;CYP2D6;*92 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*29;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*30;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*31;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*33;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*29;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*30;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*31;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*33;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*32;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
MEPHENYTOIN;CYP2C19;*32;CYP2C19*32;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;
TOLTERODINE;CYP2D6;*92 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
TOLTERODINE;CYP2D6;*92 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
CISPLATIN;TPMT;*3A;TPMT*1;TOXICITY;INCREASED;SENSITIVITY;;;
CISPLATIN;TPMT;*3A;TPMT*3A;TOXICITY;INCREASED;SENSITIVITY;;;
CISPLATIN;TPMT;*3A;TPMT*1;TOXICITY;INCREASED;SENSITIVITY;;;
CISPLATIN;TPMT;*3A;TPMT*3A;TOXICITY;INCREASED;SENSITIVITY;;;
CISPLATIN;TPMT;*3A;TPMT*1;OTHER;INCREASED;EXPRESSION;TLR4;;
CISPLATIN;TPMT;*3A;TPMT*3A;OTHER;INCREASED;EXPRESSION;TLR4;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*1;EFFICACY;INCREASED;EXPRESSION;MKI67;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*5;EFFICACY;INCREASED;EXPRESSION;MKI67;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*10;EFFICACY;INCREASED;EXPRESSION;MKI67;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*14;EFFICACY;INCREASED;EXPRESSION;MKI67;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*18;EFFICACY;INCREASED;EXPRESSION;MKI67;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*21;EFFICACY;INCREASED;EXPRESSION;MKI67;;
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*41;EFFICACY;INCREASED;EXPRESSION;MKI67;;
ADEFOVIR DIPIVOXIL;SLC22A6;T;rs11568634;OTHER;DECREASED;UPTAKE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;
;CYP3A5;*3/*3;CYP3A5*1;OTHER;DECREASED;EXPRESSION;CYP3A5;;
;CYP3A5;*3/*3;CYP3A5*3;OTHER;DECREASED;EXPRESSION;CYP3A5;;
;CYP3A5;*3/*3;CYP3A5*1;OTHER;DECREASED;EXPRESSION;CYP3A5;;
;CYP3A5;*3/*3;CYP3A5*3;OTHER;DECREASED;EXPRESSION;CYP3A5;;
METHADONE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP2C19;A;rs138142612;METABOLISM/PK;DECREASED;CLEARANCE;;;
ATORVASTATIN;SCAP;TT;rs12487736;OTHER;DECREASED;TRANSCRIPTION;SCAP;;
;NAMPT;CC + CT;rs1319501;OTHER;DECREASED;STEADY-STATE LEVEL;NAMPT;;
METHADONE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED;EXPRESSION;FKBP5;;
CLOZAPINE 5-N-GLUCURONIDE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;FORMATION;;;
DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;FORMATION;;;
;UGT1A1;*28;UGT1A1*1;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;
;UGT1A1;*28;UGT1A1*28;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;
CLOZAPINE;UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOZAPINE;UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;;
BELINOSTAT;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;;;
BELINOSTAT;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*28;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*37;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;
DICLOFENAC;CYP2C9;*62;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*62;CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;*62;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;*62;CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*62;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*62;CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;
PHENYTOIN;CYP2C9;*47;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*47;CYP2C9*47;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*49;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*49;CYP2C9*49;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*43;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*43;CYP2C9*43;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*45;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*45;CYP2C9*45;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*39;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*39;CYP2C9*39;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*42;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*42;CYP2C9*42;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*41;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*41;CYP2C9*41;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*37;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*37;CYP2C9*37;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*36;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*36;CYP2C9*36;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*33;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*33;CYP2C9*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*16;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*16;CYP2C9*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*14;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*14;CYP2C9*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*8;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*8;CYP2C9*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*50;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*50;CYP2C9*50;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*52;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*52;CYP2C9*52;METABOLISM/PK;DECREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*51;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
PHENYTOIN;CYP2C9;*51;CYP2C9*51;METABOLISM/PK;INCREASED;CLEARANCE;;;
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;;ACTIVITY;CFTR;;
;CYP2C9;AT + TT;rs7089580;OTHER;INCREASED;EXPRESSION;CYP2C9;;
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*72;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*72;CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*72;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*72;CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*72;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*72;CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*75;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*75;CYP2C9*75;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*74;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*74;CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*74;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*74;CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*74;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
TOLBUTAMIDE;CYP2C9;*74;CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*73;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
DICLOFENAC;CYP2C9;*73;CYP2C9*73;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*73;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
LOSARTAN;CYP2C9;*73;CYP2C9*73;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*6;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*21;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*26;METABOLISM/PK;DECREASED;CLEARANCE;;;
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*30;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOROURACIL;MIR27A;C;rs895819;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;DPYD;;
;CYP2D6;G;rs1058164;OTHER;DECREASED;EXPRESSION;CYP2D6;;
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*1;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*30;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*31;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*32;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*33;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*1;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*4;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*5;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*18;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*23;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*28;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*29;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*31;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*32;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*33;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*34;OTHER;DECREASED;CLEARANCE;CYP3A4;;
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*1;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*3;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*35;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;
BUFURALOL;CYP2D6;*36;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
BUFURALOL;CYP2D6;*36;CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*1;METABOLISM/PK;INCREASED;FORMATION;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*9;METABOLISM/PK;INCREASED;FORMATION;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*11;METABOLISM/PK;INCREASED;FORMATION;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*1;METABOLISM/PK;INCREASED;FORMATION;;;
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*9;METABOLISM/PK;INCREASED;FORMATION;;;
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*11;METABOLISM/PK;INCREASED;FORMATION;;;
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*1;METABOLISM/PK;INCREASED;FORMATION;;;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*11;METABOLISM/PK;INCREASED;FORMATION;;;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;
BLONANSERIN;CYP3A4;*20;CYP3A4*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*20;CYP3A4*20;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*29;CYP3A4*1;METABOLISM/PK;INCREASED;ACTIVITY;CYP3A4;;
BLONANSERIN;CYP3A4;*29;CYP3A4*29;METABOLISM/PK;INCREASED;ACTIVITY;CYP3A4;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*39;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*40;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*41;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*42;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*43;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*44;METABOLISM/PK;DECREASED;CLEARANCE;;;
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*46;METABOLISM/PK;DECREASED;CLEARANCE;;;
HYDRALAZINE;NAT2;*4/*4;NAT2*4;OTHER;INCREASED;ACTIVITY;NAT2 RAPID ACETYLATOR;;
HYDRALAZINE;NAT2;*4/*4;NAT2*5;OTHER;INCREASED;ACTIVITY;NAT2 RAPID ACETYLATOR;;
HYDRALAZINE;NAT2;*4/*4;NAT2*6;OTHER;INCREASED;ACTIVITY;NAT2 RAPID ACETYLATOR;;
SOLITHROMYCIN;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;;
SOLITHROMYCIN;NAT2;*4;NAT2*5;METABOLISM/PK;INCREASED;METABOLISM;;;
SOLITHROMYCIN;NAT2;*4;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;;;
SOLITHROMYCIN;NAT2;*4;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;;;
SOLITHROMYCIN;NAT2;*4;NAT2*14;METABOLISM/PK;INCREASED;METABOLISM;;;
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*4;OTHER;INCREASED;ACTIVITY;NAT2;;
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*5;OTHER;INCREASED;ACTIVITY;NAT2;;
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*6;OTHER;INCREASED;ACTIVITY;NAT2;;
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*7;OTHER;INCREASED;ACTIVITY;NAT2;;
;ALDH1A2;AA + AG;rs12915901;OTHER;DECREASED;EXPRESSION;ALDH1A2;;
DEXAMETHASONE;BCL2L11;CC;rs724710;TOXICITY;INCREASED;SENSITIVITY;;;
DEXAMETHASONE;BCL2L11;AA;rs2241843;TOXICITY;INCREASED;SENSITIVITY;;;
THIOXANTHINE;XDH;T;rs45442092;METABOLISM/PK;DECREASED;CLEARANCE;XDH;;
THIOXANTHINE;XDH;T;rs2295474;METABOLISM/PK;DECREASED;CLEARANCE;XDH;;
;HLA-G;C;rs1063320;OTHER;INCREASED;EXPRESSION;HLA-G;;
SIMVASTATIN;HLA-G;GG;rs1063320;OTHER;INCREASED;EXPRESSION;HLA-G;;
BUPROPION;CYP2B6;*46;CYP2B6*46;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;*47;CYP2B6*47;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;*47;CYP2B6*47;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;*46;CYP2B6*46;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;HDAC2;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;HDAC2;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;FKBP5;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;FKBP5;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;GLCCI1;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;GLCCI1;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;NR3C1;;
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;NR3C1;;
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*2;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*87;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*93;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;
;CDA;GG;rs602950;OTHER;INCREASED;EXPRESSION;CDA;;
;TPH2;T;rs4290270;OTHER;INCREASED;EXPRESSION;TPH2;;
;CDA;TT;rs532545;OTHER;INCREASED;EXPRESSION;CDA;;
CAFFEINE;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;
HALOTHANE;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;
HALOTHANE;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;
DIHYDROERGOTAMINE;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;HTR1B;;
METHYSERGIDE;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;HTR1B;;
SUMATRIPTAN;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;HTR1B;;
KETANSERIN;HTR1B;C;rs130060;PD;DECREASED;AFFINITY;HTR1B;;
;CDA;TT;rs1048977;OTHER;INCREASED;EXPRESSION;CDA;;
;TPH2;AA;rs7305115;OTHER;INCREASED;EXPRESSION;TPH2;;
;CDA;CC;rs2072671;OTHER;INCREASED;EXPRESSION;CDA;;
;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;
;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;
;DPYD;A;rs547099198;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;DPYD;A;rs568132506;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;DPYD;A;rs760663364;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;DPYD;A;rs780025995;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;DPYD;T;rs114096998;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;DPYD;G;rs748639205;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;;AA;rs2784917;OTHER;INCREASED;EXPRESSION;WNT5B;;
;;GG;rs6539870;OTHER;INCREASED;EXPRESSION;IL1B;;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;PROTEIN STABILITY;CFTR;;
IVACAFTOR;CFTR;A;rs121909047;EFFICACY;;ACTIVITY;CFTR;;
NICOTINE;CYP2A6;CC + CT;rs56113850;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;TT;rs7259706;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;AA + AG;rs28399453;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
NICOTINE;CYP2A6;CC + CG;rs8192733;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*23;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*24;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*28;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*12;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
LURASIDONE;CYP3A4;*12;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*18;METABOLISM/PK;INCREASED;CLEARANCE;;;
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;
;;C;rs9999111;OTHER;DECREASED;EXPRESSION;ABCG2;;
;ABCG2;C;rs2725263;OTHER;INCREASED;EXPRESSION;ABCG2;;
;;A;rs149713212;OTHER;DECREASED;EXPRESSION;ABCG2;;
IVACAFTOR;CFTR;A;rs74503330;OTHER;INCREASED;ACTIVITY;CFTR;;
;;G;rs12508471;OTHER;DECREASED;EXPRESSION;ABCG2;;
;ABCA12;A;rs2888327;;INCREASED;EXPRESSION;ABCA12;;
;ABCA12;C;rs10182702;;INCREASED;EXPRESSION;ABCA12;;
DAUNORUBICINOL;AKR1A1;C;rs6690497;METABOLISM/PK;DECREASED;FORMATION;;;
DOXORUBICINOL;AKR1A1;C;rs6690497;METABOLISM/PK;DECREASED;FORMATION;;;
;ABCA8;T;rs11656365;;DECREASED;EXPRESSION;ABCA8;;
;;G;rs2000068;;INCREASED;EXPRESSION;ABCA1;;
;PITPNM2;C;rs12425009;;DECREASED;EXPRESSION;ABCB9;;
DOXORUBICINOL;AKR1A1;G;rs2229540;METABOLISM/PK;DECREASED;FORMATION;;;
;PSMB8, TAP1, TAP2;T;rs2071543;;INCREASED;EXPRESSION;TAP2;;
;PSMB8, TAP2;A;rs9357155;;INCREASED;EXPRESSION;TAP2;;
;ABCB9;T;rs4148866;;INCREASED;EXPRESSION;ABCB9;;
DAUNORUBICINOL;AKR1A1;G;rs2229540;METABOLISM/PK;DECREASED;FORMATION;;;
;ABCA1;G;rs2515629;;INCREASED;EXPRESSION;ABCA1;;
;ABCA1;G;rs4149297;;INCREASED;EXPRESSION;ABCA1;;
;;T;rs2487030;;INCREASED;EXPRESSION;ABCA1;;
;ABCA1;C;rs2472507;;INCREASED;EXPRESSION;ABCA1;;
;F3;T;rs841698;;INCREASED;EXPRESSION;ABCD3;;
;ABCD2;C;rs4284427;;DECREASED;EXPRESSION;ABCD2;;
;REDIC1;T;rs10783969;;INCREASED;EXPRESSION;ABCD2;;
;;G;rs4285917;;DECREASED;EXPRESSION;ABCD2;;
;ABCC10;A;rs2487663;;DECREASED;EXPRESSION;ABCC10;;
;ABCC4;T;rs4773866;;INCREASED;EXPRESSION;ABCC4;;
;ABCC10;A;rs2185631;;DECREASED;EXPRESSION;ABCC10;;
;;G;rs12195350;;DECREASED;EXPRESSION;ABCC10;;
;ABCD1, BCAP31;C;rs17091297;;INCREASED;EXPRESSION;ABCD1;;
;ABCC10;G;rs9394952;;DECREASED;EXPRESSION;ABCC10;;
;PLXNB3;A;rs4898439;;INCREASED;EXPRESSION;ABCD1;;
;;C;rs4898437;;INCREASED;EXPRESSION;ABCD1;;
;TMPRSS11E;T;rs2168047;;INCREASED;EXPRESSION;UGT2B4;;
;;CC;rs6822259;;INCREASED;EXPRESSION;UGT2B17;;
NICOTINE;CYP2A6;AG + GG;rs57837628;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
;UGT2B4;T;rs4557343;;INCREASED;EXPRESSION;UGT2B15;;
NICOTINE;CYP2A6;GG;rs7260629;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
CLADRIBINE;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;
FLUOROURACIL;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;
GEMCITABINE;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;
CLADRIBINE;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;
FLUOROURACIL;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;
GEMCITABINE;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;
CLADRIBINE;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;
FLUOROURACIL;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;
GEMCITABINE;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;
NICOTINE;CYP2A6;CC + CT;rs4803381;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;
ETHANOL;OPRM1;GG;rs1799971;EFFICACY;DECREASED;SENSITIVITY;;;
DOXORUBICIN;RARG;A;rs2229774;TOXICITY;INCREASED;SENSITIVITY;;;
;IL18;GG + GT;rs1946518;OTHER;INCREASED;EXPRESSION;IL18;;
;IL18;CC + CG;rs5744247;OTHER;INCREASED;EXPRESSION;IL18;;
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A2;*3;CYP1A2*1;METABOLISM/PK;DECREASED;CLEARANCE;;;
DACARBAZINE;CYP1A2;*3;CYP1A2*3;METABOLISM/PK;DECREASED;CLEARANCE;;;
REMIMAZOLAM;CES1;T;rs71647871;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;
REMIMAZOLAM;CES1;C;rs151291296;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;
REMIMAZOLAM;CES1;T;rs2307240;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CES1;;
REMIMAZOLAM;CES1;G;rs143718310;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;A;rs35516286;PD;INCREASED;ACTIVITY;CFTR;;
IVACAFTOR / TEZACAFTOR;CFTR;A;rs35516286;PD;INCREASED;ACTIVITY;CFTR;;
SITAGLIPTIN;DPP4;CC;rs759717;PD;INCREASED;ACTIVITY;DPP4;;
SITAGLIPTIN;DPP4;TT;rs2909451;PD;INCREASED;ACTIVITY;DPP4;;
IVACAFTOR;CFTR;C;rs113993958;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;G;rs397508288;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs397508537;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs78769542;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;C;rs1800111;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs121909020;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;T;rs397508442;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs74551128;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs186045772;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs397508256;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;T;rs368505753;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;T;rs202179988;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs121909019;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs121908753;EFFICACY;;ACTIVITY;CFTR;;
DAUNORUBICIN;AKR1C4;G;rs17134592;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C4;;
IVACAFTOR;CFTR;T;rs77834169;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;G;rs121908752;EFFICACY;;ACTIVITY;CFTR;;
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CT;rs186089140;PD;INCREASED;ACTIVITY;CFTR;;
DAUNORUBICIN;AKR7A2;T;rs1043657;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR7A2;;
DOXORUBICIN;AKR7A2;T;rs1043657;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR7A2;;
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;T;rs141033578;EFFICACY;;ACTIVITY;CFTR;;
DAUNORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;
DOXORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;
IVACAFTOR;CFTR;T;rs121909011;EFFICACY;;ACTIVITY;CFTR;;
DAUNORUBICIN;AKR1C3;T;rs35575889;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;
DOXORUBICIN;AKR1C3;T;rs35575889;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;
IVACAFTOR;CFTR;T;rs77409459;EFFICACY;;ACTIVITY;CFTR;;
DAUNORUBICIN;AKR1C3;A;rs4987102;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;
IVACAFTOR;CFTR;C;rs397508510;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs397508139;EFFICACY;;ACTIVITY;CFTR;;
;DPYD;C;rs2297595;OTHER;DECREASED;ACTIVITY;DPYD;;
;DPYD;A;rs67376798;OTHER;DECREASED;ACTIVITY;DPYD;;
IVACAFTOR;CFTR;C;rs397508435;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs121908751;EFFICACY;;ACTIVITY;CFTR;;
;EPO;AA;rs1617640;OTHER;INCREASED;EXPRESSION;EPO;;
IVACAFTOR;CFTR;G;rs397508328;EFFICACY;;ACTIVITY;CFTR;;
DOXORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;CLEARANCE;;;
DOXORUBICIN;AKR1C3;A;rs28943579;METABOLISM/PK;DECREASED;CLEARANCE;;;
DOXORUBICIN;AKR1C3;T;rs62621365;METABOLISM/PK;DECREASED;CLEARANCE;;;
;CYP4F2;A;rs2189784;OTHER;INCREASED;EXPRESSION;CYP4F2;;
;CYP4F11;A;rs1060467;OTHER;INCREASED;EXPRESSION;CYP4F2;;
;CYP4F2;T;rs2108622;OTHER;INCREASED;EXPRESSION;CYP4F11;;
;CYP4F2;T;rs2108622;OTHER;INCREASED;EXPRESSION;CYP4F2;;
;CYP4F2;A;rs2189784;OTHER;DECREASED;EXPRESSION;CYP4F12;;
IVACAFTOR;CFTR;T;rs11971167;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;C;rs75541969;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;G;rs34911792;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;G;rs150212784;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs397508759;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;T;rs115545701;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;C;rs397508513;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;T;rs1800100;EFFICACY;;ACTIVITY;CFTR;;
ADALIMUMAB;TNF;AG;rs1800629;METABOLISM/PK;DECREASED;STEADY-STATE LEVEL;TNF;;
;TNF;AA + AG;rs1800629;METABOLISM/PK;INCREASED;ACTIVITY;TNF;;
;VKORC1;C;rs56314408;OTHER;INCREASED;TRANSCRIPTION;VKORC1;;
;NFATC2;T;rs6021191;OTHER;INCREASED;EXPRESSION;NFATC2;;
;SLC22A3;G;rs2076828;OTHER;DECREASED;EXPRESSION;SLC22A3;;
;CYP4F2;CT;rs2108622;OTHER;INCREASED;CONCENTRATIONS;CYP4F2;;
BUPROPION;POR;AG + GG;rs2868177;METABOLISM/PK;INCREASED;ACTIVITY;CYP2B6;;
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;OTHER;INCREASED;CONCENTRATIONS;;;
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;
;WBP2NL;AG + GG;rs5758550;OTHER;INCREASED;EXPRESSION;CYP2D6;;
;CYP2D6;AA + AG;rs16947;OTHER;DECREASED;EXPRESSION;CYP2D6;;
PHENYTOIN;CYP2C9;A;rs12782374;;DECREASED;EXPRESSION;CYP2C9;;
;RALGAPA2;GG;rs3827963;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;DISP1;TT;rs61840266;OTHER;INCREASED;TRANSCRIPTION;ABCC1;;
;SPAG16;CC;rs35945601;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;DISP1;GG;rs17535305;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;TXLNB;CC;rs9495425;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;ZNF890P;AA;rs62442010;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;NAF1;AA;rs17571991;OTHER;INCREASED;TRANSCRIPTION;ABCC1;;
;ECHDC1;AA;rs6569487;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;ZBED5;GG;rs10840501;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;DHRS4L1;GG;rs10147475;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;KCNQ3;AA;rs7818112;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;AMPH;CC;rs12701634;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;STXBP4;AA;rs9303363;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;ADCYAP1;AA;rs304400;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;CHD2;TT;rs28458425;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;RGMA;GG;rs7165938;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;
;UGT1A1;AG;rs4148323;METABOLISM/PK;DECREASED;FORMATION;UGT1A1;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AG;rs4148323;METABOLISM/PK;DECREASED;CLEARANCE;;;
ROSUVASTATIN;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;UPTAKE;;;
;CYP2C19;A;rs7902257;OTHER;DECREASED;EXPRESSION;CYP2C19;;
CARBOCISTEINE;PAH;G;rs75193786;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
FLUOROURACIL;DPYD;A;rs143154602;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs186169810;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs190577302;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs183105782;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs183385770;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs146356975;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs137999090;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs59086055;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs145773863;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs138616379;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs72549304;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs111858276;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs200687447;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs72549307;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs1801266;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs115232898;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs72549308;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs143986398;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs60139309;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs114096998;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs2297595;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;
VALPROIC ACID;UGT1A6;C;rs1105879;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;
;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;DECREASED;FORMATION;UGT1A1;;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;GG + GT;rs4124874;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
CALCIUM;RYR1;AG;rs118192167;OTHER;INCREASED;STEADY-STATE LEVEL;;;
;XRCC4;T;rs2075685;OTHER;INCREASED;EXPRESSION;XRCC4;;
TESTOSTERONE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;FORMATION;UGT1A1;;
MIDAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
;XRCC4;G;rs10040363;OTHER;INCREASED;EXPRESSION;ERCC1;;
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;IL12RB2;;
;ERCC1;A;rs2298881;OTHER;DECREASED;EXPRESSION;ERCC1;;
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;IL1R2;;
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;IL17A;;
;;T;rs247616;OTHER;DECREASED;EXPRESSION;CETP;;
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED;EXPRESSION;TCL1A;;
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED;EXPRESSION;IL17RA;;
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;IL12RB2;;
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED;EXPRESSION;IL17RA;;
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;IL1R2;;
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;IL17A;;
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;IL1R2;;
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;IL17A;;
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;IL12RB2;;
;SLC22A3;AA;rs555754;;INCREASED;EXPRESSION;SLC22A3;;
ESTRADIOL;;G;rs2369049;OTHER;INCREASED;EXPRESSION;IL17RA;;
;PROM1;CC;rs2286455;;DECREASED;EXPRESSION;PROM1;;
ESTRADIOL;;G;rs2369049;OTHER;INCREASED;EXPRESSION;TCL1A;;
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;IL12RB2;;
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;IL1R2;;
ESTRADIOL;;G;rs11849538;OTHER;INCREASED;EXPRESSION;IL17RA;;
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;IL17A;;
ESTRADIOL;;G;rs11849538;OTHER;INCREASED;EXPRESSION;TCL1A;;
GEMCITABINE;MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED;SENSITIVITY;;;
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED;EXPRESSION;TCL1A;;
;RARG;A;rs2229774;OTHER;DECREASED;PROTEIN STABILITY;RARG;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;CLEARANCE;;;
;NRP2;C;rs10932125;;INCREASED;EXPRESSION;CYP1B1;;
;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;FORMATION;UGT1A9;;
CAFFEINE;RYR1;AG;rs118192167;OTHER;INCREASED;SENSITIVITY;;;
REMIMAZOLAM;CES1;T;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;
CAFFEINE;RYR1;T;rs118192161;OTHER;INCREASED;SENSITIVITY;;;
VORICONAZOLE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;
SACUBITRIL;CES1;CT;rs71647871;EFFICACY;DECREASED;CATALYTIC ACTIVITY;CES1;;
VORICONAZOLE;CYP2C19;G;rs3758581;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;
VORICONAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUVOXAMINE;CYP2C19;G;rs3758581;METABOLISM/PK;INCREASED;SENSITIVITY;;;
CELECOXIB;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUCONAZOLE;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;C;rs17878459;METABOLISM/PK;DECREASED;SENSITIVITY;;;
FLUVOXAMINE;CYP2C19;C;rs181297724;METABOLISM/PK;INCREASED;SENSITIVITY;;;
OMEPRAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;INCREASED;SENSITIVITY;;;
FLUOXETINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;
KETOCONAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;
SERTRALINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;
TICLOPIDINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;
L-PHENYLALANINE;PAH;T;rs62516101;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
CARBOCISTEINE;PAH;T;rs62516101;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
BUPRENORPHINE;OPRM1;G;rs1799971;EFFICACY;DECREASED;ACTIVITY;OPRM1;;
FLUOROURACIL;DPYD;C;rs72547601;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs61757362;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs67376798;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs141044036;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs188052243;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
CARBOCISTEINE;PAH;C;rs5030860;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
FLUOROURACIL;DPYD;A;rs112766203;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs55674432;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
L-PHENYLALANINE;PAH;C;rs5030860;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
FLUOROURACIL;DPYD;A;rs1801268;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
BUSULFAN;GSTM1;C;rs3754446;METABOLISM/PK;INCREASED;CLEARANCE;;;
CARBOCISTEINE;PAH;A;rs76394784;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
L-PHENYLALANINE;PAH;A;rs76394784;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
ROSUVASTATIN;SLCO2B1;A;rs142693902;METABOLISM/PK;DECREASED;UPTAKE;;;
ROSUVASTATIN;SLCO2B1;A;rs35199625;METABOLISM/PK;DECREASED;UPTAKE;;;
METHOTREXATE;SOD2;G;rs4880;TOXICITY;DECREASED;SENSITIVITY;;;
OLANZAPINE;UGT2B10;GT + TT;rs61750900;METABOLISM/PK;DECREASED;GLUCURONIDATION;;;
;NOS3;GT + TT;rs1799983;;DECREASED;EXPRESSION;NOS3;;
;IL7;AA + AG;rs16906115;OTHER;INCREASED;EXPRESSION;IL7;;
CARBOCISTEINE;PAH;T;rs5030849;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
L-PHENYLALANINE;PAH;T;rs5030849;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;
BUPRENORPHINE;UGT2B7;A;rs7438135;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;
;CYP3A5;CC;rs776746;OTHER;DECREASED;EXPRESSION;CYP3A5;;
FLUOROURACIL;DPYD;A;rs4294451;TOXICITY;INCREASED;SENSITIVITY;;;
;DPYD;T;rs4294451;OTHER;INCREASED;EXPRESSION;DPYD;;
MIDAZOLAM;CYP3A4;C;rs12721627;METABOLISM/PK;DECREASED;CLEARANCE;;;
;PACSIN2;CT + TT;rs2413739;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
FLUOXETINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs138142612;METABOLISM/PK;DECREASED;CLEARANCE;;;
TAMOXIFEN;UGT1A4;CC;rs8330;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A4;;
FLUOXETINE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs72552267;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;C;rs118203756;METABOLISM/PK;DECREASED;CLEARANCE;;;
ANASTROZOLE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;CYP19A1;;
EXEMESTANE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;CYP19A1;;
LETROZOLE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;CYP19A1;;
FLUOXETINE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;CLEARANCE;;;
ANASTROZOLE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;CYP19A1;;
EXEMESTANE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;CYP19A1;;
LETROZOLE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;CYP19A1;;
FLUOXETINE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs559628884;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;G;rs3758581;METABOLISM/PK;DECREASED;CLEARANCE;;;
;UGT1A1;CG;rs11568319;METABOLISM/PK;DECREASED;FORMATION;UGT1A1;;
;UGT1A9;TT;rs2741049;METABOLISM/PK;INCREASED;FORMATION;UGT1A1;;
GEMCITABINE;DCTD;C;rs35932500;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;DCTD;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;CT + TT;rs2741049;METABOLISM/PK;INCREASED;CLEARANCE;;;
;UGT1A9;CT + TT;rs2741049;METABOLISM/PK;INCREASED;FORMATION;UGT1A9;;
FLUOXETINE;CYP2C19;T;rs147255955;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;T;rs145328984;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs370803989;METABOLISM/PK;DECREASED;CLEARANCE;;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;AA;rs3806598;METABOLISM/PK;INCREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;
FLUOXETINE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEMCITABINE;CDA;C;rs2072671;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CDA;;
MERCAPTOPURINE;ABCC4;TT;rs3765534;TOXICITY;INCREASED;SENSITIVITY;;;
MERCAPTOPURINE;ABCC4;TT;rs3765534;METABOLISM/PK;INCREASED;SENSITIVITY;;;
;DPYD;C;rs75017182;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;DPYD;G;rs1801265;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;
;DPYD;C;rs2297595;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;NT5E;A;rs9450278;;DECREASED;EXPRESSION;NT5E;;
;ARNT;GG;rs2134688;METABOLISM/PK;DECREASED;CONCENTRATIONS;CYP3A4;;
TAMOXIFEN;;CC;rs478437;OTHER;INCREASED;SENSITIVITY;;;
TAMOXIFEN;E2F7;CC;rs310786;OTHER;INCREASED;SENSITIVITY;;;
;;CC;rs478437;OTHER;INCREASED;EXPRESSION;USP7;;
;PPARA;AA;rs4253728;METABOLISM/PK;DECREASED;CONCENTRATIONS;CYP3A4;;
;CYP2C9;C;rs9332094;OTHER;DECREASED;TRANSCRIPTION;CYP2C9;;
;CYP2C9;C;rs4918758;OTHER;DECREASED;TRANSCRIPTION;CYP2C9;;
;UGT1A1;A;rs28967009;OTHER;INCREASED;EXPRESSION;UGT1A1;;
;CYP3A4;TT;rs2242480;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;
;CYP2B6;TT;rs3745274;OTHER;DECREASED;EXPRESSION;CYP2B6;;
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;METABOLISM/PK;DECREASED;EXPRESSION;YEATS4;;
;YEATS4;CC;rs7297610;METABOLISM/PK;INCREASED;EXPRESSION;YEATS4;;
;NQO1;A;rs1800566;;DECREASED;EXPRESSION;NQO1;;
;NQO1;AA;rs1800566;;DECREASED;ENZYME ACTIVITY;NQO1;;
;DPYD;T;rs1212037891;OTHER;INCREASED;EXPRESSION;DPYD;;
;DPYD;A;rs143879757;OTHER;INCREASED;EXPRESSION;DPYD;;
;DPYD;A;rs72549306;OTHER;INCREASED;EXPRESSION;DPYD;;
;DPYD;G;rs748620513;OTHER;INCREASED;EXPRESSION;DPYD;;
FLUOROURACIL;DPYD;C;rs1335150891;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs188052243;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs72549306;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;DPYD;T;rs1801160;OTHER;INCREASED;EXPRESSION;DPYD;;
PACLITAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED;TRANSPORT;;;
;ABCC11;AA + AG;rs17822471;OTHER;DECREASED;EXPRESSION;ABCC11;;
CAFFEINE;RYR1;CT;rs118192172;OTHER;;SENSITIVITY;;;
HALOTHANE;RYR1;CT;rs118192172;OTHER;;SENSITIVITY;;;
CAFFEINE;RYR1;GT;rs193922772;OTHER;;SENSITIVITY;;;
HALOTHANE;RYR1;GT;rs193922772;OTHER;;SENSITIVITY;;;
CAFFEINE;RYR1;CT;rs118192175;OTHER;;SENSITIVITY;;;
HALOTHANE;RYR1;CT;rs118192175;OTHER;;SENSITIVITY;;;
CAFFEINE;RYR1;AG;rs118192176;OTHER;;SENSITIVITY;;;
HALOTHANE;RYR1;AG;rs118192176;OTHER;;SENSITIVITY;;;
CAFFEINE;RYR1;CT;rs28933397;OTHER;;SENSITIVITY;;;
HALOTHANE;RYR1;CT;rs28933397;OTHER;;SENSITIVITY;;;
;VDR;T;rs11568820;OTHER;INCREASED;STEADY-STATE LEVEL;CYP3A4;;
;DPYD;T;rs1801158;OTHER;DECREASED;ACTIVITY;DPYD;;
;DPYD;T;rs1801160;OTHER;DECREASED;ACTIVITY;DPYD;;
;DPYD;G;rs1801265;OTHER;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs748620513;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs148994843;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs59086055;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs56005131;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs143879757;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;del;rs1184321568;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;
CEFOTAXIME;SLC22A8;A;rs11568482;METABOLISM/PK;DECREASED;TRANSPORT;;;
;NCOA1;T;rs1804645;;INCREASED;HALF-LIFE;NCOA1;;
TAMOXIFEN;NCOA1;T;rs1804645;;DECREASED;ACTIVITY;NCOA1;;
;A2M;T;rs669;METABOLISM/PK;INCREASED;STEADY-STATE LEVEL;A2M;;
ENDOXIFEN;;C;rs4386686;TOXICITY;INCREASED;SENSITIVITY;;;
;F12;G;rs1801020;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;F12;;
;;C;rs4386686;TOXICITY;INCREASED;EXPRESSION;MIRLET7I;;
;;C;rs4386686;OTHER;INCREASED;EXPRESSION;MIRLET7I;;
;;C;rs4386686;TOXICITY;DECREASED;EXPRESSION;TRAF1;;
;;C;rs4386686;OTHER;DECREASED;EXPRESSION;TRAF1;;
;DPYD;CT;rs1801158;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;ABCC9;T;rs704212;OTHER;INCREASED;EXPRESSION;ABCC9;;
;SLCO1B1;C;rs4149056;OTHER;DECREASED;EXPRESSION;SLCO1B1;;
IVACAFTOR;CFTR;A;rs77010898;EFFICACY;INCREASED;ACTIVITY;CFTR;;
;UGT1A3;T;rs7604115;OTHER;INCREASED;EXPRESSION;UGT1A3;;
TESTOSTERONE;CYP3A5;A;rs55817950;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP3A5;;
;IMPDH2;A;rs121434586;OTHER;DECREASED;ENZYME ACTIVITY;IMPDH2;;
;ORMDL3;AG + GG;rs2872507;METABOLISM/PK;INCREASED;EXPRESSION;ORMDL3;;
;ABCC2;T;rs717620;;INCREASED;TRANSCRIPTION;ABCC2;;
CAFFEINE;RYR1;T;rs193922753;OTHER;INCREASED;SENSITIVITY;;;
NIFEDIPINE;CYP3A5;C;rs72552791;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP3A5;;
CAFFEINE;RYR1;A;rs118192176;OTHER;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;A;rs193922809;OTHER;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;A;rs118192122;OTHER;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;T;rs193922816;OTHER;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;G;rs118192167;OTHER;INCREASED;SENSITIVITY;;;
BUMETANIDE;SLC17A3;A;rs34376145;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;
BUMETANIDE;SLC17A3;A;rs34902660;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;
BUMETANIDE;SLC17A3;A;rs11966370;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;
BUMETANIDE;SLC17A3;T;rs56027330;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;
CLOPIDOGREL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
ENALAPRIL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
SACUBITRIL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
CLOPIDOGREL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;
ENALAPRIL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;
SACUBITRIL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;
CLOPIDOGREL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;
ENALAPRIL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;
SACUBITRIL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;
ENALAPRIL;CES1;T;rs2307243;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
ENALAPRIL;CES1;C;rs202121317;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
CLOPIDOGREL;CES1;A;rs202001817;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
CYTARABINE;NT5C2;G;rs1163075;EFFICACY;DECREASED;SENSITIVITY;;;
;NT5C2;G;rs1163075;METABOLISM/PK;INCREASED;TRANSCRIPTION;NT5C2;;
CYTARABINE;NT5C2;GG;rs11191612;EFFICACY;DECREASED;SENSITIVITY;;;
;NT5C2;GG;rs11191612;METABOLISM/PK;INCREASED;TRANSCRIPTION;NT5C2;;
AMISULPRIDE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;
ARIPIPRAZOLE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;
OLANZAPINE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;
RISPERIDONE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;
ACETAMINOPHEN;UGT1A;CC;rs10929303;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A;;
CHLOROCRESOL;RYR1;T;rs193922803;OTHER;INCREASED;ACTIVITY;RYR1;;
ARACHIDONIC ACID;CYP4F2;G;rs753169154;PD;DECREASED;CATALYTIC ACTIVITY;CYP4F2;;
ARACHIDONIC ACID;CYP4F2;T;rs2108622;PD;DECREASED;CATALYTIC ACTIVITY;CYP4F2;;
ARACHIDONIC ACID;CYP4F2;A;rs114396708;PD;DECREASED;CATALYTIC ACTIVITY;CYP4F2;;
CAFFEINE;RYR1;CT;rs193922747;OTHER;;SENSITIVITY;;;
HALOTHANE;RYR1;CT;rs193922747;OTHER;;SENSITIVITY;;;
ACETAMINOPHEN;UGT1A;CC;rs1042640;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A;;
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;DECREASED;CLEARANCE;;;
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;DECREASED;CLEARANCE;;;
ACETAMINOPHEN;UGT1A;CC;rs8330;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A;;
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;DPYD;;
CAFFEINE;RYR1;T;rs118192178;OTHER;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;T;rs118192178;OTHER;INCREASED;SENSITIVITY;;;
;SLCO1A2;T;rs4148981;;DECREASED;EXPRESSION;SLCO1A2;;
ALDOSTERONE;SCNN1B;A;rs34241435;OTHER;INCREASED;TRANSCRIPTION;SCNN1B;;
INSULIN RECOMBINANT;SCNN1B;A;rs34241435;OTHER;INCREASED;TRANSCRIPTION;SCNN1B;;
;BCL2L11;T;rs724710;OTHER;DECREASED;EXPRESSION;BCL2L11;;
ESCITALOPRAM;IL11;CT + TT;rs1126757;OTHER;DECREASED;EXPRESSION;IL11;;
LORAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CLEARANCE;;;
LOSARTAN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;
;UMPS;C;rs1801019;METABOLISM/PK;INCREASED;EXPRESSION;UMPS;;
PAROMOMYCIN;MT-RNR1;G;rs267606617;PD;DECREASED;ACTIVITY;MT-RNR1;;
CLOZAPINE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;UGT1A4;;
CAFFEINE;RYR1;G;rs118192178;OTHER;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;G;rs118192178;OTHER;INCREASED;SENSITIVITY;;;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;CFTR;;
;CYP1A2;AA + AC;rs762551;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP1A2;;
;EGFR;TT;rs712829;;INCREASED;EXPRESSION;EGFR;;
DEXTROMETHORPHAN;;GG;rs729559;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;
;;GG;rs729559;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;
;;TT;rs4073010;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;
;SEPTIN3, WBP2NL;G;rs1062753;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;
DEXTROMETHORPHAN;PHETA2, SMDT1;G;rs1807493;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;;TT;rs4073010;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;G;rs1062753;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;
TERFENADINE;CYP2J2;A;rs199717190;METABOLISM/PK;DECREASED;CLEARANCE;;;
CLOPIDOGREL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
ENALAPRIL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
SACUBITRIL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;
CLOPIDOGREL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;
ENALAPRIL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;
SACUBITRIL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs200858900;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;ABCC4;;
;ABCC4;C;rs11568684;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs11568681;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs142211148;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;A;rs11568644;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;ABCC4;;
;TBXAS1;AA;rs6962291;OTHER;DECREASED;EXPRESSION;TBXAS1;;
EBASTINE;CYP2J2;A;rs201379188;METABOLISM/PK;DECREASED;CLEARANCE;;;
TERFENADINE;CYP2J2;A;rs201379188;METABOLISM/PK;DECREASED;CLEARANCE;;;
CAFFEINE;RYR1;G;rs193922878;OTHER;INCREASED;SENSITIVITY;;;
;TBXAS1;AA;rs6962291;OTHER;DECREASED;STEADY-STATE LEVEL;TBX2;;
;PHETA2, SMDT1;G;rs1807493;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;
;ABCC4;A;rs11568658;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;
;CCND1;AA + AG;rs9344;OTHER;INCREASED;TRANSCRIPTION;CCND1;;
EBASTINE;CYP2J2;A;rs759510111;METABOLISM/PK;INCREASED;CLEARANCE;;;
TERFENADINE;CYP2J2;A;rs759510111;METABOLISM/PK;INCREASED;CLEARANCE;;;
;DPYD;AT;rs67376798;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;
;GSK3B;A;rs334558;;INCREASED;TRANSCRIPTION;GSK3B;;
;FCER2;GG;rs28364072;;DECREASED;EXPRESSION;FCER2;;
GENTAMICIN;MT-RNR1;T;rs267606619;PD;DECREASED;ACTIVITY;MT-RNR1;;
;MIR27A;CC;rs895819;OTHER;INCREASED;EXPRESSION;MIR27A;;
;ADRB2;G;rs1042713;OTHER;DECREASED;ACTIVITY;ADRB2;;
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED;SENSITIVITY;;;
PAROMOMYCIN;MT-RNR1;T;rs267606619;PD;INCREASED;SENSITIVITY;;;
PROPOFOL;CYP2B6;T;rs553968231;METABOLISM/PK;DECREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;T;rs1969376664;METABOLISM/PK;DECREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;C;rs773494867;METABOLISM/PK;DECREASED;CLEARANCE;;;
CISPLATIN;UBE2I;CG;rs9597;METABOLISM/PK;INCREASED;EXPRESSION;SAE1;;
IRINOTECAN;UBE2I;CG;rs9597;METABOLISM/PK;INCREASED;EXPRESSION;SAE1;;
EFAVIRENZ;CYP2B6;T;rs553968231;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;T;rs752695347;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;A;rs772413158;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;C;rs1969136524;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;T;rs142421637;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;A;rs373442191;METABOLISM/PK;INCREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;T;rs752695347;METABOLISM/PK;DECREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;T;rs142421637;METABOLISM/PK;DECREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;T;rs1282926098;METABOLISM/PK;INCREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;C;rs1969136524;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;C;rs773494867;METABOLISM/PK;DECREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;T;rs1969376664;METABOLISM/PK;DECREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;T;rs138264188;METABOLISM/PK;DECREASED;CLEARANCE;;;
PROPOFOL;CYP2B6;A;rs373442191;METABOLISM/PK;INCREASED;CLEARANCE;;;
CAFFEINE;RYR1;A;rs193922818;OTHER;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;A;rs193922818;OTHER;INCREASED;SENSITIVITY;;;
;ABCB1;AA;rs2032582;OTHER;DECREASED;EXPRESSION;ABCB1;;
;ABCB1;AA;rs1128503;OTHER;DECREASED;EXPRESSION;ABCB1;;
;ABCB1;AA;rs1045642;OTHER;DECREASED;EXPRESSION;ABCB1;;
EFAVIRENZ;CYP2B6;T;rs1969255598;METABOLISM/PK;INCREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;G;rs1248477767;METABOLISM/PK;INCREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;T;rs1282926098;METABOLISM/PK;INCREASED;CLEARANCE;;;
EFAVIRENZ;CYP2B6;G;rs750671397;METABOLISM/PK;INCREASED;CLEARANCE;;;
;;G;rs4355801;;INCREASED;EXPRESSION;TNFRSF11B;;
EFAVIRENZ;CYP2B6;A;rs141666881;METABOLISM/PK;INCREASED;CLEARANCE;;;
;PLG;G;rs783145;METABOLISM/PK;DECREASED;TRANSCRIPTION;PRSS55;;
;PLG;G;rs783145;METABOLISM/PK;INCREASED;TRANSCRIPTION;PLG;;
;;C;rs10871454;METABOLISM/PK;INCREASED;TRANSCRIPTION;VKORC1;;
;GCLC;CC;rs761142;OTHER;DECREASED;EXPRESSION;GCLC;;
;CYP3A4;A;rs4986909;;DECREASED;STEADY-STATE LEVEL;CYP3A4;;
;;AA;rs446112;OTHER;INCREASED;EXPRESSION;AGPAT2;;
;SQSTM1;C;rs10277;METABOLISM/PK;INCREASED;TRANSCRIPTION;SQSTM1;;
;SLC22A3;C;rs884742;METABOLISM/PK;INCREASED;TRANSCRIPTION;SLC22A3;;
;MGMT;G;rs4751104;METABOLISM/PK;INCREASED;TRANSCRIPTION;MGMT;;
;KDR;G;rs34231037;OTHER;DECREASED;STEADY-STATE LEVEL;KDR;;
;GSTT1;T;rs1007888;METABOLISM/PK;INCREASED;TRANSCRIPTION;GSTT1;;
;;AG;rs10242455;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP3A5;;
;ABCC11;C;rs11861379;METABOLISM/PK;INCREASED;TRANSCRIPTION;ABCC11;;
;NAT2;A;rs4646244;OTHER;DECREASED;TRANSCRIPTION;NAT2;;
NICOTINE;CYP2A6;C;rs72549435;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;
TOLBUTAMIDE;CYP2C9;T;rs9332239;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;
PAROMOMYCIN;MT-RNR1;G;rs267606617;PD;DECREASED;ACTIVITY;MT-RNR1;;
PURINE ANALOGUES;TPMT;CT;rs1142345;OTHER;DECREASED;ACTIVITY;TPMT;;
PURINE ANALOGUES;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;
DOXORUBICIN;SLC28A3;AA;rs11140490;TOXICITY;INCREASED;SENSITIVITY;;;
PURINE ANALOGUES;PACSIN2;C;rs2413739;OTHER;INCREASED;ACTIVITY;TPMT;;
PURINE ANALOGUES;PACSIN2;C;rs2413739;METABOLISM/PK;INCREASED;ACTIVITY;TPMT;;
EFAVIRENZ;CYP2B6;G;rs1968919352;METABOLISM/PK;INCREASED;CLEARANCE;;;
COUMARIN;CYP2A6;T;rs28399454;METABOLISM/PK;DECREASED;METABOLISM;;;
QUINIDINE;KCNH2;T;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;
VORICONAZOLE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;
IVACAFTOR / LUMACAFTOR;CFTR;A;rs78655421;EFFICACY;INCREASED;ACTIVITY;CFTR;;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;CFTR;;
NPPB;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;CFTR;;
ESLICARBAZEPINE ACETATE;AADAC;G;rs144650170;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;
FLUOROURACIL;DPYD;G;rs368146607;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs371258350;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
ESLICARBAZEPINE ACETATE;AADAC;A;rs35084477;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;
FLUOROURACIL;DPYD;T;rs575853463;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs569661196;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs548783838;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs374825099;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs140989814;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs568367673;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs538336580;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs374527058;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
CAFFEINE;RYR1;A;rs112563513;DOSAGE;INCREASED;SENSITIVITY;;;
ESLICARBAZEPINE ACETATE;AADAC;A;rs1803155;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;
ESLICARBAZEPINE ACETATE;AADAC;G;rs140197497;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;
CAFFEINE;RYR1;A;rs193922832;DOSAGE;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;A;rs118192168;DOSAGE;INCREASED;SENSITIVITY;;;
DISOPYRAMIDE;KCNH2;T;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;
DISOPYRAMIDE;KCNH2;C;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;
QUINIDINE;KCNH2;C;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CG;rs80034486;PD;INCREASED;ACTIVITY;CFTR;;
CAFFEINE;RYR1;T;rs193922843;DOSAGE;INCREASED;SENSITIVITY;;;
CAFFEINE;RYR1;T;rs193922803;DOSAGE;INCREASED;SENSITIVITY;;;
ESLICARBAZEPINE ACETATE;AADAC;T;rs186388618;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;AADAC;;
ESLICARBAZEPINE ACETATE;AADAC;C;rs61733692;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;AADAC;;
FLUOROURACIL;DPYD;C;rs536577604;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs558354142;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs538703919;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs55886062;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs372307932;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs527580106;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;T;rs201268750;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;A;rs570122671;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;CBR3;A;rs8133052;;DECREASED;EXPRESSION;CBR3;;
;CBR3;A;rs1056892;;INCREASED;EXPRESSION;CBR3;;
FLUOROURACIL;DPYD;A;rs528152707;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;VKORC1;T;rs9923231;;DECREASED;EXPRESSION;VKORC1;;
;DPYD;CT + TT;rs56038477;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;SLC29A1;G;rs731780;OTHER;INCREASED;EXPRESSION;SLC29A1;;
;SLC29A1;A;rs70914;;INCREASED;EXPRESSION;SLC29A1;;
;DPYD;CT + TT;rs1801160;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;DPYD;CC + CT;rs2297595;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;MIR6076;G;rs1463411;OTHER;DECREASED;EXPRESSION;P2RY12;;
;UGT2B17;C;rs6817882;OTHER;INCREASED;EXPRESSION;UGT2B17;;
;DPYD;CT;rs115232898;OTHER;DECREASED;ACTIVITY;DPYD;;
BUPROPION;POR;AA;rs2868177;OTHER;DECREASED;ENZYME ACTIVITY;CYP2B6;;
BUPROPION;POR;AA;rs2868177;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2B6;;
;POR;AA;rs2868177;OTHER;DECREASED;ACTIVITY;CYP2B6;;
;POR;AA;rs2868177;METABOLISM/PK;DECREASED;ACTIVITY;CYP2B6;;
;ABCB1;GG;rs1128503;;INCREASED;EXPRESSION;ABCB1;;
ACETAMINOPHEN;CYP2E1;T;rs2515641;OTHER;INCREASED;EXPRESSION;CYP2E1;;
;CYP2E1;T;rs2515641;OTHER;DECREASED;EXPRESSION;CYP2E1;;
FLUOROURACIL;DPYD;T;rs376073289;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs369103276;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;C;rs367619008;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
BUPROPION;POR;GG;rs2868177;OTHER;INCREASED;ACTIVITY;CYP2B6;;
BUPROPION;POR;GG;rs2868177;METABOLISM/PK;INCREASED;ACTIVITY;CYP2B6;;
FLUOROURACIL;DPYD;T;rs758649719;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
HALOTHANE;CACNA1S;A;rs772226819;OTHER;INCREASED;SENSITIVITY;;;
ISOFLURANE;CACNA1S;A;rs772226819;OTHER;INCREASED;SENSITIVITY;;;
FLUOROURACIL;DPYD;G;rs187713395;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;G;rs140039091;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
CAFFEINE;CACNA1S;T;rs1800559;OTHER;INCREASED;SENSITIVITY;;;
;CACNA1S;T;rs1800559;OTHER;INCREASED;ACTIVITY;CACNA1S;;
BUFURALOL;CYP2D6;A;rs777560972;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;A;rs777560972;METABOLISM/PK;DECREASED;CLEARANCE;;;
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED;EXPRESSION;NR3C1;;
BUFURALOL;CYP2D6;T;rs138417770;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;T;rs138417770;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;G;rs371793722;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;G;rs371793722;METABOLISM/PK;DECREASED;CLEARANCE;;;
BUFURALOL;CYP2D6;T;rs745746329;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;T;rs745746329;METABOLISM/PK;DECREASED;CLEARANCE;;;
;HSPA5;TT;rs430397;OTHER;INCREASED;EXPRESSION;HSPA5;;
BUFURALOL;CYP2D6;T;rs750996195;METABOLISM/PK;DECREASED;CLEARANCE;;;
DEXTROMETHORPHAN;CYP2D6;T;rs750996195;METABOLISM/PK;DECREASED;CLEARANCE;;;
;POR;AG;rs2868177;EFFICACY;INCREASED;ENZYME ACTIVITY;CYP2B6;;
GEMCITABINE TRIPHOSPHATE;SLC28A3;CC;rs7867504;METABOLISM/PK;INCREASED;FORMATION;;;
MERCAPTOPURINE;TPMT;AT;rs3931660;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
MERCAPTOPURINE;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;
VITAMIN E;CYP4F2;T;rs2108622;METABOLISM/PK;INCREASED;STEADY-STATE LEVEL;;;
VITAMIN E;CYP4F2;T;rs2108622;METABOLISM/PK;INCREASED;STEADY-STATE LEVEL;;;
;HPR;G;rs2000999;OTHER;INCREASED;EXPRESSION;HP;;
;;G;rs35283911;OTHER;INCREASED;EXPRESSION;HP;;
;DCK;T;rs2306744;OTHER;INCREASED;EXPRESSION;DCK;;
XENOBIOTICS;AHR;A;rs2066853;METABOLISM/PK;INCREASED;EXPRESSION;CYP1A1;;
OMEPRAZOLE;AHR;G;rs75519181;METABOLISM/PK;DECREASED;EXPRESSION;CYP1A1;;
XENOBIOTICS;AHR;G;rs75519181;METABOLISM/PK;DECREASED;EXPRESSION;CYP1A1;;
VITAMIN E;CYP4F2;C;rs3093105;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP4F2;;
EFAVIRENZ;CYP2B6;A;rs200458614;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;A;rs200238771;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;A;rs764288403;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
;NHLH1;T;rs11265375;OTHER;INCREASED;LUCIFERASE ACTIVITY;;;
VITAMIN E;CYP4F2;T;rs2108622;OTHER;DECREASED;ENZYME ACTIVITY;CYP4F2;;
BUPROPION;CYP2B6;T;rs535039125;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;A;rs200458614;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;A;rs148009906;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;C;rs201500445;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;A;rs58871670;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;C;rs201500445;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;A;rs58871670;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;A;rs117872433;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;A;rs374099483;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;A;rs148009906;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
;SEMA6A;A;rs3806915;OTHER;INCREASED;LUCIFERASE ACTIVITY;;;
BUPROPION;CYP2B6;A;rs117872433;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;A;rs200238771;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;A;rs764288403;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
BUPROPION;CYP2B6;A;rs374099483;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
EFAVIRENZ;CYP2B6;T;rs535039125;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;
ETHANOL;ADH1B;CT + TT;rs1229984;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;ADH1B;;
METHOTREXATE;MTHFR;GT;rs1801131;;INCREASED;CATALYTIC ACTIVITY;TYMS;;
METHOTREXATE;SHMT1;AA;rs1979277;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;TYMS;;
METHOTREXATE;FASTKD3, MTRR;AG + GG;rs1801394;;INCREASED;CATALYTIC ACTIVITY;TYMS;;
FLUOROURACIL;DPYD;G;rs755692084;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;
;CYP1A2;A;rs2069514;;DECREASED;ACTIVITY;CYP1A2;;
;CYP1A2;A;rs762551;;INCREASED;ACTIVITY;CYP1A2;;
;CYP3A4;A;rs35599367;OTHER;DECREASED;EXPRESSION;CYP3A4;;
;CYP1A2;del;rs35694136;;DECREASED;ACTIVITY;CYP1A2;;
GLYBURIDE;KCNJ11;T;rs5219;METABOLISM/PK;DECREASED;ACTIVITY;KCNJ11;;
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CBR1;;
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CBR1;;
;ATP2B1;CT + TT;rs12817819;;DECREASED;EXPRESSION;ATP2B1;;
;IFNL3;C;rs4803217;OTHER;INCREASED;EXPRESSION;IFNL3;;
;CETP;GG;rs708272;OTHER;INCREASED;EXPRESSION;CETP;;
ACETAMINOPHEN;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;
PALBOCICLIB;CDKN2A;C;rs759922342;EFFICACY;INCREASED;SENSITIVITY;;;
ACETAMINOPHEN;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;T;rs765399160;METABOLISM/PK;INCREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;
ACETAMINOPHEN;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;
;UGT1A1;G;rs4124874;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;
TAPENTADOL;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;
TAPENTADOL;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;
TAPENTADOL;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;
;UGT1A1;T;rs887829;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;
OXAZEPAM;UGT2B15;A;rs1902023;OTHER;DECREASED;GLUCURONIDATION;;;
TAPENTADOL;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;
TAPENTADOL;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;
DESMETHYLNAPROXEN;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;
;UGT1A1;A;rs10929302;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;
TAPENTADOL;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;
TAPENTADOL;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;
TAPENTADOL;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;
PREGNENOLONE;SULT2B1;G;rs777924668;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;
PREGNENOLONE;SULT2B1;T;rs746398875;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;
ESTRADIOL;;GG;rs3802201;OTHER;INCREASED;EXPRESSION;MIR2052;;
ESTRADIOL;;CC;rs4476990;OTHER;INCREASED;EXPRESSION;MIR2052;;
PREGNENOLONE;SULT2B1;T;rs527454384;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;
PREGNENOLONE;SULT2B1;A;rs777140014;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;
PREGNENOLONE;SULT2B1;T;rs774212320;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;
PREGNENOLONE;SULT2B1;A;rs762765702;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;
;CYP2C19;A;rs140278421;OTHER;DECREASED;EXPRESSION;CYP2C19;;
;CYP2C19;T;rs61311738;OTHER;DECREASED;EXPRESSION;CYP2C19;;
;CYP2C19;T;rs183701923;OTHER;DECREASED;EXPRESSION;CYP2C19;;
;CYP2C9;C;rs761895497;OTHER;DECREASED;EXPRESSION;CYP2C9;;
;CYP2C9;C;rs771237265;OTHER;DECREASED;EXPRESSION;CYP2C9;;
;CYP2C9;T;rs762081829;OTHER;DECREASED;EXPRESSION;CYP2C9;;
;CYP3A5;TT;rs776746;OTHER;INCREASED;EXPRESSION;CYP3A5;;
SUMATRIPTAN;HTR1B;C;rs130060;PD;INCREASED;CONCENTRATIONS;cAMP;;
;CYP2A6;AA + AG;rs8192720;;INCREASED;EXPRESSION;CYP2A6;;
;CYP2A6;AG + GG;rs8192725;;INCREASED;EXPRESSION;CYP2A6;;
;CYP2A6;AC + CC;rs28399433;;DECREASED;EXPRESSION;CYP2A6;;
FLUOROURACIL;DPYD;TT;rs1801158;OTHER;INCREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;GG;rs1801265;OTHER;INCREASED;ACTIVITY;DPYD;;
FLUOROURACIL;DPYD;CC;rs55886062;OTHER;DECREASED;ACTIVITY;DPYD;;
OXAZEPAM;UGT1A1;A;rs10929302;OTHER;DECREASED;GLUCURONIDATION;;;
OXAZEPAM;UGT1A1;G;rs4124874;OTHER;;GLUCURONIDATION;;;
OXAZEPAM;;G;rs1976391;OTHER;DECREASED;GLUCURONIDATION;;;
OXAZEPAM;UGT1A1;T;rs887829;OTHER;DECREASED;GLUCURONIDATION;;;
;;G;rs1976391;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;
;PKNOX1;A;rs2839629;OTHER;INCREASED;EXPRESSION;PKNOX1;;
;PKNOX1;A;rs2839629;OTHER;INCREASED;EXPRESSION;CBS;;
;CBS;C;rs915854;OTHER;INCREASED;EXPRESSION;PKNOX1;;
CAFFEINE;RYR1;T;rs186983396;METABOLISM/PK;INCREASED;SENSITIVITY;;;
CHLOROCRESOL;RYR1;T;rs186983396;METABOLISM/PK;INCREASED;SENSITIVITY;;;
;CDA;CC;rs532545;OTHER;DECREASED;ACTIVITY;CDA;;
;CDA;AA;rs602950;OTHER;DECREASED;ACTIVITY;CDA;;
;CDA;AA;rs2072671;OTHER;DECREASED;ACTIVITY;CDA;;
;YAP1;C;rs1820453;;DECREASED;TRANSCRIPTION;YAP1;;
ELEXACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED;ACTIVITY;CFTR;;
TEZACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED;ACTIVITY;CFTR;;
ELEXACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED;ACTIVITY;CFTR;;
TEZACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED;ACTIVITY;CFTR;;
ELEXACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED;ACTIVITY;CFTR;;
TEZACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED;ACTIVITY;CFTR;;
ELEXACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED;ACTIVITY;CFTR;;
TEZACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED;ACTIVITY;CFTR;;
ELEXACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED;ACTIVITY;CFTR;;
TEZACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED;ACTIVITY;CFTR;;
NICOTINE;CYP2A6;AA + AT;rs1801272;TOXICITY;DECREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;
SACITUZUMAB GOVITECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
SACITUZUMAB GOVITECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
ATORVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
ATORVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
FLUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
FLUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
PITAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
PITAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
PRAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
PRAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
ROSUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
ROSUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
SIMVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
SIMVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
ETHANOL;CHRNA5;T;rs615470;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;
ETHANOL;CHRNA5;T;rs615470;OTHER;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;T;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;A;rs1799931;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED AUC24 IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED AUC24 IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
GEFITINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HEMORRHAGE NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATORVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
PRAVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
SIMVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING OPTIMAL TROUGH LEVEL IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING OPTIMAL TROUGH LEVEL IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;
NORTRIPTYLINE;UST;A;rs2500535;EFFICACY;DECREASED;NAN;EFFICACY;IMPROVEMENT OF DEPRESSION SYMPTOMS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TACROLIMUS;CYP3A4;G;rs1851426;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING NAN  NAN;
OSIMERTINIB;IL6;CG + GG;rs1800796;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
RISPERIDONE;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
TAMOXIFEN;CYP2D6;*6/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
RISPERIDONE;HTR2A;AA + AG;rs6313;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
OXAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;NAN;PK;S-OXAZEPAM GLUCURONIDATION IN HUMAN LIVER MICROSOMES NAN  NAN;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;
OXAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;NAN;PK;OXAZEPAM ORAL CLEARANCE NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ISONIAZID;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TACROLIMUS;PPARA;GG;rs4823613;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;
METHOTREXATE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;
METHOTREXATE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;
METHOTREXATE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;
METHOTREXATE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NITROUS OXIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS IN PEOPLE WITH  OTHER:SURGERY;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;
RISPERIDONE;DRD3;G;rs167771;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;
RISPERIDONE;DRD3;G;rs167771;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN MEN WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN MEN WITH  DISEASE:SCHIZOPHRENIA;
FLUCLOXACILLIN;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AMOXICILLIN;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CISPLATIN;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
CISPLATIN;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
PACLITAXEL;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
PACLITAXEL;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS NAN  NAN;
FLUCLOXACILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*1;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*5;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*9;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;UTERINE DISORDER;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEIOMYOMA;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ENDOMETRIAL HYPERPLASIA;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:POLYPS IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
CAPECITABINE;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY IN PEOPLE WITH  NAN;
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;NAN;NAN;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY IN PEOPLE WITH  NAN;
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;NAN;NAN;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY IN PEOPLE WITH  NAN;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
PEGINTERFERON ALFA-2A;IDO1;CC;rs9657182;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IDO1;CC;rs9657182;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;AA + AG;rs3129763;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
NITROUS OXIDE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS IN PEOPLE WITH  OTHER:SURGERY;
CIPROFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
LEVOFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
MOXIFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
OMEPRAZOLE;CYP2C19;TT;rs11188072;METABOLISM/PK;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
METHADONE;CYP3A4;C;rs3735451;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CARBOPLATIN;ABCB1;AA;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
ANTIPSYCHOTICS;CYP2D6;*10;CYP2D6*1;TOXICITY;NAN;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*10;CYP2D6*10;TOXICITY;NAN;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;CYP2D6*2XN;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ASPARAGINASE;ATL2;T;rs59569490;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN CHILDREN WITH  OTHER:NEOPLASMS;
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR NAN  NAN;
ESCITALOPRAM;CYP2C19;A;rs4986893;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;A;rs4986893;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PLATINUM COMPOUNDS;RETN;GG;rs1862513;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
PRIMAQUINE;MAOA;CC + CT;rs1137070;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
OMEPRAZOLE;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
PRIMAQUINE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PRIMAQUINE;CYP2D6;*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;
ESCITALOPRAM;CYP2C19;TT;rs11188072;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;TT;rs11188072;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TENOFOVIR;ABCC10;C;rs2125739;TOXICITY;INCREASED;NAN;SIDE EFFECT;KIDNEY TUBULAR DYSFUNCTION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATION/DOSAGE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATION/DOSAGE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*5;CYP2C19*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PREGNANCY;
ISONIAZID;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ISONIAZID;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PREGNANCY;
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DYSLIPIDAEMIA;
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DIABETES MELLITUS;
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CARDIOVASCULAR DISEASE;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY IN PEOPLE WITH  OTHER:NEUROLOGICAL PROBLEMS;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY IN PEOPLE WITH  OTHER:NEUROLOGICAL PROBLEMS;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY IN PEOPLE WITH  OTHER:NEUROLOGICAL PROBLEMS;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DIABETES MELLITUS;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ACUTE CORONARY SYNDROME;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DYSLIPIDAEMIA;
TACROLIMUS;CYP3A4;A;rs2687116;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
CARBOPLATIN;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ESCITALOPRAM;CYP2C19;A;rs4244285;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;A;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
NAN;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;NAN;OTHER;SPONTANEOUS HCV CLEARANCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
MERCAPTOPURINE;SLC22A1;del;rs72552763;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;INFECTIOUS DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CARBOPLATIN;;AA + AG;rs6856089;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;;AA + AG;rs6856089;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;SOD1;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;rs36232792;OTHER;DECREASED;LIKELIHOOD;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
NAN;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY DISORDER;
NAN;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY DISORDER;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA NAN  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA NAN  NAN;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3A;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3B;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3C;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3B;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CISPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
ESCITALOPRAM;CYP2C19;TT;rs12248560;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SUFENTANIL;ADRB1;GG;rs1801253;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN;
SUFENTANIL;ADRB1;GG;rs1801253;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:SURGERY;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*36;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*36;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
TENOFOVIR;ABCC10;G;rs9349256;TOXICITY;INCREASED;NAN;SIDE EFFECT;KIDNEY TUBULAR DYSFUNCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MORTALITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MORTALITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
IMATINIB;ABCB1;A;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:CHRONIC MYELOMONOCYTIC LEUKEMIA;
IMATINIB;NR1I2;TT;rs3814055;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:CHRONIC MYELOMONOCYTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;C;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;C;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:DEPRESSIVE DISORDER;
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHOTREXATE;MTRR;G;rs1801394;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*3;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
METHADONE;CYP3A4;A;rs4646437;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*14;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
AZATHIOPRINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
LAMOTRIGINE;HLA-C;*07:18;HLA-C*07:18;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
LAMOTRIGINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
RIVAROXABAN;ABCB1;CC;rs4148738;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
LAMOTRIGINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
RIVAROXABAN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;THROMBOEMBOLISM IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
TAMOXIFEN;CYP2D6;*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ENDOMETRIAL HYPERPLASIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
METHOTREXATE;MTHFD1;A;rs2236225;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;
METHADONE;CYP3A4;T;rs2242480;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
CARBOPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CISPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CARBOPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CISPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CARBOPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CISPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
HYDROMORPHONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS NAN  NAN;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS NAN  NAN;
ANTIPSYCHOTICS;CYP2D6;*2;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;*2;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*12;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*12;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*24;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*24;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;
DOXORUBICIN;CBR1;CT + TT;rs3787728;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;
DOXORUBICIN;CBR1;CT + TT;rs3787728;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEPATOCELLULAR CARCINOMA;
INFLIXIMAB;HLA-DRB1;*04:04;HLA-DRB1*04:04;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DOXORUBICIN;CBR1;CG + GG;rs1005695;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;
DOXORUBICIN;CBR1;CG + GG;rs1005695;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEPATOCELLULAR CARCINOMA;
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STATIN-RELATED MYOPATHY NAN  NAN;
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STATIN-RELATED MYOPATHY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
OLANZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
QUETIAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
QUETIAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOEMBOLISM IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:GASTROESOPHAGEAL CANCER;
PLATINUM;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PLATINUM;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:GASTROESOPHAGEAL CANCER;
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
CHOP;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;
RITUXIMAB;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
CHOP;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;
RITUXIMAB;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*6;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;NAN;NAN;EFFICACY;WORSE PROGNOSES IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION NAN  NAN;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION NAN  NAN;
WARFARIN;CYP2C9;*1/*11;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;*1/*11;CYP2C9*11;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN HEALTHY INDIVIDUALS  NAN;
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
GEMCITABINE;RRM1;C;rs1042927;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL PROBABILITY IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
PLATINUM COMPOUNDS;RRM1;C;rs1042927;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL PROBABILITY IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC + TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TREMOR;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC + TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
AMOXICILLIN;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ASTHENIA;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ASTHENIA;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ASTHENIA;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
PACLITAXEL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LUPUS ERYTHEMATOSUS;
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:AUTOIMMUNE DISEASES;
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LUPUS ERYTHEMATOSUS;
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:AUTOIMMUNE DISEASES;
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
BEVACIZUMAB;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SARCOMA;
TAMOXIFEN;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
METHOTREXATE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SARCOMA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SARCOMA;
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;C;rs1142345;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;RISK;DISEASE;MUCOSITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AMOXICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AMOXICILLIN;ERAP1, ERAP2;G;rs1363907;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;ERAP1, ERAP2;G;rs1363907;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CYCLOPHOSPHAMIDE;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
AMOXICILLIN;PTPN22;A;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CAPECITABINE;TYMS;G;rs3786362;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;TYMS;C;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;ENOSF1, TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;ENOSF1, TYMS;G;rs2790;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
NAN;NME1, NME1-NME2;TT;rs2302254;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
NAN;NME1, NME1-NME2;TT;rs2302254;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
RIVAROXABAN;SUSD3;TT;rs76292544;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:VENOUS THROMBOEMBOLISM;
NAN;CYP3A5, ZSCAN25;CC;rs776746;NAN;NAN;NAN;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
METHOTREXATE;SLCO1B1;G;rs4149081;TOXICITY;INCREASED;RISK;SIDE EFFECT;GI TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG HYPERSENSITIVITY NAN  NAN;
ASPIRIN;FCER1G;AA;rs11587213;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
NAN;MS4A2;AG + GG;rs569108;TOXICITY;INCREASED;LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA NAN  NAN;
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;CHANCE OF POSITIVE RESPONSE TO PACLITAXEL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
ETHAMBUTOL;FECH;CC;rs536560;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;CC;rs536560;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
NAN;FCER1G;AG + GG;rs11587213;TOXICITY;INCREASED;LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA NAN  NAN;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CISPLATIN;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
RADIOTHERAPY;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;
GEMCITABINE;CDA;C;rs2072671;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
PLATINUM COMPOUNDS;CDA;C;rs2072671;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
NAN;CYP2A6;*4/*4;CYP2A6*4;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;AA;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;AA;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*6;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;AA;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;DISEASE;GASTRIC PH IN PEOPLE WITH  DISEASE:HELICOBACTER INFECTIONS;
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;NAN;DISEASE;GASTRIC PH IN PEOPLE WITH  DISEASE:HELICOBACTER INFECTIONS;
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;DISEASE;GASTRIC PH IN PEOPLE WITH  DISEASE:HELICOBACTER INFECTIONS;
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
PHENPROCOUMON;VKORC1;TT;rs9923231;OTHER;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
METHOTREXATE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CARBOPLATIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;
GEMCITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLCO1B1;C;rs4149056;OTHER;DECREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG HYPERSENSITIVITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;CHRONIC KIDNEY FAILURE IN PEOPLE WITH  DISEASE:GLOMERULONEPHRITIS;
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;IGA;
SUCCINYLCHOLINE;RYR1;G;rs193922752;TOXICITY;INCREASED;RISK;SIDE EFFECT;MALIGNANT HYPERTHERMIA NAN  NAN;
VOLATILE ANESTHETICS;RYR1;G;rs193922752;TOXICITY;INCREASED;RISK;SIDE EFFECT;MALIGNANT HYPERTHERMIA NAN  NAN;
EGFR INHIBITORS;EGFR;GG;rs2227983;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEMCITABINE;RRM1;A;rs12806698;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
PLATINUM COMPOUNDS;RRM1;A;rs12806698;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
GEMCITABINE;RRM1;C;rs11030918;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
PLATINUM COMPOUNDS;RRM1;C;rs11030918;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN  NAN;
VERAPAMIL;ADRB1;AA + AG;rs1801252;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
HEROIN;DRD2;G;rs12364283;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;
REPAGLINIDE;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE AUC IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOPOIETIC TOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOPOIETIC TOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PHENYTOIN;CYP2C19;A;rs4986893;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TACROLIMUS;CYP3A4;G;rs4646437;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ASPARAGINASE;SOD2;GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;CYP1A2;AC + CC;rs762551;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:INCREASED COFFEE INTAKE;
ANTITHYROID PREPARATIONS;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
TRASTUZUMAB;ERBB2;AG + GG;rs1136201;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
BETA BLOCKING AGENTS;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
PACLITAXEL;FZD3;A;rs7001034;TOXICITY;DECREASED;RISK;SIDE EFFECT;SENSORY PERIPHERAL NEUROPATHY IN WOMEN  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;NAN;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;NAN;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
SERTRALINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
SERTRALINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
CLOZAPINE;HLA-DRB1;*04:02;HLA-DRB1*04:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEPATOCELLULAR CARCINOMA IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*5/*5;CYP2D6*5;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
ASPIRIN;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
BETA BLOCKING AGENTS;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
HMG COA REDUCTASE INHIBITORS;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPIRIN;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
TACROLIMUS;CYP3A4;C;rs6956344;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  OTHER:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:MOOD DISORDER;
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEUROPATHIC PAIN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
PACLITAXEL;ABCB1;AG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE CONTROL RATE AND LOWER OVERALL SURVIVAL RATE IN PEOPLE WITH  OTHER:METASTATIC BREAST CANCER;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;CLOPIDOGREL ACTIVE METABOLITE LEVEL IN HEALTHY INDIVIDUALS  NAN;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING TARGET CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING TARGET CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;POST-TREATMENT ADP-STIMULATED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
PACLITAXEL;CYP3A5;C;rs776746;TOXICITY;DECREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
INFLIXIMAB;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
INFLIXIMAB;HLA-DPB1;*10:01;HLA-DPB1*10:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
INFLIXIMAB;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*10X2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*14;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*21;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*36;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NAN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;DISEASE;ASPIRIN-INDUCED ASTHMA NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*6/*6;CYP2D6*6;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*6/*6;CYP2D6*6;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*5;CYP2D6*4;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*5;CYP2D6*5;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
TRAMADOL;CYP2D6;*4/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ARTHRITIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;GOUTY;
CYCLOPHOSPHAMIDE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
FOLFIRINOX;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
FOLFIRINOX;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*14;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*21;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*36;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED BLOOD LEVELS IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED BLOOD LEVELS IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A4;C;rs2242480;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;OTHER;INCREASED;NAN;OTHER;CREATININE CLEARANCE IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;OTHER;INCREASED;NAN;OTHER;CREATININE CLEARANCE IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*21;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*36;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;
TRANILAST;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:MYOCARDIAL ISCHEMIA;
TRANILAST;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:MYOCARDIAL ISCHEMIA;
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*21;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*36;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
ANTITHYROID PREPARATIONS;HLA-DQA1;*01:03;HLA-DQA1*01:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
ANTITHYROID PREPARATIONS;HLA-DQB1;*06:01;HLA-DQB1*06:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*20;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*20;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3 YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3 YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
OPIOIDS;OPRM1;T;rs548646;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;TOXICITY;INCREASED;RISK;DISEASE;ACUTE CELLULAR REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
RHODAMINE 123;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;EFFLUX OF RHODAMINE FROM CD56+ NATURAL KILLER CELLS NAN  NAN;
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPIRIN;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
TICAGRELOR;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
LAMOTRIGINE;HLA-A;*68:01;HLA-A*68:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;PAIN IN CHILDREN  NAN;
CELECOXIB;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;PAIN IN CHILDREN  NAN;
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CARBAMAZEPINE;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA NAN  NAN;
TETANUS ANTITOXIN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
ACETAMINOPHEN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
ACETAMINOPHEN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
INFLIXIMAB;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
PHENYTOIN;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
NEVIRAPINE;HLA-B;*14:02;HLA-B*14:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PHENYTOIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA NAN  NAN;
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLINDAMYCIN;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
LAMOTRIGINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
LAMOTRIGINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
INFLIXIMAB;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
OXCARBAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
NILOTINIB;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;
NILOTINIB;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
NILOTINIB;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;
NILOTINIB;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
CLINDAMYCIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ISONIAZID;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
OPIOIDS;OPRM1;A;rs609148;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;
ATAZANAVIR;UGT1A1;*1/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A1;*1/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;CYP3A4*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;CYP3A4*18;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
NEVIRAPINE;HLA-C;*08:02;HLA-C*08:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
INFLIXIMAB;HLA-C;*12:03;HLA-C*12:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NAN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;DISEASE;ASPIRIN-INDUCED ASTHMA NAN  NAN;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
PHENYTOIN;HLA-C;*15:02;HLA-C*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-C;*15:02;HLA-C*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
TACROLIMUS;CYP2J2;AA + AC;rs890293;TOXICITY;INCREASED;RISK;DISEASE;NAUSEA;
TACROLIMUS;CYP2J2;AA + AC;rs890293;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:VOMITING IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CARBAMAZEPINE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
ABACAVIR;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUPIRTINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
NEVIRAPINE;HLA-DRB1;*01:02;HLA-DRB1*01:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
HYDRALAZINE;HLA-DRB1;*04:01;HLA-DRB1*04:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LUPUS ERYTHEMATOSUS DUE TO HYDRALAZINE IN PEOPLE WITH  OTHER:HYPERTENSION;
OXCARBAZEPINE;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
ABACAVIR;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
PEGINTERFERON ALFA-2A;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA NAN  NAN;
PEGINTERFERON ALFA-2B;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA NAN  NAN;
RIBAVIRIN;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA NAN  NAN;
PRAVASTATIN;LDLR;G;rs2738466;EFFICACY;INCREASED;RISK;DISEASE;CORONARY DISEASE IN MEN  NAN;
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
FLUPIRTINE;HLA-DRB1;*16:01;HLA-DRB1*16:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
THALIDOMIDE;GSTT1;AA;rs4630;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
MINOCYCLINE;HLA-B;*35:02;HLA-B*35:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  NAN;
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE IN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;METABOLISM/PK;DECREASED;NAN;PK;DOSE IN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE IN  DISEASE:EPILEPSY;
WARFARIN;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;PROTHROMBIN TIME (PT) AT INDUCTION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;PROTHROMBIN TIME (PT) AT INDUCTION NAN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:HYPERURICEMIA;
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
TACROLIMUS;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
CYCLOSPORINE;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
CYCLOSPORINE;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN MEN  NAN;
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN MEN  NAN;
PACLITAXEL;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
CAFFEINE;CYP1A2;;CYP1A2 LOW ACTIVITY;OTHER;INCREASED;NAN;OTHER;INTAKE IN WOMEN WITH  DISEASE:PREGNANCY;
HMG-COA_REDUCTASE_INHIBITORS;GNB3;CT + TT;rs5443;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
NAN;HMGCR;AA;rs3846662;OTHER;DECREASED;NAN;OTHER;HMGCRV_1 EXPRESSION AND AN INCREASE IN THE EXPRESSION OF THE FULL-LENGTH TRANSCRIPT NAN  NAN;
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;NAN;NAN;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;NAN;NAN;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*5;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN CHILDREN WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
CAFFEINE;ADORA2A;T/del + TT;rs35320474;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BRONCHOPULMONARY DYSPLASIA IN INFANTS WITH  OTHER:APNEA OF PREMATURITY;
CAFFEINE;ADORA2A;T/del + TT;rs35320474;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:PREMATURE BIRTH;
WARFARIN;CYP2C9;*2;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;
NAN;DHFR;del/del;rs70991108;OTHER;INCREASED;NAN;OTHER;SERUM AND RED BLOOD CELL FOLATE CONCENTRATIONS NAN  NAN;
CISPLATIN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;DEPRESSION IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;EFFICACY;DECREASED;SEVERITY;EFFICACY;DEPRESSION IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY;DEPRESSION IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;ANXIETY DISORDERS IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY;ANXIETY DISORDERS IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*9;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*9;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*17;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*17;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*20;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*20;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*24;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*24;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*26;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*26;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*27;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*27;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
INTERFERON BETA-1A;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
INTERFERON BETA-1B;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*5;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*15;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*37;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EGFR INHIBITORS;EGFR;A;rs2227983;EFFICACY;NAN;NAN;EFFICACY;CYTOTOXICITY NAN  NAN;
ATAZANAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
INTERFERON BETA-1A;;G;rs4961252;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
INTERFERON BETA-1B;;G;rs4961252;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
ASPARAGINASE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
CYTARABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
DAUNORUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ETOPOSIDE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
ETOPOSIDE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
MERCAPTOPURINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
PREDNISONE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;
VINCRISTINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
GEMCITABINE;RRM1;G;rs9937;TOXICITY;DECREASED;RISK;DISEASE;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NAN;ACE;del/del;rs1799752;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;PD;DECREASED;LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  NAN;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;PD;DECREASED;LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  NAN;
ETHANOL;OPRM1;T;rs1381376;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PEGASPARGASE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
PEGASPARGASE;HLA-DQB1;*02:02;HLA-DQB1*02:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
PEGASPARGASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
METHOTREXATE;DHFR, MSH3;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ENOSF1, TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;LIKELIHOOD;OTHER;COVID-19 NAN  NAN;
CYCLOSPORINE;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
NAN;ACE;del;rs1799752;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 IN PEOPLE WITH  NAN;
ASPIRIN;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
BETA BLOCKING AGENTS;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
HMG COA REDUCTASE INHIBITORS;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
NAN;ACE;del/del;rs1799752;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:COVID-19;
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMORRHAGE NAN  NAN;
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
ANAKINRA;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;
ANAKINRA;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;
CANAKINUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;
CANAKINUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;
RILONACEPT;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;
RILONACEPT;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;
TOCILIZUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;
TOCILIZUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;
PEGINTERFERON ALFA-2A;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
FLUCLOXACILLIN;HLA-B;*57:03;HLA-B*57:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CISPLATIN;TPMT;*3B + *3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
CISPLATIN;TPMT;*3B + *3C;TPMT*3B;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
CISPLATIN;TPMT;*3B + *3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
PREDNISONE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION IN PEOPLE WITH  OTHER:HEART TRANSPLANTATION;
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION IN PEOPLE WITH  OTHER:HEART TRANSPLANTATION;
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;ORAL CLEARANCE (CL) OF ATAZANAVIR IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;ORAL CLEARANCE (CL) OF ATAZANAVIR IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIINFLAMMATORY AGENTS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
NON-STEROIDS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
EGFR INHIBITORS;EGFR;T;rs712829;TOXICITY;NAN;NAN;EFFICACY;CYTOTOXICITY NAN  NAN;
ANTINEOPLASTIC AGENTS;TYMS;TTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-A;*24:07;HLA-A*24:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LOW LEUKOCYTE COUNTS IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;
AZATHIOPRINE;TPMT;*1/*3A;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LOW LEUKOCYTE COUNTS IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;
AZATHIOPRINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LOW LEUKOCYTE COUNTS IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;
AZATHIOPRINE;TPMT;*1/*1;TPMT*1;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT DURATION IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;
AZATHIOPRINE;TPMT;*1/*1;TPMT*2;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT DURATION IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;
AZATHIOPRINE;TPMT;*1/*1;TPMT*3A;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT DURATION IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CLOPIDOGREL;CYP2C19;*4;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*4;CYP2C19*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATORVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN C-REACTIVE PROTEIN (CRP) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
PRAVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN C-REACTIVE PROTEIN (CRP) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOZAPINE;GSTM1;null/null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;
CLOZAPINE;GSTM1;null/null;GSTM1 NULL;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*7;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM OF TRAMADOL AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;DECREASED;NAN;EFFICACY;METABOLISM OF TRAMADOL AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
TAMOXIFEN;CYP2D6;*4/*6;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CARBAMAZEPINE;HLA-DRB1;*12:02;HLA-DRB1*12:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-DRB1;*12:02;HLA-DRB1*12:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;INTRAGASTRIC PH IN PEOPLE WITH  DISEASE:ULCER;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;INTRAGASTRIC PH IN PEOPLE WITH  DISEASE:ULCER;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:EPILEPSY;
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
CARBAMAZEPINE;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:EPILEPSY;
CARBAMAZEPINE;HLA-DQA1;*03:02;HLA-DQA1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:EPILEPSY;
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*22;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
TAMOXIFEN;CYP2D6;*4/*11;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*11;CYP2D6*11;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;ABCB1;AA;rs1128503;DOSAGE;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;
CYCLOSPORINE;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;
NAN;TMPRSS2;CC;rs383510;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 NAN  NAN;
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
TAMOXIFEN;CYP2D6;*3/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*36;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
CYCLOSPORINE;ABCB1;AA;rs2032582;DOSAGE;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;
CYCLOSPORINE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*17;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
METHADONE;CYP3A4;G;rs2246709;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUVOXAMINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;FLUVOXAMINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;FLUVOXAMINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*4;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) NAN  NAN;
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHAZOLAMIDE;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ACETAMINOPHEN;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;
ACETAMINOPHEN;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;
CODEINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;
CODEINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;
LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;
LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
METHADONE;CYP3A4;T;rs2242480;OTHER;INCREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
DOCETAXEL;RPL13, SNORD68, SPG7;G;rs12960;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;RPL13, SNORD68, SPG7;G;rs12960;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
DOCETAXEL;CHST3;A;rs1871450;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;CHST3;A;rs1871450;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CITALOPRAM;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE NAN  NAN;
CITALOPRAM;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE NAN  NAN;
PEGINTERFERON ALFA-2B;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHADONE;CYP3A4;A;rs4646440;OTHER;INCREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CARBAMAZEPINE;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
ETHANOL;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
ETHANOL;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
OPIOIDS;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
DOCETAXEL;NAT2;G;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;NAT2;G;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
DOCETAXEL;CYP4B1;T;rs4646487;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;CYP4B1;T;rs4646487;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*07:02;HLA-B*07:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;RESPIRATORY INSUFFICIENCY NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:02;HLA-C*07:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;RESPIRATORY INSUFFICIENCY NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;null/null;GSTM1 NULL;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
METHOTREXATE;DHFR;GGGAGCTGG/del + del/del;rs3045983;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
OPIOIDS;OPRM1;CC;rs589046;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;LEUKOCYTES AND NEUTROPHILS IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;NAN;SIDE EFFECT;LEUKOCYTES AND NEUTROPHILS IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;NAN;SIDE EFFECT;LEUKOCYTES AND NEUTROPHILS IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ALPRAZOLAM;CYP3A4;;CYP3A4 LOW ACTIVITY;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;
ALPRAZOLAM;CYP3A4;;CYP3A4 LOW ACTIVITY;EFFICACY;INCREASED;RISK;SIDE EFFECT;OTHER:ANXIETY DISORDERS;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
DOCETAXEL;VEGFA;del/del;rs144854329;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN NAN  NAN;
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531C;TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:ADENOCARCINOMA;
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
HALOPERIDOL;CYP2D6;*1/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOLIC PSYCHOSIS;
HALOPERIDOL;CYP2D6;*1/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOLIC PSYCHOSIS;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
NAN;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;DECREASED;RISK;DISEASE;ASPIRIN-INDUCED ASTHMA NAN  NAN;
CARBOPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
CARBOPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
CISPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
METHAMPHETAMINE;DAOA;T;rs947267;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN WITH  DISEASE:EPILEPSY;
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN WITH  DISEASE:EPILEPSY;
PHENOBARBITAL;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN WITH  DISEASE:EPILEPSY;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*2;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*2;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10X2;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10X2;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*36;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*36;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;NAN;NAN;OTHER;HIGHER STABLE DOSE LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;NAN;NAN;OTHER;HIGHER STABLE DOSE LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHAMPHETAMINE;OPRM1;C;rs2075572;TOXICITY;DECREASED;RISK;OTHER;METHAMPHETAMINE DEPENDENCE NAN  NAN;
ACETAMINOPHEN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
ACETAMINOPHEN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
ACETAMINOPHEN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
ACETAMINOPHEN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
ACETAMINOPHEN;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
ACETAMINOPHEN;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
ACETAMINOPHEN;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
ACETAMINOPHEN;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHADONE;CYP3A4;A;rs2246709;OTHER;DECREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;CLOPI-H4 CONCENTRATIONS AFTER 300 OR 900 MG CLOPIDOGREL LOADING DOSE IN MEN WITH  DISEASE:MYOCARDIAL INFARCTION;
ATORVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
PRAVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
COMBINATIONS;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
COMBINATIONS;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
ATENOLOL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
HYDROCHLOROTHIAZIDE;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
TRANDOLAPRIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
VERAPAMIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:LEPROSY;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
METHAMPHETAMINE;BDNF;CC;rs6265;TOXICITY;DECREASED;SEVERITY;OTHER;METHAMPHETAMINE DEPENDENCE NAN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;DELAYED GRAFT FUNCTION IN PEOPLE WITH  NAN;
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;DELAYED GRAFT FUNCTION IN PEOPLE WITH  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTICHOLINERGIC AGENTS;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;SERUM ANTICHOLINERGIC ACTIVITY NAN  NAN;
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN LIVER MICROSOMES;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN LIVER MICROSOMES;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
NAN;GSTT1;;GSTT1 NON-NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;
NAN;GSTT1;;GSTT1 NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
NAN;GSTM1;;GSTM1 NON-NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;
NAN;GSTM1;;GSTM1 NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;
METHAMPHETAMINE;DAOA;A;rs2391191;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*4;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*5;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*22;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*4;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*5;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*22;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;
IRINOTECAN;HLA-DQB3;C;rs2859101;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
CYCLOSPORINE;MTHFR;GG;rs3737967;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;MTHFR;GG;rs3737967;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
ANTIDEPRESSANTS;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
SULFASALAZINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;
CYCLOSPORINE;MTHFR;CC;rs2274976;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;MTHFR;CC;rs2274976;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
NAN;G6PD;T;rs1050828;NAN;INCREASED;NAN;OTHER;PROTECTION AGAINST SEVERE MALARIA NAN  NAN;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;
CYCLOPHOSPHAMIDE;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;JAUNDICE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;JAUNDICE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*36;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;JAUNDICE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*37;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
CAPECITABINE;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
CISPLATIN;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;
CISPLATIN;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;
CISPLATIN;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;
CISPLATIN;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;
RADIOTHERAPY;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;
RADIOTHERAPY;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;
RADIOTHERAPY;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;
RADIOTHERAPY;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
ANTIDEPRESSANTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;
ANTIEPILEPTICS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;
BETA BLOCKING AGENTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;
CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;
ANTIDEPRESSANTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;
ANTIEPILEPTICS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;
BETA BLOCKING AGENTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;
CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
IRINOTECAN;DPYD;T;rs1042482;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*37;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
METHADONE;CYP3A4;A;rs4646440;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
WARFARIN;VKORC1;CC;rs9923231;OTHER;INCREASED;LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
CYCLOPHOSPHAMIDE;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;
CYCLOPHOSPHAMIDE;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;
NAN;CHRNB2;GG;rs2072661;NAN;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ROSIGLITAZONE;PLIN1;CT + TT;rs894160;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
ROSIGLITAZONE;PLIN1;CT + TT;rs894160;TOXICITY;DECREASED;NAN;SIDE EFFECT;TYPE 2;
PLATINUM;;T;rs836554;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CYCLOSPORINE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHADONE;CYP2B6;*6;CYP2B6*6;TOXICITY;INCREASED;SEVERITY;DISEASE;PAIN IN MEN WITH  DISEASE:OPIOID-RELATED DISORDERS;
OXCARBAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
NAN;LRP5;T;rs3736228;NAN;INCREASED;RISK;OTHER;OSTEOPOROTIC FRACTURE NAN  NAN;
CYCLOPHOSPHAMIDE;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CITALOPRAM;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DRUGS USED IN NICOTINE DEPENDENCE;COMT;AA;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  NAN;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;EFFICACY;DECREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;EFFICACY;DECREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  OTHER:FEMALE GENDER;
VALGANCICLOVIR;ABCC4;AC;rs11568658;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;NFATC1;CC;rs1017860;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;NFATC1;CC;rs1017860;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PRASUGREL;PEAR1;AA;rs822442;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
TACROLIMUS;CYP2C8;*3;CYP2C8*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*07:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NICOTINE;COMT;G;rs4680;TOXICITY;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
NICOTINE;COMT;G;rs4680;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  SIDE EFFECT:EPILEPSY;
BOSENTAN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;
BOSENTAN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOZAPINE;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
BOSENTAN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;
BOSENTAN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;
ATORVASTATIN;TNF;GG;rs1800629;EFFICACY;INCREASED;NAN;EFFICACY;BONE MARROW DENSITY IN THE LUMBAR SPINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
LAMOTRIGINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
IRINOTECAN;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS;
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;TOXICITY;DECREASED;RISK;OTHER;RECURRENCE IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;TOXICITY;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
WARFARIN;CYP2C9;*6;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*6;CYP2C9*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;
METHOTREXATE;SLCO1B1;T;rs11045879;OTHER;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLCO1B1;T;rs11045879;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*11;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*11;CYP2C9*11;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*5;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*5;CYP2C9*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;PAIN IN PEOPLE WITH  DISEASE:PAIN;
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;PAIN IN PEOPLE WITH  DISEASE:PAIN;
BOSENTAN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
BOSENTAN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH LEVELS IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH LEVELS IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;DISEASE;INTERSTITIAL FIBROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;DISEASE;INTERSTITIAL FIBROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
CLOPIDOGREL;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;TOXICITY;INCREASED;RISK;PK;ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;TOXICITY;INCREASED;RISK;PK;ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACE INHIBITORS;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA;
ACE INHIBITORS;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:COUGH NAN  NAN;
PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA;
PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:COUGH NAN  NAN;
CODEINE;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;
CODEINE;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;
CODEINE;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;
TRAMADOL;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;
TRAMADOL;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;
TRAMADOL;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;
NAN;KCNE1;T;rs727957;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
AMOXICILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
OXCARBAZEPINE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACEI-RELATED COUGH IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
NAN;RGS2;TC/del + del/del;rs34717272;OTHER;INCREASED;RISK;DISEASE;HYPERTENSION NAN  NAN;
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CARBAMAZEPINE;HLA-DRB1;*14:05;HLA-DRB1*14:05;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
CYCLOPHOSPHAMIDE;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LAMOTRIGINE;HLA-A;*30:01;HLA-A*30:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;DECREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
OXCARBAZEPINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
OXCARBAZEPINE;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
OXCARBAZEPINE;HLA-B;*15:19;HLA-B*15:19;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
OXCARBAZEPINE;HLA-B;*48:04;HLA-B*48:04;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
RALOXIFENE;UGT1A1;*28/*28;UGT1A1*1;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN WOMEN WITH  DISEASE:OSTEOPOROSIS;
RALOXIFENE;UGT1A1;*28/*28;UGT1A1*28;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN WOMEN WITH  DISEASE:OSTEOPOROSIS;
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;EFFICACY;DECREASED;SEVERITY;DISEASE;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  SIDE EFFECT:ASPIRIN-INDUCED ASTHMA;
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;SEVERITY;DISEASE;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  SIDE EFFECT:ASPIRIN-INDUCED ASTHMA;
OXCARBAZEPINE;HLA-B;*27:09;HLA-B*27:09;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
NEVIRAPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED;RISK;OTHER;DISEASE RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NEVIRAPINE;HLA-B;*58:02;HLA-B*58:02;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PRASUGREL;PEAR1;TT;rs3737224;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
NEVIRAPINE;HLA-C;*02:10;HLA-C*02:10;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CYCLOSPORINE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
CAPECITABINE;MIR27A;CT;rs895819;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
OLANZAPINE;ABCB1;GG;rs4728709;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN HEALTHY INDIVIDUALS  NAN;
BUPROPION;CYP2B6;TT;rs3211371;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  OTHER:FEMALE GENDER;
CYCLOPHOSPHAMIDE;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*3;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*4;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*5;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*5;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*4;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*5;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*5;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;
PRASUGREL;PEAR1;TT;rs41273215;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD) IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD) IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED;RISK;OTHER;DISEASE RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;NAN;NAN;OTHER;SIGNIFICANTLY HIGHER TRAMADOL CONSUMPTION IN CHINESE GASTRIC CANCER PATIENTS RECOVERING FROM GASTRECTOMY NAN  NAN;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;NAN;NAN;OTHER;SIGNIFICANTLY HIGHER TRAMADOL CONSUMPTION IN CHINESE GASTRIC CANCER PATIENTS RECOVERING FROM GASTRECTOMY NAN  NAN;
PRASUGREL;PEAR1;CC;rs822441;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;CARCINOMA;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;SQUAMOUS CELL IN PEOPLE WITH  DISEASE:LUNG TRANSPLANTATION;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE;CARCINOMA;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE;SQUAMOUS CELL IN PEOPLE WITH  DISEASE:LUNG TRANSPLANTATION;
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;
CLOPIDOGREL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
CAFFEINE;CYP1A2;;CYP1A2 HIGH ACTIVITY;TOXICITY;INCREASED;RISK;DISEASE;ABORTION;
CAFFEINE;CYP1A2;;CYP1A2 HIGH ACTIVITY;TOXICITY;INCREASED;RISK;DISEASE;SPONTANEOUS IN WOMEN WITH  DISEASE:PREGNANCY;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN CHILDREN  NAN;
CYCLOPHOSPHAMIDE;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LAMOTRIGINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;DECREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*60;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CYCLOPHOSPHAMIDE;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MOOD DISORDER;
PEGINTERFERON ALFA-2A;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;
PEGINTERFERON ALFA-2B;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;
RIBAVIRIN;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
NAN;VDR;A;rs731236;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;
OLANZAPINE;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIAC RHYTHM DISEASE IN HEALTHY INDIVIDUALS  NAN;
IRINOTECAN;UGT1A1;A;rs10929302;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
CYCLOPHOSPHAMIDE;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION NAN  NAN;
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
HEROIN;OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CYCLOSPORINE;NFATC1;GG;rs8090560;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;NFATC1;GG;rs8090560;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA AND VOMITING IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
AZATHIOPRINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA AND VOMITING IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
RISPERIDONE;LEP;A;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN  NAN;
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
PEGINTERFERON ALFA-2A;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;
PEGINTERFERON ALFA-2B;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;
RIBAVIRIN;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;
CYCLOPHOSPHAMIDE;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;DHFR;GG;rs34965641;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;DHFR;GG;rs34965641;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ETRAVIRINE;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;ETRAVIRINE CLEARANCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVEL;
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;IN A GENE-DOSE-DEPENDENT MANNER;
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
FLUOROURACIL;MTHFR;TT;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PEMETREXED;GGH;A;rs11545078;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;GGH;A;rs11545078;TOXICITY;DECREASED;RISK;SIDE EFFECT;DISEASE:MESOTHELIOMA;
METFORMIN;SLC22A1;GAT/del;rs72552763;OTHER;DECREASED;NAN;EFFICACY;TROUGH METFORMIN STEADY-STATE CONCENTRATION IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC22A1;GAT/del;rs72552763;OTHER;DECREASED;NAN;EFFICACY;TYPE 2;
METFORMIN;SLC22A1;GAT/del;rs72552763;METABOLISM/PK;DECREASED;NAN;EFFICACY;TROUGH METFORMIN STEADY-STATE CONCENTRATION IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC22A1;GAT/del;rs72552763;METABOLISM/PK;DECREASED;NAN;EFFICACY;TYPE 2;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:NEUROPATHIC PAIN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PHENAZEPAM;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOL ABUSE;
PHENAZEPAM;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;OTHER:ANXIETY DISORDERS;
PHENAZEPAM;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOL ABUSE;
PHENAZEPAM;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;OTHER:ANXIETY DISORDERS;
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;RISK;DISEASE;DEHYDRATION IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA NAN  NAN;
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TAMOXIFEN;CYP2D6;*2;CYP2D6*2;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
TAMOXIFEN;CYP3A4;*22;CYP3A4*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP3A4;*22;CYP3A4*22;TOXICITY;DECREASED;NAN;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE;
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEDATION IN HEALTHY INDIVIDUALS  NAN;
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  DISEASE:SKIN DISORDER;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;ALCOHOL RESPONSE;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;CONSUMPTION;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;AND PREFERENCE NAN  NAN;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CYCLOPHOSPHAMIDE;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EXEMESTANE;;AA;rs934635;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CYCLOPHOSPHAMIDE;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
PRASUGREL;PEAR1;AA;rs12407843;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
DIGOXIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUDDEN CARDIAC DEATH NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PRASUGREL;PEAR1;AA;rs77235035;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
VENLAFAXINE;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
VENLAFAXINE;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;
DIGOXIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUDDEN CARDIAC DEATH NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;NAN;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;NAN;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
DIGOXIN;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUDDEN CARDIAC DEATH NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALL AND MINOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALL AND MINOR HEMORRHAGE NAN  NAN;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OLANZAPINE;ABCB1;G;rs10248420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;AG + GG;rs56293913;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;AG + GG;rs56293913;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:GASTROESOPHAGEAL CANCER;
FLUTICASONE PROPIONATE;CD14, TMCO6;AA;rs2569190;EFFICACY;INCREASED;NAN;EFFICACY;PC20 IN CHILDREN WITH  DISEASE:ASTHMA;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CYCLOPHOSPHAMIDE;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;
CYCLOPHOSPHAMIDE;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ASPIRIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
ASPIRIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*1;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*3;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*4;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;
CYCLOPHOSPHAMIDE;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CISPLATIN;ERCC1;AA;rs3212986;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
PALBOCICLIB;ABCG2;CT;rs2231137;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*4;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;
EXEMESTANE;;AA;rs934635;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF MUSCULOSKELETAL ADVERSE EVENTS (MSAES) IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DECREASED HEMOCRIT LEVELS IN PEOPLE WITH  DISEASE:MALARIA;
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VIVAX;
CYCLOPHOSPHAMIDE;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHAMPHETAMINE;DAOA;C;rs3916965;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;
NAN;UGT1A1;G;rs34993780;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;
NAN;UGT1A1;G;rs34993780;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;
CYCLOPHOSPHAMIDE;CYP2C9;*2 + *3;CYP2C9 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:VASCULITIS;
CYCLOPHOSPHAMIDE;CYP2C9;*2 + *3;CYP2C9 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:WEGENER GRANULOMATOSIS;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;THE INTRINSIC METABOLIC ACTIVITY (V(MAX)/K(M)) IN CHILDREN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;THE MEAN MAXIMAL ELIMINATION RATES (V(MAX)) IN CHILDREN  DISEASE:EPILEPSY;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;
RITONAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PALBOCICLIB;SULT2A1;CC;rs182420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;
PALBOCICLIB;SULT2A1;CC;rs182420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DISCONTINUATION IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
CYCLOPHOSPHAMIDE;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;NAN;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS NAN  NAN;
SULFANILAMIDE;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;NAN;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS NAN  NAN;
CHLORAMPHENICOL;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;NAN;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
CODEINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;PAIN IN CHILDREN WITH  OTHER:ANEMIA;
CODEINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;SICKLE CELL;
MORPHINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;PAIN IN CHILDREN WITH  OTHER:ANEMIA;
MORPHINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;SICKLE CELL;
TRAMADOL;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;PAIN IN CHILDREN WITH  OTHER:ANEMIA;
TRAMADOL;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;SICKLE CELL;
CISPLATIN;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
CISPLATIN;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
DOCETAXEL;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
DOCETAXEL;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
CYCLOPHOSPHAMIDE;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*8;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN NAN  NAN;
WARFARIN;CYP2C9;*8;CYP2C9*8;METABOLISM/PK;DECREASED;NAN;PK;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN NAN  NAN;
IRINOTECAN;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;G;rs1056892;TOXICITY;INCREASED;RISK;DISEASE;HEART FAILURE NAN  NAN;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN  OTHER:COLORECTAL NEOPLASMS;
CISPLATIN;ERCC2;G;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:STROKE;
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;CC;rs10836235;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIAC DAMAGE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
EXEMESTANE;UGT2B17;;UGT2B17 DEFICIENCY;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FATIGUE IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;NAN;SIDE EFFECT;BLEEDING TIME IN PEOPLE WITH  DISEASE:MOOD DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 L ALLELE-rs25531C;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLEEDING TIME IN PEOPLE WITH  DISEASE:MOOD DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLEEDING TIME IN PEOPLE WITH  DISEASE:MOOD DISORDER;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
VALPROIC ACID;XBP1;G;rs2269577;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROPHYLACTIC TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;
ACE INHIBITORS;ACE;del;rs1799752;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PLAIN;ACE;del;rs1799752;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PACLITAXEL;CYP1B1;GG;rs1056836;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOCETAXEL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
WARFARIN;CYP2C9;*8;CYP2C9*1;DOSAGE;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;
WARFARIN;CYP2C9;*8;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;
WARFARIN;CYP2C9;*8;CYP2C9*8;DOSAGE;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;
WARFARIN;CYP2C9;*8;CYP2C9*8;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;INCREASED;NAN;OTHER;HYDROCHLOROTHIAZIDE INDUCED POTASSIUM EXCRETION IN MEN WITH  DISEASE:HYPERTENSION;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VENOUS THROMBOEMBOLISM NAN  NAN;
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY RESPONSE IN WOMEN WITH  DISEASE:HYPERTENSION;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PAROXETINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*14;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*2;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*3;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*8;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*9;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;
NEVIRAPINE;CCHCR1;T;rs130072;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;INCREASED;RISK;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;APOC3;G;rs5128;TOXICITY;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDE LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
METFORMIN;BDNF;C;rs6265;EFFICACY;INCREASED;LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS NAN  NAN;
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*18;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
LUMIRACOXIB;HLA-DRB1;*15:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
LUMIRACOXIB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH ( R;
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;S )-METHADONE PLASMA CONCENTRATIONS NAN  NAN;
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;TROUGH ( R;
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;S )-METHADONE PLASMA CONCENTRATIONS NAN  NAN;
MERCAPTOPURINE;TPMT;*12;TPMT*1;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*12;TPMT*12;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*12;TPMT*1;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*12;TPMT*12;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278293;TOXICITY;DECREASED;RISK;SIDE EFFECT;BIOPSY-PROVEN ACUTE REJECTION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
MITOXANTRONE;ABCB1;AA;rs2032582;OTHER;INCREASED;NAN;OTHER;SENSITIVITY IN VITRO NAN  NAN;
LUMIRACOXIB;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;RISK;OTHER;OVERANTICOAGULATION NAN  NAN;
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;INCREASED;RISK;OTHER;OVERANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN CHILDREN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN CHILDREN  NAN;
METHADONE;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROLONGED QTC NAN  NAN;
METHADONE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROLONGED QTC NAN  NAN;
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;(S)-METHADONE PLASMA LEVELS NAN  NAN;
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;(S)-METHADONE PLASMA LEVELS NAN  NAN;
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*2XN;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*4;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*5;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;ABCB1;A;rs1045642;OTHER;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
NEVIRAPINE;HLA-C;T;rs9461684;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASPIRIN;IL1B;A;rs1143627;TOXICITY;NAN;NAN;DISEASE;PEPTIC ULCER DISEASE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
PACLITAXEL;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
PHENYTOIN;EPHX1;G;rs2234922;TOXICITY;INCREASED;RISK;DISEASE;DISORDER OF FACIAL SKELETON IN PEOPLE WITH  OTHER:FIRST TRIMESTER PREGNANCY;
PHENYTOIN;EPHX1;T;rs1051740;TOXICITY;INCREASED;RISK;DISEASE;DISORDER OF FACIAL SKELETON IN PEOPLE WITH  OTHER:FIRST TRIMESTER PREGNANCY;
NEVIRAPINE;TCF19;T;rs2073724;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RISPERIDONE;CYP2D6;*10;CYP2D6*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*10;CYP2D6*10;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CARBOPLATIN;NRG3;G;rs1649942;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  OTHER:OVARIAN NEOPLASMS;
PACLITAXEL;NRG3;G;rs1649942;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  OTHER:OVARIAN NEOPLASMS;
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BEING OVERANTICOAGULATED NAN  NAN;
NAN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;STEROL/BILE ACID METABOLITES IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CYCLOPHOSPHAMIDE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;NAN;DISEASE;ANXIETY DISORDERS NAN  NAN;
PACLITAXEL;NAT2;AG + GG;rs1208;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;NAT2;AG + GG;rs1208;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*4;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*5;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
NEMONAPRIDE;ANKK1;A;rs1800497;TOXICITY;INCREASED;NAN;SIDE EFFECT;PROLACTIN CONCENTRATIONS IN WOMEN WITH  OTHER:SCHIZOPHRENIA;
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLC19A1;TT;rs1051266;OTHER;INCREASED;NAN;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;NAN;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
FLUVOXAMINE;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;NAN;PK;AREAS UNDER THE SERUM CONCENTRATION-TIME CURVE IN HEALTHY INDIVIDUALS  NAN;
METHOTREXATE;GGH;AA;rs3758149;METABOLISM/PK;DECREASED;NAN;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
RISPERIDONE;DRD2;C;rs1799978;TOXICITY;INCREASED;RISK;DISEASE;HYPERPROLACTINEMIA NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
RISPERIDONE;ANKK1;AA + AG;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HYPERPROLACTINEMIA NAN  NAN;
MYCOPHENOLATE MOFETIL;IMPDH2;G;rs11706052;OTHER;INCREASED;NAN;OTHER;INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TREATMENT INTERRUPTION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPIRIN;CYP2C19;*2/*2 + *1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
ASPIRIN;CYP2C19;*2/*2 + *1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
MYCOPHENOLATE MOFETIL;SLCO1B3;G;rs4149117;METABOLISM/PK;DECREASED;NAN;PK;DOSE-NORMALIZED  CMAX AND DOSE-NORMALIZED  AUC0TO12 H IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTS;
ASPIRIN;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
ASPIRIN;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
INDINAVIR;UGT1A1;*6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
INDINAVIR;UGT1A1;*6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
INDINAVIR;UGT1A1;*6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ANASTROZOLE;ABCB1;AA;rs1045642;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;ARTHRALGIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;OTHER;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
WARFARIN;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1 IN CHILDREN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1 IN CHILDREN  NAN;
NAN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS IN MEN  NAN;
MERCAPTOPURINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;
FLECAINIDE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE IN HEALTHY INDIVIDUALS  NAN;
FLECAINIDE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE IN HEALTHY INDIVIDUALS  NAN;
ETHANOL;ALDH2;GG;rs671;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
DIDANOSINE;XDH;AA;rs1429376;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;
DIDANOSINE;XDH;AA;rs1429376;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DAUNORUBICIN;SZRD1;T;rs6603859;OTHER;DECREASED;NAN;PK;IC50 NAN  NAN;
DAUNORUBICIN;SZRD1;T;rs6603859;METABOLISM/PK;DECREASED;NAN;PK;IC50 NAN  NAN;
DIDANOSINE;NT5C2;CC + CT;rs11598702;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;
DIDANOSINE;NT5C2;CC + CT;rs11598702;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
DIDANOSINE;XDH;AA;rs1594160;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;
DIDANOSINE;XDH;AA;rs1594160;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;CYP2C19;*6;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*6;CYP2C19*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
DAUNORUBICIN;;GG;rs7929521;OTHER;INCREASED;NAN;PK;IC50 NAN  NAN;
DAUNORUBICIN;;GG;rs7929521;METABOLISM/PK;INCREASED;NAN;PK;IC50 NAN  NAN;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*37;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
AZACITIDINE;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MYELODYSPLASTIC SYNDROMES;
DAUNORUBICIN;MAN1B1;T;rs3750518;OTHER;INCREASED;NAN;PK;IC50 NAN  NAN;
DAUNORUBICIN;MAN1B1;T;rs3750518;METABOLISM/PK;INCREASED;NAN;PK;IC50 NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1XN;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*2XN;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*6;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*7;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
DIDANOSINE;NT5C2;CG + GG;rs11191561;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;
DIDANOSINE;NT5C2;CG + GG;rs11191561;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;*01:02;HLA-DQA1*01:02;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
IGURATIMOD;CYP2C19;A;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CYCLOSPORINE;CYP3A4;*1/*22;CYP3A4*1;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
CYCLOSPORINE;CYP3A4;*1/*22;CYP3A4*22;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
PHENYTOIN;HLA-C;*14:02;HLA-C*14:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-C;*14:02;HLA-C*14:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-B;*56:02;HLA-B*56:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*56:02;HLA-B*56:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
NICOTINE;CYP2A6;AT + TT;rs1801272;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
GEFITINIB;EGFR;(CA)16/(CA)16;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;
NAN;NAT1;*11B/*4;NAT1*4;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*11B/*4;NAT1*11B;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3A;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*21;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*32;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*33;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*34;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*3A;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*3C;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*21;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*32;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*33;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*34;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE CURVE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE CURVE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE CURVE IN HEALTHY INDIVIDUALS  NAN;
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANASTROZOLE;CYP19A1;AA;rs727479;EFFICACY;INCREASED;NAN;OTHER;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUVASTATIN;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
EFAVIRENZ;CYP2B6;*18/*18;CYP2B6*18;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CYCLOPHOSPHAMIDE;NQO2;C;rs1143684;EFFICACY;NAN;NAN;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;NQO2;C;rs1143684;EFFICACY;NAN;NAN;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;CYP2C8*1;METABOLISM/PK;DECREASED;NAN;PK;M-III:PIOGLITAZONE AUC0-48 RATIO AND M-III:M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;CYP2C8*2;METABOLISM/PK;DECREASED;NAN;PK;M-III:PIOGLITAZONE AUC0-48 RATIO AND M-III:M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
DICLOFENAC;UGT2B7;T;rs7668258;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS;
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;RISK;OTHER;STROKE;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;RISK;OTHER;REVASCULARIZATION OR DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER;STROKE;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER;REVASCULARIZATION OR DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
IBUPROFEN;CYP2C8;*1/*2;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;
IBUPROFEN;CYP2C8;*1/*2;CYP2C8*2;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
ASPIRIN;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH;
ASPIRIN;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP IN PEOPLE WITH  OTHER:DRUG-ELUTING STENTS;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP IN PEOPLE WITH  OTHER:DRUG-ELUTING STENTS;
NAN;IRS1;C;rs1801123;OTHER;NAN;NAN;OTHER;LYMPH NODE INVOLVEMENT IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ESTRADIOL;;A;rs1864729;OTHER;INCREASED;NAN;OTHER;PLASMA LEVEL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;MEDIAN SURVIVAL TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
CARBIMAZOLE;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
METHIMAZOLE;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
PROPYLTHIOURACIL;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOMYOPATHIES IN CHILDREN WITH  OTHER:NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOMYOPATHIES IN CHILDREN WITH  OTHER:NEOPLASMS;
NAN;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;NAN;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
CITALOPRAM;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
DICLOFENAC;ABCC2;T;rs717620;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
ANTIARRHYTHMICS;;GG;rs10033464;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUCCESSFUL RHYTHM CONTROL IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
CLASS I AND III;;GG;rs10033464;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUCCESSFUL RHYTHM CONTROL IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
CARBIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
HYDRALAZINE;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:HYPERTENSION;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;BETTER CLINICAL RESPONSE IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN IN CHILDREN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN IN CHILDREN  NAN;
RIFAMPIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1XN;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*3;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*4;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*5;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*6;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;
NAN;IGFBP3;T;rs2854744;OTHER;NAN;NAN;OTHER;TUMOR SIZE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS NAN  NAN;
NEVIRAPINE;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS NAN  NAN;
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
PAROXETINE;CYP2D6;*4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
NAN;GSTM3;TC/TC + TC/TCCTC;rs36120609;OTHER;INCREASED;LIKELIHOOD;OTHER;METASTATIC NEOPLASM IN CHILDREN WITH  OTHER:OSTEOSARCOMA;
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;OTHER;NAN;NAN;SIDE EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:HEPATITIS;
RIBAVIRIN;ITPA;CC;rs1127354;OTHER;NAN;NAN;SIDE EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:HEPATITIS;
TELAPREVIR;ITPA;CC;rs1127354;OTHER;NAN;NAN;SIDE EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:HEPATITIS;
CARBOPLATIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
THIOTEPA;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
NAN;IFNL3;TT;rs8099917;NAN;INCREASED;NAN;OTHER;BASELINE VIRAL LOAD IN PEOPLE WITH  DISEASE:HEPATITIS;
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;CYP2C8*3;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;CYP2D6;*3/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*3/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*3/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
HEPARIN;HLA-DRB3;*01:01;HLA-DRB3*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEPARIN-INDUCED THROMBOCYTOPENIA NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RISK;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RISK;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN  NAN;
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;RACEMIC;
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;S-IBUPROFEN AND R-IBUPROFEN METABOLISM;
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;RACEMIC;
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;S-IBUPROFEN AND R-IBUPROFEN METABOLISM;
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
TENOXICAM;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
TENOXICAM;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
TENOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
TENOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
LAMIVUDINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
LAMIVUDINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
STAVUDINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
STAVUDINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ZIDOVUDINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ZIDOVUDINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TAMOXIFEN;CYP2D6;;CYP2D6 LOW ACTIVITY;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
PIROXICAM;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*4;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*9;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*10;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;
ASPIRIN;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
ASPIRIN;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
LUMIRACOXIB;HLA-DQA1;*01:02;HLA-DQA1*01:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
LUMIRACOXIB;HLA-DQA1;*01:02;HLA-DQA1*01:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
PAROXETINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
IBUPROFEN;CYP2C9;*1/*2;CYP2C9*1;OTHER;DECREASED;NAN;OTHER;INOS EXPRESSION IN HEALTHY INDIVIDUALS  NAN;
IBUPROFEN;CYP2C9;*1/*2;CYP2C9*2;OTHER;DECREASED;NAN;OTHER;INOS EXPRESSION IN HEALTHY INDIVIDUALS  NAN;
IRINOTECAN;UGT1A6;A;rs2070959;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*3;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IMATINIB;EGFR;CC;rs2072454;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIORBITAL EDEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
PIROXICAM;CYP2C9;*1/*2;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
PIROXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
PIROXICAM;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
GEFITINIB;CYP2D6;*10/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP2D6;*10/*10;CYP2D6*114;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2A;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CITALOPRAM;CYP2D6;A;rs1065852;OTHER;NAN;NAN;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;A;rs1065852;OTHER;NAN;NAN;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN MEN WITH  DISEASE:ESSENTIAL HYPERTENSION;
ASPIRIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ASPIRIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;
ASPIRIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ASPIRIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;
NAN;CYP2D6;*2xN;CYP2D6*2XN;OTHER;INCREASED;RISK;DISEASE;SUICIDE IN PEOPLE WITH  OTHER:GENE DUPLICATION/MULTIDUPLICATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN WITH  DISEASE:NEOPLASMS;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
NAN;CYP2C19;*2/*2;CYP2C19*1;OTHER;DECREASED;SEVERITY;DISEASE;DEPRESSION NAN  NAN;
NAN;CYP2C19;*2/*2;CYP2C19*2;OTHER;DECREASED;SEVERITY;DISEASE;DEPRESSION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
IRINOTECAN;UGT1A9;C;rs11692021;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METOPROLOL;ADRB2;CG;rs1042714;TOXICITY;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDES IN PEOPLE WITH  DISEASE:HYPERTENSION;
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;
TAMOXIFEN;IGF1R;GG;rs2016347;EFFICACY;INCREASED;RISK;DISEASE;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN CHILDREN WITH  DISEASE:NEOPLASMS;
NAN;CYP2D6;*1xN;CYP2D6*1XN;OTHER;INCREASED;RISK;DISEASE;SUICIDE IN PEOPLE WITH  OTHER:GENE DUPLICATION/MULTIDUPLICATION;
ALLOPURINOL;HLA-B;*48:01;HLA-B*48:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;
PACLITAXEL;CYP2C8;C;rs10509681;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SARCOMA;
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SOFT TISSUE NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CITALOPRAM;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN HEALTHY INDIVIDUALS  NAN;
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*2;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN HEALTHY INDIVIDUALS  NAN;
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*4;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN HEALTHY INDIVIDUALS  NAN;
CAFFEINE;ADORA2A;TTTTTTT/TTTTTTT;rs35060421;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;HLA-DRB1;*14:01;HLA-DRB1*14:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;
ALLOPURINOL;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ZONISAMIDE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;NAN;NAN;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENOBARBITAL;HLA-B;*51:01;HLA-B*51:01;TOXICITY;NAN;NAN;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;OTHER;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;OTHER;POSTOPERATIVE;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;OTHER;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;OTHER;POSTOPERATIVE;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
LAMIVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;NAN;NAN;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;NAN;NAN;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
STAVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;NAN;NAN;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;TIME TO ACHIEVE THERAPEUTIC WINDOW IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;TIME TO ACHIEVE THERAPEUTIC WINDOW IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
METHOTREXATE;ABCC2;AG + GG;rs3740065;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HYPERURICEMIA;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
METOPROLOL;ADRB2;CC;rs1042714;TOXICITY;DECREASED;NAN;SIDE EFFECT;TOTAL CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERTENSION;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
METHOTREXATE;ABCC4;GG + GT;rs9516519;METABOLISM/PK;DECREASED;NAN;PK;PLASMA LEVEL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
THIOGUANINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;S-CIT SERUM CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;S-CIT SERUM CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;S-CIT SERUM CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;LOWER FINAL DAILY DOSE;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;LOWER FINAL DAILY DOSE;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*3;CYP2C19*3;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
LISINOPRIL;MMP3;del/del;rs35068180;EFFICACY;DECREASED;RISK;SIDE EFFECT;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*1;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*2;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*3;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:NEOPLASMS;
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:PAIN;
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:NEOPLASMS;
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:PAIN;
DIRECT ACTING ANTIVIRALS;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN CHILDREN  NAN;
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*2;CYP2C19*2;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*2;CYP2C19*3;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ESCITALOPRAM;CYP2C19;*2;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;DECREASED;NAN;PK;DEMETHYLATION CLEARANCE OF DESMETHYLCITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LONG QT SYNDROME IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LONG QT SYNDROME IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
EFAVIRENZ;CYP2B6;*9;CYP2B6*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*9;CYP2B6*9;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CAPECITABINE;DPYD;CT;rs56038477;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs56038477;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
IRINOTECAN;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FOLFOX;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
METHOTREXATE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;CYP2B6*1;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;CYP2B6*9;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:NEOPLASMS;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
EGFR INHIBITORS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ANTINEOPLASTIC AGENTS;UGT2B15;*2/*2 + *1/*2;UGT2B15*1;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;UGT2B15;*2/*2 + *1/*2;UGT2B15*2;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;UGT2B15*1;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;UGT2B15*2;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EGFR INHIBITORS;HLA-A;*03:01;HLA-A*03:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;NAN;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
DOCETAXEL;SLCO1B3;A;rs3834935;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;SLCO1B3;A;rs3834935;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CARBAMAZEPINE;GABRA1;GG;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;GABRA1;GG;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;GABRA1;GG;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*2;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*4;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ETHAMBUTOL;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;
AMOXICILLIN;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CITALOPRAM;;A;rs1074145;OTHER;NAN;NAN;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;;A;rs1074145;OTHER;NAN;NAN;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*06:03;HLA-DQB1*06:03;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTINEOPLASTIC AGENTS;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DRB1;*15:03;HLA-DRB1*15:03;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
IMATINIB;CYP1A2;AA;rs11636419;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIORBITAL EDEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ETHANOL;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*17;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*17;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION NAN  NAN;
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CARBAMAZEPINE;GABRA1;G;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;GABRA1;G;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;GABRA1;G;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*1;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*3;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*4;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*5;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*6;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*10;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*17;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*41;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;
BUCILLAMINE;HLA-DRB1;*08:02;HLA-DRB1*08:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROTEINURIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH NAN  NAN;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
BUCILLAMINE;HLA-DQB1;*04:02;HLA-DQB1*04:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROTEINURIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:LYMPHOMA;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*11;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;NANDISEASE;ACUTE CORONARY SYNDROME;PEOPLE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;NANDISEASE;ACUTE CORONARY SYNDROME;PEOPLE
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;OTHER;HIGH PLATELET REACTIVITY (HPR) NAN  NAN;
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
ASPIRIN;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
ASPIRIN;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HLA-DRB5;*02:02;HLA-DRB5*02:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ASPIRIN;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
ASPIRIN;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
PRASUGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
PRASUGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;JAUNDICE NAN  NAN;
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;JAUNDICE NAN  NAN;
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE);OTHER;NAN;NAN;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531C;OTHER;NAN;NAN;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;OTHER;NAN;NAN;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMOXICILLIN;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
CLAVULANATE;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA NAN  NAN;
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA NAN  NAN;
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION NAN  NAN;
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION NAN  NAN;
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
TICLOPIDINE;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*41;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
TICLOPIDINE;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
ATORVASTATIN;LEPR;GG;rs1805094;OTHER;INCREASED;NAN;OTHER;BONE MARROW DENSITY IN THE LUMBAR SPINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
TICLOPIDINE;HLA-DQB1;*06:04;HLA-DQB1*06:04;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
TICLOPIDINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;MYELOID;
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;ACUTE;
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;MYELOID;
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;ACUTE;
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;MYELOID;
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;ACUTE;
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;MYELOID;
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;ACUTE;
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;MYELOID;
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;ACUTE;
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;MYELOID;
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;ACUTE;
TICLOPIDINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
COCAINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS IN WOMEN  NAN;
ETHANOL;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS IN WOMEN  NAN;
NICOTINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS IN WOMEN  NAN;
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTIPSYCHOTICS;COMT;A;rs4680;OTHER;INCREASED;NAN;OTHER;METHYLATION AT SITES 1 AND 2 IN THE COMT PROMOTER IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ASPIRIN;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASPIRIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*5B;CYP2E1*1A;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*5B;CYP2E1*5B;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ASPIRIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;DECREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
FLUTICASONE PROPIONATE;CD14, TMCO6;AA + AG;rs2569190;OTHER;DECREASED;NAN;EFFICACY;FEV1/FVC RATIO IN CHILDREN WITH  DISEASE:ASTHMA;
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
EFAVIRENZ;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
ISONIAZID;GSTT1;;GSTT1 NULL;METABOLISM/PK;DECREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;GSTT1;;GSTT1 NULL;METABOLISM/PK;DECREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ISONIAZID;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ALLOPURINOL;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;
ETHAMBUTOL;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
METHADONE;CYP3A4;C;rs3735451;OTHER;INCREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
IRINOTECAN;UGT1A1;*1/*27;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*27;UGT1A1*27;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOZAPINE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PHENYTOIN;HLA-B;*13:01;HLA-B*07:02;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;NAN;NAN;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
NAN;TRPA1;CT + TT;rs920829;OTHER;INCREASED;LIKELIHOOD;DISEASE;PAIN IN PEOPLE WITH  DISEASE:ANEMIA;
NAN;TRPA1;CT + TT;rs920829;OTHER;INCREASED;LIKELIHOOD;DISEASE;SICKLE CELL;
ETHANOL;ALDH2;A;rs671;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
NAN;NAT2;;NAT2 DEFICIENCY;OTHER;NAN;NAN;DISEASE;INSULIN RESISTANCE NAN  NAN;
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
RITODRINE;CACNA1C;AA + AG;rs10774053;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  DISEASE:PREMATURE BIRTH;
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;rs1799752;EFFICACY;NAN;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION;
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;rs1799752;EFFICACY;NAN;NAN;EFFICACY;END-SYSTOLIC AND END-DIASTOLIC VOLUME IN PEOPLE WITH  OTHER:CHRONIC HEART FAILURE;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
WARFARIN;APOE;TT;rs429358;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;APOE;CC;rs7412;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN D-DIMER LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN D-DIMER LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
TIMOLOL;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;INCREASED;NAN;PK;PLASMA TIMOLOL CONCENTRATION AND EXCERICE HEART RATE REDUCTION IN MEN  NAN;
TIMOLOL;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;NAN;PK;PLASMA TIMOLOL CONCENTRATION AND EXCERICE HEART RATE REDUCTION IN MEN  NAN;
LANSOPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZER;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
AMOXICILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
RABEPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZER;EFFICACY;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
NAN;AREG;A;rs1615111;OTHER;DECREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
CISPLATIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
CISPLATIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:STOMACH NEOPLASMS;
EPIRUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
EPIRUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
FLUOROURACIL;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:STOMACH NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN IL-6 LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN IL-6 LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN CRP LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN CRP LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
AMOXICILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLOPIDOGREL;CYP2C9;*2/*2;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C9;*2/*2;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;DECREASED;NAN;SIDE EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
ETHANOL;CYP2E1;T;rs2031920;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
CISPLATIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;OTHER;INCREASED;LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:ATRIAL FLUTTER;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:VENOUS THROMBOSIS;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:ATRIAL FLUTTER;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:VENOUS THROMBOSIS;
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;TOLTERODINE EXPOSURE AND INCREASED ACTIVE METABOLITE (5-HM) CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;TOLTERODINE EXPOSURE AND INCREASED ACTIVE METABOLITE (5-HM) CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;TOLTERODINE EXPOSURE AND INCREASED ACTIVE METABOLITE (5-HM) CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;
AMOXICILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:EPILEPSY;
ANASTROZOLE;CYP19A1;GG;rs1008805;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;ARTHRALGIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ACE INHIBITORS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
PLAIN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
OLANZAPINE;CYP3A5;*1/*1;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;CYP3A5;*1/*1;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;
CYCLOPHOSPHAMIDE;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;ATIC;AA;rs2177735;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ATIC;AA;rs2177735;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
LEVETIRACETAM;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:EPILEPSY;
ALLOPURINOL;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CYCLOPHOSPHAMIDE;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs6759892;DOSAGE;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs6759892;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs2070959;DOSAGE;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs2070959;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;
CYCLOPHOSPHAMIDE;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;MED12L, P2RY12;T/del;rs5853517;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
EXEMESTANE;;TT;rs16964189;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPIRIN;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
ASPIRIN;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CLOPIDOGREL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
PRASUGREL;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
PRASUGREL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ANTIPSYCHOTICS;INSIG2;CC;rs11123469;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;
FENOFIBRATE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
SERTRALINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TERBINAFINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TICLOPIDINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CARBAMAZEPINE;ABCB1;T;rs2032582;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;ABCB1;T;rs2032582;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;ABCB1;T;rs2032582;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;CYP4F2;*3;CYP4F2*1;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;CYP4F2;*3;CYP4F2*3;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ASPIRIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTRITIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
ASPIRIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTRITIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA METOPROLOL CONCENTRATIONS NAN  NAN;
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA METOPROLOL CONCENTRATIONS NAN  NAN;
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
ATAZANAVIR;UGT1A1;*28;UGT1A1*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;ACE2;C;rs2285666;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 NAN  NAN;
"""ACE INHIBITORS";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;
"PLAIN""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""BETA BLOCKING AGENTS""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""CALCIUM CHANNEL BLOCKERS""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIGOXIN""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIURETICS""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;
IVACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;NAN;SIDE EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;
TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;NAN;SIDE EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;
PAMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;NAN;NAN;DISEASE;HEMOLYSIS IN  OTHER:G6PD DEFICIENT MICE;
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;OTHER;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;OTHER;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;NAN;NAN;DISEASE;HEMOLYSIS IN  OTHER:G6PD DEFICIENT MICE;
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
HMG-COA_REDUCTASE_INHIBITORS;;A;rs3764261;EFFICACY;DECREASED;NAN;EFFICACY;PROTECTION AGAINST MYOCARDIAL INFARCTION NAN  NAN;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;SIDE EFFECT;TIME BELOW THERAPEUTIC RANGE NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;SIDE EFFECT;TIME BELOW THERAPEUTIC RANGE NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;SIDE EFFECT;TIME BELOW THERAPEUTIC RANGE NAN  NAN;
OSIMERTINIB;CYP2A6;CC;rs28399433;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAZOPANIB;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
PEMETREXED;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PENICILLIN G;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
PENICILLIN V;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
ETHANOL;GHSR;AG;rs2948694;OTHER;NAN;NAN;OTHER;WEIGHT NAN  NAN;
OPIOIDS;OPRM1;AG + GG;rs495491;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;
NICOTINE;CYP2A6;*46/*46;CYP2A6*1;NAN;INCREASED;NAN;OTHER;CIGARETTES PER DAY NAN  NAN;
NICOTINE;CYP2A6;*46/*46;CYP2A6*46;NAN;INCREASED;NAN;OTHER;CIGARETTES PER DAY NAN  NAN;
OPIOIDS;OPRM1;AA + AG;rs10457090;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;STEADY STATE CONCENTRATION PER DOSAGE IN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;STEADY STATE CONCENTRATION PER DOSAGE IN  DISEASE:EPILEPSY;
ALLOPURINOL;HLA-B;*58:01/*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ARTHRITIS;
ALLOPURINOL;HLA-B;*58:01/*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;GOUTY;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;
CARBAMAZEPINE;SCN2A;A;rs17183814;EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;SCN2A;A;rs17183814;EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4 NAN  NAN;
ATORVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
PRAVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
SIMVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
METHOTREXATE;TYMS;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*6;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*18;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*18;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DOCETAXEL;CYP2A6;*4/*4;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
DOCETAXEL;CYP2A6;*4/*4;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TEGAFUR;CYP2A6;*4/*4;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TEGAFUR;CYP2A6;*4/*4;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
CISPLATIN;ERCC2;T;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
COCAINE;SLC6A3;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;rs3836790;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;NAN;NAN;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;NAN;NAN;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT NAN  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
PHENYTOIN;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;CYP2D6;*1/*4;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH IN  SIDE EFFECT:NEUROLOGICAL PATIENTS;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH IN  SIDE EFFECT:NEUROLOGICAL PATIENTS;
IBUPROFEN;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;DURATION OF INHIBITION OF PROSTANOIDS IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;THE MAXIMAL ELIMINATION RATE (VMAX) IN  DISEASE:EPILEPSY;
ACETAMINOPHEN;CYP2E1;*1/*5B;CYP2E1*1;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION RATE IN PEOPLE WITH  DISEASE:ALCOHOLIC LIVER DISEASES;
ACETAMINOPHEN;CYP2E1;*1/*5B;CYP2E1*5B;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION RATE IN PEOPLE WITH  DISEASE:ALCOHOLIC LIVER DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;NAN;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;NAN;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*4;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
MERCAPTOPURINE;CYP2A7;C;rs73032311;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;
BUPROPION;CYP2B6;*18;CYP2B6*18;METABOLISM/PK;DECREASED;NAN;PK;HYDROXYBUPROPION CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;CUTANEOUS REACTIONS IN  DISEASE:EPILEPSY;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;CUTANEOUS REACTIONS IN  DISEASE:EPILEPSY;
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS NAN  NAN;
NAN;NAT1;*10/*11A;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*10/*11A;NAT1*11A;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
NAN;NAT1;*10/*4;NAT1*4;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*10/*4;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
ISONIAZID;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PACLITAXEL;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;NAN;PK;CLERANCE OF PACLITAXEL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
BUPROPION;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;NAN;PK;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO IN HEALTHY INDIVIDUALS  NAN;
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;NAN;PK;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION NAN  NAN;
IRINOTECAN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED;RISK;DISEASE;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
RALTITREXED;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED;RISK;DISEASE;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION NAN  NAN;
TEMSIROLIMUS;NR1I2;AG + GG;rs6785049;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
NAN;NAT1;*11B/*3;NAT1*3;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*11B/*3;NAT1*11B;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*10/*10;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
DAUNORUBICIN;NRP2;C;rs10932125;DOSAGE;INCREASED;NAN;PK;IC50 NAN  NAN;
DAUNORUBICIN;NRP2;C;rs10932125;METABOLISM/PK;INCREASED;NAN;PK;IC50 NAN  NAN;
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
METOPROLOL;CYP2D6;del/del;rs5030655;OTHER;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF METOPROLOL NAN  NAN;
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;NAN;NAN;NAN;EFFICACY;LACK OF REMISSION AND LACK OF RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION AFTER THE SECOND SWITCH IN TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;C;rs1105879;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ISONIAZID;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRIDOXAL PHOSPHATE;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ATENOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN HEALTHY INDIVIDUALS  NAN;
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/(E)-10- OH-AT RATIO NAN  NAN;
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/(E)-10- OH-AT RATIO NAN  NAN;
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE/(E)-10-OH-NT RATIO NAN  NAN;
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE/(E)-10-OH-NT RATIO NAN  NAN;
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*37;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;
BENZENE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOTOXICITY NAN  NAN;
ATAZANAVIR;TPH2;TT;rs4570625;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;TPH2;TT;rs4570625;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;
METHOTREXATE;DHFR;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;EFFICACY;DECREASED;NAN;PK;PLASMA CONCENTRATION OF EFAVIRENZ IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION OF EFAVIRENZ IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTITHYROID PREPARATIONS;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;
TEGAFUR;CYP2A6;*1;CYP2A6*1;OTHER;INCREASED;NAN;PK;PLASMA FLUOROURACIL IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;CYP2A6;*1;CYP2A6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA FLUOROURACIL IN PEOPLE WITH  DISEASE:NEOPLASMS;
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE DRUG REACTIONS IN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE DRUG REACTIONS IN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE DRUG REACTIONS IN  DISEASE:EPILEPSY;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LIVER INJURY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*18;TOXICITY;INCREASED;RISK;SIDE EFFECT;LIVER INJURY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ANTIEPILEPTICS;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
ANTIEPILEPTICS;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1;EFFICACY;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1;METABOLISM/PK;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*2;EFFICACY;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*2;METABOLISM/PK;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2;UGT1A3*1;EFFICACY;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2;UGT1A3*2;EFFICACY;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
DOXEPIN;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;HOSPITAL STAY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MERCAPTOPURINE;COMT;A;rs4680;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;NAN;EFFICACY;MEAN ABSOLUTE DIFFERENCE IN HBA1C IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
NORTRIPTYLINE;CYP2D6;*1/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;
NORTRIPTYLINE;CYP2D6;*1/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;RELATIVE BIOAVAILABILITY OF PRAVASTATIN IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;RELATIVE BIOAVAILABILITY OF PRAVASTATIN IN HEALTHY INDIVIDUALS  NAN;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
NAN;CYP2C19;*17;CYP2C19*1;OTHER;NAN;RISK;DISEASE;PEPTIC ULCER DISEASE NAN  NAN;
NAN;CYP2C19;*17;CYP2C19*17;OTHER;NAN;RISK;DISEASE;PEPTIC ULCER DISEASE NAN  NAN;
CAFFEINE;ADORA2A;TT;rs5751876;OTHER;INCREASED;NAN;SIDE EFFECT;ANXIETY IN HEALTHY INDIVIDUALS  NAN;
METHOTREXATE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;SEVERITY;DISEASE;RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE) NAN  NAN;
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE) NAN  NAN;
NEVIRAPINE;ABCC10;CC;rs2125739;EFFICACY;INCREASED;LIKELIHOOD;PK;LOWER NEVIRAPINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;ABCC10;CC;rs2125739;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;LOWER NEVIRAPINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARBAMAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN) NAN  NAN;
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;TOXICITY;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;METABOLISM/PK;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;METABOLISM/PK;NAN;NAN;SIDE EFFECT;TYPE 2;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY SYNDROME IN CHILDREN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;EFFICACY;NAN;NAN;EFFICACY;ENHANCED RESPONSE TO CLOPIDOGREL (AS MEASURED BY INHIBITION OF ADP-INDUCED PLATELET AGGREGATION) NAN  NAN;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;PHENYTOIN TOXICITY IN  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;PHENYTOIN TOXICITY IN  DISEASE:EPILEPSY;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;
NAN;NAT1;*10/*11B;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*10/*11B;NAT1*11B;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
NAN;NAT1;*11A/*4;NAT1*4;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
NAN;NAT1;*11A/*4;NAT1*11A;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4 NAN  NAN;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;NAN;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;NAN;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*37;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;*1/*13;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
WARFARIN;CYP2C9;*1/*13;CYP2C9*13;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;INCREASED;RISK;DISEASE;BRADYCARDIA NAN  NAN;
METOPROLOL;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED;RISK;DISEASE;BRADYCARDIA NAN  NAN;
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
ASPIRIN;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE AFTER ADJUSTMENT FOR VKORC1*1173 NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
DOXEPIN;CYP2D6;*3/*5;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
DOXEPIN;CYP2D6;*3/*5;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
HALOPERIDOL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN MEN WITH  DISEASE:SCHIZOPHRENIA;
ATORVASTATIN;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCLE EFFECTS NAN  NAN;
DOXEPIN;CYP2D6;*4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
DOXEPIN;CYP2D6;*4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;*1/*13;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;
WARFARIN;CYP2C9;*1/*13;CYP2C9*13;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*14;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
WARFARIN;CYP2C9;*1/*14;CYP2C9*14;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT NAN  NAN;
CLOPIDOGREL;CYP2B6;*5;CYP2B6*5;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;CMAX AND AUC OF VENLAFAXINE IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUE NAN  NAN;
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUE NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
VENLAFAXINE;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;CMAX AND AUC OF VENLAFAXINE IN HEALTHY INDIVIDUALS  NAN;
VENLAFAXINE;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;CMAX AND AUC OF VENLAFAXINE IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;*1/*14;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;
WARFARIN;CYP2C9;*1/*14;CYP2C9*14;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;
PHENPROCOUMON;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING A STABLE DOSE NAN  NAN;
PHENPROCOUMON;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING A STABLE DOSE NAN  NAN;
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*10;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS IN PEOPLE WITH  DISEASE:ULCER;
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS IN PEOPLE WITH  DISEASE:ULCER;
PAROXETINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
PAROXETINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;
TAMOXIFEN;CYP2D6;*6/*7;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*6/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TAMOXIFEN;CYP2D6;*3/*6;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*4;CYP2D6*3;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*4;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*4;CYP2D6*4;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
CLOMIPRAMINE;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CLOMIPRAMINE;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO NAN  NAN;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;NAN;NAN;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO NAN  NAN;
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;NAN;NAN;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO NAN  NAN;
PAROXETINE;CYP2D6;*1/*1 + *1/*41;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
PAROXETINE;CYP2D6;*1/*1 + *1/*41;CYP2D6*41;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*2/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*2/*10;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*2/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
COTININE;CYP2A6;*1/*1;CYP2A6*1;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;
COTININE;CYP2A6;*1/*1;CYP2A6*2;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;
COTININE;CYP2A6;*1/*1;CYP2A6*9;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;
COTININE;CYP2A6;*1/*1;CYP2A6*17;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;
COTININE;CYP2A6;*1/*1;CYP2A6*20;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
PAROXETINE;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
CLOMIPRAMINE;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CLOMIPRAMINE;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PAROXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*36;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*36;CYP2D6*36;METABOLISM/PK;DECREASED;NAN;PK;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
NAN;UGT1A1;T;rs34946978;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;
NAN;UGT1A1;T;rs34946978;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;AUC;
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;AUC;
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;CYP2C8*4;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
PYRIMIDINE ANALOGUES;MIR27A;CC + CT;rs895819;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;INCREASED;NAN;PK;PLASMA RATIO CITALOPRAM (CIT)/N-DESMETHYLCIT (DCIT) IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
CLOPIDOGREL;PON1;C;rs662;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;
TENOXICAM;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;AUC AND HALF-LIFE TIME (T1/2) IN HEALTHY INDIVIDUALS  NAN;
TENOXICAM;CYP2C9;*3;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;AUC AND HALF-LIFE TIME (T1/2) IN HEALTHY INDIVIDUALS  NAN;
TENOXICAM;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;AUC AND HALF-LIFE TIME (T1/2) IN HEALTHY INDIVIDUALS  NAN;
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*3;TOXICITY;DECREASED;NAN;SIDE EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CLOPIDOGREL;P2RY12;A;rs2046934;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ANTIEPILEPTICS;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
ASPIRIN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHMA NAN  NAN;
SULFONAMIDES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
SULFONAMIDES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
UREA DERIVATIVES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
UREA DERIVATIVES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
LUMACAFTOR;CFTR;del/del;rs113993960;TOXICITY;INCREASED;NAN;EFFICACY;CHANGE IN SWEAT CHLORIDE IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ABORTION;
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SPONTANEOUS IN WOMEN  NAN;
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:LEPROSY;
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA LEVELS OF MORPHINE;
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;PLASMA LEVELS OF MORPHINE;
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE IN HEALTHY INDIVIDUALS  NAN;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;
BOSENTAN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
BOSENTAN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*3;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*4;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*5;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;
NAN;CYP1B1;CC + CG;rs1056836;NAN;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
NAN;CYP1B1;CC + CG;rs1056836;NAN;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
TETRABENAZINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;NAN;NAN;EFFICACY;LESS ROBUST TREATMENT RESPONSE NAN  NAN;
WARFARIN;CYP4F2;*3;CYP4F2*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP4F2;*3;CYP4F2*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES NAN  NAN;
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES NAN  NAN;
CLOPIDOGREL;PTGS1;T;rs1330344;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;NAN;SIDE EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE IN HEALTHY INDIVIDUALS  NAN;
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;NAN;SIDE EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;PRESENTATION IN THE NON-REPONDER GROUP IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;PRESENTATION IN THE NON-REPONDER GROUP IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PHENOBARBITAL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE DRUG REACTIONS IN CHILDREN  NAN;
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PRU IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PRU IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CARBAMAZEPINE;HLA-B;*07:02;HLA-B*07:02;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-B;*07:02;HLA-B*08:01;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
TRICHLOROETHYLENE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*3A;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*3C;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*3A/*3C;TPMT*3A;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TPMT;*3A/*3C;TPMT*3C;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;TPMT;*3A/*3C;TPMT*3A;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;TPMT;*3A/*3C;TPMT*3C;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ALLOPURINOL;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;
IRINOTECAN;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;
OSIMERTINIB;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;
OSIMERTINIB;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
MYCOPHENOLATE MOFETIL;CYP2C8;CC;rs11572076;TOXICITY;DECREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CLOZAPINE;HLA-DRB3;*02:02;HLA-DRB3*02:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MYCOPHENOLATE MOFETIL;UGT2B7;G;rs7438135;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOZAPINE;HLA-C;*07:01;HLA-C*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
PROPYLTHIOURACIL;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;
PLATINUM COMPOUNDS;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
PYRIMIDINE ANALOGUES;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:EPILEPSY;
CAPECITABINE;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
DOLASETRON;CYP2D6;*1/*1xN;CYP2D6*1;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:POSTOPERATIVE NAUSEA AND VOMITING;
DOLASETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:POSTOPERATIVE NAUSEA AND VOMITING;
CYCLOSPORINE;NFATC2;AA;rs6123048;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;NFATC2;AA;rs6123048;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2C8;*4;CYP2C8*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2C8;*4;CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CYP2C8;*4;CYP2C8*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CYP2C8;*4;CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP2C8;*4;CYP2C8*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP2C8;*4;CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
IFOSFAMIDE;ALDH1A1;AA;rs3764435;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;
IFOSFAMIDE;ALDH1A1;AA;rs3764435;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:SARCOMA;
ASPIRIN;CYP2C19;*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ASPIRIN;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CLOZAPINE;GSTT1;null/null;GSTT1 NON-NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;
CLOZAPINE;GSTT1;null/null;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;
HMG-COA_REDUCTASE_INHIBITORS;ADAMTS1;CC;rs402007;EFFICACY;NAN;NAN;EFFICACY;THE MOST BENEFIT FROM STATIN TREATMENT IN REDUCING THE RISK OF MYOCARDIAL INFARCTION NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NICOTINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*4;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CYP2A6;*1/*1;CYP2A6*1;TOXICITY;DECREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CYP2A6;*1/*1;CYP2A6*12;TOXICITY;DECREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;
ANTITHYROID PREPARATIONS;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS NAN  NAN;
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS NAN  NAN;
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;DISEASE;VIRUS DISEASES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE;VIRUS DISEASES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
GEFITINIB;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;DECREASED;RISK;EFFICACY;ALLOGRAFT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;RISK;EFFICACY;ALLOGRAFT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
LAMOTRIGINE;SCN1A;C;rs3812718;EFFICACY;INCREASED;NAN;EFFICACY;TONIC BLOCK OF NA(V) 1.1 CHANNELS NAN  NAN;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN KIDNEY MICROSOMES;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN KIDNEY MICROSOMES;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
PEMETREXED;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:MESOTHELIOMA;
METHOTREXATE;TYMS;del;rs11280056;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:PSORIASIS;
NAN;SLCO1B1;C;rs4149056;OTHER;DECREASED;NAN;OTHER;ERYTHROMYCIN TRANSPORT NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  OTHER:EPILEPSY;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MACULOPAPULAR EXANTHEMA NAN  NAN;
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;HLA-B*13:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PHENYTOIN;HLA-A;*03:01;HLA-A*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
ASPIRIN;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;THROMBOTIC DISEASE IN PEOPLE WITH  NAN;
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;THROMBOTIC DISEASE IN PEOPLE WITH  NAN;
BETA-LACTAM ANTIBACTERIALS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
PENICILLINS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
PROTON PUMP INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
PROTON PUMP INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ASPIRIN;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:HIGH ON-TREATMENT PLATELET REACTIVITY;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:HIGH ON-TREATMENT PLATELET REACTIVITY;
CYCLOSPORINE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ATENOLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
METOPROLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
ZOLEDRONATE;;CC;rs1152003;TOXICITY;INCREASED;RISK;DISEASE;OSTEONECROSIS IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ANTIDEPRESSANTS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
ANTIDEPRESSANTS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;
ANTIPSYCHOTICS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
ANTIPSYCHOTICS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;
ATORVASTATIN;HMGCR;T;rs17671591;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ANTIDEPRESSANTS;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
VORICONAZOLE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
VORICONAZOLE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
CARBOPLATIN;LIG3;T;rs1052536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
PACLITAXEL;LIG3;T;rs1052536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CYCLOSPORINE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ATORVASTATIN;HMGCR;T;rs10474433;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG-INDUCED LIVER INJURY NAN  NAN;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ATORVASTATIN;PCSK9;T;rs11591147;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"PENICILLINS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"PENICILLINS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""BETA-LACTAM ANTIBACTERIALS";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"PENICILLINS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""BETA-LACTAM ANTIBACTERIALS";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"PENICILLINS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""BETA-LACTAM ANTIBACTERIALS";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"PENICILLINS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MYOCARDIAL INFARCTION;
VALPROIC ACID;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:EPILEPSY;
VALPROIC ACID;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:EPILEPSY;
ATORVASTATIN;APOE;T;rs429358;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ENALAPRIL;;TT;rs495828;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN WOMEN WITH  DISEASE:HYPERTENSION;
RIBAVIRIN;ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
ENALAPRIL;;TT;rs495828;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
ATORVASTATIN;APOE;T;rs7412;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
NAN;GSTT1;;GSTT1 NON-NULL;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
NAN;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
NAN;GSTT1;;GSTT1 NULL;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
NAN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
SIMVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO DRUG IN HEALTHY INDIVIDUALS  NAN;
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"HYPONATREMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"HYPONATREMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"HYPONATREMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MACULOPAPULAR EXANTHEMA;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG HYPERSENSITIVITY;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ERYTHEMA MULTIFORME NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
NAN;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
NAN;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
NAN;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:DISCONTINUATION;
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HIV INFECTIOUS DISEASE;
CAPECITABINE;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO DRUG IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
CAPECITABINE;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);C.1236G>A (HAPB3);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);C.1236G>A (HAPB3);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
OSIMERTINIB;CYP2A6;*4;CYP2A6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
OSIMERTINIB;ABCG2;TT;rs2622604;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
L-ASPARAGINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDL-C IN WOMEN  NAN;
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN LDL-C IN MEN  NAN;
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
TRAMADOL;CYP2B6;;CYP2B6 POOR METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN;
TRAMADOL;CYP2B6;;CYP2B6 POOR METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2B6;;CYP2B6 POOR METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
TRAMADOL;CYP3A4;;CYP3A4 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;
TRAMADOL;CYP3A4;;CYP3A4 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP3A4;;CYP3A4 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
IRINOTECAN;HLA-B;C;rs9266271;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
ANTIINFLAMMATORY AGENTS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
NON-STEROIDS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
ANTIINFLAMMATORY AGENTS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
NON-STEROIDS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
NON-STEROIDS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
ATORVASTATIN;HMGCR;GG;rs3846662;EFFICACY;INCREASED;NAN;EFFICACY;LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IN BASAL STATE AND POSSIBLY IN RESPONSE TO ATORVASTATIN. IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:STROKE;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREMOR;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREMOR;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:CROHN DISEASE;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:AUTOIMMUNE HEPATITIS;
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING IN PEOPLE WITH  DISEASE:HEART FAILURE;
METOPROLOL;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING IN PEOPLE WITH  DISEASE:HEART FAILURE;
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;
FOLFIRI;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;ALOX5;T;rs1051713;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
ETOPOSIDE;;GG;rs6539870;OTHER;INCREASED;NAN;OTHER;SENSITIVITY TO ETOPOSIDE NAN  NAN;
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;EFFICACY;DECREASED;NAN;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"RECOMBINANT""";ITPA;CC;rs1127354;EFFICACY;DECREASED;NAN;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;DECREASED;NAN;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;STROKE NAN  NAN;
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;EFFICACY;NAN;NAN;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"RECOMBINANT""";ITPA;CC;rs1127354;EFFICACY;NAN;NAN;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;NAN;NAN;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ASPARAGINASE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;NAN;PK;ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
DESIPRAMINE;MC1R;G;rs2228478;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NAN;ABCB1;A;rs1045642;NAN;INCREASED;NAN;OTHER;LEVEL OF APOLIPOPROTEIN A1 NAN  NAN;
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED;NAN;EFFICACY;DOSE REQUIREMENT NAN  NAN;
ACENOCOUMAROL;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;DOSE REQUIREMENT NAN  NAN;
ACENOCOUMAROL;VKORC1;AA;rs9934438;TOXICITY;DECREASED;NAN;EFFICACY;DOSE REQUIREMENT NAN  NAN;
DESIPRAMINE;MC1R;A;rs2228479;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ETHAMBUTOL;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CARBAMAZEPINE;LTA, TNF;A;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SERIOUS HYPERSENSITIVITY NAN  NAN;
ASPARAGINASE;IL16;GG + GT;rs11556218;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOTIC DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
GEMCITABINE;SLC29A1;CT + TT;rs9394992;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DOCETAXEL;SPG7;A;rs2292954;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;SPG7;A;rs2292954;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
ANTINEOPLASTIC AGENTS;CTH;CC;rs648743;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOCETAXEL;ABCC6;C;rs2238472;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;ABCC6;C;rs2238472;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
DOCETAXEL;ATP7A;G;rs2227291;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;ATP7A;G;rs2227291;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ACENOCOUMAROL;CYP4F2;CC;rs2108622;OTHER;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP4F2;CC;rs2108622;METABOLISM/PK;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP4F2;CT;rs2108622;OTHER;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP4F2;CT;rs2108622;METABOLISM/PK;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENT IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
ACENOCOUMAROL;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;NAN;EFFICACY;DOSAGE REQUIREMENT IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP4F2;CC;rs2108622;EFFICACY;DECREASED;NAN;EFFICACY;DOSAGE REQUIREMENT IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;CYP4F2;CC;rs2108622;TOXICITY;DECREASED;NAN;EFFICACY;DOSAGE REQUIREMENT IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;SLCO1B1;AA + AG;rs4149015;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
NAN;CHRM3;AA + AG;rs2165870;NAN;INCREASED;RISK;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;
ISONIAZID;NAT2;*16/*16;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
SALBUTAMOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;ASTHMA EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;ASTHMA EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;
IRINOTECAN;UGT1A9;del/del;rs3832043;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ARIPIPRAZOLE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
QUETIAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CISPLATIN;SLC16A5;T;rs4788863;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5G;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*30;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*34;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5G;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*30;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*34;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;
IRINOTECAN;ABCC2;CC;rs3740066;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ENALAPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
IMIDAPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
LISINOPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
IRINOTECAN;ABCG2;CT + TT;rs2231137;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;RISK;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;RISK;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HMG-COA_REDUCTASE_INHIBITORS;SREBF1;AA + AG;rs11868035;OTHER;INCREASED;NAN;OTHER;TOTAL CHOLESTEROL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*3;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*4;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*5;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*6;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*7;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;
CISPLATIN;GSTP1;G;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ACE INHIBITORS;BDKRB2;T;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;BDKRB2;T;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
ATORVASTATIN;ABCG2;TT;rs2231142;DOSAGE;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
ATORVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
LANSOPRAZOLE;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
IRBESARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;NAN;EFFICACY;BLOOD PRESSURE RESPONSE IN PEOPLE WITH  DISEASE:HYPERTENSION;
ETHAMBUTOL;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DEXMEDETOMIDINE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;NAN;EFFICACY;BISPECTRAL INDEX AND RAMSAY SEDATION SCORES;
DEXMEDETOMIDINE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;NAN;EFFICACY;INDICATING A LONGER PERIOD FOR FALLING ASLEEP NAN  NAN;
PACLITAXEL;CYP2C8;G;rs1113129;TOXICITY;DECREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
ISONIAZID;NAT2;*6;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ROSUVASTATIN;ABCG2;TT;rs2231142;DOSAGE;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
ROSUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
ISONIAZID;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*6;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*14;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ROSUVASTATIN;ABCG2;GG;rs2231142;DOSAGE;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
ROSUVASTATIN;ABCG2;GG;rs2231142;METABOLISM/PK;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
SORAFENIB;TNF;GG;rs1800629;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
IRINOTECAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RISK;DISEASE;PAIN IN PEOPLE WITH  OTHER:EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (ESWL);
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMOGLOBIN LEVELS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"RECOMBINANT""";ITPA;CC;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMOGLOBIN LEVELS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"""RIBAVIRIN""";ITPA;CC;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMOGLOBIN LEVELS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ETHAMBUTOL;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ALFENTANIL;OPRM1;AG + GG;rs1799971;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:PAIN;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;OTHER;ASTHMA EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;
PEGINTERFERON ALFA-2B;DNAAF9, ITPA;C;rs6051702;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;DNAAF9, ITPA;C;rs6051702;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CLOPIDOGREL;MIR6076;GG + GT;rs1463411;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
LANSOPRAZOLE;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
TAMOXIFEN;LRMDA;C;rs10509373;EFFICACY;DECREASED;NAN;OTHER;RECURRENCE-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
ETHAMBUTOL;NAT2;G;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;G;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
METHOTREXATE;ABCC2;AG + GG;rs3740065;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
IRINOTECAN;NR3C1;A;rs61754806;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
IRINOTECAN;VKORC1;T;rs7294;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
CISPLATIN;TPMT;CT;rs1142345;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;TPMT;CT;rs1142345;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;*5;SLCO1B1*5;TOXICITY;DECREASED;RISK;SIDE EFFECT;CATARACT IN PEOPLE WITH  OTHER:CARDIO-METABOLIC CONDITIONS;
GEMCITABINE;RRM1;AA;rs9937;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
OLANZAPINE;DRD2;C;rs1799978;EFFICACY;DECREASED;NAN;EFFICACY;TIME UNTIL RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;DRD2;C;rs1799978;EFFICACY;DECREASED;NAN;EFFICACY;TIME UNTIL RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
METHOTREXATE;ABCC4;GG + GT;rs9516519;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PSYCHOMOTOR AGITATION;
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERKINESIS;
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:IMPULSE CONTROL DISORDER IN CHILDREN WITH  OTHER:DEPRESSION;
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ANXIETY DISORDERS;
RISPERIDONE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN CHILDREN  NAN;
PALIPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;
PALIPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WEIGHT GAIN IN CHILDREN  NAN;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;MAGNITUDE OF PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ISONIAZID;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NON-STEROIDS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ETHAMBUTOL;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CAPECITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
CAPECITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OLANZAPINE;DRD2;del;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO RESPOND IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;DRD2;del;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO RESPOND IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OPIOIDS;CYP2A7P1, CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ANTIINFLAMMATORY AGENTS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NON-STEROIDS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
PROTON PUMP INHIBITORS;CYP2C19;;CYP2C19 RAPID AND ULTRARAPID METABOLIZER GENOTYPES;TOXICITY;DECREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN CHILDREN  NAN;
ANTINEOPLASTIC AGENTS;TYMS;AG + GG;rs2853539;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:RHABDOMYOSARCOMA;
DACTINOMYCIN;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:RHABDOMYOSARCOMA;
VINCRISTINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:RHABDOMYOSARCOMA;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOPHRENIA;
OMEPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZErs;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;INCREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;AKR1C3;G;rs1937840;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIHYPERTENSIVES;ADIPOQ;CG + GG;rs266729;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;
MYCOPHENOLIC ACID;IMPDH1;T;rs2278293;EFFICACY;DECREASED;LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;IMPDH1;T;rs2278293;EFFICACY;DECREASED;LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:PAIN;
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;DECREASED;RISK;SIDE EFFECT;POSTOPERATIVE;
NICOTINE;CYP2D6;*2xN;CYP2D6*2XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CYP2D6;*2xN;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CYP2D6;*2xN;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER NAN  NAN;
GEMCITABINE;DCK;TT;rs4694362;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CYCLOPHOSPHAMIDE;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ETHAMBUTOL;NAT2;T;rs1801280;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1801280;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
PLATINUM COMPOUNDS;SLC31A1;AG + GG;rs4978536;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
OPIOIDS;BDNF-AS;CC + CT;rs11030096;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
IRINOTECAN;NAT2;AA;rs1799930;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;NAT2;AA;rs1799930;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY;
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:HEMATOLOGIC DISORDER;
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
COCAINE;SYT1;G;rs2251214;TOXICITY;INCREASED;RISK;SIDE EFFECT;COCAINE DEPENDENCE NAN  NAN;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE HEPATITIS;
VALGANCICLOVIR;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TETRABENAZINE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER PHENOTYPE;EFFICACY;NAN;NAN;OTHER;LONGER TITRATION TO ACHIEVE OPTIMAL BENEFIT NAN  NAN;
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
OLANZAPINE;CYP2C9;;CYP2C9 POOR METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
"""FOLIC ACID""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
"""VITAMIN B-COMPLEX";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
"PLAIN""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
NICOTINE;HTR3B;TT;rs3758987;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA;
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROESOPHAGEAL CANCER;
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ENALAPRIL;PCGF3;A;rs1044147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*11;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:SURGERY;
ANTICHOLINERGIC AGENTS;CYP2C19;;CYP2C19 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;SERUM ANTICHOLINERGIC ACTIVITY NAN  NAN;
VENLAFAXINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
ANTINEOPLASTIC AGENTS;ABCG2;CC + CT;rs2231164;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CITALOPRAM;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
CLOMIPRAMINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
DULOXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
ESCITALOPRAM;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
FLUOXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
FLUVOXAMINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
MIRTAZAPINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
PAROXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
SERTRALINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
VENLAFAXINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID-7-O-GLUCURONIDE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF THE ACYL GLUCURONIDE OF MYCOPHENOLIC ACID IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CAPECITABINE;DPYD;CT;rs2297595;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;DECREASED;NAN;SIDE EFFECT;NAUSEA;
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;DECREASED;NAN;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:PAIN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ATENOLOL;PAH;AA;rs2245360;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSULIN RESISTANCE IN PEOPLE WITH  OTHER:HYPERTENSION;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*3;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*5;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*7;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
OPIOIDS;DRD2;CC + CT;rs1125394;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
SORAFENIB;VEGFA;CC;rs3025040;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OPIOIDS;DRD2;CT + TT;rs1079596;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN PEOPLE WITH  OTHER:SURGERY;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;;TPMT INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
FLUOROURACIL;TYMS;AG + GG;rs2847153;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
MORPHINE;ABCC3;T;rs4148412;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;
MORPHINE;ABCC3;T;rs4148412;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;
SORAFENIB;UGT1A9;AA;rs7574296;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*28;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;DOSAGE;INCREASED;LIKELIHOOD;OTHER;DRUG DOSAGE ALTERED IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TRAMADOL;COMT;GG;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;
TRAMADOL;COMT;GG;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN PEOPLE WITH  OTHER:SURGERY;
"""FOLIC ACID""";MTHFR;AG + GG;rs1801133;EFFICACY;NAN;NAN;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
"""VITAMIN B-COMPLEX";MTHFR;AG + GG;rs1801133;EFFICACY;NAN;NAN;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
"PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;NAN;NAN;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
AMITRIPTYLINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CLOMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
DOXEPIN;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
IMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
TRIMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
SORAFENIB;SLC15A2;CC;rs2257212;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
FLUOROURACIL;CCND1;AA;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;TIME-TO-TUMOR RECURRENCE IN  DISEASE:COLONIC NEOPLASMS;
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CAPECITABINE;UMPS;CC + CT;rs2279199;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
CAPECITABINE;UMPS;CC + CT;rs2279199;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METFORMIN;;TT;rs578427;METABOLISM/PK;INCREASED;NAN;PK;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;TYMS;CT + TT;rs2853741;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C19;;CYP2C19 RAPID AND ULTRARAPID METABOLIZER GENOTYPES;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CAPECITABINE;SLC22A7;AG + GG;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;;CYP2C19 NORMAL METABOLIZErs;OTHER;DECREASED;RISK;OTHER;MAJOR ADVERSE CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
METHOTREXATE;SLC19A1;T;rs1051266;TOXICITY;INCREASED;NAN;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:PSORIASIS;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
ABT-751;UGT1A4;AC;rs6755571;METABOLISM/PK;DECREASED;NAN;PK;PLASMA PREDOSE CONCENTRATION (CTROUGH) IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;UMPS;CC + CG;rs4678145;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ABT-751;UGT1A8;CC + CT;rs6431558;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION METABOLIC RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;
IMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;MEAN AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC) OF DESIPRAMINE IN HEALTHY INDIVIDUALS  NAN;
ANTINEOPLASTIC AGENTS;DPYD;AA + AG;rs1760217;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
AZATHIOPRINE;TPMT;CC + CT;rs1142345;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
ANTINEOPLASTIC AGENTS;SERPINA3;AC + CC;rs17091162;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
VALPROIC ACID;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;TOXICITY;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:EPILEPSY;
ASPIRIN;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);
CLOPIDOGREL;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);
METFORMIN;SLC47A2;AA;rs12943590;METABOLISM/PK;INCREASED;NAN;PK;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN IN HEALTHY INDIVIDUALS  NAN;
TAMOXIFEN;NCOA1;CT;rs1804645;OTHER;INCREASED;SEVERITY;SIDE EFFECT;CHANGE IN LUMBAR BONE MINERAL DENSITY NAN  NAN;
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;CARDIOVASCULAR DEATH;
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;MYOCARDIAL INFARCTION OR STROKE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);
CITALOPRAM;;A;rs352428;EFFICACY;NAN;NAN;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;;A;rs352428;EFFICACY;NAN;NAN;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);
CITALOPRAM;;A;rs352428;EFFICACY;NAN;NAN;EFFICACY;POOR RESPONSE AT 6 WEEK OF TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;CARDIOVASCULAR DEATH;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;MYOCARDIAL INFARCTION OR STROKE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);
MIDAZOLAM;POR;CT;rs1057868;METABOLISM/PK;DECREASED;NAN;PK;MIDAZOLAM METABOLIC RATIOS BY 45% NAN  NAN;
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);
LENVATINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRY MOUTH;
LENVATINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  OTHER:THYROID TUMOR;
NICOTINE;CHRNA3;G;rs578776;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL IN  OTHER:TOBACCO USERS;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;
TRAZODONE;CYP2D6;;CYP2D6 NORMAL METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;STOMATITIS IN PEOPLE WITH  DISEASE:GASTROESOPHAGEAL CANCER;
RISPERIDONE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER PHENOTYPE;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM;
ASPIRIN;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);
LENVATINIB;CYP3A4;C;rs2242480;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:THYROID TUMOR;
LENVATINIB;CYP3A5;C;rs776746;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:THYROID TUMOR;
CAPECITABINE;ENOSF1, TYMS;TT;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
CAPECITABINE;ENOSF1, TYMS;TT;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  NAN;
HEROIN;OPRK1;C;rs6473797;TOXICITY;DECREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
HEROIN;CSNK1E;T;rs1534891;TOXICITY;DECREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CAPECITABINE;DPYD;AG;rs12119882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ETHANOL;CHRNA5;G;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;
HEROIN;GAL;A;rs694066;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
HEROIN;OPRD1;A;rs2236861;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CAPECITABINE;SLC22A7;TT;rs2270860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
METHADONE;CRHBP;G;rs1500;OTHER;DECREASED;NAN;OTHER;RECURRENCE IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
METHAMPHETAMINE;FAAH;A;rs324420;OTHER;INCREASED;LIKELIHOOD;OTHER;DEPENDENCE IN MEN  NAN;
ETHANOL;CHRNA3;G;rs1051730;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*2XN;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*6;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*7;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*35;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;PEAK CORTISOL RESPONSE NAN  NAN;
TAMOXIFEN;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER PHENOTYPE;TOXICITY;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;ENOSF1, TYMS;CT + TT;rs699517;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEIOMYOMA;
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LIVER DISORDER;
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:OVARIAN CYSTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEIOMYOMA;
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LIVER DISORDER;
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:OVARIAN CYSTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
HEROIN;HTR3B;C;rs3758987;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
METOPROLOL;CYP2D6;;CYP2D6 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
OSIMERTINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
TAMOXIFEN;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ESCITALOPRAM;HTR2C;C;rs6318;EFFICACY;DECREASED;NAN;DISEASE;PAIN IN MEN WITH  DISEASE:NEUROPATHIC PAIN;
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;NAN;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO IN HEALTHY INDIVIDUALS  NAN;
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PAIN AUC IN HEALTHY INDIVIDUALS  NAN;
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;NAN;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO IN HEALTHY INDIVIDUALS  NAN;
NICOTINE;CHRNA3;A;rs1051730;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
PAROXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;OTHER;INCREASED;NAN;OTHER;METABOLIC RATIO DEM/DOR IN PEOPLE WITH  DISEASE:ANXIETY DISORDERS;
IRINOTECAN;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION IN WOMEN WITH  DISEASE:MENTAL DISORDERS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
ESCITALOPRAM;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN AUC;
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;PLASMA HALF-LIFE AND STEADY-STATE PLASMA CONCENTRATIONS OF PAROXETINE IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
FLUOXETINE;CYP2D6;*1/*1;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROESOPHAGEAL CANCER;
ALKYLATING AGENTS;ESR1;A;rs2207396;TOXICITY;INCREASED;RISK;DISEASE;OLIGOSPERMIA IN PEOPLE WITH  OTHER:CHILDHOOD CANCER;
CISPLATIN;ESR1;A;rs2207396;TOXICITY;INCREASED;RISK;DISEASE;OLIGOSPERMIA IN PEOPLE WITH  OTHER:CHILDHOOD CANCER;
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;
ANTIDEPRESSANTS;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZErs;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IF TOLERANT TO CITALOPRAM TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6 NORMAL METABOLIZErs;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6 NORMAL METABOLIZErs;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN  NAN;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;PARKINSONIAN DISORDER;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OSIMERTINIB;STAT3;GG;rs4796793;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAIL DISORDER IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ESCITALOPRAM;CYP2D6;AA;rs1065852;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE AND REMISSION RATE IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
3;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERTENSION IN HEALTHY INDIVIDUALS  NAN;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERTENSION IN HEALTHY INDIVIDUALS  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;GG + GT;rs4149014;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
DOCETAXEL;;;POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;;;POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
NAN;;T;rs6968865;DOSAGE;INCREASED;NAN;OTHER;COFFEE CONSUMPTION NAN  NAN;
SULFAMETHOXAZOLE;GCLC;AA;rs761142;TOXICITY;DECREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;TOXICITY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;TOXICITY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
NAN;CYP1A1;T;rs2472297;DOSAGE;INCREASED;NAN;OTHER;COFFEE CONSUMPTION NAN  NAN;
SULFAMETHOXAZOLE;GCLC;A;rs761142;TOXICITY;DECREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
APIXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;
DABIGATRAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;
EDOXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;
RIVAROXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;
TRAMADOL;CYP2D6;;CYP2D6 NORMAL METABOLIZER AND ULTRARAPID METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LOW BACK PAIN;
TRAMADOL;CYP2D6;;CYP2D6 NORMAL METABOLIZER AND ULTRARAPID METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:OSTEOARTHRITIS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;AG + GG;rs2273697;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;AG + GG;rs2273697;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:SARCOMA;
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
TACROLIMUS;CYP3A4;AG;rs35599367;OTHER;INCREASED;NAN;PK;CREATININE CLEARANCE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:SARCOMA;
CLOPIDOGREL;PON1;CC;rs662;EFFICACY;DECREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (PR) AT 1 MONTH AND AT 6 MONTHS AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) IN PEOPLE WITH  DISEASE:MYOCARDIAL ISCHEMIA;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOPHRENIA;
ISONIAZID;ASTN2;C;rs117491755;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ALECTINIB;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  OTHER:EPILEPSY;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
IRINOTECAN;UGT1A1;*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
IRINOTECAN;UGT1A1;*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
IRINOTECAN;UGT1A1;*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
IRINOTECAN;UGT1A1;*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
CISPLATIN;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
CISPLATIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
CISPLATIN;GSTM1;;GSTM1 NON-NULL;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
CISPLATIN;GSTM1;;GSTM1 NULL;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
ARIPIPRAZOLE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;
ARIPIPRAZOLE;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;
CODEINE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;
CODEINE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;
ETHANOL;CRHBP;TT;rs10055255;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEXUAL DYSFUNCTION IN MEN WITH  DISEASE:SCHIZOPHRENIA;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
OXALIPLATIN;HLA-DRB1;*12:01;HLA-DRB1*12:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
CEFACLOR;HLA-DRB1;*14:54;HLA-DRB1*14:54;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;
SULFASALAZINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;
SULFASALAZINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
SULFASALAZINE;HLA-B;*56:03;HLA-B*56:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;
SULFASALAZINE;HLA-B;*56:03;HLA-B*56:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
METOPROLOL;CYP2D6;*1/*2;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;HEART RATE IN HEALTHY INDIVIDUALS  NAN;
METOPROLOL;CYP2D6;*1/*2;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;HEART RATE IN HEALTHY INDIVIDUALS  NAN;
METHAMPHETAMINE;DAOA;C;rs778293;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANAPHYLAXIS NAN  NAN;
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
ATORVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
SIMVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
ATORVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;
ATORVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:ANGINA PECTORIS NAN  NAN;
SIMVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;
SIMVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:ANGINA PECTORIS NAN  NAN;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
SORAFENIB;KDR;GG;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
ATORVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
SIMVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;HYPOKALEMIA IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
RISPERIDONE;ADRB2;G;rs1042713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEXUAL ADVERSE EVENTS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
BECLOMETHASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
BECLOMETHASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
BUDESONIDE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
BUDESONIDE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
FLUTICASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
FLUTICASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
MOMETASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
MOMETASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;
NICOTINE;CYP2A6;*1/*1x2;CYP2A6*1;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CYP2A6;*1/*1x2;CYP2A6*1X2;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:LEUKEMIA;
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL;
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LEUKEMIA;
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
CODEINE;ABCB1;A;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;
CODEINE;ABCB1;A;rs1128503;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;
CAPECITABINE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HYPERURICEMIA;
CODEINE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN WOMEN WITH  DISEASE:PAIN;
CODEINE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN WOMEN WITH  DISEASE:PAIN;
CODEINE;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;
CODEINE;ABCB1;A;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;
NAN;CELSR2, PSRC1;T;rs602633;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
INDINAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
INDINAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
METHOTREXATE;SLCO1B1;G;rs4149081;OTHER;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLCO1B1;G;rs4149081;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;EFFICACY;DECREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;
VALPROIC ACID;SCN1A;AA;rs10167228;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  OTHER:EPILEPSY;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*5;CYP2C19*5;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;
TROGLITAZONE;;C;rs10811661;EFFICACY;INCREASED;NAN;EFFICACY;BETA CELL FUNCTION IN PEOPLE WITH  OTHER:HIGH RISK FOR TYPE 2 DIABETES;
PLATINUM COMPOUNDS;ERCC2;CC + CT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;OTHER;PLASMA LEVEL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CITALOPRAM;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
METHAMPHETAMINE;PICK1;T;rs713729;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
IMATINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;
CAFFEINE;DRD2;GG;rs1110976;OTHER;DECREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;
OPIOIDS;;AG + GG;rs4530637;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;
NAN;;C;rs1111875;METABOLISM/PK;DECREASED;NAN;PK;INSULIN SECRETION AT BASELINE IN PEOPLE WITH  OTHER:HIGH RISK OF TYPE 2 DIABETES;
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN  NAN;
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
OPIOIDS;TACR3;AG + GG;rs1384401;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
FOLFIRI;ABCC2;GG;rs2273697;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:TOBACCO USE DISORDER;
METHOTREXATE;ABCC2;T;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHAMPHETAMINE;PICK1;T;rs713729;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;RECURRENCE IN PEOPLE WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;
OPIOIDS;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
FOLFIRI;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CITALOPRAM;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
OPIOIDS;DRD3;CC + CT;rs6280;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
HYDROCHLOROTHIAZIDE;;CC + CT;rs17137967;TOXICITY;INCREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*1;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*4;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*7;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*9;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
OPIOIDS;DRD3;AA + AG;rs324029;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;SEVERITY;DISEASE;BREAST TENDERNESS;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:VAGINAL DRYNESS;
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OPIOIDS;EXOC4;TT;rs718656;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
ETHAMBUTOL;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
NICOTINE;CHRNB2;T;rs2072660;OTHER;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
DIRECT ACTING ANTIVIRALS;IFNL4;GG;rs11322783;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PLATINUM COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;rs3213239;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
PLATINUM COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;rs3213239;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2A;IFNL3;GG;rs8099917;EFFICACY;NAN;NAN;EFFICACY;LACK OF TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;NAN;NAN;EFFICACY;LACK OF TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PLATINUM COMPOUNDS;ERCC2;GG;rs50872;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;ABCG2;GG;rs1448784;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ETHAMBUTOL;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
NICOTINE;CHRNB2;A;rs2072661;OTHER;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
HYDROXYCHLOROQUINE;CYP2C8;GG;rs10882526;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
HYDROXYCHLOROQUINE;CYP2C8;GG;rs10882526;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;GG;rs660652;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER IN PEOPLE WITH  DISEASE:PAIN;
METHAMPHETAMINE;;T;rs1421292;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;
ACE INHIBITORS;ABO;GT + TT;rs495828;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;
PLAIN;ABO;GT + TT;rs495828;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
GLICLAZIDE;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLICLAZIDE;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*1;EFFICACY;DECREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*2;EFFICACY;DECREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*17;EFFICACY;DECREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
OPIOIDS;ZNF804A;CC;rs7597593;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;AA;rs1051730;TOXICITY;INCREASED;SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS IN PEOPLE WITH  DISEASE:PAIN;
HYDROXYCHLOROQUINE;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
HYDROXYCHLOROQUINE;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;
PLATINUM COMPOUNDS;IL16;GT + TT;rs7170924;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
INDOMETHACIN;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN INFANTS WITH  OTHER:PATENT DUCTUS ARTERIOSUS;
INDOMETHACIN;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN INFANTS WITH  OTHER:PATENT DUCTUS ARTERIOSUS;
NAN;CHRNA3;AA + AG;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER;NON-SMALL CELL LUNG CARCINOMA NAN  NAN;
NEVIRAPINE;HLA-B;*15:10;HLA-B*15:10;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;
ASPIRIN;TBXA2R;A;rs1131882;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ASPIRIN;TBXA2R;A;rs1131882;EFFICACY;INCREASED;RISK;SIDE EFFECT;TYPE 2;
ASPIRIN;TBXA2R;A;rs1131882;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ASPIRIN;TBXA2R;A;rs1131882;TOXICITY;INCREASED;RISK;SIDE EFFECT;TYPE 2;
OPIOIDS;CNR1;TT;rs2023239;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
NAN;NQO1;AA;rs1800566;OTHER;NAN;NAN;OTHER;SIGNIFICANTLY SHORTER SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METFORMIN;SLC29A4;G;rs3889348;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
METFORMIN;SLC29A4;G;rs3889348;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TYPE 2;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
NAN;NQO1;A;rs1800566;TOXICITY;INCREASED;RISK;DISEASE;LEUKEMIA NAN  NAN;
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN WOMEN WITH  DISEASE:ESSENTIAL HYPERTENSION;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OPIOIDS;CNR1;CC;rs6928499;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NEVIRAPINE;CYP2B6;CC + CG;rs58425034;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;DISEASE;EVENT-FREE SURVIVAL;
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;DISEASE;DISEASE:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
DOCETAXEL;CHST3;C;rs4148945;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;CHST3;C;rs4148945;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
"""FOLIC ACID""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
"""VITAMIN B-COMPLEX";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
"PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;
DOCETAXEL;SLC10A2;A;rs2301159;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;SLC10A2;A;rs2301159;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
AXITINIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SORAFENIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
METHOTREXATE;SLC19A1;CC + CT;rs1051266;EFFICACY;INCREASED;SEVERITY;DISEASE;RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
WARFARIN;CYP2C9;*2;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
NICOTINE;DBH;AA + AG;rs77905;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
METHOTREXATE;ADORA2A;GG;rs2298383;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:HEMATOLOGIC NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH ADP IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH ADP IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS;
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREMOR;
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE RIGIDITY IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
NAN;CYP2B6;TT;rs3211371;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:RS1800497 GG GENOTYPES;
NAN;CYP2B6;CT;rs3211371;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:RS1800497 GG GENOTYPES;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;PSYCHOMOTOR AGITATION;
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;PSYCHOMOTOR AGITATION;
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
IRINOTECAN;UGT1A1;G;rs4124874;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;CYP24A1;C;rs2762939;OTHER;DECREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;A;rs16969968;TOXICITY;INCREASED;SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS IN PEOPLE WITH  DISEASE:PAIN;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE OUTCOME IN  OTHER:ORTHOPEDIC PATIENTS;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE OUTCOME IN  OTHER:ORTHOPEDIC PATIENTS;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE OUTCOME IN  OTHER:ORTHOPEDIC PATIENTS;
MORPHINE;ABCC3;G;rs739923;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;
MORPHINE;ABCC3;G;rs739923;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;
CITALOPRAM;PAPLN;T;rs11628713;TOXICITY;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;
SULFONAMIDES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
SULFONAMIDES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
FLUOXETINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
FLUOXETINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
IMATINIB;SLC22A1;TT;rs1867351;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIORBITAL EDEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;
FLUOROURACIL;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
VERAPAMIL;KCNIP1, KCNMB1;CT + TT;rs11739136;EFFICACY;NAN;NAN;EFFICACY;EARLIER ACHIEVEMENT OF BLOOD PRESSURE CONTROL IN PEOPLE WITH  DISEASE:HYPERTENSION;
OPIOIDS;DRD3;AG + GG;rs9288993;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
OSIMERTINIB;CYP2C9;AC;rs1057910;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
OPIOIDS;DRD3;AG + GG;rs2654754;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;
ANTIEPILEPTICS;HLA-B;*53:01;HLA-B*53:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PENICILLIN G;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
SULFAMETHOXAZOLE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
APIXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
DABIGATRAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
RIVAROXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CAROTID STENOSIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CAROTID STENOSIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CAROTID STENOSIS;
METFORMIN;AMHR2;G;rs784892;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN SECRETORY CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*2;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*4;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*17;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*8;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*8;CYP2C19*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*5;CYP2C19*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN PEOPLE WITH  OTHER:STROKE;
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN PEOPLE WITH  OTHER:STROKE;
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;
CARBOPLATIN;RRM1;GG;rs9937;TOXICITY;NAN;RISK;DISEASE;HEMATOLOGIC DISORDER IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;RRM1;GG;rs9937;TOXICITY;NAN;RISK;DISEASE;HEMATOLOGIC DISORDER IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;
METFORMIN;SLC22A1;A;rs628031;TOXICITY;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC22A1;A;rs628031;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;
METFORMIN;SLC22A1;A;rs628031;METABOLISM/PK;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC22A1;A;rs628031;METABOLISM/PK;NAN;NAN;SIDE EFFECT;TYPE 2;
OPIOIDS;GABRB3;AA;rs4906902;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*4;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*10;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
MYCOPHENOLATE MOFETIL;SLCO1B3;AA;rs7311358;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;
ISONIAZID;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ETHANOL;DRD2;GG;rs1799732;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;
SALBUTAMOL;THRB;A;rs892940;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (BDR) IN CHILDREN WITH  DISEASE:ASTHMA;
OPIOIDS;TACR1;AA;rs735668;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*9;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPIRIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ASPIRIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;
APIXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
DABIGATRAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
EDOXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
RIVAROXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
OPIOIDS;OPRM1;CC;rs510769;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN CHILDREN  NAN;
FIRST-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
FOURTH-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
OTHER CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
THIRD-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
AMOXICILLIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
"""METFORMIN""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
"""METFORMIN""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
"""SULFONAMIDES";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
"""SULFONAMIDES";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
"UREA DERIVATIVES""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
"UREA DERIVATIVES""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
ETHAMBUTOL;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
FIRST-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
FOURTH-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
OTHER CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
THIRD-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
FIRST-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
FOURTH-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
OTHER CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:CROHN DISEASE;
NICOTINE;CYP2A13;CT;rs72552266;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  NAN;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  NAN;
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  NAN;
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CYSTITIS IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CYSTITIS IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CYSTITIS IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;
NAN;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;
NAN;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;
DOXORUBICIN;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
DOXORUBICIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION NAN  NAN;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION NAN  NAN;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
SUNITINIB;KDR;TT;rs1870377;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
IRINOTECAN;UGT1A1;*28 + *6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA NAN  NAN;
IRINOTECAN;UGT1A1;*28 + *6;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA NAN  NAN;
IRINOTECAN;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;
IRINOTECAN;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE;
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN HEALTHY INDIVIDUALS  NAN;
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE;
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
METHOTREXATE;MTR;GG;rs3768142;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CARBAMAZEPINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3A;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3C;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CISPLATIN;GSTT1;non-null;GSTT1 NON-NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEARING LOSS IN CHILDREN WITH  DISEASE:NEOPLASMS;
CISPLATIN;GSTT1;non-null;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEARING LOSS IN CHILDREN WITH  DISEASE:NEOPLASMS;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*5;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*7;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*16;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;
TACROLIMUS;CYP3A4;AG + GG;rs4646437;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY;HEART FAILURE;
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:ANGINA PECTORIS IN PEOPLE WITH  OTHER:CORONARY DISEASE;
NAN;CYP4A11;AG + GG;rs1126742;METABOLISM/PK;DECREASED;NAN;PK;HDL-C CONCENTRATION IN WOMEN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*1X2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*2X2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*2XN;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*4;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*9;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*10;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*41;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*41X2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
PEMETREXED;SLC19A1;TT;rs914232;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;SLC19A1;TT;rs914232;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LUNG NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LUNG NEOPLASMS;
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;DPYD;c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) IN HEALTHY INDIVIDUALS  NAN;
PEMETREXED;SLC19A1;AA + AG;rs1051298;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;SLC19A1;AA + AG;rs1051298;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEADACHE;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE SPASM;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEADACHE;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE SPASM;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEADACHE;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE SPASM;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE;
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS IN HEALTHY INDIVIDUALS  NAN;
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
AMOXICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
AMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
BACAMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
METHAMPHETAMINE;DRD3;CC + CT;rs6280;TOXICITY;INCREASED;RISK;SIDE EFFECT;COGNITIVE DISORDER IN MEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;OTHER;DECREASED;RISK;DISEASE;LUNG NEOPLASMS IN MEN WITH  DISEASE:TOBACCO USE DISORDER;
VINCRISTINE;ACTN1;T;rs2268979;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
CAPECITABINE;UPB1;GG;rs2070474;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
PEMETREXED;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
VINCRISTINE;PAPPA;A;rs12235805;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
CAPECITABINE;UPB1;GG;rs2070474;TOXICITY;DECREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;DECREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;
FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;
PEMETREXED;SLC19A1;GG + GT;rs3788189;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;SLC19A1;GG + GT;rs3788189;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;
NICOTINE;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;TOTAL CHOLESTEROL IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;UGT1A1;*1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
ATOMOXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
VINCRISTINE;NRG3;T;rs12253008;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:METASTATIC NEOPLASM;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;;TPMT INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;LRRTM3;G;rs10997459;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
VINCRISTINE;ARHGAP5;G;rs8006511;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
MERCAPTOPURINE;TPMT;;TPMT NORMAL METABOLIZER;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;;TPMT NORMAL METABOLIZER;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NICOTINE;CYP2A6;CC;rs28399433;TOXICITY;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
VINCRISTINE;METTL8;G;rs79802223;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:HEART FAILURE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:HEART FAILURE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DEATH;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:HEART FAILURE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
NAN;UGT1A1;CT;rs4148325;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA IN INFANTS  NAN;
NAN;UGT1A1;G;rs11888492;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA IN INFANTS  NAN;
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;CORTISOL RESPONSE NAN  NAN;
CISPLATIN;CERS6;T;rs13022792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
CISPLATIN;TLR4;C;rs10759932;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
VINCRISTINE;NFIB;G;rs10961381;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
ANTIARRHYTHMICS;;GT + TT;rs10033464;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
CLASS I AND III;;GT + TT;rs10033464;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
VINCRISTINE;MCM3AP;T;rs1815857;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
VINCRISTINE;SPDYA;T;rs12474420;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
VINCRISTINE;PDE4D;C;rs12658429;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
VINCRISTINE;FBN2;T;rs12656510;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
VINCRISTINE;VTI1A;T;rs17129858;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
VINCRISTINE;ZFAND3;C;rs200858088;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANAPHYLAXIS NAN  NAN;
NON-STEROIDS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANAPHYLAXIS NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;EFFICACY;PERIPHERAL VASCULAR DISEASES NAN  NAN;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;EFFICACY;PERIPHERAL VASCULAR DISEASES NAN  NAN;
MYCOPHENOLATE MOFETIL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
PREDNISONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
PREDNISONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ACETAMINOPHEN / CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;CONSTIPATION IN PEOPLE WITH  OTHER:PAIN;
ACETAMINOPHEN / CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;
RASBURICASE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  OTHER:HYPERURICEMIA;
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
SIROLIMUS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ATRIAL FIBRILLATION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SURGERY;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ATRIAL FIBRILLATION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SURGERY;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ATRIAL FIBRILLATION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SURGERY;
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ADALIMUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
AMIODARONE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
BEVACIZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
BICALUTAMIDE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
CARBOPLATIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
CYCLOPHOSPHAMIDE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
DOCETAXEL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
ERLOTINIB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
EVEROLIMUS;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
FLUOROURACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
GEFITINIB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
GEMCITABINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
IRINOTECAN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
LEUCOVORIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
METHOTREXATE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
OXALIPLATIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
PACLITAXEL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
PEMBROLIZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
SITAGLIPTIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
TEGAFUR / GIMERACIL / OTERACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
TRASTUZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INTERSTITIAL LUNG DISEASES IN MEN  NAN;
ANASTROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
EXEMESTANE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
LETROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERYTHEMA MULTIFORME IN PEOPLE WITH  DISEASE:HYPERURICEMIA;
PEMETREXED;DHFR;AA + AG;rs1650697;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;DHFR;AA + AG;rs1650697;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MESOTHELIOMA;
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*1;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*3;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*6;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*7;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP2C8;*1/*1;CYP2C8*1;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP2C8;*1/*1;CYP2C8*3;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS;
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
ASPIRIN;PTGS2;GG;rs12042763;EFFICACY;DECREASED;RISK;DISEASE;PROSTATIC NEOPLASMS NAN  NAN;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*15;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*15;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*15;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
NAN;CYP2A6;G;rs56267346;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;
NAN;DBH;C;rs6479643;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
FLURBIPROFEN;UGT1A1;*1/*36;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLURBIPROFEN;UGT1A1;*1/*36;UGT1A1*36;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*36;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;*1/*36;UGT1A1*36;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
NAN;CASP9;T;rs1052576;EFFICACY;INCREASED;SEVERITY;EFFICACY;LEUKOCYTOSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CAPECITABINE;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CYCLOSPORINE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOSPORINE;ATIC;CC;rs17514110;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ATIC;CC;rs17514110;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOSPORINE;NFATC2;TT;rs3787186;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;NFATC2;TT;rs3787186;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOSPORINE;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CETUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY NAN  NAN;
CYCLOSPORINE;ABCC1;AA;rs8058040;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ABCC1;AA;rs8058040;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
ATAZANAVIR;TPH2;GG;rs7305115;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;TPH2;GG;rs7305115;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;
CARBAMAZEPINE;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
LAMOTRIGINE;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
PHENYTOIN;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CARBAMAZEPINE;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
LAMOTRIGINE;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
PHENYTOIN;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
LAMOTRIGINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
PHENYTOIN;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;
ATAZANAVIR;TPH2;GG;rs1386493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;
EFAVIRENZ;TPH2;GG;rs1386493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;
CARBAMAZEPINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
CAPECITABINE;ENOSF1;TT;rs2612091;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
LAMOTRIGINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
PHENYTOIN;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;
CARBAMAZEPINE;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
LAMOTRIGINE;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBOPLATIN;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
PACLITAXEL;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GI INTOLERANCE IN CHILDREN WITH  DISEASE:ORGAN TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GI INTOLERANCE IN CHILDREN WITH  DISEASE:ORGAN TRANSPLANTATION;
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ERLOTINIB;USP36;CC;rs3744797;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;USP36;CC;rs3744797;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
OSIMERTINIB;HLA-B;*51:02;HLA-B*51:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;
OSIMERTINIB;HLA-B;*51:02;HLA-B*51:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
DEXMEDETOMIDINE;CACNB2;CT;rs10764319;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;
DEXMEDETOMIDINE;CACNB2;CT;rs10764319;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;
DEXMEDETOMIDINE;CACNA2D2;AA;rs2236957;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;
DEXMEDETOMIDINE;CACNA2D2;AA;rs2236957;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DEXMEDETOMIDINE;UGT2B10;AA;rs1841042;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;
DEXMEDETOMIDINE;UGT2B10;AA;rs1841042;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;
DEXMEDETOMIDINE;ADRA2B;AA + CC;rs3813662;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;
DEXMEDETOMIDINE;ADRA2B;AA + CC;rs3813662;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;
METHYLPHENIDATE;CES1;T;rs2307227;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
PURINE ANALOGUES;NUDT15;*1/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
PURINE ANALOGUES;NUDT15;*1/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
CLOPIDOGREL;THSD7A;G;rs7807369;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;;C;rs1149515;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;
CLOPIDOGREL;;C;rs1149515;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
ONDANSETRON;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;
NAN;ERAP2;TT;rs17524572;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  ""OTHER:ADENOCARCINOMA""";
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"""OTHER:NON-SMALL CELL LUNG CARCINOMA""";
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"""OTHER:CARCINOMA";
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"SQUAMOUS CELL""";
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"""OTHER:NEUROENDOCRINE CARCINOMA""";
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"PNEUMONITIS IN PEOPLE WITH  ""OTHER:ADENOCARCINOMA""";
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-SMALL CELL LUNG CARCINOMA""";
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:CARCINOMA";
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEUROENDOCRINE CARCINOMA""";
CAPECITABINE;DPYD;CT;rs1801158;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs1801158;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
MORPHINE;SLC22A1;del/del;rs72552763;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPOVENTILATION IN CHILDREN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NAN;CASP9;C;rs4661636;EFFICACY;INCREASED;SEVERITY;EFFICACY;LEUKOCYTOSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;CASP8;G;rs6736233;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOZAPINE;LEPR;AG + GG;rs6657868;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;LEPR;AG + GG;rs6657868;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CISPLATIN;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
CISPLATIN;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
PACLITAXEL;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;
PACLITAXEL;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
NAN;UGT1A1;A;rs4148323;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;
NAN;UGT1A1;A;rs4148323;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;
CLOZAPINE;LEPR, LEPROT;AA;rs1137101;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;LEPR, LEPROT;AA;rs1137101;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
DOLUTEGRAVIR;NR1I2;CT + TT;rs2472677;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;
DOLUTEGRAVIR;NR1I2;CT + TT;rs2472677;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
CLOZAPINE;LEPR;GG;rs1805096;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;LEPR;GG;rs1805096;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;LEPR;AC + CC;rs9436746;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;LEPR;AC + CC;rs9436746;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;
NAN;UGT1A1;A;rs35350960;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;
NAN;UGT1A1;A;rs35350960;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;ASPH;T;rs4379440;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
CARBOPLATIN;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
TICAGRELOR;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
PEGINTERFERON ALFA-2A;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
PEGINTERFERON ALFA-2B;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;CETP;A;rs3764261;EFFICACY;INCREASED;NAN;OTHER;HDL CHOLESTEROL NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;CETP;A;rs3764261;METABOLISM/PK;INCREASED;NAN;OTHER;HDL CHOLESTEROL NAN  NAN;
PYRIMIDINE ANALOGUES;MTHFR;AA + AC;rs1801133;NAN;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
METHOTREXATE;ITPA;A;rs1127354;TOXICITY;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL TOXICITIES IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2A;CTLA4;A;rs231775;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
PEGINTERFERON ALFA-2B;CTLA4;A;rs231775;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
RIBAVIRIN;CTLA4;A;rs231775;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
CAFFEINE;;T;rs4410790;OTHER;NAN;NAN;OTHER;HABITUAL CONSUMPTION NAN  NAN;
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"WEIGHT LOSS IN PEOPLE WITH  ""OTHER:DIABETES MELLITUS";
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"TYPE 2""";
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"""OTHER:OBESITY""";
METHAMPHETAMINE;ESR1;CC;rs2234693;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER IN MEN  NAN;
NAN;ABCG8;CG;rs11887534;OTHER;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PLATINUM;ERCC5;GG;rs17655;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
RISPERIDONE;HTR2C;T;rs3813929;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
PACLITAXEL;FGD4;A;rs10771973;TOXICITY;INCREASED;RISK;SIDE EFFECT;SENSORY PERIPHERAL NEUROPATHY IN WOMEN  DISEASE:BREAST NEOPLASMS;
CAFFEINE;CYP1A1;T;rs2470893;OTHER;NAN;NAN;OTHER;HABITUAL CONSUMPTION NAN  NAN;
CITALOPRAM;SLC6A4;C;rs25531;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;
PEGINTERFERON ALFA-2A;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
PEGINTERFERON ALFA-2B;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
RIBAVIRIN;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
MIDAZOLAM;POR;TT;rs1057868;OTHER;INCREASED;NAN;PK;METABOLIC RATIO OF MIDAZOLAM NAN  NAN;
MIDAZOLAM;POR;TT;rs1057868;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO OF MIDAZOLAM NAN  NAN;
ENALAPRIL;PNPT1;G;rs13009649;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;
METHOTREXATE;ITPA;A;rs1127354;EFFICACY;NAN;NAN;EFFICACY;RESPONSE TO METHOTREXATE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
NICOTINE;HTR3B;CT + TT;rs11606194;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
ASPIRIN;SLC6A12;A;rs499368;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
GEFITINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
WARFARIN;CYP4F2;GG;rs2189784;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
ASPIRIN;SLC6A12;G;rs557881;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
PLATINUM COMPOUNDS;WIF1;GG + GT;rs10878232;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIEPILEPTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;AG;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PLATINUM COMPOUNDS;WNT5B;AG + GG;rs12819505;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;AXIN2;AA + AC;rs4541111;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
MERCAPTOPURINE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;ITPA;CC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PLATINUM COMPOUNDS;CXXC4;AA + AG;rs4413407;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ENALAPRIL;PNPT1;C;rs13015243;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;
AZATHIOPRINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
THIOGUANINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;
PLATINUM COMPOUNDS;ERCC2;GG;rs13181;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PNEUMONITIS IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PNEUMONITIS IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
AMPHETAMINE;DRD2;AA;rs12364283;EFFICACY;DECREASED;NAN;OTHER;STOP REACTION TIME IN HEALTHY INDIVIDUALS  NAN;
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG-RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
ANTIEPILEPTICS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG-RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATIONS DUE TO ADVERSE EVENTS AND GREATER SEVERITY OF SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CLOPIDOGREL;CD80;AA;rs34394661;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
MYCOPHENOLATE MOFETIL;UGT1A9;A;rs6714486;METABOLISM/PK;NAN;NAN;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CARBAMAZEPINE;;TT;rs1633021;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PLATINUM COMPOUNDS;AXIN2;CC + CG;rs11868547;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs17868320;METABOLISM/PK;NAN;NAN;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:PAIN;
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
CYCLOSPORINE;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;IL10;AA;rs1800871;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING TARGET CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;ARID5B;CC + CT;rs4948496;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;CYP2B6;AA;rs3760657;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
FOLLITROPIN BETA;FSHR;T;rs6166;EFFICACY;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;
FOLLITROPIN BETA;FSHR;T;rs6166;METABOLISM/PK;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;
THYROTROPIN ALFA;FSHR;T;rs6166;EFFICACY;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;
THYROTROPIN ALFA;FSHR;T;rs6166;METABOLISM/PK;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;
UROFOLLITROPIN;FSHR;T;rs6166;EFFICACY;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;
UROFOLLITROPIN;FSHR;T;rs6166;METABOLISM/PK;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;CYP2C19;AA + AG;rs4244285;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
NAN;UGT2B10;CC;rs11726322;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN WOMEN  NAN;
ASPIRIN;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;CYP2C19;CT + TT;rs12248560;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN WOMEN  NAN;
CLOPIDOGREL;ABCB1;AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CAPECITABINE;TYMP;AA + AG;rs11479;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;TYMP;AA + AG;rs11479;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;NAN;PK;PLASMA MK-4 CONCENTRATION IN CHILDREN  NAN;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;CG;rs75017182;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CG;rs75017182;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
FENOFIBRATE;PPARA;TT;rs135543;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN FASTING LDL-C NAN  NAN;
FENOFIBRATE;PPARA;CC + CT;rs9626730;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN FASTING IL-2 NAN  NAN;
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;DECREASED;NAN;OTHER;WARFARIN SENSITIVITY INDEX (INR/CPSS) IN CHILDREN  NAN;
NAN;VDR;CC;rs1544410;NAN;DECREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN PEOPLE WITH  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;DEATH NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;
FENOFIBRATE;PPARA;TT;rs135550;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN FASTING LDL-C NAN  NAN;
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED;NAN;EFFICACY;URINARY DPD/CR LEVELS IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
EXEMESTANE;CYP19A1;TT;rs7176005;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TACROLIMUS;PPARA;GG;rs4253728;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
VINCRISTINE;SLC5A7;AG + GG;rs1013940;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;
ETHANOL;ADH1B;T;rs1229984;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERURICEMIA NAN  NAN;
VINCRISTINE;NKAIN3;A;rs10504361;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
ATENOLOL;PROX1;C;rs340874;TOXICITY;INCREASED;NAN;SIDE EFFECT;GLUCOSE ELEVATION IN PEOPLE WITH  DISEASE:HYPERTENSION;
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEPSIS;
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEIZURES;
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
ABEMACICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
PALBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
RIBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
SIMVASTATIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
VINCRISTINE;ABCC1;T;rs3784867;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;SIGNIFICANTLY HIGHER ON-TREATMENT PLATELET REACTIVITY WITH A MAINTENANCE DOSE OF 75 MG DAILY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
SUNITINIB;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ABEMACICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
ABEMACICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
PALBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
PALBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
RIBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
RIBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;
METOPROLOL;CYP2D6;GG;rs1065852;EFFICACY;DECREASED;NAN;EFFICACY;HEART RATE IN PEOPLE WITH  NAN;
CONJUGATED ESTROGENS;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;OTHER;SPINE BONE MINERAL DENSITY NAN  NAN;
MEDROXYPROGESTERONE;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;OTHER;SPINE BONE MINERAL DENSITY NAN  NAN;
VERAPAMIL;CACNB2;GG;rs2357928;EFFICACY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
VERAPAMIL;CACNB2;GG;rs2357928;TOXICITY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE TO METFORMIN IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
TACROLIMUS;CYP3A5;A;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE TO METFORMIN IN HEALTHY INDIVIDUALS  NAN;
TRAZODONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PROLONGED QTC INTERVAL IN HEALTHY INDIVIDUALS  NAN;
INTERFERONS;BCL2;T;rs1800477;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;BCL2;T;rs1800477;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;NR1I2;GG;rs7643645;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:FATTY LIVER DISEASE;
PLATINUM COMPOUNDS;CCND1;AA;rs9344;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;
PLATINUM COMPOUNDS;CCND1;AA;rs9344;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
VERAPAMIL;CACNB2;AT + TT;rs11014166;EFFICACY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
VERAPAMIL;CACNB2;AT + TT;rs11014166;TOXICITY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;
FLUOROURACIL;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;;AA;rs2960436;EFFICACY;NAN;NAN;OTHER;BETTER SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;IGFBP3;TT;rs2854744;EFFICACY;NAN;NAN;OTHER;BETTER SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
COCAINE;DRD2;C;rs1125394;TOXICITY;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;
MYCOPHENOLATE MOFETIL;SLCO1B1;A;rs4149015;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs4646453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
OPIOIDS;COMT;CC;rs4633;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN WOMEN WITH  OTHER:PAIN;
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ACETAMINOPHEN / TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CONSTIPATION IN PEOPLE WITH  OTHER:PAIN;
ACETAMINOPHEN / TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
NAN;VDR;AA + AG;rs2228570;NAN;DECREASED;NAN;EFFICACY;BONE MINERAL DENSITY NAN  NAN;
OPIOIDS;COMT;CT;rs4633;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN PEOPLE WITH  OTHER:PAIN;
CAPECITABINE;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME;
CAPECITABINE;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
CAPECITABINE;ABCB1;CC;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERECTILE DYSFUNCTION;
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:INSOMNIA;
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEDATION;
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER;
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:PAIN;
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;NAN;NAN;OTHER;WARFARIN VARIABILITY NAN  NAN;
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;NAN;NAN;OTHER;WARFARIN VARIABILITY NAN  NAN;
SUNITINIB;NR1I2;TT;rs3814055;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
AMPHETAMINE;OPRM1;TT;rs510769;OTHER;DECREASED;NAN;OTHER;STIMULATION AND EUPHORIA SCORES AFTER AMPHETAMINE IN HEALTHY INDIVIDUALS  NAN;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
SUNITINIB;ABCG2;CT;rs2231137;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;LRP5;T;rs3736228;NAN;DECREASED;NAN;OTHER;BONE MINERAL DENSITY NAN  NAN;
CISPLATIN;NHLH1;CT + TT;rs11265375;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CISPLATIN;NHLH1;CT + TT;rs11265375;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:LUNG NEOPLASMS;
NAN;;A;rs4355801;NAN;DECREASED;NAN;OTHER;LUMBAR SPINE BONE MINERAL DENSITY NAN  NAN;
NAN;;A;rs4355801;NAN;INCREASED;RISK;DISEASE;OSTEOPOROSIS NAN  NAN;
NAN;LRP5;T;rs3736228;NAN;INCREASED;RISK;DISEASE;OSTEOPOROSIS NAN  NAN;
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN;
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUROPATHIC PAIN IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;
NAN;UGT2B15;AA;rs3100;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
AMPHETAMINE;OPRM1;CC;rs2281617;OTHER;INCREASED;NAN;OTHER;EUPHORIC AND ENERGETIC AFTER AMPHETAMINE (10 MG) IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;HNF4A;CC;rs6130615;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CISPLATIN;SEMA6A;A;rs3806915;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;
CISPLATIN;SEMA6A;A;rs3806915;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:LUNG NEOPLASMS;
ASPIRIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;ABCB1;AA;rs1045642;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;ABCB1;AA;rs1045642;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
WARFARIN;HNF4A;GG;rs1884613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;ITGB3;CC + CT;rs5918;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;ITGB3;CC + CT;rs5918;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
WARFARIN;HNF4A;TT;rs3212191;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ONDANSETRON;SLC6A4;AA;rs1042173;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT RESPONSE AMONG PATIENTS CARRYING THE SLC6A4 PROMOTER LENGTH POLYMORPHISM LONG/LONG GENOTYPE IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
WARFARIN;;G;rs61162043;OTHER;INCREASED;LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY NAN  NAN;
RISPERIDONE;HTR2A;GG;rs6313;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HEROIN;OPRM1;G;rs2075572;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
RISPERIDONE;;TT;rs1805054;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIHYPERTENSIVES;NEDD4L;AA;rs4149601;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;
ANTIHYPERTENSIVES;ADRB1;GG;rs1801252;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
RISPERIDONE;HTR2C;CT + TT;rs3813929;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
BLEOMYCIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
BLEOMYCIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
CYCLOPHOSPHAMIDE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
CYCLOPHOSPHAMIDE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
DOXORUBICIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
DOXORUBICIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
PREDNISONE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
PREDNISONE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
RITUXIMAB;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
RITUXIMAB;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
VINCRISTINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
VINCRISTINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
VINDESINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
VINDESINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:LUPUS ERYTHEMATOSUS;
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;CC;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;
METHADONE;OPRM1;G;rs1799971;OTHER;DECREASED;LIKELIHOOD;DISEASE;RECURRENCE IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
NAN;CYP2C9;C;rs1057910;NAN;DECREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;
NAN;CYP2C9;C;rs1057910;NAN;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
SUFENTANIL;CYP3A4;TT;rs2242480;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPOVENTILATION IN PEOPLE WITH  OTHER:PAIN;
SUFENTANIL;CYP3A4;TT;rs2242480;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
NAN;ADRA2A;A;rs3750625;OTHER;INCREASED;LIKELIHOOD;DISEASE;DIABETES;
NAN;ADRA2A;A;rs3750625;OTHER;INCREASED;LIKELIHOOD;DISEASE;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;
NAN;ADRA2A;G;rs11195418;OTHER;DECREASED;LIKELIHOOD;DISEASE;DIABETES;
NAN;ADRA2A;G;rs11195418;OTHER;DECREASED;LIKELIHOOD;DISEASE;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;
MURAGLITAZAR;REN;TT;rs2368564;TOXICITY;DECREASED;RISK;DISEASE;EDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
CHLOROQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED;SEVERITY;EFFICACY;PARASITEMIA IN PEOPLE WITH  DISEASE:MALARIA;
PRIMAQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED;SEVERITY;EFFICACY;PARASITEMIA IN PEOPLE WITH  DISEASE:MALARIA;
ASPIRIN;IL4;TT;rs2243250;OTHER;DECREASED;NAN;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
WARFARIN;CYP2C9;AC + CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO METHOTREXATE IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;
METFORMIN;AMHR2;G;rs784892;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;AMHR2;G;rs784892;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
ACETAMINOPHEN;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
ASPIRIN;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
DICLOFENAC;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
PROPIONIC ACID DERIVATIVES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
PYRAZOLONES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO FIRST THERAPEUTIC INR AND TIME TO FIRST INR>4 IN CHILDREN  NAN;
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
NEVIRAPINE;CYCSP5;A;rs3099844;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
NEVIRAPINE;CYCSP5;A;rs3099844;OTHER;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;
ACETAMINOPHEN;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
ASPIRIN;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
DICLOFENAC;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PROPIONIC ACID DERIVATIVES;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PYRAZOLONES;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
ACETAMINOPHEN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;
ACETAMINOPHEN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;
ASPIRIN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;
ASPIRIN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;
DICLOFENAC;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;
DICLOFENAC;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;
PROPIONIC ACID DERIVATIVES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;
PROPIONIC ACID DERIVATIVES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;
PYRAZOLONES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;
PYRAZOLONES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;
ANTIHYPERTENSIVES;NOS3;G;rs1799983;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:PRE-ECLAMPSIA;
ANTIHYPERTENSIVES;NOS3;C;rs2070744;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:PRE-ECLAMPSIA;
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
NAN;ADRA2A;A;rs1800038;OTHER;INCREASED;LIKELIHOOD;DISEASE;DIABETES;
NAN;ADRA2A;A;rs1800038;OTHER;INCREASED;LIKELIHOOD;DISEASE;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
CISPLATIN;SLC22A1;CG + GG;rs683369;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASM OF ESOPHAGUS;
NICOTINE;;G;rs4887074;TOXICITY;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
FLUOROURACIL;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;PON1;CC;rs854552;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
FLUOROURACIL;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CISPLATIN;PPARD;AG + GG;rs2038067;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASM OF ESOPHAGUS;
TACROLIMUS;CYP3A5;C;rs6977165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:LUPUS ERYTHEMATOSUS;
WARFARIN;VKORC1;CT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN CHILDREN  NAN;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;PROPERTION OF THE FIRST 6 MONTHS' TREATMENT TIME SPENT WITHIN THE TARGET INR RANGE (PTIR) IN CHILDREN  NAN;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;G;rs17376848;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
ACETAMINOPHEN / TRAMADOL;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PAIN;
ACETAMINOPHEN / TRAMADOL;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
LITHIUM;GSK3B;AA;rs334558;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
DOXORUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
METHOTREXATE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;
ACETAMINOPHEN / TRAMADOL;MIR23B;GG;rs1011784;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PAIN;
ACETAMINOPHEN / TRAMADOL;MIR23B;GG;rs1011784;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
ACETAMINOPHEN / TRAMADOL;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NEUROPATHIC PAIN IN PEOPLE WITH  OTHER:PAIN;
ACETAMINOPHEN / TRAMADOL;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSTOPERATIVE;
OPIOIDS;CYP1A2;AA + AG;rs2069514;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;DRD3;AA + AG;rs2654754;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
OPIOIDS;DRD3;AG + GG;rs324029;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
METHAMPHETAMINE;FAAH;A;rs324420;TOXICITY;INCREASED;RISK;SIDE EFFECT;METHAMPHETAMINE DEPENDENCE NAN  NAN;
OPIOIDS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
RISPERIDONE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
ASPIRIN;UGT1A6;AC + CC;rs1105879;EFFICACY;INCREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;
ACETAMINOPHEN / TRAMADOL;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CONSTIPATION IN PEOPLE WITH  OTHER:PAIN;
ACETAMINOPHEN / TRAMADOL;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
OPIOIDS;CYP3A5;AA + AG;rs15524;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
REGORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;
CYCLOPHOSPHAMIDE;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;
TAXANES;NR1I3;CC;rs11584174;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATAZANAVIR;UGT1A1;G;rs8330;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;G;rs8330;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CYCLOPHOSPHAMIDE;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;
EFAVIRENZ;CYP2B6;TT;rs28399499;TOXICITY;INCREASED;RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;ABCB1;TT;rs10276036;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TAXANES;UGT2B7;AA;rs7438284;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATAZANAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TAXANES;UGT2B7;TT;rs7439366;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATAZANAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TAXANES;UGT2B7;AA;rs7662029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAXANES;UGT2B7;TT;rs7668258;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER IN MEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTIPSYCHOTICS;GRM3;TT;rs1468412;TOXICITY;INCREASED;RISK;SIDE EFFECT;MEMORY IMPAIRMENT IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
RISPERIDONE;BDNF;TT;rs6265;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CORTICOSTEROIDS;FCER2;G;rs28364072;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHMA-RELATED ER VISIT OR HOSPITALIZATION IN CHILDREN WITH  DISEASE:ASTHMA;
FLUOROURACIL;CXCL8;AA;rs4073;EFFICACY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
RADIOTHERAPY;CXCL8;AA;rs4073;EFFICACY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
FLUOROURACIL;KDR;AA;rs1870377;TOXICITY;NAN;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
RADIOTHERAPY;KDR;AA;rs1870377;TOXICITY;NAN;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
PEGINTERFERON ALFA-2B;IL6;CC;rs1800795;TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IL6;CC;rs1800795;TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED;NAN;EFFICACY;MEAN PERCENTAGE REDUCTION OF TRIGLYCERIDES LEVEL IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
CANGRELOR;P2RY12;G;rs6787801;OTHER;NAN;NAN;OTHER;5% LOWER ADP-INDUCED PEAK PLATELET AGGREGATION IN-VITRO NAN  NAN;
NAN;APOC1, APOE;A;rs445925;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;
SUNITINIB;FGFR2;AA;rs2981582;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;
SUNITINIB;FLT4;CC + CT;rs307826;EFFICACY;DECREASED;NAN;DISEASE;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
SUNITINIB;NR1I3;AA + AG;rs2307424;EFFICACY;DECREASED;NAN;DISEASE;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;FADS1, FEN1, MIR611, TMEM258;T;rs174541;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;
NAN;;C;rs258494;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;
NAN;LDLR;T;rs6511720;OTHER;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;
NAN;PNMT;T;rs2934965;OTHER;DECREASED;RISK;OTHER;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  OTHER:ANEMIA;
NAN;PNMT;T;rs2934965;OTHER;DECREASED;RISK;OTHER;SICKLE CELL;
FLUOROURACIL;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
LEUCOVORIN;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
LEVAMISOLE;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
RADIOTHERAPY;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
DEXAMETHASONE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
LENALIDOMIDE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
AZATHIOPRINE;DDRGK1, ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
NAN;PNMT;GG;rs2941523;OTHER;DECREASED;RISK;OTHER;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  OTHER:ANEMIA;
NAN;PNMT;GG;rs2941523;OTHER;DECREASED;RISK;OTHER;SICKLE CELL;
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED;RISK;OTHER;CHRONIC LUNG ALLOGRAFT DYSFUNCTION IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
NAN;PNMT;AA + AG;rs876493;OTHER;DECREASED;RISK;OTHER;SICKLE CELL PAIN CRISIS IN WOMEN WITH  OTHER:ANEMIA;
NAN;PNMT;AA + AG;rs876493;OTHER;DECREASED;RISK;OTHER;SICKLE CELL;
ATENOLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE;
ATENOLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED SYSTOLIC BLOOD PRESSURE IN MEN WITH  DISEASE:HYPERTENSION;
BISOPROLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE;
BISOPROLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED SYSTOLIC BLOOD PRESSURE IN MEN WITH  DISEASE:HYPERTENSION;
LOSARTAN;KIRREL2, NPHS1;T;rs3814995;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
ASPIRIN;ADORA1;TT;rs16851030;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ANTINEOPLASTIC AGENTS;FPGS;TT;rs1544105;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
SUNITINIB;NR1I3;AA;rs4073054;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;FLT4;AA + AC;rs307821;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ALPRAZOLAM;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;
ALPRAZOLAM;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ANXIETY DISORDERS;
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;INCREASED;RISK;OTHER;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
SUNITINIB;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
OLANZAPINE;CYP1A1;T;rs2472297;METABOLISM/PK;NAN;NAN;PK;25% HIGHER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED;RISK;OTHER;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
BEVACIZUMAB;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CETUXIMAB;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OPIOIDS;ADGRV1;C;rs2366929;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;
BEVACIZUMAB;MGAT4A;G;rs885036;EFFICACY;DECREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;MGAT4A;G;rs885036;EFFICACY;DECREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;DECREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;FMO3;AA;rs1736557;EFFICACY;DECREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  EFFICACY:CORONARY ARTERY DISEASE;
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ASPIRIN;PEAR1;G;rs2644592;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;PEAR1;G;rs2644592;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ASPIRIN;PEAR1;C;rs11264580;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;PEAR1;C;rs11264580;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
BUPROPION;APOE;CC + CT;rs429358;OTHER;INCREASED;LIKELIHOOD;DISEASE;RECURRENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
NICOTINE;APOE;CC + CT;rs429358;OTHER;INCREASED;LIKELIHOOD;DISEASE;RECURRENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
ASPIRIN;PEAR1;TT;rs57731889;EFFICACY;NAN;NAN;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;PEAR1;TT;rs57731889;EFFICACY;NAN;NAN;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ALENDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;
IBANDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;
RISEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;
ZOLEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:EPILEPSY;
ANTINEOPLASTIC AGENTS;GSTM5;C;rs3754446;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ATORVASTATIN;APOE;AT + TT;rs449647;EFFICACY;INCREASED;NAN;EFFICACY;LIPID-LOWERING EFFECT IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
BEZAFIBRATE;APOE;AT + TT;rs449647;EFFICACY;INCREASED;NAN;EFFICACY;LIPID-LOWERING EFFECT IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
HALOPERIDOL;SLC6A5;AA;rs2298826;TOXICITY;NAN;NAN;SIDE EFFECT;MOTOR SIDE EFFECTS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;AHR;T;rs4410790;METABOLISM/PK;NAN;NAN;PK;29% LOWER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
ASPIRIN;PEAR1;T;rs3737224;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;PEAR1;T;rs3737224;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;SEVERITY;DISEASE;ALCOHOL ABUSE NAN  NAN;
VENLAFAXINE;CYP2D6;del;rs5030655;METABOLISM/PK;NAN;NAN;PK;IMPAIRED METABOLIC ACTIVITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
CISPLATIN;CASP3;C;rs2720376;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;CASP3;C;rs2720376;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA IN MEN  NAN;
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA IN MEN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs59502379;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
NEVIRAPINE;CCHCR1;C;rs1265112;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CISPLATIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
NAN;GLI1;CC;rs2228226;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
NICOTINE;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREMOR IN PEOPLE WITH  OTHER:EPILEPSY;
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;NAN;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CLOZAPINE;ACKR1;CC;rs2814778;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ESCITALOPRAM;;A;rs2069521;TOXICITY;INCREASED;NAN;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;NAN;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;;A;rs2069521;TOXICITY;INCREASED;NAN;SIDE EFFECT;NAUSEA/VOMITING IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;NAN;SIDE EFFECT;NAUSEA/VOMITING IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;NAN;SIDE EFFECT;NAUSEA/VOMITING IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;EFFICACY;DECREASED;NAN;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CIGARETTE SMOKERS;
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;METABOLISM/PK;DECREASED;NAN;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CIGARETTE SMOKERS;
ETHANOL;OPRK1;CC + CT;rs6473797;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ALCOHOL ABUSE IN MEN  NAN;
CYCLOPHOSPHAMIDE;NQO1;A;rs1800566;EFFICACY;NAN;NAN;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;NQO1;A;rs1800566;EFFICACY;NAN;NAN;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
HEROIN;GRM3;T;rs274618;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
THIAZOLIDINEDIONES;AQP2;T;rs296766;TOXICITY;INCREASED;RISK;DISEASE;EDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
THIAZOLIDINEDIONES;AQP2;T;rs296766;TOXICITY;INCREASED;RISK;DISEASE;TYPE 2;
ETHANOL;CHRNA3;G;rs578776;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;
ETHANOL;CHRNA3;G;rs578776;OTHER;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;
CISPLATIN;ABCC5;G;rs939338;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ABCC5;G;rs939338;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CISPLATIN;FASLG;T;rs763110;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;FASLG;T;rs763110;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CISPLATIN;MSH2;C;rs4638843;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;MSH2;C;rs4638843;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;C;rs3087879;EFFICACY;INCREASED;SEVERITY;EFFICACY;PHARMACOLOGICAL RESISTANCE IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;
COCAINE;CHRNA5;G;rs684513;OTHER;INCREASED;LIKELIHOOD;DISEASE;COCAINE DEPENDENCE NAN  NAN;
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
ALLOPURINOL;;AG + GG;rs2734583;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
ALLOPURINOL;;AG + GG;rs2734583;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;PSORS1C1;AA + AG;rs9263726;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;
ALLOPURINOL;PSORS1C1;AA + AG;rs9263726;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
FEXOFENADINE;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN HEALTHY INDIVIDUALS  NAN;
ANTINEOPLASTIC AGENTS;SLC28A3;AA;rs17343066;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION (P<0.001) IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOZAPINE;TRAT1;C;rs116982346;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PANCYTOPENIA;
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
EFAVIRENZ;CYP2A6;AC + CC;rs8192726;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION (P=0.028) IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CYCLOPHOSPHAMIDE;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
NAN;ADH1B;A;rs1789891;OTHER;INCREASED;NAN;DISEASE;ALCOHOL ABUSE NAN  NAN;
ANTINEOPLASTIC AGENTS;DCTD;AA;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
EFAVIRENZ;UGT2B7;CC + CT;rs7439366;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PANCYTOPENIA;
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
FLUOROURACIL;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOZAPINE;TRAC;A;rs377360;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
NEVIRAPINE;CCHCR1;G;rs746647;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;FGFBP1;CC;rs2245964;OTHER;INCREASED;NAN;OTHER;BONE MINERAL DENSITY NAN  NAN;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;DISEASE:GASTROINTESTINAL HEMORRHAGE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
NAN;FGFBP1;TT;rs16892645;OTHER;INCREASED;NAN;OTHER;BONE MINERAL DENSITY NAN  NAN;
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN LDL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
NAN;;G;rs2824292;OTHER;INCREASED;RISK;DISEASE;VENTRICULAR FIBRILLATION IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
NEVIRAPINE;;G;rs6545803;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NICOTINE;FMO1;C;rs10912675;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
NEVIRAPINE;POLR3G;T;rs2562519;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NICOTINE;FMO1;T;rs7877;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
ASPARAGINASE;GRIA1;T;rs4958381;TOXICITY;INCREASED;RISK;NANDISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE
PACLITAXEL;CYP17A1;AG + GG;rs743572;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ACENOCOUMAROL;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH;
ACENOCOUMAROL;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;DISEASE:GASTROINTESTINAL HEMORRHAGE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
CISPLATIN;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
FLUOROURACIL;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
CARBOPLATIN;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
DOCETAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CAPECITABINE;CES2;CG + GG;rs11075646;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:NEOPLASMS;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
"""ANALGESICS AND ANESTHETICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ANTIBIOTICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ANTIEPILEPTICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ANTIFUNGALS FOR SYSTEMIC USE""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"NON-STEROIDS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ANTIMYCOBACTERIALS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ANTITHYROID PREPARATIONS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED;LIKELIHOOD;OTHER;SHORT AND LONG-TERM WEIGHT LOSS NAN  NAN;
MITOTANE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;NAN;NAN;PK;BEING A PREDICTOR OF MITOTANE PLASMA CONCENTRATIONS OF AT LEAST 14 ΜG/ML AFTER 3 MONTHS OF TREATMENT IN PEOPLE WITH  DISEASE:ADRENOCORTICAL CARCINOMA;
BORTEZOMIB;CTLA4;GG;rs4553808;TOXICITY;NAN;NAN;SIDE EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
MELPHALAN;CTLA4;GG;rs4553808;TOXICITY;NAN;NAN;SIDE EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
PREDNISONE;CTLA4;GG;rs4553808;TOXICITY;NAN;NAN;SIDE EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PBMC-ASSOCIATED DRUG CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;CRHR1;TT;rs1876828;METABOLISM/PK;DECREASED;NAN;PK;BASELINE CORTISOL LEVELS IN CHILDREN WITH  DISEASE:ASTHMA;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;NAN;PK;INTRACELLULAR PBMC EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;INTRACELLULAR PBMC EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
VALPROIC ACID;SOD2;AG + GG;rs4880;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  OTHER:EPILEPSY;
NAN;ABCB1;AA;rs1045642;OTHER;INCREASED;LIKELIHOOD;OTHER;HELICOBACTER PYLORI INFECTION NAN  NAN;
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  OTHER:EPILEPSY;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;OTHER;ADP-STIMULATED PLATELET AGGREGATION NAN  NAN;
CAPECITABINE;CDA;AG + GG;rs10916825;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:NEOPLASMS;
ANTINEOPLASTIC AGENTS;ABCB1;CC + CT;rs4148737;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
CLOPIDOGREL;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
TICAGRELOR;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;
TICAGRELOR;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;MINIMUM PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;DECREASED;RISK;EFFICACY;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DEFERASIROX;UGT1A1;TT;rs887829;EFFICACY;DECREASED;RISK;DISEASE;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;
METFORMIN;SLC47A2;AA + AG;rs12943590;METABOLISM/PK;INCREASED;NAN;PK;RENAL AND SECRETORY CLEARANCE OF METFORMIN IN HEALTHY INDIVIDUALS  NAN;
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO METFORMIN IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:NEOPLASMS;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF ATORVASTATIN IN PEOPLE WITH  DISEASE:OBESITY;
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;
DEFERASIROX;CYP1A2;AA;rs762551;EFFICACY;DECREASED;RISK;EFFICACY;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;
ANTINEOPLASTIC AGENTS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DEFERASIROX;CYP1A1;CC;rs2606345;EFFICACY;DECREASED;RISK;EFFICACY;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;
HEROIN;GRM3;C;rs274622;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
EFAVIRENZ;ABCB1;CC + CT;rs3842;METABOLISM/PK;INCREASED;NAN;PK;ACCUMULATION OF DRUG IN PBMCS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ETHANOL;CHRNA4;G;rs1044394;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;AG;rs1799963;TOXICITY;INCREASED;RISK;DISEASE;VENOUS THROMBOSIS IN WOMEN  NAN;
OPIOIDS;ENPP2;AA;rs2249015;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;DISEASE;VENOUS THROMBOSIS IN WOMEN  NAN;
CAPECITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CISPLATIN;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DOCETAXEL;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
EPIRUBICIN;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
GEMCITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
ASPIRIN;ADORA1;GG + GT;rs2228079;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
LOVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
METHOTREXATE;MTHFR;GG + GT;rs1801131;TOXICITY;DECREASED;RISK;SIDE EFFECT;SKIN DISORDER IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;FASTKD3, MTRR;AG + GG;rs1801394;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PROPRANOLOL;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER PLASMA CONCENTRATION OF PROPRANOLOL IN HEALTHY INDIVIDUALS  NAN;
CAPECITABINE;DPYD;T;rs6668296;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs6668296;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CAPECITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CISPLATIN;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
DOCETAXEL;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
EPIRUBICIN;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
GEMCITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
NAN;APOE;CT + TT;rs7412;OTHER;INCREASED;NAN;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY DISEASE;
NAN;APOE;CT + TT;rs7412;OTHER;INCREASED;NAN;OTHER;OTHER:HYPERTENSION;
CAPECITABINE;DPYD;C;rs115349832;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;C;rs115349832;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED;LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS NAN  NAN;
NAN;APOE;CC + CT;rs429358;OTHER;INCREASED;NAN;OTHER;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  OTHER:CORONARY DISEASE;
NAN;APOE;CC + CT;rs429358;OTHER;INCREASED;NAN;OTHER;OTHER:HYPERTENSION;
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
SIMVASTATIN;APOE;C;rs429358;EFFICACY;INCREASED;RISK;OTHER;MORTALITY AFTER MYOCARDIAL INFARCTION;
SIMVASTATIN;APOE;C;rs429358;EFFICACY;INCREASED;RISK;OTHER;HOWEVER THIS CAN BE ELIMINATED NAN  NAN;
CLOZAPINE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HALOPERIDOL;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
AMISULPRIDE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
CLOZAPINE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
HALOPERIDOL;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
ILOPERIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
OLANZAPINE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
QUETIAPINE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
RISPERIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
ZIPRASIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
HEROIN;SOD2;TT;rs5746136;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
OPIOIDS;ENPP2;A;rs7832704;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
CARBOPLATIN;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
DOCETAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
DOCETAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
DOCETAXEL;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TOLCAPONE;;GG;rs4680;EFFICACY;INCREASED;NAN;EFFICACY;REACTION TIME IN  OTHER:ABSTINENT SMOKERS;
DOLASETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED;RISK;SIDE EFFECT;QTC PROLONGATION IN PEOPLE WITH  OTHER:SURGERY AS PART OF ANESTHETIC MANAGEMENT;
GRANISETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED;RISK;SIDE EFFECT;QTC PROLONGATION IN PEOPLE WITH  OTHER:SURGERY AS PART OF ANESTHETIC MANAGEMENT;
SUNITINIB;ABCB1;A;rs2032582;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CAPECITABINE;DPYD;T;rs56276561;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs56276561;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOZAPINE;ELAVL2;A;rs73482673;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;MID-DOSE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:NEOPLASMS;
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;SLCO1B3;G;rs4149118;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TOLCAPONE;COMT;AG;rs4680;EFFICACY;DECREASED;NAN;EFFICACY;REACTION TIME IN  OTHER:ABSTINENT SMOKERS;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
HEROIN;SOD2;AC + CC;rs2758339;TOXICITY;DECREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;SLCO1B3;G;rs11045585;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;SLCO1B3;A;rs7311358;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
IRINOTECAN;TOP1;GG;rs6072262;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;APOB;G;rs679899;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
ERLOTINIB;EGFR;GG;rs712829;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
ERLOTINIB;ABCG2;CC;rs2622604;OTHER;DECREASED;NAN;PK;MEAN AUC NAN  NAN;
ERLOTINIB;ABCG2;CC;rs2622604;METABOLISM/PK;DECREASED;NAN;PK;MEAN AUC NAN  NAN;
WARFARIN;APOB;G;rs1367117;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN PAIN IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN PAIN IN PEOPLE WITH  DISEASE:NEOPLASMS;
PHENYTOIN;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;
FLUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;
PRAVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;
ASPIRIN;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
LEFLUNOMIDE;CYB5A;AA + AG;rs1790834;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS IN WOMEN WITH  OTHER:RHEUMATOID ARTHRITIS;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;DISEASE;STROKE IN WOMEN  NAN;
NEVIRAPINE;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CETUXIMAB;KRAS;C;rs61764370;EFFICACY;NAN;NAN;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
PANITUMUMAB;KRAS;C;rs61764370;EFFICACY;NAN;NAN;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
EDOXABAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CYCLOSPORINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
CYCLOSPORINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
BLEOMYCIN;BLMH;CC;rs1050565;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE HEARING IMPAIRMENT IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
OPIOIDS;TH;AA + AG;rs10770141;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;DECREASED;SEVERITY;EFFICACY;COCAINE DEPENDENCE IN PEOPLE WITH  OTHER:COCAINE DEPENDENCE;
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:SUBSTANCE-RELATED DISORDERS;
OPIOIDS;COMT;AA;rs4680;TOXICITY;DECREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
NAN;VEGFA;CC + CG;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;
SOFOSBUVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
VELPATASVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
VOXILAPREVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
OPIOIDS;TH;CT + TT;rs10770140;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
PHENYTOIN;ABCB1;A;rs1128503;OTHER;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;
PHENYTOIN;ABCB1;A;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;
PHENYTOIN;ABCB1;A;rs1045642;OTHER;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;
PHENYTOIN;ABCB1;A;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;GG;rs1056892;TOXICITY;INCREASED;RISK;DISEASE;CARDIOMYOPATHIES IN PEOPLE WITH  DISEASE:NEOPLASMS;
DEXMEDETOMIDINE;PRKCB;T;rs9922316;OTHER;INCREASED;NAN;OTHER;DEXMEDETOMIDINE ED50 VALUES FOR DRUG-INDUCED DORSAL HAND VEIN (DHV) CONSTRICTION IN HEALTHY INDIVIDUALS  NAN;
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CYCLOSPORINE;ABCB1;CC;rs2229109;EFFICACY;INCREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
CYCLOSPORINE;ABCB1;CC;rs2229109;METABOLISM/PK;INCREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;RATE OF HIGH ON-TREATMENT PLATELET REACTIVITY (HTPR) AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
HMG-COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;TOXICITY;INCREASED;RISK;SIDE EFFECT;CORONARY DISEASE NAN  NAN;
EFAVIRENZ;CYP2B6;C;rs28399499;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PRASUGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING COMPLICATIONS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NICOTINE;DRD1;A;rs686;EFFICACY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
NICOTINE;DRD1;A;rs686;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
NICOTINE;DRD1;A;rs686;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;INCREASED;NAN;EFFICACY;RATE OF HYPER-RESPONSE AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED;RISK;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
MITOTANE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;MITOTANE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:ADRENOCORTICAL CARCINOMA;
NICOTINE;DRD1;T;rs4532;EFFICACY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
NICOTINE;DRD1;T;rs4532;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
NICOTINE;DRD1;T;rs4532;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
REPAGLINIDE;SLC30A8;AG;rs16889462;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
REPAGLINIDE;SLC30A8;AG;rs16889462;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;
ATAZANAVIR;UGT1A7;AA;rs17863778;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A7;AA;rs17863778;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A7;AA;rs17863778;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A7;AA;rs17863778;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
BEVACIZUMAB;EDN1;TT;rs5370;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NAN;G6PD, IKBKG;A;rs5030868;NAN;NAN;NAN;OTHER;PROTECTION FROM PLASMODIUM VIVAX MALARIA INFECTION NAN  NAN;
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;EFFICACY;DECREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ATAZANAVIR;UGT1A3;CC;rs3806596;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A3;CC;rs3806596;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A3;CC;rs3806596;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A3;CC;rs3806596;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ATAZANAVIR;UGT1A7;GG;rs7586110;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A7;GG;rs7586110;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A7;GG;rs7586110;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A7;GG;rs7586110;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
OXALIPLATIN;ERCC2, KLC3;GG + GT;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
OXALIPLATIN;ERCC2, KLC3;GG + GT;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
APREPITANT;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NAUSEA;
APREPITANT;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OLANZAPINE;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NAUSEA;
OLANZAPINE;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
ATAZANAVIR;UGT1A7;GG;rs17868323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATAZANAVIR;UGT1A7;GG;rs17868323;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A7;GG;rs17868323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;UGT1A7;GG;rs17868323;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
APREPITANT;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;
APREPITANT;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OLANZAPINE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;
OLANZAPINE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
APREPITANT;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;
APREPITANT;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
OLANZAPINE;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;
OLANZAPINE;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;
TAFENOQUINE;;A;rs62103056;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;
TAFENOQUINE;;A;rs62103056;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;VIVAX;
METHOTREXATE;GGH;CC;rs719235;EFFICACY;INCREASED;RISK;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;GGH;CC;rs719235;TOXICITY;INCREASED;RISK;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
TIMOLOL;ADRB1;AA;rs1801252;OTHER;INCREASED;NAN;OTHER;SYSTOLIC (SAP) AND DIASTOLIC (DAP) ARTERIAL PRESSURE RESPONSES TO TIMOLOL IN HEALTHY INDIVIDUALS  NAN;
CISPLATIN;LRP2;G;rs2228171;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DISULFIRAM;DBH;CT + TT;rs1611115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:ALCOHOL ABUSE;
FENTANYL;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;
PROPOFOL;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;
REMIFENTANIL;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;
SEVOFLURANE;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;NAN;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;RISK;DISEASE;DIABETES MELLITUS;
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;
THIAZIDES;SLCO2A1;T;rs34550074;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPONATREMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;SLCO2A1;T;rs34550074;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPONATREMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
ROSUVASTATIN;FMO3;A;rs1736557;EFFICACY;NAN;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
WARFARIN;GGCX;C;rs699664;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) NAN  NAN;
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:MEDULLOBLASTOMA;
WARFARIN;GGCX;G;rs11676382;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
METHYLPHENIDATE;COMT;A;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
METHYLPHENIDATE;COMT;A;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:FETAL ALCOHOL SYNDROME;
ANTIEPILEPTICS;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
WARFARIN;GGCX;G;rs11676382;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) NAN  NAN;
WARFARIN;NQO1;AA + AG;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
NAN;G6PD;T;rs1050828;NAN;INCREASED;NAN;OTHER;PROTECTION AGAINST SEVERE (P=0.006) AND MILD MALARIA (P=0.027) NAN  NAN;
ANTITHYROID PREPARATIONS;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
METHIMAZOLE;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
PROPYLTHIOURACIL;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;
OXALIPLATIN;ERCC1;AA;rs11615;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
OXALIPLATIN;ERCC1;AA;rs11615;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS;
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ACE INHIBITORS;;CC + CT;rs4267385;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;
PLAIN;;CC + CT;rs4267385;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;
ACE INHIBITORS;;AA + AT;rs4459610;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;
PLAIN;;AA + AT;rs4459610;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;
NAN;G6PD;T;rs1050828;NAN;INCREASED;NAN;OTHER;PROTECTION AGAINST DEVELOPING SEVERE MALARIA IN PEOPLE WITH  DISEASE:MALARIA;
METHOTREXATE;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;ALOPECIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ACE INHIBITORS;BDKRB2;AG;rs8016905;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;
PLAIN;BDKRB2;AG;rs8016905;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;
NAN;F5;C;rs6025;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;
CARBOPLATIN;TRIM5;C;rs7950311;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;TRIM5;C;rs7950311;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
NAN;MTHFR;G;rs1801131;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;
ANTINEOPLASTIC AGENTS;;G;rs6674079;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
NAN;MTHFR;G;rs1801133;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;
CARBOPLATIN;;C;rs2549714;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;;C;rs2549714;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
NAN;SERPINE1;A;rs2227631;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;
ANTINEOPLASTIC AGENTS;;G;rs4910232;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;DECREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) NAN  NAN;
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:ASTHMA;
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ANTINEOPLASTIC AGENTS;ZNF100;C;rs3795247;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;
ASPIRIN;PTGIR;AG + GG;rs1126510;OTHER;DECREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;NUMBER OF EXAMINATIONS ABOVE THE THERAPEUTIC RANGE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;
ASPIRIN;TBXA2R;GG;rs1131882;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;PTGER3;A;rs7551789;OTHER;INCREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR>=2 NAN  NAN;
ASPIRIN;PTGER2;GG;rs1353411;OTHER;INCREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;PTGER2;G;rs2075797;OTHER;DECREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
DOCETAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;
DOXORUBICIN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;NAN;OTHER;STABLE WARFARIN DOSE NAN  NAN;
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;VASP INDEX IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;NAN;SIDE EFFECT;DECLINE IN FEV 1 AFTER ASPIRIN PROVOCATION IN PEOPLE WITH  DISEASE:ASTHMA;
CLOPIDOGREL;CYP2C19;AG + GG;rs4986893;EFFICACY;NAN;NAN;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY IN  OTHER:UNDERGOING SCHEDULED PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;NECAB1;G;rs74569896;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;NECAB1;G;rs74569896;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY IN  OTHER:UNDERGOING SCHEDULED PERCUTANEOUS CORONARY INTERVENTION;
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;ATHEROTHROMBOTIC EVENTS DURING THE 6-YEAR FOLLOW UP IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;
WARFARIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;
ASPIRIN;EFR3A;G;rs4736529;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;EFR3A;G;rs4736529;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
GEMCITABINE;SLC28A1;GG;rs2242046;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;
WARFARIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;
GEMCITABINE;CDA;CC + CT;rs1048977;OTHER;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU AND FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEMCITABINE;CDA;CC + CT;rs1048977;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU AND FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;NAN;NAN;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC) NAN  NAN;
ETHAMBUTOL;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;NAN;NAN;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC) NAN  NAN;
PRAVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
GEMCITABINE;CMPK1;CC;rs1044457;OTHER;DECREASED;NAN;PK;FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEMCITABINE;CMPK1;CC;rs1044457;METABOLISM/PK;DECREASED;NAN;PK;FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;
ASPIRIN;WDR24;G;rs11640115;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;WDR24;G;rs11640115;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
GEMCITABINE;CDA;CC;rs4655226;OTHER;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEMCITABINE;CDA;CC;rs4655226;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU IN PEOPLE WITH  DISEASE:NEOPLASMS;
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;BIOCHEMICAL RESPONSE;
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;OPTIMAL CYTOREDUCTION;
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;BIOCHEMICAL RESPONSE;
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;OPTIMAL CYTOREDUCTION;
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
VARENICLINE;ICAM5;T;rs901886;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SLEEP DISORDERS IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
VARENICLINE;ICAM5;T;rs901886;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SMOKING CESSATION;
METHOTREXATE;ABCC1;AG;rs2238476;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSORIASIS;
MITOXANTRONE;ABCB1;AA;rs1128503;OTHER;INCREASED;NAN;OTHER;SENSITIVITY IN VITRO NAN  NAN;
MERCAPTOPURINE;FOLH1;A;rs61886492;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;FOLH1;A;rs61886492;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
ETHAMBUTOL;NAT2;TT;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME/EPIDERMAL NECROLYSIS;
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;PPARA;AA + AG;rs135561;OTHER;DECREASED;RISK;OTHER;ALL-CAUSE MORTALITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOZAPINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS;
CLOZAPINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE ACTIVITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
COMBINATIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
FLUTICASONE PROPIONATE;CYP3A4;AA + AG;rs35599367;EFFICACY;NAN;NAN;EFFICACY;IMPROVED ASTHMA CONTROL (AS MEASURED BY DECREASE IN AVERAGE ASTHMA CONTROL SCORE) IN CHILDREN WITH  DISEASE:ASTHMA;
ALLOPURINOL;CCHCR1;A;rs9263745;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ACE INHIBITORS;AGTR1;C;rs5186;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PLAIN;AGTR1;C;rs5186;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION NORMALIZED FOR THE DAILY DOSE (C) PER KILOGRAM BODY WEIGHT (D) (C/D;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;NG/ML/MG/KG/DAY) RATIO DURING THE FIRST MONTH AFTER TRANSPLANTATION NAN  NAN;
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE EFFECT;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
METHOTREXATE;FOXP3;GT;rs3761548;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSORIASIS;
NAN;CHAT;G;rs1880676;OTHER;INCREASED;RISK;DISEASE;SCHIZOPHRENIA NAN  NAN;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
COMBINATIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
OXALIPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED;NAN;SIDE EFFECT;RENAL FUNCTION (LOWER CREATININE CLEARANCE) AT 3 MONTHS OF FOLLOW-UP IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METFORMIN;SLC22A1;AA;rs622342;METABOLISM/PK;DECREASED;NAN;PK;CL RENAL REFERENCE AND LOWER AND CL SEC REFERENCE IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;PSORS1C2;T;rs9263733;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
CYCLOSPORINE;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;ABCG2;CT + TT;rs13120400;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:PSORIASIS;
ALLOPURINOL;PSORS1C1, PSORS1C2;A;rs9263726;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
EXEMESTANE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
EXEMESTANE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
EXEMESTANE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
COMBINATIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
VALPROIC ACID;POLG;C;rs2307441;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
CISPLATIN;ADH1C;CT;rs698;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;ADH1C;CT;rs698;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
OXALIPLATIN;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;DRD2;G;rs6277;NAN;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
ATORVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;
ATORVASTATIN;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;
LOVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;
LOVASTATIN;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;
SIMVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;
SIMVASTATIN;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;
NAN;DRD2;G;rs1799732;NAN;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
VALPROIC ACID;POLG;A;rs3087374;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
EDOXABAN;SLCO1B1;GG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
HYDROCHLOROTHIAZIDE;ADD1;TT;rs4961;OTHER;INCREASED;NAN;OTHER;HYDROCHLOROTHIAZIDE INDUCED CALCIUM RETENTION IN MEN WITH  DISEASE:HYPERTENSION;
EDOXABAN;SLCO1B1;AA + AC;rs999278;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
LEVODOPA;DRD3;TT;rs6280;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
LEVODOPA;DRD2;GG;rs1799732;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  SIDE EFFECT:PARKINSON DISEASE;
BUSULFAN;CTH;TT;rs1021737;TOXICITY;INCREASED;RISK;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE IN CHILDREN WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CTH;TT;rs1021737;TOXICITY;INCREASED;RISK;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE IN CHILDREN WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
FUROSEMIDE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;
SPIRONOLACTONE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;
EDOXABAN;SLCO1B1;CC + CT;rs4149057;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
SIMVASTATIN;ABCB1;AA;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;
SIMVASTATIN;ABCB1;AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;
FUROSEMIDE;ACE;CG + GG;rs4341;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;
SPIRONOLACTONE;ACE;CG + GG;rs4341;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;
SIMVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;
ATORVASTATIN;NOS3;CC;rs2070744;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-INFLAMMATORY EFFECTS IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;INCREASED;NAN;OTHER;WHOLE BLOOD NITRITE IN HEALTHY INDIVIDUALS  NAN;
PAROXETINE;CYP1A2;A;rs2472304;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FUROSEMIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;
SPIRONOLACTONE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;
PAROXETINE;CYP1A2;T;rs4646425;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ATORVASTATIN;ABCB1;AA;rs2032582;OTHER;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
CISPLATIN;ERCC1;AA;rs11615;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
DOXORUBICIN;ERCC1;AA;rs11615;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
METHAMPHETAMINE;ARRB2;C;rs4790694;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
METHOTREXATE;ABCG2;GT;rs2231142;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
PAROXETINE;CYP1A2;T;rs2470890;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PEGINTERFERON ALFA-2A;SCARB1;GG;rs10846744;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;SCARB1;GG;rs10846744;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PLATINUM COMPOUNDS;;AA;rs1829346;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
RADIOTHERAPY;;AA;rs1829346;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CISPLATIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
CISPLATIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
DOXORUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;
DOXORUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
ATORVASTATIN;ABCB1;AA;rs1128503;OTHER;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
CLOZAPINE;CYP2C19;AA;rs4244285;OTHER;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
CLOZAPINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
ATORVASTATIN;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
IRINOTECAN;SLCO1B1;GG;rs2306283;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
PLATINUM COMPOUNDS;;AG + GG;rs2027701;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
RADIOTHERAPY;;AG + GG;rs2027701;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
SIMVASTATIN;ABCB1;AA;rs1128503;OTHER;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;
SIMVASTATIN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGHER PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ANTIPSYCHOTICS;SLC18A2;TT;rs363341;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
PLATINUM COMPOUNDS;;CC;rs1059698;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
RADIOTHERAPY;;CC;rs1059698;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
ANTIPSYCHOTICS;GRIK3;CT;rs1334802;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
PLATINUM COMPOUNDS;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
PLATINUM COMPOUNDS;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
RADIOTHERAPY;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
RADIOTHERAPY;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;NAN;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
METHOTREXATE;SHMT1;AG + GG;rs1979277;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ABDOMINAL PAIN IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
PAROXETINE;CYP1A2;A;rs762551;TOXICITY;INCREASED;RISK;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIPSYCHOTICS;HTR2A;AG + GG;rs9567733;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
PLATINUM COMPOUNDS;;CC;rs36080650;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
RADIOTHERAPY;;CC;rs36080650;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
METHOTREXATE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
ANTIPSYCHOTICS;DRD2;AA + AG;rs1124491;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
PLATINUM COMPOUNDS;MEG3;CC;rs10132552;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
RADIOTHERAPY;MEG3;CC;rs10132552;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;NAN;PK;SERUM R -WARFARIN CONCENTRATION NAN  NAN;
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;NAN;NAN;SIDE EFFECT;DIMINISHED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DURING THE FIRST YEAR AFTER ENGRAFTMENT IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;ABCC2;AT + TT;rs17222723;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
METHAMPHETAMINE;SLC6A9;T;rs2486001;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
METHAMPHETAMINE;SLC6A9;T;rs2486001;OTHER;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;INCREASED;RISK;DISEASE;PROTEINURIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
NAN;KCNH2;T;rs1805123;OTHER;INCREASED;LIKELIHOOD;DISEASE;ATRIAL FIBRILLATION NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHAMPHETAMINE;ARRB2;A;rs2036657;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
METHOTREXATE;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN CHILDREN WITH  DISEASE:NON-HODGKIN LYMPHOMA;
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED;RISK;EFFICACY;ASPIRIN-RESISTANT PHENOTYPE NAN  NAN;
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
NAN;CRHR1;AA;rs110402;OTHER;INCREASED;RISK;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;
NICOTINE;ARRB2;A;rs4790694;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;NAN;EFFICACY;MEDIAN WEEKLY WARFARIN DOSE REQUIREMENTS NAN  NAN;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN CHILDREN WITH  DISEASE:NON-HODGKIN LYMPHOMA;
ATORVASTATIN;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CAPECITABINE;MTHFR;GG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CARVEDILOL;ADRB2;C;rs1042714;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN RESTING BLOOD PRESSURE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;PON1;CC + CT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;
ANTIDEPRESSANTS;NTRK2;G;rs1439050;TOXICITY;INCREASED;RISK;DISEASE;SUICIDE IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
BEVACIZUMAB;;CT + TT;rs1478947;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:PROSTATIC NEOPLASMS;
ASPIRIN;TBXA2R;AA;rs4523;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN RESISTANCE IN HEALTHY INDIVIDUALS  NAN;
METHAMPHETAMINE;ARRB2;T;rs1045280;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
ASPIRIN;GP1BA;CC;rs6065;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN RESISTANCE IN HEALTHY INDIVIDUALS  NAN;
OLANZAPINE;PMCH;G;rs7973796;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
WARFARIN;VKORC1;AA;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ASPIRIN;TGFB1;AA + AG;rs1800469;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT CHRONIC URTICARIA NAN  NAN;
WARFARIN;F7;AA;rs6046;EFFICACY;INCREASED;NAN;EFFICACY;SEN SITIVITY TO WARFARIN DURING INDUCTION NAN  NAN;
WARFARIN;F7;AA;rs6046;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CARBOPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOCETAXEL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
VINORELBINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ASPIRIN;KRTAP10-4, TSPEAR;A;rs201441480;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;KRTAP10-4, TSPEAR;A;rs201441480;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;DECREASED;NAN;OTHER;ERYTHROCYTE PLASMA MEMBRANE FLUIDITY IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;NAN;PK;S-WARFARIN CLEARANCE NAN  NAN;
ASPIRIN;ECHS1;T;rs140410716;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;ECHS1;T;rs140410716;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CYCLOPHOSPHAMIDE;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
CYCLOPHOSPHAMIDE;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
EPIRUBICIN;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
FLUOROURACIL;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATORVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
FLUVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
LOVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
PITAVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
SIMVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
ASPIRIN;AGAP3;A;rs75750968;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;AGAP3;A;rs75750968;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ATORVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
FLUVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
LOVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
PITAVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
SIMVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
GEMCITABINE;SLC28A2;CC;rs11854484;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION NAN  NAN;
ACETAMINOPHEN;TLR4;AA + AG;rs1927911;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHMA IN CHILDREN  NAN;
TIMOLOL;;AA + AG;rs16947;TOXICITY;INCREASED;RISK;DISEASE;BRADYCARDIA IN PEOPLE WITH  DISEASE:OPEN-ANGLE GLAUCOMA;
CYCLOPHOSPHAMIDE;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
CYCLOPHOSPHAMIDE;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
EPIRUBICIN;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
FLUOROURACIL;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
GEMCITABINE;SLC28A2;CC;rs1060896;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ATORVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
FLUVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
LOVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
PITAVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
SIMVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION NAN  NAN;
ASPIRIN;ZDHHC3;A;rs3749187;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;ZDHHC3;A;rs3749187;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
VENLAFAXINE;CYP2D6;CT + TT;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE CONCENTRATION PER UNIT DOSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NAN;ADORA2A;AC + CC;rs5996696;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE NAN  NAN;
NAN;ADORA2A;CT;rs71651683;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE NAN  NAN;
NAN;IFITM3;GG;rs12252;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;
CAFFEINE;CYP1A2;CC;rs762551;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE IN PEOPLE WITH  OTHER:COFFEE CONSUMPTION;
CAFFEINE;CYP1A2;CC;rs2470890;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE IN PEOPLE WITH  OTHER:COFFEE CONSUMPTION;
CLOZAPINE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
WARFARIN;VKORC1;AA;rs9934438;EFFICACY;INCREASED;NAN;EFFICACY;MEAN AUC (AREA UNDER CURVE) PROTHROMBIN TIME IN MEN  NAN;
PEGINTERFERON ALFA-2A;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NAN;KCNJ11;TT;rs5219;NAN;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS;
NAN;KCNJ11;TT;rs5219;NAN;INCREASED;LIKELIHOOD;DISEASE;TYPE 2 NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ATORVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
SIMVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
ATORVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
SIMVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;
PEGINTERFERON ALFA-2A;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DEXAMETHASONE;SERPINE1;AA + AG;rs6092;TOXICITY;INCREASED;RISK;DISEASE;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
GEMCITABINE;CDA;AA + AC;rs2072671;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
NICOTINE;CHRNB2;GG;rs2072661;EFFICACY;INCREASED;NAN;OTHER;ABSTINENCE IN  OTHER:SMOKERS;
NICOTINE;CHRNB2;GG;rs2072661;TOXICITY;INCREASED;NAN;OTHER;ABSTINENCE IN  OTHER:SMOKERS;
NICOTINE;CHRNB2;GG;rs2072661;OTHER;INCREASED;NAN;OTHER;ABSTINENCE IN  OTHER:SMOKERS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS D VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS D VIRUS INFECTION;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CLOZAPINE;CYP1A2;A;rs2069514;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED INSULIN LEVELS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CISPLATIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
DOXORUBICIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
METHOTREXATE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:KIDNEY NEOPLASMS;
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEUROENDOCRINE TUMORS;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CISPLATIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
DOXORUBICIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
METHOTREXATE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
NICOTINE;CHRM2;T;rs324650;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CHRM2;T;rs324650;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CETUXIMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PANITUMUMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;VDR;C;rs1544410;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;
CLOZAPINE;CYP1A2;del;rs35694136;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED INSULIN LEVELS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CETUXIMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PANITUMUMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
BEVACIZUMAB;VEGFA;GG;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;PON1;CT + TT;rs662;OTHER;INCREASED;NAN;OTHER;SMALL-DENSE LDL LEVELS NAN  NAN;
PROTON PUMP INHIBITORS;TRPM6;T;rs3750425;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOMAGNESEMIA PRIMARY NAN  NAN;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
NAN;FKBP5;CC + CT;rs1360780;EFFICACY;INCREASED;LIKELIHOOD;NANDISEASE;DEPRESSIVE DISORDER;PEOPLE
CLOZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
CLOZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
OLANZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
QUETIAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
RISPERIDONE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
HALOTHANE;RYR1;T;rs193922803;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;T;rs193922803;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
CETUXIMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SIMVASTATIN;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;
SIMVASTATIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;
PROTON PUMP INHIBITORS;TRPM6;C;rs2274924;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOMAGNESEMIA PRIMARY NAN  NAN;
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
DOXORUBICIN;ERCC1;AA + AC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE;
DOXORUBICIN;ERCC1;AA + AC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
CLOZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
CLOZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
OLANZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
QUETIAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
RISPERIDONE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
SIMVASTATIN;ABCB1;AA;rs2032582;OTHER;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;
SIMVASTATIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;
DESFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
NEVIRAPINE;CYP2B6;C;rs2054675;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASUNAPREVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DACLATASVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DESFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
DESFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
DESFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
NEVIRAPINE;CYP2B6;C;rs3786547;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CAPECITABINE;DPYD;CC + CT;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
DESFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
CAPECITABINE;DPYD;C;rs1801159;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
METHYLPHENIDATE;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERABILITY IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
CISPLATIN;ACYP2;AA + AG;rs1872328;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS (COMPOSITE OF CARDIAC DEATH;
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE EFFECT;MI;
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS) IN KOREAN PATIENTS AFTER PCI NAN  NAN;
DOXORUBICIN;XPC;GG + GT;rs2228001;TOXICITY;DECREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN PEOPLE WITH  OTHER:OSTEOSARCOMA;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
HEROIN;OPRM1;GG;rs9479757;TOXICITY;INCREASED;SEVERITY;OTHER;HEROIN DEPENDENCE NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;BLUNTING OF ALCOHOL CRAVING IN HEALTHY INDIVIDUALS  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;CC;rs1125338;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASMS;
BETA-LACTAM ANTIBACTERIALS;;T;rs71542416;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
PENICILLINS;;T;rs71542416;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
IRINOTECAN;ABCG1;GG;rs425215;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
XELOX;ABCA2;AA;rs2271862;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;ABCA2;AA;rs2271862;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
IRINOTECAN;ABCC5;CC;rs562;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OPIOIDS;TACR1;AG + GG;rs6715729;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE NAN  NAN;
OPIOIDS;DRD2;CT + TT;rs4436578;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE NAN  NAN;
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE NAN  NAN;
IRINOTECAN;SLCO1B1;AG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TRAMADOL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;
NAN;ABCB1;CC + TT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL NAN  NAN;
CARBOPLATIN;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METHOTREXATE;FPGS;CC + CT;rs10106;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
NAN;HIF1A;AG;rs11549467;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL NAN  NAN;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;GG;rs12596638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;GG;rs12596638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASMS;
COUMARIN;CYP2A6;C;rs28399433;OTHER;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;
COUMARIN;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;
NICOTINE;CYP2A6;C;rs28399433;OTHER;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;
NICOTINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;PEMT;T;rs7946;NAN;INCREASED;RISK;DISEASE;FATTY LIVER DISEASE NAN  NAN;
ANTIBIOTICS;LGALS3;AT + TT;rs11125;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CG + GG;rs12600192;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
METHOTREXATE;DHFR;T;rs1650723;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CC;rs12600192;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CC;rs12600192;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASMS;
METHOTREXATE;ABCG2;AG;rs2231135;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
NICOTINE;HINT1;CC;rs3852209;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN MEN WITH  OTHER:TOBACCO USE DISORDER;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;RISK;EFFICACY;METASTATIC NEOPLASM IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
NAN;VDR;CC;rs1544410;OTHER;DECREASED;LIKELIHOOD;OTHER;PRE-ECLAMPSIA IN WOMEN WITH  OTHER:PREGNANCY;
ETHAMBUTOL;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RISPERIDONE;SLC6A4;AA;rs3813034;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ISONIAZID;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CYCLOPHOSPHAMIDE;ALDH1A1;A;rs3764435;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ALDH1A1;A;rs3764435;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ALDH1A1;A;rs168351;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ALDH1A1;A;rs168351;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CARBOPLATIN;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;INTOXICATION IN HEALTHY INDIVIDUALS  NAN;
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;INTOXICATION IN HEALTHY INDIVIDUALS  NAN;
ISONIAZID;NAT2;TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;TT;rs1799929;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;TT;rs1799929;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OPIOIDS;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERALGESIA IN PEOPLE WITH  OTHER:PAIN;
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;DHFR;CC;rs1053129;TOXICITY;INCREASED;RISK;EFFICACY;METASTATIC NEOPLASM IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
TAMOXIFEN;HS6ST3;A;rs118042719;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
PHENYTOIN;ABCB1;A;rs2229107;OTHER;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;
PHENYTOIN;ABCB1;A;rs2229107;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;
"""3";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
"4-METHYLENEDIOXYMETHAMPHETAMINE""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
"""COCAINE""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
"""ETHANOL""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
"""OPIOIDS""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN  DISEASE:BREAST NEOPLASMS;
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"PRIMARY GRAFT FAILURE""";
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"""EFFICACY:KIDNEY TUBULAR NECROSIS";
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"ACUTE"" IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION";
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"PRIMARY GRAFT FAILURE""";
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"""EFFICACY:KIDNEY TUBULAR NECROSIS";
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"ACUTE"" IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION";
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN WITH  ""OTHER:PAIN";
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE""";
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SCOLIOSIS""";
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
SUCCINYLCHOLINE;BCHE;C;rs1799807;METABOLISM/PK;NAN;NAN;SIDE EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY NAN  NAN;
SUCCINYLCHOLINE;BCHE;T;rs1803274;METABOLISM/PK;NAN;NAN;SIDE EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY NAN  NAN;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN WOMEN WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C18;A;rs1042192;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
CLOZAPINE;HNMT;GG;rs2737385;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SEDATION IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HNMT;GG;rs2737385;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
FLUOROURACIL;DPYD;CT;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN WITH  ""OTHER:PAIN";
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE""";
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SCOLIOSIS""";
CLOPIDOGREL;NOC3L;A;rs12572897;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
TAMOXIFEN;LPP;A;rs6790761;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ETHAMBUTOL;NAT2;T;rs1799929;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1799929;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CLOPIDOGREL;CYP2C8;A;rs1058932;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
SUNITINIB;ABCB1;AA + AC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;ABCB1;AA + AC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;
NICOTINE;CHRNA3;A;rs578776;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
TAMOXIFEN;LPP;A;rs77693286;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROBLASTOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
RIFAMPIN;RIPOR2;C;rs10946739;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROBLASTOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
NAN;EGFR;AA;rs763317;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
NAN;GAL;C;rs948854;OTHER;INCREASED;SEVERITY;DISEASE;ANXIETY DISORDERS IN WOMEN WITH  DISEASE:ANXIETY DISORDERS;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;rs3869066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;rs3869066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ATAZANAVIR;ABCB1;AA;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;
HMG-COA_REDUCTASE_INHIBITORS;EYS;G;rs1337512;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
RIFAMPIN;AGBL4;A;rs393994;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ATAZANAVIR;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:EPILEPSY;
HMG COA REDUCTASE INHIBITORS;EYS;A;rs9342288;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
OTHER COMBINATIONS;EYS;A;rs9342288;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
ASPIRIN;SLC30A9;A;rs1047626;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;SLC30A9;A;rs1047626;OTHER;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ESCITALOPRAM;BDNF;C;rs962369;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;BDNF;C;rs962369;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;BDNF;C;rs962369;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NORTRIPTYLINE;BDNF;C;rs962369;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ACE INHIBITORS;KCNMA1;G;rs2253201;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;KCNMA1;G;rs2253201;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
HMG COA REDUCTASE INHIBITORS;EYS;A;rs3857532;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
OTHER COMBINATIONS;EYS;A;rs3857532;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
ASPIRIN;TSC1;C;rs7862221;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;TSC1;C;rs7862221;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
RIFAMPIN;AGBL4;G;rs320003;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ASPIRIN;THRA;G;rs11819745;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;THRA;G;rs11819745;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
RIFAMPIN;CUX2;G;rs7958375;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROBLASTOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
HMG-COA_REDUCTASE_INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
ASPIRIN;CHIA;A;rs3818822;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;CHIA;A;rs3818822;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ATAZANAVIR;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;
ASPIRIN;;C;rs1074373;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;;C;rs1074373;OTHER;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;T;rs1799853;METABOLISM/PK;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;
HEROIN;GRM3;A;rs1990040;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
ASPIRIN;ZBTB22;C;rs3130100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;ZBTB22;C;rs3130100;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
CYCLOSPORINE;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
SIROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:EPILEPSY;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
ASPIRIN;HLA-DPB1;C;rs3097671;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB1;C;rs3097671;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB2;C;rs3129294;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB2;C;rs3129294;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB1;G;rs1042151;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB1;G;rs1042151;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB1;C;rs1042136;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;HLA-DPB1;C;rs1042136;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
RIFAMPIN;RIPOR2;A;rs10946737;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PREDNISOLONE;GATA3;AA;rs3824662;PD;INCREASED;RISK;SIDE EFFECT;SEPSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
RIFAMPIN;AGBL4;A;rs319952;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
NICOTINE;OPRM1;AA;rs10485057;TOXICITY;INCREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;
ETHANOL;DPP6;C;rs2533200;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CISPLATIN;EPHX1;CT;rs1051740;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY GRADES 1-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;EPHX1;CT;rs1051740;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY GRADES 1-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CARBAMAZEPINE;;G;rs192543598;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ETHANOL;;T;rs7900002;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;;T;rs2582405;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CISPLATIN;NAT2;CT;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;NAT2;CT;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ETHANOL;;T;rs56722963;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CISPLATIN;MUTYH;CT;rs3219484;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;MUTYH;CT;rs3219484;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CARBAMAZEPINE;ALK;G;rs187926838;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ETHANOL;MED19, TMX2;A;rs576859;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
METHOTREXATE;ATIC;CC;rs7563206;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ENZYMES;A2M;TT;rs669;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGIC TRANSFORMATION IN PEOPLE WITH  DISEASE:STROKE;
METHOTREXATE;ATIC;GT + TT;rs3821353;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;
ENZYMES;F12;GG;rs1801020;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:STROKE;
SUNITINIB;ABCB1;A;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;ABCB1;A;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
METHOTREXATE;ATIC;CG + GG;rs2372536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ETHANOL;;T;rs6589386;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN MEN  NAN;
ETHANOL;ADH1C;A;rs13125415;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
METHOTREXATE;ATIC;CC;rs12995526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CISPLATIN;RAD52;AG;rs11226;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;RAD52;AG;rs11226;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ETHANOL;SLC39A8;A;rs13135092;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CISPLATIN;LIG3;CC;rs1052536;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;LIG3;CC;rs1052536;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ABIRATERONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
PREDNISOLONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
CISPLATIN;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
CISPLATIN;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
FLUOROURACIL;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
FLUOROURACIL;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
RADIOTHERAPY;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
RADIOTHERAPY;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
INDINAVIR;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
METHOTREXATE;FPGS;AA;rs10760502;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;FPGS;AA;rs10760502;TOXICITY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;FPGS;AA;rs10760502;OTHER;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;FPGS;TT;rs10106;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;FPGS;TT;rs10106;OTHER;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CAPECITABINE;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ETHANOL;;T;rs9679319;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;;A;rs1402398;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;THSD7B;A;rs13382553;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHOTREXATE;ABCB1;TT;rs868755;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ETHANOL;;A;rs2673136;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;;A;rs13129401;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
METHOTREXATE;ABCB1;TT;rs10280623;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ETHANOL;CADM2;A;rs62250713;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;ADH1B;T;rs75967634;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;HEROIN DEPENDENCE IN MEN  NAN;
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NAN;CYP2A6;T;rs56113850;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;
ETHANOL;PDE4B;A;rs6421482;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;;A;rs61767420;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;GCKR;T;rs1260326;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;;T;rs494904;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
NAN;CHRNA5;AA + AT;rs503464;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;
METHOTREXATE;SPATA9;A;rs72783407;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
METHOTREXATE;BIRC5;GG;rs9904341;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
PROTEIN KINASE INHIBITORS;STAT6;TT;rs324011;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;
TAMOXIFEN;C1QTNF6;C;rs114557570;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
NAN;CHRNA5;AA + AT;rs637137;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;
DOCETAXEL;VEGFA;CC;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOCETAXEL;VEGFA;GG;rs13207351;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOCETAXEL;VEGFA;GG;rs35864111;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPARAGINASE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LEUCOVORIN;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LEUCOVORIN;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOCETAXEL;VEGFA;AA;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EXEMESTANE;;C;rs62293499;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
ASPIRIN;CYP4F2;CT;rs2108622;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP4F2;CT;rs2108622;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
FLUOROURACIL;DPYD;AT + TT;rs4294451;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL NAN  NAN;
CITALOPRAM;COL26A1;T;rs17135437;TOXICITY;INCREASED;NAN;SIDE EFFECT;HEARING AND VISION-RELATED SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;;A;rs16965962;TOXICITY;INCREASED;NAN;SIDE EFFECT;GENERAL SIDE-EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ALLOPURINOL;PSORS1C1, PSORS1C2;A;rs9263726;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ASPIRIN;ACE;CC + CT;rs4292;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;NAN;NAN;EFFICACY;STRONGER AGGREAGTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;T;rs4982753;TOXICITY;DECREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;T;rs4982753;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
FLUOROURACIL;DPYD;AT + TT;rs4294451;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
NAN;ACE2;T;rs2074192;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED;RISK;EFFICACY;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED;NAN;EFFICACY;NET DECREASE IN AA-INDUCED PLATELET AGGREGATION AFTER ASPIRIN TREATMENT IN HEALTHY INDIVIDUALS  NAN;
MERCAPTOPURINE;ITPA;AC;rs1127354;METABOLISM/PK;INCREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;FGFR2;G;rs1219648;TOXICITY;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN  DISEASE:HODGKIN DISEASE;
NAN;FGFR2;G;rs1219648;OTHER;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN  DISEASE:HODGKIN DISEASE;
ANASTROZOLE;;T;rs6735923;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
ACENOCOUMAROL;CYP2C9;CT + TT;rs1799853;TOXICITY;INCREASED;RISK;DISEASE;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:STROKE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:STROKE;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;A;rs7319981;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;A;rs7319981;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;
NAN;AGT;AG;rs699;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 NAN  NAN;
ANASTROZOLE;;C;rs1877193;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
CAPECITABINE;DPYD;A;rs2786783;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER;PAIN IN CHILDREN WITH  OTHER:DENTAL CARIES;
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER;OTHER:TOOTH DISORDER;
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER;OTHER:TOOTHACHE;
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;G;rs7662029;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;C;rs7439366;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CEFACLOR;LIMD1;C;rs62242178;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
CEFACLOR;LIMD1;G;rs62242177;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
REPAGLINIDE;SLCO1B1;CC;rs4149056;OTHER;INCREASED;NAN;PK;MEAN PLASMA AUC NAN  NAN;
REPAGLINIDE;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;MEAN PLASMA AUC NAN  NAN;
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;AG + GG;rs1048101;EFFICACY;DECREASED;RISK;EFFICACY;KIDNEY DISORDER NAN  NAN;
THALIDOMIDE;XRCC5;AG;rs1051685;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
THALIDOMIDE;ERCC1;AC + CC;rs735482;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
CLOZAPINE;GCG;C;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;GCG;C;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
NICOTINE;OPRM1;AA + AG;rs1799971;DOSAGE;INCREASED;NAN;OTHER;SMOKING IN CHILDREN  NAN;
NICOTINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;NAN;OTHER;SMOKING IN CHILDREN  NAN;
TOLCAPONE;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;ALCOHOL ABUSE IN PEOPLE WITH  OTHER:ALCOHOL-RELATED DISORDERS;
NICOTINE;UGT2B10;AG + GG;rs112561475;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION OF NICOTINE NAN  NAN;
NICOTINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;NAN;PK;NICOTINE GLUCURONIDATION NAN  NAN;
CLOZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;KIDNEY DISORDER NAN  NAN;
METHAMPHETAMINE;HTR1A;A;rs878567;TOXICITY;NAN;NAN;DISEASE;PSYCHOTIC DISORDER IN PEOPLE WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;
METHAMPHETAMINE;HTR1A;A;rs878567;OTHER;NAN;NAN;DISEASE;PSYCHOTIC DISORDER IN PEOPLE WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:LYMPHOMA;
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
CAPTOPRIL;ACE;AA;rs4291;EFFICACY;DECREASED;SEVERITY;DISEASE;KIDNEY FAILURE IN PEOPLE WITH  DISEASE:ALZHEIMER DISEASE;
ANTIEPILEPTICS;;T;rs4471527;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ANTIEPILEPTICS;;T;rs4471527;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ANTIPSYCHOTICS;LEPR;G;rs1137101;OTHER;INCREASED;LIKELIHOOD;DISEASE;OBESITY IN WOMEN  NAN;
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;A;rs2232228;TOXICITY;DECREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;A;rs2232228;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN CHILDREN  NAN;
ANTIEPILEPTICS;;T;rs77542827;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ANTIEPILEPTICS;;T;rs77542827;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
STAVUDINE;SAMHD1;A;rs8124728;TOXICITY;DECREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE (HEART-RATE LOWERING) IN PEOPLE WITH  DISEASE:HEART FAILURE;
IRINOTECAN;TGFB1;AG + GG;rs1800469;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
ANTIEPILEPTICS;NIPAL2;A;rs199755581;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ANTIEPILEPTICS;NIPAL2;A;rs199755581;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
OXALIPLATIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
OXALIPLATIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
AMLODIPINE;ACE;AA + AT;rs4291;OTHER;DECREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;
CHLORTHALIDONE;ACE;AA + AT;rs4291;OTHER;DECREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;
LISINOPRIL;ACE;AA + AT;rs4291;OTHER;DECREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME NAN  NAN;
IRINOTECAN;TGFBR2;GG;rs3087465;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION NAN  NAN;
SUNITINIB;FLT4;CT;rs307826;EFFICACY;NAN;NAN;EFFICACY;REDUCED PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE REDUCTIONS DUE TO TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
RITODRINE;PDE4B;AA;rs17128809;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
CYCLOPHOSPHAMIDE;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
DOCETAXEL;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
EPIRUBICIN;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
SUNITINIB;FLT4;AC;rs307821;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
BETA BLOCKING AGENTS;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;HEART TRANSPLANTATION;
BETA BLOCKING AGENTS;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;
SALBUTAMOL;;C;rs9552679;EFFICACY;DECREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;COL22A1;T;rs6988229;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;T;rs17495520;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
ASPIRIN;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
ASPIRIN;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
CLOPIDOGREL;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
CLOPIDOGREL;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
ANTIEPILEPTICS;DDX12P;C;rs77491650;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ANTIEPILEPTICS;DDX12P;C;rs77491650;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
SALBUTAMOL;;T;rs1663332;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;G;rs1663330;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;A;rs17701271;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;T;rs518350;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;G;rs10511905;EFFICACY;DECREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SORAFENIB;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SALBUTAMOL;CLOCK;A;rs1522113;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;A;rs1423515;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;T;rs1419555;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SALBUTAMOL;;C;rs6002674;EFFICACY;DECREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
NAN;ACE2;A;rs2106809;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 IN MEN WITH  OTHER:COVID-19;
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:LYMPHOMA;
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPIRIN;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
ASPIRIN;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
CLOPIDOGREL;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;
CLOPIDOGREL;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
ALLOPURINOL;;T;rs1634776;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
PACLITAXEL;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
SALBUTAMOL;;A;rs11252394;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;
SORAFENIB;SLCO1B1;CT + TT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA NAN  NAN;
COCAINE;GABRA2;G;rs11503014;TOXICITY;INCREASED;SEVERITY;OTHER;COCAINE DEPENDENCE NAN  NAN;
COCAINE;OPRM1;C;rs2236256;TOXICITY;DECREASED;SEVERITY;OTHER;COCAINE DEPENDENCE NAN  NAN;
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA NAN  NAN;
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:LYMPHOMA;
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OSTEOSARCOMA;
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;AGT;A;rs699;OTHER;DECREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;
CANGRELOR;P2RY12;TT;rs9859552;OTHER;NAN;NAN;OTHER;20% AND 17% LESS INHIBITION OF PLATELET AGGREGATION WITH CRANGRELOR (0.05 AND 0.25 MICROM) IN-VITRO NAN  NAN;
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
RADIOTHERAPY;TANC1;C;rs10497203;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
GLUCOCORTICOIDS;GLCCI1;GG;rs37973;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POOR RESPONSE IN PEOPLE WITH  DISEASE:ASTHMA;
FLUOROURACIL;ABCG2;A;rs7699188;EFFICACY;INCREASED;NAN;EFFICACY;TUMOR RESPONSE RATE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCG2;A;rs7699188;EFFICACY;INCREASED;NAN;EFFICACY;TUMOR RESPONSE RATE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCG2;A;rs7699188;EFFICACY;INCREASED;NAN;EFFICACY;TUMOR RESPONSE RATE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;DECREASED;NAN;SIDE EFFECT;INTERVAL OF THERAPY TO LEUKOPENIA ONSET IN PEOPLE WITH  DISEASE:LEUKOPENIA;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;AG + GG;rs3087243;TOXICITY;DECREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;GG;rs10782001;TOXICITY;INCREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;AG;rs11209026;TOXICITY;INCREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;INCREASED;SEVERITY;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;
METHOTREXATE;MTHFR;A;rs1801133;METABOLISM/PK;INCREASED;RISK;PK;PROLONGED HIGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LEUKEMIA;
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:PAIN;
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
COLISTIMETHATE;SLC15A2;T;rs2257212;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
ASPARAGINASE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISOLONE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISOLONE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;CYP2C9;CT;rs28371685;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
CETUXIMAB;CCND1;G;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;F7;GT + TT;rs510335;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
TACROLIMUS;IL10;AA;rs1800871;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
ESCITALOPRAM;HTR1B;AC + CC;rs11568817;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE COGNITIVE EFFECTS IN PEOPLE WITH  DISEASE:ANXIETY DISORDERS;
CETUXIMAB;CCND1;AA;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
FLUVOXAMINE;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXSUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
MILNACIPRAN;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXSUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXSUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;NAN;SIDE EFFECT;NON-HDL CHOLESTEROL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"COMBINATIONS""";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;NAN;SIDE EFFECT;NON-HDL CHOLESTEROL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"""RITONAVIR""";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;NAN;SIDE EFFECT;NON-HDL CHOLESTEROL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE COGNITIVE EFFECTS IN PEOPLE WITH  DISEASE:ANXIETY DISORDERS;
TACROLIMUS;IL10;TT;rs1800872;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
NAN;;G;rs17234657;NAN;INCREASED;RISK;DISEASE;CROHN DISEASE NAN  NAN;
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED;RISK;DISEASE;DYSKINESIAS IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
CYCLOPHOSPHAMIDE;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
DOCETAXEL;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
EPIRUBICIN;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED;RISK;DISEASE;HALLUCINATIONS IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
NAN;;T;rs2200733;NAN;INCREASED;RISK;DISEASE;ATRIAL FIBRILLATION NAN  NAN;
ESTRADIOL;NFE2L2;T;rs6721961;TOXICITY;INCREASED;RISK;DISEASE;VENOUS THROMBOEMBOLISM NAN  NAN;
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
NAN;HLA-DRA;A;rs3135388;NAN;INCREASED;RISK;DISEASE;MULTIPLE SCLEROSIS NAN  NAN;
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:NON-HODGKIN LYMPHOMA;
NAN;NOD2;G;rs17221417;NAN;INCREASED;RISK;DISEASE;CROHN DISEASE NAN  NAN;
CISPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;NAN;EFFICACY;ONE YEAR PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;NAN;EFFICACY;ONE YEAR PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FLU-LIKE SYMPTOMS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CLOPIDOGREL;CES1;CT;rs71647871;PD;INCREASED;LIKELIHOOD;EFFICACY;PLATELET REACTIVITY NAN  NAN;
NAN;TCF7L2;T;rs12255372;NAN;INCREASED;RISK;DISEASE;DIABETES MELLITUS;
NAN;TCF7L2;T;rs12255372;NAN;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;
NAN;IL6;AG + GG;rs1800797;OTHER;INCREASED;SEVERITY;OTHER;PAIN IN CHILDREN WITH  OTHER:NEOPLASMS;
NAN;TCF7L2;C;rs12243326;NAN;INCREASED;RISK;DISEASE;DIABETES MELLITUS;
NAN;TCF7L2;C;rs12243326;NAN;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;
NAN;TCF7L2;T;rs4506565;NAN;INCREASED;RISK;DISEASE;DIABETES MELLITUS;
NAN;TCF7L2;T;rs4506565;NAN;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
NAN;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED;NAN;EFFICACY;NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN DURING PAINFUL PROCEDURE NAN  NAN;
ETHANOL;RABGAP1L;G;rs61826952;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL MEAN NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN NAN  NAN;
NAN;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;
TRAMADOL;CYP2D6;CC;rs1058172;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE IN PEOPLE WITH  OTHER:DEATH;
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
TRAMADOL;CYP2B6;CC;rs4803419;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE IN PEOPLE WITH  OTHER:DEATH;
NAN;ACE2;CC;rs4240157;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:COVID-19;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
NAN;ACE2;C;rs4240157;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 IN PEOPLE WITH  NAN;
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;CONCENTRATION-TO-ADJUSTED DOSE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PANCREATITIS;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
HMG-COA_REDUCTASE_INHIBITORS;COQ5;AA + AG;rs10849757;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:STROKE;
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
ZOLEDRONATE;FDPS;TT;rs2297480;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;COQ3;TT;rs11548336;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:STROKE;
IMATINIB;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
IMATINIB;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
HMG-COA_REDUCTASE_INHIBITORS;COQ2;CG + GG;rs4693075;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:STROKE;
CYCLOPHOSPHAMIDE;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ATORVASTATIN;CLMN;A;rs8014194;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN TOTAL CHOLESTEROL NAN  NAN;
PRAVASTATIN;CLMN;A;rs8014194;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN TOTAL CHOLESTEROL NAN  NAN;
SIMVASTATIN;CLMN;A;rs8014194;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN TOTAL CHOLESTEROL NAN  NAN;
CYCLOPHOSPHAMIDE;CYP2B6;AG;rs12721655;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2B6;AG;rs12721655;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NINTEDANIB;DSP;TT;rs2076295;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:PULMONARY FIBROSIS;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs8192709;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO PROGRESSION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2B6;CT;rs8192709;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO PROGRESSION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;MTHFR;GG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;MTHFR;GG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
BUSULFAN;CYP2C19;CC;rs12248560;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
CAPECITABINE;MTHFR;TT;rs1801131;TOXICITY;DECREASED;NAN;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
WARFARIN;F7;GG;rs510317;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;CT;rs1135216;TOXICITY;DECREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;
OLANZAPINE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HEADACHE IN HEALTHY INDIVIDUALS  NAN;
QUETIAPINE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HEADACHE IN HEALTHY INDIVIDUALS  NAN;
RISPERIDONE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HEADACHE IN HEALTHY INDIVIDUALS  NAN;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;AA;rs651630;TOXICITY;DECREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;
RADIOTHERAPY;TANC1;A;rs264588;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RADIOTHERAPY;TANC1;G;rs264631;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
BUSULFAN;CYP2C9;CT + TT;rs1799853;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;
CYCLOPHOSPHAMIDE;SLC22A16;C;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;C;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN  DISEASE:BREAST NEOPLASMS;
RADIOTHERAPY;TANC1;T;rs7582141;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
FLUOROURACIL;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
RADIOTHERAPY;TANC1;T;rs6432512;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
RADIOTHERAPY;TANC1;T;rs264663;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
FLUOROURACIL;ABCB1;CC;rs2032582;EFFICACY;NAN;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCB1;CC;rs2032582;EFFICACY;NAN;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;ABCB1;CC;rs2032582;EFFICACY;NAN;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
RADIOTHERAPY;TANC1;G;rs264651;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;T;rs8192709;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2B6;T;rs8192709;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEMATOLOGIC DISORDER;
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SECUKINUMAB;ERAP2;GG;rs2248374;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:PSORIASIS;
CYCLOPHOSPHAMIDE;SLC22A16;G;rs12210538;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;G;rs12210538;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;SLC22A16;G;rs723685;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;G;rs723685;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;SLC22A16;G;rs6907567;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;G;rs6907567;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPIRIN;LTC4S;C;rs730012;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;
ATORVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:HYPERLIPOPROTEINEMIA TYPE II;
ROSUVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:HYPERLIPOPROTEINEMIA TYPE II;
ATEZOLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AVELUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DURVALUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
IPILIMUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NIVOLUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
PEMBROLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
WARFARIN;VKORC1;CC;rs2884737;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NELFINAVIR;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NELFINAVIR;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;FAVORABLE VIROLOGIC RESPONSES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ATEZOLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
AVELUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DURVALUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
IPILIMUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NIVOLUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
PEMBROLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
DOXORUBICIN;ABCC2;A;rs17222723;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
DOXORUBICIN;ABCC2;A;rs17222723;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
AMITRIPTYLINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROMYELITIS OPTICA;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROMYELITIS OPTICA;
NAN;ATP8B3;G;rs10421558;TOXICITY;DECREASED;LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  OTHER:ASTHMA;
NAN;ABCB1;AA;rs1045642;OTHER;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS NAN  NAN;
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;T;rs1799929;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;T;rs1799929;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;T;rs1799929;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;GG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
RITONAVIR;APOC3;T;rs2854117;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;AGTR1;CC;rs5186;OTHER;INCREASED;RISK;DISEASE;ISCHEMIA IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
IMATINIB;ARID5B;TT;rs10821936;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;
IMATINIB;ARID5B;TT;rs10821936;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BCR-ABL1 POSITIVE;
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;T;rs1041983;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;T;rs1041983;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;T;rs1041983;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;C;rs1801280;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;C;rs1801280;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;C;rs1801280;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
FEXOFENADINE;ABCB1;AA;rs1045642;DOSAGE;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
FEXOFENADINE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CMIN VALUES IN  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;T;rs4803419;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CMIN VALUES IN  DISEASE:HIV INFECTIOUS DISEASE;
IMATINIB;ATIC;G;rs2372536;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;
IMATINIB;ATIC;G;rs2372536;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BCR-ABL1 POSITIVE;
ATORVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED;RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING NAN  NAN;
SIMVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED;RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING NAN  NAN;
FEXOFENADINE;ABCB1;AA;rs2032582;DOSAGE;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
FEXOFENADINE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
RITODRINE;KCNMB2;GG;rs7625907;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CMIN VALUES IN  DISEASE:HIV INFECTIOUS DISEASE;
DOXORUBICIN;ABCC1;T;rs45511401;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
DOXORUBICIN;ABCC1;T;rs45511401;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
DOXORUBICIN;ABCC2;A;rs8187710;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
CAPECITABINE;SMAD7;CC;rs4939827;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;SMAD7;CC;rs4939827;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
TEGAFUR;SMAD7;CC;rs4939827;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
DOXORUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
NAN;ATP8B3;A;rs10403288;TOXICITY;DECREASED;LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  OTHER:ASTHMA;
SIMVASTATIN;ABCB1;A;rs1128503;EFFICACY;DECREASED;RISK;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
NAN;ACE2;T;rs2074192;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 NAN  NAN;
DOXORUBICIN;CYBA;A;rs4673;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
SIMVASTATIN;ABCB1;A;rs1045642;EFFICACY;DECREASED;RISK;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
DOXORUBICIN;RAC2;T;rs13058338;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
SIMVASTATIN;ABCB1;C;rs2032582;EFFICACY;INCREASED;RISK;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
NAN;ABO;T;rs8176746;NAN;INCREASED;NAN;OTHER;ACE ACTIVITY IN PEOPLE WITH  DISEASE:HYPERTENSION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION-TO-ADJUSTED DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
ATORVASTATIN;PON1;AA + AG;rs705379;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
SIMVASTATIN;PON1;AA + AG;rs705379;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
ATORVASTATIN;PON1;CC + CT;rs662;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
SIMVASTATIN;PON1;CC + CT;rs662;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
ATORVASTATIN;PON1;GG;rs705379;OTHER;DECREASED;NAN;OTHER;OXIDATIVE STRESS IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
CLOZAPINE;TACR1;C;rs58933792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRY MOUTH NAN  NAN;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
FLUCONAZOLE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;
FLUCONAZOLE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;NAN;PK;TIME TO REACH STABLE DOSE IN CHILDREN WITH  DISEASE:TRANSPLANTATION;
TAMOXIFEN;SLCO1A2;AG + GG;rs10841795;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIZZINESS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
CLOZAPINE;ERBB4;C;rs3942465;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRY MOUTH NAN  NAN;
DIAZEPAM;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;
"""ACE INHIBITORS";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"PLAIN""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""ANGIOTENSIN II ANTAGONISTS""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""BETA BLOCKING AGENTS""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIGOXIN""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIURETICS""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""SPIRONOLACTONE""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
PEGINTERFERON ALFA-2B;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
L-ASPARAGINE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CUSHING SYNDROME IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CUSHING SYNDROME IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CUSHING SYNDROME IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
"""ACE INHIBITORS";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"PLAIN""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""ANGIOTENSIN II ANTAGONISTS""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""BETA BLOCKING AGENTS""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIGOXIN""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIURETICS""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""SPIRONOLACTONE""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;
EFAVIRENZ;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
LOPINAVIR;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
RITONAVIR;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DIAZEPAM;CYP2C19;CT + TT;rs12248560;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;
"""ACE INHIBITORS";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
"PLAIN""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""ANGIOTENSIN II ANTAGONISTS""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""BETA BLOCKING AGENTS""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIGOXIN""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""DIURETICS""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
"""SPIRONOLACTONE""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;
L-ASPARAGINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
OLANZAPINE;UGT1A4;GG + GT;rs2011425;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;AUTONOMIC NERVOUS SYSTEM DISORDER IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRY MOUTH IN HEALTHY INDIVIDUALS  NAN;
CABAZITAXEL;ABCB1;T;rs17327624;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
CABAZITAXEL;ABCB1;T;rs17327624;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PROSTATIC NEOPLASMS;
SIMVASTATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;
OLANZAPINE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATED METABOLITES OF OLANZAPINE NAN  NAN;
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;FRACTURES;
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;BONE NAN  NAN;
CYCLOSPORINE;ABCB1;AG;rs1045642;TOXICITY;INCREASED;SEVERITY;DISEASE;GINGIVAL HYPERPLASIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE REJECTION IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:CORONARY DISEASE;
CABAZITAXEL;ABCB1;T;rs2235040;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
CABAZITAXEL;ABCB1;T;rs2235040;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PROSTATIC NEOPLASMS;
TACROLIMUS;NOD2;CC;rs2066844;OTHER;INCREASED;NAN;OTHER;HOSPITAL STAY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;TT;rs776746;EFFICACY;INCREASED;RISK;OTHER;ACUTE REJECTION IN  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED;RISK;OTHER;ACUTE REJECTION IN  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  NAN;
TACROLIMUS;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  NAN;
WARFARIN;VKORC1;AA + AG;rs2359612;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;NAN;NAN;PK;SIGNIFICANTLY LARGER MEAN AUC OF OSELTAMIVIR;
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;NAN;NAN;PK;LOWER CMAX OF OSELTAMIVIR CARBOXYLATE;
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;NAN;NAN;PK;AND A SMALLER OSELTAMIVIR CARBOXYLATE-TO-OSELTAMIVIR AUC RATIO IN HEALTHY INDIVIDUALS  NAN;
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;PBMC CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CABAZITAXEL;CYP2C8;T;rs11572093;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
CABAZITAXEL;CYP2C8;T;rs11572093;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PROSTATIC NEOPLASMS;
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;
CITALOPRAM;CYP2C19;A;rs4244285;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;NAN;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;VKORC1;CG + GG;rs8050894;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SLEEP INITIATION AND MAINTENANCE DISORDERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;VKORC1;AC + CC;rs2884737;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;
NORTRIPTYLINE;GNB3;TT;rs5443;EFFICACY;NAN;NAN;EFFICACY;IMPROVEMENTS IN NEUROVEGETATIVE SYMPTOMS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
NAN;SLC19A1;C;rs1051266;OTHER;INCREASED;LIKELIHOOD;OTHER;DOWN SYNDROME IN WOMEN WITH  OTHER:PREGNANCY;
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;NAN;PK;DUODENAL ABSORPTION OF DIGOXIN AFTER DIRECT DELIVERY TO THE SURFACE OF THE DUODENUM BY ENDOSCOPE NAN  NAN;
OLANZAPINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  OTHER:PSYCHIATRIC DISORDERS;
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
OLANZAPINE;ABCB1;A;rs1045642;EFFICACY;NAN;NAN;EFFICACY;POSITIVE RELATIONSHIP BETWEEN OLANZAPINE PLASMA LEVELS AND POSITIVE SYMPTOM REDUCTION COMPARED TO SUBJECTS WITH THE GG GENOTYPE NAN  NAN;
OLANZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  OTHER:PSYCHIATRIC DISORDERS;
NICOTINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
OLANZAPINE;DRD2;A;rs6275;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
OLANZAPINE;DRD2;A;rs6275;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;GG;rs9024;TOXICITY;INCREASED;RISK;DISEASE;CARDIOMYOPATHIES IN PEOPLE WITH  DISEASE:NEOPLASMS;
OLANZAPINE;DRD2;G;rs6279;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
OLANZAPINE;DRD2;G;rs6279;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
CEPHALEXIN;;T;rs34545984;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
OLANZAPINE;DRD2;T;rs1124493;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
OLANZAPINE;DRD2;T;rs1124493;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
OLANZAPINE;DRD2;A;rs2734841;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
OLANZAPINE;DRD2;A;rs2734841;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
ASPIRIN;;A;rs115346678;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
METHOTREXATE;MTHFD1;A;rs2236225;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SIMVASTATIN;PPARA;AA;rs4253728;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL NAN  NAN;
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CODEINE;WBP2NL;G;rs9620007;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;
CODEINE;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
HYDROCODONE;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
OXYCODONE;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
TRAMADOL;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
METFORMIN;SLC22A2;CC;rs316009;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
METFORMIN;SLC22A2;CC;rs316009;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
METFORMIN;SLC22A2;CC;rs316019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
METFORMIN;SLC22A2;CC;rs316019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
SIMVASTATIN;PPARA;GG;rs4823613;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL NAN  NAN;
NAN;ANKK1;GG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE NAN  NAN;
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION;
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS;
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DELIBERATE SELF-HARM IN CHILDREN WITH  OTHER:DEPRESSION;
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ANXIETY DISORDERS;
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
AMIODARONE;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;
ANTIBIOTICS;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;
ANTIPSYCHOTICS;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;
DIURETICS;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;
QUINIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;
SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;
NICOTINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
NICOTINE;OPRM1;AG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
BUPROPION;ANKK1;GG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
OLANZAPINE;DRD2;G;rs2734842;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
OLANZAPINE;DRD2;G;rs2734842;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
PYRIMIDINE ANALOGUES;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
ROSUVASTATIN;ABCG2;GG;rs2231142;EFFICACY;DECREASED;NAN;EFFICACY;PERCENTAGE CHANGE IN LDL-CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
AMITRIPTYLINE;CYP2C19;AA;rs4244285;OTHER;INCREASED;NAN;PK;LOG METABOLIC RATIO OF AMITRIPTYLINE/NORTRIPTYLINE NAN  NAN;
AMITRIPTYLINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;LOG METABOLIC RATIO OF AMITRIPTYLINE/NORTRIPTYLINE NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR DEATH;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;OR STROKE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ROSUVASTATIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS OF ROSUVASTATIN IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR DEATH;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;OR STROKE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ROSUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF ROSUVASTATIN IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR DEATH;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;OR STROKE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"ANEMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"ANEMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"ANEMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
NAN;SERPINE1;T;rs7242;OTHER;INCREASED;LIKELIHOOD;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;
NAN;SERPINE1;G;rs2227684;OTHER;INCREASED;LIKELIHOOD;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CLINICAL RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
GEMCITABINE;CDA;A;rs60369023;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEMCITABINE;CDA;A;rs60369023;METABOLISM/PK;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BISPHOSPHONATES;IL1B;GG;rs16944;EFFICACY;INCREASED;LIKELIHOOD;PK;RESISTANCE IN PEOPLE WITH  DISEASE:OSTEITIS DEFORMANS;
CLODRONATE;VDR;C;rs1544410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:OSTEITIS DEFORMANS;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;
CLODRONATE;VDR;A;rs731236;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:OSTEITIS DEFORMANS;
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;INDUCTION FAILURE IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;INDUCTION FAILURE IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;
ATORVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDLC IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
LOVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDLC IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
SIMVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDLC IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
CITALOPRAM;HTR2A;T;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
SERTRALINE;HTR2A;T;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ANEMIA IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BUPRENORPHINE / NALOXONE;OPRM1;AG + GG;rs648893;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
METHOTREXATE;ADORA2A;T;rs2267076;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;ADORA2A;T;rs2236624;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;ADORA2A;T;rs2298383;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER;INCREASED;NAN;PK;BLOOD PRESSURE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;ADORA2A;T;rs3761422;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:STROKE;
ASPIRIN;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"NEUTROPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"NEUTROPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"NEUTROPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";
HYDROCHLOROTHIAZIDE;NELL1;C;rs12279250;METABOLISM/PK;INCREASED;NAN;SIDE EFFECT;PLASMA TRIGLYCERIDES IN PEOPLE WITH  DISEASE:HYPERTENSION;
BUPRENORPHINE / NALOXONE;OPRD1;TT;rs678849;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANXIETY DISORDERS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
ARIPIPRAZOLE;DAOA;A;rs2391191;EFFICACY;DECREASED;NAN;EFFICACY;BRIEF PSYCHIATRIC RATING SCALE SCORES IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
BUPRENORPHINE / NALOXONE;OPRD1;A;rs569356;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CRAVING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
OLANZAPINE;HTR2C;C;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;RISK;OTHER;TACROLIMUS NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RISK;OTHER;SUBCLINICAL ALLOGRAFT NEPHROPATHY IN  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;RISK;OTHER;SUBCLINICAL ALLOGRAFT NEPHROPATHY IN  DISEASE:KIDNEY TRANSPLANTATION;
SIMVASTATIN;CYBA;AA + AG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DNA DAMAGE IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;
BUPROPION;CYP2B6;CT;rs3211371;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  OTHER:FEMALE GENDER;
ASPIRIN;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:STROKE;
OLANZAPINE;DRD3;CC;rs6280;EFFICACY;NAN;NAN;EFFICACY;GREATER POSITIVE SYMPTOM IMPROVEMENT AND POSITIVE SYMPTOM REMISSION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;
OLANZAPINE;RGS4;CT;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CABAZITAXEL;TUBB1;G;rs151352;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
CABAZITAXEL;TUBB1;G;rs151352;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:PROSTATIC NEOPLASMS;
RISPERIDONE;RGS4;TT;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;RGS4;CC;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSITIVE RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PERPHENAZINE;RGS4;CC;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSITIVE RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CABAZITAXEL;CYP2C8;C;rs1341164;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;
CABAZITAXEL;CYP2C8;C;rs1341164;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:PROSTATIC NEOPLASMS;
OLANZAPINE;LEP;GG;rs4731426;TOXICITY;INCREASED;RISK;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HEROIN;GRM3;T;rs13242038;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
AMITRIPTYLINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
NAN;ACE;G;rs4343;METABOLISM/PK;INCREASED;NAN;OTHER;ACE ACTIVITY IN PEOPLE WITH  DISEASE:HYPERTENSION;
ANTIDEPRESSANTS;HTR1A;GG;rs6295;EFFICACY;DECREASED;NAN;EFFICACY;TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
OPIOIDS;ABCB1;CC + CT;rs9282564;TOXICITY;DECREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAXANES;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAXANES;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PAROXETINE;HTR1A;CC;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:PANIC DISORDER;
SERTRALINE;HTR1A;CC;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:PANIC DISORDER;
OPIOIDS;KCNJ6;TT;rs2070995;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF RESCUE ANALGESIC ADMINISTRATION IN PEOPLE WITH  DISEASE:PAIN;
WARFARIN;VKORC1;G;rs8050894;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;G;rs8050894;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;
NEVIRAPINE;CYP2B6;CT;rs28399499;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NEVIRAPINE;CYP3A5;CC + CT;rs776746;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;T;rs3849942;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHAMPHETAMINE;DTNBP1;C;rs3213207;TOXICITY;INCREASED;RISK;SIDE EFFECT;PSYCHOTIC DISORDER NAN  NAN;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;T;rs2814707;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHAMPHETAMINE;PICK1;T;rs2076369;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;RELAPSE OF PSYCHOSIS NAN  NAN;
NEVIRAPINE;CYP2B6;CT + TT;rs12721646;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;A;rs928655;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OVERALL GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;C;rs774359;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;T;rs983332;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs868856;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE BASE ON DISEASE ACTIVITY SCORE IN 44 JOINTS IMPROVEMENT AT 6 MONTHS OF TREATMENT IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;LESS PATIENT-ASSESSED DIFFICULTY WITH PHYSICAL TASKS;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;AND FEWER SWOLLEN JOINTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIANDROGENS;AKR1C3;CC;rs12529;EFFICACY;INCREASED;RISK;EFFICACY;PROSTATE CANCER-SPECIFIC MORTALITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;NAN;OTHER;MAINTENANCE DOSE OF WARFARIN NAN  NAN;
CISPLATIN;ERCC1;AG;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;ERCC1;AG;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;TP53;GG;rs1042522;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;CYP2C8;TT;rs11572080;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;ABCC1;GG;rs2238476;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;T;rs6028945;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;C;rs6071980;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:NEOPLASMS;
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;T;rs6138150;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CISPLATIN;GSTP1;AA;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
ANTIPSYCHOTICS;CLCN6, MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854548;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854555;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs7046653;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
BUPRENORPHINE;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED;RISK;OTHER;SUBSTANCE WITHDRAWAL SYNDROME IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
WARFARIN;VKORC1;AG;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE OF INR (TTR) NAN  NAN;
DOCETAXEL;;CT;rs11185648;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS NAN  NAN;
DOCETAXEL;RXRA;AG;rs11185647;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;
DOCETAXEL;RXRA;AG;rs11185647;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DOCETAXEL;RXRA;AG;rs2234753;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;RXRA;GT;rs6413517;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;RXRA;GG;rs62576288;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
NAN;DRD2;GG;rs1799732;NAN;INCREASED;LIKELIHOOD;DISEASE;SCHIZOPHRENIA NAN  NAN;
NAN;SCN1A;CT;rs2298771;OTHER;INCREASED;LIKELIHOOD;DISEASE;EPILEPSY NAN  NAN;
METHOTREXATE;;G;rs9345389;TOXICITY;NAN;NAN;SIDE EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE. NAN  NAN;
DOCETAXEL;HNF4A;TT;rs6130615;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
ANTIPSYCHOTICS;HTR2A;GG;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
SIMVASTATIN;;A;rs76103438;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
DIAZEPAM;CYP3A4;GG;rs35599367;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;
ANTIPSYCHOTICS;HTR2A;AG;rs6314;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
DOCETAXEL;HNF4A;CT;rs2273618;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;HNF4A;CT;rs3746574;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;NAN;NAN;OTHER;A MORE RAPID ATTAINMENT OF TARGET INR AND HIGHER FREQUENCY OF DOSE ADJUSTMENTS NAN  NAN;
WARFARIN;VKORC1;A;rs9934438;EFFICACY;NAN;NAN;OTHER;A MORE RAPID ATTAINMENT OF TARGET INR AND HIGHER FREQUENCY OF DOSE ADJUSTMENTS NAN  NAN;
DOCETAXEL;NR1I2;TT;rs3732360;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
NAN;NRXN1;C;rs985919;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
"""BETA BLOCKING AGENTS";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:HYPERTENSION;
"SELECTIVE""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:HYPERTENSION;
"""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:HYPERTENSION;
MEPERIDINE;SERINC5;C;rs185462714;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
CISPLATIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTA1;AA;rs3957357;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
DOCETAXEL;NR1I2;AA;rs3732359;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
NAN;CHRNA5;C;rs17408276;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
BETA BLOCKING AGENTS;;T;rs139945292;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:HYPERTENSION;
NICOTINE;COMT;AA;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES NAN  NAN;
PENICILLIN G;;A;rs115200108;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
PENICILLIN V;;A;rs115200108;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
NICOTINE;COMT;AG;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE NAN  NAN;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
DOCETAXEL;NR1I2;CC + TT;rs3814058;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
NAN;NRXN1;C;rs1882296;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;
DOCETAXEL;NR1I3;TT;rs10538494;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CODEINE;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
HYDROCODONE;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
OXYCODONE;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
TRAMADOL;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
MEPERIDINE;FIP1L1;G;rs113100019;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
DOCETAXEL;NR1I3;AG;rs75114882;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
NAN;NRXN1;C;rs10865246;OTHER;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DOCETAXEL;NR1I3;CC;rs2501873;TOXICITY;DECREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CISPLATIN;ERCC2;CT;rs1799793;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;ERCC1;AC;rs3212986;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;ERCC1;AC;rs3212986;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CISPLATIN;XRCC1;CC;rs25487;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;XRCC1;CC;rs25487;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
MEPERIDINE;;A;rs11049274;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
DOCETAXEL;RXRA;AG;rs1536475;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CISPLATIN;XPC;G;rs2228001;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOCETAXEL;NR1I3;GG;rs2502815;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
DOCETAXEL;NR1I3;AA;rs9725457;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
CISPLATIN;ERCC2, KLC3;G;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
ETHANOL;ACSS2;T;rs6088638;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;AG;rs17376848;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs1058164;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
CISPLATIN;ERCC1;G;rs11615;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
NAN;APOE;CC;rs429358;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs1985842;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
NAN;NAT2;T;rs1801280;OTHER;INCREASED;SEVERITY;DISEASE;INSULIN RESISTANCE NAN  NAN;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs1135840;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs28371713;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
NAN;NAT2;A;rs1208;OTHER;INCREASED;SEVERITY;DISEASE;INSULIN RESISTANCE NAN  NAN;
AMOXICILLIN;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
GEFITINIB;ABCG2;GT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs112568578;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
CAPECITABINE;MIR23A, MIR24-2, MIR27A;C;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;MIR23A, MIR24-2, MIR27A;C;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;NAN;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
AMOXICILLIN;PTPN22;A;rs2476601;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SLEEP APNEA SYNDROMES IN MEN  NAN;
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;
NAN;PTGS2;G;rs20417;NAN;INCREASED;RISK;DISEASE;STROKE NAN  NAN;
ATENOLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
BETA BLOCKING AGENTS;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CARVEDILOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
METOPROLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
DOXORUBICIN;RARG;AG;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY NAN  NAN;
FLUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
ASPIRIN;TMEM196;T;rs9886152;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
PAZOPANIB;HIF1A;AG;rs11549467;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;CLOCK;AA + AG;rs1801260;OTHER;INCREASED;LIKELIHOOD;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN CHILDREN  NAN;
MERCAPTOPURINE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
METHOTREXATE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE RESPONSE RATE IN PEOPLE WITH  DISEASE:LYMPHOMA;
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
MERCAPTOPURINE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
RITUXIMAB;FCGR3A;AA;rs396991;NAN;DECREASED;NAN;OTHER;LEVELS OF IGG IN PEOPLE WITH  OTHER:NON-HODGKIN'S LYMPHOMA AND STEM CELL TRANSPLANTATION;
COCAINE;CNR1;C;rs806368;OTHER;DECREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;
MERCAPTOPURINE;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN BONE MINERAL DENSITY IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;
RALOXIFENE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN BONE MINERAL DENSITY IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
RALOXIFENE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;
ASPARAGINASE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
INTERFERONS;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PAZOPANIB;CXCL8;AA;rs4073;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
INTERFERONS;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR) TO INTERFERON MONOTHERAPY IN HCV GENOTYPE 1 PATIENTS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;;G;rs4888024;TOXICITY;NAN;NAN;SIDE EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE NAN  NAN;
TACROLIMUS;ABCB1;AG;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;ABCB1;AC + CT;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;ABCC1;AA;rs3784862;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;
ETHANOL;OPRM1;A;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE IN MEN  NAN;
CAPECITABINE;DPYD;CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS NAN  NAN;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;A;rs945665113;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN  OTHER:PCI-SCHEDULED PATIENTS;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CAPECITABINE;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:DEPRESSION;
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:MAJOR DEPRESSIVE DISORDER;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SUNITINIB;SLC22A5;C;rs2631367;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;PRIMARY CLINICAL ENDPOINT OF DEATH DUE TO CARDIOVASCULAR CAUSES;
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;NON-FATAL MI OR STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;PRIMARY CLINICAL ENDPOINT OF DEATH DUE TO CARDIOVASCULAR CAUSES;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NON-FATAL MI OR STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
SUNITINIB;SLC22A5;C;rs2631370;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
NAN;PTGS2;CG + GG;rs20417;NAN;DECREASED;RISK;DISEASE;STROKE NAN  NAN;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;G;rs376695472;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:DEPRESSION;
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:MAJOR DEPRESSIVE DISORDER;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS NAN  NAN;
BETA BLOCKING AGENTS;ADRB2;GG;rs1042713;EFFICACY;DECREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MYOCARDIAL INFARCTION;
FLUOROURACIL;DPYS;G;rs2959023;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
SUNITINIB;IL4R;C;rs1805015;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;CG + GG;rs20417;OTHER;INCREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;
NAN;PTGS2;CG + GG;rs20417;OTHER;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
FLUOROURACIL;DPYS;G;rs2669429;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;CLCN6, MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SUNITINIB;SLC22A5;C;rs2631372;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;IL4R;G;rs1801275;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
HEROIN;BDNF;TT;rs16917234;TOXICITY;DECREASED;AGE AT ONSET;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;T;rs267606619;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;
TENOFOVIR;ABCC4;CC + CT;rs1751034;METABOLISM/PK;INCREASED;NAN;PK;INTRACELLULAR TENOFOVIR DIPHOSPHATE (TFV-DP) CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN;
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:INFLUENZA;
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN;
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:INFLUENZA;
CORTICOSTEROIDS;DTNBP1;T;rs35514893;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
NAN;CYP1B1;CC + CG;rs1056836;OTHER;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN WITH  DISEASE:TOBACCO USE DISORDER;
THIOTEPA;GSTP1;T;rs1138272;OTHER;INCREASED;NAN;PK;NON-INDUCIBLE THIOTEPA CLEARANCE AND DECREASED TEPA CLEARANCE NAN  NAN;
TENOFOVIR;ABCC4;TT;rs1751034;OTHER;INCREASED;NAN;PK;TENOFOVIR RENAL CLEARANCE;
TENOFOVIR;ABCC4;TT;rs1751034;OTHER;INCREASED;NAN;PK;AND LOWER AUC NAN  NAN;
FLUOROURACIL;DPYD;A;rs2786783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
NAN;G6PD;T;rs72554664;OTHER;INCREASED;LIKELIHOOD;OTHER;DIABETES MELLITUS;
NAN;G6PD;T;rs72554664;OTHER;INCREASED;LIKELIHOOD;OTHER;TYPE 2 NAN  NAN;
OPIOIDS;;T;rs12442183;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
CORTICOSTEROIDS;KL;G;rs450789;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
INTERFERON BETA-1A;IRF6;G;rs2205986;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
INTERFERON BETA-1B;IRF6;G;rs2205986;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
METHOTREXATE;NR1I2;C;rs3814058;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ABCC2;A;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;BONE MARROW DISORDER IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
FLUOROURACIL;WNT5B;CC;rs2010851;EFFICACY;DECREASED;NAN;OTHER;TIME TO TUMOR RECURRENCE (TTR) IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
CORTICOSTEROIDS;ME3;A;rs2125362;EFFICACY;INCREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
HEROIN;OPRD1;GG;rs508448;TOXICITY;DECREASED;AGE AT ONSET;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;
METHOTREXATE;NR1I2;G;rs6785049;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
CORTICOSTEROIDS;LHX2;A;rs7851998;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
FLUOROURACIL;DPYD;C;rs2811178;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CORTICOSTEROIDS;LHFPL3;G;rs61585310;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
ASPARAGINASE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CORTICOSTEROIDS;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;BONE MARROW DISORDER;
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
HEROIN;BDNF;TT;rs6265;TOXICITY;DECREASED;AGE AT ONSET;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;
MORPHINE;SLC22A1;T;rs12208357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;
CORTICOSTEROIDS;TRDN;T;rs4897302;EFFICACY;INCREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
NICOTINE;CHRNA5;G;rs55781567;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;
HEROIN;OPRD1;AA;rs4654327;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;
OLANZAPINE;GIPR;AA + AT;rs10423928;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;
NICOTINE;CHRNA5;A;rs503464;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
FLUOROURACIL;DPYD;G;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
DAUNORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DOXORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
NICOTINE;CHRNA5;G;rs55853698;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;
AMANTADINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
AMANTADINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
AMANTADINE;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
ANTICHOLINERGICS;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
ANTICHOLINERGICS;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
ANTICHOLINERGICS;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
DOPAMINE AGONISTS;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
DOPAMINE AGONISTS;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
DOPAMINE AGONISTS;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
LEVODOPA;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
LEVODOPA;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
LEVODOPA;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
SELEGILINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
SELEGILINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
SELEGILINE;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;
MELPHALAN;POLR1G;A;rs967591;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND TIME-TO-TREAT FAILURE IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
MELPHALAN;POLR1G;A;rs967591;TOXICITY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND TIME-TO-TREAT FAILURE IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
CORTICOSTEROIDS;ACOT7;G;rs11121611;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:COGNITIVE DISORDER;
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
DAUNORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DOXORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
ROSUVASTATIN;SCAP;CC + CT;rs12487736;EFFICACY;DECREASED;SEVERITY;EFFICACY;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:METABOLIC SYNDROME;
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CORTICOSTEROIDS;APOBEC3B;A;rs5995653;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
GEMCITABINE;CDA;CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
PACLITAXEL;CDA;CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;
MONTELUKAST;ABCC1;CT;rs119774;EFFICACY;INCREASED;NAN;EFFICACY;CHANGES IN FEV1 IN PEOPLE WITH  DISEASE:ASTHMA;
TRIAMCINOLONE;HCG22;T;rs2523864;TOXICITY;INCREASED;NAN;SIDE EFFECT;OCULAR HYPERTENSION IN PEOPLE WITH  DISEASE:RETINAL DISEASES;
ANTIDEPRESSANTS;CREB1, METTL21A;GG;rs7569963;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;A;rs184278615;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
CITALOPRAM;;T;rs4675690;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT-EMERGENT SUICIDALITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;CREB1, METTL21A;A;rs7569963;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT-EMERGENT SUICIDALITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;T;rs201469165;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"COMBINATIONS""";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"""RITONAVIR""";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
TRIAMCINOLONE;HCG22;G;rs3873352;TOXICITY;INCREASED;NAN;SIDE EFFECT;OCULAR HYPERTENSION IN PEOPLE WITH  DISEASE:RETINAL DISEASES;
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;C;rs1071748;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ASPIRIN;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
METHOTREXATE;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
MERCAPTOPURINE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CHLORTHALIDONE;NPPA;G;rs5065;EFFICACY;DECREASED;NAN;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:HYPERTENSION;
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;SOD2;G;rs4880;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP3A4;C;rs2740574;TOXICITY;DECREASED;RISK;SIDE EFFECT;PRIMARY OVARIAN FAILURE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;CC;rs714368;TOXICITY;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;CC;rs714368;METABOLISM/PK;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
MERCAPTOPURINE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS;
MERCAPTOPURINE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS;
METHOTREXATE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CARBAMAZEPINE;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
CARBAMAZEPINE;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
PHENYTOIN;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
PHENYTOIN;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;RISK;SIDE EFFECT;ORAL MUCOSITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ORAL MUCOSITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGIC CYSTITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;HEMORRHAGIC CYSTITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;G;rs973541788;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
AMOXICILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CLAVULANATE;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
FLUCLOXACILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;TOXICITY;DECREASED;RISK;SIDE EFFECT;VENOOCCLUSIVE DISEASE OF THE LIVER IN PEOPLE WITH  OTHER:HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;VENOOCCLUSIVE DISEASE OF THE LIVER IN PEOPLE WITH  OTHER:HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs28371725;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SLEEP DISORDERS IN PEOPLE WITH  OTHER:PAIN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CYCLOSPORINE;MTHFR;A;rs1801133;OTHER;NAN;NAN;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;MTHFR;A;rs1801133;OTHER;NAN;NAN;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CARBOPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:GALLBLADDER NEOPLASMS;
CISPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:GALLBLADDER NEOPLASMS;
GEMCITABINE;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:GALLBLADDER NEOPLASMS;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs2004511;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
MERCAPTOPURINE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
METHOTREXATE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;CBR3;G;rs8133052;EFFICACY;DECREASED;NAN;EFFICACY;TUMOR RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;G;rs8133052;METABOLISM/PK;DECREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;A;rs1056892;DOSAGE;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;A;rs1056892;METABOLISM/PK;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ANTIHYPERTENSIVES;ATP2B1;AA + AG;rs1401982;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;A;rs28371702;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS IN WOMEN WITH  OTHER:PAIN;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
MERCAPTOPURINE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
HEROIN;GRM3;A;rs724226;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:ATRIAL FLUTTER;
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:VENOUS THROMBOSIS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
CORTICOSTEROIDS;CRHR1;AA;rs242941;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT CHANGE IN FEV IN PEOPLE WITH  DISEASE:ASTHMA;
METHOTREXATE;CLCN6, MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
CORTICOSTEROIDS;FKBP5;AA + AG;rs4713916;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GLUCOCORTICOID RESPONSIVENESS IN PEOPLE WITH  DISEASE:CROHN DISEASE;
BUDESONIDE;CRHR1;AA;rs242941;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;
FLUTICASONE PROPIONATE;CRHR1;AA;rs242941;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;
OPIOIDS;ABCB1;G;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:LOW BACK PAIN;
CORTICOSTEROIDS;CRHR1;TT;rs1876828;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT CHANGE IN FEV IN PEOPLE WITH  DISEASE:ASTHMA;
GEMCITABINE;;C;rs1155463;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA NAN  NAN;
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BUDESONIDE;CRHR1;TT;rs1876828;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;
FLUTICASONE PROPIONATE;CRHR1;TT;rs1876828;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CHLOROTHIAZIDE;;A;rs61824877;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
CHLOROTHIAZIDE;;A;rs61824877;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
HYDROCHLOROTHIAZIDE;;A;rs61824877;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
HYDROCHLOROTHIAZIDE;;A;rs61824877;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
TRAMADOL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA NAN  NAN;
CHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
CHLOROTHIAZIDE;HMGCS2;G;rs9943291;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
METHOTREXATE;CLCN6, MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHADONE;DAO;TT;rs55944529;EFFICACY;INCREASED;SEVERITY;EFFICACY;SUBSTANCE WITHDRAWAL SYNDROME IN PEOPLE WITH  OTHER:HEROIN DEPENDENCE;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;KCNIP1, KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;RISK;DISEASE;HYPERTENSION NAN  NAN;
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ATAZANAVIR;ABCB1;AT;rs2032582;TOXICITY;INCREASED;RISK;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DABIGATRAN;ABCB1;CC + CT;rs4148738;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
INFLIXIMAB;IL23R;TT;rs10489629;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
INFLIXIMAB;SLCO1C1;GG;rs3794271;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR FUNCTION (LVEF) IN PEOPLE WITH  DISEASE:HEART FAILURE;
PEGINTERFERON ALFA-2A;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;A;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;ABCC1;CT + TT;rs3743527;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
IRINOTECAN;ABCB1;AC + CC;rs12720066;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NICOTINE;CHRNA3;C;rs3743078;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NICOTINE;CHRNB4;G;rs3813567;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
IRINOTECAN;ABCC1;AG + GG;rs17501331;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY GREATER IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION (LVEF) IN PEOPLE WITH  DISEASE:HEART FAILURE;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CEREBRAL PALSY;
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEARING LOSS IN CHILDREN WITH  OTHER:NEONATAL HYPERBILIRUBINEMIA;
PEGINTERFERON ALFA-2A;NT5C2;CT;rs10883841;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
INFLIXIMAB;ADAM17;TT;rs10929587;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;
CLOPIDOGREL;MED12L, P2RY12;AG;rs10935838;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
NAN;AGO2;AA + AC;rs4961280;OTHER;DECREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
STAVUDINE;TNF;C;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROPATHY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;MED12L, P2RY12;AG;rs2046934;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;MED12L, P2RY12;AC;rs6809699;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NICOTINE;CHRNA5;G;rs684513;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;C;rs267606618;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NICOTINE;CHRNA5;A;rs637137;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
NAN;IL1A;A;rs1800587;OTHER;INCREASED;SEVERITY;DISEASE;PAIN IN PEOPLE WITH  DISEASE:ANEMIA;
NAN;IL1A;A;rs1800587;OTHER;INCREASED;SEVERITY;DISEASE;SICKLE CELL;
FLUTICASONE / SALMETEROL;CRHR1;CC;rs242941;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CHANGE IN FEV IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;
PROPRANOLOL;COMT;G;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;
PROPRANOLOL;COMT;G;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGINTERFERON ALFA-2A;CYP27B1, METTL1;GT + TT;rs10877012;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS B VIRUS INFECTION;
PROPRANOLOL;COMT;G;rs4818;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;
PROPRANOLOL;COMT;G;rs4818;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;
CORTICOSTEROIDS;APOBEC3B;T;rs6001366;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS B VIRUS INFECTION;
CORTICOSTEROIDS;KCNN1;C;rs2278992;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
PEGINTERFERON ALFA-2A;VDR;AA;rs7975232;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS B VIRUS INFECTION;
CORTICOSTEROIDS;ANKRD30B;A;rs12959468;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
ROSUVASTATIN;CRP;CT + TT;rs1205;EFFICACY;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ROSUVASTATIN;CRP;CT + TT;rs1205;OTHER;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ROSUVASTATIN;CRP;CT + TT;rs1205;METABOLISM/PK;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
PROPRANOLOL;COMT;G;rs6269;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;
PROPRANOLOL;COMT;G;rs6269;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
RISPERIDONE;HTR2A;TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
HEROIN;GRM3;T;rs2189814;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;
ROSUVASTATIN;;CC + CT;rs2808630;EFFICACY;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ROSUVASTATIN;;CC + CT;rs2808630;OTHER;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ROSUVASTATIN;;CC + CT;rs2808630;METABOLISM/PK;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
METHADONE;OPRD1;AT + TT;rs204076;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;EFFICACY;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;OTHER;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;METABOLISM/PK;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING AND GREATER INCREASE IN LVEF (LEFT VENTRICULAR EJECTION FRACTION) IN PEOPLE WITH  DISEASE:HEART FAILURE;
PROPRANOLOL;COMT;C;rs4633;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;
PROPRANOLOL;COMT;C;rs4633;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:HEART FAILURE;
ERYTHROMYCIN;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;
ERYTHROMYCIN;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:INFLUENZA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
NAN;KCNIP1, KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;NAN;OTHER;BLOOD PRESSURE IN MEN  NAN;
TACROLIMUS;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN CHILDREN WITH  OTHER:KIDNEY TRANSPLANTATION;
CAFFEINE;RYR1;AC;rs118192162;TOXICITY;NAN;NAN;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;AC;rs118192162;TOXICITY;NAN;NAN;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
RISPERIDONE;NR1I2;GG;rs7643645;METABOLISM/PK;DECREASED;NAN;PK;9-HYDROXY-RISPERIDONE LEVELS IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
REPAGLINIDE;SLCO1B1;GG;rs2306283;OTHER;DECREASED;NAN;PK;REPAGLINIDE PLASMA CONCENTRATION (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
REPAGLINIDE;SLCO1B1;GG;rs2306283;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE PLASMA CONCENTRATION (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
HALOTHANE;RYR1;CT;rs118192161;TOXICITY;NAN;NAN;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
RISPERIDONE;NR1I2;GG;rs7643645;METABOLISM/PK;DECREASED;NAN;PK;ACTIVE MOIETY LEVELS IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
TACROLIMUS;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN CHILDREN WITH  OTHER:KIDNEY TRANSPLANTATION;
GEFITINIB;CYP2D6;AA + AG;rs1065852;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;DECREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
EGFR INHIBITORS;PIK3CA;C;rs6443624;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;
EGFR INHIBITORS;PIK3CA;T;rs2677760;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;
MISOPROSTOL;SLCO1B1;GG;rs4149087;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER IN WOMEN WITH  DISEASE:POST-PARTUM HEMORRHAGE;
MISOPROSTOL;ABCC4;AA;rs11568658;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER IN WOMEN WITH  DISEASE:POST-PARTUM HEMORRHAGE;
MISOPROSTOL;ABCC4;AA;rs11568658;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:THERAPEUTIC ABORTION;
ASPIRIN;PEAR1;A;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION NAN  NAN;
CLOPIDOGREL;PEAR1;A;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION NAN  NAN;
ETHAMBUTOL;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CARBOPLATIN;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOCETAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
OLANZAPINE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;
ANTIINFLAMMATORY AGENTS;ALOX15;C;rs3892408;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
NON-STEROIDS;ALOX15;C;rs3892408;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
METHADONE;CCL11;A;rs1129844;TOXICITY;INCREASED;NAN;SIDE EFFECT;INSOMNIA IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
EGFR INHIBITORS;PIK3CA;C;rs2699905;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOXETINE;;GG;rs2433320;EFFICACY;DECREASED;NAN;EFFICACY;HAMD SCORES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ANTIPSYCHOTICS;MTHFR;G;rs1801133;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;MTHFR;G;rs1801133;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
ASPARAGINASE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISOLONE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIINFLAMMATORY AGENTS;PTGS1;C;rs5789;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
NON-STEROIDS;PTGS1;C;rs5789;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
CLOZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CYCLOPHOSPHAMIDE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA;
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA;
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
GEFITINIB;EGFR;T;rs121434568;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION NEGATIVE NON-SMALL-CELL LUNG CANCER;
CARBOPLATIN;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOCETAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ETHAMBUTOL;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FLUOROURACIL;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
TAXANES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ETHAMBUTOL;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG NAN  NAN;
ANTIINFLAMMATORY AGENTS;PTGS1;A;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
NON-STEROIDS;PTGS1;A;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;NAN;DISEASE;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;NAN;DISEASE;BCR-ABL1 POSITIVE;
ANTIPSYCHOTICS;GABRG3;A;rs2061051;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
GEMCITABINE;;CT + TT;rs642990;TOXICITY;DECREASED;RISK;DISEASE;NEUTROPENIA NAN  NAN;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;LONGER MEDIAN PROGRESSION-FREE SURVIVAL TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
CARBOPLATIN;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOCETAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;RRM1;A;rs1042858;DOSAGE;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CARBOPLATIN;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOCETAXEL;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DOCETAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METHOTREXATE;ABCC1;AG + GG;rs246240;TOXICITY;DECREASED;RISK;SIDE EFFECT;ONSET OF TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;
BUPROPION;EPB41;AA;rs6702335;EFFICACY;INCREASED;NAN;EFFICACY;ABSTINENCE IN MEN WITH  DISEASE:TOBACCO USE DISORDER;
NICOTINE;EPB41;AA;rs6702335;EFFICACY;INCREASED;NAN;EFFICACY;ABSTINENCE IN MEN WITH  DISEASE:TOBACCO USE DISORDER;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;G;rs62328061;TOXICITY;DECREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
NAN;IL17F;CC;rs763780;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS IN WOMEN WITH  OTHER:PREGNANCY;
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
NAN;IL17A;AA;rs2275913;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS IN WOMEN WITH  OTHER:PREGNANCY;
ACE INHIBITORS;KCNIP4;A;rs145489027;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
PLAIN;KCNIP4;A;rs145489027;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
PEMETREXED;ATIC;C;rs12995526;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
OPIOIDS;PDYN;A;rs910080;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BILIARY TRACT NEOPLASM;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:PANCREATIC NEOPLASMS;
ACE INHIBITORS;KCNIP4;C;rs1495509;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
PLAIN;KCNIP4;C;rs1495509;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
FOLFIRI;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
GEMCITABINE;ALG10;AA + AG;rs1705772;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY NAN  NAN;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
CYCLOPHOSPHAMIDE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
RITONAVIR;APOC3;C;rs2854116;OTHER;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PEMETREXED;GGH;CT + TT;rs16930092;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANASTROZOLE;UGT1A4;GG;rs3732218;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION IN  OTHER:HUMAN LIVER MICROSOMES;
HALOPERIDOL;CYP2D6;CT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL WITHDRAWAL DELIRIUM;
FOLFIRI;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ACE INHIBITORS;KCNIP4;A;rs7675300;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
PLAIN;KCNIP4;A;rs7675300;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;
CYCLOPHOSPHAMIDE;VEGFA;CC;rs2010963;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING IN WOMEN  OTHER:SMOKERS WHO ARE PREGNANT;
NEVIRAPINE;TRAF3IP2;C;rs76228616;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;TRAF3IP2;C;rs76228616;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
GEMCITABINE;ALOX5AP;AG + GG;rs4769060;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND A LOWER MEAN AUC NAN  NAN;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
SUFENTANIL;OPRM1;AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
SUFENTANIL;OPRM1;AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
IPILIMUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
NIVOLUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
PEMBROLIZUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEATH IN CHILDREN WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;NAN;SIDE EFFECT;MYELOID;
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;NAN;SIDE EFFECT;ACUTE;
FOLFIRI;BRAF;T;rs113488022;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;BRAF;T;rs113488022;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;BRAF;T;rs113488022;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
METHOTREXATE;CLCN6, MTHFR;AG + GG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
OPIOIDS;TH;G;rs2070762;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
ISONIAZID;CYP2E1, DUX1;AT;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2E1, DUX1;AT;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;
ANTINEOPLASTIC AGENTS;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO TUMOR RECURRENCE IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO TUMOR RECURRENCE IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
LEUCOVORIN;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO TUMOR RECURRENCE IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OPIOIDS;DBH;G;rs1611131;TOXICITY;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
ANTIPSYCHOTICS;HSPG2;C;rs2445142;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
FOLFIRI;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ANTIPSYCHOTICS;HSPG2;T;rs878949;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
QUETIAPINE;RIMS1;CC + CT;rs502046;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
QUETIAPINE;RIMS1;CC + CT;rs502046;TOXICITY;DECREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ETHANOL;TAS2R16;C;rs846664;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;G;rs1139130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
METHOTREXATE;C1orf167, CLCN6, MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
FLUOROURACIL;SCN1A;CC;rs3812718;OTHER;DECREASED;NAN;OTHER;TIME TO TUMOR RECURRENCE (TTR) IN  DISEASE:COLORECTAL NEOPLASMS;
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"""ACETAMINOPHEN""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ACETAMINOPHEN""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;
"""ANTIEPILEPTICS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ANTIEPILEPTICS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;
"""ANTIINFLAMMATORY AGENTS";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ANTIINFLAMMATORY AGENTS";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;
"NON-STEROIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"NON-STEROIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;
"""OPIOIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""OPIOIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;
OPIOIDS;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
EFAVIRENZ;NR1I2;TT;rs2472677;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;NAN;EFFICACY;VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CISPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
CYCLOPHOSPHAMIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
DACTINOMYCIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
VINCRISTINE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;
SORAFENIB;VEGFA;CG + GG;rs2010963;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CISPLATIN;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CYCLOPHOSPHAMIDE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DACTINOMYCIN;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
VINCRISTINE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
SORAFENIB;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SORAFENIB;VEGFA;AA + AG;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCULAR DISEASES;
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:RHABDOMYOLYSIS;
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE NAN  NAN;
COCAINE;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;COCAINE DEPENDENCE;
COCAINE;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DISEASE:HEROIN DEPENDENCE NAN  NAN;
HEROIN;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;COCAINE DEPENDENCE;
HEROIN;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DISEASE:HEROIN DEPENDENCE NAN  NAN;
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
EFAVIRENZ;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CETUXIMAB;KRAS;A;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PANITUMUMAB;KRAS;A;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;T;rs1799853;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
NAN;MTR;GG;rs1805087;OTHER;INCREASED;LIKELIHOOD;DISEASE;RHEUMATOID ARTHRITIS NAN  NAN;
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METHOTREXATE-INDUCED NODULOSIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
"""ACETAMINOPHEN""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ACETAMINOPHEN""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
"""ANTIEPILEPTICS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ANTIEPILEPTICS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
"""ANTIINFLAMMATORY AGENTS";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ANTIINFLAMMATORY AGENTS";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
"NON-STEROIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"NON-STEROIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
"""OPIOIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""OPIOIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;AUC0-12 IN HEALTHY INDIVIDUALS  NAN;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUOROURACIL;SCN1A;TT;rs3812718;OTHER;DECREASED;NAN;OTHER;TIME TO TUMOR RECURRENCE (TTR) IN  DISEASE:COLORECTAL NEOPLASMS;
ATAZANAVIR;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
SIMVASTATIN;SLCO1B1;CC;rs4363657;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;TOXICITY;DECREASED;RISK;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
TACROLIMUS;CYP3A5;CT;rs776746;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
EFAVIRENZ;CYP2B6;CT + TT;rs4803419;TOXICITY;INCREASED;RISK;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
FLUOROURACIL;DPYD;CT;rs1801160;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
ALLOPURINOL;PSORS1C1;AG + GG;rs3131003;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
FLUOROURACIL;MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;DISEASE;EVENT-FREE SURVIVAL;
FLUOROURACIL;MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;DISEASE;DISEASE:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
OPIOIDS;PDYN;CT + TT;rs1997794;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:LEUKEMIA;
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
DEXMEDETOMIDINE;CYP2A6;GG;rs8192733;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;
DEXMEDETOMIDINE;CYP2A6;GG;rs8192733;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
"""ACETAMINOPHEN""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ACETAMINOPHEN""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;
"""ANTIEPILEPTICS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ANTIEPILEPTICS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;
"""ANTIINFLAMMATORY AGENTS";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""ANTIINFLAMMATORY AGENTS";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;
"NON-STEROIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"NON-STEROIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;
"""OPIOIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
"""OPIOIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;
OPIOIDS;PDYN;CC;rs1022563;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RISPERIDONE;LEP;GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;
RISPERIDONE;LEP;GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;
PERINDOPRIL;AGTR1;TT;rs5182;EFFICACY;DECREASED;RISK;EFFICACY;CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYTARABINE;CDA;GG;rs602950;EFFICACY;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;GG;rs602950;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;CDA;GG;rs602950;METABOLISM/PK;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;GG;rs602950;METABOLISM/PK;INCREASED;NAN;EFFICACY;MYELOID;
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  DISEASE:ALCOHOLIC PSYCHOSIS;
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:ALCOHOL ABUSE;
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:ALCOHOL-RELATED DISORDERS;
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;CDA;TT;rs532545;METABOLISM/PK;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;TT;rs532545;METABOLISM/PK;INCREASED;NAN;EFFICACY;MYELOID;
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
BISPHOSPHONATES;RBMS3;A;rs17024608;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OSTEONECROSIS NAN  NAN;
NAN;NEDD4L;AG;rs4149601;OTHER;INCREASED;RISK;DISEASE;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:HYPERTENSION;
FLUOROURACIL;DPYD;AC;rs55886062;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
ANTIPSYCHOTICS;INSIG2;C;rs17587100;OTHER;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:LEUKEMIA;
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
NAN;CTLA4;A;rs3087243;OTHER;DECREASED;RISK;DISEASE;RHEUMATOID ARTHRITIS NAN  NAN;
EPIRUBICIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OXALIPLATIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs115232898;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:LIVER CIRRHOSIS;
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:LIVER CIRRHOSIS;
TENOFOVIR;ABCC4;G;rs1059751;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EPIRUBICIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OXALIPLATIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
CYTARABINE;CDA;CC;rs2072671;EFFICACY;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;CC;rs2072671;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;CDA;CC;rs2072671;METABOLISM/PK;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;CC;rs2072671;METABOLISM/PK;INCREASED;NAN;EFFICACY;MYELOID;
WARFARIN;VKORC1;A;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ALLOPURINOL;NOTCH4;AA + AG;rs367398;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
EPIRUBICIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OXALIPLATIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
NAN;NQO1;AA;rs1800566;OTHER;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
EPIRUBICIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OXALIPLATIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:CHEMOREFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
EFAVIRENZ;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;RISK;EFFICACY;IMMUNOLOGICAL FAILURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY;
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;
EFAVIRENZ;CYP2B6;GT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SLEEP DISORDERS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
SUNITINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
VERAPAMIL;CACNA1C;AA;rs1051375;EFFICACY;DECREASED;RISK;OTHER;PRIMARY OUTCOME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;MEDIAN SURVIVAL TIME (MST) IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
SUNITINIB;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
EFAVIRENZ;CYP2A6;AC + CC;rs28399433;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
VERAPAMIL;CACNA1C;GG;rs1051375;EFFICACY;INCREASED;RISK;EFFICACY;PRIMARY OUTCOME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
EPIRUBICIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
FLUOROURACIL;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OXALIPLATIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG NAN  NAN;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG IN USERS WITH A STARTING DOSE OF MORE THAN 20 MG NAN  NAN;
CARBOPLATIN;;AG;rs12118636;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;;AG;rs12118636;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;;AG;rs12118636;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;NAN;NAN;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;TT;rs116855232;TOXICITY;NAN;NAN;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
ANTINEOPLASTIC AGENTS;ABCB1;AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;MEDIAN SURVIAL TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  EFFICACY:NON-SMALL-CELL LUNG CANCER;
CARBOPLATIN;NRAS;CT;rs1065634;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;NRAS;CT;rs1065634;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;NRAS;CT;rs1065634;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  EFFICACY:NON-SMALL-CELL LUNG CANCER;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
CARBOPLATIN;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
VINCRISTINE;ACTG1;A;rs1135989;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ACENOCOUMAROL;VKORC1;T;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
METHADONE;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME IN INFANTS  NAN;
CARBOPLATIN;ATP7B;AA;rs1801249;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;ATP7B;AA;rs1801249;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
VINCRISTINE;CAPG;T;rs3770102;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VALPROIC ACID;COL1A1;AA + AC;rs1800012;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:EPILEPSY;
VINCRISTINE;ABCB1;A;rs4728709;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;AKR1C3;GG;rs1937840;OTHER;DECREASED;NAN;OTHER;ABSOLUTE LEUCOCYTE AND NEUTROPHIL COUNTS ON DAY 15 IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHADONE;CYP2B6;AA;rs2279343;TOXICITY;INCREASED;SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME IN INFANTS  NAN;
KETOPROFEN;CYP2C9;CC;rs1799853;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DYSPEPSIA IN PEOPLE WITH  OTHER:PAIN;
KETOPROFEN;CYP2C9;CC;rs1799853;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;
ACENOCOUMAROL;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
REMIFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN WOMEN WITH  DISEASE:PAIN;
REMIFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LEUKEMIA;
CARBOPLATIN;GSR;CC;rs3594;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;GSR;CC;rs3594;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ACENOCOUMAROL;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
ETHANOL;SLC6A4;T;rs4251417;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CARBOPLATIN;VEGFA;TT;rs6900017;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;VEGFA;TT;rs6900017;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ACENOCOUMAROL;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
METHYLPHENIDATE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
NALOXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;CORTISOL RESPONSE NAN  NAN;
ETHANOL;SLC6A4;C;rs25531;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
INTERFERONS;VDR;AG + GG;rs2228570;TOXICITY;DECREASED;RISK;SIDE EFFECT;CRYOGLOBULINEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;VDR;AG + GG;rs2228570;TOXICITY;DECREASED;RISK;SIDE EFFECT;CRYOGLOBULINEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
EGFR INHIBITORS;PIK3CA;C;rs2677760;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CETUXIMAB;EGFR;AA + AG;rs2227983;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;
EGFR INHIBITORS;PIK3CA;T;rs2459693;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
METHOTREXATE;ATIC;GG;rs2372536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ETHANOL;SLC6A4;A;rs2066713;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;
ANTIPSYCHOTICS;IL1B;AA + AG;rs4849127;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;IL1B;AA + AG;rs4849127;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
BETA BLOCKING AGENTS;CYP2D6;GG;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
FLUOROURACIL;DPYD;GG;rs1801265;METABOLISM/PK;INCREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  OTHER:WITHOUT THE RS115232898 A>G VARIANT (DPYD Y186C);
EGFR INHIBITORS;PIK3CA;C;rs6443624;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;
ANTIPSYCHOTICS;IL1B;AG;rs16944;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;IL1B;AG;rs16944;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
DAUNORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DOXORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GINGIVAL OVERGROWTH IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:LIVER TRANSPLANTATION;
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TRANSPLANTATION;
EGFR INHIBITORS;PIK3CA;T;rs2677760;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;UNCONTROLLED ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTIPSYCHOTICS;IL1B;AA;rs1143634;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;IL1B;AA;rs1143634;TOXICITY;DECREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;TOXICITY;DECREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
METHYLPHENIDATE;ADGRL3;CG + GG;rs2345039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
DAUNORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
DOXORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LEUKEMIA;
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
CARBOPLATIN;ATP7B;TT;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;ATP7B;TT;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;T;rs4379368;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
NAN;FMO3;AG + GG;rs2266780;OTHER;DECREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;C;rs710446;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;
ASPIRIN;LPA;CT;rs3798220;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN WOMEN  NAN;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
WARFARIN;CYP2C19;T;rs3814637;TOXICITY;NAN;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
FLUOROURACIL;DPYD;CT;rs72728438;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
FLUOROURACIL;ABCC11;GG + GT;rs7194667;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
EGFR INHIBITORS;PIK3CA;C;rs2699905;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs115632870;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;del;rs56392308;TOXICITY;DECREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ETHANOL;SLC6A3;AG;rs6350;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;C;rs8176719;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;G;rs9574;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;T;rs2289252;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;INFECTIOUS DISEASE;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXMEDETOMIDINE;NR1I2;CC;rs3814057;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;
DEXMEDETOMIDINE;NR1I2;CC;rs3814057;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;
NAN;MAOA;TT;rs1137070;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER IN WOMEN  NAN;
NAN;MAOB;CC;rs1799836;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER IN WOMEN  NAN;
CAPECITABINE;;C;rs9936750;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;NAN;SIDE EFFECT;INFECTIOUS DISEASE;
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;NAN;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY;
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;NAN;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FOLFIRI;UGT1A1;GG;rs4124874;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION NAN  NAN;
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CETUXIMAB;EGF;GG;rs4444903;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE PATHOLOGIC RESPONSE IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
AFATINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
AFATINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ERLOTINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
ERLOTINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
GEFITINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
GEFITINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
NAN;HAVCR2;AA + AC;rs10515746;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
NAN;HAVCR2;AC + CC;rs1036199;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
AFATINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
AFATINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ERLOTINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
ERLOTINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
GEFITINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
GEFITINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
GLATIRAMER ACETATE;;T;rs12459996;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
FLUOROURACIL;OR10AE3P, PSMB3P;A;rs10876844;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY NAN  NAN;
HEROIN;BDNF;TT;rs6265;OTHER;INCREASED;RISK;OTHER;ADDICTION NAN  NAN;
METHAMPHETAMINE;BDNF;T;rs6265;OTHER;INCREASED;RISK;OTHER;ADDICTION NAN  NAN;
DOXORUBICIN;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TRASTUZUMAB;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TRASTUZUMAB;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FENTANYL;OPRM1;T;rs540825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:PAIN;
FENTANYL;OPRM1;T;rs540825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
ASPIRIN;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ASPIRIN;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;
TICAGRELOR;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
TICAGRELOR;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;ABCB1;T;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AFATINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
AFATINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ERLOTINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
ERLOTINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
GEFITINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
GEFITINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
NAN;;GG;rs2207418;OTHER;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:HEART FAILURE;
ALFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;RESPIRATORY INSUFFICIENCY IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;CYP2C9;C;rs9332197;EFFICACY;NAN;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;NAN;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP2C18;AG + GG;rs2901783;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
WARFARIN;F5;G;rs6018;TOXICITY;NAN;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;PROS1;AA;rs8178607;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
NAN;CHRM3;GG;rs2165870;TOXICITY;INCREASED;RISK;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
CISPLATIN;CDA;AA;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CAPECITABINE;DPYD;G;rs1801265;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;NAN;SIDE EFFECT;MICRONUCLEATED BINUCLEATED CELLS NAN  NAN;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG;rs1801274;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
NAN;SCN5A;GT + TT;rs7626962;OTHER;INCREASED;LIKELIHOOD;DISEASE;CARDIAC RHYTHM DISEASE NAN  NAN;
CARBOPLATIN;VEGFA;GG;rs879825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;VEGFA;GG;rs879825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
EXEMESTANE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;MTRR;AG + GG;rs1801394;METABOLISM/PK;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CARBOPLATIN;SCN10A;TT;rs9825762;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;SCN10A;TT;rs9825762;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;VEGFA;CC;rs9369421;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;VEGFA;CC;rs9369421;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
LETROZOLE;ESR1;TT;rs4870061;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN MEN  NAN;
METHOTREXATE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
EXEMESTANE;ESR1;TT;rs9322335;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CISPLATIN;NQO1;AA;rs1800566;OTHER;DECREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ETOPOSIDE;NQO1;AA;rs1800566;OTHER;DECREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;SLC22A2;AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
LETROZOLE;ESR2;CC;rs10140457;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EXEMESTANE;ESR1;AA;rs2813543;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BISPHOSPHONATES;;C;rs2736308;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BISPHOSPHONATES;;C;rs2736308;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:OSTEOPOROSIS;
ANTIINFLAMMATORY AGENTS;PTGS1;TT;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;PTGS1;TT;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
BEVACIZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
CISPLATIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
DOCETAXEL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
EPIRUBICIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
OXALIPLATIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
TRASTUZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
CARBOPLATIN;TNF;A;rs1800629;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;TNF;A;rs1800629;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;KDR;CC;rs2305948;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SORAFENIB;KDR;CC;rs2305948;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
NAN;COMT;AG + GG;rs4680;OTHER;DECREASED;NAN;OTHER;LENGTH OF HOSPITAL STAY IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;
CARBOPLATIN;PRRC2A;G;rs11229;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;PRRC2A;G;rs11229;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;PRRC2A;T;rs10885;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;PRRC2A;T;rs10885;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
METHADONE;COMT;AG + GG;rs4680;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  OTHER:NEONATAL ABSTINENCE SYNDROME;
MORPHINE;COMT;AG + GG;rs4680;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  OTHER:NEONATAL ABSTINENCE SYNDROME;
SORAFENIB;FLT1;TT;rs664393;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SORAFENIB;FLT1;TT;rs664393;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
CARBOPLATIN;MSH5;T;rs3115672;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;MSH5;T;rs3115672;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CYCLOPHOSPHAMIDE;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
DOXORUBICIN;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
FEC100;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
FLUOROURACIL;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;ATP2B1;T;rs17381194;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
CARBOPLATIN;DOCK8;A;rs10491684;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;DOCK8;A;rs10491684;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
HMG-COA_REDUCTASE_INHIBITORS;;C;rs4693570;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
NAN;EPO;A;rs1617640;OTHER;INCREASED;NAN;OTHER;ENDOGENOUS LEVELS OF EPO IN HEALTHY INDIVIDUALS  NAN;
HMG-COA_REDUCTASE_INHIBITORS;DMPK;G;rs672348;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;
ASPIRIN;EYA1;T;rs12678747;TOXICITY;INCREASED;RISK;SIDE EFFECT;PEPTIC ULCER DISEASE NAN  NAN;
CARBOPLATIN;CYP2C8;A;rs1058932;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;CYP2C8;A;rs1058932;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;CYP2C8;A;rs11572078;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;CYP2C8;A;rs11572078;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
AZITHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CHLORPROMAZINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CILOSTAZOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CIPROFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CITALOPRAM;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CLARITHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
DOFETILIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
DONEPEZIL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
DRONEDARONE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
ERYTHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
ESCITALOPRAM;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
FLECAINIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
FLUCONAZOLE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
HALOPERIDOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
HYDROXYCHLOROQUINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
LEVOFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
METHADONE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
MOXIFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
ONDANSETRON;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
OXALIPLATIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
PAPAVERINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
PENTAMIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
PROCAINAMIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
PROPOFOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
QUINIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
CARBOPLATIN;C6orf15;A;rs2233980;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;C6orf15;A;rs2233980;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;CDSN;T;rs3130985;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;CDSN;T;rs3130985;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ETOPOSIDE;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
PLATINUM COMPOUNDS;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:BRONCHIOLOALVEOLAR CARCINOMA AND ADENOCARCINOMA PATIENTS;
METHADONE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;
MORPHINE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
ETOPOSIDE;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
PLATINUM COMPOUNDS;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
HMG-COA_REDUCTASE_INHIBITORS;COQ2;A;rs6535454;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN INTOLERANCE;
HMG-COA_REDUCTASE_INHIBITORS;COQ2;A;rs6535454;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN INTOLERANCE;
HMG-COA_REDUCTASE_INHIBITORS;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY NAN  NAN;
CARBOPLATIN;HLA-C;C;rs1049709;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;HLA-C;C;rs1049709;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:BRONCHIOLOALVEOLAR CARCINOMA AND ADENOCARCINOMA PATIENTS;
CARBOPLATIN;HCP5;G;rs3130907;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;HCP5;G;rs3130907;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
LENALIDOMIDE;CTNNB1;AA;rs4135385;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
CARBOPLATIN;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
CARBOPLATIN;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
PACLITAXEL;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;SERPINC1;C;rs5877;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;SERPINC1;C;rs5877;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIAC RHYTHM DISEASE;
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SIDE EFFECT:CARDIOTOXICITY IN PEOPLE WITH  ""OTHER:LEUKEMIA";
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOCYTIC;
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CHRONIC;
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"B-CELL""";
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WALDENSTROM MACROGLOBULINEMIA""";
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:MANTLE CELL LYMPHOMA""";
TAMOXIFEN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;SCN5A;GG;rs7626962;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUDDEN INFANT DEATH NAN  NAN;
LENALIDOMIDE;CTNNB1;AA;rs4533622;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
CARBOPLATIN;;C;rs886423;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;;C;rs886423;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;;T;rs886424;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;;T;rs886424;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CARBOPLATIN;ATAT1;C;rs9262132;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;ATAT1;C;rs9262132;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
NAN;ABO;GG;rs495828;METABOLISM/PK;INCREASED;NAN;OTHER;ACE ACTIVITY IN PEOPLE WITH  DISEASE:HYPERTENSION;
CARBOPLATIN;PPP1R18;T;rs9262143;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;PPP1R18;T;rs9262143;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
NAN;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;NAN;OTHER;LENGTH OF HOSPITAL STAY IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;;CC;rs4604006;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIAC RHYTHM DISEASE;
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SIDE EFFECT:CARDIOTOXICITY IN PEOPLE WITH  ""OTHER:LEUKEMIA";
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOCYTIC;
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CHRONIC;
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"B-CELL""";
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WALDENSTROM MACROGLOBULINEMIA""";
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:MANTLE CELL LYMPHOMA""";
CARBOPLATIN;MUCL3;A;rs3094086;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;MUCL3;A;rs3094086;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
OLANZAPINE;GIPR;AA;rs10423928;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA INSULIN LEVELS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
SORAFENIB;;CC;rs4604006;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
ANTHRACYCLINES AND RELATED SUBSTANCES;;A;rs28714259;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;CTLA4;A;rs231775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GINGIVAL OVERGROWTH IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
SORAFENIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SORAFENIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:PAIN;
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
NAN;ABCC4;AA + AC;rs2274407;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PHYSICAL AND LIFE WELL-BEING QUALITY OF LIFE (QOL) SCALES IN  OTHER:PEOPLE WITH EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;INCREASED;RISK;EFFICACY;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RISK;EFFICACY;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;EFFICACY;OVER-ANTICOAGULATION NAN  NAN;
PAZOPANIB;HFE;TT;rs2858996;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;;GG;rs2207418;OTHER;INCREASED;RISK;DISEASE;HEART FAILURE NAN  NAN;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
GLATIRAMER ACETATE;;A;rs75041078;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
GLATIRAMER ACETATE;;A;rs1056854;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE;METHAMPHETAMINE DEPENDENCE;
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:PSYCHOTIC DISORDER;
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS NAN  NAN;
GLICLAZIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
GLICLAZIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;
GLYBURIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
GLYBURIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER;
PEGINTERFERON ALFA-2A;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TACROLIMUS;ABCB1;CT + TT;rs2229109;EFFICACY;INCREASED;RISK;EFFICACY;RENAL TRANSPLANT FAILURE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PEGINTERFERON ALFA-2A;IFNL3;CC;rs4803217;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
FENTANYL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPOVENTILATION IN PEOPLE WITH  DISEASE:PAIN;
FENTANYL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;NAN;PK;TROUGH LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;TROUGH LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
AFATINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
AFATINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ERLOTINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
ERLOTINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
GEFITINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
GEFITINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CT + TT;rs2031920;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEPRESSION;
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:GASTRITIS;
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERSENSITIVITY IN PEOPLE WITH  OTHER:ACUTE RESPIRATORY DISEASES;
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SUSPECTED INFLUENZA A/H1N1 INFECTION;
METHOTREXATE;ABCC3;AA + AT;rs9895420;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ABCC3;AA + AT;rs9895420;METABOLISM/PK;INCREASED;NAN;SIDE EFFECT;PLASMA LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
COCAINE;OPRD1;T;rs678849;TOXICITY;DECREASED;RISK;OTHER;COCAINE DEPENDENCE NAN  NAN;
CERIVASTATIN;RYR2;AA;rs2819742;TOXICITY;DECREASED;RISK;DISEASE;RHABDOMYOLYSIS NAN  NAN;
CYCLOPHOSPHAMIDE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIEPILEPTICS;ABCC2;A;rs2273697;EFFICACY;INCREASED;NAN;EFFICACY;PROBABILITY OF ANTIEPILEPTIC DRUG RESPONSE IN CHILDREN WITH  DISEASE:EPILEPSY;
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;INCREASED;RISK;EFFICACY;RELAPSE IN THE CENTRAL NERVOUS SYSTEM IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;CYP1A2;T;rs35694136;OTHER;INCREASED;LIKELIHOOD;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE NAN  NAN;
ANTITHYMOCYTE GLOBULIN;FCGR3A;AC + CC;rs396991;OTHER;INCREASED;NAN;OTHER;SENSITIVE TO ANTILYMPHOCYTE SERUM IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOPHOSPHAMIDE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;ARHGAP28;T;rs9958628;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
CYCLOPHOSPHAMIDE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CARBOPLATIN;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;
ETOPOSIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;
IFOSFAMIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;
THEOPHYLLINE;CYP1A2;T/del + TT;rs35694136;EFFICACY;INCREASED;SEVERITY;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;
THEOPHYLLINE;CYP1A2;T;rs35694136;EFFICACY;DECREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;
THEOPHYLLINE;CYP1A2;T;rs35694136;METABOLISM/PK;DECREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;
NAN;CYP1A2;C;rs762551;OTHER;INCREASED;LIKELIHOOD;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE NAN  NAN;
ETHAMBUTOL;ATP7B;CC;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;CC;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;
NAN;DDC;T;rs921451;NAN;NAN;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;
NAN;DDC;C;rs3735273;NAN;NAN;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;
SEVOFLURANE;KCNK2;CC + CG;rs6686529;EFFICACY;INCREASED;NAN;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
NAN;DDC;T;rs1451371;NAN;NAN;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
PROTEASE INHIBITORS;APOC3;CC + CT;rs2854116;EFFICACY;DECREASED;SEVERITY;SIDE EFFECT;HYPERTRIGLYCERIDEMIA NAN  NAN;
VARENICLINE;CHRNB1, ZBTB4;C;rs2302764;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
PROTEASE INHIBITORS;APOC3;CT + TT;rs2854117;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERTRIGLYCERIDEMIA NAN  NAN;
VARENICLINE;CHRNB2;A;rs2072661;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CYCLOPHOSPHAMIDE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DEXAMETHASONE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGASPARGASE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIOGUANINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VARENICLINE;CHRNB2;T;rs4292956;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
VARENICLINE;CHRNB2;C;rs2072660;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CARBOPLATIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;
ETOPOSIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;
IFOSFAMIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;
AZATHIOPRINE;DDRGK1, ITPA;A;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MORPHINE;FAAH;AA;rs324420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;RESPIRATORY INSUFFICIENCY IN CHILDREN WITH  DISEASE:KYPHOSIS;
MORPHINE;FAAH;AA;rs324420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCOLIOSIS;
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
MORPHINE;FAAH;TT;rs11576941;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN WITH  DISEASE:KYPHOSIS;
MORPHINE;FAAH;TT;rs11576941;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCOLIOSIS;
PROTEASE INHIBITORS;APOC3;CG + GG;rs5128;TOXICITY;DECREASED;NAN;SIDE EFFECT;HYPERTRIGLYCERIDEMIA NAN  NAN;
SUNITINIB;ABCB1;AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
DOCETAXEL;SLCO1B3;G;rs11045585;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA NAN  NAN;
APIXABAN;ABCB1;CT + TT;rs4148738;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
DOCETAXEL;ABCC2;G;rs12762549;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA NAN  NAN;
NAN;DTNBP1;T;rs3213207;NAN;DECREASED;RISK;DISEASE;BIPOLAR DISORDER NAN  NAN;
ASPIRIN;ITGB3;CT;rs5918;OTHER;INCREASED;NAN;OTHER;SENSITIVITY TO ASPIRIN NAN  NAN;
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
CYTARABINE;CDA;C/del + del/del;rs3215400;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY NAN  NAN;
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS IN MEN  NAN;
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;PSYCHOTIC DISORDER IN MEN WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;
CYTARABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY NAN  NAN;
ANTIPSYCHOTICS;;GG + GT;rs9346455;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
NAN;DTNBP1;T;rs3213207;NAN;DECREASED;SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS NAN  NAN;
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:PAIN;
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
NAN;DTNBP1;C;rs2619539;NAN;DECREASED;SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS NAN  NAN;
CYTARABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY NAN  NAN;
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CYTARABINE;CDA;CT + TT;rs532545;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY IN HEALTHY INDIVIDUALS  NAN;
HEROIN;OPRD1;A;rs2236855;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
SUNITINIB;ABCB1;AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;THROMBOEMBOLISM NAN  NAN;
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
NICOTINE;NRXN1;C;rs2193225;OTHER;NAN;NAN;OTHER;SMOKING QUANTITY IN  OTHER:SMOKERS;
HEROIN;OPRD1;C;rs2298897;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
NICOTINE;NRXN1;C;rs2193225;OTHER;NAN;NAN;OTHER;SMOKING QUANTITY;
NICOTINE;NRXN1;C;rs2193225;OTHER;NAN;NAN;OTHER;HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE IN  OTHER:SMOKERS;
NICOTINE;NRXN1;A;rs6721498;OTHER;NAN;NAN;OTHER;SMOKING QUANTITY;
NICOTINE;NRXN1;A;rs6721498;OTHER;NAN;NAN;OTHER;HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE IN  OTHER:SMOKERS;
SUNITINIB;ABCB1;AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CHOP;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:PAIN;
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;
NAN;DTNBP1;T;rs2619538;NAN;DECREASED;SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS NAN  NAN;
ETHANOL;FUT2;A;rs492602;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;FTO;A;rs9937709;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
PLATINUM;RICTOR;GG;rs6878291;TOXICITY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIDEPRESSANTS;NR3C1;G;rs852977;EFFICACY;INCREASED;NAN;PK;ANTIDEPRESSANT RESPONSE NAN  NAN;
CERIVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;RHABDOMYOLYSIS NAN  NAN;
PAROXETINE;HTR3B;AA;rs1176744;TOXICITY;INCREASED;RISK;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
ETHANOL;;A;rs1783835;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
CISPLATIN;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
CISPLATIN;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
FLUOROURACIL;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
FLUOROURACIL;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
RADIOTHERAPY;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
RADIOTHERAPY;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;
SUNITINIB;ABCB1;A;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CISPLATIN;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
CISPLATIN;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
FLUOROURACIL;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
FLUOROURACIL;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
RADIOTHERAPY;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN MEN WITH  OTHER:CARCINOMA;
RADIOTHERAPY;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;
ETHANOL;SLC4A8;C;rs12296477;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;NAN;NAN;OTHER;SHORTER BLEEDING TIME IN HEALTHY INDIVIDUALS  NAN;
NAN;NR3C1;G;rs10482633;NAN;INCREASED;NAN;EFFICACY;ANTIDEPRESSANT RESPONSE NAN  NAN;
ESCITALOPRAM;HTR2A;C;rs9316233;EFFICACY;INCREASED;NAN;EFFICACY;ANTIDEPRESSANT RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
ETHANOL;ARID4A;T;rs61974485;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
ETHANOL;;T;rs8008020;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
NICOTINE;OPRM1;AG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;
ETHANOL;TNRC6A;A;rs72768626;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;
GLIMEPIRIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;HYPOGLYCEMIA IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
GLIMEPIRIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;TYPE 2;
GLIPIZIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;HYPOGLYCEMIA IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
GLIPIZIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;TYPE 2;
GLYBURIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;HYPOGLYCEMIA IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
GLYBURIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;TYPE 2;
KETOROLAC;;CC;rs2562456;EFFICACY;NAN;NAN;EFFICACY;SLOWER ANALGESIC ONSET IN EUROPEAN AMERICANS UNDERGOING ORAL SURGERY NAN  NAN;
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING NAN  NAN;
AZATHIOPRINE;ABCC1;CC + CG;rs2074087;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
FLUVASTATIN;SREBF1;CC;rs60282872;EFFICACY;INCREASED;NAN;EFFICACY;APOLIPOPROTEIN A1 AND C3 IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
BEVACIZUMAB;SLC19A1;G;rs1051298;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PEMETREXED;SLC19A1;G;rs1051298;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CISPLATIN;TP53;CG;rs1042522;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  OTHER:UTERINE CERVICAL NEOPLASM;
RADIOTHERAPY;TP53;CG;rs1042522;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  OTHER:UTERINE CERVICAL NEOPLASM;
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;NAN;OTHER;BASELINE PROINSULIN LEVELS AFTER ADJUSTING FOR INSULIN LEVELS IN PEOPLE WITH  OTHER:SUSPECTED INCREASED RISK OF DIABETES;
NAN;SLC30A8;C;rs13266634;METABOLISM/PK;INCREASED;NAN;OTHER;BASELINE PROINSULIN LEVELS AFTER ADJUSTING FOR INSULIN LEVELS IN PEOPLE WITH  OTHER:SUSPECTED INCREASED RISK OF DIABETES;
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN PEOPLE WITH  OTHER:PAIN;
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;
ANTIINFLAMMATORY AGENTS;AGT;GG;rs943580;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;AGT;GG;rs943580;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ANTIINFLAMMATORY AGENTS;MMP1, MMP10;AG + GG;rs2071230;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;MMP1, MMP10;AG + GG;rs2071230;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
LEVONORGESTREL;ADAMTS10;CG;rs7255721;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN  NAN;
ANTIINFLAMMATORY AGENTS;MMP1, MMP10;CT + TT;rs7945189;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;MMP1, MMP10;CT + TT;rs7945189;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEART PALPITATIONS IN PEOPLE WITH  DISEASE:DEPRESSION;
ANTIINFLAMMATORY AGENTS;PTGS1;TT;rs12353214;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;PTGS1;TT;rs12353214;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ANTIINFLAMMATORY AGENTS;KL;CG + GG;rs211247;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;KL;CG + GG;rs211247;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ANTIINFLAMMATORY AGENTS;CRP;CT + TT;rs1205;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;CRP;CT + TT;rs1205;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NICOTINE;CHRNA4;AG;rs1044396;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING INITIATION IN MEN  NAN;
ANTIINFLAMMATORY AGENTS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NICOTINE;CHRNA4;GG;rs1044396;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER IN MEN  NAN;
ANTIINFLAMMATORY AGENTS;AGT;GG;rs699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NON-STEROIDS;AGT;GG;rs699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NICOTINE;CHRNA4;CC;rs1044397;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER IN MEN  NAN;
COXIBS;PTGS2;CG + GG;rs20417;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
COXIBS;PTGS2;AG + GG;rs4648276;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
SEVOFLURANE;FASTKD3, MTRR;CC + CT;rs3733784;EFFICACY;INCREASED;NAN;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
HEROIN;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
HEROIN;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
HEROIN;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
AZATHIOPRINE;ADK;TT;rs10824095;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CISPLATIN;ACYP2;A;rs1872328;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  DISEASE:BRAIN NEOPLASMS;
AZATHIOPRINE;SLC29A1;CG + GG;rs747199;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AZATHIOPRINE;IMPDH2;AG + GG;rs11706052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
AZATHIOPRINE;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
CLOZAPINE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HEROIN;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
CLOZAPINE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
HEROIN;;A;rs9478495;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
NAN;;G;rs9424490;NAN;INCREASED;RISK;OTHER;CURRENT SMOKING NAN  NAN;
NAN;USH2A;C;rs12126638;NAN;INCREASED;RISK;OTHER;CURRENT SMOKING NAN  NAN;
NAN;AK4;C;rs1109374;NAN;INCREASED;RISK;OTHER;CURRENT SMOKING NAN  NAN;
ASPIRIN;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
NAN;ITGB1;AA;rs1187075;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
HEROIN;OPRM1;C;rs562859;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
PLATINUM;STMN1;AA;rs182455;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  NAN;
VINORELBINE;STMN1;AA;rs182455;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  NAN;
TEGAFUR;DPYD;TT;rs1801159;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
NAN;ITGB1;GG;rs2230395;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
HEROIN;OPRM1;C;rs3778150;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
BEVACIZUMAB;GGH;G;rs3780126;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PEMETREXED;GGH;G;rs3780126;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
NAN;TPH2;TT;rs1843809;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;AGGRESSION;
NAN;TPH2;TT;rs1843809;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
HEROIN;;C;rs9384169;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;
ANTIPSYCHOTICS;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;NAN;SIDE EFFECT;QT INTERVAL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIDEPRESSANTS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;
ANTIDEPRESSANTS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;
ANTIPSYCHOTICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;
ANTIPSYCHOTICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;
BENZODIAZEPINE DERIVATIVES;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;
BENZODIAZEPINE DERIVATIVES;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;
SYMPATHOMIMETICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;
SYMPATHOMIMETICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;
BEVACIZUMAB;GGH;CT;rs11545077;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PEMETREXED;GGH;CT;rs11545077;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
DIGOXIN;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;NAN;SIDE EFFECT;SHORTENED QT INTERVAL NAN  NAN;
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME;
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE;
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;COLLAGEN;
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;AND EPINEPHRINE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE;
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;COLLAGEN;
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;AND EPINEPHRINE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;NAN;NAN;EFFICACY;HIGHER FENTANYL DOSE REQUIREMENT TO ACHIEVE ADEQUATE PAIN RELIEF IN CHINESE WOMEN UNDERGOING GYNECOLOGIC SURGERY NAN  NAN;
CANNABINOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
COCAINE;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
ETHANOL;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
NICOTINE;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
CAPECITABINE;MIR27A;CT;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
SUNITINIB;FLT1;GG;rs7993418;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CISPLATIN;NFE2L2;GG + GT;rs6721961;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;NAN;NAN;EFFICACY;HIGHER RESPONSIVENESS TO OPIOIDS AND REQUIRED LESS ANALGESIC DRUGS IN LABORING WOMEN IN WOMEN  NAN;
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;NAN;NAN;EFFICACY;HIGHER RESPONSIVENESS TO OPIOIDS AND REQUIRED LESS ANALGESIC DRUGS IN LABORING WOMEN IN WOMEN  NAN;
FLUVOXAMINE;HTR2A;CC + CT;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;NAN;NAN;EFFICACY;LESS PAIN CONTROL IN JAPANESE PATIENTS UNDERGOING PAINFUL OROFACIAL COSMETIC SURGERY NAN  NAN;
OLANZAPINE;FMO3;GG;rs2266780;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED SERUM OLANZAPINE N-OXIDE CONCENTRATIONS NAN  NAN;
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF METOPROLOL AND GREATER REDUCTIONS IN HEART RATE;
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED;NAN;PK;DIASTOLIC BLOOD PRESSURE;
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED;NAN;PK;AND MEAN ARTERIAL PRESSURE IN PMS THAN IN NON-PMS. NAN  NAN;
METOPROLOL;CYP2D6;T;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF METOPROLOL AND GREATER REDUCTIONS IN HEART RATE;
METOPROLOL;CYP2D6;T;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;DIASTOLIC BLOOD PRESSURE;
METOPROLOL;CYP2D6;T;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;AND MEAN ARTERIAL PRESSURE IN PMS THAN IN NON-PMS. NAN  NAN;
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
PLATINUM COMPOUNDS;CCN4;AA + AC;rs10956697;EFFICACY;DECREASED;RISK;EFFICACY;OVERALL SURVIVAL;
PLATINUM COMPOUNDS;CCN4;AA + AC;rs10956697;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;INCREASED;RISK;EFFICACY;THE LACK OF ASPIRIN EFFECT IN MEN  NAN;
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
OLANZAPINE;FMO1;AA + AC;rs12720462;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PSYCHOMOTOR AGITATION IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SCHIZOPHRENIA;
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
PLATINUM;ABCB1;CC;rs2032582;TOXICITY;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
PLATINUM;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;ABCB1;CC;rs2032582;TOXICITY;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
TAXANES;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
OLANZAPINE;FMO1;CT + TT;rs7877;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;NAN;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
BUMETANIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;NAN;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM IN HEALTHY INDIVIDUALS  NAN;
FUROSEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;NAN;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM IN HEALTHY INDIVIDUALS  NAN;
TORASEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;NAN;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM IN HEALTHY INDIVIDUALS  NAN;
AMPHETAMINE;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
CANNABINOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
COCAINE;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
OPIOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
IMATINIB;ABCG2;TT;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ASPIRIN;NAT2;C;rs4271002;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"NAUSEA IN PEOPLE WITH  ""OTHER:PAIN""";
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:PAIN";
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE""";
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED;RISK;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
BUMETANIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;
FUROSEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;
TORASEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;
PLATINUM COMPOUNDS;CCN4;GG + GT;rs2929973;EFFICACY;DECREASED;RISK;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
ENALAPRIL;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
ANTIPSYCHOTICS;HTR2A;TT;rs6311;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED;RISK;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;MYOCD;AA + AG;rs1714984;EFFICACY;NAN;NAN;EFFICACY;INCREASED RISK OF BEING NONRESPONDERS NAN  NAN;
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED;RISK;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
BUMETANIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;
FUROSEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;
TORASEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIPSYCHOTICS;CYP2D6;A;rs1065852;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;DECREASED;RISK;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PRAVASTATIN;CETP;AG;rs708272;EFFICACY;DECREASED;SEVERITY;EFFICACY;CORONARY ARTERY DISEASE IN MEN WITH  OTHER:CORONARY ARTERY DISEASE;
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;NAN;EFFICACY;BENEFIT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;NAN;NAN;EFFICACY;ASPIRIN-DEPRESSED THROMBIN GENERATION AND PROLONGED BLEEDING TIME AFTER ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITION OF FXIII ACTIVATION BY ASPIRIN IN MEN  NAN;
VERAPAMIL;ADRB1;CC + CG;rs1801253;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AZATHIOPRINE;ITPA;C;rs1127354;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;DECREASED;SEVERITY;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;
PRAVASTATIN;CETP;GG;rs708272;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LUMINAL DIAMETER IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;
DIURETICS;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;
SOTALOL;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;
ANTIPSYCHOTICS;;CT + TT;rs6977820;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;
WARFARIN;VKORC1;T;rs17880887;DOSAGE;NAN;NAN;EFFICACY;LOWER LEVELS OF TRANSTHYRETIN PRECUROR NAN  NAN;
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;NAN;NAN;SIDE EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;
ASPIRIN;HNMT;G;rs1050891;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACETYLSALICYLIC ACID-INTOLERANT CHRONIC URTICARIA NAN  NAN;
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;NAN;NAN;SIDE EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;
ASPIRIN;LTC4S;AC + CC;rs730012;TOXICITY;INCREASED;RISK;SIDE EFFECT;SENSITIVITY TO ASPIRIN NAN  NAN;
ANTIPSYCHOTICS;SMYD3;T;rs2485914;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ETHAMBUTOL;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;
LEVONORGESTREL;TP53;CG;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN  NAN;
ASPIRIN;GP6;AG;rs1613662;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
IFOSFAMIDE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3-YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3-YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;
CISPLATIN;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
IFOSFAMIDE;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;NAN;NAN;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) NAN  NAN;
PHENPROCOUMON;CYP4F2;CT + TT;rs2108622;DOSAGE;NAN;NAN;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) NAN  NAN;
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;NAN;NAN;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) NAN  NAN;
ASPIRIN;ITGB3;CT;rs5918;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD LOSS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:NON-HODGKIN LYMPHOMA;
SUNITINIB;KDR;C;rs2305948;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;KDR;C;rs2305948;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;
CAPECITABINE;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
EPIRUBICIN;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PLATINUM;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NAN;ITGB3;CC + CT;rs5918;OTHER;NAN;NAN;OTHER;SHORTER BLEEDING TIME IN HEALTHY INDIVIDUALS  NAN;
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
HYDROMORPHONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
BEVACIZUMAB;CXCR4;AA + AG;rs2228014;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;OTHER;DECREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;
DOCETAXEL;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FEC100;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
GEMCITABINE;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
TRASTUZUMAB;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ZOLEDRONATE;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
SUNITINIB;FLT4;GG;rs6877011;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
HALOPERIDOL;ABCB5;CT;rs17143212;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
DOCETAXEL;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
FEC100;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
GEMCITABINE;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
TRASTUZUMAB;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
ZOLEDRONATE;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;
SUNITINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
OPIOIDS;CNIH3;A;rs10799590;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SUNITINIB;VEGFA;CT + TT;rs3025039;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
SUNITINIB;CYP3A4;AA + AG;rs4646437;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ATORVASTATIN;ABCB1;C;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
"""ACE INHIBITORS";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"PLAIN""";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"""ANGIOTENSIN II ANTAGONISTS""";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
CISPLATIN;NFE2L2;T;rs6721961;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CARVEDILOL;ADRB2;CC;rs1042714;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;IMPROVED LEFT VENTRICULAR EJECTION FRACTION IN PEOPLE WITH  DISEASE:HEART FAILURE;
TACROLIMUS;FOXP3;GT + TT;rs3761548;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
METHOTREXATE;RAVER2;A;rs72675408;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;ATAXIA;
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIPLOPIA;
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIZZINESS;
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DYSARTHRIA IN PEOPLE WITH  OTHER:EPILEPSY;
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;ATAXIA;
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIPLOPIA;
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIZZINESS;
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DYSARTHRIA IN PEOPLE WITH  OTHER:EPILEPSY;
CAPECITABINE;PPARD;T;rs2016520;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;PPARD;T;rs2016520;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
EFAVIRENZ;CYP2B6;CT + TT;rs8192719;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;SULT1A1, SULT1A2;CC + CT;rs1801030;OTHER;INCREASED;LIKELIHOOD;DISEASE;HOT FLASHES IN PEOPLE WITH  OTHER:MENOPAUSE;
OPIOIDS;MCOLN1;A;rs116181528;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OVERDOSE NAN  NAN;
CERIVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
NAN;AKT1;CC;rs2494732;OTHER;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER IN PEOPLE WITH  DISEASE:MARIJUANA ABUSE;
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;
BEVACIZUMAB;KCNAB1;G;rs6770663;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:NEOPLASMS;
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ASPIRIN;CEP68;AA;rs7572857;TOXICITY;INCREASED;NAN;SIDE EFFECT;DECLINE OF FORCED EXPIRATORY VOLUME IN 1S (FEV(1)) BY ASPIRIN PROVOCATION IN PEOPLE WITH  DISEASE:ASTHMA;
OPIOIDS;MCOLN1;T;rs114077267;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OVERDOSE NAN  NAN;
ACENOCOUMAROL;VKORC1;TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
PLATINUM COMPOUNDS;MDM2;GT + TT;rs2279744;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASPIRIN;ITGB3;CT;rs5918;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION BY ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
NAN;SLC2A9;AG;rs62293298;OTHER;DECREASED;LIKELIHOOD;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ASPIRIN;TLR3;CT + TT;rs3775291;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-EXACERBATED RESPIRATORY DISEASE IN PEOPLE WITH  DISEASE:ASTHMA;
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
OPIOIDS;MCOLN1;G;rs115208233;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OVERDOSE NAN  NAN;
TACROLIMUS;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
NICOTINE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;NAN;SIDE EFFECT;CRAVING IN CHILDREN  NAN;
NICOTINE;DRD2;GG;rs1800497;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CRAVING IN CHILDREN  NAN;
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;
PEGINTERFERON ALFA-2A;IL6;CC;rs1800795;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IL6;CC;rs1800795;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IL6;CC;rs1800795;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NAN;ABCG2;GT + TT;rs2231142;OTHER;INCREASED;LIKELIHOOD;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
ACENOCOUMAROL;CYP2C9;AG;rs72558189;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP2C9;AG;rs72558189;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
TELBIVUDINE;TK2;CC + CT;rs3826160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION IN PEOPLE WITH  OTHER:HEPATITIS B;
TELBIVUDINE;TK2;CC + CT;rs3826160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CHRONIC;
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;
NAN;SLC22A12;CT;rs3825017;OTHER;INCREASED;LIKELIHOOD;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;
OLANZAPINE;DRD2;T;rs2440390;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PRAVASTATIN;ADAMTS1;GG;rs428785;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;FATAL CORONARY DISEASE OR NONFATAL MYOCARDIAL INFARCTION IN MEN  NAN;
OLANZAPINE;HTR2C;G;rs6318;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN WOMEN WITH  DISEASE:MENTAL DISORDERS;
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NEURAL TUBE DEFECTS IN WOMEN  OTHER:WHO ARE PREGNANT;
OLANZAPINE;HTR2C;C;rs2497538;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN WOMEN WITH  DISEASE:MENTAL DISORDERS;
OLANZAPINE;HTR2C;G;rs1414334;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN WOMEN WITH  DISEASE:MENTAL DISORDERS;
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PIOGLITAZONE;LPL;CG + GG;rs328;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE RATE AFTER 10 WEEKS OF PIOGLITAZONE TREATMENT IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
PIOGLITAZONE;LPL;CG + GG;rs328;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
PACLITAXEL;EPHA5;CT + TT;rs7349683;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;
NAN;SCN1A;T;rs3812718;OTHER;INCREASED;RISK;DISEASE;SEIZURES;
NAN;SCN1A;T;rs3812718;OTHER;INCREASED;RISK;DISEASE;FEBRILE IN PEOPLE WITH  DISEASE:EPILEPSY;
NAN;UGT1A1;AA + AG;rs4148323;OTHER;INCREASED;SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA;
NAN;UGT1A1;AA + AG;rs4148323;OTHER;INCREASED;SEVERITY;OTHER;OTHER:HYPERBILIRUBINEMIA IN CHILDREN  NAN;
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
PACLITAXEL;ABCB1;AG + GG;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;
VERAPAMIL;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;RISK;SIDE EFFECT;QTC PROLONGATION NAN  NAN;
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;;A;rs1051730;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;
NAN;CYP2R1;A;rs12794714;OTHER;INCREASED;LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY NAN  NAN;
OLANZAPINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;SOCIAL AND CLINICAL NEEDS IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ETHAMBUTOL;NAT2;A;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
NAN;CYP2R1;A;rs10741657;OTHER;DECREASED;LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY NAN  NAN;
ETHAMBUTOL;NAT2;T;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE AT 4 WEEKS AFTER THE INITIATION OF TREATMENT IN PEOPLE WITH  DISEASE:PANIC DISORDER;
TAMOXIFEN;E2F7;CC;rs310786;TOXICITY;INCREASED;NAN;SIDE EFFECT;LUMBAR BONE LOSS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ALENDRONATE;DKK1;AA;rs2241529;EFFICACY;DECREASED;NAN;EFFICACY;BONE DENSITY IN WOMEN WITH  DISEASE:METABOLIC BONE DISORDER;
ALENDRONATE;DKK1;AA;rs2241529;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:OSTEOPOROSIS;
CLOPIDOGREL;CES1;G;rs8192950;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CES1;G;rs8192950;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;
ANTIPSYCHOTICS;DRD2;GG;rs1799732;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS NAN  NAN;
SUNITINIB;KDR;CC;rs2305948;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
WARFARIN;CYP2C9;C;rs4918758;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS NAN  NAN;
SUNITINIB;VEGFA;CC;rs3025039;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;NAN;PK;AREA UNDER THE CURVE FROM BASELINE TO THE LAST MEASURED CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;
EXEMESTANE;ESR1;CC;rs9322336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;CYP2C9;T;rs9332096;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS NAN  NAN;
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;NAN;OTHER;PEAK PLASMA CONCENTRATION OF INCREASED PROLACTIN IN HEALTHY INDIVIDUALS  NAN;
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;FLT4;C;rs6877011;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;FLT4;C;rs6877011;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
OLANZAPINE;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SYNCOPE IN HEALTHY INDIVIDUALS  NAN;
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;AA;rs2232228;TOXICITY;INCREASED;RISK;DISEASE;CARDIOMYOPATHIES IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;
NORTRIPTYLINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ORTHOSTATIC HYPOTENSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
MORPHINE;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
OXYCODONE;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
MORPHINE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
CARBAMAZEPINE;HNF4A;GG;rs2071197;EFFICACY;INCREASED;NAN;PK;CONCENTRATION-TO-DOSE RATIOS IN PEOPLE WITH  DISEASE:EPILEPSY;
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
PRAVASTATIN;MTHFR;GG;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;CORONARY ARTERY DISEASE;
PRAVASTATIN;MTHFR;GG;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;DISEASE:MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;
SUNITINIB;ABCB1;AA;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CYCLOSPORINE;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;TNF;AA + AG;rs1800629;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;TNF;AA + AG;rs1800629;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
CYCLOSPORINE;IL10;TT;rs1800872;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;IL10;TT;rs1800872;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
SUNITINIB;ABCB1;AA + AT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;
SUNITINIB;VEGFA;G;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER;SMOKING IN PEOPLE WITH  OTHER:SCHIZOPHRENIA WHO ARE SMOKERS;
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER;SMOKING IN PEOPLE WITH  OTHER:SMOKING;
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE;SCHIZOPHRENIA NAN  NAN;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
CLOPIDOGREL;N6AMT1;GG;rs2254638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED;SEVERITY;OTHER;CRAVING IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ERYTHROMYCIN;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;ERYTHROMYCIN METABOLISM IN PEOPLE WITH  DISEASE:NEOPLASMS;
PAZOPANIB;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NEOPLASMS;
SIMVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NEOPLASMS;
GENTAMICIN;MT-RNR1;G;rs267606617;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN INFANTS  NAN;
CYCLOSPORINE;LEP;A;rs2167270;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;LEP;A;rs2167270;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ERLOTINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
MERCAPTOPURINE;NUDT15;GT;rs73189762;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ETHANOL;HTR3B;C;rs1176744;OTHER;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE IN MEN  NAN;
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;ADORA2A, SPECC1L;G;rs5760410;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CALCIUM CHANNEL BLOCKERS;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
NITRENDIPINE;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
CLOPIDOGREL;KDR;CC;rs7667298;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANGINA PECTORIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;RISK;DISEASE;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;RISK;DISEASE;BCR-ABL1 POSITIVE;
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RISK;DISEASE;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RISK;DISEASE;BCR-ABL1 POSITIVE;
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED;SEVERITY;OTHER;CRAVING IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;LYMPHOCYTIC;
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;CHRONIC;
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;B-CELL;
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;LYMPHOCYTIC;
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;CHRONIC;
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;B-CELL;
BUSULFAN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS NAN  NAN;
CYCLOPHOSPHAMIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS NAN  NAN;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS NAN  NAN;
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ERLOTINIB;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;RISK;EFFICACY;RELAPSE IN PEOPLE WITH  OTHER:ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA.;
CLOPIDOGREL;KDR;TT;rs2305948;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGINA PECTORIS;
CLOPIDOGREL;KDR;TT;rs2305948;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
METHOTREXATE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ORAL MUCOSITIS IN PEOPLE WITH  OTHER:HEMATOPOIETIC-CELL-TRANSPLANTATION;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ERLOTINIB;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;FKBP5;CC + CT;rs1360780;NAN;INCREASED;RISK;OTHER;POST-TRAUMATIC STRESS DISORDER (PTSD) IN PEOPLE WITH  OTHER:HISTORY OF CHILD ABUSE;
NAN;FKBP5;AA + AC;rs3800373;OTHER;INCREASED;RISK;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN PEOPLE WITH  OTHER:HISTORY OF CHILD ABUSE;
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;TBX21;A;rs17244587;NAN;INCREASED;RISK;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;
NAN;PSMB4;T;rs2296840;OTHER;INCREASED;RISK;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;
METFORMIN;SLC22A1;A;rs34059508;DOSAGE;INCREASED;NAN;PK;BIOAVAILABILITY NAN  NAN;
METFORMIN;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;NAN;PK;BIOAVAILABILITY NAN  NAN;
METFORMIN;SLC22A1;C;rs12208357;DOSAGE;INCREASED;NAN;PK;BIOAVAILABILITY (AUC;
METFORMIN;SLC22A1;C;rs12208357;DOSAGE;INCREASED;NAN;PK;CL & AUC/CL RATIO) NAN  NAN;
METFORMIN;SLC22A1;C;rs12208357;METABOLISM/PK;INCREASED;NAN;PK;BIOAVAILABILITY (AUC;
METFORMIN;SLC22A1;C;rs12208357;METABOLISM/PK;INCREASED;NAN;PK;CL & AUC/CL RATIO) NAN  NAN;
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NAN;CHRNA5;C;rs680244;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;
METHOTREXATE;PTPN22;AA;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
NAN;CHRNA3;G;rs1051730;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
METHOTREXATE;TNFAIP3;A;rs6920220;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:ARTHRITIS;
NAN;CHRNA3, CHRNA5;G;rs578776;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;CHRNA5;A;rs16969968;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN WOMEN WITH  DISEASE:BIPOLAR DISORDER;
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
NAN;CHRNA5;C;rs569207;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CARBAMAZEPINE;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENOBARBITAL;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENOBARBITAL;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;
NAN;SLCO1B3;C;rs2417940;OTHER;INCREASED;SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA;
NAN;SLCO1B3;C;rs2417940;OTHER;INCREASED;SEVERITY;OTHER;OTHER:HYPERBILIRUBINEMIA IN CHILDREN  NAN;
SERTRALINE;;G;rs13432159;TOXICITY;INCREASED;NAN;SIDE EFFECT;GENERAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;NAN;EFFICACY;RELAPSE FREE TIME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
NAN;KIF6;AG + GG;rs20455;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ROSUVASTATIN;GATM;AA + AG;rs9806699;TOXICITY;DECREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
TAMOXIFEN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;DECREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
PEGINTERFERON ALFA-2B;ITPA;C;rs7270101;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES;
FLUOROURACIL;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES;
IRINOTECAN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES;
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;NAN;OTHER;CORONARY FLOW RESERVE IN MEN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;;G;rs116561224;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NAN;KCNH2;T;rs3815459;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
FENOFIBRATE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
SERTRALINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TERBINAFINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TICLOPIDINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
ANTIDEPRESSANTS;HTR2A;CC;rs17288723;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
NAN;KCNH2;CT + TT;rs3807375;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
CITALOPRAM;GRIK4;C;rs1954787;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;
NAN;KCNH2;GT + TT;rs1805123;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
CYCLOSPORINE;NR1I2;C;rs2276707;DOSAGE;DECREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;NR1I2;C;rs2276707;METABOLISM/PK;DECREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT + TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
PLATINUM COMPOUNDS;GSTP1;G;rs1695;TOXICITY;DECREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;GSTP1;G;rs1695;METABOLISM/PK;DECREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOZAPINE;;T;rs149104283;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799931;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
NAN;KCNH2;G;rs1805123;OTHER;DECREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
ASPARAGINASE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISOLONE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NAN;KCNH2;T;rs3807375;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
OXALIPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;KCNQ1;G;rs757092;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
NAN;KCNH2;T;rs3815459;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;NAN;OTHER;ADENOSINE-STIMULATED MYOCARDIAL FLOW IN MEN  NAN;
NAN;VEGFA;CG + GG;rs2010963;OTHER;INCREASED;RISK;OTHER;PREMATURE BIRTH IN WOMEN  NAN;
NAN;KCNH2;GG;rs1805123;OTHER;DECREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
NAN;KCNQ1;G;rs757092;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;
OXALIPLATIN;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;SEVERITY;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;INFECTIOUS DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOSPORINE;NR1I2;T;rs2276707;DOSAGE;INCREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;NR1I2;T;rs2276707;METABOLISM/PK;INCREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
RIFAMPIN;NR1I2;TT;rs3814055;OTHER;INCREASED;NAN;PK;ERYTHROMYCIN BREATH TEST NAN  NAN;
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977549;EFFICACY;DECREASED;RISK;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
CITALOPRAM;HTR2A;AA;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;
TACROLIMUS;CYP3A4;CC + TT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A4;CC + TT;rs2740574;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;NR1I2;C;rs3814055;DOSAGE;DECREASED;NAN;PK;BIOAVAILABILTY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CYCLOSPORINE;NR1I2;C;rs3814055;METABOLISM/PK;DECREASED;NAN;PK;BIOAVAILABILTY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ASPIRIN;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
ANTIDEPRESSANTS;HTR2A;G;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;
SUFENTANIL;COMT;AA + AG;rs4680;DOSAGE;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PREGNANCY;
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PREGNANCY;
ANTIDEPRESSANTS;GRIK4;GG;rs12800734;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;
NAN;KIF6;AG + GG;rs20455;OTHER;INCREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;
PRAVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AUC NAN  NAN;
PRAVASTATIN;SLCO1B1;AG;rs4149015;OTHER;INCREASED;NAN;PK;AUC0-12 IN HEALTHY INDIVIDUALS  NAN;
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;NAN;PK;AUC0-12 IN HEALTHY INDIVIDUALS  NAN;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977551;EFFICACY;DECREASED;RISK;EFFICACY;OVERALL SURVIVAL;
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977551;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
FLUOROURACIL;TP53;GG;rs1042522;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
PEGINTERFERON ALFA-2A;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
NICOTINE;CHRNA3, CHRNA5;GG;rs578776;TOXICITY;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
NICOTINE;CHRNA4;AA;rs1044396;TOXICITY;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
NICOTINE;CHRNA4;CC;rs2229959;TOXICITY;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;T;rs13306278;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PRAVASTATIN;TLR4;AG + GG;rs4986790;EFFICACY;DECREASED;RISK;EFFICACY;CARDIOVASCULAR EVENTS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;G;rs267606617;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;
PEGINTERFERON ALFA-2A;VDR;TT;rs1544410;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;VDR;TT;rs1544410;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
FLUOROURACIL;IGFBP3;CC;rs2854746;EFFICACY;NAN;NAN;OTHER;BETTER SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DYING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PLATINUM COMPOUNDS;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;RISK;EFFICACY;DYING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;EFFICACY;DYING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;ABCB1;AA;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;
IRINOTECAN;UGT1A1;AA + AG;rs10929302;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;
NICOTINE;CHRNA4;G;rs1044396;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
CISPLATIN;LRP2;T;rs2075252;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;CDA;C/del + CC;rs3215400;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;POR;GG;rs2286823;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
SUNITINIB;POR;TT;rs1057868;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
SUNITINIB;SLCO1B3;GG;rs4149117;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  EFFICACY:GASTROINTESTINAL STROMAL TUMORS;
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CES1P1;AC + CC;rs3785161;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
METHOTREXATE;ATIC;G;rs2372536;NAN;NAN;SEVERITY;DISEASE;RHEUMATOID ARTHRITIS NAN  NAN;
LEUCOVORIN;FASTKD3, MTRR;GG;rs1801394;TOXICITY;INCREASED;SEVERITY;DISEASE;STOMATITIS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR;FASTKD3, MTRR;GG;rs1801394;TOXICITY;INCREASED;SEVERITY;DISEASE;STOMATITIS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANY GRADE 3 ADVERSE EVENT IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANY GRADE 3 ADVERSE EVENT IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PAZOPANIB;CXCL8;TT;rs1126647;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
NICOTINE;CHRNA4;G;rs2236196;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;CT;rs111564371;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;CT;rs111564371;EFFICACY;DECREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:OSTEOSARCOMA;
NICOTINE;CHRNA3;AA + AG;rs1051730;TOXICITY;DECREASED;NAN;SIDE EFFECT;LUNG FUNCTION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CYCLOPHOSPHAMIDE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
LEDIPASVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CARBAMAZEPINE;HSPA1A;T;rs1043620;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
LEDIPASVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CARBAMAZEPINE;HSPA1A;G;rs506770;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
ASPIRIN;F13A1;AA;rs5985;EFFICACY;DECREASED;NAN;EFFICACY;FIBRIN CLOT FORMATION TIME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;F13A1;AA;rs5985;EFFICACY;DECREASED;NAN;EFFICACY;FIBRIN CLOT FORMATION TIME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CYCLOPHOSPHAMIDE;TP53;G;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;TP53;G;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CARBAMAZEPINE;HSPA1L;G;rs2227956;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;
CLOPIDOGREL;P2RY12;AG + GG;rs6787801;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;NAN;SIDE EFFECT;HYPERTENSION IN MEN WITH  DISEASE:SCHIZOPHRENIA;
CARBAMAZEPINE;MLN;A;rs2894342;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY SYNDROME NAN  NAN;
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN MEN WITH  NAN;
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;
CAFFEINE;ADORA2A;CC;rs2298383;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;
CAFFEINE;;CC;rs4822492;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;
NAN;MT-RNR1;G;rs267606617;OTHER;INCREASED;LIKELIHOOD;OTHER;HEARING LOSS;
NAN;MT-RNR1;G;rs267606617;OTHER;INCREASED;LIKELIHOOD;OTHER;SENSORINEURAL NAN  NAN;
CARBAMAZEPINE;;T;rs3130690;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
CAFFEINE;ADORA2A;CC;rs5751876;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BEING SENSITIVE TO CAFFEINE NAN  NAN;
CAFFEINE;ADORA2A;CC;rs5751876;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSOMNIA NAN  NAN;
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE;
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEROIN DEPENDENCE;
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:METHAMPHETAMINE DEPENDENCE NAN  NAN;
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE;
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEROIN DEPENDENCE;
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:METHAMPHETAMINE DEPENDENCE NAN  NAN;
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE;
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEROIN DEPENDENCE;
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:METHAMPHETAMINE DEPENDENCE NAN  NAN;
CARBAMAZEPINE;MICA;C;rs2848716;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
"NON-STEROIDS""";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
"""ASPIRIN""";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
CAFFEINE;ADORA2A;TT;rs5751876;DOSAGE;DECREASED;NAN;OTHER;HABITUAL CONSUMPTION NAN  NAN;
CARBAMAZEPINE;BAG6, PRRC2A;C;rs750332;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
"NON-STEROIDS""";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
"""ASPIRIN""";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
NAN;CHRNA5;T;rs588765;EFFICACY;NAN;NAN;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP NAN  NAN;
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;INCREASED;NAN;EFFICACY;PERCENTAGE CHANGE IN HDL-C LEVELS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ALENDRONATE;SOST;CC;rs1234612;EFFICACY;INCREASED;NAN;EFFICACY;BONE DENSITY IN WOMEN WITH  DISEASE:METABOLIC BONE DISORDER;
ALENDRONATE;SOST;CC;rs1234612;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:OSTEOPOROSIS;
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:LEUKEMIA;
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:LEUKEMIA;
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COLITIS IN CHILDREN WITH  OTHER:LEUKEMIA;
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COLITIS IN CHILDREN WITH  OTHER:LEUKEMIA;
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:LEUKEMIA;
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:LEUKEMIA;
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;
ALENDRONATE;SOST;GG;rs865429;EFFICACY;DECREASED;NAN;EFFICACY;BONE DENSITY IN WOMEN WITH  DISEASE:METABOLIC BONE DISORDER;
ALENDRONATE;SOST;GG;rs865429;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:OSTEOPOROSIS;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
CLOPIDOGREL;MED12L, P2RY12;T;rs6801273;EFFICACY;DECREASED;NAN;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
CLOPIDOGREL;MED12L;G;rs6798347;EFFICACY;DECREASED;NAN;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
SEVOFLURANE;ABCB1;GG;rs1128503;OTHER;DECREASED;LIKELIHOOD;OTHER;ADVERSE EVENTS IN CHILDREN WITH  OTHER:TONSILLECTOMY;
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES MELLITUS;
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE EFFECT;TYPE 2 IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:KIDNEY TRANSPLANTATION;
ACE INHIBITORS;ETV6;GG;rs2724635;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;ETV6;GG;rs2724635;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
ASPIRIN;TAPBP;CC + CG;rs2071888;TOXICITY;INCREASED;NAN;SIDE EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE IN PEOPLE WITH  DISEASE:ASTHMA;
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;AG + GG;rs3740065;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE OUTCOME OF NON-FATAL MI;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALL CAUSE DEATH AND STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
HYDROCHLOROTHIAZIDE;KCNJ1;C;rs12795437;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
VALPROIC ACID;LEPR;AA + AG;rs1137101;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;CFHR4;G;rs78239784;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs11600347;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
CABAZITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;
VALPROIC ACID;ANKK1;AG + GG;rs1800497;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:EPILEPSY;
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs658903;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
CABAZITAXEL;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;
CLOPIDOGREL;P2RY12;G;rs6787801;EFFICACY;DECREASED;NAN;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CABAZITAXEL;CYP3A5;T;rs776746;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;
ACE INHIBITORS;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs675388;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
DOXORUBICIN;GSTP1;GG;rs1695;EFFICACY;DECREASED;RISK;EFFICACY;CHEMORESISTANCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CABAZITAXEL;ABCB1;A;rs1128503;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;
PROPOFOL;DRD2;AA + AC;rs2283265;OTHER;DECREASED;NAN;OTHER;HEART RATE NAN  NAN;
NICOTINE;CHRNA4;A;rs2236196;OTHER;INCREASED;LIKELIHOOD;OTHER;NICOTINE DEPENDENCE NAN  NAN;
ACETAMINOPHEN;UGT1A;CG + GG;rs1042640;TOXICITY;DECREASED;RISK;DISEASE;LIVER FAILURE;
ACETAMINOPHEN;UGT1A;CG + GG;rs1042640;TOXICITY;DECREASED;RISK;DISEASE;ACUTE NAN  NAN;
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;NAN;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ACETAMINOPHEN;UGT1A;CG + GG;rs8330;TOXICITY;DECREASED;RISK;DISEASE;LIVER FAILURE;
ACETAMINOPHEN;UGT1A;CG + GG;rs8330;TOXICITY;DECREASED;RISK;DISEASE;ACUTE NAN  NAN;
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;
HYDROCHLOROTHIAZIDE;KCNJ1;AG;rs59172778;TOXICITY;INCREASED;NAN;SIDE EFFECT;SERUM POTASSIUM IN PEOPLE WITH  DISEASE:HYPERTENSION;
ETHANOL;CACNA1C;TT;rs1034936;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;
DOXORUBICIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
DOXORUBICIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
VINCRISTINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
WARFARIN;EPHA7;A;rs114504854;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ACETAMINOPHEN;UGT1A;CT + TT;rs10929303;TOXICITY;DECREASED;RISK;DISEASE;LIVER FAILURE;
ACETAMINOPHEN;UGT1A;CT + TT;rs10929303;TOXICITY;DECREASED;RISK;DISEASE;ACUTE NAN  NAN;
ACE INHIBITORS;XPNPEP2;T;rs2050011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;XPNPEP2;T;rs2050011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
ETHAMBUTOL;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
NICOTINE;ADGRL3;AG;rs2271339;TOXICITY;INCREASED;RISK;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
NICOTINE;ADGRL3;AT;rs1456862;TOXICITY;INCREASED;RISK;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
ETHANOL;MAP2K4;CT;rs2159140;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN PEOPLE WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
SUNITINIB;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA;
SUNITINIB;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SORAFENIB;UGT1A9;T;rs17868320;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOVENTILATION IN CHILDREN  NAN;
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) (MORE THAN ONE YEAR) WHEN RECEIVING A LOADING DOSE OF 300 MG IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
DOCETAXEL;ABCC10;CT;rs2125739;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
NAN;ARNT;CG + GG;rs2228099;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
ETHAMBUTOL;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;
ISONIAZID;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;
PYRAZINAMIDE;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;
RIFAMPIN;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
NAN;DEPTOR;AA + AG;rs4871827;OTHER;INCREASED;NAN;OTHER;HDL CHOLESTEROL IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
NAN;DEPTOR;AA + AG;rs4871827;OTHER;INCREASED;NAN;OTHER;TYPE 2;
CISPLATIN;SYNE3;CC;rs8020368;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;BRAIN ISCHEMIA;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;OTHER:MYOCARDIAL INFARCTION;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;OTHER:PERIPHERAL VASCULAR DISEASES IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;TYPE 2;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;DIABETIC RETINOPATHY;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;OTHER:CHRONIC KIDNEY FAILURE IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;TYPE 2;
LOSARTAN;STK39;GG + GT;rs6749447;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN AMBULATORY BLOOD PRESSURE IN MEN WITH  DISEASE:HYPERTENSION;
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
NAN;AHR;AA + AG;rs2066853;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION;
RISPERIDONE;HTR6;CC + CT;rs9659997;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;
CISPLATIN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
CISPLATIN;;AG + GG;rs7186128;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;;AG + GG;rs7186128;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
RISPERIDONE;TYMS;A;rs3786362;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
NAN;TNF;C;rs1800630;EFFICACY;INCREASED;SEVERITY;EFFICACY;LEUKOCYTOSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CISPLATIN;;TT;rs2166219;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;;TT;rs2166219;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
RISPERIDONE;HTR2A;CC;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;
CISPLATIN;;CC;rs4655567;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;;CC;rs4655567;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
ANTINEOPLASTIC AGENTS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;
ANTINEOPLASTIC AGENTS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CORTICOSTEROIDS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;
CORTICOSTEROIDS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CISPLATIN;;TT;rs2018683;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;;TT;rs2018683;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
RISPERIDONE;BDNF;CT + TT;rs6265;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;
ANTINEOPLASTIC AGENTS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CORTICOSTEROIDS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LEUCOVORIN;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;NAN;PK;DISTRIBUTION VOLUME IN PEOPLE WITH  DISEASE:LYMPHOMA;
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;NAN;PK;DISTRIBUTION VOLUME IN PEOPLE WITH  DISEASE:LYMPHOMA;
CISPLATIN;;TT;rs2018683;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;;TT;rs2018683;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
NAN;OPRM1;G;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HEROIN DEPENDENCE NAN  NAN;
CISPLATIN;SYNE3;CC;rs8020368;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
CISPLATIN;;CC;rs4655567;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;;CC;rs4655567;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
METHOTREXATE;ABCC4;AA;rs7317112;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
RISPERIDONE;UGT1A1;AG;rs1976391;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
RISPERIDONE;HTR2C;C;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;
CYCLOSPORINE;;GG;rs2275913;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
LENALIDOMIDE;ABCB1;AA;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
HEROIN;DBH;TT;rs1611114;TOXICITY;DECREASED;RISK;SIDE EFFECT;MEMORY IMPAIRMENT IN PEOPLE WITH  OTHER:HEROIN DEPENDENCE;
DILTIAZEM;PLCD3;T;rs12946454;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
CAPECITABINE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
CAPECITABINE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
FLUOROURACIL;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
OXALIPLATIN;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PEGINTERFERON ALFA-2B;ITPA;AC;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA NAN  NAN;
"""BETA BLOCKING AGENTS""";;C;rs11191548;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
"""THIAZIDES";;C;rs11191548;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
"PLAIN""";;C;rs11191548;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;SEVERITY;SIDE EFFECT;WITHDRAWAL IN WOMEN  DISEASE:TOBACCO USE DISORDER;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;MINIMUM PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
MORPHINE;ABCB1;CC + CT;rs9282564;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOVENTILATION IN CHILDREN  NAN;
ANTINEOPLASTIC AGENTS;ABCC1;GG;rs246240;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CORTICOSTEROIDS;ABCC1;GG;rs246240;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LENALIDOMIDE;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;NAN;OTHER;BLOOD PRESSURE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
LENALIDOMIDE;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
CISPLATIN;ABCC4;CT;rs16950650;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
IRINOTECAN;ABCC4;CT;rs16950650;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;
ASPIRIN;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;NAN;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION IN  OTHER:PATIENTS UNDERGOING CORONARY STENTING;
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;NAN;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION IN  OTHER:PATIENTS UNDERGOING CORONARY STENTING;
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
EFAVIRENZ;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
LAMIVUDINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
TENOFOVIR;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
GEMCITABINE;SLC29A3;CT + TT;rs780668;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
PEGINTERFERON ALFA-2B;ITPA;C;rs7270101;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CAFFEINE;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALBUMINURIA;
CAFFEINE;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERTENSION NAN  NAN;
GEMCITABINE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN WOMEN  DISEASE:OVARIAN NEOPLASMS;
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;METABOLISM/PK;DECREASED;NAN;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCULAR DISEASES;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:RHABDOMYOLYSIS;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE NAN  NAN;
ALLOPURINOL;CFLAR;A;rs1594;TOXICITY;NAN;NAN;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
OXYCODONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;
OXYCODONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
CAPECITABINE;CES2;CG + GG;rs11075646;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE OF DISEASE IN WOMEN  DISEASE:OVARIAN NEOPLASMS;
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS IN HEALTHY INDIVIDUALS  NAN;
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;DECREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS IN HEALTHY INDIVIDUALS  NAN;
ASPIRIN;AGT;GG;rs5050;TOXICITY;INCREASED;RISK;DISEASE;PEPTIC ULCER HEMORRHAGE NAN  NAN;
SUNITINIB;NR1I2;A;rs6785049;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
BUPROPION;SACM1L;C;rs2251954;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ROSUVASTATIN;GATM;AA;rs9806699;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
BUPROPION;SACM1L;G;rs2742421;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ETHAMBUTOL;CYP3A4;AG;rs28371759;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;AG;rs28371759;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ROSUVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
BUPROPION;SACM1L;G;rs2742423;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;NAN;NAN;SIDE EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY NAN  NAN;
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;METABOLISM/PK;DECREASED;NAN;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
BUPROPION;SACM1L;T;rs1969624;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
EFAVIRENZ;NR1I3;GG;rs2307424;TOXICITY;NAN;NAN;SIDE EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY NAN  NAN;
BUPROPION;SACM1L;C;rs2245705;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
BUPROPION;SACM1L;G;rs2742435;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS IN HEALTHY INDIVIDUALS  NAN;
BUPROPION;SACM1L;A;rs2742390;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
SIMVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;LIKELIHOOD;OTHER;EARLY RELAPSE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SIMVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
PEMETREXED;DHFR;GG;rs442767;TOXICITY;INCREASED;RISK;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
BUPROPION;SACM1L;T;rs2742417;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
TEMSIROLIMUS;NR1I2;T;rs3814055;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
SUNITINIB;FLT3;AA;rs1933437;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;
SUNITINIB;FLT3;AA;rs1933437;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CAPECITABINE;CES1;CT + TT;rs71647871;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HAND-FOOT SYNDROME;
CAPECITABINE;CES1;CT + TT;rs71647871;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
GEMCITABINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ROSUVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
NALTREXONE;OPRD1;A;rs4654327;EFFICACY;INCREASED;NAN;EFFICACY;NALTREXONE-INDUCED BLUNTING OF ALCOHOL STIMULATION AND ALCOHOL CRAVING IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
IRINOTECAN;UGT1A;AG + GG;rs11563250;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ATORVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES;
ATORVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:MYALGIA IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
SIMVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES;
SIMVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:MYALGIA IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
CAPECITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
FLUOROURACIL;SPARC;GG;rs2347128;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
GEMCITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
NAN;MET;AG + GG;rs40239;OTHER;INCREASED;NAN;OTHER;OVERALL SURVIVAL IN MEN  DISEASE:STOMACH NEOPLASMS;
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION;
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:CROHN DISEASE;
CAPECITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
FLUOROURACIL;SPARC;TT;rs17718347;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
GEMCITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
NAN;MET;AG + GG;rs40239;OTHER;INCREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"COMBINATIONS""";ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;
EFAVIRENZ;CYP2B6;T;rs3745274;OTHER;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE (AUC) DURING THE FIRST 24 WEEKS OF ANTIRETROVIRAL THERAPY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE (AUC) DURING THE FIRST 24 WEEKS OF ANTIRETROVIRAL THERAPY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
DESFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
EFAVIRENZ;CYP3A4;C;rs2740574;OTHER;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
EFAVIRENZ;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
EFAVIRENZ;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE IN PEOPLE WITH  PK:HIV;
CLOPIDOGREL;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ACE INHIBITORS;MME;CT + TT;rs989692;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PLAIN;MME;CT + TT;rs989692;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;LILRB5;TT;rs12975366;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;LILRB5;TT;rs12975366;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;
ESCITALOPRAM;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
FLUOXETINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
SERTRALINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
CABAZITAXEL;CYP3A5;CT;rs776746;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;
ESCITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;
FLUOXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;
SERTRALINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;
CABAZITAXEL;TUBB1;AC;rs463312;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CLOPIDOGREL;CYP2C19;AA;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NEVIRAPINE;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;NAN;OTHER;PLASMA LEVEL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;SLC2A9;T;rs16890979;METABOLISM/PK;DECREASED;NAN;PK;SERUM URIC ACID IN HEALTHY INDIVIDUALS  NAN;
CYCLOPHOSPHAMIDE;IKZF3;CC;rs9908694;EFFICACY;INCREASED;NAN;DISEASE;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:NEUROBLASTOMA;
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
DESFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
DESFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
METHAMPHETAMINE;DRD4;CC + CT;rs1800955;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG PSYCHOSIS IN PEOPLE WITH  OTHER:METHAMPHETAMINE DEPENDENCE;
BEVACIZUMAB;GC;TT;rs4588;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
BEVACIZUMAB;GC;TT;rs4588;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:METASTATIC NEOPLASM;
CETUXIMAB;GC;TT;rs4588;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CETUXIMAB;GC;TT;rs4588;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:METASTATIC NEOPLASM;
DESFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ASPIRIN;TAPBP;AG + GG;rs1059288;TOXICITY;INCREASED;NAN;SIDE EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE IN PEOPLE WITH  DISEASE:ASTHMA;
"""ACE INHIBITORS";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"PLAIN""";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"""ANGIOTENSIN II ANTAGONISTS""";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
GEFITINIB;IKBKB;CC;rs2272733;TOXICITY;DECREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
"""METFORMIN""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
"""METFORMIN""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
"""SULFONAMIDES";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
"""SULFONAMIDES";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
"UREA DERIVATIVES""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;
"UREA DERIVATIVES""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
DESFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ENFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
HALOTHANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
ISOFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SEVOFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
SUCCINYLCHOLINE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
FENOTEROL;SLC22A1;T;rs12208357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;
FENOTEROL;SLC22A1;A;rs34130495;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;
ACE INHIBITORS;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;
NAN;P2RY12;G;rs2046934;OTHER;INCREASED;RISK;DISEASE;PERIPHERAL VASCULAR DISEASES NAN  NAN;
GEFITINIB;RELA;CC;rs11227247;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
FENOTEROL;SLC22A1;C;rs55918055;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;
IRINOTECAN;KCNQ5;C;rs9351963;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FENOTEROL;SLC22A1;A;rs34059508;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;
NAN;P2RY12;G;rs2046934;OTHER;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;
GEFITINIB;IKBKE;AG + GG;rs2151222;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
PHENYTOIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
PHENYTOIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
PHENYTOIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
PHENYTOIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
TAMOXIFEN;CYP2D6;T;rs28371725;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;NAN;NAN;EFFICACY;IMPROVED RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;
GABAPENTIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEUROPATHIC PAIN;
PREGABALIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEUROPATHIC PAIN;
BEVACIZUMAB;CXCR2;TT;rs2230054;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;CXCR2;TT;rs2230054;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
GEMCITABINE;SLCO1B1;AG + GG;rs4149086;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION IN PEOPLE WITH  DISEASE:DEPRESSION;
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;TT;rs5443;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:HEART FAILURE;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;RISK;DISEASE;LUNG NEOPLASMS IN PEOPLE WITH  OTHER:WHO HAVE EVER BEEN SMOKERS;
CITALOPRAM;GRIK2;CC;rs2518224;TOXICITY;INCREASED;RISK;SIDE EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
IRINOTECAN;UGT1A9;G;rs7586110;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
WARFARIN;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
NAN;HYKK;C;rs8034191;OTHER;INCREASED;RISK;DISEASE;LUNG NEOPLASMS IN PEOPLE WITH  OTHER:WHO HAVE EVER BEEN SMOKERS;
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
PHENYTOIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
PHENYTOIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
TACROLIMUS;TCF7L2;CC + CT;rs290487;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;
ACE INHIBITORS;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;
GEMCITABINE;POLR2A;CC;rs2228130;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
VALPROIC ACID;CYP2C9;AC;rs1057910;OTHER;INCREASED;NAN;PK;MEAN PLASMA DRUG CONCENTRATIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
VALPROIC ACID;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;NAN;PK;MEAN PLASMA DRUG CONCENTRATIONS IN PEOPLE WITH  DISEASE:EPILEPSY;
CITALOPRAM;GRIA3;G;rs4825476;TOXICITY;INCREASED;RISK;SIDE EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
IMATINIB;SLC22A5;AA + AG;rs274558;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
IMATINIB;SLC22A5;AA + AG;rs274558;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ISONIAZID;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
ISONIAZID;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
PHENYTOIN;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
PHENYTOIN;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
ANTIPSYCHOTICS;COMT;CC + CG;rs4818;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL VASCULAR DISEASES IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;DISEASE;LUNG NEOPLASMS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
DACARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
PHENYTOIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
PHENYTOIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;NAN;OTHER;NUMBER OF CIGARETTES SMOKED PER DAY IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
PHENYTOIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;
PHENYTOIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;
IMATINIB;ABCB1;CT;rs2235040;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
IMATINIB;ABCB1;CT;rs2235040;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
DEXAMETHASONE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
DOXORUBICIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
VINCRISTINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
DACARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;
IMATINIB;EGFR;CT + TT;rs10258429;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
IMATINIB;EGFR;CT + TT;rs10258429;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ANTIPSYCHOTICS;COMT;AG;rs165599;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TARDIVE DYSKINESIA IN MEN WITH  OTHER:SCHIZOPHRENIA;
IMATINIB;SLC22A1;CG + GG;rs683369;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
IMATINIB;SLC22A1;CG + GG;rs683369;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;
DACLATASVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"""ANALGESICS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANALGESICS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANTIINFLAMMATORY AGENTS";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"NON-STEROIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"NON-STEROIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ERGOT ALKALOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ERGOT ALKALOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""OPIOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""OPIOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""SUMATRIPTAN""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""SUMATRIPTAN""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
ASPIRIN;TBXA2R;AA;rs4523;EFFICACY;INCREASED;RISK;OTHER;HIGH ON-ASPIRIN RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  OTHER:OFF-PUMP CORONARY ARTERY BYPASS GRAFTING;
"""ANALGESICS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANALGESICS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANTIINFLAMMATORY AGENTS";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"NON-STEROIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"NON-STEROIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ERGOT ALKALOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ERGOT ALKALOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""OPIOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""OPIOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""SUMATRIPTAN""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""SUMATRIPTAN""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
RISPERIDONE;DRD2;CT;rs1799978;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSULIN RESISTANCE IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;
RISPERIDONE;DRD2;CT;rs1799978;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;
PACLITAXEL;ABCB1;AA;rs2032582;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
"""ANALGESICS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANALGESICS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANTIINFLAMMATORY AGENTS";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"NON-STEROIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"NON-STEROIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ERGOT ALKALOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ERGOT ALKALOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""OPIOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""OPIOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""SUMATRIPTAN""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""SUMATRIPTAN""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
"""ANALGESICS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANALGESICS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANTIINFLAMMATORY AGENTS";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"NON-STEROIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"NON-STEROIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ERGOT ALKALOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ERGOT ALKALOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""OPIOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""OPIOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""SUMATRIPTAN""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""SUMATRIPTAN""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
ANTIPSYCHOTICS;COMT;AA;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;
"""ANALGESICS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANALGESICS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANTIINFLAMMATORY AGENTS";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"NON-STEROIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"NON-STEROIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ERGOT ALKALOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ERGOT ALKALOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""OPIOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""OPIOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""SUMATRIPTAN""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""SUMATRIPTAN""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;
TACROLIMUS;CAPN10;CT;rs5030952;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
WARFARIN;CYP2C18;G;rs2901783;DOSAGE;NAN;NAN;OTHER;OUTCOME TIME TO STABLE DOSE NAN  NAN;
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;
"""ANALGESICS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANALGESICS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ANTIINFLAMMATORY AGENTS";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ANTIINFLAMMATORY AGENTS";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"NON-STEROIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"NON-STEROIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""ERGOT ALKALOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""ERGOT ALKALOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""OPIOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""OPIOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
"""SUMATRIPTAN""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;
"""SUMATRIPTAN""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;
OPIOIDS;OPRM1;AG;rs9479757;OTHER;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;
PEGINTERFERON ALFA-2B;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PROTEASE INHIBITORS;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
OPIOIDS;GAL;CC;rs948854;OTHER;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;ABCB1;GG;rs1045642;OTHER;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;OPRD1;A;rs2236861;OTHER;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
HYDROCHLOROTHIAZIDE;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;
PRAVASTATIN;CETP;A;rs708272;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;
PEGINTERFERON ALFA-2B;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PROTEASE INHIBITORS;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
DACLATASVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DIURETICS;PDE4D;TT;rs702553;EFFICACY;DECREASED;NAN;EFFICACY;BASELINE MEAN ARTERIAL BLOOD PRESSURE IN PEOPLE WITH  DISEASE:NEPHROSCLEROSIS;
CITALOPRAM;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUVOXAMINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
SERTRALINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ESCITALOPRAM;KCNE1;C;rs1805127;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ESCITALOPRAM;KCNE1;TT;rs4817668;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;OTHER;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE UNDERGOING STENT IMPLANTATION;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs588765;EFFICACY;NAN;NAN;EFFICACY;INCREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY) NAN  NAN;
NAN;CHRNA3;A;rs1051730;EFFICACY;NAN;NAN;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP NAN  NAN;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;A;rs1051730;EFFICACY;NAN;NAN;EFFICACY;INCREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY) NAN  NAN;
CITALOPRAM;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUVOXAMINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
PAROXETINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
SERTRALINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
VENLAFAXINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NEOPLASMS;
CISPLATIN;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CYCLOPHOSPHAMIDE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
VINCRISTINE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CISPLATIN;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CYCLOPHOSPHAMIDE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
VINCRISTINE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
NAN;FOXO3;TT;rs4946936;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NAN;FOXO3;GG;rs17069665;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;
NAN;ARNT;T/del + del/del;rs3215133;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ETHANOL;GHSR;AG;rs2232165;OTHER;NAN;NAN;OTHER;HEAVY CONSUMPTION NAN  NAN;
CYCLOPHOSPHAMIDE;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CISPLATIN;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CYCLOPHOSPHAMIDE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
VINCRISTINE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
ANTIPSYCHOTICS;NEFM;G;rs1379357;EFFICACY;NAN;NAN;EFFICACY;RESPONSE TIME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CISPLATIN;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CYCLOPHOSPHAMIDE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
DOXORUBICIN;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
METHOTREXATE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
VINCRISTINE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
ANTIPSYCHOTICS;NEFM;G;rs1457266;EFFICACY;NAN;NAN;EFFICACY;RESPONSE TIME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
NAN;ARNT;AA + AG;rs12410394;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
CELECOXIB;IL23R;A;rs7518660;TOXICITY;INCREASED;RISK;DISEASE;ADENOMA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CELECOXIB;ALOX12;A;rs11078659;TOXICITY;INCREASED;RISK;DISEASE;ADENOMA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;CYP1A2;CT + TT;rs2470890;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
NAN;;CT + TT;rs11072508;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
CELECOXIB;PTGES;C;rs2302821;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR TOXICITY AND SYMPTOMS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;CSK;CG + GG;rs4886410;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;
CELECOXIB;PTGER4;T;rs4133101;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITIES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CARBOPLATIN;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;CYSTITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;CYSTITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
THIOTEPA;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;CYSTITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
TAMOXIFEN;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE OF BREAST CANCER IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;ABCC2;AA;rs3740065;METABOLISM/PK;INCREASED;RISK;EFFICACY;RECURRENCE OF BREAST CANCER IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSOMNIA NAN  NAN;
DEXAMETHASONE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
DOXORUBICIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
VINCRISTINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
FARGLITAZAR;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
FARGLITAZAR;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;
INSULINS AND ANALOGUES;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
INSULINS AND ANALOGUES;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;
HYDROCHLOROTHIAZIDE;SCNN1G;CC;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
FARGLITAZAR;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
FARGLITAZAR;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;
GLYBURIDE;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
GLYBURIDE;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;
HYDROCHLOROTHIAZIDE;SCNN1G;TT;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
GEFITINIB;IKBKE;CC;rs12142086;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
NICOTINE;CHRNA5;C;rs680244;OTHER;DECREASED;LIKELIHOOD;OTHER;ABSTINENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ORAL ULCER IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;DECREASED;NAN;EFFICACY;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
LORAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE VISUAL ANALOG SCALE-TIME CURVE DURING THE INDUCED STATE NAN  NAN;
CYCLOPHOSPHAMIDE;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NALOXONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;
OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
NICOTINE;CHRNA5;A;rs16969968;OTHER;DECREASED;LIKELIHOOD;OTHER;ABSTINENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
BISOPROLOL;CYP3A5;TT;rs776746;EFFICACY;INCREASED;SEVERITY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE;
BISOPROLOL;CYP3A5;TT;rs776746;EFFICACY;INCREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
NALOXONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;
PAZOPANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
HYDROCHLOROTHIAZIDE;WNK1;GG;rs1159744;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:LUPUS NEPHRITIS;
NAN;SLC22A3;TT;rs2504938;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
NALOXONE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:PAIN;
OXYCODONE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:PAIN;
CYCLOPHOSPHAMIDE;CYP2B6;GT;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUPUS NEPHRITIS;
FLUOROURACIL;UMPS;CC + CG;rs1801019;TOXICITY;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
FLUOROURACIL;UMPS;CC + CG;rs1801019;METABOLISM/PK;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
LEUCOVORIN;UMPS;CC + CG;rs1801019;TOXICITY;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
LEUCOVORIN;UMPS;CC + CG;rs1801019;METABOLISM/PK;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
FLUOROURACIL;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
FLUOROURACIL;UMPS;CC;rs1801019;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
LEUCOVORIN;UMPS;CC;rs1801019;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
BUPRENORPHINE;COMT;AG + GG;rs4680;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
METHADONE;COMT;AG + GG;rs4680;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;SLC22A3;AA;rs512077;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
BUPRENORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
METHADONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
CAPECITABINE;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:GASTROESOPHAGEAL CANCER;
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:GASTROESOPHAGEAL CANCER;
GLUCARPIDASE;ABCC4;AG + GG;rs7317112;TOXICITY;INCREASED;RISK;OTHER;NEPHROTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
HYDROCHLOROTHIAZIDE;ADRB2;AA + AG;rs2400707;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:LUPUS NEPHRITIS;
NICOTINE;CHRNA5;GG;rs16969968;OTHER;INCREASED;NAN;OTHER;FUNCTIONAL MRI REACTIVITY TO SMOKING IMAGES IN WOMEN WITH  OTHER:NICOTINE DEPENDENCE;
HYDROCHLOROTHIAZIDE;WNK1;CC;rs1159744;OTHER;INCREASED;NAN;SIDE EFFECT;URINARY POTASSIUM EXCRETION IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
HEROIN;DRD2;A;rs1076560;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HEROIN DEPENDENCE NAN  NAN;
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN;
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;"POSTOPERATIVE IN PEOPLE WITH  ""OTHER:SURGERY""";
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;"""OTHER:FRACTURES";
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;"BONE""";
HYDROCHLOROTHIAZIDE;WNK1;CC + CT;rs2107614;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
HYDROCHLOROTHIAZIDE;RAD52, WNK1;CC;rs2277869;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
ASPARAGINASE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METFORMIN;SLC47A2;T;rs34399035;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN UPTAKE IN HEK-293 CELLS AND REDUCTION IN PROTEIN EXPRESSION LEVELS NAN  NAN;
OXALIPLATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:LEUKEMIA;
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:LEUKEMIA;
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;
WARFARIN;;T;rs16871327;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
WARFARIN;EPHA7;C;rs78132896;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
FENOFIBRATE;FABP1;CC + CT;rs2241883;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HYPERTRIGLYCERIDEMIA;
ANTIPSYCHOTICS;SNAP25;TT;rs1051312;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
GEFITINIB;TAB2;CT + TT;rs577001;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
PEGINTERFERON ALFA-2B;IFIT1;TT;rs304478;EFFICACY;INCREASED;NAN;EFFICACY;SVR (SUSTAINED VIROLOGICAL RESPONSE) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFIT1;TT;rs304478;EFFICACY;INCREASED;NAN;EFFICACY;SVR (SUSTAINED VIROLOGICAL RESPONSE) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;OASL;T;rs12819210;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;OASL;T;rs12819210;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
OXALIPLATIN;ABCB1;AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PAZOPANIB;VEGFA;TT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
COCAINE;SLC6A3;TT;rs6347;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
ATORVASTATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
CYCLOPHOSPHAMIDE;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;
ANTIINFLAMMATORY AGENTS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
NON-STEROIDS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
CYCLOPHOSPHAMIDE;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;
GEFITINIB;NFKBIA;AA + AT;rs2233407;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CYCLOPHOSPHAMIDE;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
GEFITINIB;NR1H2;CT + TT;rs2695121;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CYCLOPHOSPHAMIDE;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
SUNITINIB;VEGFA;CG + GG;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CYCLOPHOSPHAMIDE;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;;G;rs115112393;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
ANTIPSYCHOTICS;HTR2C;GG;rs6318;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;HTR2C;GG;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ATORVASTATIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
ANTIPSYCHOTICS;DRD2;A;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;DRD2;CC;rs7131056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;INSIG2;C;rs17047764;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;GNB3;TT;rs5443;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;MC4R;AA;rs489693;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
TIANEPTINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUICIDAL IDEATION IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
ATORVASTATIN;ABCB1;A;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
ANTIPSYCHOTICS;BDNF, BDNF-AS;CC;rs6265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANTIPSYCHOTICS;ADRA2A;G;rs1800544;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;
THEOPHYLLINE;CYP1A2;GG;rs2069514;METABOLISM/PK;INCREASED;NAN;PK;RATIO OF 1;
THEOPHYLLINE;CYP1A2;GG;rs2069514;METABOLISM/PK;INCREASED;NAN;PK;3 DMU/THEOPHYLLINE IN PEOPLE WITH  DISEASE:ASTHMA;
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
GEFITINIB;NFKBIA;AG + GG;rs2233409;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;NFKBIA;AG + GG;rs8904;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;CLOPIDOGREL RESISTANCE IN  OTHER:PATIENTS WHO UNDERWENT SUCCESSFUL PERCUTANEOUS CORONARY INTERVENTION;
GEFITINIB;NFKBIB;CC;rs2053071;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
LEVODOPA;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HALLUCINATIONS IN PEOPLE WITH  OTHER:PARKINSON DISEASE;
GEFITINIB;NFKBIA;AG + GG;rs2233406;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;ITGB3;C;rs5918;EFFICACY;NAN;NAN;EFFICACY;LESS DECREASE IN THE PLATELET REACTIVITY AFTER 600 MG OF CLOPIDOGREL IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;ITGB3;CT;rs5918;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET EFFECT TO A 300 MG CLOPIDOGREL LOADING-DOSE UP TO 24 H FOLLOWING INTERVENTION IN  OTHER:PATIENTS UNDERGOING CORONARY STENT IMPLANTATION;
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
PERINDOPRIL;AGTR1;TT;rs275651;EFFICACY;DECREASED;RISK;EFFICACY;CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;
ESCITALOPRAM;KCNH2;AA;rs3807372;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;
HEROIN;OPRM1;AA + AG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;ADDICTION NAN  NAN;
GEFITINIB;IKBKB;AA;rs9694958;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;
GEFITINIB;IKBKE;CC + CT;rs3748022;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ASPIRIN;FSIP1;G;rs7179742;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
ASPIRIN;PTGS1;G;rs10306114;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;AA;rs4430924;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ASPIRIN;CEP68;AA + AG;rs7572857;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
CYCLOSPORINE;ABCB1;A;rs2032582;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;ABCB1;A;rs2032582;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;G;rs10945919;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;
DAUNORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH  OTHER:NEOPLASMS;
EPIRUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH  OTHER:NEOPLASMS;
ETHAMBUTOL;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CETUXIMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PANITUMUMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ETHAMBUTOL;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CYCLOPHOSPHAMIDE;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CLOPIDOGREL;CES1;CT;rs71647871;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED;NAN;EFFICACY;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED;NAN;EFFICACY;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;NAN;PK;CMAX OF THE ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;PK;CMAX OF THE ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
CARBOPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PEMETREXED;MTHFR;AA;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
VEMURAFENIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:MELANOMA;
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARCINOMA;
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""SIDE EFFECT:HYPERBILIRUBINEMIA""";
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""SIDE EFFECT:NAUSEA"" IN PEOPLE WITH  OTHER:MELANOMA";
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING IN HEALTHY INDIVIDUALS  NAN;
CITALOPRAM;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
ESCITALOPRAM;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
FLUOXETINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
PAROXETINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
SERTRALINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING IN HEALTHY INDIVIDUALS  NAN;
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
FLUOROURACIL;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;NAN;NAN;PK;RISK OF BEING UNDERDOSED IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;NAN;NAN;PK;RISK OF BEING UNDERDOSED IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
OPIOIDS;SLC18A2;A;rs363332;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;SLC18A2;G;rs363334;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
OPIOIDS;SLC18A2;C;rs363338;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;
CYCLOPHOSPHAMIDE;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;NAN;NAN;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO CLOPIDOGREL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
SUNITINIB;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
PAZOPANIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:LEUKEMIA;
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:LEUKEMIA;
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;RISK;DISEASE;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO CLOPIDOGREL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
WARFARIN;VEGFA;CC;rs35410204;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
PACLITAXEL;EPHA8;G;rs209709;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;EPHA8;G;rs209709;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:CHOLANGITIS;
GLUCOCORTICOIDS;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
RADIOTHERAPY;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
MYCOPHENOLATE MOFETIL;IMPDH2;AG;rs11706052;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;DECREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:LEUKEMIA;
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:LEUKEMIA;
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;
WARFARIN;VEGFA;AA;rs866236;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
PACLITAXEL;ABCG1;AA;rs492338;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;
OXALIPLATIN;ABCB1;AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PACLITAXEL;EPHA6;AA;rs301927;TOXICITY;DECREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS NAN  NAN;
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE;LUNG NEOPLASMS NAN  NAN;
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;OTHER;LYMPH NODE METASTASIS IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET RESPONSIVENESS TO CLOPIDOGREL IN HEALTHY INDIVIDUALS  NAN;
AMITRIPTYLINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
DOXEPIN;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
IMIPRAMINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
MAPROTILINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
NORTRIPTYLINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
OPIPRAMOL;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;
CALCIUM;VDR;G;rs731236;EFFICACY;INCREASED;RISK;DISEASE;FRACTURES;
CALCIUM;VDR;G;rs731236;EFFICACY;INCREASED;RISK;DISEASE;BONE NAN  NAN;
NAN;SULT1A1;T;rs1042028;OTHER;DECREASED;LIKELIHOOD;DISEASE;UROLOGIC NEOPLASMS NAN  NAN;
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET RESPONSIVENESS TO CLOPIDOGREL IN HEALTHY INDIVIDUALS  NAN;
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS NAN  NAN;
AMITRIPTYLINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
AMITRIPTYLINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"PLATELET REACTIVITY IN PEOPLE WITH  ""DISEASE:CORONARY ARTERY DISEASE""";
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"""DISEASE:DIABETES MELLITUS";
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"TYPE 2""";
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"PLATELET REACTIVITY IN PEOPLE WITH  ""DISEASE:CORONARY ARTERY DISEASE""";
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"""DISEASE:DIABETES MELLITUS";
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"TYPE 2""";
DOCETAXEL;VAC14;T;rs875858;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;
CLOPIDOGREL;CYP3A4;CT + TT;rs2242480;EFFICACY;NAN;NAN;EFFICACY;REDUCED GP IIB/IIIA ACTIVATION AND LOWER PLATELET ACTIVATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
AMITRIPTYLINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
DIRECT FACTOR XA INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
DIRECT THROMBIN INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
AMITRIPTYLINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
OPIOIDS;COMT;AG + GG;rs6269;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
OSIMERTINIB;EGFR;T;rs121434569;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;
OSIMERTINIB;EGFR;T;rs121434569;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
AMITRIPTYLINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
OPIOIDS;COMT;AG + GG;rs4680;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;
ETHANOL;ADH1B;TT;rs1229984;METABOLISM/PK;INCREASED;NAN;PK;VMAX IN HEALTHY INDIVIDUALS  NAN;
AMITRIPTYLINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
OPIOIDS;COMT;CG + GG;rs4818;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;AVERAGE DAILY DOSE DURING THE FIRST PERIOD OF STABILITY IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;
OPIOIDS;COMT;CC + CT;rs4633;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;
AMITRIPTYLINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
ETHAMBUTOL;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ETHAMBUTOL;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ANTINEOPLASTIC AGENTS;UGT1A;TT;rs6744284;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTINEOPLASTIC AGENTS;UGT1A;TT;rs6744284;EFFICACY;INCREASED;NAN;EFFICACY;SIDE EFFECT:HYPERBILIRUBINEMIA;
DIRECT FACTOR XA INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
DIRECT THROMBIN INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
BORTEZOMIB;PKNOX1;A;rs2839629;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;
ANTINEOPLASTIC AGENTS;UGT1A;T;rs6744284;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
SUNITINIB;VEGFA;A;rs699947;TOXICITY;INCREASED;NAN;SIDE EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED RISK OF DEVELOPING GRADE 3 HYPERTENSION NAN  NAN;
AMITRIPTYLINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
ATENOLOL;FTO;G;rs9940629;OTHER;NAN;NAN;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
SUNITINIB;VEGFA;C;rs833061;TOXICITY;INCREASED;NAN;SIDE EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED RISK OF DEVELOPING GRADE 3 HYPERTENSION NAN  NAN;
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:TONSILLECTOMY;
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:TONSILLECTOMY;
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;NAN;SIDE EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED RISK OF DEVELOPING GRADE 3 HYPERTENSION NAN  NAN;
AMITRIPTYLINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
CITALOPRAM;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;
ATENOLOL;ABCB1;G;rs10267099;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;DECREASED;NAN;OTHER;PLATELET FUNCTION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ATENOLOL;ABCB1;G;rs3213619;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
CORTICOSTEROIDS;DCAF4;CC;rs7160796;EFFICACY;INCREASED;NAN;EFFICACY;CHANGE IN FORCED EXPIRATORY VOLUME IN 1 S (FEV1) IN PEOPLE WITH  DISEASE:ASTHMA;
SUNITINIB;NOS3;CC + CT;rs2070744;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3 HYPERTENSION NAN  NAN;
ATENOLOL;PRKCB;GT + TT;rs11649514;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
ATENOLOL;PRKCB;GT + TT;rs11649514;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
ATENOLOL;FTO;AA;rs12595985;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;OTHER;DECREASED;NAN;OTHER;PLATELET FUNCTION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
ATENOLOL;GALNT2;T;rs2144297;OTHER;NAN;NAN;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
ATENOLOL;GALNT2;C;rs2144300;OTHER;NAN;NAN;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
ETHANOL;ANKK1, DRD2;A;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;NAN;PK;IN VIVO METABOLISM OF (S)-WARFARIN BUT NOT (R)-WARFARIN NAN  NAN;
WARFARIN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;NAN;PK;IN VIVO METABOLISM OF (S)-WARFARIN BUT NOT (R)-WARFARIN NAN  NAN;
ATENOLOL;PLA2G4A;C;rs10157410;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION VALUES IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ATENOLOL;PTGS2;G;rs4648287;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
ISONIAZID;NOS2;CC;rs11080344;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;NOS2;CC;rs11080344;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ENALAPRIL;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;
ISONIAZID;BACH1;GG;rs2070401;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;BACH1;GG;rs2070401;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION VALUES IN PEOPLE WITH  EFFICACY:CORONARY ARTERY DISEASE;
ISONIAZID;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CLOPIDOGREL;CYP2C19;CC;rs12248560;EFFICACY;NAN;NAN;EFFICACY;GREATER PLATELET INHIBITION 2 H AFTER A 600-MG DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;NAT2;G;rs1495741;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
CLOPIDOGREL;CYP2C9;C;rs1057910;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION 7H AFTER A CLOPIDOGREL 600-MG LOADING DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CAPECITABINE;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
PEGINTERFERON ALFA-2A;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
ANASTROZOLE;ESR1;A;rs9340799;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;
LETROZOLE;ESR1;A;rs9340799;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;
CLOPIDOGREL;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ANASTROZOLE;ESR1;C;rs2234693;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;
LETROZOLE;ESR1;C;rs2234693;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
NAN;CYP3A4;CC;rs2740574;OTHER;INCREASED;LIKELIHOOD;OTHER;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;
NAN;CYP3A4;CC;rs2740574;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:HYPERLIPIDEMIAS;
OPIOIDS;OPRM1;AA + AG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;ADDICTION NAN  NAN;
CAPECITABINE;DPYD;C;rs75017182;DOSAGE;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;C;rs75017182;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;C;rs75017182;DOSAGE;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
REPAGLINIDE;PAX4;AA + AG;rs114202595;EFFICACY;DECREASED;NAN;EFFICACY;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
REPAGLINIDE;PAX4;AA + AG;rs114202595;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
NAN;CYP3A4;CT;rs2740574;OTHER;INCREASED;RISK;DISEASE;ENDOMETRIAL NEOPLASMS NAN  NAN;
VINCRISTINE;COCH;CG + GG;rs1045644;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CETUXIMAB;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TEGAFUR;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
TAMOXIFEN;CYP3A4;CT;rs2740574;OTHER;INCREASED;RISK;DISEASE;ENDOMETRIAL NEOPLASMS IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
VINCRISTINE;;C;rs7963521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;DIFFERENCE IN FASTING PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
NAN;VDR;G;rs3782905;OTHER;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;
OPIOIDS;OPRL1;C;rs6090043;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH-ON CLOPIDOGREL PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING ELECTIVE CORONARY STENT PLACEMENT;
CLOPIDOGREL;P2RY12;A;rs6785930;EFFICACY;INCREASED;RISK;SIDE EFFECT;NEUROLOGICAL EVENTS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;
OPIOIDS;COMT;AA + AG;rs165599;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:PAIN;
OPIOIDS;COMT;AA + AG;rs165599;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
DOCETAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
NAN;VDR;G;rs2239185;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;
NAN;VDR;T;rs1540339;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET EFFECT IN HEALTHY INDIVIDUALS  NAN;
CALCITRIOL;VDR;A;rs2228570;EFFICACY;INCREASED;RISK;DISEASE;FRACTURES;
CALCITRIOL;VDR;A;rs2228570;EFFICACY;INCREASED;RISK;DISEASE;BONE NAN  NAN;
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
PERINDOPRIL;BDKRB1;AA;rs12050217;EFFICACY;DECREASED;RISK;EFFICACY;CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CISPLATIN;AQP1;CC;rs1049305;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;
ATENOLOL;GRK4;TT;rs1801058;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;
ATENOLOL;GRK4;TT;rs1801058;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;
ATENOLOL;GRK4;TT;rs1801058;OTHER;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;
VERAPAMIL;GRK4;TT;rs1801058;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;
VERAPAMIL;GRK4;TT;rs1801058;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;
VERAPAMIL;GRK4;TT;rs1801058;OTHER;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TOBACCO USE DISORDER;
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED;RISK;SIDE EFFECT;BIOPSY-PROVEN ACUTE REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANT;
PLATINUM COMPOUNDS;HLA-DOB;CT + TT;rs2071554;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PLATINUM COMPOUNDS;;AA + AG;rs2900420;EFFICACY;DECREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
CYCLOPHOSPHAMIDE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
OPIOIDS;DRD2;AG + GG;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:PAIN;
OPIOIDS;DRD2;AG + GG;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
ISONIAZID;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:TUBERCULOSIS;
CISPLATIN;;AG + GG;rs3746444;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
ACENOCOUMAROL;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
ASPIRIN;PTGS2;G;rs20417;OTHER;DECREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;
CISPLATIN;AQP1;AG;rs28362731;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;
ETHAMBUTOL;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ISONIAZID;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
PYRAZINAMIDE;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
RIFAMPIN;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
ASPIRIN;PTGS2;G;rs20417;OTHER;INCREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
FOLFIRI;ABCC1;AA + AG;rs17501011;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
OPIOIDS;OPRL1;G;rs6090041;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET EFFECT IN HEALTHY INDIVIDUALS  NAN;
ANTIDEPRESSANTS;CUX1;G;rs365836;EFFICACY;NAN;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
NAN;SULT1A1;CC + CT;rs1042028;NAN;INCREASED;RISK;DISEASE;PROSTATIC NEOPLASMS NAN  NAN;
NAN;SULT1A1;CT + TT;rs1042028;OTHER;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN WITH  DISEASE:TOBACCO USE DISORDER;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;
NAN;SULT1A1;CT + TT;rs1042028;OTHER;DECREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  OTHER:AT LEAST THREE PREGNANCIES AND PREMENOPAUSAL;
CLOZAPINE;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ACENOCOUMAROL;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;
ANTIDEPRESSANTS;CUX1;A;rs201522;EFFICACY;NAN;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN;
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUROPATHIC PAIN IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY IN CHILDREN WITH  NAN;
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FOLFIRI;CES1;CC;rs9921399;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
DEXTROAMPHETAMINE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER;SOCIAL WITHDRAWAL IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER;SOCIAL WITHDRAWAL IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
METHAMPHETAMINE;GRIN1;GG;rs1126442;TOXICITY;INCREASED;RISK;DISEASE;PSYCHOTIC DISORDER IN MEN WITH  DISEASE:METHAMPHETAMINE DEPENDENCE;
FOLFIRI;UGT1A10, UGT1A8;AA;rs1113193;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIALOADENITIS IN PEOPLE WITH  OTHER:THYROID TUMOR;
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIALOADENITIS IN PEOPLE WITH  OTHER:THYROID TUMOR;
NICOTINE;CHRNA5;CT + TT;rs588765;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN  OTHER:SMOKERS;
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED;SEVERITY;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED;SEVERITY;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ATENOLOL;DPYS;AG + GG;rs2669429;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LYMPHOMA;
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MYELODYSPLASTIC SYNDROMES;
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;IFNL3, IFNL4;CC;rs12979860;OTHER;INCREASED;NAN;OTHER;SPONTANEOUS HCV CLEARANCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RISPERIDONE;LEP;G;rs7799039;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CARBOPLATIN;EIF4E2, TIGD1;CC;rs1656402;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;EIF4E2, TIGD1;CC;rs1656402;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IODINE (131I) COMPOUNDS;ATM;AG;rs11212570;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;
RADIOTHERAPY;ATM;AG;rs11212570;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;
NICOTINE;;CT + TT;rs2056527;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN  OTHER:SMOKERS;
NICOTINE;;CT + TT;rs2056527;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN  OTHER:SMOKERS;
CAPECITABINE;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
PIRFENIDONE;TOLLIP;CC + CT;rs5743890;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:PULMONARY FIBROSIS;
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;
IMATINIB;ABCB1;GG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
IMATINIB;ABCB1;GG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;BCR-ABL1 POSITIVE;
PLATINUM COMPOUNDS;XBP1;GG;rs2269577;TOXICITY;INCREASED;RISK;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IMATINIB;SLC22A1;CC;rs683369;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;
IMATINIB;SLC22A1;CC;rs683369;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;BCR-ABL1 POSITIVE;
CARBOPLATIN;DSCAM;TT;rs9981861;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;DSCAM;TT;rs9981861;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
IODINE (131I) COMPOUNDS;ATG10;TT;rs1864183;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:THYROID TUMOR;
RADIOTHERAPY;ATG10;TT;rs1864183;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:THYROID TUMOR;
MERCAPTOPURINE;NUDT15;A;rs186364861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
AMISULPRIDE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
CLOZAPINE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
OLANZAPINE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
PALIPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
QUETIAPINE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
RISPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
AMISULPRIDE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
AMISULPRIDE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
ARIPIPRAZOLE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ARIPIPRAZOLE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
HALOPERIDOL;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
HALOPERIDOL;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
QUETIAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
ZIPRASIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ZIPRASIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;
ATENOLOL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
VERAPAMIL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;NAN;DISEASE;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;NAN;DISEASE;DISEASE:MYOCARDIAL INFARCTION;
REGADENOSON;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE NAN  NAN;
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CAPECITABINE;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER;SUBSTANCE-RELATED DISORDERS IN PEOPLE WITH  OTHER:METHAMPHETAMINE DEPENDENCE;
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER;OTHER:ALCOHOL ABUSE;
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER;OTHER:EATING DISORDERS;
CISPLATIN;ERCC2;CT;rs1799793;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;
NICOTINE;DBH;CC;rs1541333;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;END OF TREATMENT ABSTINENCE IN  OTHER:SMOKERS WITH LOW DEPENDENCY;
REGADENOSON;AMPD1;AA + AG;rs17602729;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
RISPERIDONE;CNR1;T;rs806378;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
RISPERIDONE;CNR1;C;rs1049353;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
MERCAPTOPURINE;ABCC4;T;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;NFATC2;T;rs6021191;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;HLA-DRB1;T;rs17885382;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;CYSTIC FIBROSIS PULMONARY EXACERBATION IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;
VANCOMYCIN;;A;rs2789047;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;
LISINOPRIL;MMP3;AA;rs35068180;EFFICACY;INCREASED;RISK;SIDE EFFECT;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;
CARBOPLATIN;SERPINA5;C;rs6113;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;SERPINA5;C;rs6113;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;EFFICACY;SUBOPTIMAL REPERFUSION (POST-PCI TIMI FLOW <3) IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CARBOPLATIN;SERPINA5;T;rs6118;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;SERPINA5;T;rs6118;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;XYLT2;G;rs6504649;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;XYLT2;G;rs6504649;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
CARBOPLATIN;SERPINA5;G;rs6119;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;SERPINA5;G;rs6119;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
CARBOPLATIN;ETS2;A;rs73450548;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;ETS2;A;rs73450548;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
BEVACIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-VEGF INJECTIONS IN PEOPLE WITH  DISEASE:CHOROIDAL NEOVASCULARIZATION;
PEGAPTANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-VEGF INJECTIONS IN PEOPLE WITH  DISEASE:CHOROIDAL NEOVASCULARIZATION;
RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-VEGF INJECTIONS IN PEOPLE WITH  DISEASE:CHOROIDAL NEOVASCULARIZATION;
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;RECURRENCE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:SARCOMA;
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
OLANZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
PALIPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED;SEVERITY;DISEASE;ALCOHOL ABUSE IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;
NAN;ERCC1;AC;rs3212986;OTHER;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DEXMEDETOMIDINE;GABRA2;GG;rs279847;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEART RATE IN WOMEN  NAN;
TAMOXIFEN;ESR1;AG + GG;rs9340799;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
"""ACE INHIBITORS";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"PLAIN""";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
MORPHINE;FAAH;AA + AG;rs3766246;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;
CLOZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
FLUOROURACIL;DPYD;AT;rs67376798;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
MORPHINE;FAAH;CT + TT;rs4141964;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;
NAN;ABCB11;GG;rs2287622;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOCELLULAR INJURY NAN  NAN;
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOVENTILATION IN WOMEN WITH  DISEASE:PREGNANCY;
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN WOMEN WITH  DISEASE:PREGNANCY;
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE;
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS NAN  NAN;
OPIOIDS;GNB3;CT + TT;rs5443;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INCREASED PULSE RATE IN PEOPLE WITH  SIDE EFFECT:WITHDRAWAL FROM OPIOID ADDICTION;
OPIOIDS;GNB3;CT + TT;rs5443;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;INCREASED PULSE RATE IN PEOPLE WITH  SIDE EFFECT:WITHDRAWAL FROM OPIOID ADDICTION;
ARIPIPRAZOLE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
CLOZAPINE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
HALOPERIDOL;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
OLANZAPINE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
QUETIAPINE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
RISPERIDONE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;
MORPHINE;FAAH;GT + TT;rs2295632;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;
CAFFEINE;CYP1A2;AC + CC;rs762551;OTHER;DECREASED;RISK;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  OTHER:BRCA1 MUTATIONS;
MORPHINE;FAAH;AA + AC;rs324420;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;
PEGINTERFERON ALFA-2B;VDR;AA + AG;rs2228570;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;VDR;AA + AG;rs2228570;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NAN;ABCB11;GG;rs2287622;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DOCETAXEL;NR1I3;AA;rs3003593;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;
ANTITHYROID PREPARATIONS;EHMT2;G;rs652888;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;
IODINE (131I) COMPOUNDS;TNF;AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
RADIOTHERAPY;TNF;AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;CONSTIPATION IN WOMEN WITH  DISEASE:PREGNANCY;
HMG-COA_REDUCTASE_INHIBITORS;HLA-G;G;rs1063320;OTHER;DECREASED;LIKELIHOOD;DISEASE;ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;DRY MOUTH IN WOMEN WITH  DISEASE:PREGNANCY;
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;EFFICACY;INCREASED;NAN;EFFICACY;SEDATION IN WOMEN  NAN;
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BETA-THALASSEMIA AND RELATED DISEASES;
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BETA-THALASSEMIA AND RELATED DISEASES;
ANTITHYROID PREPARATIONS;;del;rs111618861;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;
ANTITHYROID PREPARATIONS;HLA-B;C;rs1071816;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;
IODINE (131I) COMPOUNDS;ATM;AA + AG;rs11212570;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
RADIOTHERAPY;ATM;AA + AG;rs11212570;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
EFAVIRENZ;IL10;TT;rs1800896;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
ETHANOL;ANKK1, DRD2;A;rs1800497;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
IODINE (131I) COMPOUNDS;NFKB1;AT;rs230493;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
RADIOTHERAPY;NFKB1;AT;rs230493;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;
ETHANOL;DRD2;A;rs1800497;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
IODINE (131I) COMPOUNDS;TGFB1;TT;rs2241716;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
RADIOTHERAPY;TGFB1;TT;rs2241716;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
IODINE (131I) COMPOUNDS;TGFB1;GG;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
RADIOTHERAPY;TGFB1;GG;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;
ANTITHYROID PREPARATIONS;FOXF2;del;rs199564443;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;
CAPECITABINE;CES1P1;T;rs7187684;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ASPARAGINASE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
HYDROCORTISONE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CAPECITABINE;CES1P1;G;rs11861118;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
PLATINUM;XRCC1;TT;rs25487;EFFICACY;NAN;NAN;OTHER;WORSE OVERALL SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CAPECITABINE;CES1;G;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
PLATINUM;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOZAPINE;CYP1A2;GG;rs2069514;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;
ETHANOL;CYP1A2;GG;rs2069514;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;
MERCAPTOPURINE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ASPARAGINASE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
HYDROCORTISONE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CAPECITABINE;CES1;G;rs2244614;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CITALOPRAM;CYP2C19;AG;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;
CITALOPRAM;CYP2C19;AG;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MAJOR DEPRESSIVE DISORDER;
IODINE (131I) COMPOUNDS;ATM;TT;rs620815;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:THYROID TUMOR;
RADIOTHERAPY;ATM;TT;rs620815;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:THYROID TUMOR;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;
RIBAVIRIN;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;
TENOFOVIR;ABCC2;A;rs17222723;TOXICITY;DECREASED;RISK;SIDE EFFECT;RENAL PROXIMAL TUBULOPATHY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
TENOFOVIR;ABCC2;A;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;RENAL PROXIMAL TUBULOPATHY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
FLUOROURACIL;DPYD;CT;rs1801160;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
CYTARABINE;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
ASPARAGINASE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
HYDROCORTISONE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NEVIRAPINE;CYP2B6;CC + CT;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;CYP2B6;CC + CT;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PEGINTERFERON ALFA-2B;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
ASPARAGINASE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYTARABINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DAUNORUBICIN;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
HYDROCORTISONE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;TT;rs2248359;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2C19;GG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN WOMEN WITH  DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;GG;rs4646536;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
NICOTINE;DDC;C;rs2060761;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;AA + AG;rs10946737;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;
NICOTINE;DDC;A;rs12718541;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
IMIPRAMINE;CYP2C19;CT + TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
IMIPRAMINE;CYP2C19;CT + TT;rs11188072;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
NAN;CXCL5;GG;rs352046;OTHER;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
CAPECITABINE;CDA;G;rs602950;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
CAPECITABINE;CDA;A;rs6690069;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;
TENOFOVIR;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;SIDE EFFECT;KIDNEY TUBULAR DYSFUNCTION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER;SOCIAL WITHDRAWAL IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
CAPECITABINE;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;SUBCLINICAL INTRA-STENT THROMBUS IN  OTHER:PATIENTS UNDERGOING DRUG-ELUTING STENT (DES) IMPLANTATION;
CAPECITABINE;CES1;G;rs3217164;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;CDA;A;rs10916825;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;CT + TT;rs11854484;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED;NAN;EFFICACY;SERUM OSTEOCALCIN IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;INCREASED;RISK;EFFICACY;INADEQUATE INHIBITION OF PLATELET ACTIVITY NAN  NAN;
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
TICAGRELOR;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSPNEA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;NAN;NAN;EFFICACY;A 22% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT AFTER ADJUSTMENT FOR CLINICAL AND GENETIC COVARIATES IN HISPANIC-AMERICANS NAN  NAN;
AMOXICILLIN;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:DRUG TOXICITY;
CLAVULANATE;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:DRUG TOXICITY;
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"TOXIC LIVER DISEASE IN PEOPLE WITH  ""DISEASE:BURKITT LYMPHOMA""";
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:LYMPHOMA";
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"T-CELL""";
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";
CYCLOPHOSPHAMIDE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOCETAXEL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EPIRUBICIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
GOSERELIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
WARFARIN;NQO1;A;rs1800566;DOSAGE;NAN;NAN;EFFICACY;A 34% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT WHILE HOLDING CLINICAL AND GENETIC PREDICTORS CONSTANT IN HISPANIC-AMERICANS NAN  NAN;
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CETUXIMAB;RASSF1;CC;rs2236947;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
ANTIPSYCHOTICS;RGS2;C;rs4606;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS;
ANTIPSYCHOTICS;RGS2;C;rs4606;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:PARKINSONIAN DISORDER IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;
DEXMEDETOMIDINE;WBP2NL;AA;rs5758550;EFFICACY;INCREASED;SEVERITY;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:SURGERY;
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CARBOPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CYCLOSPORINE;NFATC1;CC;rs2280055;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
MYCOPHENOLIC ACID;NFATC1;CC;rs2280055;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
PREDNISONE;NFATC1;CC;rs2280055;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CARBOPLATIN;;AA + AC;rs2498804;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;;AA + AC;rs2498804;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOZAPINE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE EFFECT;BODY WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE EFFECT;BODY WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE EFFECT;BODY WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
TELAPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
VINCRISTINE;ABCC2;T;rs12826;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
NICOTINE;GRIN3A;C;rs10121600;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CITALOPRAM;HTR1B;CC;rs6296;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGITATION IN CHILDREN WITH  DISEASE:ANXIETY DISORDERS;
CITALOPRAM;HTR1B;CC;rs6296;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MAJOR DEPRESSIVE DISORDER;
PRAVASTATIN;ABCA1;TT;rs2230806;EFFICACY;INCREASED;NAN;EFFICACY;HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
DEXMEDETOMIDINE;ABCG2;GG;rs2231142;EFFICACY;INCREASED;SEVERITY;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:SURGERY;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"""ANTIINFLAMMATORY AGENTS";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
"NON-STEROIDS""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
"""CELECOXIB""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
"""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
"""IBUPROFEN""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
"""NAPROXEN""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
"""PIROXICAM""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
NICOTINE;GRIN3A;G;rs11788456;OTHER;NAN;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"""ANTIINFLAMMATORY AGENTS";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;
"NON-STEROIDS""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;
"""CELECOXIB""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;
"""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SLEEP DISORDERS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE;CORONARY DISEASE IN PEOPLE WITH  OTHER:PRIOR VASCULAR DISEASE;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"DRUG TOXICITY IN PEOPLE WITH  ""DISEASE:BURKITT LYMPHOMA""";
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:LYMPHOMA";
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"T-CELL""";
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";
"""ACE INHIBITORS";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"PLAIN""";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;NAN;OTHER;HEART RATE NAN  NAN;
CARBOPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;NAN;OTHER;HEART RATE NAN  NAN;
CARBOPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CARBOPLATIN;AKT1;C;rs3803304;EFFICACY;NAN;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;AKT1;C;rs3803304;EFFICACY;NAN;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
COCAINE;BCHE;TT;rs1803274;OTHER;NAN;NAN;DISEASE;COCAINE DEPENDENCE IN  NAN;
PRAVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;MEAN PEAK CONCENTRATION IN PLASMA AND AREA UNDER THE PLASMA CONCENTRATION IN MEN  NAN;
PEGINTERFERON ALFA-2A;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2B;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
CISPLATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL RATE IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
FLUOROURACIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL RATE IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
ASPIRIN;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;STAT4;T;rs7574865;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:DRUG-INDUCED LIVER INJURY;
CISPLATIN;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RISK;EFFICACY;LYMPH NODE METASTASES IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
FLUOROURACIL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RISK;EFFICACY;LYMPH NODE METASTASES IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
HEROIN;ALDH2;AA + AG;rs671;OTHER;INCREASED;NAN;DISEASE;HEROIN DEPENDENCE NAN  NAN;
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE EFFECT;"POSTOPERATIVE NAUSEA AND VOMITING IN WOMEN WITH  ""OTHER:PAIN";
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE EFFECT;"POSTOPERATIVE""";
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE EFFECT;"""OTHER:CAESARIAN SECTION""";
"""METFORMIN""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
"""METFORMIN""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;
"""SULFONAMIDES";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
"""SULFONAMIDES";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;
"UREA DERIVATIVES""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
"UREA DERIVATIVES""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;
ANTIHYPERTENSIVES;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE IN PEOPLE WITH  OTHER:HYPERTENSION;
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE IN PEOPLE WITH  OTHER:HYPERTENSION;
DIURETICS;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE IN PEOPLE WITH  OTHER:HYPERTENSION;
NICOTINE;GRIN3A;T;rs17189632;OTHER;NAN;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1A2;T;rs4149000;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;POOR-RESPONSE TO CLOPIDOGREL IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI);
TRAMADOL;SLC22A1;del;rs35167514;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL IN HEALTHY INDIVIDUALS  NAN;
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
SEVOFLURANE;FASTKD3, MTRR;AA + AG;rs2307116;EFFICACY;INCREASED;NAN;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
ASPIRIN;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
TRAMADOL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL IN HEALTHY INDIVIDUALS  NAN;
TRAMADOL;SLC22A1;T;rs12208357;METABOLISM/PK;NAN;NAN;PK;HIGHER PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL IN HEALTHY INDIVIDUALS  NAN;
METHADONE;KCNJ6;TT;rs2070995;TOXICITY;DECREASED;RISK;SIDE EFFECT;WITHDRAWAL EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;
IMATINIB;SLCO1A2;CC;rs3764043;METABOLISM/PK;DECREASED;NAN;PK;IMATINIB CLEARANCE NAN  NAN;
IMATINIB;SLCO1A2;CC;rs4148978;METABOLISM/PK;INCREASED;NAN;PK;IMATINIB CLEARANCE NAN  NAN;
VINCRISTINE;ABCC2;T;rs3740066;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
IMATINIB;SLCO1A2;CC;rs4148977;METABOLISM/PK;INCREASED;NAN;PK;IMATINIB CLEARANCE NAN  NAN;
FLUOROURACIL;DPYD;AC;rs55886062;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUCLOXACILLIN;NR1I2;CC;rs3814055;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;
CYCLOSPORINE;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLIC ACID;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISONE;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SEVOFLURANE;FASTKD3, MTRR;AG + GG;rs1801394;EFFICACY;INCREASED;NAN;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
EFAVIRENZ;CYP2B6;CC;rs28399499;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
"""ACE INHIBITORS";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"PLAIN""";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"""ANGIOTENSIN II ANTAGONISTS""";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
"""ACE INHIBITORS";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"PLAIN""";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;NAN;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
CARBAMAZEPINE;SCN1A;CC;rs3812718;OTHER;INCREASED;NAN;OTHER;CORTICAL SILENT PERIOD DURATION IN HEALTHY INDIVIDUALS  NAN;
METHOTREXATE;MIR1206;GG;rs2114358;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
ATORVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
FOLIC ACID;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENT IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENT IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;
SORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
SORAFENIB;PIK3R5;T;rs444904;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs17868323;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CYTARABINE;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;
IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;
METHOTREXATE;ABCC2;AA;rs2273697;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CYTARABINE;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;
CYTARABINE;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;
IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;
IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;
METHOTREXATE;ABCB1;AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
AZATHIOPRINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
METHOTREXATE;ABCC2;CC + CT;rs4148396;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME TO DISCONTINUATION OR DOSE REDUCTION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;ABCC2;CC;rs4148396;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALOPECIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CYTARABINE;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;
CYTARABINE;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;
IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;
IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;
FOLIC ACID;TLR4;G;rs4986790;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;TLR4;G;rs4986790;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ROSUVASTATIN;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
ROSUVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
HYDROCHLOROTHIAZIDE;;G;rs10792367;EFFICACY;DECREASED;NAN;EFFICACY;BLOOD PRESSURE (BP) REDUCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs17868323;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;NAN;OTHER;SERUM TOTAL CHOLESTEROL NAN  NAN;
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"CARDIOTOXICITY IN CHILDREN WITH  ""OTHER:NEOPLASMS""";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WILMS TUMOR""";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SARCOMA";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"EWING'S""";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:HODGKIN DISEASE""";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-HODGKIN LYMPHOMA""";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:OSTEOSARCOMA""";
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEUROBLASTOMA""";
HMG-COA_REDUCTASE_INHIBITORS;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;
NICOTINE;CHRNA3;T;rs3743075;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOBACCO USE DISORDER IN MEN  NAN;
NICOTINE;CHRNB4;G;rs7178270;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOBACCO USE DISORDER IN MEN  NAN;
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;
NICOTINE;CHRNB4;A;rs1948;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOBACCO USE DISORDER IN MEN  NAN;
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
HMG COA REDUCTASE INHIBITORS;;T;rs1719247;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;
SIMVASTATIN;;T;rs1719247;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;
HMG COA REDUCTASE INHIBITORS;;C;rs1346268;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;
SIMVASTATIN;;C;rs1346268;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
CYCLOPHOSPHAMIDE;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IMATINIB;UGT2A1;CC;rs11249454;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;A;rs11155012;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;
CYCLOPHOSPHAMIDE;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
GEMCITABINE;SLC28A1;AA;rs3825876;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
ATORVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
RISPERIDONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;PROLONGED QTC INTERVAL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
PITAVASTATIN;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;NAN;PK;PITAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;
SORAFENIB;EGFR;C;rs2330951;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
ROSUVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;AUC (P=0.002) AND CMAX (P=0.003) IN HEALTHY INDIVIDUALS  NAN;
HMG-COA_REDUCTASE_INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
EVEROLIMUS;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;ABCB1;A;rs2032582;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
AZATHIOPRINE;;C;rs2647087;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;;C;rs2647087;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
EVEROLIMUS;RPTOR;T;rs9906827;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;RPTOR;T;rs9906827;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
RADIOTHERAPY;XPC;G;rs2228001;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;
EVEROLIMUS;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;ABCB1;A;rs1045642;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
AZATHIOPRINE;NUDT15;C;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
MERCAPTOPURINE;NUDT15;C;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL ISCHEMIA;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
AZACITIDINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MYELODYSPLASTIC SYNDROMES;
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION (PCI);
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL ISCHEMIA;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;
CYCLOPHOSPHAMIDE;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IMATINIB;SLC22A1;GG;rs628031;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ACETAMINOPHEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ACETAMINOPHEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
IBUPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
IBUPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
LOXOPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
LOXOPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
SALICYLAMIDE;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SALICYLAMIDE;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
IMATINIB;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;CC;rs1994862;OTHER;DECREASED;RISK;SIDE EFFECT;AROUSAL DYSFUNCTION IN PEOPLE WITH  DISEASE:DEPRESSION;
EVEROLIMUS;RPTOR;CT + TT;rs9906827;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IMATINIB;CHST1;AA + AG;rs9787901;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
IMATINIB;CYP2F1;AA;rs305968;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
ACETAMINOPHEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
ACETAMINOPHEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
IBUPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
IBUPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
LOXOPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
LOXOPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
SALICYLAMIDE;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;
SALICYLAMIDE;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;
CYCLOPHOSPHAMIDE;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
SORAFENIB;PRKCE;G;rs11125039;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTIINFLAMMATORY AGENTS;IL10;C;rs1800896;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
NON-STEROIDS;IL10;C;rs1800896;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
CYCLOPHOSPHAMIDE;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTIINFLAMMATORY AGENTS;CTLA4;G;rs231775;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
NON-STEROIDS;CTLA4;G;rs231775;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
NAN;ADH7;CT + TT;rs971074;OTHER;INCREASED;SEVERITY;OTHER;PAIN IN PEOPLE WITH  OTHER:ANEMIA;
NAN;ADH7;CT + TT;rs971074;OTHER;INCREASED;SEVERITY;OTHER;SICKLE CELL;
SORAFENIB;ADAMTS18;A;rs1346563;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CISPLATIN;SLC31A1;GG + GT;rs10981694;TOXICITY;INCREASED;SEVERITY;DISEASE;OTOTOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CYCLOPHOSPHAMIDE;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DEXMEDETOMIDINE;ABCC9;AA;rs11046209;EFFICACY;INCREASED;SEVERITY;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:SURGERY;
CYCLOPHOSPHAMIDE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:MEDULLOBLASTOMA;
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOMA;
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CYCLOPHOSPHAMIDE;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
AZATHIOPRINE;FTO;A;rs79206939;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
MERCAPTOPURINE;FTO;A;rs79206939;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
CYCLOPHOSPHAMIDE;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
CYCLOPHOSPHAMIDE;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
DOXORUBICIN;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
FLUOROURACIL;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
ANTINEOPLASTIC AGENTS;ABCC4;AC;rs2274407;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;ABCC4;AC;rs2274407;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;ABCC4;AC;rs2274407;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION (PCI);
CYCLOPHOSPHAMIDE;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOPHOSPHAMIDE;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;FGFR4;A;rs351855;TOXICITY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;FGFR4;A;rs351855;OTHER;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  ""OTHER:MEDULLOBLASTOMA""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:GLIOMA""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:BRAIN NEOPLASMS""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:LYMPHOMA";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"B-CELL""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:LEUKEMIA""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SARCOMA";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"EWING'S""";
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-HODGKIN LYMPHOMA""";
AZATHIOPRINE;;T;rs2834826;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
MERCAPTOPURINE;;T;rs2834826;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
CYCLOPHOSPHAMIDE;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IMATINIB;SLC19A1;AG + GG;rs12659;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
AZATHIOPRINE;FTO;C;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
MERCAPTOPURINE;FTO;C;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;
AZACITIDINE;XRCC1;CC;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MYELODYSPLASTIC SYNDROMES;
IMATINIB;NQO1;GG;rs10517;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;PIK3R1;G;rs10515074;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DESLORATADINE;HRH1;CC;rs901865;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:URTICARIA;
IMATINIB;ABCC2;GG;rs2273697;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
CYTARABINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOXORUBICIN;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LEUCOVORIN;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PREDNISONE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
IMATINIB;ABCB4;AA + AG;rs1202283;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
EVEROLIMUS;PIK3R1;G;rs10515074;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:AUTOIMMUNE DISEASES;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SJOGREN'S SYNDROME;
METHOTREXATE;DHFR;CT + TT;rs1105525;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIPSYCHOTICS;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
METHADONE;NECTIN4;AA;rs11265549;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:AUTOIMMUNE DISEASES;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SJOGREN'S SYNDROME;
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;
RIVAROXABAN;CYP3A4;AA;rs2246709;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
METHOTREXATE;GGH;A;rs11545078;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;
NAN;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;NAN;OTHER;SERUM LDL NAN  NAN;
CYCLOPHOSPHAMIDE;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
CYCLOPHOSPHAMIDE;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
DOXORUBICIN;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
FLUOROURACIL;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
PRAVASTATIN;HMGCR;AT;rs17244841;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;TT;rs12654264;EFFICACY;DECREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
ANTIPSYCHOTICS;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RIVAROXABAN;CYP3A4;TT;rs3735451;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
ANTINEOPLASTIC AGENTS;RBFOX1;G;rs6500843;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;ANEMIA;
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CLOZAPINE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
OLANZAPINE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
RISPERIDONE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
IRINOTECAN;ABCC1;A;rs17287570;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
SORAFENIB;EPAS1;C;rs1868089;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2A6;A;rs143731390;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
IRINOTECAN;ABCG2;T;rs2622604;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
FOLIC ACID;MTHFD1;AA;rs2236225;OTHER;DECREASED;LIKELIHOOD;OTHER;DIABETES;
FOLIC ACID;MTHFD1;AA;rs2236225;OTHER;DECREASED;LIKELIHOOD;OTHER;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;
METHOTREXATE;DHFR;GG;rs442767;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;CT + TT;rs11692021;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
APIXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
RIVAROXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
IRINOTECAN;SLCO1B3;G;rs7977213;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;DHFR;TT;rs408626;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
IRINOTECAN;SLCO1B3;T;rs10841661;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;DHFR;AA;rs1650697;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
APIXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
RIVAROXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE;DIARRHEA;
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:NAUSEA;
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:VOMITING IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA;
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NAUSEA;
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:VOMITING IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
MEPHENYTOIN;CYP2C19;C;rs41291556;METABOLISM/PK;NAN;NAN;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE NAN  NAN;
TOLBUTAMIDE;CYP2C19;C;rs41291556;METABOLISM/PK;NAN;NAN;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE NAN  NAN;
PLATINUM;CD74;A;rs2748249;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ASPIRIN;TBXAS1;AA;rs6962291;OTHER;DECREASED;RISK;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;
PLATINUM;CD74;C;rs1560661;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;GRADE III/IV LIVER TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;
CYTARABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;GRADE III/IV LIVER TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;MYELOID;
CYTARABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;ACUTE;
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS;
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;INDEPENDENT OF CYP2C9*2 AND CYP2C9*3. NAN  NAN;
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS;
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;INDEPENDENT OF CYP2C9*2 AND CYP2C9*3. NAN  NAN;
NAN;ALDH1A2;A;rs12915901;OTHER;INCREASED;LIKELIHOOD;OTHER;OSTEOARTHRITIS NAN  NAN;
RALOXIFENE;;G;rs10030044;EFFICACY;INCREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;;G;rs10030044;EFFICACY;INCREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS;
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS;
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;
NAN;SLC2A1;CG + GG;rs841844;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
CAPECITABINE;DPYD;TT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;DPYD;TT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;INSUFFICIENT ANTIPLATELET RESPONSE TO CLOPIDOGREL IN  OTHER:PATIENTS UNDERGOING ELECTIVE CORONARY STENT IMPLANTATION;
DASATINIB;ABL1;CT;rs121913459;OTHER;DECREASED;NAN;PK;AUC 0-4 HOURS IN PEOPLE WITH  DISEASE:LEUKEMIA;
DASATINIB;ABL1;CT;rs121913459;METABOLISM/PK;DECREASED;NAN;PK;AUC 0-4 HOURS IN PEOPLE WITH  DISEASE:LEUKEMIA;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;DECREASED;SEVERITY;DISEASE;HEPATITIS C VIRUS INFECTION NAN  NAN;
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;DECREASED;SEVERITY;DISEASE;HEPATITIS C VIRUS INFECTION NAN  NAN;
HYDROCHLOROTHIAZIDE;AGT;T;rs5051;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN WOMEN WITH  DISEASE:ESSENTIAL HYPERTENSION;
HYDROCHLOROTHIAZIDE;AGTR1;A;rs5186;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN WOMEN WITH  DISEASE:ESSENTIAL HYPERTENSION;
TAMOXIFEN;ESR2;CC;rs4986938;OTHER;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDES IN POSTMENOPAUSAL WOMAN NAN  NAN;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA;
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA;
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
ONDANSETRON;ABCB1;AA;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;
TAMOXIFEN;ESR1;GG;rs9340799;OTHER;DECREASED;NAN;SIDE EFFECT;IN TOTAL CHOLESTEROL IN POSTMENOPAUSAL WOMAN AND INCREASE IN TRIGLYCERIDES AND DECREASE IN HIGH DENSITY LIPOPROTEIN IN PREMENOPAUSAL WOMEN NAN  NAN;
TALINOLOL;ABCC2;A;rs2273697;OTHER;INCREASED;NAN;PK;RESIDUAL CLEARANCE OF INTRAVENOUS TALINOLOL AND LOWER BIOAVAILABLILTY OF ORALLY ADMINISTERED TALINOLOL NAN  NAN;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;CBR3;G;rs8133052;METABOLISM/PK;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
ONDANSETRON;ABCB1;AA;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;
CLOZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
BEVACIZUMAB;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;
CYANOCOBALAMIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;
FOLIC ACID;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;
PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;
ARTESUNATE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
PRIMAQUINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
PYRIMETHAMINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
SULFADOXINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
RALOXIFENE;ZNF423;A;rs8060157;EFFICACY;DECREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;ZNF423;A;rs8060157;EFFICACY;DECREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
TACROLIMUS;ABCB1;AA + AG;rs1045642;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROLOGICAL ADR IN PEOPLE WITH  DISEASE:EPILEPSY;
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;NEUROLOGICAL ADR IN PEOPLE WITH  DISEASE:EPILEPSY;
ARTESUNATE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
PRIMAQUINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
PYRIMETHAMINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
SULFADOXINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;
SORAFENIB;VEGFB;T;rs12366035;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;NAN;EFFICACY;5 YEAR SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:LEUKEMIA;
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE;MYELOID;
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE;ACUTE;
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;
CYCLOSPORINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
TACROLIMUS;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;
CLOPIDOGREL;P2RY12;GG;rs2046934;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE CORONARY SYNDROME NAN  NAN;
VINCRISTINE;MIR6076;CC + CG;rs35650931;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SORAFENIB;WWOX;A;rs9927200;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
DOXEPIN;CYP2C19;AA;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;
VINCRISTINE;MIR4481;G;rs7896283;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOMIPRAMINE;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
CAPECITABINE;DPYD;CC;rs2297595;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;DPYD;CC;rs2297595;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;INCREASED;RISK;OTHER;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CORTICOSTEROIDS;ACP1;TT;rs11553746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
SORAFENIB;MAP2K6;C;rs11651488;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED;RISK;OTHER;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
SORAFENIB;CDH13;C;rs17682789;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:NEPHROTIC SYNDROME;
CLOMIPRAMINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
CLOMIPRAMINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
LIOTHYRONINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
LITHIUM;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
NEFAZODONE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
ILOPERIDONE;CYP2D6;GG;rs1065852;OTHER;INCREASED;NAN;SIDE EFFECT;QTC INTERVAL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
GEMCITABINE;SLC28A1;A;rs12148896;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOMIPRAMINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
LIOTHYRONINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
LITHIUM;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
NEFAZODONE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;HTR1B;A;rs130058;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
GEMCITABINE;CDA;A;rs471760;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;
CANNABIDIOL;ABCC5;AA + AG;rs3749442;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:EPILEPSY;
CISPLATIN;ACYP2;AG;rs1872328;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CLOMIPRAMINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
LIOTHYRONINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
LITHIUM;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
NEFAZODONE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
PAROXETINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
VENLAFAXINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;
MELPHALAN;SLC7A5;AA + AG;rs4240803;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
ANTIPSYCHOTICS;MC4R;CC + CT;rs17782313;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;
PLATINUM;SLC2A1;T;rs3738514;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"CARDIOTOXICITY IN CHILDREN WITH  ""OTHER:NEOPLASMS""";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WILMS TUMOR""";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SARCOMA";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"EWING'S""";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:HODGKIN DISEASE""";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-HODGKIN LYMPHOMA""";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:OSTEOSARCOMA""";
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEUROBLASTOMA""";
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;
SORAFENIB;EGFR;A;rs917881;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;
CARBOPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CISPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
FLUOROURACIL;ERCC2, KLC3;GT;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;ERCC2, KLC3;GT;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PLATINUM;SLC2A1;CC;rs4658;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  NAN;
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
FLUOROURACIL;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;ADD1;GT + TT;rs4961;OTHER;INCREASED;NAN;OTHER;AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
BLEOMYCIN;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:STROKE;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
NAN;RAD52, WNK1;CC;rs2277869;OTHER;INCREASED;NAN;OTHER;AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
FENTANYL;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
FENTANYL;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
FENTANYL;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;
FENTANYL;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
THIAZIDES;ADD1;GG;rs4961;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;ADD1;GG;rs4961;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;
BLEOMYCIN;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;
FENTANYL;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;
ACE INHIBITORS;SH2B1;T;rs192613545;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;SH2B1;T;rs192613545;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
RADIOTHERAPY;OSMR;T;rs1239344;TOXICITY;INCREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;
BLEOMYCIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;PAIN IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;PAIN IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;PAIN IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
RADIOTHERAPY;CDK1;G;rs10711;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONITIS NAN  NAN;
BLEOMYCIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CELECOXIB;CYP2C9;CT;rs1799853;METABOLISM/PK;NAN;NAN;PK;HIGHER PLASMA CONCENTRATIONS OF CELECOXIB IN HEALTHY INDIVIDUALS  NAN;
HYDROCHLOROTHIAZIDE;REN;GG;rs11240688;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN SBP IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
HYDROCHLOROTHIAZIDE;YEATS4;C;rs7297610;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
ACE INHIBITORS;RBFOX3;C;rs62063838;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;RBFOX3;C;rs62063838;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
RADIOTHERAPY;PRKCE;G;rs940052;TOXICITY;DECREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;
ACE INHIBITORS;MBOAT1;T;rs10946364;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;MBOAT1;T;rs10946364;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
RADIOTHERAPY;PRKCE;T;rs11125035;TOXICITY;DECREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;
ROFECOXIB;PTGS1;T;rs3842787;EFFICACY;NAN;NAN;EFFICACY;REDUCTION IN COX-1 INHIBITION AND DEPRESSION OF THE URINARY THROMBOXANE METABOLITE IN HEALTHY INDIVIDUALS  NAN;
BLEOMYCIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;FEBRILE NEUTROPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;FEBRILE NEUTROPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;FEBRILE NEUTROPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
RADIOTHERAPY;RIGI;C;rs11795343;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONITIS NAN  NAN;
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;
ACE INHIBITORS;RBFOX3;G;rs56044629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;RBFOX3;G;rs56044629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
HYDROCHLOROTHIAZIDE;WNK1;TT;rs880054;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN SBP IN PEOPLE WITH  DISEASE:HYPERTENSION;
RADIOTHERAPY;;C;rs7259857;TOXICITY;DECREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;
CELECOXIB;PTGS1;T;rs3842787;EFFICACY;NAN;NAN;EFFICACY;REDUCTION IN COX-1 INHIBITION IN HEALTHY INDIVIDUALS  NAN;
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;FRACTURES;
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;BONE NAN  NAN;
HYDROCHLOROTHIAZIDE;ADD1;T;rs4961;EFFICACY;DECREASED;NAN;EFFICACY;ABSOLUTE MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
ACE INHIBITORS;GABRG2;G;rs77370934;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;GABRG2;G;rs77370934;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
NAN;COL1A1;AA + AC;rs1800012;NAN;DECREASED;NAN;OTHER;BONE MINERAL DENSITY (BMD) NAN  NAN;
VINCRISTINE;BAHD1;AA + AC;rs3803357;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ACE INHIBITORS;RBFOX3;G;rs56209714;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;RBFOX3;G;rs56209714;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
METHYLPREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
BLEOMYCIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ANASTROZOLE;ZNF613;C;rs8113308;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LETROZOLE;ZNF613;C;rs8113308;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
TAMOXIFEN;ZNF613;C;rs8113308;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
PIRFENIDONE;CYP1A2;AA;rs762551;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PULMONARY FIBROSIS;
BLEOMYCIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;OTOS;CC + CT;rs2291767;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ACE INHIBITORS;RBFOX3;G;rs2061538;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
PLAIN;RBFOX3;G;rs2061538;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIMINISHED ABILITY TO CONCENTRATE IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;
TACROLIMUS;CYP3A5;CT + TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MERCAPTOPURINE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;RISK;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;RISK;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SUNITINIB;CXCL8;TT;rs1126647;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
BEVACIZUMAB;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
ETHANOL;PNPLA3;GG;rs738409;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN MEN  NAN;
BEVACIZUMAB;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SORAFENIB;EPAS1;T;rs9973653;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
NAN;WT1;CC + CT;rs16754;OTHER;INCREASED;LIKELIHOOD;DISEASE;EVENT-FREE SURVIVAL IN CHILDREN WITH  NAN;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MERCAPTOPURINE;ITPA;A;rs1127354;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CANNABINOIDS;FAAH;AA;rs324420;TOXICITY;DECREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;
SORAFENIB;;C;rs315498;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
CYCLOPHOSPHAMIDE;GSTA1;A;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
VINCRISTINE;MRPL47;CT + TT;rs10513762;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
VINCRISTINE;SYNE2;A;rs2781377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SORAFENIB;EPAS1;A;rs4035887;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ELEVATED SYSTOLIC BLOOD PRESSURE IN CHILDREN  NAN;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;
METHOTREXATE;DHFR;CC;rs408626;EFFICACY;DECREASED;NAN;OTHER;EVENT-FREE SURVIVAL;
METHOTREXATE;DHFR;CC;rs408626;EFFICACY;DECREASED;NAN;OTHER;OTHER:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED TRANSAMINASES IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
EFAVIRENZ;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXICITY-RELATED TREATMENT FAILURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
DOXORUBICIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;
ASPIRIN;CYP2D6;CC;rs28360521;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
ASPIRIN;CYP2D6;CC;rs28360521;OTHER;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;
DESFLURANE;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;
DESFLURANE;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:SURGERY;
PROPOFOL;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;
PROPOFOL;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:SURGERY;
LOSARTAN;CAMK1D;AG + GG;rs10752271;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ARTHRITIS;
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;PSORIATIC;
METHOTREXATE;DHFR;TT;rs408626;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LOSARTAN;CAMK1D;AG + GG;rs10737062;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
METHOTREXATE;MTHFR;T;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;DHFR;GT;rs442767;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CELECOXIB;CYP2C9;C;rs1057910;EFFICACY;DECREASED;RISK;DISEASE;ADENOMA IN PEOPLE WITH  DISEASE:ADENOMA;
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTIONS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
BLEOMYCIN;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
MERCAPTOPURINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
EFAVIRENZ;ABCB1;A;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EMERGING VIRAL DRUG RESISTANCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
BEVACIZUMAB;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
FLUOROURACIL;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
IRINOTECAN;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
LEUCOVORIN;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
SORAFENIB;;G;rs10958704;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
METHOTREXATE;SHMT1;AG;rs1979277;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;FASTKD3, MTRR;AG;rs1801394;TOXICITY;INCREASED;NAN;SIDE EFFECT;SPEED OF PLATELET RECOVERY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SORAFENIB;EPAS1;G;rs7557402;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
METHOTREXATE;MTHFR;TT;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;RED BLOOD CELL TRANSFUSIONS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
APIXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
RIVAROXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
EFAVIRENZ;ABCB1;A;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EMERGING VIRAL DRUG RESISTANCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;
CYCLOPHOSPHAMIDE;VEGFA;AA;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
DOCETAXEL;VEGFA;AA;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
CARBOPLATIN;OR4D6;CC;rs1453542;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;OR4D6;CC;rs1453542;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SORAFENIB;MAP2K6;G;rs12948059;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;
CARBOPLATIN;DDX53;T;rs5925720;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
GEMCITABINE;DDX53;T;rs5925720;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METHOTREXATE;MTHFD1;AA;rs2236225;OTHER;INCREASED;NAN;PK;RED BLOOD CELL FOLATE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;FASTKD3, MTRR;AA;rs1801394;OTHER;INCREASED;NAN;PK;RED BLOOD CELL FOLATE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
IRINOTECAN;SEMA3C;T;rs11979430;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIPSYCHOTICS;DRD2;A;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS NAN  NAN;
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
IRINOTECAN;SEMA3C;C;rs7779029;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;NAN;NAN;EFFICACY;PROTECTION FROM DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;NAN;NAN;EFFICACY;PROTECTION FROM DRUG RESISTANCE IN MEN WITH  DISEASE:EPILEPSY;
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
IRINOTECAN;;G;rs1661167;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;NAN;NAN;EFFICACY;PROTECTION FROM DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
AMISULPRIDE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
AMISULPRIDE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
QUETIAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CISPLATIN;CYP2E1;TT;rs6413432;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2E1;TT;rs6413432;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
BUDESONIDE;FCER2;G;rs28364072;OTHER;NAN;NAN;OTHER;SEVERE EXACERBATIONS WITH ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;
CYCLOPHOSPHAMIDE;NOS3;TT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
AMISULPRIDE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
AMISULPRIDE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
QUETIAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
MYCOPHENOLATE MOFETIL;IL12A;A;rs568408;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;
IRINOTECAN;PLCB1;C;rs2745761;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CYCLOPHOSPHAMIDE;NOS3;CC;rs2070744;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
AMISULPRIDE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
AMISULPRIDE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
QUETIAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
QUETIAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CYCLOPHOSPHAMIDE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
DOXORUBICIN;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
FLUOROURACIL;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
METHOTREXATE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;PDZRN3;C;rs11128347;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METHADONE;UGT2B7;TT;rs4554144;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;TT;rs4554144;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
DAPSONE;HLA-DRB1;A;rs201929247;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
OLANZAPINE;PPARG;CG;rs1801282;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
METHADONE;UGT2B7;CC;rs11940316;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;CC;rs11940316;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
CORTICOSTEROIDS;BCL2L11;AA;rs2241843;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHADONE;UGT2B7;AA;rs7438135;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;AA;rs7438135;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHADONE;UGT2B7;GG;rs7662029;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;GG;rs7662029;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
CISPLATIN;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
OXALIPLATIN;PIN1;CC + CG;rs2233678;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;
OXALIPLATIN;PIN1;CC + CG;rs2233678;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
METHADONE;UGT2B7;CC;rs7668258;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;CC;rs7668258;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
ETHAMBUTOL;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
PYRAZINAMIDE;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
METHOTREXATE;ABCG2;TT;rs2231142;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
METHOTREXATE;AMPD1;AG;rs17602729;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
ANTIEPILEPTICS;ABCB1;A;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN MEN WITH  DISEASE:EPILEPSY;
METHADONE;UGT2B7;CC;rs7439366;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;CC;rs7439366;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
ANTIEPILEPTICS;ABCB1;A;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN MEN WITH  DISEASE:EPILEPSY;
METHADONE;UGT2B7;GG;rs4292394;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;GG;rs4292394;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
ETHAMBUTOL;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
PYRAZINAMIDE;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;
CISPLATIN;CYP2E1;CG;rs2070676;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE EMESIS IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
CYCLOPHOSPHAMIDE;CYP2E1;CG;rs2070676;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE EMESIS IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;
THIAZIDES;GNB3;CC;rs5443;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;
PLAIN;GNB3;CC;rs5443;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;
AMLODIPINE;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;DISEASE;HEART FAILURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
FLUOROURACIL;GSTP1;GG;rs1695;TOXICITY;DECREASED;RISK;SIDE EFFECT;HAEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;
NAN;COL1A1;AA;rs1800012;NAN;DECREASED;NAN;OTHER;BONE MINERAL DENSITY AT FEMORAL NECK AND LUMBAR SPINE NAN  NAN;
METHADONE;UGT2B7;GG;rs6600879;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;GG;rs6600879;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
NAN;COL1A1;AA + AC;rs1800012;NAN;DECREASED;NAN;OTHER;BMD VALUES AT THE LUMBAR SPINE AND FEMORAL NECK NAN  NAN;
METHADONE;UGT2B7;AA;rs6600880;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;AA;rs6600880;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA;
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
THIAZIDES;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;
PLAIN;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;
THIAZIDES;ACE;GG;rs4341;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;
PLAIN;ACE;GG;rs4341;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;
ATORVASTATIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;NAN;NAN;PK;A NEARLY TRIPLED INCREASED PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN NAN  NAN;
RIFAMPIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;NAN;NAN;PK;A NEARLY TRIPLED INCREASED PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN NAN  NAN;
CAPECITABINE;MIR27A;C;rs895819;TOXICITY;NAN;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
FLUOROURACIL;MIR27A;C;rs895819;TOXICITY;NAN;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;
ATORVASTATIN;FDPS;TT;rs2297480;TOXICITY;INCREASED;NAN;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;SUBJECTIVE FEELINGS OF INTOXICATION;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;STIMULATION;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;SEDATION;
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;AND HAPPINESS NAN  NAN;
NAN;ABCC2;C;rs3740066;METABOLISM/PK;NAN;NAN;OTHER;ALLELIC IMBALENCE NAN  NAN;
CISPLATIN;GSTM4;CC;rs560018;EFFICACY;INCREASED;NAN;EFFICACY;IC-50 NAN  NAN;
CISPLATIN;GSTM4;CC;rs560018;TOXICITY;INCREASED;NAN;EFFICACY;IC-50 NAN  NAN;
ATORVASTATIN;FDPS;AA;rs11264359;TOXICITY;INCREASED;NAN;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;
IRINOTECAN;C8orf34;C;rs1517114;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
DICLOXACILLIN;ABCB1;GG;rs1045642;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
DICLOXACILLIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
PROBENECID;ABCB1;GG;rs1045642;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
PROBENECID;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;
ETHANOL;OPRM1;G;rs1799971;OTHER;NAN;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
CYCLOSPORINE;ABCB1;CC;rs2032582;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
CYCLOSPORINE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
DICLOXACILLIN;ABCB1;CC;rs2032582;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
DICLOXACILLIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;
ETHAMBUTOL;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ISONIAZID;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
PYRAZINAMIDE;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
RIFAMPIN;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;
ATORVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;
FLUVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;
PRAVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;
ROSUVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;
SIMVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;
PLATINUM COMPOUNDS;MDM2;CC;rs1690924;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
SEVOFLURANE;GRIN2B;AA + AG;rs1806201;OTHER;INCREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;GG;rs1042714;EFFICACY;INCREASED;NAN;OTHER;STATUS ASTHMATICUS IN CHILDREN WITH  DISEASE:ASTHMA;
METHOTREXATE;CCND1;AA;rs9344;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
RISPERIDONE;ABCB1;A;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:SCHIZOPHRENIA;
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PACLITAXEL;SOD2;AA;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHYLPHENIDATE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
DOCETAXEL;ERCC2;TT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
DOCETAXEL;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;RATES OF TARGET LESION REVASCULARIZATION AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
METFORMIN;SP1;C;rs2683511;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN SECRETORY CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
NICOTINE;CHRNA3, CHRNA5;A;rs16969968;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;
METFORMIN;;G;rs10747673;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;;G;rs10747673;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TO BE CLASSIFIED AS CLOPIDOGREL POOR RESPONDERS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
METFORMIN;;G;rs10747673;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN SECRETORY CLEARANCE IN HEALTHY INDIVIDUALS  NAN;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOPIDOGREL;ATP10A;AA + AG;rs12913988;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:LYMPHOMA;
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;LARGE B-CELL;
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIFFUSE;
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:LYMPHOMA;
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;LARGE B-CELL;
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIFFUSE;
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;EFFICACY;CLOPIDOGREL POOR RESPONSE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;
MERCAPTOPURINE;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
CLOZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
ACENOCOUMAROL;ABCB1;GG + GT;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
RISPERIDONE;ABCB1;A;rs2032582;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:SCHIZOPHRENIA;
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
SEVOFLURANE;KCNK3;CT + TT;rs1275988;OTHER;INCREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
LEUCOVORIN;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
LEUCOVORIN;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
DOCETAXEL;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFUSION RELATED REACTION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METFORMIN;SP1;G;rs784888;EFFICACY;DECREASED;SEVERITY;DISEASE;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SP1;G;rs784888;EFFICACY;DECREASED;SEVERITY;DISEASE;TYPE 2;
PLATINUM COMPOUNDS;MTR;AA + AG;rs1805087;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
SEVOFLURANE;GABRA2;CC + CT;rs279858;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
LEUCOVORIN;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STAYING IN REMISSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
MERCAPTOPURINE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STAYING IN REMISSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STAYING IN REMISSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;CYP2C8;CG + GG;rs1113129;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
METFORMIN;PPARA;T;rs149711321;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;PPARA;T;rs149711321;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
NAN;COL1A1;AA;rs1800012;NAN;INCREASED;RISK;DISEASE;FRACTURES;
NAN;COL1A1;AA;rs1800012;NAN;INCREASED;RISK;DISEASE;BONE NAN  NAN;
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
PLATINUM COMPOUNDS;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;
PACLITAXEL;CYP2C8;CT + TT;rs1934951;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
LENALIDOMIDE;VEGFA;AA;rs699947;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
METFORMIN;SP1;C;rs2683511;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
METFORMIN;SP1;C;rs2683511;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;
SEVOFLURANE;FASTKD3, MTRR;AG + GG;rs1801394;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
BUPROPION;DRD1;A;rs2168631;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
NICOTINE;DRD1;A;rs2168631;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
SIMVASTATIN;HMGCR;TT;rs17238540;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION OF LDL CHOLESTEROL NAN  NAN;
NAN;NR3C1;C;rs9324918;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  DISEASE:ANEMIA;
NAN;NR3C1;C;rs9324918;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL;
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
SEVOFLURANE;FASTKD3, MTRR;AA + AG;rs2307116;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
PACLITAXEL;ERCC1;AA + AC;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
MORPHINE;ABCC3;C;rs1978153;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;
MORPHINE;ABCC3;C;rs1978153;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;
NAN;P2RY12;G;rs2046934;NAN;INCREASED;RISK;SIDE EFFECT;CORONARY ARTERY DISEASE NAN  NAN;
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
BUPROPION;DRD1;T;rs11749035;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
NICOTINE;DRD1;T;rs11749035;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
PAZOPANIB;CXCL8;T;rs1126647;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;CXCL8;T;rs1126647;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
NAN;NR3C1;G;rs2963155;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  DISEASE:ANEMIA;
NAN;NR3C1;G;rs2963155;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL;
MORPHINE;ABCC3;G;rs733392;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;
MORPHINE;ABCC3;G;rs733392;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;
METHADONE;UGT2B7;CC;rs6600893;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
METHADONE;UGT2B7;CC;rs6600893;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;
FENTANYL;MYD88;G;rs6853;TOXICITY;DECREASED;RISK;SIDE EFFECT;COGNITIVE DISORDER IN PEOPLE WITH  DISEASE:NEOPLASMS;
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
PREDNISONE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;
BUPROPION;DRD1;G;rs11746641;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
NICOTINE;DRD1;G;rs11746641;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;
NAN;NR3C1;T;rs33389;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  DISEASE:ANEMIA;
NAN;NR3C1;T;rs33389;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL;
SPIRONOLACTONE;ACE;AA + AG;rs4343;EFFICACY;NAN;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION;
SPIRONOLACTONE;ACE;AA + AG;rs4343;EFFICACY;NAN;NAN;EFFICACY;END-SYSTOLIC AND END-DIASTOLIC VOLUME IN PEOPLE WITH  OTHER:CHRONIC HEART FAILURE;
SIMVASTATIN;HMGCR;AA;rs17244841;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION OF LDL CHOLESTEROL NAN  NAN;
DOCETAXEL;ERCC1;CC;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
SEVOFLURANE;CYP2E1;CC + CG;rs3813867;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
SEVOFLURANE;CYP2E1, DUX1;CT + TT;rs2031920;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;
ANTIHYPERTENSIVES;NOS3;CC;rs2070744;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  DISEASE:HYPERTENSION;
DIURETICS;NOS3;CC;rs2070744;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  DISEASE:HYPERTENSION;
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;
IBUPROFEN;PTGS2;CG + GG;rs20417;EFFICACY;INCREASED;NAN;EFFICACY;PAIN RELIEF NAN  NAN;
DIFLOMOTECAN;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF DIFLOMOTECAN NAN  NAN;
CYCLOSPORINE;ABCB1;AA;rs2032582;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;
CYCLOSPORINE;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
ROFECOXIB;PTGS2;CC;rs20417;EFFICACY;INCREASED;NAN;EFFICACY;PAIN RELIEF NAN  NAN;
FENTANYL;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
HMG-COA_REDUCTASE_INHIBITORS;;C;rs13210472;TOXICITY;INCREASED;RISK;OTHER;NEOPLASMS IN WOMEN  NAN;
FENTANYL;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
PAZOPANIB;CXCL8;A;rs4073;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
SUNITINIB;CXCL8;A;rs4073;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;
BLEOMYCIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
FENTANYL;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
MORPHINE;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OPIOIDS;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
OXYCODONE;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PHARMACODYNAMIC RESPONSE IN HEALTHY INDIVIDUALS  NAN;
METHOTREXATE;CCND1;AA;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
BLEOMYCIN;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ASPIRIN;PTGS1;AA + AG;rs10306114;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:CEREBRAL INFARCTION;
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;CC;rs2032582;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;
CYCLOSPORINE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
TACROLIMUS;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:TRANSPLANTATION;
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;PLASMA EXPOSURE TO THE ACTIVE METABOLITE OF CLOPIDOGREL IN HEALTHY INDIVIDUALS  NAN;
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
FLUOROURACIL;DPYD;T;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
FLUOROURACIL;DPYD;T;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
MORPHINE;ABCC3;G;rs886493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;
MORPHINE;ABCC3;G;rs886493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;
BLEOMYCIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
CISPLATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
ETOPOSIDE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;
MORPHINE;ABCC3;T;rs7216383;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;
MORPHINE;ABCC3;T;rs7216383;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
ETHANOL;;A;rs10516440;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;
TRAMADOL;ABCB1;A;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS IN PEOPLE WITH  DISEASE:FRACTURES;
TRAMADOL;ABCB1;A;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BONE;
CITALOPRAM;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES NAN  NAN;
TRAMADOL;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS IN PEOPLE WITH  DISEASE:FRACTURES;
TRAMADOL;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BONE;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;
METHOTREXATE;ABCC2;A;rs17222723;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
RISPERIDONE;UGT1A1;CT;rs887829;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
FLUOXETINE;CRHR1;CC;rs242941;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE IN PEOPLE WITH  OTHER:MAJOR DEPRESSION AND HIGH ANXIETY;
RISPERIDONE;UGT1A1;AG;rs10929302;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
CISPLATIN;GSTP1;CT + TT;rs1138272;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;
CISPLATIN;GSTP1;CT + TT;rs1138272;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;
SARILUMAB;IL6R;TT;rs4845625;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
VITAMIN K ANTAGONISTS;CYP4F2;TT;rs2108622;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;
RISPERIDONE;HTR2C;GG;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM;
WARFARIN;CRP;CT + TT;rs1205;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
HYDROCHLOROTHIAZIDE;TCF7L2;A;rs4132670;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES IN PEOPLE WITH  DISEASE:HYPERTENSION;
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs7917983;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
ATORVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
CERIVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
FLUVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ROSUVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
SIMVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs4506565;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;
CITALOPRAM;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE NAN  NAN;
LENALIDOMIDE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
FLUOROURACIL;XRCC1;CC;rs25487;OTHER;NAN;NAN;OTHER;LATER ONSET OF SENSORY NEUROPATHY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
LEUCOVORIN;XRCC1;CC;rs25487;OTHER;NAN;NAN;OTHER;LATER ONSET OF SENSORY NEUROPATHY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
OXALIPLATIN;XRCC1;CC;rs25487;OTHER;NAN;NAN;OTHER;LATER ONSET OF SENSORY NEUROPATHY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
DOCETAXEL;CHST3;A;rs4148950;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
THALIDOMIDE;CHST3;A;rs4148950;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
BUPRENORPHINE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
SARILUMAB;IL6R;CC;rs4537545;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSLIPIDAEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
CALCIUM;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;MEAN SPINAL BONE MINERAL DENSITY CHANGES IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
CALCIUM;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;
ETIDRONIC ACID;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;MEAN SPINAL BONE MINERAL DENSITY CHANGES IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;
ETIDRONIC ACID;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;
SARILUMAB;IL6R;AA;rs2228145;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSLIPIDAEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
BUPRENORPHINE;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
VALPROIC ACID;SOD2;AA + AG;rs4880;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:EPILEPSY;
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
BUPRENORPHINE;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
BISPHOSPHONATES;CYP2C8;TT;rs1934951;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;
BUPRENORPHINE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
BUPRENORPHINE;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
BUPRENORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
BUPRENORPHINE;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;
BUPRENORPHINE;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;
FENTANYL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;
TRAMADOL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
NAN;IFNL3, IFNL4;CC;rs12979860;OTHER;INCREASED;LIKELIHOOD;DISEASE;JAUNDICE IN WOMEN  DISEASE:HEPATITIS C VIRUS INFECTION;
BUPRENORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FLUOROURACIL;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
LEUCOVORIN;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
OXALIPLATIN;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
BUPRENORPHINE;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
LENALIDOMIDE;CRBN;CC;rs1705814;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;
LENALIDOMIDE;CRBN;CC;rs1705814;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DISCONTINUATION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
LENALIDOMIDE;CRBN;CC;rs1705814;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;
LENALIDOMIDE;CRBN;CC;rs1705814;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DISCONTINUATION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;
BUPRENORPHINE;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FENTANYL;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
TRAMADOL;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;
FLUOROURACIL;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
LEUCOVORIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
OXALIPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
FLUOROURACIL;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
LEUCOVORIN;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
OXALIPLATIN;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
RIFAMPIN;NR1I2;T;rs2472677;OTHER;DECREASED;NAN;PK;CYP3A4 ACITVITY NAN  NAN;
RIFAMPIN;NR1I2;T;rs2472677;METABOLISM/PK;DECREASED;NAN;PK;CYP3A4 ACITVITY NAN  NAN;
CARBAMAZEPINE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
LAMOTRIGINE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
OXCARBAZEPINE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
PHENYTOIN;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
TOPIRAMATE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;
CAPECITABINE;PTGS2;AA;rs5275;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
OXALIPLATIN;PTGS2;AA;rs5275;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
NAN;CETP;A;rs708272;NAN;NAN;NAN;OTHER;VARIANCE IN LDL;
NAN;CETP;A;rs708272;NAN;NAN;NAN;OTHER;HDL AND LDL/HDL NAN  NAN;
HMG-COA_REDUCTASE_INHIBITORS;CETP;A;rs708272;EFFICACY;DECREASED;RISK;EFFICACY;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;
DIURETICS;ADD1;GT + TT;rs4961;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;NAN;NAN;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT NAN  NAN;
ETHANOL;DRD2;A;rs1076560;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET ACTIVATION RESPONSE TO ADP IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
FLUOROURACIL;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
LEUCOVORIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
OXALIPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;
BROMPERIDOL;DRD2;GG;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
NEMONAPRIDE;DRD2;GG;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;
THIAZIDES;SLC12A3;CC;rs13306673;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
PLAIN;SLC12A3;CC;rs13306673;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA;
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ALOPECIA;
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERSENSITIVITY IN CHILDREN WITH  OTHER:EPILEPSY;
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERLIPIDEMIAS;
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERTENSION;
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OBESITY;
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERLIPIDEMIAS;
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERTENSION;
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OBESITY;
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;
THIAZIDES;ADRB3;AA;rs4994;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
PLAIN;ADRB3;AA;rs4994;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;
ASPARAGINASE;CPA2;T;rs199695765;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
DAPSONE;HLA-DRB1;T;rs701829;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
TACROLIMUS;POR;CT + TT;rs1057868;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
WARFARIN;THBD;CC + CT;rs1042580;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
METHYLPHENIDATE;CES1;AC + CC;rs3815583;TOXICITY;INCREASED;RISK;SIDE EFFECT;APPETITE SUPPRESSION IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;
ACE INHIBITORS;BDKRB2;C;rs8012552;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;BDKRB2;C;rs8012552;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
CORTICOSTEROIDS;BCL2L11;CC;rs724710;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;
ACE INHIBITORS;MME;A;rs2016848;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;MME;A;rs2016848;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
IRINOTECAN;PIN1;CC + CG;rs2233678;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;
HYDROCHLOROTHIAZIDE;ADD1;GT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN ARTERIAL PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;
ASPIRIN;ACE;AT + TT;rs4291;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;
MYCOPHENOLATE MOFETIL;CYP2C8;A;rs11572103;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;
MYCOPHENOLATE MOFETIL;CYP2C8;T;rs11572076;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;
ACE INHIBITORS;PTGER3;C;rs11209716;TOXICITY;DECREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
PLAIN;PTGER3;C;rs11209716;TOXICITY;DECREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;
MYCOPHENOLATE MOFETIL;HUS1;T;rs1056663;TOXICITY;DECREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;
DAPSONE;HLA-DRB1;A;rs17211071;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;
TACROLIMUS;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;
MYCOPHENOLATE MOFETIL;HUS1;A;rs2037483;TOXICITY;DECREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;
NAN;ADD1;GT + TT;rs4961;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTENSION NAN  NAN;
FLUOROURACIL;ABCB1;C;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOROURACIL;SLCO1B1;A;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
NAN;ARG1;TT;rs2781666;OTHER;INCREASED;SEVERITY;OTHER;ASTHMA NAN  NAN;
TACROLIMUS;CYP3A4;TT;rs2740574;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
EPIRUBICIN;ABCC1;CT;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;
LEVODOPA;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSKINESIA;
LEVODOPA;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED IN PEOPLE WITH  OTHER:PARKINSON DISEASE;
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"TOXIC LIVER DISEASE IN PEOPLE WITH  ""DISEASE:BURKITT LYMPHOMA""";
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:LYMPHOMA";
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"T-CELL""";
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";
DAUNORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);C.1236G>A (HAPB3);EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;
DAUNORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DAUNORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DAUNORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DAUNORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DAUNORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DAUNORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DAUNORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
DOXORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;
CEFAZOLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CEFDINIR;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CEFTRIAXONE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CEFUROXIME;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
CEPHALEXIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;
TACROLIMUS;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
CORTICOSTEROIDS;WNT7B;A;rs73175102;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;
CORTICOSTEROIDS;WNT7B;A;rs73175102;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
CORTICOSTEROIDS;POGK;A;rs115587273;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;
CORTICOSTEROIDS;POGK;A;rs115587273;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
CORTICOSTEROIDS;FAM240C;A;rs78233573;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;
CORTICOSTEROIDS;FAM240C;A;rs78233573;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
CORTICOSTEROIDS;ZNF37A;A;rs376867011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;
CORTICOSTEROIDS;ZNF37A;A;rs376867011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;
CODEINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EMERGENCIES;
CODEINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PAIN IN PEOPLE WITH  OTHER:PAIN;
HYDROCODONE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EMERGENCIES;
HYDROCODONE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PAIN IN PEOPLE WITH  OTHER:PAIN;
TRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EMERGENCIES;
TRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PAIN IN PEOPLE WITH  OTHER:PAIN;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;
VALPROIC ACID;ACOT1;T;rs758109;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;
TACROLIMUS;SLCO1B1;AA + AG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;MOCOS;GT;rs73430958;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
VALPROIC ACID;GABPA;CC;rs59288687;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;
VALPROIC ACID;NQO1;GG;rs10517;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;
VALPROIC ACID;PPARA;G;rs881740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;
METHOTREXATE;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
METHOTREXATE;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;
APIXABAN;APOE;C;rs7412;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INTRACRANIAL HEMORRHAGES IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
APIXABAN;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INTRACRANIAL HEMORRHAGES IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs8099917;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs8099917;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:TOBACCO USE DISORDER;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs12980275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:TOBACCO USE DISORDER;
TACROLIMUS;ABCB1;TT;rs9282564;EFFICACY;DECREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;ABCC2;GG;rs2273697;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
TACROLIMUS;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;RRM1;AG + GG;rs1735053;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;GT + TT;rs9465102;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"NEPHROTOXICITY IN PEOPLE WITH  ""OTHER:CARCINOMA";
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:CARCINOMA""";
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";
FOLFOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FLUOXETINE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT MODIFICATION NAN  NAN;
FLUOXETINE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT MODIFICATION NAN  NAN;
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN CHILDREN WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LEUKEMIA;
AFATINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
ERLOTINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
GEFITINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;
FOLFOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
FOLFOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
XELOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
FOLFOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;
XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
FOLFOX;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
XELOX;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
HMG-COA_REDUCTASE_INHIBITORS;ABCG2;T;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;
HMG-COA_REDUCTASE_INHIBITORS;ABCG2;T;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE NAN  NAN;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*1XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*4XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*9;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*29;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*35;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*41;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;URINARY RETENTION;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ABDOMINAL PAIN;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WHEEZING;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PAIN;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;URINARY RETENTION;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ABDOMINAL PAIN;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WHEEZING;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PAIN;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;URINARY RETENTION;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ABDOMINAL PAIN;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WHEEZING;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PAIN;
